Sentence: In unanesthetized, spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous clonidine, 5 to 20 micrograms/kg, was inhibited or reversed by nalozone, 0.2 to 2 mg/kg.
Entity: 227508	33	45	hypertensive	Disease	D006973
Entity: 227508	121	130	clonidine	Chemical	D003000
Entity: 227508	184	192	nalozone	Chemical	-1
Relation: 227508	CID	121	130	D003000	33	45	D006973	false
Relation: 227508	CID	184	192	-1	33	45	D006973	false

Sentence: The hypotensive effect of 100 mg/kg alpha-methyldopa was also partially reversed by naloxone.
Entity: 227508	4	15	hypotensive	Disease	D007022
Entity: 227508	36	52	alpha-methyldopa	Chemical	D008750
Entity: 227508	84	92	naloxone	Chemical	D009270
Relation: 227508	CID	36	52	D008750	4	15	D007022	true
Relation: 227508	CID	84	92	D009270	4	15	D007022	false

Sentence: In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).
Entity: 227508	38	50	hypertensive	Disease	D006973
Entity: 227508	56	65	clonidine	Chemical	D003000
Entity: 227508	132	145	[3H]-naloxone	Chemical	-1
Entity: 227508	158	166	naloxone	Chemical	D009270
Entity: 227508	206	215	clonidine	Chemical	D003000
Entity: 227508	240	264	[3H]-dihydroergocryptine	Chemical	-1
Relation: 227508	CID	56	65	D003000	38	50	D006973	false
Relation: 227508	CID	132	145	-1	38	50	D006973	false
Relation: 227508	CID	158	166	D009270	38	50	D006973	false
Relation: 227508	CID	206	215	D003000	38	50	D006973	false
Relation: 227508	CID	240	264	-1	38	50	D006973	false

Sentence: Lidocaine induced cardiac asystole.
Entity: 354896	0	9	Lidocaine	Chemical	D008012
Entity: 354896	18	34	cardiac asystole	Disease	D006323
Relation: 354896	CID	0	9	D008012	18	34	D006323	true

Sentence: Intravenous administration of a single 50-mg bolus of lidocaine in a 67-year-old man resulted in profound depression of the activity of the sinoatrial and atrioventricular nodal pacemakers.
Entity: 354896	54	63	lidocaine	Chemical	D008012
Entity: 354896	106	116	depression	Disease	D003866
Relation: 354896	CID	54	63	D008012	106	116	D003866	false

Sentence: Suxamethonium infusion rate and observed fasciculations.
Entity: 435349	0	13	Suxamethonium	Chemical	D013390
Entity: 435349	41	55	fasciculations	Disease	D005207
Relation: 435349	CID	0	13	D013390	41	55	D005207	true

Sentence: The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.
Entity: 435349	76	83	tetanic	Disease	D013746
Entity: 435349	123	126	Sch	Chemical	D013390
Relation: 435349	CID	123	126	D013390	76	83	D013746	false

Sentence: Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.
Entity: 603022	0	25	Galanthamine hydrobromide	Chemical	D005702
Entity: 603022	157	168	scopolamine	Chemical	D012601
Entity: 603022	170	178	hyoscine	Chemical	D012601
Entity: 603022	180	190	overdosage	Disease	D062787
Relation: 603022	CID	0	25	D005702	180	190	D062787	false
Relation: 603022	CID	157	168	D012601	180	190	D062787	true
Relation: 603022	CID	170	178	D012601	180	190	D062787	true

Sentence: Effects of uninephrectomy and high protein feeding on lithium induced chronic renal failure in rats.
Entity: 1378968	54	61	lithium	Chemical	D008094
Entity: 1378968	70	91	chronic renal failure	Disease	D007676
Relation: 1378968	CID	54	61	D008094	70	91	D007676	true

Sentence: Rats with lithium induced nephropathy were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to induce glomerular hyperfiltration and further progression of renal failure.
Entity: 1378968	10	17	lithium	Chemical	D008094
Entity: 1378968	26	37	nephropathy	Disease	D007674
Entity: 1378968	208	221	renal failure	Disease	D051437
Relation: 1378968	CID	10	17	D008094	26	37	D007674	false
Relation: 1378968	CID	10	17	D008094	208	221	D051437	false

Sentence: Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis.
Entity: 1378968	0	7	Lithium	Chemical	D008094
Entity: 1378968	20	31	proteinuria	Disease	D011507
Entity: 1378968	45	57	hypertension	Disease	D006973
Entity: 1378968	72	90	glomerulosclerosis	Disease	D005921
Relation: 1378968	CID	0	7	D008094	20	31	D011507	true
Relation: 1378968	CID	0	7	D008094	45	57	D006973	true
Relation: 1378968	CID	0	7	D008094	72	90	D005921	false

Sentence: HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.
Entity: 1378968	40	53	renal failure	Disease	D051437
Entity: 1378968	109	119	creatinine	Chemical	D003404
Entity: 1378968	130	137	lithium	Chemical	D008094
Relation: 1378968	CID	109	119	D003404	40	53	D051437	false
Relation: 1378968	CID	130	137	D008094	40	53	D051437	false

Sentence: The results indicate that Li induced nephropathy, even when the GFR is only modestly reduced, is associated with proteinuria and arterial systolic hypertension.
Entity: 1378968	26	28	Li	Chemical	D008094
Entity: 1378968	37	48	nephropathy	Disease	D007674
Entity: 1378968	113	124	proteinuria	Disease	D011507
Entity: 1378968	147	159	hypertension	Disease	D006973
Relation: 1378968	CID	26	28	D008094	37	48	D007674	false
Relation: 1378968	CID	26	28	D008094	113	124	D011507	true
Relation: 1378968	CID	26	28	D008094	147	159	D006973	true

Sentence: Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.
Entity: 1420741	13	28	Crohn's disease	Disease	D003424
Entity: 1420741	34	46	fusidic acid	Chemical	D005672
Entity: 1420741	107	118	cyclosporin	Chemical	D016572
Relation: 1420741	CID	34	46	D005672	13	28	D003424	false
Relation: 1420741	CID	107	118	D016572	13	28	D003424	false

Sentence: Because of the need for the development of new treatments for Crohn's disease, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients.
Entity: 1420741	62	77	Crohn's disease	Disease	D003424
Entity: 1420741	161	173	fusidic acid	Chemical	D005672
Relation: 1420741	CID	161	173	D005672	62	77	D003424	false

Sentence: The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn's disease patients in whom conventional treatment is ineffective.
Entity: 1420741	45	57	fusidic acid	Chemical	D005672
Entity: 1420741	103	118	Crohn's disease	Disease	D003424
Relation: 1420741	CID	45	57	D005672	103	118	D003424	false

Sentence: Electrocardiographic evidence of myocardial injury in psychiatrically hospitalized cocaine abusers.
Entity: 1601297	33	50	myocardial injury	Disease	D009202
Entity: 1601297	83	90	cocaine	Chemical	D003042
Relation: 1601297	CID	83	90	D003042	33	50	D009202	false

Sentence: The electrocardiograms (ECG) of 99 cocaine-abusing patients were compared with the ECGs of 50 schizophrenic controls.
Entity: 1601297	35	42	cocaine	Chemical	D003042
Entity: 1601297	94	107	schizophrenic	Disease	D012559
Relation: 1601297	CID	35	42	D003042	94	107	D012559	false

Sentence: Sulpiride induced tardive dystonia.
Entity: 1967484	0	9	Sulpiride	Chemical	D013469
Entity: 1967484	18	34	tardive dystonia	Disease	D004421
Relation: 1967484	CID	0	9	D013469	18	34	D004421	true

Sentence: Although initially thought to be free of extrapyramidal side effects, sulpiride induced tardive dyskinesia and parkinsonism have been reported occasionally.
Entity: 1967484	70	79	sulpiride	Chemical	D013469
Entity: 1967484	88	106	tardive dyskinesia	Disease	D004409
Entity: 1967484	111	123	parkinsonism	Disease	D010302
Relation: 1967484	CID	70	79	D013469	88	106	D004409	false
Relation: 1967484	CID	70	79	D013469	111	123	D010302	false

Sentence: We studied a 37-year-old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy.
Entity: 1967484	64	72	dystonia	Disease	D004421
Entity: 1967484	104	113	sulpiride	Chemical	D013469
Relation: 1967484	CID	104	113	D013469	64	72	D004421	true

Sentence: Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.
Entity: 2234245	0	6	Ocular	Disease	D014786
Entity: 2234245	11	19	auditory	Disease	D006311
Entity: 2234245	64	79	desferrioxamine	Chemical	D003676
Relation: 2234245	CID	64	79	D003676	0	6	D014786	true
Relation: 2234245	CID	64	79	D003676	11	19	D006311	false

Sentence: During an 18-month period of study 41 hemodialyzed patients receiving desferrioxamine (10-40 mg/kg BW/3 times weekly) for the first time were monitored for detection of audiovisual toxicity. 6 patients presented clinical symptoms of visual or auditory toxicity.
Entity: 2234245	70	85	desferrioxamine	Chemical	D003676
Entity: 2234245	169	189	audiovisual toxicity	Disease	D014786
Entity: 2234245	169	189	audiovisual toxicity	Disease	D006311
Entity: 2234245	233	239	visual	Disease	D014786
Entity: 2234245	243	251	auditory	Disease	D006311
Relation: 2234245	CID	70	85	D003676	169	189	D014786	true
Relation: 2234245	CID	70	85	D003676	169	189	D006311	false
Relation: 2234245	CID	70	85	D003676	233	239	D014786	true
Relation: 2234245	CID	70	85	D003676	243	251	D006311	false

Sentence: Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of hearing loss in 3 patients and partial recovery in 3.
Entity: 2234245	0	15	Desferrioxamine	Chemical	D003676
Entity: 2234245	145	157	hearing loss	Disease	D034381
Relation: 2234245	CID	0	15	D003676	145	157	D034381	false

Sentence: This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels.
Entity: 2234245	5	13	toxicity	Disease	D064420
Entity: 2234245	65	80	desferrioxamine	Chemical	D003676
Entity: 2234245	132	141	aluminium	Chemical	-1
Relation: 2234245	CID	65	80	D003676	5	13	D064420	false
Relation: 2234245	CID	132	141	-1	5	13	D064420	false

Sentence: Myasthenia gravis presenting as weakness after magnesium administration.
Entity: 2385256	0	17	Myasthenia gravis	Disease	D009157
Entity: 2385256	47	56	magnesium	Chemical	D008274
Relation: 2385256	CID	47	56	D008274	0	17	D009157	true

Sentence: We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.
Entity: 2385256	46	67	neuromuscular disease	Disease	D009468
Entity: 2385256	89	101	quadriplegic	Disease	D011782
Entity: 2385256	119	128	magnesium	Chemical	D008274
Entity: 2385256	148	160	preeclampsia	Disease	D011225
Relation: 2385256	CID	119	128	D008274	46	67	D009468	false
Relation: 2385256	CID	119	128	D008274	89	101	D011782	false
Relation: 2385256	CID	119	128	D008274	148	160	D011225	false

Sentence: Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease.
Entity: 2385256	9	18	paralysis	Disease	D010243
Entity: 2385256	25	34	magnesium	Chemical	D008274
Entity: 2385256	92	109	myasthenia gravis	Disease	D009157
Relation: 2385256	CID	25	34	D008274	9	18	D010243	false
Relation: 2385256	CID	25	34	D008274	92	109	D009157	true

Sentence: Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.
Entity: 2505783	40	58	chloroacetaldehyde	Chemical	C004656
Entity: 2505783	60	63	CAA	Chemical	C004656
Entity: 2505783	197	200	CAA	Chemical	C004656
Entity: 2505783	223	234	hemorrhagic	Disease	D006470
Entity: 2505783	235	243	cystitis	Disease	D003556
Relation: 2505783	CID	40	58	C004656	223	234	D006470	true
Relation: 2505783	CID	40	58	C004656	235	243	D003556	true
Relation: 2505783	CID	60	63	C004656	223	234	D006470	true
Relation: 2505783	CID	60	63	C004656	235	243	D003556	true
Relation: 2505783	CID	197	200	C004656	223	234	D006470	true
Relation: 2505783	CID	197	200	C004656	235	243	D003556	true

Sentence: The data demonstrate that CAA after i.v. administration does not contribute to bladder damage.
Entity: 2505783	26	29	CAA	Chemical	C004656
Entity: 2505783	79	93	bladder damage	Disease	D001745
Relation: 2505783	CID	26	29	C004656	79	93	D001745	false

Sentence: Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin (10 patients) or placebo ointment (10 patients) in a double blind study.
Entity: 2515254	14	22	migraine	Disease	D008881
Entity: 2515254	83	96	nitroglycerin	Chemical	D005996
Relation: 2515254	CID	83	96	D005996	14	22	D008881	true

Sentence: Early onset migraine attacks were induced by nitroglycerin in seven out of 10 patients versus no patient in the placebo group.
Entity: 2515254	12	20	migraine	Disease	D008881
Entity: 2515254	45	58	nitroglycerin	Chemical	D005996
Relation: 2515254	CID	45	58	D005996	12	20	D008881	true

Sentence: Subsequently 20 migraine patients, who developed an early onset attack with frontotemporal nitroglycerin, received the drug in a second induction test at other body areas.
Entity: 2515254	16	24	migraine	Disease	D008881
Entity: 2515254	91	104	nitroglycerin	Chemical	D005996
Relation: 2515254	CID	91	104	D005996	16	24	D008881	true

Sentence: Thus the migraine-inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain, suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis.
Entity: 2515254	9	17	migraine	Disease	D008881
Entity: 2515254	37	50	nitroglycerin	Chemical	D005996
Entity: 2515254	113	117	pain	Disease	D010146
Entity: 2515254	210	218	migraine	Disease	D008881
Relation: 2515254	CID	37	50	D005996	9	17	D008881	true
Relation: 2515254	CID	37	50	D005996	113	117	D010146	false
Relation: 2515254	CID	37	50	D005996	210	218	D008881	true

Sentence: Clotiazepam induced acute hepatitis.
Entity: 2572625	0	11	Clotiazepam	Chemical	C084599
Entity: 2572625	26	35	hepatitis	Disease	D056486
Relation: 2572625	CID	0	11	C084599	26	35	D056486	true

Sentence: We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.
Entity: 2572625	52	61	hepatitis	Disease	D056486
Entity: 2572625	67	100	extensive hepatocellular necrosis	Disease	D047508
Entity: 2572625	148	159	clotiazepam	Chemical	C084599
Entity: 2572625	163	178	thienodiazepine	Chemical	C013295
Relation: 2572625	CID	148	159	C084599	52	61	D056486	true
Relation: 2572625	CID	148	159	C084599	67	100	D047508	false
Relation: 2572625	CID	163	178	C013295	52	61	D056486	false
Relation: 2572625	CID	163	178	C013295	67	100	D047508	false

Sentence: The administration of several benzodiazepines, chemically related to clotiazepam, did not interfere with recovery and did not induce any relapse of hepatitis.
Entity: 2572625	30	45	benzodiazepines	Chemical	D001569
Entity: 2572625	69	80	clotiazepam	Chemical	C084599
Entity: 2572625	148	157	hepatitis	Disease	D056486
Relation: 2572625	CID	30	45	D001569	148	157	D056486	false
Relation: 2572625	CID	69	80	C084599	148	157	D056486	true

Sentence: Arterial hypertension as a complication of prolonged ketoconazole treatment.
Entity: 2632720	9	21	hypertension	Disease	D006973
Entity: 2632720	53	65	ketoconazole	Chemical	D007654
Relation: 2632720	CID	53	65	D007654	9	21	D006973	true

Sentence: Two of 14 patients with Cushing's syndrome treated on a long-term basis with ketoconazole developed sustained hypertension.
Entity: 2632720	24	42	Cushing's syndrome	Disease	D003480
Entity: 2632720	77	89	ketoconazole	Chemical	D007654
Entity: 2632720	110	122	hypertension	Disease	D006973
Relation: 2632720	CID	77	89	D007654	24	42	D003480	false
Relation: 2632720	CID	77	89	D007654	110	122	D006973	true

Sentence: In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment.
Entity: 2632720	45	53	cortisol	Chemical	D006854
Entity: 2632720	89	101	ketoconazole	Chemical	D007654
Entity: 2632720	165	177	hypertension	Disease	D006973
Relation: 2632720	CID	45	53	D006854	165	177	D006973	false
Relation: 2632720	CID	89	101	D007654	165	177	D006973	true

Sentence: Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.
Entity: 2670794	27	38	angiotensin	Chemical	D000809
Entity: 2670794	58	67	Captopril	Chemical	D002216
Entity: 2670794	72	81	pulmonary	Disease	D011665
Entity: 2670794	86	91	renal	Disease	D051437
Entity: 2670794	113	138	intravascular coagulation	Disease	D004211
Relation: 2670794	CID	27	38	D000809	72	81	D011665	false
Relation: 2670794	CID	27	38	D000809	86	91	D051437	false
Relation: 2670794	CID	27	38	D000809	113	138	D004211	false
Relation: 2670794	CID	58	67	D002216	72	81	D011665	false
Relation: 2670794	CID	58	67	D002216	86	91	D051437	false
Relation: 2670794	CID	58	67	D002216	113	138	D004211	false

Sentence: Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.
Entity: 2670794	13	38	intravascular coagulation	Disease	D004211
Entity: 2670794	99	114	tranexamic acid	Chemical	D014148
Entity: 2670794	116	120	AMCA	Chemical	D014148
Entity: 2670794	147	156	pulmonary	Disease	D011665
Entity: 2670794	161	166	renal	Disease	D051437
Entity: 2670794	213	219	trauma	Disease	D014947
Entity: 2670794	223	229	sepsis	Disease	D018805
Relation: 2670794	CID	99	114	D014148	13	38	D004211	true
Relation: 2670794	CID	99	114	D014148	147	156	D011665	false
Relation: 2670794	CID	99	114	D014148	161	166	D051437	false
Relation: 2670794	CID	99	114	D014148	213	219	D014947	false
Relation: 2670794	CID	99	114	D014148	223	229	D018805	false
Relation: 2670794	CID	116	120	D014148	13	38	D004211	true
Relation: 2670794	CID	116	120	D014148	147	156	D011665	false
Relation: 2670794	CID	116	120	D014148	161	166	D051437	false
Relation: 2670794	CID	116	120	D014148	213	219	D014947	false
Relation: 2670794	CID	116	120	D014148	223	229	D018805	false

Sentence: Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model.
Entity: 2670794	13	22	Captopril	Chemical	D002216
Entity: 2670794	50	61	angiotensin	Chemical	D000809
Entity: 2670794	100	109	pulmonary	Disease	D011665
Entity: 2670794	114	119	renal	Disease	D051437
Relation: 2670794	CID	13	22	D002216	100	109	D011665	false
Relation: 2670794	CID	13	22	D002216	114	119	D051437	false
Relation: 2670794	CID	50	61	D000809	100	109	D011665	false
Relation: 2670794	CID	50	61	D000809	114	119	D051437	false

Sentence: Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril.
Entity: 2670794	0	12	Renal damage	Disease	D007674
Entity: 2670794	50	54	urea	Chemical	D014508
Entity: 2670794	93	102	Captopril	Chemical	D002216
Relation: 2670794	CID	50	54	D014508	0	12	D007674	false
Relation: 2670794	CID	93	102	D002216	0	12	D007674	false

Sentence: A randomized comparison of labetalol and nitroprusside for induced hypotension.
Entity: 2696505	27	36	labetalol	Chemical	D007741
Entity: 2696505	41	54	nitroprusside	Chemical	D009599
Entity: 2696505	67	78	hypotension	Disease	D007022
Relation: 2696505	CID	27	36	D007741	67	78	D007022	true
Relation: 2696505	CID	41	54	D009599	67	78	D007022	true

Sentence: In a randomized study, labetalol induced hypotension and nitroprusside induced hypotension were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures.
Entity: 2696505	23	32	labetalol	Chemical	D007741
Entity: 2696505	41	52	hypotension	Disease	D007022
Entity: 2696505	57	70	nitroprusside	Chemical	D009599
Entity: 2696505	79	90	hypotension	Disease	D007022
Relation: 2696505	CID	23	32	D007741	41	52	D007022	true
Relation: 2696505	CID	23	32	D007741	79	90	D007022	true
Relation: 2696505	CID	57	70	D009599	41	52	D007022	true
Relation: 2696505	CID	57	70	D009599	79	90	D007022	true

Sentence: Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.
Entity: 2696505	76	117	increase in heart rate and cardiac output	Disease	D016534
Entity: 2696505	127	139	hypertension	Disease	D006973
Entity: 2696505	196	209	nitroprusside	Chemical	D009599
Relation: 2696505	CID	196	209	D009599	76	117	D016534	true
Relation: 2696505	CID	196	209	D009599	127	139	D006973	false

Sentence: Chronic carbamazepine treatment in the rat: efficacy, toxicity, and effect on plasma and tissue folate concentrations.
Entity: 2924746	8	21	carbamazepine	Chemical	D002220
Entity: 2924746	54	62	toxicity	Disease	D064420
Entity: 2924746	96	102	folate	Chemical	D005492
Relation: 2924746	CID	8	21	D002220	54	62	D064420	false
Relation: 2924746	CID	96	102	D005492	54	62	D064420	false

Sentence: In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.
Entity: 2924746	58	74	propylene glycol	Chemical	D019946
Entity: 2924746	160	168	seizures	Disease	D012640
Entity: 2924746	183	194	weight gain	Disease	D015430
Relation: 2924746	CID	58	74	D019946	160	168	D012640	false
Relation: 2924746	CID	58	74	D019946	183	194	D015430	false

Sentence: Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).
Entity: 2924746	0	8	Seizures	Disease	D012640
Entity: 2924746	20	43	hexafluorodiethyl ether	Chemical	D005481
Entity: 2924746	45	49	HFDE	Chemical	D005481
Entity: 2924746	115	118	CBZ	Chemical	D002220
Entity: 2924746	124	132	seizures	Disease	D012640
Relation: 2924746	CID	20	43	D005481	0	8	D012640	true
Relation: 2924746	CID	20	43	D005481	124	132	D012640	true
Relation: 2924746	CID	45	49	D005481	0	8	D012640	true
Relation: 2924746	CID	45	49	D005481	124	132	D012640	true
Relation: 2924746	CID	115	118	D002220	0	8	D012640	false
Relation: 2924746	CID	115	118	D002220	124	132	D012640	false

Sentence: Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.
Entity: 2924746	23	26	CBZ	Chemical	D002220
Entity: 2924746	121	125	HFDE	Chemical	D005481
Entity: 2924746	134	142	seizures	Disease	D012640
Entity: 2924746	182	193	weight gain	Disease	D015430
Relation: 2924746	CID	23	26	D002220	134	142	D012640	false
Relation: 2924746	CID	23	26	D002220	182	193	D015430	false
Relation: 2924746	CID	121	125	D005481	134	142	D012640	true
Relation: 2924746	CID	121	125	D005481	182	193	D015430	false

Sentence: Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.
Entity: 2951327	258	269	tachycardia	Disease	D013610
Entity: 2951327	297	311	norepinephrine	Chemical	D009638
Entity: 2951327	404	415	hypotension	Disease	D007022
Entity: 2951327	427	438	hydralazine	Chemical	D006830
Entity: 2951327	442	455	nitroglycerin	Chemical	D005996
Relation: 2951327	CID	297	311	D009638	258	269	D013610	false
Relation: 2951327	CID	297	311	D009638	404	415	D007022	false
Relation: 2951327	CID	427	438	D006830	258	269	D013610	false
Relation: 2951327	CID	427	438	D006830	404	415	D007022	true
Relation: 2951327	CID	442	455	D005996	258	269	D013610	false
Relation: 2951327	CID	442	455	D005996	404	415	D007022	true

Sentence: Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of methotrexate.
Entity: 3409645	0	9	Impotence	Disease	D007172
Entity: 3409645	127	139	methotrexate	Chemical	D008727
Relation: 3409645	CID	127	139	D008727	0	9	D007172	true

Sentence: Does paracetamol cause urothelial cancer or renal papillary necrosis.
Entity: 3412544	5	16	paracetamol	Chemical	D000082
Entity: 3412544	23	40	urothelial cancer	Disease	D014523
Entity: 3412544	44	68	renal papillary necrosis	Disease	D007681
Relation: 3412544	CID	5	16	D000082	23	40	D014523	false
Relation: 3412544	CID	5	16	D000082	44	68	D007681	false

Sentence: The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.
Entity: 3412544	23	47	renal papillary necrosis	Disease	D007681
Entity: 3412544	51	96	cancer of the renal pelvis, ureter or bladder	Disease	D007680|D014516|D001749	cancer of the renal pelvis|cancer of the ureter|cancer of the bladder
Entity: 3412544	135	145	phenacetin	Chemical	D010615
Entity: 3412544	149	160	paracetamol	Chemical	D000082
Relation: 3412544	CID	135	145	D010615	23	47	D007681	true
Relation: 3412544	CID	135	145	D010615	51	96	D007680|D014516|D001749	cancer of the renal pelvis|cancer of the ureter|cancer of the bladder	false
Relation: 3412544	CID	149	160	D000082	23	47	D007681	false
Relation: 3412544	CID	149	160	D000082	51	96	D007680|D014516|D001749	cancer of the renal pelvis|cancer of the ureter|cancer of the bladder	false

Sentence: The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.
Entity: 3412544	12	36	renal papillary necrosis	Disease	D007681
Entity: 3412544	84	94	phenacetin	Chemical	D010615
Entity: 3412544	130	136	cancer	Disease	D007680
Entity: 3412544	130	136	cancer	Disease	D001749
Entity: 3412544	181	196	ureteric cancer	Disease	D014516
Relation: 3412544	CID	84	94	D010615	12	36	D007681	true
Relation: 3412544	CID	84	94	D010615	130	136	D007680	true
Relation: 3412544	CID	84	94	D010615	130	136	D001749	true
Relation: 3412544	CID	84	94	D010615	181	196	D014516	false

Sentence: Dapsone-associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait.
Entity: 3425586	0	7	Dapsone	Chemical	D003622
Entity: 3425586	30	46	hemolytic anemia	Disease	D000743
Relation: 3425586	CID	0	7	D003622	30	46	D000743	true

Sentence: A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.
Entity: 3425586	51	58	leprosy	Disease	D007918
Entity: 3425586	82	98	hemolytic anemia	Disease	D000743
Entity: 3425586	122	129	dapsone	Chemical	D003622
Entity: 3425586	179	188	hemolysis	Disease	D006461
Relation: 3425586	CID	122	129	D003622	51	58	D007918	false
Relation: 3425586	CID	122	129	D003622	82	98	D000743	true
Relation: 3425586	CID	122	129	D003622	179	188	D006461	false

Sentence: Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals.
Entity: 3425586	105	112	dapsone	Chemical	D003622
Entity: 3425586	128	144	hemolytic anemia	Disease	D000743
Relation: 3425586	CID	105	112	D003622	128	144	D000743	true

Sentence: Triazolam induced brief episodes of secondary mania in a depressed patient.
Entity: 3693336	0	9	Triazolam	Chemical	D014229
Entity: 3693336	46	51	mania	Disease	D001714
Entity: 3693336	57	66	depressed	Disease	D003866
Relation: 3693336	CID	0	9	D014229	46	51	D001714	true
Relation: 3693336	CID	0	9	D014229	57	66	D003866	false

Sentence: Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman.
Entity: 3693336	15	24	triazolam	Chemical	D014229
Entity: 3693336	62	67	mania	Disease	D001714
Entity: 3693336	73	82	depressed	Disease	D003866
Relation: 3693336	CID	15	24	D014229	62	67	D001714	true
Relation: 3693336	CID	15	24	D014229	73	82	D003866	false

Sentence: Manic excitement was coincident with the duration of action of triazolam.
Entity: 3693336	0	5	Manic	Disease	D001714
Entity: 3693336	63	72	triazolam	Chemical	D014229
Relation: 3693336	CID	63	72	D014229	0	5	D001714	true

Sentence: On the mechanisms of the development of tolerance to the muscular rigidity produced by morphine in rats.
Entity: 3780846	57	74	muscular rigidity	Disease	D009127
Entity: 3780846	87	95	morphine	Chemical	D009020
Relation: 3780846	CID	87	95	D009020	57	74	D009127	true

Sentence: The development of tolerance to the muscular rigidity produced by morphine was studied in rats.
Entity: 3780846	36	53	muscular rigidity	Disease	D009127
Entity: 3780846	66	74	morphine	Chemical	D009020
Relation: 3780846	CID	66	74	D009020	36	53	D009127	true

Sentence: Saline-pretreated controls given a test dose of morphine (20 mg/kg i.p.) showed a pronounced rigidity recorded as tonic activity in the electromyogram.
Entity: 3780846	48	56	morphine	Chemical	D009020
Entity: 3780846	93	101	rigidity	Disease	D009127
Relation: 3780846	CID	48	56	D009020	93	101	D009127	true

Sentence: Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).
Entity: 3780846	30	38	morphine	Chemical	D009020
Entity: 3780846	152	160	rigidity	Disease	D009127
Entity: 3780846	184	192	morphine	Chemical	D009020
Entity: 3780846	255	263	akinetic	Disease	D018476
Relation: 3780846	CID	30	38	D009020	152	160	D009127	true
Relation: 3780846	CID	30	38	D009020	255	263	D018476	true
Relation: 3780846	CID	184	192	D009020	152	160	D009127	true
Relation: 3780846	CID	184	192	D009020	255	263	D018476	true

Sentence: In a further series of experiments, haloperidol (0.2 mg/kg i.p.) was used in order to block the dopaminergic activation and to estimate the real degree of the tolerance to the rigidity without any dopaminergic interference.
Entity: 3780846	36	47	haloperidol	Chemical	D006220
Entity: 3780846	176	184	rigidity	Disease	D009127
Relation: 3780846	CID	36	47	D006220	176	184	D009127	true

Sentence: Haloperidol enhanced the rigidity in the A group.
Entity: 3780846	0	11	Haloperidol	Chemical	D006220
Entity: 3780846	25	33	rigidity	Disease	D009127
Relation: 3780846	CID	0	11	D006220	25	33	D009127	true

Sentence: The results suggest that rigidity, which is assumed to be due to an action of morphine in the striatum, can be antagonized by another process leading to dopaminergic activation in the striatum.
Entity: 3780846	25	33	rigidity	Disease	D009127
Entity: 3780846	78	86	morphine	Chemical	D009020
Relation: 3780846	CID	78	86	D009020	25	33	D009127	true

Sentence: Compression neuropathy of the radial nerve due to pentazocine induced fibrous myopathy.
Entity: 3800626	0	11	Compression	Disease	D009408
Entity: 3800626	12	22	neuropathy	Disease	D020425
Entity: 3800626	50	61	pentazocine	Chemical	D010423
Entity: 3800626	70	86	fibrous myopathy	Disease	D005355
Entity: 3800626	70	86	fibrous myopathy	Disease	D009135
Relation: 3800626	CID	50	61	D010423	0	11	D009408	true
Relation: 3800626	CID	50	61	D010423	12	22	D020425	true
Relation: 3800626	CID	50	61	D010423	70	86	D005355	true
Relation: 3800626	CID	50	61	D010423	70	86	D009135	true

Sentence: Fibrous myopathy is a common, well-known side effect of repeated pentazocine injection.
Entity: 3800626	0	16	Fibrous myopathy	Disease	D005355
Entity: 3800626	0	16	Fibrous myopathy	Disease	D009135
Entity: 3800626	65	76	pentazocine	Chemical	D010423
Relation: 3800626	CID	65	76	D010423	0	16	D005355	true
Relation: 3800626	CID	65	76	D010423	0	16	D009135	true

Sentence: However, compression neuropathy due to fibrotic muscle affected by pentazocine induced myopathy has not previously been reported.
Entity: 3800626	9	31	compression neuropathy	Disease	D009408
Entity: 3800626	67	78	pentazocine	Chemical	D010423
Entity: 3800626	87	95	myopathy	Disease	D009135
Relation: 3800626	CID	67	78	D010423	9	31	D009408	true
Relation: 3800626	CID	67	78	D010423	87	95	D009135	true

Sentence: Recurrent reversible acute renal failure from amphotericin.
Entity: 3827439	21	40	acute renal failure	Disease	D058186
Entity: 3827439	46	58	amphotericin	Chemical	D000666
Relation: 3827439	CID	46	58	D000666	21	40	D058186	true

Sentence: A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.
Entity: 3827439	27	36	cirrhosis	Disease	D005355
Entity: 3827439	54	68	sporotrichosis	Disease	D013174
Entity: 3827439	79	98	acute renal failure	Disease	D058186
Entity: 3827439	143	157	amphotericin B	Chemical	D000666
Relation: 3827439	CID	143	157	D000666	27	36	D005355	false
Relation: 3827439	CID	143	157	D000666	54	68	D013174	false
Relation: 3827439	CID	143	157	D000666	79	98	D058186	true

Sentence: Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.
Entity: 3997294	17	24	pleural	Disease	D010996
Entity: 3997294	29	40	pericardial	Disease	D010490
Entity: 3997294	54	64	neuropathy	Disease	D009422
Entity: 3997294	72	82	amiodarone	Chemical	D000638
Relation: 3997294	CID	72	82	D000638	17	24	D010996	true
Relation: 3997294	CID	72	82	D000638	29	40	D010490	true
Relation: 3997294	CID	72	82	D000638	54	64	D009422	false

Sentence: A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.
Entity: 3997294	15	33	sinuatrial disease	Disease	D002318
Entity: 3997294	75	85	amiodarone	Chemical	D000638
Entity: 3997294	170	203	supraventricular tachyarrhythmias	Disease	D013617
Relation: 3997294	CID	75	85	D000638	15	33	D002318	false
Relation: 3997294	CID	75	85	D000638	170	203	D013617	false

Sentence: Indomethacin induced renal insufficiency: recurrence on rechallenge.
Entity: 4071154	0	12	Indomethacin	Chemical	D007213
Entity: 4071154	21	40	renal insufficiency	Disease	D051437
Relation: 4071154	CID	0	12	D007213	21	40	D051437	false

Sentence: We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.
Entity: 4071154	42	55	renal failure	Disease	D051437
Entity: 4071154	61	73	hyperkalemia	Disease	D006947
Entity: 4071154	92	101	cirrhosis	Disease	D005355
Entity: 4071154	103	110	ascites	Disease	D001201
Entity: 4071154	116	129	cor pulmonale	Disease	D011660
Entity: 4071154	136	148	indomethacin	Chemical	D007213
Relation: 4071154	CID	136	148	D007213	42	55	D051437	false
Relation: 4071154	CID	136	148	D007213	61	73	D006947	true
Relation: 4071154	CID	136	148	D007213	92	101	D005355	true
Relation: 4071154	CID	136	148	D007213	103	110	D001201	true
Relation: 4071154	CID	136	148	D007213	116	129	D011660	true

Sentence: Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria.
Entity: 4071154	101	113	indomethacin	Chemical	D007213
Entity: 4071154	152	160	oliguria	Disease	D009846
Relation: 4071154	CID	101	113	D007213	152	160	D009846	true

Sentence: Changes in heart size during long-term timolol treatment after myocardial infarction.
Entity: 6229975	39	46	timolol	Chemical	D013999
Entity: 6229975	63	84	myocardial infarction	Disease	D009203
Relation: 6229975	CID	39	46	D013999	63	84	D009203	false

Sentence: The effect of long-term timolol treatment on heart size after myocardial infarction was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, timolol 115).
Entity: 6229975	24	31	timolol	Chemical	D013999
Entity: 6229975	62	83	myocardial infarction	Disease	D009203
Entity: 6229975	168	175	timolol	Chemical	D013999
Relation: 6229975	CID	24	31	D013999	62	83	D009203	false
Relation: 6229975	CID	168	175	D013999	62	83	D009203	false

Sentence: These differences may be caused by timolol induced bradycardia and a compensatory increase in end-diastolic volume.
Entity: 6229975	35	42	timolol	Chemical	D013999
Entity: 6229975	51	62	bradycardia	Disease	D001919
Relation: 6229975	CID	35	42	D013999	51	62	D001919	false

Sentence: Vitamin D3 toxicity in dairy cows.
Entity: 6286738	0	10	Vitamin D3	Chemical	D002762
Entity: 6286738	11	19	toxicity	Disease	D064420
Relation: 6286738	CID	0	10	D002762	11	19	D064420	false

Sentence: Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.
Entity: 6286738	26	36	vitamin D3	Chemical	D002762
Entity: 6286738	60	70	vitamin D3	Chemical	D002762
Entity: 6286738	103	116	hypercalcemia	Disease	D006934
Entity: 6286738	118	135	hyperphosphatemia	Disease	D054559
Entity: 6286738	160	170	vitamin D3	Chemical	D002762
Relation: 6286738	CID	26	36	D002762	103	116	D006934	true
Relation: 6286738	CID	26	36	D002762	118	135	D054559	true
Relation: 6286738	CID	60	70	D002762	103	116	D006934	true
Relation: 6286738	CID	60	70	D002762	118	135	D054559	true
Relation: 6286738	CID	160	170	D002762	103	116	D006934	true
Relation: 6286738	CID	160	170	D002762	118	135	D054559	true

Sentence: None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.
Entity: 6286738	30	40	vitamin D3	Chemical	D002762
Entity: 6286738	57	67	milk fever	Disease	D010319
Entity: 6286738	159	169	milk fever	Disease	D010319
Relation: 6286738	CID	30	40	D002762	57	67	D010319	false
Relation: 6286738	CID	30	40	D002762	159	169	D010319	false

Sentence: Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.
Entity: 6286738	9	19	vitamin D3	Chemical	D002762
Entity: 6286738	20	28	toxicity	Disease	D064420
Entity: 6286738	139	149	vitamin D3	Chemical	D002762
Entity: 6286738	150	158	toxicity	Disease	D064420
Relation: 6286738	CID	9	19	D002762	20	28	D064420	false
Relation: 6286738	CID	9	19	D002762	150	158	D064420	false
Relation: 6286738	CID	139	149	D002762	20	28	D064420	false
Relation: 6286738	CID	139	149	D002762	150	158	D064420	false

Sentence: Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.
Entity: 6287825	0	21	Peripheral neuropathy	Disease	D010523
Entity: 6287825	29	51	nutritional deficiency	Disease	D044342
Entity: 6287825	55	63	thiamine	Chemical	D013831
Entity: 6287825	68	78	riboflavin	Chemical	D012256
Entity: 6287825	134	158	sensori-motor neuropathy	Disease	D010523
Relation: 6287825	CID	55	63	D013831	0	21	D010523	true
Relation: 6287825	CID	55	63	D013831	29	51	D044342	false
Relation: 6287825	CID	55	63	D013831	134	158	D010523	true
Relation: 6287825	CID	68	78	D012256	0	21	D010523	true
Relation: 6287825	CID	68	78	D012256	29	51	D044342	false
Relation: 6287825	CID	68	78	D012256	134	158	D010523	true

Sentence: Isoniazid was the most frequent agent in drug induced neuropathy.
Entity: 6287825	0	9	Isoniazid	Chemical	D007538
Entity: 6287825	54	64	neuropathy	Disease	D009422
Relation: 6287825	CID	0	9	D007538	54	64	D009422	false

Sentence: A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder.
Entity: 6386793	51	74	dothiepin hydrochloride	Chemical	D004308
Entity: 6386793	101	120	depressive disorder	Disease	D003866
Relation: 6386793	CID	51	74	D004308	101	120	D003866	false

Sentence: In a 6-week double-blind parallel treatment study, dothiepin and amitriptyline were compared to placebo in the treatment of 33 depressed outpatients.
Entity: 6386793	51	60	dothiepin	Chemical	D004308
Entity: 6386793	65	78	amitriptyline	Chemical	D000639
Entity: 6386793	127	136	depressed	Disease	D003866
Relation: 6386793	CID	51	60	D004308	127	136	D003866	false
Relation: 6386793	CID	65	78	D000639	127	136	D003866	false

Sentence: Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness, and both were significantly superior to placebo.
Entity: 6386793	0	9	Dothiepin	Chemical	D004308
Entity: 6386793	14	27	amitriptyline	Chemical	D000639
Entity: 6386793	82	100	depressive illness	Disease	D003866
Relation: 6386793	CID	0	9	D004308	82	100	D003866	false
Relation: 6386793	CID	14	27	D000639	82	100	D003866	false

Sentence: The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.
Entity: 6386793	72	86	blurred vision	Disease	D014786
Entity: 6386793	88	97	dry mouth	Disease	D014987
Entity: 6386793	143	152	dothiepin	Chemical	D004308
Entity: 6386793	163	176	amitriptyline	Chemical	D000639
Relation: 6386793	CID	143	152	D004308	72	86	D014786	false
Relation: 6386793	CID	143	152	D004308	88	97	D014987	false
Relation: 6386793	CID	163	176	D000639	72	86	D014786	true
Relation: 6386793	CID	163	176	D000639	88	97	D014987	true

Sentence: Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.
Entity: 6387529	22	30	diazepam	Chemical	D003975
Entity: 6387529	35	46	propranolol	Chemical	D011433
Entity: 6387529	64	78	panic disorder	Disease	D016584
Entity: 6387529	83	94	agoraphobia	Disease	D000379
Relation: 6387529	CID	22	30	D003975	64	78	D016584	false
Relation: 6387529	CID	22	30	D003975	83	94	D000379	false
Relation: 6387529	CID	35	46	D011433	64	78	D016584	false
Relation: 6387529	CID	35	46	D011433	83	94	D000379	false

Sentence: The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.
Entity: 6387529	29	37	diazepam	Chemical	D003975
Entity: 6387529	108	119	propranolol	Chemical	D011433
Entity: 6387529	233	248	panic disorders	Disease	D016584
Entity: 6387529	253	264	agoraphobia	Disease	D000379
Relation: 6387529	CID	29	37	D003975	233	248	D016584	false
Relation: 6387529	CID	29	37	D003975	253	264	D000379	false
Relation: 6387529	CID	108	119	D011433	233	248	D016584	false
Relation: 6387529	CID	108	119	D011433	253	264	D000379	false

Sentence: Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol.
Entity: 6387529	11	41	impaired immediate free recall	Disease	D008569
Entity: 6387529	75	83	diazepam	Chemical	D003975
Entity: 6387529	89	100	propranolol	Chemical	D011433
Relation: 6387529	CID	75	83	D003975	11	41	D008569	true
Relation: 6387529	CID	89	100	D011433	11	41	D008569	true

Sentence: The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT induced bladder carcinomas but a concomitant induction of forestomach tumors.
Entity: 6692345	25	32	aspirin	Chemical	D001241
Entity: 6692345	38	83	N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide	Chemical	D005200
Entity: 6692345	85	90	FANFT	Chemical	D005200
Entity: 6692345	135	140	FANFT	Chemical	D005200
Entity: 6692345	149	167	bladder carcinomas	Disease	D001749
Entity: 6692345	199	217	forestomach tumors	Disease	D013274
Relation: 6692345	CID	25	32	D001241	149	167	D001749	false
Relation: 6692345	CID	25	32	D001241	199	217	D013274	false
Relation: 6692345	CID	38	83	D005200	149	167	D001749	true
Relation: 6692345	CID	38	83	D005200	199	217	D013274	true
Relation: 6692345	CID	85	90	D005200	149	167	D001749	true
Relation: 6692345	CID	85	90	D005200	199	217	D013274	true
Relation: 6692345	CID	135	140	D005200	149	167	D001749	true
Relation: 6692345	CID	135	140	D005200	199	217	D013274	true

Sentence: The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.
Entity: 6692345	124	129	FANFT	Chemical	D005200
Entity: 6692345	130	144	carcinogenesis	Disease	D063646
Entity: 6692345	186	193	aspirin	Chemical	D001241
Entity: 6692345	206	211	FANFT	Chemical	D005200
Relation: 6692345	CID	124	129	D005200	130	144	D063646	false
Relation: 6692345	CID	186	193	D001241	130	144	D063646	false
Relation: 6692345	CID	206	211	D005200	130	144	D063646	false

Sentence: Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy.
Entity: 6773726	24	35	hypotension	Disease	D007022
Entity: 6773726	39	52	nitroglycerin	Chemical	D005996
Entity: 6773726	56	85	diabetic autonomic neuropathy	Disease	D003929
Relation: 6773726	CID	39	52	D005996	24	35	D007022	true
Relation: 6773726	CID	39	52	D005996	56	85	D003929	false

Sentence: The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.
Entity: 6773726	14	27	nitroglycerin	Chemical	D005996
Entity: 6773726	108	116	diabetic	Disease	D003920
Entity: 6773726	134	154	autonomic neuropathy	Disease	D009422
Entity: 6773726	162	170	diabetic	Disease	D003920
Entity: 6773726	185	205	autonomic neuropathy	Disease	D009422
Relation: 6773726	CID	14	27	D005996	108	116	D003920	false
Relation: 6773726	CID	14	27	D005996	134	154	D009422	false
Relation: 6773726	CID	14	27	D005996	162	170	D003920	false
Relation: 6773726	CID	14	27	D005996	185	205	D009422	false

Sentence: The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.
Entity: 6773726	110	123	nitroglycerin	Chemical	D005996
Entity: 6773726	155	163	diabetic	Disease	D003920
Entity: 6773726	181	201	autonomic neuropathy	Disease	D009422
Entity: 6773726	309	317	diabetic	Disease	D003920
Entity: 6773726	332	352	autonomic neuropathy	Disease	D009422
Relation: 6773726	CID	110	123	D005996	155	163	D003920	false
Relation: 6773726	CID	110	123	D005996	181	201	D009422	false
Relation: 6773726	CID	110	123	D005996	309	317	D003920	false
Relation: 6773726	CID	110	123	D005996	332	352	D009422	false

Sentence: Characterization of estrogen induced adenohypophyseal tumors in the Fischer 344 rat.
Entity: 6888657	20	28	estrogen	Chemical	D004967
Entity: 6888657	37	60	adenohypophyseal tumors	Disease	D010911
Relation: 6888657	CID	20	28	D004967	37	60	D010911	false

Sentence: Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.
Entity: 6888657	0	16	Pituitary tumors	Disease	D010911
Entity: 6888657	76	94	diethylstilbestrol	Chemical	D004054
Entity: 6888657	96	99	DES	Chemical	D004054
Relation: 6888657	CID	76	94	D004054	0	16	D010911	true
Relation: 6888657	CID	96	99	D004054	0	16	D010911	true

Sentence: Triamterene nephrolithiasis complicating dyazide therapy.
Entity: 7265370	0	11	Triamterene	Chemical	D014223
Entity: 7265370	12	27	nephrolithiasis	Disease	D053040
Entity: 7265370	41	48	dyazide	Chemical	C020743
Relation: 7265370	CID	0	11	D014223	12	27	D053040	true
Relation: 7265370	CID	41	48	C020743	12	27	D053040	false

Sentence: A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension.
Entity: 7265370	10	21	triamterene	Chemical	D014223
Entity: 7265370	22	37	nephrolithiasis	Disease	D053040
Entity: 7265370	76	107	hydrochlorothiazide-triamterene	Chemical	C020743
Entity: 7265370	120	132	hypertension	Disease	D006973
Relation: 7265370	CID	10	21	D014223	22	37	D053040	true
Relation: 7265370	CID	10	21	D014223	120	132	D006973	false
Relation: 7265370	CID	76	107	C020743	22	37	D053040	false
Relation: 7265370	CID	76	107	C020743	120	132	D006973	false

Sentence: Metabolic involvement in adriamycin cardiotoxicity.
Entity: 7423039	25	35	adriamycin	Chemical	D004317
Entity: 7423039	36	50	cardiotoxicity	Disease	D066126
Relation: 7423039	CID	25	35	D004317	36	50	D066126	true

Sentence: The cardiotoxic effects of adriamycin were studied in mammalian myocardial cells in culture as a model system.
Entity: 7423039	4	15	cardiotoxic	Disease	D066126
Entity: 7423039	27	37	adriamycin	Chemical	D004317
Relation: 7423039	CID	27	37	D004317	4	15	D066126	true

Sentence: Age-dependent sensitivity of the rat to neurotoxic effects of streptomycin.
Entity: 7444978	40	50	neurotoxic	Disease	D020258
Entity: 7444978	62	74	streptomycin	Chemical	D013307
Relation: 7444978	CID	62	74	D013307	40	50	D020258	false

Sentence: Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis.
Entity: 7834920	22	40	glomerulonephritis	Disease	D005921
Entity: 7834920	70	78	rifampin	Chemical	D012293
Entity: 7834920	91	113	pulmonary tuberculosis	Disease	D014397
Relation: 7834920	CID	70	78	D012293	22	40	D005921	true
Relation: 7834920	CID	70	78	D012293	91	113	D014397	false

Sentence: This case study reveals an unusual finding of rapidly proliferative crescentic glomerulonephritis in a patient treated with rifampin who had no other identifiable causes for developing this disease.
Entity: 7834920	79	97	glomerulonephritis	Disease	D005921
Entity: 7834920	124	132	rifampin	Chemical	D012293
Relation: 7834920	CID	124	132	D012293	79	97	D005921	true

Sentence: This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.
Entity: 7834920	45	53	rifampin	Chemical	D012293
Entity: 7834920	58	67	isoniazid	Chemical	D007538
Entity: 7834920	72	94	pulmonary tuberculosis	Disease	D014397
Entity: 7834920	148	161	renal failure	Disease	D051437
Relation: 7834920	CID	45	53	D012293	72	94	D014397	false
Relation: 7834920	CID	45	53	D012293	148	161	D051437	true
Relation: 7834920	CID	58	67	D007538	72	94	D014397	false
Relation: 7834920	CID	58	67	D007538	148	161	D051437	false

Sentence: Time course of lipid peroxidation in puromycin aminonucleoside induced nephropathy.
Entity: 7881871	37	62	puromycin aminonucleoside	Chemical	D011692
Entity: 7881871	71	82	nephropathy	Disease	D007674
Relation: 7881871	CID	37	62	D011692	71	82	D007674	true

Sentence: Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN) induced nephropathy, with antioxidants significantly reducing the proteinuria.
Entity: 7881871	9	15	oxygen	Chemical	D010100
Entity: 7881871	74	99	puromycin aminonucleoside	Chemical	D011692
Entity: 7881871	101	104	PAN	Chemical	D011692
Entity: 7881871	114	125	nephropathy	Disease	D007674
Entity: 7881871	172	183	proteinuria	Disease	D011507
Relation: 7881871	CID	9	15	D010100	114	125	D007674	false
Relation: 7881871	CID	9	15	D010100	172	183	D011507	false
Relation: 7881871	CID	74	99	D011692	114	125	D007674	true
Relation: 7881871	CID	74	99	D011692	172	183	D011507	true
Relation: 7881871	CID	101	104	D011692	114	125	D007674	true
Relation: 7881871	CID	101	104	D011692	172	183	D011507	true

Sentence: Clomipramine induced sleep disturbance does not impair its prolactin-releasing action.
Entity: 7930386	0	12	Clomipramine	Chemical	D002997
Entity: 7930386	21	38	sleep disturbance	Disease	D012893
Relation: 7930386	CID	0	12	D002997	21	38	D012893	true

Sentence: The present study was undertaken to examine the role of sleep disturbance, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect.
Entity: 7930386	56	73	sleep disturbance	Disease	D012893
Entity: 7930386	86	98	clomipramine	Chemical	D002997
Relation: 7930386	CID	86	98	D002997	56	73	D012893	true

Sentence: Angioedema following the intravenous administration of metoprolol.
Entity: 7988234	0	10	Angioedema	Disease	D000799
Entity: 7988234	55	65	metoprolol	Chemical	D008790
Relation: 7988234	CID	55	65	D008790	0	10	D000799	true

Sentence: A history of angioedema secondary to lisinopril therapy was elicited.
Entity: 7988234	13	23	angioedema	Disease	D000799
Entity: 7988234	37	47	lisinopril	Chemical	D017706
Relation: 7988234	CID	37	47	D017706	13	23	D000799	true

Sentence: During the first day of hospitalization (while intubated), intravenous metoprolol was given, resulting in severe angioedema.
Entity: 7988234	71	81	metoprolol	Chemical	D008790
Entity: 7988234	113	123	angioedema	Disease	D000799
Relation: 7988234	CID	71	81	D008790	113	123	D000799	true

Sentence: However, coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits.
Entity: 8073369	9	16	coniine	Chemical	C007112
Entity: 8073369	39	53	arthrogryposis	Disease	D001176
Relation: 8073369	CID	9	16	C007112	39	53	D001176	true

Sentence: The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes.
Entity: 8073369	4	16	deformations	Disease	D009140
Entity: 8073369	32	39	coniine	Chemical	C007112
Entity: 8073369	44	52	nicotine	Chemical	D009538
Entity: 8073369	66	116	excessive flexion or extension of one or more toes	Disease	D009140
Relation: 8073369	CID	32	39	C007112	4	16	D009140	false
Relation: 8073369	CID	32	39	C007112	66	116	D009140	false
Relation: 8073369	CID	44	52	D009538	4	16	D009140	false
Relation: 8073369	CID	44	52	D009538	66	116	D009140	false

Sentence: No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group; however, extensive cranial hemorrhage occurred in all nicotine sulfate-treated chicks.
Entity: 8073369	146	164	cranial hemorrhage	Disease	D002543
Entity: 8073369	181	189	nicotine	Chemical	D009538
Relation: 8073369	CID	181	189	D009538	146	164	D002543	true

Sentence: Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension.
Entity: 8302922	27	43	prostaglandin E1	Chemical	D000527
Entity: 8302922	47	59	trimethaphan	Chemical	D014294
Entity: 8302922	68	79	hypotension	Disease	D007022
Relation: 8302922	CID	27	43	D000527	68	79	D007022	true
Relation: 8302922	CID	47	59	D014294	68	79	D007022	true

Sentence: To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.
Entity: 8302922	26	42	prostaglandin E1	Chemical	D000527
Entity: 8302922	44	48	PGE1	Chemical	D000527
Entity: 8302922	53	65	trimethaphan	Chemical	D014294
Entity: 8302922	67	70	TMP	Chemical	D014294
Entity: 8302922	80	91	hypotension	Disease	D007022
Entity: 8302922	261	271	isoflurane	Chemical	D007530
Relation: 8302922	CID	26	42	D000527	80	91	D007022	true
Relation: 8302922	CID	44	48	D000527	80	91	D007022	true
Relation: 8302922	CID	53	65	D014294	80	91	D007022	true
Relation: 8302922	CID	67	70	D014294	80	91	D007022	true
Relation: 8302922	CID	261	271	D007530	80	91	D007022	false

Sentence: After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.
Entity: 8302922	15	19	PGE1	Chemical	D000527
Entity: 8302922	23	26	TMP	Chemical	D014294
Entity: 8302922	151	162	hypotension	Disease	D007022
Entity: 8302922	170	174	PGE1	Chemical	D000527
Relation: 8302922	CID	15	19	D000527	151	162	D007022	true
Relation: 8302922	CID	23	26	D014294	151	162	D007022	true
Relation: 8302922	CID	170	174	D000527	151	162	D007022	true

Sentence: Focal injury in the cortex was produced by infusion of lactate at acid pH or by stab caused by needle insertion.
Entity: 8410052	6	26	injury in the cortex	Disease	D001480
Entity: 8410052	55	62	lactate	Chemical	D019344
Relation: 8410052	CID	55	62	D019344	6	26	D001480	false

Sentence: Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine induced status epilepticus.
Entity: 8410052	0	44	Infarcts in substantia nigra pars reticulata	Disease	D002544
Entity: 8410052	70	81	pilocarpine	Chemical	D010862
Entity: 8410052	90	108	status epilepticus	Disease	D013226
Relation: 8410052	CID	70	81	D010862	0	44	D002544	true
Relation: 8410052	CID	70	81	D010862	90	108	D013226	true

Sentence: Increase of Parkinson disability after fluoxetine medication.
Entity: 8423889	12	32	Parkinson disability	Disease	D009069
Entity: 8423889	39	49	fluoxetine	Chemical	D005473
Relation: 8423889	CID	39	49	D005473	12	32	D009069	true

Sentence: We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.
Entity: 8423889	34	50	motor disability	Disease	D009069
Entity: 8423889	73	103	idiopathic Parkinson's disease	Disease	D010300
Entity: 8423889	126	140	antidepressant	Chemical	D000928
Entity: 8423889	141	151	fluoxetine	Chemical	D005473
Relation: 8423889	CID	126	140	D000928	34	50	D009069	false
Relation: 8423889	CID	126	140	D000928	73	103	D010300	false
Relation: 8423889	CID	141	151	D005473	34	50	D009069	true
Relation: 8423889	CID	141	151	D005473	73	103	D010300	false

Sentence: Acetaminophen induced hypotension.
Entity: 8682684	0	13	Acetaminophen	Chemical	D000082
Entity: 8682684	22	33	hypotension	Disease	D007022
Relation: 8682684	CID	0	13	D000082	22	33	D007022	true

Sentence: The potential for acetaminophen to produce cardiovascular toxicities is very low.
Entity: 8682684	18	31	acetaminophen	Chemical	D000082
Entity: 8682684	43	68	cardiovascular toxicities	Disease	D002318
Relation: 8682684	CID	18	31	D000082	43	68	D002318	false

Sentence: However, acetaminophen has been demonstrated to produce symptoms of anaphylaxis, including hypotension, in sensitive individuals.
Entity: 8682684	9	22	acetaminophen	Chemical	D000082
Entity: 8682684	68	79	anaphylaxis	Disease	D000707
Entity: 8682684	91	102	hypotension	Disease	D007022
Relation: 8682684	CID	9	22	D000082	68	79	D000707	false
Relation: 8682684	CID	9	22	D000082	91	102	D007022	true

Sentence: This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen.
Entity: 8682684	27	41	critically ill	Disease	D016638
Entity: 8682684	81	92	hypotension	Disease	D007022
Entity: 8682684	140	153	acetaminophen	Chemical	D000082
Relation: 8682684	CID	140	153	D000082	27	41	D016638	false
Relation: 8682684	CID	140	153	D000082	81	92	D007022	true

Sentence: Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.
Entity: 9625142	6	15	hepatitis	Disease	D056486
Entity: 9625142	17	44	autoimmune hemolytic anemia	Disease	D000744
Entity: 9625142	50	72	erythroblastocytopenia	Disease	-1
Entity: 9625142	84	95	ceftriaxone	Chemical	D002443
Relation: 9625142	CID	84	95	D002443	6	15	D056486	true
Relation: 9625142	CID	84	95	D002443	17	44	D000744	true
Relation: 9625142	CID	84	95	D002443	50	72	-1	false

Sentence: An 80-yr-old man developed acute hepatitis shortly after ingesting oral ceftriaxone.
Entity: 9625142	33	42	hepatitis	Disease	D056486
Entity: 9625142	72	83	ceftriaxone	Chemical	D002443
Relation: 9625142	CID	72	83	D002443	33	42	D056486	true

Sentence: Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia.
Entity: 9625142	80	91	beta lactam	Chemical	D047090
Entity: 9625142	142	151	bilirubin	Chemical	D001663
Entity: 9625142	208	235	autoimmune hemolytic anemia	Disease	D000744
Entity: 9625142	240	262	erythroblastocytopenia	Disease	-1
Relation: 9625142	CID	80	91	D047090	208	235	D000744	false
Relation: 9625142	CID	80	91	D047090	240	262	-1	false
Relation: 9625142	CID	142	151	D001663	208	235	D000744	false
Relation: 9625142	CID	142	151	D001663	240	262	-1	false

Sentence: Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.
Entity: 10193204	11	22	tetrandrine	Chemical	C009438
Entity: 10193204	27	40	fangchinoline	Chemical	C060802
Entity: 10193204	57	67	thrombosis	Disease	D013927
Entity: 10193204	86	106	platelet aggregation	Disease	D001791
Relation: 10193204	CID	11	22	C009438	57	67	D013927	false
Relation: 10193204	CID	11	22	C009438	86	106	D001791	false
Relation: 10193204	CID	27	40	C060802	57	67	D013927	false
Relation: 10193204	CID	27	40	C060802	86	106	D001791	false

Sentence: The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.
Entity: 10193204	63	66	TET	Chemical	C009438
Entity: 10193204	71	74	FAN	Chemical	C060802
Entity: 10193204	95	105	thrombosis	Disease	D013927
Entity: 10193204	131	142	epinephrine	Chemical	D004837
Entity: 10193204	144	146	EP	Chemical	D004837
Entity: 10193204	161	181	platelet aggregation	Disease	D001791
Entity: 10193204	186	203	blood coagulation	Disease	D001778
Relation: 10193204	CID	63	66	C009438	95	105	D013927	false
Relation: 10193204	CID	63	66	C009438	161	181	D001791	false
Relation: 10193204	CID	63	66	C009438	186	203	D001778	false
Relation: 10193204	CID	71	74	C060802	95	105	D013927	false
Relation: 10193204	CID	71	74	C060802	161	181	D001791	false
Relation: 10193204	CID	71	74	C060802	186	203	D001778	false
Relation: 10193204	CID	131	142	D004837	95	105	D013927	true
Relation: 10193204	CID	131	142	D004837	161	181	D001791	false
Relation: 10193204	CID	131	142	D004837	186	203	D001778	false
Relation: 10193204	CID	144	146	D004837	95	105	D013927	true
Relation: 10193204	CID	144	146	D004837	161	181	D001791	false
Relation: 10193204	CID	144	146	D004837	186	203	D001778	false

Sentence: In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.
Entity: 10193204	61	64	TET	Chemical	C009438
Entity: 10193204	69	72	FAN	Chemical	C060802
Entity: 10193204	106	116	thrombosis	Disease	D013927
Entity: 10193204	153	173	acetylsalicylic acid	Chemical	D001241
Entity: 10193204	175	178	ASA	Chemical	D001241
Relation: 10193204	CID	61	64	C009438	106	116	D013927	false
Relation: 10193204	CID	69	72	C060802	106	116	D013927	false
Relation: 10193204	CID	153	173	D001241	106	116	D013927	false
Relation: 10193204	CID	175	178	D001241	106	116	D013927	false

Sentence: In the vitro human platelet aggregations induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.
Entity: 10193204	19	40	platelet aggregations	Disease	D001791
Entity: 10193204	80	83	TET	Chemical	C009438
Entity: 10193204	88	91	FAN	Chemical	C060802
Relation: 10193204	CID	80	83	C009438	19	40	D001791	false
Relation: 10193204	CID	88	91	C060802	19	40	D001791	false

Sentence: Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.
Entity: 10526274	0	11	Gemcitabine	Chemical	C056507
Entity: 10526274	17	28	vinorelbine	Chemical	C030852
Entity: 10526274	32	60	nonsmall cell lung carcinoma	Disease	D002289
Entity: 10526274	123	132	cisplatin	Chemical	D002945
Relation: 10526274	CID	0	11	C056507	32	60	D002289	false
Relation: 10526274	CID	17	28	C030852	32	60	D002289	false
Relation: 10526274	CID	123	132	D002945	32	60	D002289	false

Sentence: Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.
Entity: 10526274	55	66	vinorelbine	Chemical	C030852
Entity: 10526274	68	71	VNB	Chemical	C030852
Entity: 10526274	76	87	gemcitabine	Chemical	C056507
Entity: 10526274	89	92	GEM	Chemical	C056507
Entity: 10526274	168	176	toxicity	Disease	D064420
Relation: 10526274	CID	55	66	C030852	168	176	D064420	false
Relation: 10526274	CID	68	71	C030852	168	176	D064420	false
Relation: 10526274	CID	76	87	C056507	168	176	D064420	false
Relation: 10526274	CID	89	92	C056507	168	176	D064420	false

Sentence: In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.
Entity: 10526274	38	46	toxicity	Disease	D064420
Entity: 10526274	69	72	GEM	Chemical	C056507
Entity: 10526274	77	80	VNB	Chemical	C030852
Entity: 10526274	115	120	NSCLC	Disease	D002289
Entity: 10526274	170	179	cisplatin	Chemical	D002945
Relation: 10526274	CID	69	72	C056507	38	46	D064420	false
Relation: 10526274	CID	69	72	C056507	115	120	D002289	false
Relation: 10526274	CID	77	80	C030852	38	46	D064420	false
Relation: 10526274	CID	77	80	C030852	115	120	D002289	false
Relation: 10526274	CID	170	179	D002945	38	46	D064420	false
Relation: 10526274	CID	170	179	D002945	115	120	D002289	false

Sentence: METHODS: Forty-nine patients with advanced NSCLC were included, 38 of whom were age >/= 70 years and 11 were age < 70 years but who had some contraindication to receiving cisplatin.
Entity: 10526274	43	48	NSCLC	Disease	D002289
Entity: 10526274	171	180	cisplatin	Chemical	D002945
Relation: 10526274	CID	171	180	D002945	43	48	D002289	false

Sentence: Warfarin induced artery calcification is accelerated by growth and vitamin D.
Entity: 10669626	0	8	Warfarin	Chemical	D014859
Entity: 10669626	17	37	artery calcification	Disease	D061205
Entity: 10669626	67	76	vitamin D	Chemical	D014807
Relation: 10669626	CID	0	8	D014859	17	37	D061205	true
Relation: 10669626	CID	67	76	D014807	17	37	D061205	false

Sentence: The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.
Entity: 10669626	48	57	vitamin D	Chemical	D014807
Entity: 10669626	90	110	artery calcification	Disease	D061205
Entity: 10669626	145	153	Warfarin	Chemical	D014859
Entity: 10669626	210	223	calcification	Disease	D002114
Relation: 10669626	CID	48	57	D014807	90	110	D061205	false
Relation: 10669626	CID	48	57	D014807	210	223	D002114	false
Relation: 10669626	CID	145	153	D014859	90	110	D061205	true
Relation: 10669626	CID	145	153	D014859	210	223	D002114	false

Sentence: The first series of experiments examined the influence of age and growth status on artery calcification in Warfarin-treated rats.
Entity: 10669626	83	103	artery calcification	Disease	D061205
Entity: 10669626	107	115	Warfarin	Chemical	D014859
Relation: 10669626	CID	107	115	D014859	83	103	D061205	true

Sentence: Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20-day-old rats and less extensive focal calcification in 42-day-old rats.
Entity: 10669626	27	35	Warfarin	Chemical	D014859
Entity: 10669626	57	84	calcification of the artery	Disease	D061205
Entity: 10669626	135	148	calcification	Disease	D002114
Relation: 10669626	CID	27	35	D014859	57	84	D061205	true
Relation: 10669626	CID	27	35	D014859	135	148	D002114	false

Sentence: In contrast, no artery calcification could be detected in 10-month-old adult rats even after 4 weeks of Warfarin treatment.
Entity: 10669626	16	36	artery calcification	Disease	D061205
Entity: 10669626	104	112	Warfarin	Chemical	D014859
Relation: 10669626	CID	104	112	D014859	16	36	D061205	true

Sentence: To directly examine the importance of growth to Warfarin induced artery calcification in animals of the same age, 20-day-old rats were fed for 2 weeks either an ad libitum diet or a 6-g/d restricted diet that maintains weight but prevents growth.
Entity: 10669626	48	56	Warfarin	Chemical	D014859
Entity: 10669626	65	85	artery calcification	Disease	D061205
Relation: 10669626	CID	48	56	D014859	65	85	D061205	true

Sentence: Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.
Entity: 10669626	49	57	Warfarin	Chemical	D014859
Entity: 10669626	81	108	calcification of the artery	Disease	D061205
Entity: 10669626	160	180	artery calcification	Disease	D061205
Relation: 10669626	CID	49	57	D014859	81	108	D061205	true
Relation: 10669626	CID	49	57	D014859	160	180	D061205	true

Sentence: Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.
Entity: 10669626	53	73	artery calcification	Disease	D061205
Entity: 10669626	183	192	phosphate	Chemical	D010710
Entity: 10669626	215	235	artery calcification	Disease	D061205
Entity: 10669626	269	278	phosphate	Chemical	D010710
Entity: 10669626	366	374	Warfarin	Chemical	D014859
Entity: 10669626	383	403	artery calcification	Disease	D061205
Relation: 10669626	CID	183	192	D010710	53	73	D061205	false
Relation: 10669626	CID	183	192	D010710	215	235	D061205	false
Relation: 10669626	CID	183	192	D010710	383	403	D061205	false
Relation: 10669626	CID	269	278	D010710	53	73	D061205	false
Relation: 10669626	CID	269	278	D010710	215	235	D061205	false
Relation: 10669626	CID	269	278	D010710	383	403	D061205	false
Relation: 10669626	CID	366	374	D014859	53	73	D061205	true
Relation: 10669626	CID	366	374	D014859	215	235	D061205	true
Relation: 10669626	CID	366	374	D014859	383	403	D061205	true

Sentence: This observation suggests that increased susceptibility to Warfarin induced artery calcification could be related to higher serum phosphate levels.
Entity: 10669626	59	67	Warfarin	Chemical	D014859
Entity: 10669626	76	96	artery calcification	Disease	D061205
Entity: 10669626	130	139	phosphate	Chemical	D010710
Relation: 10669626	CID	59	67	D014859	76	96	D061205	true
Relation: 10669626	CID	130	139	D010710	76	96	D061205	false

Sentence: The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification.
Entity: 10669626	68	77	vitamin D	Chemical	D014807
Entity: 10669626	82	90	Warfarin	Chemical	D014859
Entity: 10669626	94	114	artery calcification	Disease	D061205
Relation: 10669626	CID	68	77	D014807	94	114	D061205	false
Relation: 10669626	CID	82	90	D014859	94	114	D061205	true

Sentence: High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days.
Entity: 10669626	14	23	vitamin D	Chemical	D014807
Entity: 10669626	43	70	calcification of the artery	Disease	D061205
Relation: 10669626	CID	14	23	D014807	43	70	D061205	false

Sentence: High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.
Entity: 10669626	18	27	vitamin K	Chemical	D014812
Entity: 10669626	39	47	Warfarin	Chemical	D014859
Entity: 10669626	72	99	calcification of the artery	Disease	D061205
Relation: 10669626	CID	18	27	D014812	72	99	D061205	false
Relation: 10669626	CID	39	47	D014859	72	99	D061205	true

Sentence: In the current study, we investigated the synergy between these 2 treatments and found that concurrent Warfarin administration dramatically increased the extent of calcification in the media of vitamin D-treated rats at 3 and 4 days.
Entity: 10669626	103	111	Warfarin	Chemical	D014859
Entity: 10669626	164	177	calcification	Disease	D002114
Entity: 10669626	194	203	vitamin D	Chemical	D014807
Relation: 10669626	CID	103	111	D014859	164	177	D002114	false
Relation: 10669626	CID	194	203	D014807	164	177	D002114	false

Sentence: There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.
Entity: 10669626	49	58	vitamin D	Chemical	D014807
Entity: 10669626	67	87	artery calcification	Disease	D061205
Entity: 10669626	106	115	vitamin D	Chemical	D014807
Entity: 10669626	147	154	calcium	Chemical	D002118
Entity: 10669626	176	185	vitamin D	Chemical	D014807
Entity: 10669626	197	217	artery calcification	Disease	D061205
Entity: 10669626	246	253	calcium	Chemical	D002118
Relation: 10669626	CID	49	58	D014807	67	87	D061205	false
Relation: 10669626	CID	49	58	D014807	197	217	D061205	false
Relation: 10669626	CID	106	115	D014807	67	87	D061205	false
Relation: 10669626	CID	106	115	D014807	197	217	D061205	false
Relation: 10669626	CID	147	154	D002118	67	87	D061205	false
Relation: 10669626	CID	147	154	D002118	197	217	D061205	false
Relation: 10669626	CID	176	185	D014807	67	87	D061205	false
Relation: 10669626	CID	176	185	D014807	197	217	D061205	false
Relation: 10669626	CID	246	253	D002118	67	87	D061205	false
Relation: 10669626	CID	246	253	D002118	197	217	D061205	false

Sentence: Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.
Entity: 10669626	8	16	Warfarin	Chemical	D014859
Entity: 10669626	67	74	calcium	Chemical	D002118
Entity: 10669626	87	96	vitamin D	Chemical	D014807
Entity: 10669626	118	126	Warfarin	Chemical	D014859
Entity: 10669626	131	140	vitamin D	Chemical	D014807
Entity: 10669626	191	199	Warfarin	Chemical	D014859
Entity: 10669626	249	262	calcification	Disease	D002114
Relation: 10669626	CID	8	16	D014859	249	262	D002114	false
Relation: 10669626	CID	67	74	D002118	249	262	D002114	false
Relation: 10669626	CID	87	96	D014807	249	262	D002114	false
Relation: 10669626	CID	118	126	D014859	249	262	D002114	false
Relation: 10669626	CID	131	140	D014807	249	262	D002114	false
Relation: 10669626	CID	191	199	D014859	249	262	D002114	false

Sentence: High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.
Entity: 10669626	56	76	artery calcification	Disease	D061205
Entity: 10669626	98	107	vitamin D	Chemical	D014807
Entity: 10669626	113	121	Warfarin	Chemical	D014859
Entity: 10669626	201	219	gamma-carboxylated	Chemical	D015055
Relation: 10669626	CID	98	107	D014807	56	76	D061205	false
Relation: 10669626	CID	113	121	D014859	56	76	D061205	true
Relation: 10669626	CID	201	219	D015055	56	76	D061205	false

Sentence: Antidepressant induced mania in bipolar patients: identification of risk factors.
Entity: 11379838	0	14	Antidepressant	Chemical	D000928
Entity: 11379838	23	28	mania	Disease	D001714
Entity: 11379838	32	39	bipolar	Disease	D001714
Relation: 11379838	CID	0	14	D000928	23	28	D001714	true
Relation: 11379838	CID	0	14	D000928	32	39	D001714	true

Sentence: BACKGROUND: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.
Entity: 11379838	58	63	mania	Disease	D001714
Entity: 11379838	80	95	antidepressants	Chemical	D000928
Entity: 11379838	178	196	bipolar depression	Disease	D001714
Relation: 11379838	CID	80	95	D000928	58	63	D001714	true
Relation: 11379838	CID	80	95	D000928	178	196	D001714	true

Sentence: Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.
Entity: 11379838	27	32	manic	Disease	D001714
Entity: 11379838	36	45	hypomanic	Disease	D001714
Entity: 11379838	142	158	DSM-IV bipolar I	Disease	D001714
Entity: 11379838	163	173	bipolar II	Disease	D001714
Entity: 11379838	195	200	manic	Disease	D001714
Entity: 11379838	219	233	antidepressant	Chemical	D000928
Entity: 11379838	278	292	antidepressant	Chemical	D000928
Entity: 11379838	333	362	serotonin reuptake inhibitors	Chemical	D017367
Entity: 11379838	364	369	SSRIs	Chemical	D017367
Entity: 11379838	407	414	lithium	Chemical	D008094
Relation: 11379838	CID	219	233	D000928	27	32	D001714	true
Relation: 11379838	CID	219	233	D000928	36	45	D001714	true
Relation: 11379838	CID	219	233	D000928	142	158	D001714	true
Relation: 11379838	CID	219	233	D000928	163	173	D001714	true
Relation: 11379838	CID	219	233	D000928	195	200	D001714	true
Relation: 11379838	CID	278	292	D000928	27	32	D001714	true
Relation: 11379838	CID	278	292	D000928	36	45	D001714	true
Relation: 11379838	CID	278	292	D000928	142	158	D001714	true
Relation: 11379838	CID	278	292	D000928	163	173	D001714	true
Relation: 11379838	CID	278	292	D000928	195	200	D001714	true
Relation: 11379838	CID	333	362	D017367	27	32	D001714	true
Relation: 11379838	CID	333	362	D017367	36	45	D001714	true
Relation: 11379838	CID	333	362	D017367	142	158	D001714	true
Relation: 11379838	CID	333	362	D017367	163	173	D001714	true
Relation: 11379838	CID	333	362	D017367	195	200	D001714	true
Relation: 11379838	CID	364	369	D017367	27	32	D001714	true
Relation: 11379838	CID	364	369	D017367	36	45	D001714	true
Relation: 11379838	CID	364	369	D017367	142	158	D001714	true
Relation: 11379838	CID	364	369	D017367	163	173	D001714	true
Relation: 11379838	CID	364	369	D017367	195	200	D001714	true
Relation: 11379838	CID	407	414	D008094	27	32	D001714	false
Relation: 11379838	CID	407	414	D008094	36	45	D001714	false
Relation: 11379838	CID	407	414	D008094	142	158	D001714	false
Relation: 11379838	CID	407	414	D008094	163	173	D001714	false
Relation: 11379838	CID	407	414	D008094	195	200	D001714	false

Sentence: RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.
Entity: 11379838	21	30	hypomania	Disease	D001714
Entity: 11379838	34	39	mania	Disease	D001714
Entity: 11379838	134	139	SSRIs	Chemical	D017367
Entity: 11379838	173	178	manic	Disease	D001714
Entity: 11379838	217	226	hypomanic	Disease	D001714
Relation: 11379838	CID	134	139	D017367	21	30	D001714	true
Relation: 11379838	CID	134	139	D017367	34	39	D001714	true
Relation: 11379838	CID	134	139	D017367	173	178	D001714	true
Relation: 11379838	CID	134	139	D017367	217	226	D001714	true

Sentence: Caffeine induced cardiac arrhythmia: an unrecognised danger of healthfood products.
Entity: 11419773	0	8	Caffeine	Chemical	D002110
Entity: 11419773	17	35	cardiac arrhythmia	Disease	D001145
Relation: 11419773	CID	0	8	D002110	17	35	D001145	false

Sentence: Bladder retention of urine as a result of continuous intravenous infusion of fentanyl: 2 case reports.
Entity: 11581460	8	26	retention of urine	Disease	D016055
Entity: 11581460	77	85	fentanyl	Chemical	D005283
Relation: 11581460	CID	77	85	D005283	8	26	D016055	true

Sentence: Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.
Entity: 11581460	33	41	fentanyl	Chemical	D005283
Entity: 11581460	65	84	chest wall rigidity	Disease	D009127
Entity: 11581460	86	97	hypotension	Disease	D007022
Entity: 11581460	99	121	respiratory depression	Disease	D012131
Entity: 11581460	127	138	bradycardia	Disease	D001919
Relation: 11581460	CID	33	41	D005283	65	84	D009127	false
Relation: 11581460	CID	33	41	D005283	86	97	D007022	true
Relation: 11581460	CID	33	41	D005283	99	121	D012131	true
Relation: 11581460	CID	33	41	D005283	127	138	D001919	true

Sentence: Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.
Entity: 11706060	39	53	cardiomyopathy	Disease	D009202
Entity: 11706060	74	81	lactate	Chemical	D019344
Entity: 11706060	96	100	AIDS	Disease	D000163
Relation: 11706060	CID	74	81	D019344	39	53	D009202	false
Relation: 11706060	CID	74	81	D019344	96	100	D000163	false

Sentence: Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.
Entity: 11706060	62	76	cardiomyopathy	Disease	D009202
Entity: 11706060	78	80	CM	Disease	D009202
Entity: 11706060	105	112	lactate	Chemical	D019344
Entity: 11706060	114	116	LA	Chemical	D019344
Entity: 11706060	121	125	AIDS	Disease	D000163
Entity: 11706060	148	173	mitochondrial dysfunction	Disease	D028361
Relation: 11706060	CID	105	112	D019344	62	76	D009202	false
Relation: 11706060	CID	105	112	D019344	78	80	D009202	false
Relation: 11706060	CID	105	112	D019344	121	125	D000163	false
Relation: 11706060	CID	105	112	D019344	148	173	D028361	false
Relation: 11706060	CID	114	116	D019344	62	76	D009202	false
Relation: 11706060	CID	114	116	D019344	78	80	D009202	false
Relation: 11706060	CID	114	116	D019344	121	125	D000163	false
Relation: 11706060	CID	114	116	D019344	148	173	D028361	false

Sentence: To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.
Entity: 11706060	87	91	AIDS	Disease	D000163
Entity: 11706060	197	207	zidovudine	Chemical	D015215
Entity: 11706060	209	219	lamivudine	Chemical	D019259
Entity: 11706060	225	234	indinavir	Chemical	D019469
Relation: 11706060	CID	197	207	D015215	87	91	D000163	false
Relation: 11706060	CID	209	219	D019259	87	91	D000163	false
Relation: 11706060	CID	225	234	D019469	87	91	D000163	false

Sentence: At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.
Entity: 11706060	118	120	CM	Disease	D009202
Entity: 11706060	197	204	calcium	Chemical	D002118
Entity: 11706060	251	253	LA	Chemical	D019344
Relation: 11706060	CID	197	204	D002118	118	120	D009202	false
Relation: 11706060	CID	251	253	D019344	118	120	D009202	false

Sentence: Oral contraceptives and the risk of myocardial infarction.
Entity: 11752354	0	19	Oral contraceptives	Chemical	D003276
Entity: 11752354	36	57	myocardial infarction	Disease	D009203
Relation: 11752354	CID	0	19	D003276	36	57	D009203	true

Sentence: BACKGROUND: An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some, but not all, studies.
Entity: 11752354	46	65	oral contraceptives	Chemical	D003276
Entity: 11752354	82	103	myocardial infarction	Disease	D009203
Relation: 11752354	CID	46	65	D003276	82	103	D009203	true

Sentence: We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.
Entity: 11752354	59	70	progestagen	Chemical	D011372
Entity: 11752354	107	118	desogestrel	Chemical	D017135
Entity: 11752354	122	131	gestodene	Chemical	C033273
Entity: 11752354	162	176	levonorgestrel	Chemical	D016912
Entity: 11752354	178	197	oral contraceptives	Chemical	D003276
Entity: 11752354	211	219	estrogen	Chemical	D004967
Entity: 11752354	424	445	myocardial infarction	Disease	D009203
Entity: 11752354	508	529	myocardial infarction	Disease	D009203
Relation: 11752354	CID	59	70	D011372	424	445	D009203	false
Relation: 11752354	CID	59	70	D011372	508	529	D009203	false
Relation: 11752354	CID	107	118	D017135	424	445	D009203	false
Relation: 11752354	CID	107	118	D017135	508	529	D009203	false
Relation: 11752354	CID	122	131	C033273	424	445	D009203	false
Relation: 11752354	CID	122	131	C033273	508	529	D009203	false
Relation: 11752354	CID	162	176	D016912	424	445	D009203	false
Relation: 11752354	CID	162	176	D016912	508	529	D009203	false
Relation: 11752354	CID	178	197	D003276	424	445	D009203	true
Relation: 11752354	CID	178	197	D003276	508	529	D009203	true
Relation: 11752354	CID	211	219	D004967	424	445	D009203	false
Relation: 11752354	CID	211	219	D004967	508	529	D009203	false

Sentence: An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).
Entity: 11752354	156	177	myocardial infarction	Disease	D009203
Entity: 11752354	220	238	oral contraceptive	Chemical	D003276
Relation: 11752354	CID	220	238	D003276	156	177	D009203	true

Sentence: Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.
Entity: 11752354	21	40	oral contraceptives	Chemical	D003276
Entity: 11752354	257	278	myocardial infarction	Disease	D009203
Entity: 11752354	332	351	oral contraceptives	Chemical	D003276
Relation: 11752354	CID	21	40	D003276	257	278	D009203	true
Relation: 11752354	CID	332	351	D003276	257	278	D009203	true

Sentence: Effects of 5-HT1B receptor ligands microinjected into the accumbal shell or core on the cocaine induced locomotor hyperactivity in rats.
Entity: 12369736	88	95	cocaine	Chemical	D003042
Entity: 12369736	104	127	locomotor hyperactivity	Disease	D009069
Relation: 12369736	CID	88	95	D003042	104	127	D009069	true

Sentence: The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor hyperactivity induced by cocaine in rats.
Entity: 12369736	171	194	locomotor hyperactivity	Disease	D009069
Entity: 12369736	206	213	cocaine	Chemical	D003042
Relation: 12369736	CID	206	213	D003042	171	194	D009069	true

Sentence: GR 55562 (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant induced locomotor hyperactivity.
Entity: 12369736	0	8	GR 55562	Chemical	C103477
Entity: 12369736	75	82	cocaine	Chemical	D003042
Entity: 12369736	140	163	locomotor hyperactivity	Disease	D009069
Relation: 12369736	CID	0	8	C103477	140	163	D009069	false
Relation: 12369736	CID	75	82	D003042	140	163	D009069	true

Sentence: Ticlopidine induced cholestatic hepatitis.
Entity: 12639165	0	11	Ticlopidine	Chemical	D013988
Entity: 12639165	20	31	cholestatic	Disease	D002779
Entity: 12639165	32	41	hepatitis	Disease	D056486
Relation: 12639165	CID	0	11	D013988	20	31	D002779	true
Relation: 12639165	CID	0	11	D013988	32	41	D056486	true

Sentence: OBJECTIVE: To report 2 cases of ticlopidine induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases.
Entity: 12639165	32	43	ticlopidine	Chemical	D013988
Entity: 12639165	52	63	cholestatic	Disease	D002779
Entity: 12639165	64	73	hepatitis	Disease	D056486
Relation: 12639165	CID	32	43	D013988	52	63	D002779	true
Relation: 12639165	CID	32	43	D013988	64	73	D056486	true

Sentence: CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty, with complete remission during the follow-up period.
Entity: 12639165	49	60	cholestatic	Disease	D002779
Entity: 12639165	61	70	hepatitis	Disease	D056486
Entity: 12639165	87	98	ticlopidine	Chemical	D013988
Relation: 12639165	CID	87	98	D013988	49	60	D002779	true
Relation: 12639165	CID	87	98	D013988	61	70	D056486	true

Sentence: DISCUSSION: Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine; several cases have been reported but few in the English literature.
Entity: 12639165	12	23	Cholestatic	Disease	D002779
Entity: 12639165	24	33	hepatitis	Disease	D056486
Entity: 12639165	83	94	ticlopidine	Chemical	D013988
Relation: 12639165	CID	83	94	D013988	12	23	D002779	true
Relation: 12639165	CID	83	94	D013988	24	33	D056486	true

Sentence: Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug.
Entity: 12639165	23	31	jaundice	Disease	D007565
Entity: 12639165	57	68	ticlopidine	Chemical	D013988
Entity: 12639165	127	138	cholestatic	Disease	D002779
Entity: 12639165	139	148	hepatitis	Disease	D056486
Relation: 12639165	CID	57	68	D013988	23	31	D007565	true
Relation: 12639165	CID	57	68	D013988	127	138	D002779	true
Relation: 12639165	CID	57	68	D013988	139	148	D056486	true

Sentence: The mechanisms of this ticlopidine induced cholestasis are unclear.
Entity: 12639165	23	34	ticlopidine	Chemical	D013988
Entity: 12639165	43	54	cholestasis	Disease	D002779
Relation: 12639165	CID	23	34	D013988	43	54	D002779	true

Sentence: CONCLUSIONS: Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated.
Entity: 12639165	13	24	Cholestatic	Disease	D002779
Entity: 12639165	25	34	hepatitis	Disease	D056486
Entity: 12639165	63	74	ticlopidine	Chemical	D013988
Relation: 12639165	CID	63	74	D013988	13	24	D002779	true
Relation: 12639165	CID	63	74	D013988	25	34	D056486	true

Sentence: Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside induced nephrotic syndrome.
Entity: 12653683	11	17	sodium	Chemical	D012964
Entity: 12653683	82	107	puromycin aminonucleoside	Chemical	D011692
Entity: 12653683	116	134	nephrotic syndrome	Disease	D009404
Relation: 12653683	CID	11	17	D012964	116	134	D009404	false
Relation: 12653683	CID	82	107	D011692	116	134	D009404	true

Sentence: In experimental nephrotic syndrome, urinary sodium excretion is decreased during the early phase of the disease.
Entity: 12653683	16	34	nephrotic syndrome	Disease	D009404
Entity: 12653683	44	50	sodium	Chemical	D012964
Relation: 12653683	CID	44	50	D012964	16	34	D009404	false

Sentence: We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN) induced nephrotic syndrome.
Entity: 12653683	64	89	puromycin aminonucleoside	Chemical	D011692
Entity: 12653683	91	94	PAN	Chemical	D011692
Entity: 12653683	104	122	nephrotic syndrome	Disease	D009404
Relation: 12653683	CID	64	89	D011692	104	122	D009404	true
Relation: 12653683	CID	91	94	D011692	104	122	D009404	true

Sentence: The time courses of urinary sodium excretion, plasma aldosterone concentration and proteinuria were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.
Entity: 12653683	28	34	sodium	Chemical	D012964
Entity: 12653683	53	64	aldosterone	Chemical	D000450
Entity: 12653683	83	94	proteinuria	Disease	D011507
Entity: 12653683	173	176	PAN	Chemical	D011692
Relation: 12653683	CID	28	34	D012964	83	94	D011507	false
Relation: 12653683	CID	53	64	D000450	83	94	D011507	false
Relation: 12653683	CID	173	176	D011692	83	94	D011507	true

Sentence: The kinetics of urinary sodium excretion and the appearance of proteinuria were comparable with those reported previously.
Entity: 12653683	24	30	sodium	Chemical	D012964
Entity: 12653683	63	74	proteinuria	Disease	D011507
Relation: 12653683	CID	24	30	D012964	63	74	D011507	false

Sentence: NO induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.
Entity: 14659530	0	2	NO	Chemical	D009569
Entity: 14659530	11	19	migraine	Disease	D008881
Entity: 14659530	54	85	calcitonin gene-related peptide	Chemical	D015740
Entity: 14659530	87	91	CGRP	Chemical	D015740
Entity: 14659530	146	155	serotonin	Chemical	D012701
Relation: 14659530	CID	0	2	D009569	11	19	D008881	false
Relation: 14659530	CID	54	85	D015740	11	19	D008881	false
Relation: 14659530	CID	87	91	D015740	11	19	D008881	false
Relation: 14659530	CID	146	155	D012701	11	19	D008881	false

Sentence: The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.
Entity: 14659530	70	101	calcitonin gene-related peptide	Chemical	D015740
Entity: 14659530	103	107	CGRP	Chemical	D015740
Entity: 14659530	136	145	serotonin	Chemical	D012701
Entity: 14659530	147	166	5-hydroxytriptamine	Chemical	D012701
Entity: 14659530	168	172	5-HT	Chemical	D012701
Entity: 14659530	203	211	headache	Disease	D006261
Entity: 14659530	236	244	migraine	Disease	D008881
Entity: 14659530	264	277	nitroglycerin	Chemical	D005996
Relation: 14659530	CID	70	101	D015740	203	211	D006261	false
Relation: 14659530	CID	70	101	D015740	236	244	D008881	false
Relation: 14659530	CID	103	107	D015740	203	211	D006261	false
Relation: 14659530	CID	103	107	D015740	236	244	D008881	false
Relation: 14659530	CID	136	145	D012701	203	211	D006261	false
Relation: 14659530	CID	136	145	D012701	236	244	D008881	false
Relation: 14659530	CID	147	166	D012701	203	211	D006261	false
Relation: 14659530	CID	147	166	D012701	236	244	D008881	false
Relation: 14659530	CID	168	172	D012701	203	211	D006261	false
Relation: 14659530	CID	168	172	D012701	236	244	D008881	false
Relation: 14659530	CID	264	277	D005996	203	211	D006261	false
Relation: 14659530	CID	264	277	D005996	236	244	D008881	false

Sentence: Blood was collected from the antecubital vein four times: 60 min before and after the nitroglycerin application, and 60 and 120 min after the beginning of the migraine attack (mean 344 and 404 min; 12 subjects).
Entity: 14659530	86	99	nitroglycerin	Chemical	D005996
Entity: 14659530	159	167	migraine	Disease	D008881
Relation: 14659530	CID	86	99	D005996	159	167	D008881	false

Sentence: Plasma CGRP concentration increased significantly (P<0.01) during the migraine attack and returned to baseline after the cessation of the migraine.
Entity: 14659530	7	11	CGRP	Chemical	D015740
Entity: 14659530	70	78	migraine	Disease	D008881
Entity: 14659530	138	146	migraine	Disease	D008881
Relation: 14659530	CID	7	11	D015740	70	78	D008881	false
Relation: 14659530	CID	7	11	D015740	138	146	D008881	false

Sentence: However, plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack.
Entity: 14659530	16	20	CGRP	Chemical	D015740
Entity: 14659530	70	78	headache	Disease	D006261
Entity: 14659530	107	115	migraine	Disease	D008881
Relation: 14659530	CID	16	20	D015740	70	78	D006261	false
Relation: 14659530	CID	16	20	D015740	107	115	D008881	false

Sentence: Basal CGRP concentration was significantly higher and platelet 5-HT content tended to be lower in subjects who experienced a migraine attack.
Entity: 14659530	6	10	CGRP	Chemical	D015740
Entity: 14659530	63	67	5-HT	Chemical	D012701
Entity: 14659530	125	133	migraine	Disease	D008881
Relation: 14659530	CID	6	10	D015740	125	133	D008881	false
Relation: 14659530	CID	63	67	D012701	125	133	D008881	false

Sentence: Platelet serotonin content decreased significantly (P<0.01) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack.
Entity: 14659530	9	18	serotonin	Chemical	D012701
Entity: 14659530	66	79	nitroglycerin	Chemical	D005996
Entity: 14659530	100	108	migraine	Disease	D008881
Entity: 14659530	171	179	migraine	Disease	D008881
Relation: 14659530	CID	9	18	D012701	100	108	D008881	false
Relation: 14659530	CID	9	18	D012701	171	179	D008881	false
Relation: 14659530	CID	66	79	D005996	100	108	D008881	false
Relation: 14659530	CID	66	79	D005996	171	179	D008881	false

Sentence: In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.
Entity: 14659530	36	40	CGRP	Chemical	D015740
Entity: 14659530	100	108	migraine	Disease	D008881
Entity: 14659530	109	117	headache	Disease	D006261
Entity: 14659530	157	161	CGRP	Chemical	D015740
Entity: 14659530	166	174	migraine	Disease	D008881
Relation: 14659530	CID	36	40	D015740	100	108	D008881	false
Relation: 14659530	CID	36	40	D015740	109	117	D006261	false
Relation: 14659530	CID	36	40	D015740	166	174	D008881	false
Relation: 14659530	CID	157	161	D015740	100	108	D008881	false
Relation: 14659530	CID	157	161	D015740	109	117	D006261	false
Relation: 14659530	CID	157	161	D015740	166	174	D008881	false

Sentence: Coronary aneurysm after implantation of a paclitaxel-eluting stent.
Entity: 15804801	0	17	Coronary aneurysm	Disease	D003323
Entity: 15804801	42	52	paclitaxel	Chemical	D017239
Relation: 15804801	CID	42	52	D017239	0	17	D003323	true

Sentence: We present a 43-year-old man who developed a coronary aneurysm in the right coronary artery 6 months after receiving a paclitaxel-eluting stent.
Entity: 15804801	45	62	coronary aneurysm	Disease	D003323
Entity: 15804801	119	129	paclitaxel	Chemical	D017239
Relation: 15804801	CID	119	129	D017239	45	62	D003323	true

Sentence: Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.
Entity: 16160878	46	50	U-II	Chemical	D014579
Entity: 16160878	58	70	hypertension	Disease	D006973
Entity: 16160878	75	86	bradycardia	Disease	D001919
Relation: 16160878	CID	46	50	D014579	58	70	D006973	false
Relation: 16160878	CID	46	50	D014579	75	86	D001919	false

Sentence: Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine induced penile erection and climbing behavior, and stress induced plasma corticosterone level.
Entity: 16160878	53	57	U-II	Chemical	D014579
Entity: 16160878	106	117	apomorphine	Chemical	D001058
Entity: 16160878	126	141	penile erection	Disease	D010409
Entity: 16160878	191	205	corticosterone	Chemical	D003345
Relation: 16160878	CID	53	57	D014579	126	141	D010409	false
Relation: 16160878	CID	106	117	D001058	126	141	D010409	true
Relation: 16160878	CID	191	205	D003345	126	141	D010409	false

Sentence: Recurrent dysphonia and acitretin.
Entity: 16274958	10	19	dysphonia	Disease	D055154
Entity: 16274958	24	33	acitretin	Chemical	D017255
Relation: 16274958	CID	24	33	D017255	10	19	D055154	true

Sentence: We report the case of a woman complaining of dysphonia while she was treated by acitretin.
Entity: 16274958	45	54	dysphonia	Disease	D055154
Entity: 16274958	80	89	acitretin	Chemical	D017255
Relation: 16274958	CID	80	89	D017255	45	54	D055154	true

Sentence: The aim of this study was to assess the effects of gabapentin, a drug effective in neuropathic pain patients, on brain processing of nociceptive information in normal and central sensitization states.
Entity: 16330766	51	61	gabapentin	Chemical	C040029
Entity: 16330766	83	99	neuropathic pain	Disease	D009437
Relation: 16330766	CID	51	61	C040029	83	99	D009437	false

Sentence: Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the gabapentin induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin induced secondary hyperalgesia.
Entity: 16330766	88	98	gabapentin	Chemical	C040029
Entity: 16330766	205	214	capsaicin	Chemical	D002211
Entity: 16330766	223	245	secondary hyperalgesia	Disease	D006930
Relation: 16330766	CID	88	98	C040029	223	245	D006930	false
Relation: 16330766	CID	205	214	D002211	223	245	D006930	true

Sentence: MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.
Entity: 16574712	0	4	MDMA	Chemical	D018817
Entity: 16574712	85	134	impaired social and emotional judgement processes	Disease	D003072
Relation: 16574712	CID	0	4	D018817	85	134	D003072	true

Sentence: In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).
Entity: 16574712	24	39	memory deficits	Disease	D008569
Entity: 16574712	71	75	MDMA	Chemical	D018817
Entity: 16574712	77	110	3,4-methylenedioxymethamphetamine	Chemical	D018817
Entity: 16574712	112	119	ecstasy	Chemical	D018817
Relation: 16574712	CID	71	75	D018817	24	39	D008569	false
Relation: 16574712	CID	77	110	D018817	24	39	D008569	false
Relation: 16574712	CID	112	119	D018817	24	39	D008569	false

Sentence: Severe citrate toxicity complicating volunteer apheresis platelet donation.
Entity: 17111419	7	14	citrate	Chemical	C102006
Entity: 17111419	15	23	toxicity	Disease	D064420
Relation: 17111419	CID	7	14	C102006	15	23	D064420	false

Sentence: We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection.
Entity: 17111419	27	34	citrate	Chemical	C102006
Entity: 17111419	35	43	toxicity	Disease	D064420
Relation: 17111419	CID	27	34	C102006	35	43	D064420	false

Sentence: Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes.
Entity: 17111419	37	54	calcium gluconate	Chemical	D002125
Entity: 17111419	74	93	muscle contractions	Disease	C536214
Relation: 17111419	CID	37	54	D002125	74	93	C536214	false

Sentence: The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia.
Entity: 17111419	52	59	calcium	Chemical	D002118
Entity: 17111419	73	87	sodium citrate	Chemical	C102006
Entity: 17111419	136	148	hypocalcemia	Disease	D006996
Relation: 17111419	CID	52	59	D002118	136	148	D006996	false
Relation: 17111419	CID	73	87	C102006	136	148	D006996	true

Sentence: Upon additional retrospective analysis, it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia.
Entity: 17111419	58	68	bumetanide	Chemical	D002034
Entity: 17111419	74	87	loop diuretic	Chemical	D049994
Entity: 17111419	115	127	hypocalcemia	Disease	D006996
Relation: 17111419	CID	58	68	D002034	115	127	D006996	false
Relation: 17111419	CID	74	87	D049994	115	127	D006996	false

Sentence: We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to citrate toxicity.
Entity: 17111419	93	105	hypocalcemia	Disease	D006996
Entity: 17111419	161	168	citrate	Chemical	C102006
Entity: 17111419	169	177	toxicity	Disease	D064420
Relation: 17111419	CID	161	168	C102006	93	105	D006996	true
Relation: 17111419	CID	161	168	C102006	169	177	D064420	false

Sentence: Proteinuria after conversion to sirolimus in renal transplant recipients.
Entity: 17175308	0	11	Proteinuria	Disease	D011507
Entity: 17175308	32	41	sirolimus	Chemical	D020123
Relation: 17175308	CID	32	41	D020123	0	11	D011507	true

Sentence: More recently, proteinuria has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear.
Entity: 17175308	15	26	proteinuria	Disease	D011507
Entity: 17175308	65	74	sirolimus	Chemical	D020123
Relation: 17175308	CID	65	74	D020123	15	26	D011507	true

Sentence: We retrospectively examined the records of 25 renal transplant patients, who developed or displayed increased proteinuria after SRL conversion.
Entity: 17175308	110	121	proteinuria	Disease	D011507
Entity: 17175308	128	131	SRL	Chemical	D020123
Relation: 17175308	CID	128	131	D020123	110	121	D011507	true

Sentence: The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).
Entity: 17175308	55	58	SRL	Chemical	D020123
Entity: 17175308	89	118	chronic allograft nephropathy	Disease	D051436
Entity: 17175308	120	123	CAN	Disease	D007674
Entity: 17175308	134	143	neoplasia	Disease	D009369
Entity: 17175308	153	169	Kaposi's sarcoma	Disease	D012514
Entity: 17175308	176	188	skin cancers	Disease	D012878
Entity: 17175308	194	211	intestinal tumors	Disease	D007414
Entity: 17175308	217	236	renal cell carsinom	Disease	D002292
Entity: 17175308	250	261	nephropathy	Disease	D007674
Relation: 17175308	CID	55	58	D020123	89	118	D051436	false
Relation: 17175308	CID	55	58	D020123	120	123	D007674	false
Relation: 17175308	CID	55	58	D020123	134	143	D009369	false
Relation: 17175308	CID	55	58	D020123	153	169	D012514	false
Relation: 17175308	CID	55	58	D020123	176	188	D012878	false
Relation: 17175308	CID	55	58	D020123	194	211	D007414	false
Relation: 17175308	CID	55	58	D020123	217	236	D002292	false
Relation: 17175308	CID	55	58	D020123	250	261	D007674	false

Sentence: Heavy proteinuria was common after the use of SRL as rescue therapy for renal transplantation.
Entity: 17175308	6	17	proteinuria	Disease	D011507
Entity: 17175308	46	49	SRL	Chemical	D020123
Relation: 17175308	CID	46	49	D020123	6	17	D011507	true

Sentence: In vitro characterization of parasympathetic and sympathetic responses in cyclophosphamide induced cystitis in the rat.
Entity: 17244258	74	90	cyclophosphamide	Chemical	D003520
Entity: 17244258	99	107	cystitis	Disease	D003556
Relation: 17244258	CID	74	90	D003520	99	107	D003556	true

Sentence: In cyclophosphamide induced cystitis in the rat, detrusor function is impaired and the expression and effects of muscarinic receptors altered.
Entity: 17244258	3	19	cyclophosphamide	Chemical	D003520
Entity: 17244258	28	36	cystitis	Disease	D003556
Relation: 17244258	CID	3	19	D003520	28	36	D003556	true

Sentence: However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.
Entity: 18020536	16	20	BZDs	Chemical	D001569
Entity: 18020536	45	54	dizziness	Disease	D004244
Entity: 18020536	56	74	inability to sleep	Disease	D007319
Entity: 18020536	102	111	tiredness	Disease	D005221
Entity: 18020536	181	200	depressive symptoms	Disease	D003866
Relation: 18020536	CID	16	20	D001569	45	54	D004244	true
Relation: 18020536	CID	16	20	D001569	56	74	D007319	true
Relation: 18020536	CID	16	20	D001569	102	111	D005221	true
Relation: 18020536	CID	16	20	D001569	181	200	D003866	true

Sentence: Acute vocal fold palsy after acute disulfiram intoxication.
Entity: 18023325	6	22	vocal fold palsy	Disease	D014826
Entity: 18023325	35	45	disulfiram	Chemical	D004221
Relation: 18023325	CID	35	45	D004221	6	22	D014826	true

Sentence: Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.
Entity: 18023325	6	27	peripheral neuropathy	Disease	D010523
Entity: 18023325	40	50	disulfiram	Chemical	D004221
Entity: 18023325	51	59	overdose	Disease	D062787
Entity: 18023325	113	129	vocal fold palsy	Disease	D014826
Relation: 18023325	CID	40	50	D004221	6	27	D010523	true
Relation: 18023325	CID	40	50	D004221	51	59	D062787	false
Relation: 18023325	CID	40	50	D004221	113	129	D014826	true

Sentence: Higher optical density of an antigen assay predicts thrombosis in patients with heparin induced thrombocytopenia.
Entity: 18208574	52	62	thrombosis	Disease	D013927
Entity: 18208574	80	87	heparin	Chemical	D006493
Entity: 18208574	96	112	thrombocytopenia	Disease	D013921
Relation: 18208574	CID	80	87	D006493	52	62	D013927	true
Relation: 18208574	CID	80	87	D006493	96	112	D013921	true

Sentence: OBJECTIVES: To correlate optical density and percent inhibition of a two-step heparin induced thrombocytopenia (HIT) antigen assay with thrombosis; the assay utilizes reaction inhibition characteristics of a high heparin concentration.
Entity: 18208574	78	85	heparin	Chemical	D006493
Entity: 18208574	94	110	thrombocytopenia	Disease	D013921
Entity: 18208574	112	115	HIT	Disease	D013921
Entity: 18208574	136	146	thrombosis	Disease	D013927
Entity: 18208574	213	220	heparin	Chemical	D006493
Relation: 18208574	CID	78	85	D006493	94	110	D013921	true
Relation: 18208574	CID	78	85	D006493	112	115	D013921	true
Relation: 18208574	CID	78	85	D006493	136	146	D013927	true
Relation: 18208574	CID	213	220	D006493	94	110	D013921	true
Relation: 18208574	CID	213	220	D006493	112	115	D013921	true
Relation: 18208574	CID	213	220	D006493	136	146	D013927	true

Sentence: PATIENTS AND METHODS: Patients with more than 50% decrease in platelet count or thrombocytopenia (<150 x 10(9)/L) after exposure to heparin, who had a positive two-step antigen assay [optical density (OD) >0.4 and >50 inhibition with high concentration of heparin] were included in the study.
Entity: 18208574	80	96	thrombocytopenia	Disease	D013921
Entity: 18208574	132	139	heparin	Chemical	D006493
Entity: 18208574	256	263	heparin	Chemical	D006493
Relation: 18208574	CID	132	139	D006493	80	96	D013921	true
Relation: 18208574	CID	256	263	D006493	80	96	D013921	true

Sentence: Central retinal vein occlusion associated with clomiphene induced ovulation.
Entity: 18343374	8	30	retinal vein occlusion	Disease	D012170
Entity: 18343374	47	57	clomiphene	Chemical	D002996
Relation: 18343374	CID	47	57	D002996	8	30	D012170	true

Sentence: OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).
Entity: 18343374	39	61	retinal vein occlusion	Disease	D012170
Entity: 18343374	78	96	clomiphene citrate	Chemical	D002996
Entity: 18343374	98	100	CC	Chemical	D002996
Relation: 18343374	CID	78	96	D002996	39	61	D012170	true
Relation: 18343374	CID	98	100	D002996	39	61	D012170	true

Sentence: MAIN OUTCOME MEASURE(S): Central retinal vein occlusion after ovulation induction with CC.
Entity: 18343374	33	55	retinal vein occlusion	Disease	D012170
Entity: 18343374	87	89	CC	Chemical	D002996
Relation: 18343374	CID	87	89	D002996	33	55	D012170	true

Sentence: RESULT(S): A 36-year-old Chinese woman developed central retinal vein occlusion after eight courses of CC.
Entity: 18343374	57	79	retinal vein occlusion	Disease	D012170
Entity: 18343374	103	105	CC	Chemical	D002996
Relation: 18343374	CID	103	105	D002996	57	79	D012170	true

Sentence: A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.
Entity: 18343374	34	48	thromboembolic	Disease	D013923
Entity: 18343374	66	68	CC	Chemical	D002996
Entity: 18343374	137	155	visual disturbance	Disease	D014786
Entity: 18343374	162	164	CC	Chemical	D002996
Relation: 18343374	CID	66	68	D002996	34	48	D013923	false
Relation: 18343374	CID	66	68	D002996	137	155	D014786	true
Relation: 18343374	CID	162	164	D002996	34	48	D013923	false
Relation: 18343374	CID	162	164	D002996	137	155	D014786	true

Sentence: CONCLUSION(S): This is the first reported case of central retinal vein occlusion after treatment with CC.
Entity: 18343374	58	80	retinal vein occlusion	Disease	D012170
Entity: 18343374	102	104	CC	Chemical	D002996
Relation: 18343374	CID	102	104	D002996	58	80	D012170	true

Sentence: Nicotine induced nystagmus correlates with midpontine activation.
Entity: 18417364	0	8	Nicotine	Chemical	D009538
Entity: 18417364	17	26	nystagmus	Disease	D009759
Relation: 18417364	CID	0	8	D009538	17	26	D009759	true

Sentence: The pathomechanism of nicotine induced nystagmus (NIN) is unknown.
Entity: 18417364	22	30	nicotine	Chemical	D009538
Entity: 18417364	39	48	nystagmus	Disease	D009759
Entity: 18417364	50	53	NIN	Disease	D009759
Relation: 18417364	CID	22	30	D009538	39	48	D009759	true
Relation: 18417364	CID	22	30	D009538	50	53	D009759	true

Sentence: NIN correlated with blood oxygen level-dependent (BOLD) activity levels in a midpontine site in the posterior basis pontis.
Entity: 18417364	0	3	NIN	Disease	D009759
Entity: 18417364	26	32	oxygen	Chemical	D010100
Relation: 18417364	CID	26	32	D010100	0	3	D009759	false

Sentence: Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.
Entity: 18442015	21	30	verapamil	Chemical	D014700
Entity: 18442015	34	53	gastric hemorrhagic	Disease	D006471
Entity: 18442015	54	60	ulcers	Disease	D014456
Entity: 18442015	71	86	atherosclerotic	Disease	D050197
Relation: 18442015	CID	21	30	D014700	34	53	D006471	false
Relation: 18442015	CID	21	30	D014700	54	60	D014456	false
Relation: 18442015	CID	21	30	D014700	71	86	D050197	false

Sentence: The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.
Entity: 18442015	87	96	histamine	Chemical	D006632
Entity: 18442015	191	209	gastric hemorrhage	Disease	D006471
Entity: 18442015	214	219	ulcer	Disease	D014456
Entity: 18442015	233	248	atherosclerosis	Disease	D050197
Entity: 18442015	280	290	vitamin D2	Chemical	D004872
Entity: 18442015	295	306	cholesterol	Chemical	D002784
Relation: 18442015	CID	87	96	D006632	191	209	D006471	false
Relation: 18442015	CID	87	96	D006632	214	219	D014456	false
Relation: 18442015	CID	87	96	D006632	233	248	D050197	false
Relation: 18442015	CID	280	290	D004872	191	209	D006471	true
Relation: 18442015	CID	280	290	D004872	214	219	D014456	true
Relation: 18442015	CID	280	290	D004872	233	248	D050197	true
Relation: 18442015	CID	295	306	D002784	191	209	D006471	true
Relation: 18442015	CID	295	306	D002784	214	219	D014456	true
Relation: 18442015	CID	295	306	D002784	233	248	D050197	true

Sentence: Additionally, the protective effect of verapamil on this ulcer model was evaluated.
Entity: 18442015	39	48	verapamil	Chemical	D014700
Entity: 18442015	57	62	ulcer	Disease	D014456
Relation: 18442015	CID	39	48	D014700	57	62	D014456	false

Sentence: Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.
Entity: 18442015	110	120	vitamin D2	Chemical	D004872
Entity: 18442015	125	136	cholesterol	Chemical	D002784
Entity: 18442015	147	162	atherosclerosis	Disease	D050197
Relation: 18442015	CID	110	120	D004872	147	162	D050197	true
Relation: 18442015	CID	125	136	D002784	147	162	D050197	true

Sentence: Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.
Entity: 18442015	53	62	histamine	Chemical	D006632
Entity: 18442015	106	113	luminal	Chemical	D010634
Entity: 18442015	137	142	ulcer	Disease	D014456
Relation: 18442015	CID	53	62	D006632	137	142	D014456	false
Relation: 18442015	CID	106	113	D010634	137	142	D014456	false

Sentence: Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.
Entity: 18442015	9	24	atherosclerotic	Disease	D050197
Entity: 18442015	51	58	calcium	Chemical	D002118
Entity: 18442015	66	77	cholesterol	Chemical	D002784
Entity: 18442015	137	152	atherosclerotic	Disease	D050197
Relation: 18442015	CID	51	58	D002118	9	24	D050197	false
Relation: 18442015	CID	51	58	D002118	137	152	D050197	false
Relation: 18442015	CID	66	77	D002784	9	24	D050197	true
Relation: 18442015	CID	66	77	D002784	137	152	D050197	true

Sentence: Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.
Entity: 18442015	15	21	ulcers	Disease	D014456
Entity: 18442015	109	118	histamine	Chemical	D006632
Entity: 18442015	147	154	luminal	Chemical	D010634
Relation: 18442015	CID	109	118	D006632	15	21	D014456	false
Relation: 18442015	CID	147	154	D010634	15	21	D014456	false

Sentence: Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.
Entity: 18442015	36	45	histamine	Chemical	D006632
Entity: 18442015	49	67	gastric hemorrhage	Disease	D006471
Entity: 18442015	75	80	ulcer	Disease	D014456
Entity: 18442015	100	115	atherosclerotic	Disease	D050197
Relation: 18442015	CID	36	45	D006632	49	67	D006471	false
Relation: 18442015	CID	36	45	D006632	75	80	D014456	false
Relation: 18442015	CID	36	45	D006632	100	115	D050197	false

Sentence: This hemorrhagic ulcer and various ulcerogenic parameters were dose-dependently ameliorated by daily intragastric verapamil.
Entity: 18442015	5	16	hemorrhagic	Disease	D006471
Entity: 18442015	17	22	ulcer	Disease	D014456
Entity: 18442015	114	123	verapamil	Chemical	D014700
Relation: 18442015	CID	114	123	D014700	5	16	D006471	false
Relation: 18442015	CID	114	123	D014700	17	22	D014456	false

Sentence: Adriamycin induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure.
Entity: 18619688	0	10	Adriamycin	Chemical	D004317
Entity: 18619688	44	49	death	Disease	D003643
Entity: 18619688	92	105	heart failure	Disease	D006333
Relation: 18619688	CID	0	10	D004317	44	49	D003643	false
Relation: 18619688	CID	0	10	D004317	92	105	D006333	true

Sentence: BACKGROUND: The mechanisms underlying heart failure induced by adriamycin are very complicated and still unclear.
Entity: 18619688	38	51	heart failure	Disease	D006333
Entity: 18619688	63	73	adriamycin	Chemical	D004317
Relation: 18619688	CID	63	73	D004317	38	51	D006333	true

Sentence: The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.
Entity: 18619688	94	107	heart failure	Disease	D006333
Entity: 18619688	119	129	adriamycin	Chemical	D004317
Entity: 18619688	185	198	heart failure	Disease	D006333
Relation: 18619688	CID	119	129	D004317	94	107	D006333	true
Relation: 18619688	CID	119	129	D004317	185	198	D006333	true

Sentence: METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.
Entity: 18619688	9	24	3-methyladenine	Chemical	C025946
Entity: 18619688	26	29	3MA	Chemical	C025946
Entity: 18619688	80	93	heart failure	Disease	D006333
Entity: 18619688	119	129	adriamycin	Chemical	D004317
Relation: 18619688	CID	9	24	C025946	80	93	D006333	false
Relation: 18619688	CID	26	29	C025946	80	93	D006333	false
Relation: 18619688	CID	119	129	D004317	80	93	D006333	true

Sentence: CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin.
Entity: 18619688	37	42	death	Disease	D003643
Entity: 18619688	90	103	heart failure	Disease	D006333
Entity: 18619688	123	133	adriamycin	Chemical	D004317
Relation: 18619688	CID	123	133	D004317	37	42	D003643	false
Relation: 18619688	CID	123	133	D004317	90	103	D006333	true

Sentence: Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.
Entity: 19308880	0	9	Confusion	Disease	D003221
Entity: 19308880	55	68	valproic acid	Chemical	D014635
Relation: 19308880	CID	55	68	D014635	0	9	D003221	true

Sentence: INTRODUCTION: Confusion is an adverse drug reaction frequently observed with valproic acid.
Entity: 19308880	14	23	Confusion	Disease	D003221
Entity: 19308880	77	90	valproic acid	Chemical	D014635
Relation: 19308880	CID	77	90	D014635	14	23	D003221	true

Sentence: METHODS: Using the French Pharmacovigilance database, we selected the cases of confusion reported since 1985 with valproic acid.
Entity: 19308880	79	88	confusion	Disease	D003221
Entity: 19308880	114	127	valproic acid	Chemical	D014635
Relation: 19308880	CID	114	127	D014635	79	88	D003221	true

Sentence: RESULTS: 272 cases of confusion were reported with valproic acid: 153 women and 119 men.
Entity: 19308880	22	31	confusion	Disease	D003221
Entity: 19308880	51	64	valproic acid	Chemical	D014635
Relation: 19308880	CID	51	64	D014635	22	31	D003221	true

Sentence: Confusion mostly occurred during the two first weeks following valproic acid exposure (39.7%).
Entity: 19308880	0	9	Confusion	Disease	D003221
Entity: 19308880	63	76	valproic acid	Chemical	D014635
Relation: 19308880	CID	63	76	D014635	0	9	D003221	true

Sentence: Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task.
Entity: 19631624	0	8	Learning	Disease	D007859
Entity: 19631624	13	19	memory	Disease	D008569
Entity: 19631624	32	39	ecstasy	Chemical	D018817
Relation: 19631624	CID	32	39	D018817	0	8	D007859	true
Relation: 19631624	CID	32	39	D018817	13	19	D008569	true

Sentence: It has been consistently shown that ecstasy users display impairments in learning and memory performance.
Entity: 19631624	36	43	ecstasy	Chemical	D018817
Entity: 19631624	58	69	impairments	Disease	D007859
Entity: 19631624	58	69	impairments	Disease	D008569
Relation: 19631624	CID	36	43	D018817	58	69	D007859	true
Relation: 19631624	CID	36	43	D018817	58	69	D008569	true

Sentence: Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.
Entity: 19631624	0	8	Deficits	Disease	D007859
Entity: 19631624	0	8	Deficits	Disease	D008569
Entity: 19631624	49	62	hyperactivity	Disease	D006948
Entity: 19631624	98	106	cannabis	Chemical	D002188
Relation: 19631624	CID	98	106	D002188	0	8	D007859	false
Relation: 19631624	CID	98	106	D002188	0	8	D008569	false
Relation: 19631624	CID	98	106	D002188	49	62	D006948	false

Sentence: A conjunction analysis of the encode and recall phases of the task revealed ecstasy-specific hyperactivity in bilateral frontal regions, left temporal, right parietal, bilateral temporal, and bilateral occipital brain regions.
Entity: 19631624	76	83	ecstasy	Chemical	D018817
Entity: 19631624	93	106	hyperactivity	Disease	D006948
Relation: 19631624	CID	76	83	D018817	93	106	D006948	false

Sentence: Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin induced thrombocytopenia with thrombosis.
Entity: 20003049	30	40	argatroban	Chemical	C031942
Entity: 20003049	101	108	heparin	Chemical	D006493
Entity: 20003049	117	133	thrombocytopenia	Disease	D013921
Entity: 20003049	139	149	thrombosis	Disease	D013927
Relation: 20003049	CID	30	40	C031942	117	133	D013921	false
Relation: 20003049	CID	30	40	C031942	139	149	D013927	false
Relation: 20003049	CID	101	108	D006493	117	133	D013921	false
Relation: 20003049	CID	101	108	D006493	139	149	D013927	false

Sentence: BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).
Entity: 20003049	126	133	heparin	Chemical	D006493
Entity: 20003049	142	158	thrombocytopenia	Disease	D013921
Entity: 20003049	160	163	HIT	Disease	D013921
Entity: 20003049	168	171	HIT	Disease	D013921
Entity: 20003049	177	187	thrombosis	Disease	D013927
Entity: 20003049	189	193	HITT	Disease	D013921
Entity: 20003049	189	193	HITT	Disease	D013927
Relation: 20003049	CID	126	133	D006493	142	158	D013921	false
Relation: 20003049	CID	126	133	D006493	160	163	D013921	false
Relation: 20003049	CID	126	133	D006493	168	171	D013921	false
Relation: 20003049	CID	126	133	D006493	177	187	D013927	false
Relation: 20003049	CID	126	133	D006493	189	193	D013921	false
Relation: 20003049	CID	126	133	D006493	189	193	D013927	false

Sentence: In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation.
Entity: 20003049	39	53	critically ill	Disease	D016638
Entity: 20003049	90	94	HITT	Disease	D013921
Entity: 20003049	90	94	HITT	Disease	D013927
Entity: 20003049	112	122	argatroban	Chemical	C031942
Relation: 20003049	CID	112	122	C031942	39	53	D016638	false
Relation: 20003049	CID	112	122	C031942	90	94	D013921	false
Relation: 20003049	CID	112	122	C031942	90	94	D013927	false

Sentence: RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).
Entity: 20003049	45	55	argatroban	Chemical	C031942
Entity: 20003049	135	145	argatroban	Chemical	C031942
Entity: 20003049	265	283	hepatic impairment	Disease	D008107
Relation: 20003049	CID	45	55	C031942	265	283	D008107	false
Relation: 20003049	CID	135	145	C031942	265	283	D008107	false

Sentence: CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended coagulopathy.
Entity: 20003049	35	45	argatroban	Chemical	C031942
Entity: 20003049	172	182	argatroban	Chemical	C031942
Entity: 20003049	230	242	coagulopathy	Disease	D001778
Relation: 20003049	CID	35	45	C031942	230	242	D001778	false
Relation: 20003049	CID	172	182	C031942	230	242	D001778	false

Sentence: Antituberculosis therapy induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome.
Entity: 20196116	0	16	Antituberculosis	Chemical	D000995
Entity: 20196116	33	52	acute liver failure	Disease	D017114
Relation: 20196116	CID	0	16	D000995	33	52	D017114	true

Sentence: Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug induced ALF in South Asia.
Entity: 20196116	0	16	Antituberculosis	Chemical	D000995
Entity: 20196116	42	61	acute liver failure	Disease	D017114
Entity: 20196116	67	70	ALF	Disease	D017114
Entity: 20196116	102	105	ALF	Disease	D017114
Relation: 20196116	CID	0	16	D000995	42	61	D017114	true
Relation: 20196116	CID	0	16	D000995	67	70	D017114	true
Relation: 20196116	CID	0	16	D000995	102	105	D017114	true

Sentence: In multivariate analysis, three factors independently predicted mortality: serum bilirubin (>or=10.8 mg/dL), prothrombin time (PT) prolongation (>or=26 seconds), and grade III/IV encephalopathy at presentation.
Entity: 20196116	81	90	bilirubin	Chemical	D001663
Entity: 20196116	179	193	encephalopathy	Disease	D001927
Relation: 20196116	CID	81	90	D001663	179	193	D001927	false

Sentence: CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).
Entity: 20470218	48	67	leukoencephalopathy	Disease	D056784
Entity: 20470218	87	93	stroke	Disease	D020521
Entity: 20470218	103	125	temporal lobe epilepsy	Disease	D004833
Entity: 20470218	145	157	methotrexate	Chemical	D008727
Entity: 20470218	158	166	toxicity	Disease	D064420
Entity: 20470218	188	232	inappropriate antidiuretic hormone secretion	Disease	D007177
Relation: 20470218	CID	145	157	D008727	48	67	D056784	false
Relation: 20470218	CID	145	157	D008727	87	93	D020521	false
Relation: 20470218	CID	145	157	D008727	103	125	D004833	false
Relation: 20470218	CID	145	157	D008727	158	166	D064420	false
Relation: 20470218	CID	145	157	D008727	188	232	D007177	false

Sentence: IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.
Entity: 20722491	25	42	Fluoropyrimidines	Chemical	-1
Entity: 20722491	58	72	5-fluorouracil	Chemical	D005472
Entity: 20722491	74	78	5-FU	Chemical	D005472
Entity: 20722491	135	141	tumors	Disease	D009369
Entity: 20722491	153	197	colorectal, breast and head and neck cancers	Disease	D015179|D001943|D006258	colorectal cancers|breast cancers|head and neck cancers
Relation: 20722491	CID	25	42	-1	135	141	D009369	false
Relation: 20722491	CID	25	42	-1	153	197	D015179|D001943|D006258	colorectal cancers|breast cancers|head and neck cancers	false
Relation: 20722491	CID	58	72	D005472	135	141	D009369	false
Relation: 20722491	CID	58	72	D005472	153	197	D015179|D001943|D006258	colorectal cancers|breast cancers|head and neck cancers	false
Relation: 20722491	CID	74	78	D005472	135	141	D009369	false
Relation: 20722491	CID	74	78	D005472	153	197	D015179|D001943|D006258	colorectal cancers|breast cancers|head and neck cancers	false

Sentence: WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.
Entity: 20722491	82	94	capecitabine	Chemical	C110904
Entity: 20722491	154	178	renal and kidney disease	Disease	D007674
Relation: 20722491	CID	82	94	C110904	154	178	D007674	false

Sentence: The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.
Entity: 20722491	44	56	capecitabine	Chemical	C110904
Entity: 20722491	61	69	diarrhea	Disease	D003967
Entity: 20722491	71	77	nausea	Disease	D009325
Entity: 20722491	79	87	vomiting	Disease	D014839
Entity: 20722491	89	99	stomatitis	Disease	D013280
Entity: 20722491	104	122	hand-foot syndrome	Disease	D060831
Relation: 20722491	CID	44	56	C110904	61	69	D003967	true
Relation: 20722491	CID	44	56	C110904	71	77	D009325	true
Relation: 20722491	CID	44	56	C110904	79	87	D014839	true
Relation: 20722491	CID	44	56	C110904	89	99	D013280	true
Relation: 20722491	CID	44	56	C110904	104	122	D060831	true

Sentence: Effects of pallidal neurotensin on haloperidol induced parkinsonian catalepsy: behavioral and electrophysiological studies.
Entity: 20882060	20	31	neurotensin	Chemical	D009496
Entity: 20882060	35	46	haloperidol	Chemical	D006220
Entity: 20882060	55	77	parkinsonian catalepsy	Disease	D002375
Relation: 20882060	CID	20	31	D009496	55	77	D002375	false
Relation: 20882060	CID	35	46	D006220	55	77	D002375	true

Sentence: The present study aimed to investigate the effects of pallidal neurotensin on haloperidol induced parkinsonian symptoms.
Entity: 20882060	63	74	neurotensin	Chemical	D009496
Entity: 20882060	78	89	haloperidol	Chemical	D006220
Entity: 20882060	98	119	parkinsonian symptoms	Disease	D010302
Relation: 20882060	CID	63	74	D009496	98	119	D010302	false
Relation: 20882060	CID	78	89	D006220	98	119	D010302	false

Sentence: RESULTS: Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol induced parkinsonian catalepsy in rats.
Entity: 20882060	32	43	neurotensin	Chemical	D009496
Entity: 20882060	78	89	haloperidol	Chemical	D006220
Entity: 20882060	98	120	parkinsonian catalepsy	Disease	D002375
Relation: 20882060	CID	32	43	D009496	98	120	D002375	false
Relation: 20882060	CID	78	89	D006220	98	120	D002375	true

Sentence: Pulmonary shunt and cardiovascular responses to CPAP during nitroprusside induced hypotension.
Entity: 322550	60	73	nitroprusside	Chemical	D009599
Entity: 322550	82	93	hypotension	Disease	D007022
Relation: 322550	CID	60	73	D009599	82	93	D007022	true

Sentence: Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.
Entity: 322550	7	10	H2O	Chemical	D014867
Entity: 322550	23	36	nitroprusside	Chemical	D009599
Entity: 322550	65	100	decrease in arterial blood pressure	Disease	D007022
Entity: 322550	144	168	decreased cardiac output	Disease	D002303
Relation: 322550	CID	7	10	D014867	65	100	D007022	false
Relation: 322550	CID	7	10	D014867	144	168	D002303	false
Relation: 322550	CID	23	36	D009599	65	100	D007022	true
Relation: 322550	CID	23	36	D009599	144	168	D002303	false

Sentence: Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT.
Entity: 322550	0	13	Nitroprusside	Chemical	D009599
Entity: 322550	33	69	decreases in arterial blood pressure	Disease	D007022
Relation: 322550	CID	0	13	D009599	33	69	D007022	true

Sentence: Mediation of enhanced reflex vagal bradycardia by L-dopa via central dopamine formation in dogs.
Entity: 869641	35	46	bradycardia	Disease	D001919
Entity: 869641	50	56	L-dopa	Chemical	D007980
Entity: 869641	69	77	dopamine	Chemical	D004298
Relation: 869641	CID	50	56	D007980	35	46	D001919	false
Relation: 869641	CID	69	77	D004298	35	46	D001919	false

Sentence: In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.
Entity: 869641	20	31	bradycardia	Disease	D001919
Entity: 869641	51	65	norepinephrine	Chemical	D009638
Entity: 869641	96	102	L-dopa	Chemical	D007980
Entity: 869641	104	134	DL-Threo-dihydroxyphenylserine	Chemical	D015103
Entity: 869641	202	216	norepinephrine	Chemical	D009638
Relation: 869641	CID	51	65	D009638	20	31	D001919	true
Relation: 869641	CID	96	102	D007980	20	31	D001919	false
Relation: 869641	CID	104	134	D015103	20	31	D001919	false
Relation: 869641	CID	202	216	D009638	20	31	D001919	true

Sentence: FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of L-dopa.
Entity: 869641	0	6	FLA-63	Chemical	D005406
Entity: 869641	10	18	dopamine	Chemical	D004298
Entity: 869641	74	85	hypotension	Disease	D007022
Entity: 869641	87	98	bradycardia	Disease	D001919
Entity: 869641	129	135	L-dopa	Chemical	D007980
Relation: 869641	CID	0	6	D005406	74	85	D007022	false
Relation: 869641	CID	0	6	D005406	87	98	D001919	false
Relation: 869641	CID	10	18	D004298	74	85	D007022	false
Relation: 869641	CID	10	18	D004298	87	98	D001919	false
Relation: 869641	CID	129	135	D007980	74	85	D007022	false
Relation: 869641	CID	129	135	D007980	87	98	D001919	false

Sentence: However, L-dopa restored the bradycardia caused by norepinephrine in addition to decreasing blood pressure and heart rate. 5-HTP (5 mg/kg i.v.) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine.
Entity: 869641	9	15	L-dopa	Chemical	D007980
Entity: 869641	29	40	bradycardia	Disease	D001919
Entity: 869641	51	65	norepinephrine	Chemical	D009638
Entity: 869641	123	128	5-HTP	Chemical	D006916
Entity: 869641	209	220	bradycardia	Disease	D001919
Entity: 869641	224	238	norepinephrine	Chemical	D009638
Relation: 869641	CID	9	15	D007980	29	40	D001919	false
Relation: 869641	CID	9	15	D007980	209	220	D001919	false
Relation: 869641	CID	51	65	D009638	29	40	D001919	true
Relation: 869641	CID	51	65	D009638	209	220	D001919	true
Relation: 869641	CID	123	128	D006916	29	40	D001919	false
Relation: 869641	CID	123	128	D006916	209	220	D001919	false
Relation: 869641	CID	224	238	D009638	29	40	D001919	true
Relation: 869641	CID	224	238	D009638	209	220	D001919	true

Sentence: It is concluded that L-dopa enhances reflex bradycardia through central alpha-receptor stimulation.
Entity: 869641	21	27	L-dopa	Chemical	D007980
Entity: 869641	44	55	bradycardia	Disease	D001919
Relation: 869641	CID	21	27	D007980	44	55	D001919	false

Sentence: Cocaine induced myocardial infarction: clinical observations and pathogenetic considerations.
Entity: 1749407	0	7	Cocaine	Chemical	D003042
Entity: 1749407	16	37	myocardial infarction	Disease	D009203
Relation: 1749407	CID	0	7	D003042	16	37	D009203	true

Sentence: Clinical and experimental data published to date suggest several possible mechanisms by which cocaine may result in acute myocardial infarction.
Entity: 1749407	94	101	cocaine	Chemical	D003042
Entity: 1749407	116	143	acute myocardial infarction	Disease	D009203
Relation: 1749407	CID	94	101	D003042	116	143	D009203	true

Sentence: In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine induced increase in rate-pressure product.
Entity: 1749407	73	100	acute myocardial infarction	Disease	D009203
Entity: 1749407	143	149	oxygen	Chemical	D010100
Entity: 1749407	173	180	cocaine	Chemical	D003042
Relation: 1749407	CID	143	149	D010100	73	100	D009203	false
Relation: 1749407	CID	173	180	D003042	73	100	D009203	true

Sentence: With regard to spasm, the clinical findings are largely circumstantial, and the locus of cocaine induced vasoconstriction remains speculative.
Entity: 1749407	15	20	spasm	Disease	D013035
Entity: 1749407	89	96	cocaine	Chemical	D003042
Relation: 1749407	CID	89	96	D003042	15	20	D013035	false

Sentence: Rabbit syndrome, antidepressant use, and cerebral perfusion SPECT scan findings.
Entity: 1786266	0	15	Rabbit syndrome	Disease	D001480
Entity: 1786266	17	31	antidepressant	Chemical	D000928
Relation: 1786266	CID	17	31	D000928	0	15	D001480	false

Sentence: Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.
Entity: 1835291	33	52	ipratropium bromide	Chemical	D009241
Entity: 1835291	57	69	theophylline	Chemical	D013806
Entity: 1835291	73	110	chronic obstructive pulmonary disease	Disease	D029424
Relation: 1835291	CID	33	52	D009241	73	110	D029424	false
Relation: 1835291	CID	57	69	D013806	73	110	D029424	false

Sentence: The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.
Entity: 1835291	47	66	ipratropium bromide	Chemical	D009241
Entity: 1835291	108	120	theophylline	Chemical	D013806
Entity: 1835291	288	325	chronic obstructive pulmonary disease	Disease	D029424
Relation: 1835291	CID	47	66	D009241	288	325	D029424	false
Relation: 1835291	CID	108	120	D013806	288	325	D029424	false

Sentence: While side effects were rare, those experienced after theophylline use did involve the cardiovascular and gastrointestinal systems.
Entity: 1835291	54	66	theophylline	Chemical	D013806
Entity: 1835291	87	101	cardiovascular	Disease	D002318
Entity: 1835291	106	122	gastrointestinal	Disease	D005767
Relation: 1835291	CID	54	66	D013806	87	101	D002318	true
Relation: 1835291	CID	54	66	D013806	106	122	D005767	true

Sentence: Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.
Entity: 1919871	0	24	Renal papillary necrosis	Disease	D007681
Entity: 1919871	26	29	RPN	Disease	D007681
Entity: 1919871	130	137	aspirin	Chemical	D001241
Entity: 1919871	142	153	paracetamol	Chemical	D000082
Relation: 1919871	CID	130	137	D001241	0	24	D007681	true
Relation: 1919871	CID	130	137	D001241	26	29	D007681	true
Relation: 1919871	CID	142	153	D000082	0	24	D007681	true
Relation: 1919871	CID	142	153	D000082	26	29	D007681	true

Sentence: Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues.
Entity: 2054792	10	20	adriamycin	Chemical	D004317
Entity: 2054792	46	58	hyperthermia	Disease	D005334
Entity: 2054792	62	67	tumor	Disease	D009369
Relation: 2054792	CID	10	20	D004317	46	58	D005334	false
Relation: 2054792	CID	10	20	D004317	62	67	D009369	false

Sentence: Thermal enhancement of Adriamycin-mediated antitumor activity and normal tissue toxicities by whole body hyperthermia were compared using a F344 rat model.
Entity: 2054792	23	33	Adriamycin	Chemical	D004317
Entity: 2054792	80	90	toxicities	Disease	D064420
Entity: 2054792	105	117	hyperthermia	Disease	D005334
Relation: 2054792	CID	23	33	D004317	80	90	D064420	false
Relation: 2054792	CID	23	33	D004317	105	117	D005334	false

Sentence: Whole body hyperthermia (120 min at 41.5 degrees C) enhanced both Adriamycin-mediated antitumor activity and toxic side effects.
Entity: 2054792	11	23	hyperthermia	Disease	D005334
Entity: 2054792	66	76	Adriamycin	Chemical	D004317
Relation: 2054792	CID	66	76	D004317	11	23	D005334	false

Sentence: Prazosin induced stress incontinence.
Entity: 2304736	0	8	Prazosin	Chemical	D011224
Entity: 2304736	17	36	stress incontinence	Disease	D014550
Relation: 2304736	CID	0	8	D011224	17	36	D014550	true

Sentence: A case of genuine stress incontinence due to prazosin, a common antihypertensive drug, is presented.
Entity: 2304736	18	37	stress incontinence	Disease	D014550
Entity: 2304736	45	53	prazosin	Chemical	D011224
Relation: 2304736	CID	45	53	D011224	18	37	D014550	true

Sentence: Myocardial infarction following sublingual administration of isosorbide dinitrate.
Entity: 2312209	0	21	Myocardial infarction	Disease	D009203
Entity: 2312209	61	81	isosorbide dinitrate	Chemical	D007548
Relation: 2312209	CID	61	81	D007548	0	21	D009203	true

Sentence: A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.
Entity: 2312209	33	41	necrosis	Disease	D009336
Entity: 2312209	63	84	myocardial infarction	Disease	D009203
Entity: 2312209	138	158	isosorbide dinitrate	Chemical	D007548
Relation: 2312209	CID	138	158	D007548	33	41	D009336	false
Relation: 2312209	CID	138	158	D007548	63	84	D009203	true

Sentence: Fluoxetine induced akathisia: clinical and theoretical implications.
Entity: 2549018	0	10	Fluoxetine	Chemical	D005473
Entity: 2549018	19	28	akathisia	Disease	D017109
Relation: 2549018	CID	0	10	D005473	19	28	D017109	true

Sentence: Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.
Entity: 2549018	24	34	fluoxetine	Chemical	D005473
Entity: 2549018	56	85	obsessive compulsive disorder	Disease	D009771
Entity: 2549018	89	105	major depression	Disease	D003865
Entity: 2549018	116	125	akathisia	Disease	D017109
Relation: 2549018	CID	24	34	D005473	56	85	D009771	false
Relation: 2549018	CID	24	34	D005473	89	105	D003865	false
Relation: 2549018	CID	24	34	D005473	116	125	D017109	true

Sentence: The typical fluoxetine induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic induced akathisia.
Entity: 2549018	12	22	fluoxetine	Chemical	D005473
Entity: 2549018	129	136	anxiety	Disease	D001008
Entity: 2549018	194	203	akathisia	Disease	D017109
Relation: 2549018	CID	12	22	D005473	129	136	D001008	false
Relation: 2549018	CID	12	22	D005473	194	203	D017109	true

Sentence: Three patients who had experienced neuroleptic induced akathisia in the past reported that the symptoms of fluoxetine induced akathisia were identical, although somewhat milder.
Entity: 2549018	55	64	akathisia	Disease	D017109
Entity: 2549018	107	117	fluoxetine	Chemical	D005473
Entity: 2549018	126	135	akathisia	Disease	D017109
Relation: 2549018	CID	107	117	D005473	55	64	D017109	true
Relation: 2549018	CID	107	117	D005473	126	135	D017109	true

Sentence: Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.
Entity: 2549018	0	9	Akathisia	Disease	D017109
Entity: 2549018	49	59	fluoxetine	Chemical	D005473
Entity: 2549018	138	149	propranolol	Chemical	D011433
Relation: 2549018	CID	49	59	D005473	0	9	D017109	true
Relation: 2549018	CID	138	149	D011433	0	9	D017109	false

Sentence: Chronic active hepatitis associated with diclofenac sodium therapy.
Entity: 2611118	0	24	Chronic active hepatitis	Disease	D006521
Entity: 2611118	41	58	diclofenac sodium	Chemical	D004008
Relation: 2611118	CID	41	58	D004008	0	24	D006521	false

Sentence: Although generally well-tolerated, asymptomatic abnormalities of liver function have been recorded and, less commonly, severe hepatitis induced by diclofenac.
Entity: 2611118	48	79	abnormalities of liver function	Disease	D056486
Entity: 2611118	126	135	hepatitis	Disease	D056486
Entity: 2611118	147	157	diclofenac	Chemical	D004008
Relation: 2611118	CID	147	157	D004008	48	79	D056486	true
Relation: 2611118	CID	147	157	D004008	126	135	D056486	true

Sentence: Stroke associated with cocaine use.
Entity: 2673163	0	6	Stroke	Disease	D020521
Entity: 2673163	23	30	cocaine	Chemical	D003042
Relation: 2673163	CID	23	30	D003042	0	6	D020521	false

Sentence: We describe eight patients in whom cocaine use was related to stroke and review 39 cases from the literature.
Entity: 2673163	35	42	cocaine	Chemical	D003042
Entity: 2673163	62	68	stroke	Disease	D020521
Relation: 2673163	CID	35	42	D003042	62	68	D020521	false

Sentence: Stroke followed cocaine use by inhalation, intranasal, intravenous, and intramuscular routes.
Entity: 2673163	0	6	Stroke	Disease	D020521
Entity: 2673163	16	23	cocaine	Chemical	D003042
Relation: 2673163	CID	16	23	D003042	0	6	D020521	false

Sentence: These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing.
Entity: 2673163	55	61	stroke	Disease	D020521
Entity: 2673163	73	80	cocaine	Chemical	D003042
Relation: 2673163	CID	73	80	D003042	55	61	D020521	false

Sentence: (2) cocaine-associated stroke occurs primarily in young adults.
Entity: 2673163	4	11	cocaine	Chemical	D003042
Entity: 2673163	23	29	stroke	Disease	D020521
Relation: 2673163	CID	4	11	D003042	23	29	D020521	false

Sentence: (3) stroke may follow any route of cocaine administration.
Entity: 2673163	4	10	stroke	Disease	D020521
Entity: 2673163	35	42	cocaine	Chemical	D003042
Relation: 2673163	CID	35	42	D003042	4	10	D020521	false

Sentence: Glyburide induced hepatitis.
Entity: 3107448	0	9	Glyburide	Chemical	D005905
Entity: 3107448	18	27	hepatitis	Disease	D056486
Relation: 3107448	CID	0	9	D005905	18	27	D056486	true

Sentence: Drug induced hepatotoxicity, although common, has been reported only infrequently with sulfonylureas.
Entity: 3107448	13	27	hepatotoxicity	Disease	D056486
Entity: 3107448	87	100	sulfonylureas	Chemical	D013453
Relation: 3107448	CID	87	100	D013453	13	27	D056486	false

Sentence: For glyburide, a second-generation sulfonylurea, only two brief reports of hepatotoxicity exist.
Entity: 3107448	4	13	glyburide	Chemical	D005905
Entity: 3107448	35	47	sulfonylurea	Chemical	D013453
Entity: 3107448	75	89	hepatotoxicity	Disease	D056486
Relation: 3107448	CID	4	13	D005905	75	89	D056486	true
Relation: 3107448	CID	35	47	D013453	75	89	D056486	false

Sentence: Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of glyburide therapy.
Entity: 3107448	18	43	type II diabetes mellitus	Disease	D003924
Entity: 3107448	57	86	acute hepatitis-like syndrome	Disease	D056486
Entity: 3107448	112	121	glyburide	Chemical	D005905
Relation: 3107448	CID	112	121	D005905	18	43	D003924	false
Relation: 3107448	CID	112	121	D005905	57	86	D056486	true

Sentence: Systolic pressure variation is greater during hemorrhage than during sodium nitroprusside induced hypotension in ventilated dogs.
Entity: 3341566	46	56	hemorrhage	Disease	D006470
Entity: 3341566	69	89	sodium nitroprusside	Chemical	D009599
Entity: 3341566	98	109	hypotension	Disease	D007022
Relation: 3341566	CID	69	89	D009599	46	56	D006470	false
Relation: 3341566	CID	69	89	D009599	98	109	D007022	true

Sentence: Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).
Entity: 3341566	74	84	hemorrhage	Disease	D006470
Entity: 3341566	86	89	HEM	Disease	D006470
Entity: 3341566	127	147	sodium nitroprusside	Chemical	D009599
Entity: 3341566	149	152	SNP	Chemical	D009599
Relation: 3341566	CID	127	147	D009599	74	84	D006470	false
Relation: 3341566	CID	127	147	D009599	86	89	D006470	false
Relation: 3341566	CID	149	152	D009599	74	84	D006470	false
Relation: 3341566	CID	149	152	D009599	86	89	D006470	false

Sentence: During HEM induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the SNP group.
Entity: 3341566	7	10	HEM	Disease	D006470
Entity: 3341566	19	30	hypotension	Disease	D007022
Entity: 3341566	140	143	SNP	Chemical	D009599
Relation: 3341566	CID	140	143	D009599	7	10	D006470	false
Relation: 3341566	CID	140	143	D009599	19	30	D007022	true

Sentence: The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).
Entity: 3341566	15	26	hypotension	Disease	D007022
Entity: 3341566	57	60	HEM	Disease	D006470
Entity: 3341566	107	110	SNP	Chemical	D009599
Relation: 3341566	CID	107	110	D009599	15	26	D007022	true
Relation: 3341566	CID	107	110	D009599	57	60	D006470	false

Sentence: The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).
Entity: 3341566	130	133	HEM	Disease	D006470
Entity: 3341566	138	141	SNP	Chemical	D009599
Entity: 3341566	171	182	hypotension	Disease	D007022
Relation: 3341566	CID	138	141	D009599	130	133	D006470	false
Relation: 3341566	CID	138	141	D009599	171	182	D007022	true

Sentence: Drug induced arterial spasm relieved by lidocaine.
Entity: 3564823	22	27	spasm	Disease	D013035
Entity: 3564823	40	49	lidocaine	Chemical	D008012
Relation: 3564823	CID	40	49	D008012	22	27	D013035	false

Sentence: Following major intracranial surgery in a 35-year-old man, sodium pentothal was intravenously infused to minimize cerebral ischaemia.
Entity: 3564823	59	75	sodium pentothal	Chemical	D013874
Entity: 3564823	114	132	cerebral ischaemia	Disease	D002545
Relation: 3564823	CID	59	75	D013874	114	132	D002545	false

Sentence: Cerebral blood flow and metabolism during isoflurane induced hypotension in patients subjected to surgery for cerebral aneurysms.
Entity: 3676049	42	52	isoflurane	Chemical	D007530
Entity: 3676049	61	72	hypotension	Disease	D007022
Entity: 3676049	110	128	cerebral aneurysms	Disease	D002532
Relation: 3676049	CID	42	52	D007530	61	72	D007022	true
Relation: 3676049	CID	42	52	D007530	110	128	D002532	false

Sentence: Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.
Entity: 3676049	52	58	oxygen	Chemical	D010100
Entity: 3676049	80	90	isoflurane	Chemical	D007530
Entity: 3676049	99	110	hypotension	Disease	D007022
Entity: 3676049	168	185	cerebral aneurysm	Disease	D002532
Relation: 3676049	CID	52	58	D010100	99	110	D007022	false
Relation: 3676049	CID	52	58	D010100	168	185	D002532	false
Relation: 3676049	CID	80	90	D007530	99	110	D007022	true
Relation: 3676049	CID	80	90	D007530	168	185	D002532	false

Sentence: Flow and metabolism were measured 5-13 days after the subarachnoid haemorrhage by a modification of the classical Kety-Schmidt technique using xenon-133 i.v.
Entity: 3676049	54	78	subarachnoid haemorrhage	Disease	D013345
Entity: 3676049	143	148	xenon	Chemical	D014978
Relation: 3676049	CID	143	148	D014978	54	78	D013345	false

Sentence: Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%.
Entity: 3676049	11	22	hypotension	Disease	D007022
Entity: 3676049	53	55	Hg	Chemical	D008628
Entity: 3676049	94	104	isoflurane	Chemical	D007530
Relation: 3676049	CID	53	55	D008628	11	22	D007022	false
Relation: 3676049	CID	94	104	D007530	11	22	D007022	true

Sentence: After the clipping of the aneurysm the isoflurane concentration was reduced to 0.75%.
Entity: 3676049	26	34	aneurysm	Disease	D000783
Entity: 3676049	39	49	isoflurane	Chemical	D007530
Relation: 3676049	CID	39	49	D007530	26	34	D000783	false

Sentence: Allergic reaction to 5-fluorouracil infusion.
Entity: 3719553	0	17	Allergic reaction	Disease	D004342
Entity: 3719553	21	35	5-fluorouracil	Chemical	D005472
Relation: 3719553	CID	21	35	D005472	0	17	D004342	false

Sentence: An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin induced impaired renal function.
Entity: 3719553	3	20	allergic reaction	Disease	D004342
Entity: 3719553	35	54	angioneurotic edema	Disease	D000799
Entity: 3719553	88	102	5-fluorouracil	Chemical	D005472
Entity: 3719553	140	168	carcinoma of the oral cavity	Disease	D009062
Entity: 3719553	170	179	cirrhosis	Disease	D005355
Entity: 3719553	185	194	cisplatin	Chemical	D002945
Entity: 3719553	203	226	impaired renal function	Disease	D007674
Relation: 3719553	CID	88	102	D005472	3	20	D004342	false
Relation: 3719553	CID	88	102	D005472	35	54	D000799	true
Relation: 3719553	CID	88	102	D005472	140	168	D009062	false
Relation: 3719553	CID	88	102	D005472	170	179	D005355	false
Relation: 3719553	CID	88	102	D005472	203	226	D007674	false
Relation: 3719553	CID	185	194	D002945	3	20	D004342	false
Relation: 3719553	CID	185	194	D002945	35	54	D000799	false
Relation: 3719553	CID	185	194	D002945	140	168	D009062	false
Relation: 3719553	CID	185	194	D002945	170	179	D005355	false
Relation: 3719553	CID	185	194	D002945	203	226	D007674	false

Sentence: Amiodarone induced sinoatrial block.
Entity: 4008111	0	10	Amiodarone	Chemical	D000638
Entity: 4008111	19	35	sinoatrial block	Disease	D012848
Relation: 4008111	CID	0	10	D000638	19	35	D012848	true

Sentence: We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.
Entity: 4008111	12	28	sinoatrial block	Disease	D012848
Entity: 4008111	44	54	amiodarone	Chemical	D000638
Entity: 4008111	95	117	primary cardiomyopathy	Disease	D009202
Entity: 4008111	119	149	Wolff-Parkinson-White syndrome	Disease	D014927
Entity: 4008111	154	182	supraventricular tachycardia	Disease	D013617
Relation: 4008111	CID	44	54	D000638	12	28	D012848	true
Relation: 4008111	CID	44	54	D000638	95	117	D009202	false
Relation: 4008111	CID	44	54	D000638	119	149	D014927	false
Relation: 4008111	CID	44	54	D000638	154	182	D013617	false

Sentence: Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.
Entity: 6133211	40	66	inflammatory bowel disease	Disease	D015212
Entity: 6133211	95	109	sulphasalazine	Chemical	D012460
Entity: 6133211	157	177	congenital anomalies	Disease	D000013
Relation: 6133211	CID	95	109	D012460	40	66	D015212	false
Relation: 6133211	CID	95	109	D012460	157	177	D000013	false

Sentence: Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.
Entity: 6503301	0	28	Veno-occlusive liver disease	Disease	D006504
Entity: 6503301	35	46	dacarbazine	Chemical	D003606
Entity: 6503301	56	60	DTIC	Chemical	D003606
Entity: 6503301	66	74	melanoma	Disease	D008545
Relation: 6503301	CID	35	46	D003606	0	28	D006504	true
Relation: 6503301	CID	35	46	D003606	66	74	D008545	false
Relation: 6503301	CID	56	60	D003606	0	28	D006504	true
Relation: 6503301	CID	56	60	D003606	66	74	D008545	false

Sentence: A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.
Entity: 6503301	10	45	veno-occlusive disease of the liver	Disease	D006504
Entity: 6503301	71	82	dacarbazine	Chemical	D003606
Entity: 6503301	84	88	DTIC	Chemical	D003606
Entity: 6503301	102	110	melanoma	Disease	D008545
Relation: 6503301	CID	71	82	D003606	10	45	D006504	true
Relation: 6503301	CID	71	82	D003606	102	110	D008545	false
Relation: 6503301	CID	84	88	D003606	10	45	D006504	true
Relation: 6503301	CID	84	88	D003606	102	110	D008545	false

Sentence: A case of tardive dyskinesia caused by metoclopramide.
Entity: 6727060	10	28	tardive dyskinesia	Disease	D004409
Entity: 6727060	39	53	metoclopramide	Chemical	D008787
Relation: 6727060	CID	39	53	D008787	10	28	D004409	true

Sentence: Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.
Entity: 6727060	0	30	Abnormal involuntary movements	Disease	D004409
Entity: 6727060	123	137	metoclopramide	Chemical	D008787
Entity: 6727060	142	167	gastrointestinal disorder	Disease	D005767
Relation: 6727060	CID	123	137	D008787	0	30	D004409	true
Relation: 6727060	CID	123	137	D008787	142	167	D005767	false

Sentence: When the metoclopramide administration was discontinued, the abnormal movements gradually improved to a considerable extent.
Entity: 6727060	9	23	metoclopramide	Chemical	D008787
Entity: 6727060	61	79	abnormal movements	Disease	D004409
Relation: 6727060	CID	9	23	D008787	61	79	D004409	true

Sentence: A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.
Entity: 7083920	36	54	intra-Hisian block	Disease	D006327
Entity: 7083920	71	81	amiodarone	Chemical	D000638
Entity: 7083920	96	114	atrial tachycardia	Disease	D013617
Entity: 7083920	142	183	intraventricular conduction abnormalities	Disease	D006345
Relation: 7083920	CID	71	81	D000638	36	54	D006327	true
Relation: 7083920	CID	71	81	D000638	96	114	D013617	false
Relation: 7083920	CID	71	81	D000638	142	183	D006345	false

Sentence: Thirty days after amiodarone discontinuation, His bundle electrograms showed atrial flutter without intra-Hisian or infra-Hisian delay.
Entity: 7083920	18	28	amiodarone	Chemical	D000638
Entity: 7083920	77	91	atrial flutter	Disease	D001282
Relation: 7083920	CID	18	28	D000638	77	91	D001282	false

Sentence: Busulfan induced hemorrhagic cystitis.
Entity: 7269015	0	8	Busulfan	Chemical	D002066
Entity: 7269015	17	28	hemorrhagic	Disease	D006470
Entity: 7269015	29	37	cystitis	Disease	D003556
Relation: 7269015	CID	0	8	D002066	17	28	D006470	true
Relation: 7269015	CID	0	8	D002066	29	37	D003556	true

Sentence: A case of a busulfan induced hemorrhage cystitis is reported.
Entity: 7269015	12	20	busulfan	Chemical	D002066
Entity: 7269015	29	39	hemorrhage	Disease	D006470
Entity: 7269015	40	48	cystitis	Disease	D003556
Relation: 7269015	CID	12	20	D002066	29	39	D006470	true
Relation: 7269015	CID	12	20	D002066	40	48	D003556	true

Sentence: The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide induced cystitis is discussed and the world literature reviewed.
Entity: 7269015	53	61	busulfan	Chemical	D002066
Entity: 7269015	62	70	cystitis	Disease	D003556
Entity: 7269015	94	110	cyclophosphamide	Chemical	D003520
Entity: 7269015	119	127	cystitis	Disease	D003556
Relation: 7269015	CID	53	61	D002066	62	70	D003556	true
Relation: 7269015	CID	53	61	D002066	119	127	D003556	true
Relation: 7269015	CID	94	110	D003520	62	70	D003556	false
Relation: 7269015	CID	94	110	D003520	119	127	D003556	false

Sentence: Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats.
Entity: 7352670	8	20	hypertensive	Disease	D006973
Entity: 7352670	27	47	sodium nitroprusside	Chemical	D009599
Entity: 7352670	61	70	saralasin	Chemical	D012504
Relation: 7352670	CID	27	47	D009599	8	20	D006973	false
Relation: 7352670	CID	61	70	D012504	8	20	D006973	false

Sentence: The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP) induced hypotension was evaluated.
Entity: 7352670	23	34	angiotensin	Chemical	D000809
Entity: 7352670	86	95	halothane	Chemical	D006221
Entity: 7352670	111	131	sodium nitroprusside	Chemical	D009599
Entity: 7352670	133	136	SNP	Chemical	D009599
Entity: 7352670	146	157	hypotension	Disease	D007022
Relation: 7352670	CID	23	34	D000809	146	157	D007022	false
Relation: 7352670	CID	86	95	D006221	146	157	D007022	true
Relation: 7352670	CID	111	131	D009599	146	157	D007022	true
Relation: 7352670	CID	133	136	D009599	146	157	D007022	true

Sentence: During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr, whereas the saralasin-treated animals showed no change.
Entity: 7352670	11	14	SNP	Chemical	D009599
Entity: 7352670	71	97	increase in blood pressure	Disease	D006973
Entity: 7352670	122	131	saralasin	Chemical	D012504
Relation: 7352670	CID	11	14	D009599	71	97	D006973	false
Relation: 7352670	CID	122	131	D012504	71	97	D006973	false

Sentence: Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.
Entity: 7504976	0	15	Toxic hepatitis	Disease	D056486
Entity: 7504976	101	112	carbimazole	Chemical	D002231
Entity: 7504976	117	133	benzylthiouracil	Chemical	C019269
Relation: 7504976	CID	101	112	D002231	0	15	D056486	true
Relation: 7504976	CID	117	133	C019269	0	15	D056486	false

Sentence: Two patients had a cholestatic hepatitis induced by carbimazole (N  omercazole).
Entity: 7504976	19	30	cholestatic	Disease	D002779
Entity: 7504976	31	40	hepatitis	Disease	D056486
Entity: 7504976	52	63	carbimazole	Chemical	D002231
Entity: 7504976	65	78	N  omercazole	Chemical	D002231
Relation: 7504976	CID	52	63	D002231	19	30	D002779	true
Relation: 7504976	CID	52	63	D002231	31	40	D056486	true
Relation: 7504976	CID	65	78	D002231	19	30	D002779	true
Relation: 7504976	CID	65	78	D002231	31	40	D056486	true

Sentence: Two others had a mixed (cholestatic and cytolytic) hepatitis following carbimazole.
Entity: 7504976	24	35	cholestatic	Disease	D002779
Entity: 7504976	51	60	hepatitis	Disease	D056486
Entity: 7504976	71	82	carbimazole	Chemical	D002231
Relation: 7504976	CID	71	82	D002231	24	35	D002779	true
Relation: 7504976	CID	71	82	D002231	51	60	D056486	true

Sentence: One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.
Entity: 7504976	63	72	hepatitis	Disease	D056486
Entity: 7504976	94	110	Benzylthiouracil	Chemical	C019269
Entity: 7504976	112	120	Basd  ne	Chemical	C019269
Entity: 7504976	135	146	carbimazole	Chemical	D002231
Relation: 7504976	CID	94	110	C019269	63	72	D056486	false
Relation: 7504976	CID	112	120	C019269	63	72	D056486	false
Relation: 7504976	CID	135	146	D002231	63	72	D056486	true

Sentence: Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.
Entity: 7628595	21	32	vitamin B12	Chemical	D014805
Entity: 7628595	37	49	folinic acid	Chemical	D002955
Entity: 7628595	92	100	toxicity	Disease	D064420
Entity: 7628595	104	114	zidovudine	Chemical	D015215
Relation: 7628595	CID	21	32	D014805	92	100	D064420	false
Relation: 7628595	CID	37	49	D002955	92	100	D064420	false
Relation: 7628595	CID	104	114	D015215	92	100	D064420	false

Sentence: A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV) induced bone marrow suppression.
Entity: 7628595	70	81	vitamin B12	Chemical	D014805
Entity: 7628595	86	98	folinic acid	Chemical	D002955
Entity: 7628595	129	139	zidovudine	Chemical	D015215
Entity: 7628595	141	144	ZDV	Chemical	D015215
Entity: 7628595	154	177	bone marrow suppression	Disease	D001855
Relation: 7628595	CID	70	81	D014805	154	177	D001855	false
Relation: 7628595	CID	86	98	D002955	154	177	D001855	false
Relation: 7628595	CID	129	139	D015215	154	177	D001855	true
Relation: 7628595	CID	141	144	D015215	154	177	D001855	true

Sentence: Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).
Entity: 7628595	13	56	human immunodeficiency virus (HIV)-infected	Disease	D015658
Entity: 7628595	132	135	ZDV	Chemical	D015215
Entity: 7628595	198	210	folinic acid	Chemical	D002955
Entity: 7628595	243	254	vitamin B12	Chemical	D014805
Relation: 7628595	CID	132	135	D015215	13	56	D015658	false
Relation: 7628595	CID	198	210	D002955	13	56	D015658	false
Relation: 7628595	CID	243	254	D014805	13	56	D015658	false

Sentence: There was no correlation between vitamin B12 or folate levels and development of myelosuppression.
Entity: 7628595	33	44	vitamin B12	Chemical	D014805
Entity: 7628595	48	54	folate	Chemical	D005492
Entity: 7628595	81	97	myelosuppression	Disease	D001855
Relation: 7628595	CID	33	44	D014805	81	97	D001855	false
Relation: 7628595	CID	48	54	D005492	81	97	D001855	false

Sentence: Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.
Entity: 7858459	6	15	confusion	Disease	D003221
Entity: 7858459	51	65	5-fluorouracil	Chemical	D005472
Entity: 7858459	70	82	folinic acid	Chemical	D002955
Relation: 7858459	CID	51	65	D005472	6	15	D003221	true
Relation: 7858459	CID	70	82	D002955	6	15	D003221	true

Sentence: A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.
Entity: 7858459	74	85	cisplatinum	Chemical	D002945
Entity: 7858459	87	96	etoposide	Chemical	D005047
Entity: 7858459	108	122	5-fluorouracil	Chemical	D005472
Entity: 7858459	150	162	folinic acid	Chemical	D002955
Entity: 7858459	181	203	gastric adenocarcinoma	Disease	D013274
Relation: 7858459	CID	74	85	D002945	181	203	D013274	false
Relation: 7858459	CID	87	96	D005047	181	203	D013274	false
Relation: 7858459	CID	108	122	D005472	181	203	D013274	false
Relation: 7858459	CID	150	162	D002955	181	203	D013274	false

Sentence: He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.
Entity: 7858459	49	58	confusion	Disease	D003221
Entity: 7858459	60	74	disorientation	Disease	D003221
Entity: 7858459	79	91	irritability	Disease	D001523
Entity: 7858459	121	125	coma	Disease	D003128
Entity: 7858459	195	209	5-fluorouracil	Chemical	D005472
Entity: 7858459	214	226	folinic acid	Chemical	D002955
Relation: 7858459	CID	195	209	D005472	49	58	D003221	true
Relation: 7858459	CID	195	209	D005472	60	74	D003221	true
Relation: 7858459	CID	195	209	D005472	79	91	D001523	false
Relation: 7858459	CID	195	209	D005472	121	125	D003128	true
Relation: 7858459	CID	214	226	D002955	49	58	D003221	true
Relation: 7858459	CID	214	226	D002955	60	74	D003221	true
Relation: 7858459	CID	214	226	D002955	79	91	D001523	false
Relation: 7858459	CID	214	226	D002955	121	125	D003128	true

Sentence: Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.
Entity: 7858459	8	20	folinic acid	Chemical	D002955
Entity: 7858459	72	85	neurotoxicity	Disease	D020258
Entity: 7858459	103	117	5-fluorouracil	Chemical	D005472
Relation: 7858459	CID	8	20	D002955	72	85	D020258	false
Relation: 7858459	CID	103	117	D005472	72	85	D020258	false

Sentence: The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.
Entity: 7858459	20	34	5-fluorouracil	Chemical	D005472
Entity: 7858459	35	48	neurotoxicity	Disease	D020258
Entity: 7858459	89	102	fluoroacetate	Chemical	D005463
Entity: 7858459	107	120	fluorocitrate	Chemical	C007744
Entity: 7858459	122	130	thiamine	Chemical	D013831
Entity: 7858459	146	159	dihydrouracil	Chemical	C007419
Relation: 7858459	CID	20	34	D005472	35	48	D020258	false
Relation: 7858459	CID	89	102	D005463	35	48	D020258	false
Relation: 7858459	CID	107	120	C007744	35	48	D020258	false
Relation: 7858459	CID	122	130	D013831	35	48	D020258	false
Relation: 7858459	CID	146	159	C007419	35	48	D020258	false

Sentence: Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.
Entity: 7862923	0	13	Carbamazepine	Chemical	D002220
Entity: 7862923	51	64	oxcarbazepine	Chemical	C036006
Entity: 7862923	94	107	schizophrenic	Disease	D012559
Entity: 7862923	111	128	organic psychotic	Disease	D019965
Entity: 7862923	158	169	haloperidol	Chemical	D006220
Entity: 7862923	171	185	chlorpromazine	Chemical	D002746
Entity: 7862923	189	198	clozapine	Chemical	D003024
Relation: 7862923	CID	0	13	D002220	94	107	D012559	false
Relation: 7862923	CID	0	13	D002220	111	128	D019965	false
Relation: 7862923	CID	51	64	C036006	94	107	D012559	false
Relation: 7862923	CID	51	64	C036006	111	128	D019965	false
Relation: 7862923	CID	158	169	D006220	94	107	D012559	false
Relation: 7862923	CID	158	169	D006220	111	128	D019965	false
Relation: 7862923	CID	171	185	D002746	94	107	D012559	false
Relation: 7862923	CID	171	185	D002746	111	128	D019965	false
Relation: 7862923	CID	189	198	D003024	94	107	D012559	false
Relation: 7862923	CID	189	198	D003024	111	128	D019965	false

Sentence: Erythema multiforme and hypersensitivity myocarditis caused by ampicillin.
Entity: 7919560	0	19	Erythema multiforme	Disease	D004892
Entity: 7919560	24	52	hypersensitivity myocarditis	Disease	D009205
Entity: 7919560	63	73	ampicillin	Chemical	D000667
Relation: 7919560	CID	63	73	D000667	0	19	D004892	true
Relation: 7919560	CID	63	73	D000667	24	52	D009205	true

Sentence: OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin.
Entity: 7919560	31	50	erythema multiforme	Disease	D004892
Entity: 7919560	55	83	hypersensitivity myocarditis	Disease	D009205
Entity: 7919560	94	104	ampicillin	Chemical	D000667
Relation: 7919560	CID	94	104	D000667	31	50	D004892	true
Relation: 7919560	CID	94	104	D000667	55	83	D009205	true

Sentence: CASE SUMMARY: A 13-year-old boy was treated with ampicillin and gentamicin because of suspected septicemia.
Entity: 7919560	49	59	ampicillin	Chemical	D000667
Entity: 7919560	64	74	gentamicin	Chemical	D005839
Entity: 7919560	96	106	septicemia	Disease	D018805
Relation: 7919560	CID	49	59	D000667	96	106	D018805	false
Relation: 7919560	CID	64	74	D005839	96	106	D018805	false

Sentence: Immediate allergic reactions to amoxicillin.
Entity: 8092427	10	28	allergic reactions	Disease	D004342
Entity: 8092427	32	43	amoxicillin	Chemical	D000658
Relation: 8092427	CID	32	43	D000658	10	28	D004342	true

Sentence: A large group of patients with suspected allergic reactions to beta-lactam antibiotics was evaluated.
Entity: 8092427	41	59	allergic reactions	Disease	D004342
Entity: 8092427	63	74	beta-lactam	Chemical	D047090
Relation: 8092427	CID	63	74	D047090	41	59	D004342	false

Sentence: A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.
Entity: 8092427	159	167	allergic	Disease	D004342
Entity: 8092427	171	182	beta-lactam	Chemical	D047090
Entity: 8092427	219	227	allergic	Disease	D004342
Entity: 8092427	241	252	amoxicillin	Chemical	D000658
Entity: 8092427	254	256	AX	Chemical	D000658
Entity: 8092427	292	302	penicillin	Chemical	D010406
Relation: 8092427	CID	171	182	D047090	159	167	D004342	false
Relation: 8092427	CID	171	182	D047090	219	227	D004342	false
Relation: 8092427	CID	241	252	D000658	159	167	D004342	true
Relation: 8092427	CID	241	252	D000658	219	227	D004342	true
Relation: 8092427	CID	254	256	D000658	159	167	D004342	true
Relation: 8092427	CID	254	256	D000658	219	227	D004342	true
Relation: 8092427	CID	292	302	D010406	159	167	D004342	false
Relation: 8092427	CID	292	302	D010406	219	227	D004342	false

Sentence: A total of 177 patients were diagnosed as allergic to beta-lactam antibiotics.
Entity: 8092427	42	50	allergic	Disease	D004342
Entity: 8092427	54	65	beta-lactam	Chemical	D047090
Relation: 8092427	CID	54	65	D047090	42	50	D004342	false

Sentence: We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG.
Entity: 8092427	46	48	AX	Chemical	D000658
Entity: 8092427	49	56	allergy	Disease	D004342
Entity: 8092427	80	82	PG	Chemical	D010400
Relation: 8092427	CID	46	48	D000658	49	56	D004342	true
Relation: 8092427	CID	80	82	D010400	49	56	D004342	false

Sentence: All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.
Entity: 8092427	44	47	BPO	Chemical	-1
Entity: 8092427	86	89	MDM	Disease	D007645
Entity: 8092427	113	115	PG	Chemical	D010400
Relation: 8092427	CID	44	47	-1	86	89	D007645	false
Relation: 8092427	CID	113	115	D010400	86	89	D007645	false

Sentence: Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.
Entity: 8092427	21	23	AX	Chemical	D000658
Entity: 8092427	100	117	allergic reaction	Disease	D004342
Entity: 8092427	121	123	AX	Chemical	D000658
Entity: 8092427	175	177	AX	Chemical	D000658
Relation: 8092427	CID	21	23	D000658	100	117	D004342	true
Relation: 8092427	CID	121	123	D000658	100	117	D004342	true
Relation: 8092427	CID	175	177	D000658	100	117	D004342	true

Sentence: We describe the largest group of AX-allergic patients who have tolerated PG reported so far.
Entity: 8092427	33	35	AX	Chemical	D000658
Entity: 8092427	36	44	allergic	Disease	D004342
Entity: 8092427	73	75	PG	Chemical	D010400
Relation: 8092427	CID	33	35	D000658	36	44	D004342	true
Relation: 8092427	CID	73	75	D010400	36	44	D004342	false

Sentence: Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids.
Entity: 8638206	11	20	paralysis	Disease	D010243
Entity: 8638206	44	54	atracurium	Chemical	D001279
Relation: 8638206	CID	44	54	D001279	11	20	D010243	true

Sentence: Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as vecuronium bromide, especially when used in conjunction with corticosteroids.
Entity: 8638206	22	31	paralysis	Disease	D010243
Entity: 8638206	130	148	vecuronium bromide	Chemical	D014673
Relation: 8638206	CID	130	148	D014673	22	31	D010243	true

Sentence: Atracurium besylate, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent paralysis, but only when used with corticosteroids.
Entity: 8638206	0	19	Atracurium besylate	Chemical	D001279
Entity: 8638206	36	56	benzylisoquinolinium	Chemical	-1
Entity: 8638206	166	175	paralysis	Disease	D010243
Relation: 8638206	CID	0	19	D001279	166	175	D010243	true
Relation: 8638206	CID	36	56	-1	166	175	D010243	false

Sentence: Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin.
Entity: 8669433	16	29	acetaminophen	Chemical	D000082
Entity: 8669433	51	72	chronic renal failure	Disease	D007676
Entity: 8669433	92	102	phenacetin	Chemical	D010615
Relation: 8669433	CID	16	29	D000082	51	72	D007676	false
Relation: 8669433	CID	92	102	D010615	51	72	D007676	true

Sentence: Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.
Entity: 8669433	88	98	phenacetin	Chemical	D010615
Entity: 8669433	137	158	chronic renal failure	Disease	D007676
Entity: 8669433	163	186	end-stage renal disease	Disease	D007676
Entity: 8669433	188	192	ESRD	Disease	D007676
Relation: 8669433	CID	88	98	D010615	137	158	D007676	true
Relation: 8669433	CID	88	98	D010615	163	186	D007676	true
Relation: 8669433	CID	88	98	D010615	188	192	D007676	true

Sentence: However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.
Entity: 8669433	138	151	acetaminophen	Chemical	D000082
Entity: 8669433	176	197	chronic renal failure	Disease	D007676
Entity: 8669433	202	206	ESRD	Disease	D007676
Relation: 8669433	CID	138	151	D000082	176	197	D007676	false
Relation: 8669433	CID	138	151	D000082	202	206	D007676	false

Sentence: These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD, with the risk of the latter being somewhat less than that of the former.
Entity: 8669433	32	42	phenacetin	Chemical	D010615
Entity: 8669433	47	60	acetaminophen	Chemical	D000082
Entity: 8669433	93	97	ESRD	Disease	D007676
Relation: 8669433	CID	32	42	D010615	93	97	D007676	true
Relation: 8669433	CID	47	60	D000082	93	97	D007676	false

Sentence: Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin induced diabetic nephropathy.
Entity: 8690168	13	29	heparan sulphate	Chemical	D006497
Entity: 8690168	104	118	streptozotocin	Chemical	D013311
Entity: 8690168	127	147	diabetic nephropathy	Disease	D003928
Relation: 8690168	CID	13	29	D006497	127	147	D003928	false
Relation: 8690168	CID	104	118	D013311	127	147	D003928	true

Sentence: Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.
Entity: 8690168	0	16	Heparan sulphate	Chemical	D006497
Entity: 8690168	127	135	diabetes	Disease	D003920
Entity: 8690168	139	153	streptozotocin	Chemical	D013311
Entity: 8690168	223	238	cuprolinic blue	Chemical	C015445
Relation: 8690168	CID	0	16	D006497	127	135	D003920	false
Relation: 8690168	CID	139	153	D013311	127	135	D003920	false
Relation: 8690168	CID	223	238	C015445	127	135	D003920	false

Sentence: The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.
Entity: 8739323	4	15	nephrotoxic	Disease	D007674
Entity: 8739323	51	66	nitrogranulogen	Chemical	D008466
Entity: 8739323	68	70	NG	Chemical	D008466
Entity: 8739323	73	85	methotrexate	Chemical	D008727
Entity: 8739323	87	90	MTX	Chemical	D008727
Entity: 8739323	93	107	5-fluorouracil	Chemical	D005472
Entity: 8739323	109	113	5-FU	Chemical	D005472
Entity: 8739323	119	135	cyclophosphamide	Chemical	D003520
Entity: 8739323	137	139	CY	Chemical	D003520
Entity: 8739323	179	182	MTX	Chemical	D008727
Entity: 8739323	185	189	5-FU	Chemical	D005472
Entity: 8739323	192	194	CY	Chemical	D003520
Relation: 8739323	CID	51	66	D008466	4	15	D007674	false
Relation: 8739323	CID	68	70	D008466	4	15	D007674	false
Relation: 8739323	CID	73	85	D008727	4	15	D007674	false
Relation: 8739323	CID	87	90	D008727	4	15	D007674	false
Relation: 8739323	CID	93	107	D005472	4	15	D007674	false
Relation: 8739323	CID	109	113	D005472	4	15	D007674	false
Relation: 8739323	CID	119	135	D003520	4	15	D007674	false
Relation: 8739323	CID	137	139	D003520	4	15	D007674	false
Relation: 8739323	CID	179	182	D008727	4	15	D007674	false
Relation: 8739323	CID	185	189	D005472	4	15	D007674	false
Relation: 8739323	CID	192	194	D003520	4	15	D007674	false

Sentence: CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.
Entity: 8739323	0	2	CY	Chemical	D003520
Entity: 8739323	10	21	hemorrhagic	Disease	D006470
Entity: 8739323	22	30	cystitis	Disease	D003556
Entity: 8739323	105	109	5-FU	Chemical	D005472
Entity: 8739323	114	117	MTX	Chemical	D008727
Relation: 8739323	CID	0	2	D003520	10	21	D006470	true
Relation: 8739323	CID	0	2	D003520	22	30	D003556	true
Relation: 8739323	CID	105	109	D005472	10	21	D006470	false
Relation: 8739323	CID	105	109	D005472	22	30	D003556	false
Relation: 8739323	CID	114	117	D008727	10	21	D006470	false
Relation: 8739323	CID	114	117	D008727	22	30	D003556	false

Sentence: Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.
Entity: 8752018	0	7	Lithium	Chemical	D008094
Entity: 8752018	19	52	cognitive and functional deficits	Disease	D003072
Entity: 8752018	76	93	divalproex sodium	Chemical	D014635
Relation: 8752018	CID	0	7	D008094	19	52	D003072	true
Relation: 8752018	CID	76	93	D014635	19	52	D003072	false

Sentence: BACKGROUND: Lithium remains a first-line treatment for the acute and maintenance treatment of bipolar disorder.
Entity: 8752018	12	19	Lithium	Chemical	D008094
Entity: 8752018	94	110	bipolar disorder	Disease	D001714
Relation: 8752018	CID	12	19	D008094	94	110	D001714	false

Sentence: Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.
Entity: 8752018	90	97	lithium	Chemical	D008094
Entity: 8752018	107	115	polyuria	Disease	D011141
Entity: 8752018	120	126	tremor	Disease	D014202
Entity: 8752018	140	147	lithium	Chemical	D008094
Entity: 8752018	169	187	cognitive deficits	Disease	D003072
Entity: 8752018	189	207	loss of creativity	Disease	D003072
Entity: 8752018	213	235	functional impairments	Disease	D003072
Relation: 8752018	CID	90	97	D008094	107	115	D011141	false
Relation: 8752018	CID	90	97	D008094	120	126	D014202	false
Relation: 8752018	CID	90	97	D008094	169	187	D003072	true
Relation: 8752018	CID	90	97	D008094	189	207	D003072	true
Relation: 8752018	CID	90	97	D008094	213	235	D003072	true
Relation: 8752018	CID	140	147	D008094	107	115	D011141	false
Relation: 8752018	CID	140	147	D008094	120	126	D014202	false
Relation: 8752018	CID	140	147	D008094	169	187	D003072	true
Relation: 8752018	CID	140	147	D008094	189	207	D003072	true
Relation: 8752018	CID	140	147	D008094	213	235	D003072	true

Sentence: This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.
Entity: 8752018	51	58	bipolar	Disease	D001714
Entity: 8752018	73	80	lithium	Chemical	D008094
Entity: 8752018	84	101	divalproex sodium	Chemical	D014635
Entity: 8752018	120	156	cognitive and functional impairments	Disease	D003072
Relation: 8752018	CID	73	80	D008094	51	58	D001714	false
Relation: 8752018	CID	73	80	D008094	120	156	D003072	true
Relation: 8752018	CID	84	101	D014635	51	58	D001714	false
Relation: 8752018	CID	84	101	D014635	120	156	D003072	false

Sentence: RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.
Entity: 8752018	53	60	lithium	Chemical	D008094
Entity: 8752018	94	111	divalproex sodium	Chemical	D014635
Entity: 8752018	150	195	cognitive, motivational, or creative deficits	Disease	D003072
Entity: 8752018	210	217	lithium	Chemical	D008094
Entity: 8752018	225	232	bipolar	Disease	D001714
Relation: 8752018	CID	53	60	D008094	150	195	D003072	true
Relation: 8752018	CID	53	60	D008094	225	232	D001714	false
Relation: 8752018	CID	94	111	D014635	150	195	D003072	false
Relation: 8752018	CID	94	111	D014635	225	232	D001714	false
Relation: 8752018	CID	210	217	D008094	150	195	D003072	true
Relation: 8752018	CID	210	217	D008094	225	232	D001714	false

Sentence: Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.
Entity: 9390208	43	56	breast cancer	Disease	D001943
Entity: 9390208	60	72	mitoxantrone	Chemical	D008942
Entity: 9390208	118	122	5-FU	Chemical	D005472
Entity: 9390208	127	137	leucovorin	Chemical	D002955
Entity: 9390208	139	142	MFL	Chemical	C085788
Entity: 9390208	195	203	toxicity	Disease	D064420
Relation: 9390208	CID	60	72	D008942	43	56	D001943	false
Relation: 9390208	CID	60	72	D008942	195	203	D064420	false
Relation: 9390208	CID	118	122	D005472	43	56	D001943	false
Relation: 9390208	CID	118	122	D005472	195	203	D064420	false
Relation: 9390208	CID	127	137	D002955	43	56	D001943	false
Relation: 9390208	CID	127	137	D002955	195	203	D064420	false
Relation: 9390208	CID	139	142	C085788	43	56	D001943	false
Relation: 9390208	CID	139	142	C085788	195	203	D064420	false

Sentence: From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.
Entity: 9390208	107	120	breast cancer	Disease	D001943
Entity: 9390208	124	136	mitoxantrone	Chemical	D008942
Entity: 9390208	184	188	5-FU	Chemical	D005472
Entity: 9390208	216	226	leucovorin	Chemical	D002955
Relation: 9390208	CID	124	136	D008942	107	120	D001943	false
Relation: 9390208	CID	184	188	D005472	107	120	D001943	false
Relation: 9390208	CID	216	226	D002955	107	120	D001943	false

Sentence: The MFL regimen achieves little palliative benefit and induces severe toxicity at a fairly high rate.
Entity: 9390208	4	15	MFL regimen	Chemical	C085788
Entity: 9390208	70	78	toxicity	Disease	D064420
Relation: 9390208	CID	4	15	C085788	70	78	D064420	false

Sentence: Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium induced diabetes insipidus rat.
Entity: 9406968	34	45	vasopressin	Chemical	D014667
Entity: 9406968	103	110	lithium	Chemical	D008094
Entity: 9406968	119	137	diabetes insipidus	Disease	D003919
Relation: 9406968	CID	34	45	D014667	119	137	D003919	false
Relation: 9406968	CID	103	110	D008094	119	137	D003919	false

Sentence: The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li) induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.
Entity: 9406968	18	38	arginine vasopressin	Chemical	D001127
Entity: 9406968	40	43	AVP	Chemical	D001127
Entity: 9406968	137	144	lithium	Chemical	D008094
Entity: 9406968	146	148	Li	Chemical	D008094
Entity: 9406968	158	166	polyuria	Disease	D011141
Relation: 9406968	CID	18	38	D001127	158	166	D011141	false
Relation: 9406968	CID	40	43	D001127	158	166	D011141	false
Relation: 9406968	CID	137	144	D008094	158	166	D011141	false
Relation: 9406968	CID	146	148	D008094	158	166	D011141	false

Sentence: The male Wistar rats consuming a diet that contained LiCl (60 mmol/kg) for 4 weeks developed marked polyuria.
Entity: 9406968	53	57	LiCl	Chemical	D018021
Entity: 9406968	100	108	polyuria	Disease	D011141
Relation: 9406968	CID	53	57	D018021	100	108	D011141	true

Sentence: Suxamethonium induced cardiac arrest and death following 5 days of immobilization.
Entity: 9587734	0	13	Suxamethonium	Chemical	D013390
Entity: 9587734	22	36	cardiac arrest	Disease	D006323
Entity: 9587734	41	46	death	Disease	D003643
Relation: 9587734	CID	0	13	D013390	22	36	D006323	true
Relation: 9587734	CID	0	13	D013390	41	46	D003643	false

Sentence: The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.
Entity: 9587734	39	53	cardiac arrest	Disease	D006323
Entity: 9587734	69	74	death	Disease	D003643
Entity: 9587734	90	103	hyperkalaemia	Disease	D006947
Entity: 9587734	125	138	suxamethonium	Chemical	D013390
Relation: 9587734	CID	125	138	D013390	39	53	D006323	true
Relation: 9587734	CID	125	138	D013390	69	74	D003643	false
Relation: 9587734	CID	125	138	D013390	90	103	D006947	true

Sentence: Forty seconds after injection of suxamethonium, bradycardia and cardiac arrest occurred.
Entity: 9587734	33	46	suxamethonium	Chemical	D013390
Entity: 9587734	48	59	bradycardia	Disease	D001919
Entity: 9587734	64	78	cardiac arrest	Disease	D006323
Relation: 9587734	CID	33	46	D013390	48	59	D001919	true
Relation: 9587734	CID	33	46	D013390	64	78	D006323	true

Sentence: Apart from the reduction in the patient's level of consciousness, there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium.
Entity: 9587734	167	180	hyperkalaemia	Disease	D006947
Entity: 9587734	213	226	suxamethonium	Chemical	D013390
Relation: 9587734	CID	213	226	D013390	167	180	D006947	true

Sentence: An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.
Entity: 9698967	3	29	increase in blood pressure	Disease	D006973
Entity: 9698967	46	65	atrial fibrillation	Disease	D001281
Entity: 9698967	67	76	agitation	Disease	D011595
Entity: 9698967	78	101	incomprehensible shouts	Disease	D019954
Entity: 9698967	106	127	loss of consciousness	Disease	D014474
Entity: 9698967	267	278	mepivacaine	Chemical	D008619
Entity: 9698967	297	307	adrenaline	Chemical	D004837
Entity: 9698967	336	359	Dupuytren's contracture	Disease	D004387
Relation: 9698967	CID	267	278	D008619	3	29	D006973	true
Relation: 9698967	CID	267	278	D008619	46	65	D001281	true
Relation: 9698967	CID	267	278	D008619	67	76	D011595	false
Relation: 9698967	CID	267	278	D008619	78	101	D019954	false
Relation: 9698967	CID	267	278	D008619	106	127	D014474	false
Relation: 9698967	CID	267	278	D008619	336	359	D004387	false
Relation: 9698967	CID	297	307	D004837	3	29	D006973	true
Relation: 9698967	CID	297	307	D004837	46	65	D001281	true
Relation: 9698967	CID	297	307	D004837	67	76	D011595	false
Relation: 9698967	CID	297	307	D004837	78	101	D019954	false
Relation: 9698967	CID	297	307	D004837	106	127	D014474	false
Relation: 9698967	CID	297	307	D004837	336	359	D004387	false

Sentence: RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).
Entity: 9855119	141	156	IgA nephropathy	Disease	D005922
Entity: 9855119	210	215	FK506	Chemical	D016559
Entity: 9855119	216	227	nephropathy	Disease	D007674
Entity: 9855119	251	256	FK506	Chemical	D016559
Entity: 9855119	257	268	nephropathy	Disease	D007674
Relation: 9855119	CID	210	215	D016559	141	156	D005922	false
Relation: 9855119	CID	210	215	D016559	216	227	D007674	false
Relation: 9855119	CID	210	215	D016559	257	268	D007674	false
Relation: 9855119	CID	251	256	D016559	141	156	D005922	false
Relation: 9855119	CID	251	256	D016559	216	227	D007674	false
Relation: 9855119	CID	251	256	D016559	257	268	D007674	false

Sentence: Of the nonepisode biopsies, 7 and 4 biopsies showed minimal-type and mild-type chronic FK506 nephropathy, respectively.
Entity: 9855119	87	92	FK506	Chemical	D016559
Entity: 9855119	93	104	nephropathy	Disease	D007674
Relation: 9855119	CID	87	92	D016559	93	104	D007674	false

Sentence: Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).
Entity: 9855119	8	13	FK506	Chemical	D016559
Entity: 9855119	14	25	nephropathy	Disease	D007674
Entity: 9855119	163	197	focal segmental glomerulosclerosis	Disease	D005923
Entity: 9855119	235	256	interstitial fibrosis	Disease	D005355
Relation: 9855119	CID	8	13	D016559	14	25	D007674	false
Relation: 9855119	CID	8	13	D016559	163	197	D005923	true
Relation: 9855119	CID	8	13	D016559	235	256	D005355	false

Sentence: The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).
Entity: 9855119	10	20	creatinine	Chemical	D003404
Entity: 9855119	65	70	FK506	Chemical	D016559
Entity: 9855119	71	82	nephropathy	Disease	D007674
Entity: 9855119	190	195	FK506	Chemical	D016559
Entity: 9855119	196	207	nephropathy	Disease	D007674
Relation: 9855119	CID	10	20	D003404	71	82	D007674	false
Relation: 9855119	CID	10	20	D003404	196	207	D007674	false
Relation: 9855119	CID	65	70	D016559	71	82	D007674	false
Relation: 9855119	CID	65	70	D016559	196	207	D007674	false
Relation: 9855119	CID	190	195	D016559	71	82	D007674	false
Relation: 9855119	CID	190	195	D016559	196	207	D007674	false

Sentence: In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.
Entity: 9869257	37	41	PG-9	Chemical	C087567
Entity: 9869257	122	129	amnesia	Disease	D000647
Entity: 9869257	184	195	scopolamine	Chemical	D012601
Entity: 9869257	228	240	S-(-)-ET-126	Chemical	C098725
Relation: 9869257	CID	37	41	C087567	122	129	D000647	false
Relation: 9869257	CID	184	195	D012601	122	129	D000647	true
Relation: 9869257	CID	228	240	C098725	122	129	D000647	true

Sentence: In the same experimental conditions, PG-9 (5-20 microg per mouse, i.c.v.) was also able to prevent antimuscarine induced amnesia, demonstrating a central localization of the activity.
Entity: 9869257	37	41	PG-9	Chemical	C087567
Entity: 9869257	121	128	amnesia	Disease	D000647
Relation: 9869257	CID	37	41	C087567	121	128	D000647	false

Sentence: Angioedema due to ACE inhibitors: common and inadequately diagnosed.
Entity: 10342929	0	10	Angioedema	Disease	D000799
Entity: 10342929	18	32	ACE inhibitors	Chemical	D000806
Relation: 10342929	CID	18	32	D000806	0	10	D000799	true

Sentence: Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.
Entity: 10739826	23	42	oral contraceptives	Chemical	D003276
Entity: 10739826	59	81	venous thromboembolism	Disease	D054556
Relation: 10739826	CID	23	42	D003276	59	81	D054556	true

Sentence: The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.
Entity: 10739826	54	76	venous thromboembolism	Disease	D054556
Entity: 10739826	78	81	VTE	Disease	D054556
Entity: 10739826	105	124	oral contraceptives	Chemical	D003276
Entity: 10739826	126	128	OC	Chemical	D003276
Entity: 10739826	170	172	OC	Chemical	D003276
Relation: 10739826	CID	105	124	D003276	54	76	D054556	true
Relation: 10739826	CID	105	124	D003276	78	81	D054556	true
Relation: 10739826	CID	126	128	D003276	54	76	D054556	true
Relation: 10739826	CID	126	128	D003276	78	81	D054556	true
Relation: 10739826	CID	170	172	D003276	54	76	D054556	true
Relation: 10739826	CID	170	172	D003276	78	81	D054556	true

Sentence: The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.
Entity: 10739826	27	30	VTE	Disease	D054556
Entity: 10739826	68	70	OC	Chemical	D003276
Relation: 10739826	CID	68	70	D003276	27	30	D054556	true

Sentence: Development of apomorphine induced aggressive behavior: comparison of adult male and female Wistar rats.
Entity: 10791295	15	26	apomorphine	Chemical	D001058
Entity: 10791295	35	54	aggressive behavior	Disease	D010554
Relation: 10791295	CID	15	26	D001058	35	54	D010554	true

Sentence: The development of apomorphine induced (1.0 mg/kg s.c. once daily) aggressive behavior of adult male and female Wistar rats obtained from the same breeder was studied in two consecutive sets.
Entity: 10791295	19	30	apomorphine	Chemical	D001058
Entity: 10791295	67	86	aggressive behavior	Disease	D010554
Relation: 10791295	CID	19	30	D001058	67	86	D010554	true

Sentence: In male animals, repeated apomorphine treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent.
Entity: 10791295	26	37	apomorphine	Chemical	D001058
Entity: 10791295	81	100	aggressive behavior	Disease	D010554
Entity: 10791295	144	158	aggressiveness	Disease	D010554
Relation: 10791295	CID	26	37	D001058	81	100	D010554	true
Relation: 10791295	CID	26	37	D001058	144	158	D010554	true

Sentence: Serotonergic antidepressants and urinary incontinence.
Entity: 11147747	0	28	Serotonergic antidepressants	Chemical	D018490
Entity: 11147747	33	53	urinary incontinence	Disease	D014549
Relation: 11147747	CID	0	28	D018490	33	53	D014549	true

Sentence: This concerns 2 male patients who experienced incontinence while taking venlafaxine.
Entity: 11147747	46	58	incontinence	Disease	D014549
Entity: 11147747	72	83	venlafaxine	Chemical	C047426
Relation: 11147747	CID	72	83	C047426	46	58	D014549	true

Sentence: In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.
Entity: 11147747	74	86	incontinence	Disease	D014549
Entity: 11147747	114	123	serotonin	Chemical	D012701
Entity: 11147747	144	154	paroxetine	Chemical	D017374
Entity: 11147747	159	169	sertraline	Chemical	D020280
Entity: 11147747	224	235	venlafaxine	Chemical	C047426
Relation: 11147747	CID	114	123	D012701	74	86	D014549	false
Relation: 11147747	CID	144	154	D017374	74	86	D014549	true
Relation: 11147747	CID	159	169	D020280	74	86	D014549	true
Relation: 11147747	CID	224	235	C047426	74	86	D014549	true

Sentence: In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.
Entity: 11147747	50	67	lithium carbonate	Chemical	D016651
Entity: 11147747	131	143	incontinence	Disease	D014549
Relation: 11147747	CID	50	67	D016651	131	143	D014549	true

Sentence: Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.
Entity: 11198499	0	11	Hypotension	Disease	D007022
Entity: 11198499	40	50	tizanidine	Chemical	C023754
Entity: 11198499	80	91	angiotensin	Chemical	D000809
Entity: 11198499	132	144	hypertension	Disease	D006973
Relation: 11198499	CID	40	50	C023754	0	11	D007022	true
Relation: 11198499	CID	40	50	C023754	132	144	D006973	false
Relation: 11198499	CID	80	91	D000809	0	11	D007022	false
Relation: 11198499	CID	80	91	D000809	132	144	D006973	false

Sentence: Adults chronically treated with angiotensin converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked.
Entity: 11198499	32	43	angiotensin	Chemical	D000809
Entity: 11198499	114	125	hypotension	Disease	D007022
Relation: 11198499	CID	32	43	D000809	114	125	D007022	false

Sentence: The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.
Entity: 11198499	63	73	lisinopril	Chemical	D017706
Entity: 11198499	78	89	angiotensin	Chemical	D000809
Entity: 11198499	130	142	hypertension	Disease	D006973
Entity: 11198499	157	168	hypotension	Disease	D007022
Entity: 11198499	195	205	tizanidine	Chemical	C023754
Entity: 11198499	248	258	spasticity	Disease	D009128
Relation: 11198499	CID	63	73	D017706	130	142	D006973	false
Relation: 11198499	CID	63	73	D017706	157	168	D007022	true
Relation: 11198499	CID	63	73	D017706	248	258	D009128	false
Relation: 11198499	CID	78	89	D000809	130	142	D006973	false
Relation: 11198499	CID	78	89	D000809	157	168	D007022	false
Relation: 11198499	CID	78	89	D000809	248	258	D009128	false
Relation: 11198499	CID	195	205	C023754	130	142	D006973	false
Relation: 11198499	CID	195	205	C023754	157	168	D007022	true
Relation: 11198499	CID	195	205	C023754	248	258	D009128	false

Sentence: These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.
Entity: 11391224	27	49	malignant hypertension	Disease	D006974
Entity: 11391224	51	77	thrombotic microangiopathy	Disease	D057049
Entity: 11391224	79	94	lupus nephritis	Disease	D008181
Entity: 11391224	96	122	Henoch-Schonlein nephritis	Disease	D011695
Entity: 11391224	135	153	glomerulonephritis	Disease	D005921
Entity: 11391224	159	166	cocaine	Chemical	D003042
Entity: 11391224	175	194	acute renal failure	Disease	D058186
Relation: 11391224	CID	159	166	D003042	27	49	D006974	false
Relation: 11391224	CID	159	166	D003042	51	77	D057049	false
Relation: 11391224	CID	159	166	D003042	79	94	D008181	false
Relation: 11391224	CID	159	166	D003042	96	122	D011695	false
Relation: 11391224	CID	159	166	D003042	135	153	D005921	false
Relation: 11391224	CID	159	166	D003042	175	194	D058186	true

Sentence: In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine induced convulsions and lethality.
Entity: 11426838	50	56	BD1018	Chemical	-1
Entity: 11426838	58	64	BD1063	Chemical	C093337
Entity: 11426838	69	74	LR132	Chemical	-1
Entity: 11426838	100	107	cocaine	Chemical	D003042
Entity: 11426838	116	127	convulsions	Disease	D012640
Relation: 11426838	CID	50	56	-1	116	127	D012640	false
Relation: 11426838	CID	58	64	C093337	116	127	D012640	false
Relation: 11426838	CID	69	74	-1	116	127	D012640	false
Relation: 11426838	CID	100	107	D003042	116	127	D012640	true

Sentence: In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.
Entity: 11426838	114	133	di-o-tolylguanidine	Chemical	C050232
Entity: 11426838	135	138	DTG	Chemical	C050232
Entity: 11426838	177	183	BD1031	Chemical	-1
Entity: 11426838	185	249	3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane	Chemical	-1
Entity: 11426838	280	288	toxicity	Disease	D064420
Entity: 11426838	292	299	cocaine	Chemical	D003042
Relation: 11426838	CID	114	133	C050232	280	288	D064420	false
Relation: 11426838	CID	135	138	C050232	280	288	D064420	false
Relation: 11426838	CID	177	183	-1	280	288	D064420	false
Relation: 11426838	CID	185	249	-1	280	288	D064420	false
Relation: 11426838	CID	292	299	D003042	280	288	D064420	false

Sentence: To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.
Entity: 11426838	49	56	cocaine	Chemical	D003042
Entity: 11426838	139	159	oligodeoxynucleotide	Chemical	D009838
Entity: 11426838	231	241	convulsive	Disease	D012640
Entity: 11426838	279	286	cocaine	Chemical	D003042
Relation: 11426838	CID	49	56	D003042	231	241	D012640	true
Relation: 11426838	CID	139	159	D009838	231	241	D012640	false
Relation: 11426838	CID	279	286	D003042	231	241	D012640	true

Sentence: TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline). 2.
Entity: 11569530	0	3	TDP	Disease	D016171
Entity: 11569530	87	98	terfenadine	Chemical	D016593
Entity: 11569530	103	113	terodiline	Chemical	C010637
Relation: 11569530	CID	87	98	D016593	0	3	D016171	true
Relation: 11569530	CID	103	113	C010637	0	3	D016171	true

Sentence: Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.
Entity: 11569530	55	58	TDP	Disease	D016171
Entity: 11569530	78	89	terfenadine	Chemical	D016593
Entity: 11569530	91	101	terodiline	Chemical	C010637
Entity: 11569530	103	112	cisapride	Chemical	D020117
Entity: 11569530	117	122	E4031	Chemical	C063968
Relation: 11569530	CID	78	89	D016593	55	58	D016171	true
Relation: 11569530	CID	91	101	C010637	55	58	D016171	true
Relation: 11569530	CID	103	112	D020117	55	58	D016171	true
Relation: 11569530	CID	117	122	C063968	55	58	D016171	false

Sentence: For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.
Entity: 11569530	30	33	TDP	Disease	D016171
Entity: 11569530	49	60	terfenadine	Chemical	D016593
Entity: 11569530	62	72	terodiline	Chemical	C010637
Entity: 11569530	74	83	cisapride	Chemical	D020117
Relation: 11569530	CID	49	60	D016593	30	33	D016171	true
Relation: 11569530	CID	62	72	C010637	30	33	D016171	true
Relation: 11569530	CID	74	83	D020117	30	33	D016171	true

Sentence: Fatal myeloencephalopathy due to accidental intrathecal vincristin administration: a report of two cases.
Entity: 11587867	6	25	myeloencephalopathy	Disease	D001927
Entity: 11587867	56	66	vincristin	Chemical	D014750
Relation: 11587867	CID	56	66	D014750	6	25	D001927	false

Sentence: We report on two fatal cases of accidental intrathecal vincristine instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with lymphoblastic lymphoma.
Entity: 11587867	55	66	vincristine	Chemical	D014750
Entity: 11587867	116	144	acute lymphoblastic leucemia	Disease	D054198
Entity: 11587867	172	194	lymphoblastic lymphoma	Disease	D054198
Relation: 11587867	CID	55	66	D014750	116	144	D054198	false
Relation: 11587867	CID	55	66	D014750	172	194	D054198	false

Sentence: Histological and immunohistochemical investigations (HE-LFB, CD-68, Neurofilament) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine, accompanied by secondary changes with numerous prominent macrophages.
Entity: 11587867	92	104	degeneration	Disease	D003711
Entity: 11587867	92	104	degeneration	Disease	D009410
Entity: 11587867	136	163	pseudocystic transformation	Disease	-1
Entity: 11587867	184	195	vincristine	Chemical	D014750
Relation: 11587867	CID	184	195	D014750	92	104	D003711	true
Relation: 11587867	CID	184	195	D014750	92	104	D009410	true
Relation: 11587867	CID	184	195	D014750	136	163	-1	false

Sentence: Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.
Entity: 11679859	30	46	prochlorperazine	Chemical	D011346
Entity: 11679859	124	133	akathisia	Disease	D017109
Relation: 11679859	CID	30	46	D011346	124	133	D017109	true

Sentence: STUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.
Entity: 11679859	50	59	akathisia	Disease	D017109
Entity: 11679859	96	112	prochlorperazine	Chemical	D011346
Relation: 11679859	CID	96	112	D011346	50	59	D017109	true

Sentence: Patients aged 18 years or older treated with prochlorperazine for headache, nausea, or vomiting were eligible for inclusion.
Entity: 11679859	45	61	prochlorperazine	Chemical	D011346
Entity: 11679859	66	74	headache	Disease	D006261
Entity: 11679859	76	82	nausea	Disease	D009325
Entity: 11679859	87	95	vomiting	Disease	D014839
Relation: 11679859	CID	45	61	D011346	66	74	D006261	false
Relation: 11679859	CID	45	61	D011346	76	82	D009325	false
Relation: 11679859	CID	45	61	D011346	87	95	D014839	false

Sentence: CONCLUSION: A 50% reduction in the incidence of akathisia when prochlorperazine was administered by means of 15-minute intravenous infusion versus a 2-minute intravenous push was not detected.
Entity: 11679859	48	57	akathisia	Disease	D017109
Entity: 11679859	63	79	prochlorperazine	Chemical	D011346
Relation: 11679859	CID	63	79	D011346	48	57	D017109	true

Sentence: Antithymocyte globulin in the treatment of D-penicillamine induced aplastic anemia.
Entity: 12041669	0	22	Antithymocyte globulin	Chemical	D000961
Entity: 12041669	43	58	D-penicillamine	Chemical	D010396
Entity: 12041669	67	82	aplastic anemia	Disease	D000741
Relation: 12041669	CID	0	22	D000961	67	82	D000741	false
Relation: 12041669	CID	43	58	D010396	67	82	D000741	true

Sentence: A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.
Entity: 12041669	23	45	antithymocyte globulin	Chemical	D000961
Entity: 12041669	58	73	aplastic anemia	Disease	D000741
Entity: 12041669	81	96	D-penicillamine	Chemical	D010396
Relation: 12041669	CID	23	45	D000961	58	73	D000741	false
Relation: 12041669	CID	81	96	D010396	58	73	D000741	true

Sentence: The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal seizure-resistant selected mouse lines.
Entity: 12198388	37	50	acetylcholine	Chemical	D000109
Entity: 12198388	112	119	seizure	Disease	D012640
Entity: 12198388	141	148	seizure	Disease	D012640
Relation: 12198388	CID	37	50	D000109	112	119	D012640	false
Relation: 12198388	CID	37	50	D000109	141	148	D012640	false

Sentence: METHODS: Cholinergic convulsant sensitivity was examined in alcohol-na  ve Withdrawal Seizure-Prone (WSP) and-Resistant (WSR) mice.
Entity: 12198388	60	67	alcohol	Chemical	D000431
Entity: 12198388	86	93	Seizure	Disease	D012640
Relation: 12198388	CID	60	67	D000431	86	93	D012640	false

Sentence: Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.
Entity: 12198388	26	34	nicotine	Chemical	D009538
Entity: 12198388	36	45	carbachol	Chemical	D002217
Entity: 12198388	50	61	neostigmine	Chemical	D009388
Entity: 12198388	122	128	tremor	Disease	D014202
Relation: 12198388	CID	26	34	D009538	122	128	D014202	false
Relation: 12198388	CID	36	45	D002217	122	128	D014202	false
Relation: 12198388	CID	50	61	D009388	122	128	D014202	false

Sentence: Hippocampal ACh also was measured during testing for handling induced convulsions.
Entity: 12198388	12	15	ACh	Chemical	D000109
Entity: 12198388	70	81	convulsions	Disease	D012640
Relation: 12198388	CID	12	15	D000109	70	81	D012640	false

Sentence: RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.
Entity: 12198388	32	42	convulsion	Disease	D012640
Entity: 12198388	64	72	nicotine	Chemical	D009538
Entity: 12198388	74	83	carbachol	Chemical	D002217
Entity: 12198388	89	100	neostigmine	Chemical	D009388
Relation: 12198388	CID	64	72	D009538	32	42	D012640	true
Relation: 12198388	CID	74	83	D002217	32	42	D012640	true
Relation: 12198388	CID	89	100	D009388	32	42	D012640	true

Sentence: When hippocampal ACh was measured during testing for handling induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.
Entity: 12198388	17	20	ACh	Chemical	D000109
Entity: 12198388	70	81	convulsions	Disease	D012640
Entity: 12198388	97	100	ACh	Chemical	D000109
Relation: 12198388	CID	17	20	D000109	70	81	D012640	false
Relation: 12198388	CID	97	100	D000109	70	81	D012640	false

Sentence: CONCLUSIONS: These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal.
Entity: 12198388	120	131	convulsants	Disease	D012640
Entity: 12198388	155	162	ethanol	Chemical	D000431
Entity: 12198388	223	230	alcohol	Chemical	D000431
Relation: 12198388	CID	155	162	D000431	120	131	D012640	false
Relation: 12198388	CID	223	230	D000431	120	131	D012640	false

Sentence: Prenatal dexamethasone programs hypertension and renal injury in the rat.
Entity: 12574103	9	22	dexamethasone	Chemical	D003907
Entity: 12574103	32	44	hypertension	Disease	D006973
Entity: 12574103	49	61	renal injury	Disease	D007674
Relation: 12574103	CID	9	22	D003907	32	44	D006973	true
Relation: 12574103	CID	9	22	D003907	49	61	D007674	true

Sentence: The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats.
Entity: 12574103	62	75	dexamethasone	Chemical	D003907
Entity: 12574103	101	127	increase in blood pressure	Disease	D006973
Entity: 12574103	132	144	renal injury	Disease	D007674
Relation: 12574103	CID	62	75	D003907	101	127	D006973	true
Relation: 12574103	CID	62	75	D003907	132	144	D007674	true

Sentence: Offspring of rats administered dexamethasone on days 15 and 16 gestation had a 20% reduction in glomerular number compared with control at 6 to 9 months of age (22 527+/-509 versus 28 050+/-561, P<0.05), which was comparable to the percent reduction in glomeruli measured at 3 weeks of age.
Entity: 12574103	31	44	dexamethasone	Chemical	D003907
Entity: 12574103	83	113	reduction in glomerular number	Disease	D007674
Relation: 12574103	CID	31	44	D003907	83	113	D007674	true

Sentence: Male rats that received prenatal dexamethasone on days 15 and 16, 17 and 18, and 13 and 14 of gestation had elevated blood pressures at 6 months of age; the latter group did not have a reduction in glomerular number.
Entity: 12574103	33	46	dexamethasone	Chemical	D003907
Entity: 12574103	108	132	elevated blood pressures	Disease	D006973
Entity: 12574103	185	215	reduction in glomerular number	Disease	D007674
Relation: 12574103	CID	33	46	D003907	108	132	D006973	true
Relation: 12574103	CID	33	46	D003907	185	215	D007674	true

Sentence: Adult rats given dexamethasone on days 15 and 16 of gestation had more glomeruli with glomerulosclerosis than control rats.
Entity: 12574103	17	30	dexamethasone	Chemical	D003907
Entity: 12574103	86	104	glomerulosclerosis	Disease	D005921
Relation: 12574103	CID	17	30	D003907	86	104	D005921	false

Sentence: This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number, glomerulosclerosis, and hypertension when administered at specific points during gestation.
Entity: 12574103	31	44	dexamethasone	Chemical	D003907
Entity: 12574103	66	96	reduction in glomerular number	Disease	D007674
Entity: 12574103	98	116	glomerulosclerosis	Disease	D005921
Entity: 12574103	122	134	hypertension	Disease	D006973
Relation: 12574103	CID	31	44	D003907	66	96	D007674	true
Relation: 12574103	CID	31	44	D003907	98	116	D005921	false
Relation: 12574103	CID	31	44	D003907	122	134	D006973	true

Sentence: The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.
Entity: 12615818	12	34	venous thromboembolism	Disease	D054556
Entity: 12615818	55	74	cyproterone acetate	Chemical	D017373
Entity: 12615818	95	112	ethinyl estradiol	Chemical	D004997
Relation: 12615818	CID	55	74	D017373	12	34	D054556	true
Relation: 12615818	CID	95	112	D004997	12	34	D054556	true

Sentence: BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).
Entity: 12615818	12	31	Cyproterone acetate	Chemical	D017373
Entity: 12615818	46	63	ethinyl estradiol	Chemical	D004997
Entity: 12615818	65	68	CPA	Chemical	D017373
Entity: 12615818	69	71	EE	Chemical	D004997
Entity: 12615818	127	131	acne	Disease	D000152
Entity: 12615818	136	145	hirsutism	Disease	D006628
Entity: 12615818	181	206	polycystic ovary syndrome	Disease	D011085
Entity: 12615818	208	212	PCOS	Disease	D011085
Relation: 12615818	CID	12	31	D017373	127	131	D000152	false
Relation: 12615818	CID	12	31	D017373	136	145	D006628	false
Relation: 12615818	CID	12	31	D017373	181	206	D011085	false
Relation: 12615818	CID	12	31	D017373	208	212	D011085	false
Relation: 12615818	CID	46	63	D004997	127	131	D000152	false
Relation: 12615818	CID	46	63	D004997	136	145	D006628	false
Relation: 12615818	CID	46	63	D004997	181	206	D011085	false
Relation: 12615818	CID	46	63	D004997	208	212	D011085	false
Relation: 12615818	CID	65	68	D017373	127	131	D000152	false
Relation: 12615818	CID	65	68	D017373	136	145	D006628	false
Relation: 12615818	CID	65	68	D017373	181	206	D011085	false
Relation: 12615818	CID	65	68	D017373	208	212	D011085	false
Relation: 12615818	CID	69	71	D004997	127	131	D000152	false
Relation: 12615818	CID	69	71	D004997	136	145	D006628	false
Relation: 12615818	CID	69	71	D004997	181	206	D011085	false
Relation: 12615818	CID	69	71	D004997	208	212	D011085	false

Sentence: Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).
Entity: 12615818	56	78	venous thromboembolism	Disease	D054556
Entity: 12615818	80	83	VTE	Disease	D054556
Entity: 12615818	101	104	CPA	Chemical	D017373
Entity: 12615818	105	107	EE	Chemical	D004997
Entity: 12615818	144	163	oral contraceptives	Chemical	D003276
Relation: 12615818	CID	101	104	D017373	56	78	D054556	true
Relation: 12615818	CID	101	104	D017373	80	83	D054556	true
Relation: 12615818	CID	105	107	D004997	56	78	D054556	true
Relation: 12615818	CID	105	107	D004997	80	83	D054556	true
Relation: 12615818	CID	144	163	D003276	56	78	D054556	false
Relation: 12615818	CID	144	163	D003276	80	83	D054556	false

Sentence: METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.
Entity: 12615818	178	182	acne	Disease	D000152
Entity: 12615818	184	193	hirsutism	Disease	D006628
Entity: 12615818	197	201	PCOS	Disease	D011085
Entity: 12615818	226	229	VTE	Disease	D054556
Entity: 12615818	246	249	CPA	Chemical	D017373
Entity: 12615818	250	252	EE	Chemical	D004997
Relation: 12615818	CID	246	249	D017373	178	182	D000152	false
Relation: 12615818	CID	246	249	D017373	184	193	D006628	false
Relation: 12615818	CID	246	249	D017373	197	201	D011085	false
Relation: 12615818	CID	246	249	D017373	226	229	D054556	true
Relation: 12615818	CID	250	252	D004997	178	182	D000152	false
Relation: 12615818	CID	250	252	D004997	184	193	D006628	false
Relation: 12615818	CID	250	252	D004997	197	201	D011085	false
Relation: 12615818	CID	250	252	D004997	226	229	D054556	true

Sentence: Pseudoacromegaly induced by the long-term use of minoxidil.
Entity: 12789195	0	16	Pseudoacromegaly	Disease	D004194
Entity: 12789195	49	58	minoxidil	Chemical	D008914
Relation: 12789195	CID	49	58	D008914	0	16	D004194	false

Sentence: We present a patient with pseudoacromegaly that resulted from the long-term use of minoxidil at an unusually high dose.
Entity: 12789195	26	42	pseudoacromegaly	Disease	D004194
Entity: 12789195	83	92	minoxidil	Chemical	D008914
Relation: 12789195	CID	83	92	D008914	26	42	D004194	false

Sentence: All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).
Entity: 12820454	27	45	leuprolide acetate	Chemical	D016729
Entity: 12820454	47	53	LHRH-A	Chemical	D016729
Entity: 12820454	107	116	flutamide	Chemical	D005485
Entity: 12820454	154	160	anemia	Disease	D000740
Relation: 12820454	CID	27	45	D016729	154	160	D000740	true
Relation: 12820454	CID	47	53	D016729	154	160	D000740	true
Relation: 12820454	CID	107	116	D005485	154	160	D000740	true

Sentence: Reversible dilated cardiomyopathy related to amphotericin B therapy.
Entity: 14657095	11	33	dilated cardiomyopathy	Disease	D002311
Entity: 14657095	45	59	amphotericin B	Chemical	D000666
Relation: 14657095	CID	45	59	D000666	11	33	D002311	true

Sentence: We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.
Entity: 14657095	36	58	dilated cardiomyopathy	Disease	D002311
Entity: 14657095	83	96	heart failure	Disease	D006333
Entity: 14657095	128	142	amphotericin B	Chemical	D000666
Entity: 14657095	144	147	AmB	Chemical	D000666
Entity: 14657095	166	184	coccidioidomycosis	Disease	D003047
Relation: 14657095	CID	128	142	D000666	36	58	D002311	true
Relation: 14657095	CID	128	142	D000666	83	96	D006333	true
Relation: 14657095	CID	128	142	D000666	166	184	D003047	false
Relation: 14657095	CID	144	147	D000666	36	58	D002311	true
Relation: 14657095	CID	144	147	D000666	83	96	D006333	true
Relation: 14657095	CID	144	147	D000666	166	184	D003047	false

Sentence: His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB.
Entity: 14657095	40	53	heart failure	Disease	D006333
Entity: 14657095	69	81	posaconazole	Chemical	C101425
Entity: 14657095	102	105	AmB	Chemical	D000666
Relation: 14657095	CID	69	81	C101425	40	53	D006333	false
Relation: 14657095	CID	102	105	D000666	40	53	D006333	true

Sentence: Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy, quinine is widely available in beverages including tonic water and bitter lemon.
Entity: 14765563	75	95	nocturnal leg cramps	Disease	D020922
Entity: 14765563	132	139	quinine	Chemical	D011803
Relation: 14765563	CID	132	139	D011803	75	95	D020922	false

Sentence: Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.
Entity: 14765563	60	67	quinine	Chemical	D011803
Entity: 14765563	80	106	neurological complications	Disease	D002493
Entity: 14765563	118	127	confusion	Disease	D003221
Entity: 14765563	152	160	seizures	Disease	D012640
Entity: 14765563	166	170	coma	Disease	D003128
Relation: 14765563	CID	60	67	D011803	80	106	D002493	false
Relation: 14765563	CID	60	67	D011803	118	127	D003221	true
Relation: 14765563	CID	60	67	D011803	152	160	D012640	true
Relation: 14765563	CID	60	67	D011803	166	170	D003128	true

Sentence: Organophosphate induced convulsions and prevention of neuropathological damages.
Entity: 15036754	0	15	Organophosphate	Chemical	D010755
Entity: 15036754	24	35	convulsions	Disease	D012640
Entity: 15036754	54	79	neuropathological damages	Disease	D004194
Relation: 15036754	CID	0	15	D010755	24	35	D012640	false
Relation: 15036754	CID	0	15	D010755	54	79	D004194	false

Sentence: The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.
Entity: 15036754	10	18	toxicity	Disease	D064420
Entity: 15036754	22	25	OPs	Chemical	D010755
Entity: 15036754	133	146	acetylcholine	Chemical	D000109
Entity: 15036754	148	151	ACh	Chemical	D000109
Relation: 15036754	CID	22	25	D010755	10	18	D064420	false
Relation: 15036754	CID	133	146	D000109	10	18	D064420	false
Relation: 15036754	CID	148	151	D000109	10	18	D064420	false

Sentence: The rats treated with DFP-atropine showed severe typical OP induced toxicity signs.
Entity: 15036754	22	25	DFP	Chemical	D007531
Entity: 15036754	26	34	atropine	Chemical	D001285
Entity: 15036754	57	59	OP	Chemical	D010755
Entity: 15036754	68	76	toxicity	Disease	D064420
Relation: 15036754	CID	22	25	D007531	68	76	D064420	false
Relation: 15036754	CID	26	34	D001285	68	76	D064420	false
Relation: 15036754	CID	57	59	D010755	68	76	D064420	false

Sentence: When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.
Entity: 15036754	5	8	CPA	Chemical	C048599
Entity: 15036754	10	18	diazepam	Chemical	D003975
Entity: 15036754	22	26	2PAM	Chemical	D011220
Entity: 15036754	55	58	DFP	Chemical	D007531
Entity: 15036754	59	67	atropine	Chemical	D001285
Entity: 15036754	153	162	poisoning	Disease	D011041
Relation: 15036754	CID	5	8	C048599	153	162	D011041	false
Relation: 15036754	CID	10	18	D003975	153	162	D011041	false
Relation: 15036754	CID	22	26	D011220	153	162	D011041	false
Relation: 15036754	CID	55	58	D007531	153	162	D011041	false
Relation: 15036754	CID	59	67	D001285	153	162	D011041	false

Sentence: Atropine-MK801 did not offer any additional protection against DFP toxicity.
Entity: 15036754	0	8	Atropine	Chemical	D001285
Entity: 15036754	9	14	MK801	Chemical	D016291
Entity: 15036754	63	66	DFP	Chemical	D007531
Entity: 15036754	67	75	toxicity	Disease	D064420
Relation: 15036754	CID	0	8	D001285	67	75	D064420	false
Relation: 15036754	CID	9	14	D016291	67	75	D064420	false
Relation: 15036754	CID	63	66	D007531	67	75	D064420	false

Sentence: Differential modulation by estrogen of alpha2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats.
Entity: 15145918	27	35	estrogen	Chemical	D004967
Entity: 15145918	64	75	imidazoline	Chemical	D048288
Entity: 15145918	94	105	hypotension	Disease	D007022
Relation: 15145918	CID	27	35	D004967	94	105	D007022	false
Relation: 15145918	CID	64	75	D048288	94	105	D007022	false

Sentence: We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine (mixed alpha2-/I1-receptor agonist) in female rats and implicates the cardiovascular autonomic control in this interaction.
Entity: 15145918	28	36	estrogen	Chemical	D004967
Entity: 15145918	62	73	hypotensive	Disease	D007022
Entity: 15145918	84	93	clonidine	Chemical	D003000
Relation: 15145918	CID	28	36	D004967	62	73	D007022	false
Relation: 15145918	CID	84	93	D003000	62	73	D007022	false

Sentence: In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.
Entity: 15145918	23	34	rilmenidine	Chemical	C032302
Entity: 15145918	38	54	alpha-methyldopa	Chemical	D008750
Entity: 15145918	72	83	hypotension	Disease	D007022
Relation: 15145918	CID	23	34	C032302	72	83	D007022	true
Relation: 15145918	CID	38	54	D008750	72	83	D007022	true

Sentence: Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.
Entity: 15145918	31	42	hypotensive	Disease	D007022
Entity: 15145918	55	71	alpha-methyldopa	Chemical	D008750
Entity: 15145918	101	112	rilmenidine	Chemical	C032302
Entity: 15145918	113	124	hypotension	Disease	D007022
Relation: 15145918	CID	55	71	D008750	31	42	D007022	true
Relation: 15145918	CID	55	71	D008750	113	124	D007022	true
Relation: 15145918	CID	101	112	C032302	31	42	D007022	true
Relation: 15145918	CID	101	112	C032302	113	124	D007022	true

Sentence: The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.
Entity: 15145918	13	29	alpha-methyldopa	Chemical	D008750
Entity: 15145918	30	41	hypotension	Disease	D007022
Entity: 15145918	104	132	a reduced locomotor activity	Disease	D001523
Relation: 15145918	CID	13	29	D008750	30	41	D007022	true
Relation: 15145918	CID	13	29	D008750	104	132	D001523	false

Sentence: Cardioprotective effect of tincture of Crataegus on isoproterenol induced myocardial infarction in rats.
Entity: 15233872	27	48	tincture of Crataegus	Chemical	C007145
Entity: 15233872	52	65	isoproterenol	Chemical	D007545
Entity: 15233872	74	95	myocardial infarction	Disease	D009203
Relation: 15233872	CID	27	48	C007145	74	95	D009203	false
Relation: 15233872	CID	52	65	D007545	74	95	D009203	true

Sentence: The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats.
Entity: 15233872	67	70	TCR	Chemical	C007145
Entity: 15233872	97	118	myocardial infarction	Disease	D009203
Relation: 15233872	CID	67	70	C007145	97	118	D009203	false

Sentence: METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis.
Entity: 15458908	34	44	Raloxifene	Chemical	D020849
Entity: 15458908	145	157	osteoporosis	Disease	D010024
Relation: 15458908	CID	34	44	D020849	145	157	D010024	false

Sentence: RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).
Entity: 15458908	47	57	raloxifene	Chemical	D020849
Entity: 15458908	100	122	venous thromboembolism	Disease	D054556
Relation: 15458908	CID	47	57	D020849	100	122	D054556	true

Sentence: Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).
Entity: 15458908	0	10	Raloxifene	Chemical	D020849
Entity: 15458908	37	46	cataracts	Disease	D002386
Entity: 15458908	73	92	gallbladder disease	Disease	D005705
Entity: 15458908	119	142	endometrial hyperplasia	Disease	D004714
Entity: 15458908	172	190	endometrial cancer	Disease	D016889
Relation: 15458908	CID	0	10	D020849	37	46	D002386	false
Relation: 15458908	CID	0	10	D020849	73	92	D005705	false
Relation: 15458908	CID	0	10	D020849	119	142	D004714	false
Relation: 15458908	CID	0	10	D020849	172	190	D016889	false

Sentence: Ceftriaxone-associated biliary pseudolithiasis in paediatric surgical patients.
Entity: 15737522	0	11	Ceftriaxone	Chemical	D002443
Entity: 15737522	23	46	biliary pseudolithiasis	Disease	D001660
Relation: 15737522	CID	0	11	D002443	23	46	D001660	true

Sentence: It is well known that ceftriaxone leads to pseudolithiasis in some patients.
Entity: 15737522	22	33	ceftriaxone	Chemical	D002443
Entity: 15737522	43	58	pseudolithiasis	Disease	D001660
Relation: 15737522	CID	22	33	D002443	43	58	D001660	true

Sentence: In this study, we prospectively evaluated the incidence and clinical importance of pseudolithiasis in paediatric surgical patients receiving ceftriaxone treatment, who often had to fast in the post-operative period.
Entity: 15737522	83	98	pseudolithiasis	Disease	D001660
Entity: 15737522	141	152	ceftriaxone	Chemical	D002443
Relation: 15737522	CID	141	152	D002443	83	98	D001660	true

Sentence: Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose.
Entity: 16005948	50	57	GNC92H2	Chemical	-1
Entity: 16005948	82	98	cocaine overdose	Disease	D062787
Relation: 16005948	CID	50	57	-1	82	98	D062787	false

Sentence: The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive.
Entity: 16005948	19	26	cocaine	Chemical	D003042
Entity: 16005948	79	95	cocaine overdose	Disease	D062787
Relation: 16005948	CID	19	26	D003042	79	95	D062787	false

Sentence: The therapeutic potential of the anticocaine antibody GNC92H2 was examined using a model of cocaine overdose.
Entity: 16005948	54	61	GNC92H2	Chemical	-1
Entity: 16005948	92	108	cocaine overdose	Disease	D062787
Relation: 16005948	CID	54	61	-1	92	108	D062787	false

Sentence: Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.
Entity: 16005948	24	31	cocaine	Chemical	D003042
Entity: 16005948	32	40	toxicity	Disease	D064420
Entity: 16005948	78	85	GNC92H2	Chemical	-1
Entity: 16005948	149	157	seizures	Disease	D012640
Entity: 16005948	172	177	death	Disease	D003643
Relation: 16005948	CID	24	31	D003042	32	40	D064420	false
Relation: 16005948	CID	24	31	D003042	149	157	D012640	true
Relation: 16005948	CID	24	31	D003042	172	177	D003643	false
Relation: 16005948	CID	78	85	-1	32	40	D064420	false
Relation: 16005948	CID	78	85	-1	149	157	D012640	false
Relation: 16005948	CID	78	85	-1	172	177	D003643	false

Sentence: Importantly, GNC92H2 prevented death even post-cocaine injection.
Entity: 16005948	13	20	GNC92H2	Chemical	-1
Entity: 16005948	31	36	death	Disease	D003643
Entity: 16005948	47	54	cocaine	Chemical	D003042
Relation: 16005948	CID	13	20	-1	31	36	D003643	false
Relation: 16005948	CID	47	54	D003042	31	36	D003643	false

Sentence: Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.
Entity: 16403073	0	12	Ketoconazole	Chemical	D007654
Entity: 16403073	21	40	torsades de pointes	Disease	D016171
Relation: 16403073	CID	0	12	D007654	21	40	D016171	true

Sentence: We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.
Entity: 16403073	23	46	coronary artery disease	Disease	D003324
Entity: 16403073	72	93	prolonged QT interval	Disease	D008133
Entity: 16403073	98	117	torsades de pointes	Disease	D016171
Entity: 16403073	119	122	TdP	Disease	D016171
Entity: 16403073	137	149	ketoconazole	Chemical	D007654
Entity: 16403073	167	183	fungal infection	Disease	D009181
Relation: 16403073	CID	137	149	D007654	23	46	D003324	false
Relation: 16403073	CID	137	149	D007654	72	93	D008133	true
Relation: 16403073	CID	137	149	D007654	98	117	D016171	true
Relation: 16403073	CID	137	149	D007654	119	122	D016171	true
Relation: 16403073	CID	137	149	D007654	167	183	D009181	false

Sentence: We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP.
Entity: 16403073	66	78	ketoconazole	Chemical	D007654
Entity: 16403073	120	123	TdP	Disease	D016171
Relation: 16403073	CID	66	78	D007654	120	123	D016171	true

Sentence: Diazepam-, scopolamine- and ageing induced amnesia served as the interoceptive behavioral models.
Entity: 16755009	0	8	Diazepam	Chemical	D003975
Entity: 16755009	11	22	scopolamine	Chemical	D012601
Entity: 16755009	43	50	amnesia	Disease	D000647
Relation: 16755009	CID	0	8	D003975	43	50	D000647	true
Relation: 16755009	CID	11	22	D012601	43	50	D000647	true

Sentence: Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).
Entity: 16755009	13	16	DCE	Chemical	D010936
Entity: 16755009	30	37	amnesia	Disease	D000647
Entity: 16755009	49	60	scopolamine	Chemical	D012601
Entity: 16755009	83	91	diazepam	Chemical	D003975
Relation: 16755009	CID	13	16	D010936	30	37	D000647	false
Relation: 16755009	CID	49	60	D012601	30	37	D000647	true
Relation: 16755009	CID	83	91	D003975	30	37	D000647	true

Sentence: Cauda equina syndrome after epidural steroid injection: a case report.
Entity: 16904497	0	21	Cauda equina syndrome	Disease	D011128
Entity: 16904497	37	44	steroid	Chemical	D013256
Relation: 16904497	CID	37	44	D013256	0	21	D011128	false

Sentence: OBJECTIVE: Conventional treatment methods of lumbusacral radiculopathy are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy.
Entity: 16904497	57	70	radiculopathy	Disease	D011843
Entity: 16904497	102	109	steroid	Chemical	D013256
Relation: 16904497	CID	102	109	D013256	57	70	D011843	false

Sentence: The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.
Entity: 16904497	34	55	cauda equina syndrome	Disease	D011128
Entity: 16904497	97	110	triamcinolone	Chemical	D014221
Entity: 16904497	115	126	bupivacaine	Chemical	D002045
Relation: 16904497	CID	97	110	D014221	34	55	D011128	false
Relation: 16904497	CID	115	126	D002045	34	55	D011128	true

Sentence: CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection.
Entity: 16904497	44	47	low	Disease	D017116
Entity: 16904497	67	71	pain	Disease	D010146
Entity: 16904497	99	106	steroid	Chemical	D013256
Relation: 16904497	CID	99	106	D013256	44	47	D017116	false
Relation: 16904497	CID	99	106	D013256	67	71	D010146	false

Sentence: High-dose testosterone is associated with atherosclerosis in postmenopausal women.
Entity: 16938416	10	22	testosterone	Chemical	D013739
Entity: 16938416	42	57	atherosclerosis	Disease	D050197
Relation: 16938416	CID	10	22	D013739	42	57	D050197	true

Sentence: METHODS: In a population-based study in 513 naturally postmenopausal women aged 54-67 years, we studied the association between self-reported intramuscularly administered high-dose estrogen-testosterone therapy (estradiol- and testosterone esters) and aortic atherosclerosis.
Entity: 16938416	181	189	estrogen	Chemical	D004967
Entity: 16938416	190	202	testosterone	Chemical	D013739
Entity: 16938416	212	246	estradiol- and testosterone esters	Chemical	C032109
Entity: 16938416	259	274	atherosclerosis	Disease	D050197
Relation: 16938416	CID	181	189	D004967	259	274	D050197	false
Relation: 16938416	CID	190	202	D013739	259	274	D050197	true
Relation: 16938416	CID	212	246	C032109	259	274	D050197	false

Sentence: The association remained after additional adjustment for diabetes, cholesterol level, systolic blood pressure, or alcohol use.
Entity: 16938416	57	65	diabetes	Disease	D003920
Entity: 16938416	67	78	cholesterol	Chemical	D002784
Entity: 16938416	114	121	alcohol	Chemical	D000431
Relation: 16938416	CID	67	78	D002784	57	65	D003920	false
Relation: 16938416	CID	114	121	D000431	57	65	D003920	false

Sentence: Sirolimus-associated proteinuria and renal dysfunction.
Entity: 17147461	0	9	Sirolimus	Chemical	D020123
Entity: 17147461	21	32	proteinuria	Disease	D011507
Entity: 17147461	37	54	renal dysfunction	Disease	D007674
Relation: 17147461	CID	0	9	D020123	21	32	D011507	true
Relation: 17147461	CID	0	9	D020123	37	54	D007674	true

Sentence: Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy.
Entity: 17147461	0	9	Sirolimus	Chemical	D020123
Entity: 17147461	124	135	nephropathy	Disease	D007674
Relation: 17147461	CID	0	9	D020123	124	135	D007674	true

Sentence: Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'.
Entity: 17147461	8	17	sirolimus	Chemical	D020123
Entity: 17147461	136	147	nephrotoxic	Disease	D007674
Relation: 17147461	CID	8	17	D020123	136	147	D007674	true

Sentence: However, clinical reports suggest that, under some circumstances, sirolimus is associated with proteinuria and acute renal dysfunction.
Entity: 17147461	66	75	sirolimus	Chemical	D020123
Entity: 17147461	95	106	proteinuria	Disease	D011507
Entity: 17147461	111	134	acute renal dysfunction	Disease	D058186
Relation: 17147461	CID	66	75	D020123	95	106	D011507	true
Relation: 17147461	CID	66	75	D020123	111	134	D058186	false

Sentence: The mechanisms of sirolimus-associated proteinuria are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal.
Entity: 17147461	18	27	sirolimus	Chemical	D020123
Entity: 17147461	39	50	proteinuria	Disease	D011507
Relation: 17147461	CID	18	27	D020123	39	50	D011507	true

Sentence: The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.
Entity: 17147461	4	27	acute renal dysfunction	Disease	D058186
Entity: 17147461	44	53	sirolimus	Chemical	D020123
Relation: 17147461	CID	44	53	D020123	4	27	D058186	false

Sentence: Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.
Entity: 17147461	132	141	sirolimus	Chemical	D020123
Entity: 17147461	168	177	sirolimus	Chemical	D020123
Entity: 17147461	234	245	proteinuria	Disease	D011507
Entity: 17147461	273	284	angiotensin	Chemical	D000809
Entity: 17147461	317	331	angiotensin II	Chemical	D000804
Entity: 17147461	353	364	proteinuria	Disease	D011507
Relation: 17147461	CID	132	141	D020123	234	245	D011507	true
Relation: 17147461	CID	132	141	D020123	353	364	D011507	true
Relation: 17147461	CID	168	177	D020123	234	245	D011507	true
Relation: 17147461	CID	168	177	D020123	353	364	D011507	true
Relation: 17147461	CID	273	284	D000809	234	245	D011507	false
Relation: 17147461	CID	273	284	D000809	353	364	D011507	false
Relation: 17147461	CID	317	331	D000804	234	245	D011507	false
Relation: 17147461	CID	317	331	D000804	353	364	D011507	false

Sentence: Progressive myopathy with up-regulation of MHC-I associated with statin therapy.
Entity: 17241784	12	20	myopathy	Disease	D009135
Entity: 17241784	65	71	statin	Chemical	D019821
Relation: 17241784	CID	65	71	D019821	12	20	D009135	true

Sentence: Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug.
Entity: 17241784	0	7	Statins	Chemical	D019821
Entity: 17241784	32	40	myopathy	Disease	D009135
Entity: 17241784	45	57	hyperCKaemia	Disease	-1
Relation: 17241784	CID	0	7	D019821	32	40	D009135	true
Relation: 17241784	CID	0	7	D019821	45	57	-1	false

Sentence: What is less well known is a phenomenon whereby statins may induce a myopathy, which persists or may progress after stopping the drug.
Entity: 17241784	48	55	statins	Chemical	D019821
Entity: 17241784	69	77	myopathy	Disease	D009135
Relation: 17241784	CID	48	55	D019821	69	77	D009135	true

Sentence: These observations suggest that statins may initiate an immune-mediated myopathy that persists after withdrawal of the drug and responds to immunosuppressive therapy.
Entity: 17241784	32	39	statins	Chemical	D019821
Entity: 17241784	72	80	myopathy	Disease	D009135
Relation: 17241784	CID	32	39	D019821	72	80	D009135	true

Sentence: Clonidine induced bradycardia in conscious alpha2ABC-/- mice was 32.3% (10 microg/kg) and 26.6% (100 microg/kg) of the effect in wild-type mice.
Entity: 17261653	0	9	Clonidine	Chemical	D003000
Entity: 17261653	18	29	bradycardia	Disease	D001919
Relation: 17261653	CID	0	9	D003000	18	29	D001919	true

Sentence: The influence of smoking during pregnancy on the developing cochlea has not been estimated, although smoking has been positively associated with hearing loss in adults.
Entity: 17343925	17	24	smoking	Chemical	D012906
Entity: 17343925	101	108	smoking	Chemical	D012906
Entity: 17343925	145	157	hearing loss	Disease	D034381
Relation: 17343925	CID	17	24	D012906	145	157	D034381	true
Relation: 17343925	CID	101	108	D012906	145	157	D034381	true

Sentence: Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.
Entity: 17400887	0	17	Neuroinflammation	Disease	D020078
Entity: 17400887	22	46	behavioral abnormalities	Disease	D001523
Entity: 17400887	62	73	terbutaline	Chemical	D013726
Entity: 17400887	110	116	autism	Disease	D001321
Relation: 17400887	CID	62	73	D013726	0	17	D020078	false
Relation: 17400887	CID	62	73	D013726	22	46	D001523	false
Relation: 17400887	CID	62	73	D013726	110	116	D001321	true

Sentence: Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.
Entity: 17400887	0	11	Terbutaline	Chemical	D013726
Entity: 17400887	57	70	preterm labor	Disease	D007752
Entity: 17400887	123	129	autism	Disease	D001321
Relation: 17400887	CID	0	11	D013726	57	70	D007752	false
Relation: 17400887	CID	0	11	D013726	123	129	D001321	true

Sentence: Acute myocarditis associated with clozapine.
Entity: 17612891	6	17	myocarditis	Disease	D009205
Entity: 17612891	34	43	clozapine	Chemical	D003024
Relation: 17612891	CID	34	43	D003024	6	17	D009205	true

Sentence: OBJECTIVE: A case of acute myocarditis associated with the commencement of clozapine is described, highlighting the onset, course and possible contributing factors.
Entity: 17612891	27	38	myocarditis	Disease	D009205
Entity: 17612891	75	84	clozapine	Chemical	D003024
Relation: 17612891	CID	75	84	D003024	27	38	D009205	true

Sentence: RESULTS: A 20-year-old male with schizophrenia developed a sudden onset of myocarditis after commencement of clozapine.
Entity: 17612891	33	46	schizophrenia	Disease	D012559
Entity: 17612891	75	86	myocarditis	Disease	D009205
Entity: 17612891	109	118	clozapine	Chemical	D003024
Relation: 17612891	CID	109	118	D003024	33	46	D012559	false
Relation: 17612891	CID	109	118	D003024	75	86	D009205	true

Sentence: CONCLUSIONS: Myocarditis is an increasingly recognized complication associated with the use of clozapine.
Entity: 17612891	13	24	Myocarditis	Disease	D009205
Entity: 17612891	95	104	clozapine	Chemical	D003024
Relation: 17612891	CID	95	104	D003024	13	24	D009205	true

Sentence: Considering that clozapine remains the gold standard in treatment of resistant psychosis, there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients.
Entity: 17612891	17	26	clozapine	Chemical	D003024
Entity: 17612891	79	88	psychosis	Disease	D011618
Relation: 17612891	CID	17	26	D003024	79	88	D011618	false

Sentence: Encephalopathy induced by levetiracetam added to valproate.
Entity: 18081909	0	14	Encephalopathy	Disease	D001927
Entity: 18081909	26	39	levetiracetam	Chemical	C026098
Entity: 18081909	49	58	valproate	Chemical	D014635
Relation: 18081909	CID	26	39	C026098	0	14	D001927	true
Relation: 18081909	CID	49	58	D014635	0	14	D001927	true

Sentence: BACKGROUND: We report on the manifestation of a levetiracetam (LEV) induced encephalopathy.
Entity: 18081909	48	61	levetiracetam	Chemical	C026098
Entity: 18081909	63	66	LEV	Chemical	C026098
Entity: 18081909	76	90	encephalopathy	Disease	D001927
Relation: 18081909	CID	48	61	C026098	76	90	D001927	true
Relation: 18081909	CID	63	66	C026098	76	90	D001927	true

Sentence: FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).
Entity: 18081909	43	62	idiopathic epilepsy	Disease	C562694
Entity: 18081909	80	88	seizures	Disease	D012640
Entity: 18081909	106	109	LEV	Chemical	C026098
Entity: 18081909	129	138	valproate	Chemical	D014635
Entity: 18081909	140	143	VPA	Chemical	D014635
Relation: 18081909	CID	106	109	C026098	43	62	C562694	false
Relation: 18081909	CID	106	109	C026098	80	88	D012640	false
Relation: 18081909	CID	129	138	D014635	43	62	C562694	false
Relation: 18081909	CID	129	138	D014635	80	88	D012640	false
Relation: 18081909	CID	140	143	D014635	43	62	C562694	false
Relation: 18081909	CID	140	143	D014635	80	88	D012640	false

Sentence: Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine induced anxiety.
Entity: 18083142	0	14	Norepinephrine	Chemical	D009638
Entity: 18083142	89	96	cocaine	Chemical	D003042
Entity: 18083142	105	112	anxiety	Disease	D001008
Relation: 18083142	CID	0	14	D009638	105	112	D001008	false
Relation: 18083142	CID	89	96	D003042	105	112	D001008	true

Sentence: While the mechanisms underlying cocaine's rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by cocaine, such as anxiety.
Entity: 18083142	32	39	cocaine	Chemical	D003042
Entity: 18083142	167	174	cocaine	Chemical	D003042
Entity: 18083142	184	191	anxiety	Disease	D001008
Relation: 18083142	CID	32	39	D003042	184	191	D001008	true
Relation: 18083142	CID	167	174	D003042	184	191	D001008	true

Sentence: METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine induced anxiety.
Entity: 18083142	56	64	dopamine	Chemical	D004298
Entity: 18083142	118	132	norepinephrine	Chemical	D009638
Entity: 18083142	134	136	NE	Chemical	D009638
Entity: 18083142	229	236	cocaine	Chemical	D003042
Entity: 18083142	245	252	anxiety	Disease	D001008
Relation: 18083142	CID	56	64	D004298	245	252	D001008	false
Relation: 18083142	CID	118	132	D009638	245	252	D001008	false
Relation: 18083142	CID	134	136	D009638	245	252	D001008	false
Relation: 18083142	CID	229	236	D003042	245	252	D001008	true

Sentence: RESULTS: We found that cocaine dose-dependently increased anxiety-like behavior in control (Dbh +/-) mice, as measured by a decrease in open arm exploration.
Entity: 18083142	23	30	cocaine	Chemical	D003042
Entity: 18083142	58	65	anxiety	Disease	D001008
Relation: 18083142	CID	23	30	D003042	58	65	D001008	true

Sentence: Cocaine induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.
Entity: 18083142	0	7	Cocaine	Chemical	D003042
Entity: 18083142	16	23	anxiety	Disease	D001008
Entity: 18083142	88	98	disulfiram	Chemical	D004221
Entity: 18083142	102	110	dopamine	Chemical	D004298
Relation: 18083142	CID	0	7	D003042	16	23	D001008	true
Relation: 18083142	CID	88	98	D004221	16	23	D001008	false
Relation: 18083142	CID	102	110	D004298	16	23	D001008	false

Sentence: In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.
Entity: 18083142	126	137	propranolol	Chemical	D011433
Entity: 18083142	146	153	cocaine	Chemical	D003042
Entity: 18083142	162	169	anxiety	Disease	D001008
Entity: 18083142	254	262	prazosin	Chemical	D011224
Entity: 18083142	291	300	yohimbine	Chemical	D015016
Relation: 18083142	CID	126	137	D011433	162	169	D001008	false
Relation: 18083142	CID	146	153	D003042	162	169	D001008	true
Relation: 18083142	CID	254	262	D011224	162	169	D001008	false
Relation: 18083142	CID	291	300	D015016	162	169	D001008	false

Sentence: Clonidine for attention-deficit/hyperactivity disorder: II.
Entity: 18182964	0	9	Clonidine	Chemical	D003000
Entity: 18182964	14	54	attention-deficit/hyperactivity disorder	Disease	D001289
Relation: 18182964	CID	0	9	D003000	14	54	D001289	false

Sentence: OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD).
Entity: 18182964	53	62	clonidine	Chemical	D003000
Entity: 18182964	82	97	methylphenidate	Chemical	D008774
Entity: 18182964	115	155	attention-deficit/hyperactivity disorder	Disease	D001289
Entity: 18182964	157	161	ADHD	Disease	D001289
Relation: 18182964	CID	53	62	D003000	115	155	D001289	false
Relation: 18182964	CID	53	62	D003000	157	161	D001289	false
Relation: 18182964	CID	82	97	D008774	115	155	D001289	false
Relation: 18182964	CID	82	97	D008774	157	161	D001289	false

Sentence: METHOD: In a 16-week multicenter, double-blind trial, 122 children with ADHD were randomly assigned to clonidine (n = 31), methylphenidate (n = 29), clonidine and methylphenidate (n = 32), or placebo (n = 30).
Entity: 18182964	72	76	ADHD	Disease	D001289
Entity: 18182964	103	112	clonidine	Chemical	D003000
Entity: 18182964	123	138	methylphenidate	Chemical	D008774
Entity: 18182964	149	158	clonidine	Chemical	D003000
Entity: 18182964	163	178	methylphenidate	Chemical	D008774
Relation: 18182964	CID	103	112	D003000	72	76	D001289	false
Relation: 18182964	CID	123	138	D008774	72	76	D001289	false
Relation: 18182964	CID	149	158	D003000	72	76	D001289	false
Relation: 18182964	CID	163	178	D008774	72	76	D001289	false

Sentence: RESULTS: There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine (17.5% versus 3.4%; p =.02), but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes.
Entity: 18182964	38	49	bradycardia	Disease	D001919
Entity: 18182964	75	84	clonidine	Chemical	D003000
Entity: 18182964	122	131	clonidine	Chemical	D003000
Relation: 18182964	CID	75	84	D003000	38	49	D001919	true
Relation: 18182964	CID	122	131	D003000	38	49	D001919	true

Sentence: Drowsiness was common on clonidine, but generally resolved by 6 to 8 weeks.
Entity: 18182964	0	10	Drowsiness	Disease	D006970
Entity: 18182964	25	34	clonidine	Chemical	D003000
Relation: 18182964	CID	25	34	D003000	0	10	D006970	false

Sentence: CONCLUSIONS: Clonidine, used alone or with methylphenidate, appears safe and well tolerated in childhood ADHD.
Entity: 18182964	13	22	Clonidine	Chemical	D003000
Entity: 18182964	43	58	methylphenidate	Chemical	D008774
Entity: 18182964	105	109	ADHD	Disease	D001289
Relation: 18182964	CID	13	22	D003000	105	109	D001289	false
Relation: 18182964	CID	43	58	D008774	105	109	D001289	false

Sentence: Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.
Entity: 18217897	0	11	Thalidomide	Chemical	D013792
Entity: 18217897	81	102	non-Hodgkin lymphomas	Disease	D008228
Entity: 18217897	128	134	Cancer	Disease	D009369
Entity: 18217897	139	147	Leukemia	Disease	D007938
Relation: 18217897	CID	0	11	D013792	81	102	D008228	false
Relation: 18217897	CID	0	11	D013792	128	134	D009369	false
Relation: 18217897	CID	0	11	D013792	139	147	D007938	false

Sentence: Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.
Entity: 18217897	0	11	Thalidomide	Chemical	D013792
Entity: 18217897	71	87	multiple myeloma	Disease	D009101
Entity: 18217897	89	109	mantle cell lymphoma	Disease	D020522
Entity: 18217897	114	140	lymphoplasmacytic lymphoma	Disease	D008223
Relation: 18217897	CID	0	11	D013792	71	87	D009101	false
Relation: 18217897	CID	0	11	D013792	89	109	D020522	false
Relation: 18217897	CID	0	11	D013792	114	140	D008223	false

Sentence: Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.
Entity: 18217897	80	89	lymphomas	Disease	D008223
Entity: 18217897	99	110	thalidomide	Chemical	D013792
Relation: 18217897	CID	99	110	D013792	80	89	D008223	false

Sentence: Intracavernous epinephrine: a minimally invasive treatment for priapism in the emergency department.
Entity: 18996674	15	26	epinephrine	Chemical	D004837
Entity: 18996674	63	71	priapism	Disease	D011317
Relation: 18996674	CID	15	26	D004837	63	71	D011317	false

Sentence: A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after cocaine use.
Entity: 18996674	40	47	cocaine	Chemical	D003042
Entity: 18996674	141	149	priapism	Disease	D011317
Entity: 18996674	156	163	cocaine	Chemical	D003042
Relation: 18996674	CID	40	47	D003042	141	149	D011317	true
Relation: 18996674	CID	156	163	D003042	141	149	D011317	true

Sentence: Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.
Entity: 19058010	10	19	green tea	Chemical	D010936
Entity: 19058010	24	33	vitamin E	Chemical	D014810
Entity: 19058010	49	62	isoproterenol	Chemical	D007545
Entity: 19058010	71	92	myocardial infarction	Disease	D009203
Relation: 19058010	CID	10	19	D010936	71	92	D009203	false
Relation: 19058010	CID	24	33	D014810	71	92	D009203	false
Relation: 19058010	CID	49	62	D007545	71	92	D009203	true

Sentence: The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO) induced myocardial infarction in rats.
Entity: 19058010	67	76	green tea	Chemical	D010936
Entity: 19058010	81	90	vitamin E	Chemical	D014810
Entity: 19058010	217	230	isoproterenol	Chemical	D007545
Entity: 19058010	232	235	ISO	Chemical	D007545
Entity: 19058010	245	266	myocardial infarction	Disease	D009203
Relation: 19058010	CID	67	76	D010936	245	266	D009203	false
Relation: 19058010	CID	81	90	D014810	245	266	D009203	false
Relation: 19058010	CID	217	230	D007545	245	266	D009203	true
Relation: 19058010	CID	232	235	D007545	245	266	D009203	true

Sentence: Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.
Entity: 19581773	15	32	ocular myasthenia	Disease	D009157
Entity: 19581773	40	60	pegylated interferon	Chemical	C417083
Entity: 19581773	65	74	ribavirin	Chemical	D012254
Entity: 19581773	89	108	chronic hepatitis C	Disease	D019698
Relation: 19581773	CID	40	60	C417083	15	32	D009157	true
Relation: 19581773	CID	40	60	C417083	89	108	D019698	false
Relation: 19581773	CID	65	74	D012254	15	32	D009157	true
Relation: 19581773	CID	65	74	D012254	89	108	D019698	false

Sentence: A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).
Entity: 19581773	38	46	diplopia	Disease	D004172
Entity: 19581773	82	117	pegylated interferon (IFN) alpha-2b	Chemical	C417083
Entity: 19581773	122	131	ribavirin	Chemical	D012254
Entity: 19581773	136	155	chronic hepatitis C	Disease	D019698
Entity: 19581773	157	160	CHC	Disease	D019698
Relation: 19581773	CID	82	117	C417083	38	46	D004172	false
Relation: 19581773	CID	82	117	C417083	136	155	D019698	false
Relation: 19581773	CID	82	117	C417083	157	160	D019698	false
Relation: 19581773	CID	122	131	D012254	38	46	D004172	false
Relation: 19581773	CID	122	131	D012254	136	155	D019698	false
Relation: 19581773	CID	122	131	D012254	157	160	D019698	false

Sentence: Schizophrenia has been initially associated with dysfunction in dopamine neurotransmission.
Entity: 19759529	0	13	Schizophrenia	Disease	D012559
Entity: 19759529	64	72	dopamine	Chemical	D004298
Relation: 19759529	CID	64	72	D004298	0	13	D012559	false

Sentence: However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.
Entity: 19759529	49	58	glutamate	Chemical	D018698
Entity: 19759529	59	79	N-methyl-D-aspartate	Chemical	D016202
Entity: 19759529	81	85	NMDA	Chemical	D016202
Entity: 19759529	104	117	schizophrenic	Disease	D012559
Entity: 19759529	218	222	NMDA	Chemical	D016202
Relation: 19759529	CID	49	58	D018698	104	117	D012559	false
Relation: 19759529	CID	59	79	D016202	104	117	D012559	false
Relation: 19759529	CID	81	85	D016202	104	117	D012559	false
Relation: 19759529	CID	218	222	D016202	104	117	D012559	false

Sentence: This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).
Entity: 19759529	81	90	SSR103800	Chemical	-1
Entity: 19759529	129	142	hyperactivity	Disease	D006948
Entity: 19759529	181	192	amphetamine	Chemical	D000661
Entity: 19759529	197	203	MK-801	Chemical	D016291
Entity: 19759529	229	233	NMDA	Chemical	D016202
Relation: 19759529	CID	81	90	-1	129	142	D006948	false
Relation: 19759529	CID	181	192	D000661	129	142	D006948	true
Relation: 19759529	CID	197	203	D016291	129	142	D006948	true
Relation: 19759529	CID	229	233	D016202	129	142	D006948	false

Sentence: Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.
Entity: 19759529	20	29	SSR103800	Chemical	-1
Entity: 19759529	57	70	hyperactivity	Disease	D006948
Entity: 19759529	102	106	NMDA	Chemical	D016202
Entity: 19759529	128	134	MK-801	Chemical	D016291
Entity: 19759529	170	183	hyperactivity	Disease	D006948
Entity: 19759529	187	191	NMDA	Chemical	D016202
Relation: 19759529	CID	20	29	-1	57	70	D006948	false
Relation: 19759529	CID	20	29	-1	170	183	D006948	false
Relation: 19759529	CID	102	106	D016202	57	70	D006948	false
Relation: 19759529	CID	102	106	D016202	170	183	D006948	false
Relation: 19759529	CID	128	134	D016291	57	70	D006948	true
Relation: 19759529	CID	128	134	D016291	170	183	D006948	true
Relation: 19759529	CID	187	191	D016202	57	70	D006948	false
Relation: 19759529	CID	187	191	D016202	170	183	D006948	false

Sentence: In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).
Entity: 19759529	13	22	SSR103800	Chemical	-1
Entity: 19759529	40	53	hyperactivity	Disease	D006948
Entity: 19759529	65	76	amphetamine	Chemical	D000661
Entity: 19759529	102	110	dopamine	Chemical	D004298
Relation: 19759529	CID	13	22	-1	40	53	D006948	false
Relation: 19759529	CID	65	76	D000661	40	53	D006948	true
Relation: 19759529	CID	102	110	D004298	40	53	D006948	false

Sentence: Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.
Entity: 19759529	29	40	haloperidol	Chemical	D006220
Entity: 19759529	56	66	olanzapine	Chemical	C076029
Entity: 19759529	68	77	clozapine	Chemical	D003024
Entity: 19759529	82	94	aripiprazole	Chemical	C094645
Entity: 19759529	149	162	hyperactivity	Disease	D006948
Relation: 19759529	CID	29	40	D006220	149	162	D006948	false
Relation: 19759529	CID	56	66	C076029	149	162	D006948	false
Relation: 19759529	CID	68	77	D003024	149	162	D006948	false
Relation: 19759529	CID	82	94	C094645	149	162	D006948	false

Sentence: However, unlike these latter, SSR103800 did not produce catalepsy (retention on the bar test) up to 30 mg/kg p.o.
Entity: 19759529	30	39	SSR103800	Chemical	-1
Entity: 19759529	56	65	catalepsy	Disease	D002375
Relation: 19759529	CID	30	39	-1	56	65	D002375	false

Sentence: Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia induced hypotension.
Entity: 19957053	0	13	Phenylephrine	Chemical	D010656
Entity: 19957053	22	31	ephedrine	Chemical	D004809
Entity: 19957053	32	64	reduces frontal lobe oxygenation	Disease	D002534
Entity: 19957053	94	105	hypotension	Disease	D007022
Relation: 19957053	CID	0	13	D010656	32	64	D002534	true
Relation: 19957053	CID	0	13	D010656	94	105	D007022	false
Relation: 19957053	CID	22	31	D004809	32	64	D002534	false
Relation: 19957053	CID	22	31	D004809	94	105	D007022	false

Sentence: We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia induced hypotension.
Entity: 19957053	26	39	phenylephrine	Chemical	D010656
Entity: 19957053	44	53	ephedrine	Chemical	D004809
Entity: 19957053	122	133	hypotension	Disease	D007022
Relation: 19957053	CID	26	39	D010656	122	133	D007022	false
Relation: 19957053	CID	44	53	D004809	122	133	D007022	false

Sentence: RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.
Entity: 20619828	9	21	Clomipramine	Chemical	D002997
Entity: 20619828	126	133	anxiety	Disease	D001008
Entity: 20619828	175	199	behavioral inflexibility	Disease	-1
Entity: 20619828	292	309	memory impairment	Disease	D008569
Entity: 20619828	338	346	hoarding	Disease	D060845
Entity: 20619828	352	379	corticostriatal dysfunction	Disease	-1
Relation: 20619828	CID	9	21	D002997	126	133	D001008	true
Relation: 20619828	CID	9	21	D002997	175	199	-1	false
Relation: 20619828	CID	9	21	D002997	292	309	D008569	true
Relation: 20619828	CID	9	21	D002997	338	346	D060845	true
Relation: 20619828	CID	9	21	D002997	352	379	-1	false

Sentence: A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives.
Entity: 891050	26	51	hemolytic uremic syndrome	Disease	D006463
Entity: 891050	53	56	HUS	Disease	D006463
Entity: 891050	76	95	oral contraceptives	Chemical	D003276
Relation: 891050	CID	76	95	D003276	26	51	D006463	true
Relation: 891050	CID	76	95	D003276	53	56	D006463	true

Sentence: She was treated with heparin, dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped.
Entity: 891050	21	28	heparin	Chemical	D006493
Entity: 891050	30	42	dipyridamole	Chemical	D004176
Entity: 891050	167	173	anuria	Disease	D001002
Relation: 891050	CID	21	28	D006493	167	173	D001002	false
Relation: 891050	CID	30	42	D004176	167	173	D001002	false

Sentence: Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine induced myocardial injury in dogs.
Entity: 983936	11	31	acetylsalicylic acid	Chemical	D001241
Entity: 983936	33	45	dipyridamole	Chemical	D004176
Entity: 983936	51	65	hydrocortisone	Chemical	D006854
Entity: 983936	69	80	epinephrine	Chemical	D004837
Entity: 983936	89	106	myocardial injury	Disease	D009202
Relation: 983936	CID	11	31	D001241	89	106	D009202	false
Relation: 983936	CID	33	45	D004176	89	106	D009202	false
Relation: 983936	CID	51	65	D006854	89	106	D009202	false
Relation: 983936	CID	69	80	D004837	89	106	D009202	true

Sentence: A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction.
Entity: 983936	43	60	myocardial injury	Disease	D009202
Entity: 983936	62	73	epinephrine	Chemical	D004837
Entity: 983936	205	226	myocardial infarction	Disease	D009203
Relation: 983936	CID	62	73	D004837	43	60	D009202	true
Relation: 983936	CID	62	73	D004837	205	226	D009203	false

Sentence: Eight glaucomatous patients chronically treated with timolol 0.5%/12h, suffering from depression diagnosed through DMS-III-R criteria, were included in the study.
Entity: 1428568	6	18	glaucomatous	Disease	D005901
Entity: 1428568	53	60	timolol	Chemical	D013999
Entity: 1428568	86	96	depression	Disease	D003866
Relation: 1428568	CID	53	60	D013999	6	18	D005901	false
Relation: 1428568	CID	53	60	D013999	86	96	D003866	true

Sentence: In a double blind cross-over study with control group, the patients under timolol treatment presented higher depression values measured through the Beck and the Zung-Conde scales (p < 0.001 vs control).
Entity: 1428568	74	81	timolol	Chemical	D013999
Entity: 1428568	109	119	depression	Disease	D003866
Relation: 1428568	CID	74	81	D013999	109	119	D003866	true

Sentence: Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.
Entity: 1720453	23	33	ifosfamide	Chemical	D007069
Entity: 1720453	34	48	renal toxicity	Disease	D007674
Entity: 1720453	73	101	malignant mesenchymal tumors	Disease	C535700
Relation: 1720453	CID	23	33	D007069	34	48	D007674	true
Relation: 1720453	CID	23	33	D007069	73	101	C535700	false

Sentence: The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.
Entity: 1720453	39	67	malignant mesenchymal tumors	Disease	C535700
Entity: 1720453	121	131	ifosfamide	Chemical	D007069
Entity: 1720453	199	226	Malignant Mesenchymal Tumor	Disease	C535700
Relation: 1720453	CID	121	131	D007069	39	67	C535700	false
Relation: 1720453	CID	121	131	D007069	199	226	C535700	false

Sentence: Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.
Entity: 1720453	78	88	glucosuria	Disease	D006030
Entity: 1720453	90	101	proteinuria	Disease	D011507
Entity: 1720453	103	116	aminoaciduria	Disease	D000608
Entity: 1720453	142	152	creatinine	Chemical	D003404
Entity: 1720453	164	173	phosphate	Chemical	D010710
Relation: 1720453	CID	142	152	D003404	78	88	D006030	false
Relation: 1720453	CID	142	152	D003404	90	101	D011507	false
Relation: 1720453	CID	142	152	D003404	103	116	D000608	false
Relation: 1720453	CID	164	173	D010710	78	88	D006030	false
Relation: 1720453	CID	164	173	D010710	90	101	D011507	false
Relation: 1720453	CID	164	173	D010710	103	116	D000608	false

Sentence: Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.
Entity: 1720453	146	154	toxicity	Disease	D064420
Entity: 1720453	168	186	Fanconi's syndrome	Disease	D005198
Entity: 1720453	188	192	TDFS	Disease	D005198
Entity: 1720453	286	295	phosphate	Chemical	D010710
Relation: 1720453	CID	286	295	D010710	146	154	D064420	false
Relation: 1720453	CID	286	295	D010710	168	186	D005198	false
Relation: 1720453	CID	286	295	D010710	188	192	D005198	false

Sentence: Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of ifosfamide, a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic tumor involvement.
Entity: 1720453	7	15	toxicity	Disease	D064420
Entity: 1720453	77	87	ifosfamide	Chemical	D007069
Entity: 1720453	170	175	tumor	Disease	D009369
Relation: 1720453	CID	77	87	D007069	7	15	D064420	false
Relation: 1720453	CID	77	87	D007069	170	175	D009369	false

Sentence: Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine induced hyperactivity in rats.
Entity: 1833784	41	49	dopamine	Chemical	D004298
Entity: 1833784	73	81	nicotine	Chemical	D009538
Entity: 1833784	90	103	hyperactivity	Disease	D006948
Relation: 1833784	CID	41	49	D004298	90	103	D006948	false
Relation: 1833784	CID	73	81	D009538	90	103	D006948	true

Sentence: Nicotine (1.0 mg/kg) caused a significant increase in locomotor activity in rats that were habituated to the test environment, but had only a weak and delayed stimulant action in rats that were unfamiliar with the test environment.
Entity: 1833784	0	8	Nicotine	Chemical	D009538
Entity: 1833784	42	72	increase in locomotor activity	Disease	D006948
Relation: 1833784	CID	0	8	D009538	42	72	D006948	true

Sentence: Nicotine induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.
Entity: 1833784	0	8	Nicotine	Chemical	D009538
Entity: 1833784	17	30	hyperactivity	Disease	D006948
Entity: 1833784	74	83	SCH 23390	Chemical	C534628
Entity: 1833784	113	123	raclopride	Chemical	D020891
Entity: 1833784	149	161	fluphenazine	Chemical	D005476
Relation: 1833784	CID	0	8	D009538	17	30	D006948	true
Relation: 1833784	CID	74	83	C534628	17	30	D006948	false
Relation: 1833784	CID	113	123	D020891	17	30	D006948	false
Relation: 1833784	CID	149	161	D005476	17	30	D006948	false

Sentence: Pretreatment with the D2 agonist PHNO enhanced nicotine induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.
Entity: 1833784	33	37	PHNO	Chemical	-1
Entity: 1833784	47	55	nicotine	Chemical	D009538
Entity: 1833784	64	77	hyperactivity	Disease	D006948
Entity: 1833784	102	111	SKF 38393	Chemical	D015647
Relation: 1833784	CID	33	37	-1	64	77	D006948	false
Relation: 1833784	CID	47	55	D009538	64	77	D006948	true
Relation: 1833784	CID	102	111	D015647	64	77	D006948	false

Sentence: The results indicate that acute nicotine injection induces a pronounced hyperactivity in rats habituated to the test environment.
Entity: 1833784	32	40	nicotine	Chemical	D009538
Entity: 1833784	72	85	hyperactivity	Disease	D006948
Relation: 1833784	CID	32	40	D009538	72	85	D006948	true

Sentence: Reduction in injection pain using buffered lidocaine as a local anesthetic before cardiac catheterization.
Entity: 2070391	23	27	pain	Disease	D010146
Entity: 2070391	43	52	lidocaine	Chemical	D008012
Relation: 2070391	CID	43	52	D008012	23	27	D010146	true

Sentence: Previous reports have suggested that pain associated with the injection of lidocaine is related to the acidic pH of the solution.
Entity: 2070391	37	41	pain	Disease	D010146
Entity: 2070391	75	84	lidocaine	Chemical	D008012
Relation: 2070391	CID	75	84	D008012	37	41	D010146	true

Sentence: To determine if the addition of a buffering solution to adjust the pH of lidocaine into the physiologic range would reduce pain during injection, we performed a blinded randomized study in patients undergoing cardiac catheterization.
Entity: 2070391	73	82	lidocaine	Chemical	D008012
Entity: 2070391	123	127	pain	Disease	D010146
Relation: 2070391	CID	73	82	D008012	123	127	D010146	true

Sentence: Twenty patients were asked to quantify the severity of pain after receiving standard lidocaine in one femoral area and buffered lidocaine in the opposite femoral area.
Entity: 2070391	55	59	pain	Disease	D010146
Entity: 2070391	85	94	lidocaine	Chemical	D008012
Entity: 2070391	128	137	lidocaine	Chemical	D008012
Relation: 2070391	CID	85	94	D008012	55	59	D010146	true
Relation: 2070391	CID	128	137	D008012	55	59	D010146	true

Sentence: The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine (2.7 +/- 1.9 vs. 3.8 +/- 2.2, P = 0.03).
Entity: 2070391	9	13	pain	Disease	D010146
Entity: 2070391	33	42	lidocaine	Chemical	D008012
Entity: 2070391	100	109	lidocaine	Chemical	D008012
Relation: 2070391	CID	33	42	D008012	9	13	D010146	true
Relation: 2070391	CID	100	109	D008012	9	13	D010146	true

Sentence: Randomized, double-blind trial of mazindol in Duchenne dystrophy.
Entity: 2266990	34	42	mazindol	Chemical	D008454
Entity: 2266990	46	64	Duchenne dystrophy	Disease	D020388
Relation: 2266990	CID	34	42	D008454	46	64	D020388	false

Sentence: We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.
Entity: 2266990	44	52	mazindol	Chemical	D008454
Entity: 2266990	117	135	Duchenne dystrophy	Disease	D020388
Relation: 2266990	CID	44	52	D008454	117	135	D020388	false

Sentence: Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.
Entity: 2266990	29	37	mazindol	Chemical	D008454
Entity: 2266990	47	65	decreased appetite	Disease	D001068
Entity: 2266990	73	82	dry mouth	Disease	D014987
Entity: 2266990	119	144	gastrointestinal symptoms	Disease	D012817
Entity: 2266990	152	160	mazindol	Chemical	D008454
Relation: 2266990	CID	29	37	D008454	47	65	D001068	true
Relation: 2266990	CID	29	37	D008454	73	82	D014987	true
Relation: 2266990	CID	29	37	D008454	119	144	D012817	true
Relation: 2266990	CID	152	160	D008454	47	65	D001068	true
Relation: 2266990	CID	152	160	D008454	73	82	D014987	true
Relation: 2266990	CID	152	160	D008454	119	144	D012817	true

Sentence: Pentoxifylline (Trental) does not inhibit dipyridamole induced coronary hyperemia: implications for dipyridamole-thallium-201 myocardial imaging.
Entity: 2348231	0	14	Pentoxifylline	Chemical	D010431
Entity: 2348231	16	23	Trental	Chemical	D010431
Entity: 2348231	42	54	dipyridamole	Chemical	D004176
Entity: 2348231	72	81	hyperemia	Disease	D006940
Entity: 2348231	100	112	dipyridamole	Chemical	D004176
Entity: 2348231	113	121	thallium	Chemical	D013793
Relation: 2348231	CID	0	14	D010431	72	81	D006940	false
Relation: 2348231	CID	16	23	D010431	72	81	D006940	false
Relation: 2348231	CID	42	54	D004176	72	81	D006940	true
Relation: 2348231	CID	100	112	D004176	72	81	D006940	true
Relation: 2348231	CID	113	121	D013793	72	81	D006940	false

Sentence: Dipyridamole-thallium-201 imaging is often performed in patients unable to exercise because of peripheral vascular disease.
Entity: 2348231	0	12	Dipyridamole	Chemical	D004176
Entity: 2348231	13	21	thallium	Chemical	D013793
Entity: 2348231	95	122	peripheral vascular disease	Disease	D016491
Relation: 2348231	CID	0	12	D004176	95	122	D016491	false
Relation: 2348231	CID	13	21	D013793	95	122	D016491	false

Sentence: Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.
Entity: 2348231	34	48	pentoxifylline	Chemical	D010431
Entity: 2348231	50	57	Trental	Chemical	D010431
Entity: 2348231	62	76	methylxanthine	Chemical	C008514
Entity: 2348231	106	131	intermittent claudication	Disease	D007383
Relation: 2348231	CID	34	48	D010431	106	131	D007383	true
Relation: 2348231	CID	50	57	D010431	106	131	D007383	true
Relation: 2348231	CID	62	76	C008514	106	131	D007383	false

Sentence: Whether pentoxifylline inhibits dipyridamole induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.
Entity: 2348231	8	22	pentoxifylline	Chemical	D010431
Entity: 2348231	32	44	dipyridamole	Chemical	D004176
Entity: 2348231	62	71	hyperemia	Disease	D006940
Entity: 2348231	83	98	methylxanthines	Chemical	C008514
Entity: 2348231	107	119	theophylline	Chemical	D013806
Entity: 2348231	151	163	dipyridamole	Chemical	D004176
Entity: 2348231	164	172	thallium	Chemical	D013793
Relation: 2348231	CID	8	22	D010431	62	71	D006940	false
Relation: 2348231	CID	32	44	D004176	62	71	D006940	true
Relation: 2348231	CID	83	98	C008514	62	71	D006940	false
Relation: 2348231	CID	107	119	D013806	62	71	D006940	false
Relation: 2348231	CID	151	163	D004176	62	71	D006940	true
Relation: 2348231	CID	164	172	D013793	62	71	D006940	false

Sentence: Neither dose of pentoxifylline significantly decreased the dipyridamole induced hyperemia, while peak coronary blood flow was significantly lower after theophylline (p less than 0.01).
Entity: 2348231	16	30	pentoxifylline	Chemical	D010431
Entity: 2348231	59	71	dipyridamole	Chemical	D004176
Entity: 2348231	80	89	hyperemia	Disease	D006940
Entity: 2348231	152	164	theophylline	Chemical	D013806
Relation: 2348231	CID	16	30	D010431	80	89	D006940	false
Relation: 2348231	CID	59	71	D004176	80	89	D006940	true
Relation: 2348231	CID	152	164	D013806	80	89	D006940	false

Sentence: Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever.
Entity: 2445283	34	43	ribavirin	Chemical	D012254
Entity: 2445283	61	88	Argentine hemorrhagic fever	Disease	D006478
Relation: 2445283	CID	34	43	D012254	61	88	D006478	false

Sentence: Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution.
Entity: 2445283	34	43	ribavirin	Chemical	D012254
Entity: 2445283	75	102	Argentine hemorrhagic fever	Disease	D006478
Entity: 2445283	104	107	AHF	Disease	D006478
Relation: 2445283	CID	34	43	D012254	75	102	D006478	false
Relation: 2445283	CID	34	43	D012254	104	107	D006478	false

Sentence: Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers.
Entity: 2445283	18	27	ribavirin	Chemical	D012254
Entity: 2445283	60	67	viremia	Disease	D014766
Relation: 2445283	CID	18	27	D012254	60	67	D014766	false

Sentence: From these results, we conclude that ribavirin has an antiviral effect in advanced cases of AHF, and that anemia, the only secondary reaction observed, can be easily managed.
Entity: 2445283	37	46	ribavirin	Chemical	D012254
Entity: 2445283	92	95	AHF	Disease	D006478
Entity: 2445283	106	112	anemia	Disease	D000740
Relation: 2445283	CID	37	46	D012254	92	95	D006478	false
Relation: 2445283	CID	37	46	D012254	106	112	D000740	true

Sentence: Dipyridamole induced myocardial ischemia.
Entity: 2950248	0	12	Dipyridamole	Chemical	D004176
Entity: 2950248	21	40	myocardial ischemia	Disease	D017202
Relation: 2950248	CID	0	12	D004176	21	40	D017202	false

Sentence: Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures.
Entity: 2950248	0	6	Angina	Disease	D000787
Entity: 2950248	87	99	dipyridamole	Chemical	D004176
Relation: 2950248	CID	87	99	D004176	0	6	D000787	true

Sentence: To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.
Entity: 2950248	89	101	dipyridamole	Chemical	D004176
Entity: 2950248	120	132	dipyridamole	Chemical	D004176
Entity: 2950248	141	160	myocardial ischemia	Disease	D017202
Entity: 2950248	219	242	coronary artery disease	Disease	D003324
Relation: 2950248	CID	89	101	D004176	141	160	D017202	false
Relation: 2950248	CID	89	101	D004176	219	242	D003324	false
Relation: 2950248	CID	120	132	D004176	141	160	D017202	false
Relation: 2950248	CID	120	132	D004176	219	242	D003324	false

Sentence: Nitroprusside induced hypotension evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin-releasing factor (irCRF) into the hypophysial-portal circulation.
Entity: 3015567	0	13	Nitroprusside	Chemical	D009599
Entity: 3015567	22	33	hypotension	Disease	D007022
Relation: 3015567	CID	0	13	D009599	22	33	D007022	true

Sentence: Noradrenergic involvement in catalepsy induced by delta 9-tetrahydrocannabinol.
Entity: 3031535	29	38	catalepsy	Disease	D002375
Entity: 3031535	50	78	delta 9-tetrahydrocannabinol	Chemical	D013759
Relation: 3031535	CID	50	78	D013759	29	38	D002375	true

Sentence: Intracranial pressure increases during alfentanil induced rigidity.
Entity: 3125768	39	49	alfentanil	Chemical	D015760
Entity: 3125768	58	66	rigidity	Disease	D009127
Relation: 3125768	CID	39	49	D015760	58	66	D009127	true

Sentence: Intracranial pressure (ICP) was measured during alfentanil induced rigidity in rats.
Entity: 3125768	48	58	alfentanil	Chemical	D015760
Entity: 3125768	67	75	rigidity	Disease	D009127
Relation: 3125768	CID	48	58	D015760	67	75	D009127	true

Sentence: These variables returned to baseline when rigidity was abolished with metocurine.
Entity: 3125768	42	50	rigidity	Disease	D009127
Entity: 3125768	70	80	metocurine	Chemical	C032943
Relation: 3125768	CID	70	80	C032943	42	50	D009127	false

Sentence: Verapamil induced carbamazepine neurotoxicity.
Entity: 3371379	0	9	Verapamil	Chemical	D014700
Entity: 3371379	18	31	carbamazepine	Chemical	D002220
Entity: 3371379	32	45	neurotoxicity	Disease	D020258
Relation: 3371379	CID	0	9	D014700	32	45	D020258	true
Relation: 3371379	CID	18	31	D002220	32	45	D020258	true

Sentence: Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.
Entity: 3371379	27	40	carbamazepine	Chemical	D002220
Entity: 3371379	41	54	neurotoxicity	Disease	D020258
Entity: 3371379	85	94	verapamil	Chemical	D014700
Entity: 3371379	149	156	calcium	Chemical	D002118
Relation: 3371379	CID	27	40	D002220	41	54	D020258	true
Relation: 3371379	CID	85	94	D014700	41	54	D020258	true
Relation: 3371379	CID	149	156	D002118	41	54	D020258	false

Sentence: Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.
Entity: 3503576	18	40	auditory neurotoxicity	Disease	D006311
Entity: 3503576	63	75	deferoxamine	Chemical	D003676
Relation: 3503576	CID	63	75	D003676	18	40	D006311	false

Sentence: Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.
Entity: 3503576	0	6	Visual	Disease	D014786
Entity: 3503576	11	19	auditory	Disease	D006311
Entity: 3503576	108	114	anemia	Disease	D000740
Entity: 3503576	134	138	iron	Chemical	D007501
Entity: 3503576	181	193	deferoxamine	Chemical	D003676
Relation: 3503576	CID	134	138	D007501	0	6	D014786	false
Relation: 3503576	CID	134	138	D007501	11	19	D006311	false
Relation: 3503576	CID	134	138	D007501	108	114	D000740	false
Relation: 3503576	CID	181	193	D003676	0	6	D014786	true
Relation: 3503576	CID	181	193	D003676	11	19	D006311	false
Relation: 3503576	CID	181	193	D003676	108	114	D000740	false

Sentence: Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg/kg per dose, therapy was restarted with lower doses, usually 50 mg/kg per dose or less depending on the degree of auditory abnormality, and with the exception of two cases no further toxicity was demonstrated.
Entity: 3503576	53	65	deferoxamine	Chemical	D003676
Entity: 3503576	230	250	auditory abnormality	Disease	D006311
Entity: 3503576	299	307	toxicity	Disease	D064420
Relation: 3503576	CID	53	65	D003676	230	250	D006311	false
Relation: 3503576	CID	53	65	D003676	299	307	D064420	false

Sentence: Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.
Entity: 3503576	113	125	deferoxamine	Chemical	D003676
Entity: 3503576	210	222	deferoxamine	Chemical	D003676
Entity: 3503576	242	253	ototoxicity	Disease	D006311
Relation: 3503576	CID	113	125	D003676	242	253	D006311	false
Relation: 3503576	CID	210	222	D003676	242	253	D006311	false

Sentence: Flurbiprofen in the treatment of juvenile rheumatoid arthritis.
Entity: 3560095	0	12	Flurbiprofen	Chemical	D005480
Entity: 3560095	33	62	juvenile rheumatoid arthritis	Disease	D001171
Relation: 3560095	CID	0	12	D005480	33	62	D001171	false

Sentence: Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.
Entity: 3560095	26	55	juvenile rheumatoid arthritis	Disease	D001171
Entity: 3560095	79	91	flurbiprofen	Chemical	D005480
Entity: 3560095	185	194	arthritis	Disease	D001168
Relation: 3560095	CID	79	91	D005480	26	55	D001171	false
Relation: 3560095	CID	79	91	D005480	185	194	D001168	false

Sentence: The correlation between neurotoxic esterase inhibition and mipafox induced neuropathic damage in rats.
Entity: 3714122	24	34	neurotoxic	Disease	D020258
Entity: 3714122	59	66	mipafox	Chemical	C005238
Entity: 3714122	75	93	neuropathic damage	Disease	D009422
Relation: 3714122	CID	59	66	C005238	24	34	D020258	false
Relation: 3714122	CID	59	66	C005238	75	93	D009422	false

Sentence: The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.
Entity: 3714122	24	42	neuropathic damage	Disease	D009422
Entity: 3714122	61	71	neurotoxic	Disease	D020258
Entity: 3714122	84	94	neuropathy	Disease	D009422
Entity: 3714122	155	162	Mipafox	Chemical	C005238
Entity: 3714122	164	207	N, N'-diisopropylphosphorodiamidofluoridate	Chemical	C005238
Entity: 3714122	212	222	neurotoxic	Disease	D020258
Entity: 3714122	223	238	organophosphate	Chemical	D010755
Relation: 3714122	CID	155	162	C005238	24	42	D009422	false
Relation: 3714122	CID	155	162	C005238	61	71	D020258	false
Relation: 3714122	CID	155	162	C005238	84	94	D009422	false
Relation: 3714122	CID	155	162	C005238	212	222	D020258	false
Relation: 3714122	CID	164	207	C005238	24	42	D009422	false
Relation: 3714122	CID	164	207	C005238	61	71	D020258	false
Relation: 3714122	CID	164	207	C005238	84	94	D009422	false
Relation: 3714122	CID	164	207	C005238	212	222	D020258	false
Relation: 3714122	CID	223	238	D010755	24	42	D009422	false
Relation: 3714122	CID	223	238	D010755	61	71	D020258	false
Relation: 3714122	CID	223	238	D010755	84	94	D009422	false
Relation: 3714122	CID	223	238	D010755	212	222	D020258	false

Sentence: In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.
Entity: 3714122	24	31	Mipafox	Chemical	C005238
Entity: 3714122	199	210	cord damage	Disease	D013118
Relation: 3714122	CID	24	31	C005238	199	210	D013118	true

Sentence: Cerebral infarction with a single oral dose of phenylpropanolamine.
Entity: 3828020	0	19	Cerebral infarction	Disease	D002544
Entity: 3828020	47	66	phenylpropanolamine	Chemical	D010665
Relation: 3828020	CID	47	66	D010665	0	19	D002544	true

Sentence: Treatment of psoriasis with azathioprine.
Entity: 4812392	13	22	psoriasis	Disease	D011565
Entity: 4812392	28	40	azathioprine	Chemical	D001379
Relation: 4812392	CID	28	40	D001379	13	22	D011565	false

Sentence: Azathioprine treatment benefited 19 (66%) out of 29 patients suffering from severe psoriasis.
Entity: 4812392	0	12	Azathioprine	Chemical	D001379
Entity: 4812392	83	92	psoriasis	Disease	D011565
Relation: 4812392	CID	0	12	D001379	83	92	D011565	false

Sentence: Maternal lithium and neonatal Ebstein's anomaly: evaluation with cross-sectional echocardiography.
Entity: 6518066	9	16	lithium	Chemical	D008094
Entity: 6518066	30	47	Ebstein's anomaly	Disease	D004437
Relation: 6518066	CID	9	16	D008094	30	47	D004437	true

Sentence: The effects of exercise on the severity of isoproterenol induced myocardial infarction were studied in female albino rats of 20,40,60 and 80 weeks of age.
Entity: 6534871	43	56	isoproterenol	Chemical	D007545
Entity: 6534871	65	86	myocardial infarction	Disease	D009203
Relation: 6534871	CID	43	56	D007545	65	86	D009203	true

Sentence: Effect of polyethylene glycol 400 on adriamycin toxicity in mice.
Entity: 6538499	10	33	polyethylene glycol 400	Chemical	D011092
Entity: 6538499	37	47	adriamycin	Chemical	D004317
Entity: 6538499	48	56	toxicity	Disease	D064420
Relation: 6538499	CID	10	33	D011092	48	56	D064420	false
Relation: 6538499	CID	37	47	D004317	48	56	D064420	false

Sentence: Light microscopic analysis showed a significant protection against ADR induced cardiac morphological alterations.
Entity: 6538499	67	70	ADR	Chemical	D004317
Entity: 6538499	79	112	cardiac morphological alterations	Disease	D009202
Relation: 6538499	CID	67	70	D004317	79	112	D009202	true

Sentence: Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.
Entity: 6747681	15	19	BCNU	Chemical	D002330
Entity: 6747681	50	67	malignant gliomas	Disease	D005910
Relation: 6747681	CID	15	19	D002330	50	67	D005910	false

Sentence: Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas.
Entity: 6747681	43	47	BCNU	Chemical	D002330
Entity: 6747681	49	86	1,3-bis-(2-chloroethyl)-1-nitrosourea	Chemical	D002330
Entity: 6747681	211	228	malignant gliomas	Disease	D005910
Relation: 6747681	CID	43	47	D002330	211	228	D005910	false
Relation: 6747681	CID	49	86	D002330	211	228	D005910	false

Sentence: Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.
Entity: 6747681	50	62	astrocytomas	Disease	D001254
Entity: 6747681	164	168	BCNU	Chemical	D002330
Relation: 6747681	CID	164	168	D002330	50	62	D001254	false

Sentence: Intrarenal infusion of noradrenaline caused hypertension at doses which did not do so when infused intravenously.
Entity: 6861444	23	36	noradrenaline	Chemical	D009638
Entity: 6861444	44	56	hypertension	Disease	D006973
Relation: 6861444	CID	23	36	D009638	44	56	D006973	true

Sentence: There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.
Entity: 7053303	27	35	dementia	Disease	D003704
Entity: 7053303	52	62	cimetidine	Chemical	D002927
Entity: 7053303	155	160	liver	Disease	D008107
Entity: 7053303	164	170	kidney	Disease	D007674
Entity: 7053303	187	197	cimetidine	Chemical	D002927
Relation: 7053303	CID	52	62	D002927	27	35	D003704	true
Relation: 7053303	CID	52	62	D002927	155	160	D008107	false
Relation: 7053303	CID	52	62	D002927	164	170	D007674	false
Relation: 7053303	CID	187	197	D002927	27	35	D003704	true
Relation: 7053303	CID	187	197	D002927	155	160	D008107	false
Relation: 7053303	CID	187	197	D002927	164	170	D007674	false

Sentence: Development of clear cell adenocarcinoma in DES-exposed offspring under observation.
Entity: 7088431	15	40	clear cell adenocarcinoma	Disease	D018262
Entity: 7088431	44	47	DES	Chemical	D004054
Relation: 7088431	CID	44	47	D004054	15	40	D018262	true

Sentence: Two cases of clear cell adenocarcinoma of the vagina detected at follow-up in young women exposed in utero to diethylstilbestrol are reported.
Entity: 7088431	13	18	clear	Disease	D018262
Entity: 7088431	24	38	adenocarcinoma	Disease	D014625
Entity: 7088431	110	128	diethylstilbestrol	Chemical	D004054
Relation: 7088431	CID	110	128	D004054	13	18	D018262	true
Relation: 7088431	CID	110	128	D004054	24	38	D014625	true

Sentence: Phenobarbitone induced enlargement of the liver in the rat: its relationship to carbon tetrachloride induced cirrhosis.
Entity: 7248170	0	14	Phenobarbitone	Chemical	D010634
Entity: 7248170	23	47	enlargement of the liver	Disease	D006529
Entity: 7248170	80	100	carbon tetrachloride	Chemical	D002251
Entity: 7248170	109	118	cirrhosis	Disease	D005355
Relation: 7248170	CID	0	14	D010634	23	47	D006529	true
Relation: 7248170	CID	0	14	D010634	109	118	D005355	false
Relation: 7248170	CID	80	100	D002251	23	47	D006529	false
Relation: 7248170	CID	80	100	D002251	109	118	D005355	false

Sentence: The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial "calibrating" dose of carbon tetrachloride at the peak of the phenobarbitone induced enlargement of the liver.
Entity: 7248170	20	42	cirrhosis of the liver	Disease	D008103
Entity: 7248170	116	123	ascites	Disease	D001201
Entity: 7248170	179	191	splenomegaly	Disease	D013163
Entity: 7248170	225	232	atrophy	Disease	D001284
Entity: 7248170	285	305	carbon tetrachloride	Chemical	D002251
Entity: 7248170	336	350	phenobarbitone	Chemical	D010634
Entity: 7248170	436	456	carbon tetrachloride	Chemical	D002251
Entity: 7248170	476	490	phenobarbitone	Chemical	D010634
Entity: 7248170	499	523	enlargement of the liver	Disease	D006529
Relation: 7248170	CID	285	305	D002251	20	42	D008103	true
Relation: 7248170	CID	285	305	D002251	116	123	D001201	false
Relation: 7248170	CID	285	305	D002251	179	191	D013163	false
Relation: 7248170	CID	285	305	D002251	225	232	D001284	false
Relation: 7248170	CID	285	305	D002251	499	523	D006529	false
Relation: 7248170	CID	336	350	D010634	20	42	D008103	true
Relation: 7248170	CID	336	350	D010634	116	123	D001201	false
Relation: 7248170	CID	336	350	D010634	179	191	D013163	false
Relation: 7248170	CID	336	350	D010634	225	232	D001284	false
Relation: 7248170	CID	336	350	D010634	499	523	D006529	true
Relation: 7248170	CID	436	456	D002251	20	42	D008103	true
Relation: 7248170	CID	436	456	D002251	116	123	D001201	false
Relation: 7248170	CID	436	456	D002251	179	191	D013163	false
Relation: 7248170	CID	436	456	D002251	225	232	D001284	false
Relation: 7248170	CID	436	456	D002251	499	523	D006529	false
Relation: 7248170	CID	476	490	D010634	20	42	D008103	true
Relation: 7248170	CID	476	490	D010634	116	123	D001201	false
Relation: 7248170	CID	476	490	D010634	179	191	D013163	false
Relation: 7248170	CID	476	490	D010634	225	232	D001284	false
Relation: 7248170	CID	476	490	D010634	499	523	D006529	true

Sentence: Attenuation of the lithium induced diabetes-insipidus-like syndrome by amiloride in rats.
Entity: 7453952	19	26	lithium	Chemical	D008094
Entity: 7453952	35	67	diabetes-insipidus-like syndrome	Disease	D003919
Entity: 7453952	71	80	amiloride	Chemical	D000584
Relation: 7453952	CID	19	26	D008094	35	67	D003919	true
Relation: 7453952	CID	71	80	D000584	35	67	D003919	false

Sentence: The effect of amiloride on lithium induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.
Entity: 7453952	14	23	amiloride	Chemical	D000584
Entity: 7453952	27	34	lithium	Chemical	D008094
Entity: 7453952	43	53	polydipsia	Disease	D059606
Entity: 7453952	58	66	polyuria	Disease	D011141
Entity: 7453952	78	85	lithium	Chemical	D008094
Entity: 7453952	209	213	LiCl	Chemical	D018021
Relation: 7453952	CID	14	23	D000584	43	53	D059606	false
Relation: 7453952	CID	14	23	D000584	58	66	D011141	false
Relation: 7453952	CID	27	34	D008094	43	53	D059606	false
Relation: 7453952	CID	27	34	D008094	58	66	D011141	false
Relation: 7453952	CID	78	85	D008094	43	53	D059606	false
Relation: 7453952	CID	78	85	D008094	58	66	D011141	false
Relation: 7453952	CID	209	213	D018021	43	53	D059606	false
Relation: 7453952	CID	209	213	D018021	58	66	D011141	false

Sentence: In all the experiments, the attenuation of the lithium induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.
Entity: 7453952	47	54	lithium	Chemical	D008094
Entity: 7453952	63	95	diabetes-insipidus-like syndrome	Disease	D003919
Entity: 7453952	99	108	amiloride	Chemical	D000584
Entity: 7453952	165	172	lithium	Chemical	D008094
Entity: 7453952	267	276	potassium	Chemical	D011188
Relation: 7453952	CID	47	54	D008094	63	95	D003919	true
Relation: 7453952	CID	99	108	D000584	63	95	D003919	false
Relation: 7453952	CID	165	172	D008094	63	95	D003919	true
Relation: 7453952	CID	267	276	D011188	63	95	D003919	false

Sentence: The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured.
Entity: 7802851	16	26	alprazolam	Chemical	D000525
Entity: 7802851	42	56	panic disorder	Disease	D016584
Entity: 7802851	62	73	agoraphobia	Disease	D000379
Relation: 7802851	CID	16	26	D000525	42	56	D016584	false
Relation: 7802851	CID	16	26	D000525	62	73	D000379	false

Sentence: METHOD: In London and Toronto 154 patients who met DSM-III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo.
Entity: 7802851	72	86	panic disorder	Disease	D016584
Entity: 7802851	92	103	agoraphobia	Disease	D000379
Entity: 7802851	123	133	alprazolam	Chemical	D000525
Relation: 7802851	CID	123	133	D000525	72	86	D016584	false
Relation: 7802851	CID	123	133	D000525	92	103	D000379	false

Sentence: Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.
Entity: 7802851	32	42	alprazolam	Chemical	D000525
Entity: 7802851	100	110	depression	Disease	D003866
Entity: 7802851	112	120	enuresis	Disease	D004775
Entity: 7802851	140	150	aggression	Disease	D001523
Entity: 7802851	198	210	irritability	Disease	D001523
Entity: 7802851	212	227	impaired memory	Disease	D008569
Entity: 7802851	229	240	weight loss	Disease	D015431
Entity: 7802851	245	251	ataxia	Disease	D001259
Relation: 7802851	CID	32	42	D000525	100	110	D003866	true
Relation: 7802851	CID	32	42	D000525	112	120	D004775	true
Relation: 7802851	CID	32	42	D000525	140	150	D001523	false
Relation: 7802851	CID	32	42	D000525	198	210	D001523	false
Relation: 7802851	CID	32	42	D000525	212	227	D008569	true
Relation: 7802851	CID	32	42	D000525	229	240	D015431	true
Relation: 7802851	CID	32	42	D000525	245	251	D001259	true

Sentence: Dup 753 prevents the development of puromycin aminonucleoside induced nephrosis.
Entity: 8319760	0	7	Dup 753	Chemical	D019808
Entity: 8319760	36	61	puromycin aminonucleoside	Chemical	D011692
Entity: 8319760	70	79	nephrosis	Disease	D009401
Relation: 8319760	CID	0	7	D019808	70	79	D009401	false
Relation: 8319760	CID	36	61	D011692	70	79	D009401	false

Sentence: The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.
Entity: 8319760	18	37	nephrotic syndromes	Disease	D009404
Entity: 8319760	46	57	proteinuria	Disease	D011507
Entity: 8319760	59	74	hypoalbuminemia	Disease	D034141
Entity: 8319760	76	96	hypercholesterolemia	Disease	D006937
Entity: 8319760	113	132	blood nitrogen urea	Chemical	D001806
Entity: 8319760	166	191	puromycin aminonucleoside	Chemical	D011692
Entity: 8319760	241	248	Dup 753	Chemical	D019808
Entity: 8319760	250	258	losartan	Chemical	D019808
Entity: 8319760	269	283	angiotensin II	Chemical	D000804
Relation: 8319760	CID	113	132	D001806	18	37	D009404	false
Relation: 8319760	CID	113	132	D001806	46	57	D011507	false
Relation: 8319760	CID	113	132	D001806	59	74	D034141	false
Relation: 8319760	CID	113	132	D001806	76	96	D006937	false
Relation: 8319760	CID	166	191	D011692	18	37	D009404	true
Relation: 8319760	CID	166	191	D011692	46	57	D011507	true
Relation: 8319760	CID	166	191	D011692	59	74	D034141	true
Relation: 8319760	CID	166	191	D011692	76	96	D006937	true
Relation: 8319760	CID	241	248	D019808	18	37	D009404	false
Relation: 8319760	CID	241	248	D019808	46	57	D011507	false
Relation: 8319760	CID	241	248	D019808	59	74	D034141	false
Relation: 8319760	CID	241	248	D019808	76	96	D006937	false
Relation: 8319760	CID	250	258	D019808	18	37	D009404	false
Relation: 8319760	CID	250	258	D019808	46	57	D011507	false
Relation: 8319760	CID	250	258	D019808	59	74	D034141	false
Relation: 8319760	CID	250	258	D019808	76	96	D006937	false
Relation: 8319760	CID	269	283	D000804	18	37	D009404	false
Relation: 8319760	CID	269	283	D000804	46	57	D011507	false
Relation: 8319760	CID	269	283	D000804	59	74	D034141	false
Relation: 8319760	CID	269	283	D000804	76	96	D006937	false

Sentence: Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.
Entity: 8386779	0	18	Sodium bicarbonate	Chemical	D017693
Entity: 8386779	30	41	penile pain	Disease	D004414
Entity: 8386779	83	103	erectile dysfunction	Disease	D007172
Relation: 8386779	CID	0	18	D017693	30	41	D004414	false
Relation: 8386779	CID	0	18	D017693	83	103	D007172	false

Sentence: In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.
Entity: 8386779	35	46	penile pain	Disease	D004414
Entity: 8386779	195	206	penile pain	Disease	D004414
Entity: 8386779	275	293	sodium bicarbonate	Chemical	D017693
Relation: 8386779	CID	275	293	D017693	35	46	D004414	false
Relation: 8386779	CID	275	293	D017693	195	206	D004414	false

Sentence: A total of 38 consecutive patients who presented to our clinic with impotence received 0.2 ml. of a combination of 3 drugs: 6 mg. papaverine, 100 micrograms. phentolamine and 10 micrograms. prostaglandin E1 with (pH 7.05) or without (pH 4.17) the addition of sodium bicarbonate (0.03 mEq.).
Entity: 8386779	68	77	impotence	Disease	D007172
Entity: 8386779	130	140	papaverine	Chemical	D010208
Entity: 8386779	158	170	phentolamine	Chemical	D010646
Entity: 8386779	190	206	prostaglandin E1	Chemical	D000527
Entity: 8386779	259	277	sodium bicarbonate	Chemical	D017693
Relation: 8386779	CID	130	140	D010208	68	77	D007172	false
Relation: 8386779	CID	158	170	D010646	68	77	D007172	false
Relation: 8386779	CID	190	206	D000527	68	77	D007172	false
Relation: 8386779	CID	259	277	D017693	68	77	D007172	false

Sentence: Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.
Entity: 8386779	27	45	sodium bicarbonate	Chemical	D017693
Entity: 8386779	93	104	penile pain	Disease	D004414
Entity: 8386779	173	191	sodium bicarbonate	Chemical	D017693
Entity: 8386779	206	217	penile pain	Disease	D004414
Relation: 8386779	CID	27	45	D017693	93	104	D004414	false
Relation: 8386779	CID	27	45	D017693	206	217	D004414	false
Relation: 8386779	CID	173	191	D017693	93	104	D004414	false
Relation: 8386779	CID	173	191	D017693	206	217	D004414	false

Sentence: Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.
Entity: 8421099	67	77	octreotide	Chemical	D015282
Entity: 8421099	107	116	gallstone	Disease	D042882
Entity: 8421099	138	149	acromegalic	Disease	D000172
Relation: 8421099	CID	67	77	D015282	107	116	D042882	true
Relation: 8421099	CID	67	77	D015282	138	149	D000172	false

Sentence: This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300-1500 micrograms/day for a mean of 24.2 +/- 13.9 months.
Entity: 8421099	120	130	acromegaly	Disease	D000172
Entity: 8421099	184	194	octreotide	Chemical	D015282
Relation: 8421099	CID	184	194	D015282	120	130	D000172	false

Sentence: During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.
Entity: 8421099	22	32	octreotide	Chemical	D015282
Entity: 8421099	71	81	gallstones	Disease	D042882
Entity: 8421099	99	118	acute cholecystitis	Disease	D041881
Relation: 8421099	CID	22	32	D015282	71	81	D042882	true
Relation: 8421099	CID	22	32	D015282	99	118	D041881	true

Sentence: After withdrawal of octreotide in 10 patients without gallstones, 8 patients assessed had return of normal gallbladder contractility within 1 month.
Entity: 8421099	20	30	octreotide	Chemical	D015282
Entity: 8421099	54	64	gallstones	Disease	D042882
Relation: 8421099	CID	20	30	D015282	54	64	D042882	true

Sentence: Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.
Entity: 8421099	127	137	gallstones	Disease	D042882
Entity: 8421099	143	156	cholecystitis	Disease	D002764
Entity: 8421099	164	174	octreotide	Chemical	D015282
Entity: 8421099	194	205	acromegalic	Disease	D000172
Relation: 8421099	CID	164	174	D015282	127	137	D042882	true
Relation: 8421099	CID	164	174	D015282	143	156	D002764	false
Relation: 8421099	CID	164	174	D015282	194	205	D000172	false

Sentence: Improvement of levodopa induced dyskinesia by propranolol in Parkinson's disease.
Entity: 8649546	15	23	levodopa	Chemical	D007980
Entity: 8649546	32	42	dyskinesia	Disease	D004409
Entity: 8649546	46	57	propranolol	Chemical	D011433
Entity: 8649546	61	80	Parkinson's disease	Disease	D010300
Relation: 8649546	CID	15	23	D007980	32	42	D004409	true
Relation: 8649546	CID	15	23	D007980	61	80	D010300	false
Relation: 8649546	CID	46	57	D011433	32	42	D004409	false
Relation: 8649546	CID	46	57	D011433	61	80	D010300	false

Sentence: Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.
Entity: 8649546	30	49	Parkinson's disease	Disease	D010300
Entity: 8649546	51	53	PD	Disease	D010300
Entity: 8649546	79	89	dyskinesia	Disease	D004409
Entity: 8649546	108	119	propranolol	Chemical	D011433
Relation: 8649546	CID	108	119	D011433	30	49	D010300	false
Relation: 8649546	CID	108	119	D011433	51	53	D010300	false
Relation: 8649546	CID	108	119	D011433	79	89	D004409	false

Sentence: Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats.
Entity: 8919272	26	40	encephalopathy	Disease	D001927
Entity: 8919272	96	105	valproate	Chemical	D014635
Relation: 8919272	CID	96	105	D014635	26	40	D001927	true

Sentence: Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral "Polfa") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage ("valproate encephalopathy").
Entity: 8919272	61	77	sodium valproate	Chemical	D014635
Entity: 8919272	193	215	neurological disorders	Disease	D009422
Entity: 8919272	227	244	cerebellum damage	Disease	D002526
Entity: 8919272	247	256	valproate	Chemical	D014635
Entity: 8919272	257	271	encephalopathy	Disease	D001927
Relation: 8919272	CID	61	77	D014635	193	215	D009422	false
Relation: 8919272	CID	61	77	D014635	227	244	D002526	false
Relation: 8919272	CID	61	77	D014635	257	271	D001927	true
Relation: 8919272	CID	247	256	D014635	193	215	D009422	false
Relation: 8919272	CID	247	256	D014635	227	244	D002526	false
Relation: 8919272	CID	247	256	D014635	257	271	D001927	true

Sentence: Macula toxicity after intravitreal amikacin.
Entity: 9199746	7	15	toxicity	Disease	D064420
Entity: 9199746	35	43	amikacin	Chemical	D000583
Relation: 9199746	CID	35	43	D000583	7	15	D064420	false

Sentence: BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.
Entity: 9199746	34	49	aminoglycosides	Chemical	D000617
Entity: 9199746	98	113	endophthalmitis	Disease	D009877
Entity: 9199746	123	133	infarction	Disease	D007238
Relation: 9199746	CID	34	49	D000617	98	113	D009877	false
Relation: 9199746	CID	34	49	D000617	123	133	D007238	false

Sentence: METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.
Entity: 9199746	39	47	amikacin	Chemical	D000583
Entity: 9199746	48	64	retinal toxicity	Disease	D012164
Entity: 9199746	90	98	amikacin	Chemical	D000583
Entity: 9199746	103	113	vancomycin	Chemical	D014640
Entity: 9199746	135	164	streptococcal endophthalmitis	Disease	D013290
Relation: 9199746	CID	39	47	D000583	48	64	D012164	true
Relation: 9199746	CID	39	47	D000583	135	164	D013290	false
Relation: 9199746	CID	90	98	D000583	48	64	D012164	true
Relation: 9199746	CID	90	98	D000583	135	164	D013290	false
Relation: 9199746	CID	103	113	D014640	48	64	D012164	false
Relation: 9199746	CID	103	113	D014640	135	164	D013290	false

Sentence: Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis.
Entity: 9199746	7	18	fluorescein	Chemical	D019793
Entity: 9199746	71	85	telangiectasis	Disease	D013684
Relation: 9199746	CID	7	18	D019793	71	85	D013684	false

Sentence: Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.
Entity: 9249847	35	73	atrioventricular reentrant tachycardia	Disease	D013611
Entity: 9249847	80	89	verapamil	Chemical	D014700
Entity: 9249847	130	160	Wolff-Parkinson-White syndrome	Disease	D014927
Entity: 9249847	165	198	idiopathic dilated cardiomyopathy	Disease	D002311
Relation: 9249847	CID	80	89	D014700	35	73	D013611	true
Relation: 9249847	CID	80	89	D014700	130	160	D014927	false
Relation: 9249847	CID	80	89	D014700	165	198	D002311	false

Sentence: Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.
Entity: 9284778	12	25	liver disease	Disease	D008107
Entity: 9284778	36	60	hydrochlorofluorocarbons	Chemical	-1
Entity: 9284778	69	74	ozone	Chemical	D010126
Entity: 9284778	98	117	chlorofluorocarbons	Chemical	D017402
Relation: 9284778	CID	36	60	-1	12	25	D008107	false
Relation: 9284778	CID	69	74	D010126	12	25	D008107	false
Relation: 9284778	CID	98	117	D017402	12	25	D008107	false

Sentence: We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).
Entity: 9284778	31	44	liver disease	Disease	D008107
Entity: 9284778	129	163	1,1-dichloro-2,2,2-trifluoroethane	Chemical	C067411
Entity: 9284778	165	173	HCFC 123	Chemical	C067411
Entity: 9284778	179	213	1-chloro-1,2,2,2-tetrafluoroethane	Chemical	C072959
Entity: 9284778	215	223	HCFC 124	Chemical	C072959
Relation: 9284778	CID	129	163	C067411	31	44	D008107	true
Relation: 9284778	CID	165	173	C067411	31	44	D008107	true
Relation: 9284778	CID	179	213	C072959	31	44	D008107	true
Relation: 9284778	CID	215	223	C072959	31	44	D008107	true

Sentence: Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.
Entity: 9284778	50	88	1-bromo-1-chloro-2,2,2-trifluoroethane	Chemical	D006221
Entity: 9284778	90	99	halothane	Chemical	D006221
Entity: 9284778	118	133	trifluoroacetyl	Chemical	D014269
Entity: 9284778	190	204	hepatotoxicity	Disease	D056486
Entity: 9284778	208	217	halothane	Chemical	D006221
Relation: 9284778	CID	50	88	D006221	190	204	D056486	false
Relation: 9284778	CID	90	99	D006221	190	204	D056486	false
Relation: 9284778	CID	118	133	D014269	190	204	D056486	false
Relation: 9284778	CID	208	217	D006221	190	204	D056486	false

Sentence: We aimed to test whether HCFCs 123 and 124 can result in serious liver disease.
Entity: 9284778	25	30	HCFCs	Chemical	C067411
Entity: 9284778	25	30	HCFCs	Chemical	C072959
Entity: 9284778	65	78	liver disease	Disease	D008107
Relation: 9284778	CID	25	30	C067411	65	78	D008107	true
Relation: 9284778	CID	25	30	C072959	65	78	D008107	true

Sentence: INTERPRETATION: Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population.
Entity: 9284778	53	58	HCFCs	Chemical	C067411
Entity: 9284778	53	58	HCFCs	Chemical	C072959
Entity: 9284778	93	105	liver injury	Disease	D056486
Relation: 9284778	CID	53	58	C067411	93	105	D056486	false
Relation: 9284778	CID	53	58	C072959	93	105	D056486	false

Sentence: Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).
Entity: 9522143	15	25	prilocaine	Chemical	D011318
Entity: 9522143	54	66	hearing loss	Disease	D034381
Entity: 9522143	99	110	bupivacaine	Chemical	D002045
Relation: 9522143	CID	15	25	D011318	54	66	D034381	true
Relation: 9522143	CID	99	110	D002045	54	66	D034381	true

Sentence: The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.
Entity: 9522143	12	24	hearing loss	Disease	D034381
Entity: 9522143	70	80	prilocaine	Chemical	D011318
Entity: 9522143	97	108	bupivacaine	Chemical	D002045
Relation: 9522143	CID	70	80	D011318	12	24	D034381	true
Relation: 9522143	CID	97	108	D002045	12	24	D034381	true

Sentence: A transient neurological deficit following intrathecal injection of 1% hyperbaric bupivacaine for unilateral spinal anaesthesia.
Entity: 9522152	12	32	neurological deficit	Disease	D009461
Entity: 9522152	82	93	bupivacaine	Chemical	D002045
Relation: 9522152	CID	82	93	D002045	12	32	D009461	false

Sentence: We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric bupivacaine slowly injected through a 25-gauge pencil-point spinal needle.
Entity: 9522152	32	52	neurological deficit	Disease	D009461
Entity: 9522152	130	141	bupivacaine	Chemical	D002045
Relation: 9522152	CID	130	141	D002045	32	52	D009461	false

Sentence: Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.
Entity: 9672936	0	9	Pethidine	Chemical	D008614
Entity: 9672936	21	28	seizure	Disease	D012640
Entity: 9672936	63	72	pethidine	Chemical	D008614
Entity: 9672936	77	95	postoperative pain	Disease	D010149
Relation: 9672936	CID	0	9	D008614	21	28	D012640	true
Relation: 9672936	CID	0	9	D008614	77	95	D010149	false
Relation: 9672936	CID	63	72	D008614	21	28	D012640	true
Relation: 9672936	CID	63	72	D008614	77	95	D010149	false

Sentence: A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.
Entity: 9672936	67	76	pethidine	Chemical	D008614
Entity: 9672936	141	159	postoperative pain	Disease	D010149
Relation: 9672936	CID	67	76	D008614	141	159	D010149	false

Sentence: A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use.
Entity: 9721172	76	104	vanishing bile duct syndrome	Disease	D001649
Entity: 9721172	119	143	Stevens-Johnson syndrome	Disease	D013262
Entity: 9721172	194	203	ibuprofen	Chemical	D007052
Relation: 9721172	CID	194	203	D007052	76	104	D001649	false
Relation: 9721172	CID	194	203	D007052	119	143	D013262	true

Sentence: Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.
Entity: 9721172	21	41	ursodeoxycholic acid	Chemical	D014580
Entity: 9721172	43	53	prednisone	Chemical	D011241
Entity: 9721172	64	74	tacrolimus	Chemical	D016559
Entity: 9721172	80	99	cholestatic disease	Disease	D002779
Entity: 9721172	122	131	cirrhosis	Disease	D005355
Relation: 9721172	CID	21	41	D014580	80	99	D002779	false
Relation: 9721172	CID	21	41	D014580	122	131	D005355	false
Relation: 9721172	CID	43	53	D011241	80	99	D002779	false
Relation: 9721172	CID	43	53	D011241	122	131	D005355	false
Relation: 9721172	CID	64	74	D016559	80	99	D002779	false
Relation: 9721172	CID	64	74	D016559	122	131	D005355	false

Sentence: High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium.
Entity: 9727773	18	48	primary pulmonary hypertension	Disease	D006976
Entity: 9727773	65	86	appetite suppressants	Chemical	D001067
Relation: 9727773	CID	65	86	D001067	18	48	D006976	true

Sentence: Primary pulmonary hypertension is a rare, progressive and incurable disease, which has been associated with the intake of appetite suppressant drugs.
Entity: 9727773	0	30	Primary pulmonary hypertension	Disease	D006976
Entity: 9727773	122	142	appetite suppressant	Chemical	D001067
Relation: 9727773	CID	122	142	D001067	0	30	D006976	true

Sentence: In 8 patients the diagnosis of primary pulmonary hypertension was uncertain, 5 of them had taken appetite suppressants.
Entity: 9727773	31	61	primary pulmonary hypertension	Disease	D006976
Entity: 9727773	97	118	appetite suppressants	Chemical	D001067
Relation: 9727773	CID	97	118	D001067	31	61	D006976	true

Sentence: A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension.
Entity: 9727773	41	62	appetite suppressants	Chemical	D001067
Entity: 9727773	106	136	primary pulmonary hypertension	Disease	D006976
Relation: 9727773	CID	41	62	D001067	106	136	D006976	true

Sentence: Choreoathetoid movements associated with rapid adjustment to methadone.
Entity: 9754849	0	24	Choreoathetoid movements	Disease	D002819
Entity: 9754849	61	70	methadone	Chemical	D008691
Relation: 9754849	CID	61	70	D008691	0	24	D002819	true

Sentence: Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates.
Entity: 9754849	0	12	Choreatiform	Disease	D002819
Entity: 9754849	13	26	hyperkinesias	Disease	D006948
Entity: 9754849	54	76	movement abnormalities	Disease	D020820
Entity: 9754849	103	110	cocaine	Chemical	D003042
Relation: 9754849	CID	103	110	D003042	0	12	D002819	true
Relation: 9754849	CID	103	110	D003042	13	26	D006948	true
Relation: 9754849	CID	103	110	D003042	54	76	D020820	false

Sentence: Cocaine induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.
Entity: 10365197	0	7	Cocaine	Chemical	D003042
Entity: 10365197	16	29	mood disorder	Disease	D019964
Entity: 10365197	52	63	psychiatric	Disease	D001523
Entity: 10365197	90	97	cocaine	Chemical	D003042
Relation: 10365197	CID	0	7	D003042	16	29	D019964	true
Relation: 10365197	CID	0	7	D003042	52	63	D001523	false
Relation: 10365197	CID	90	97	D003042	16	29	D019964	true
Relation: 10365197	CID	90	97	D003042	52	63	D001523	false

Sentence: This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance induced and other mood disorders. 243 cocaine-dependent outpatients with cocaine induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.
Entity: 10365197	116	130	mood disorders	Disease	D019964
Entity: 10365197	136	143	cocaine	Chemical	D003042
Entity: 10365197	171	178	cocaine	Chemical	D003042
Entity: 10365197	187	200	mood disorder	Disease	D019964
Entity: 10365197	202	206	CIMD	Disease	D019970
Entity: 10365197	215	229	mood disorders	Disease	D019964
Entity: 10365197	237	250	mood disorder	Disease	D019964
Entity: 10365197	280	291	psychiatric	Disease	D001523
Relation: 10365197	CID	136	143	D003042	116	130	D019964	true
Relation: 10365197	CID	136	143	D003042	187	200	D019964	true
Relation: 10365197	CID	136	143	D003042	202	206	D019970	false
Relation: 10365197	CID	136	143	D003042	215	229	D019964	true
Relation: 10365197	CID	136	143	D003042	237	250	D019964	true
Relation: 10365197	CID	136	143	D003042	280	291	D001523	false
Relation: 10365197	CID	171	178	D003042	116	130	D019964	true
Relation: 10365197	CID	171	178	D003042	187	200	D019964	true
Relation: 10365197	CID	171	178	D003042	202	206	D019970	false
Relation: 10365197	CID	171	178	D003042	215	229	D019964	true
Relation: 10365197	CID	171	178	D003042	237	250	D019964	true
Relation: 10365197	CID	171	178	D003042	280	291	D001523	false

Sentence: Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure.
Entity: 10704919	0	9	Hemolysis	Disease	D006461
Entity: 10704919	43	52	tamoxifen	Chemical	D013629
Relation: 10704919	CID	43	52	D013629	0	9	D006461	true

Sentence: Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.
Entity: 10704919	0	9	Tamoxifen	Chemical	D013629
Entity: 10704919	11	14	TAM	Chemical	D013629
Entity: 10704919	87	100	breast cancer	Disease	D001943
Entity: 10704919	162	178	hemolytic anemia	Disease	D000743
Relation: 10704919	CID	0	9	D013629	87	100	D001943	false
Relation: 10704919	CID	0	9	D013629	162	178	D000743	true
Relation: 10704919	CID	11	14	D013629	87	100	D001943	false
Relation: 10704919	CID	11	14	D013629	162	178	D000743	true

Sentence: This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms.
Entity: 10704919	35	38	TAM	Chemical	D013629
Entity: 10704919	123	126	TAM	Chemical	D013629
Entity: 10704919	135	151	hemolytic anemia	Disease	D000743
Relation: 10704919	CID	35	38	D013629	135	151	D000743	true
Relation: 10704919	CID	123	126	D013629	135	151	D000743	true

Sentence: TAM induces hemolysis of erythrocytes as a function of concentration.
Entity: 10704919	0	3	TAM	Chemical	D013629
Entity: 10704919	12	21	hemolysis	Disease	D006461
Relation: 10704919	CID	0	3	D013629	12	21	D006461	true

Sentence: The extension of hemolysis is variable with erythrocyte samples, but 12.5 microM TAM induces total hemolysis of all tested suspensions.
Entity: 10704919	17	26	hemolysis	Disease	D006461
Entity: 10704919	81	84	TAM	Chemical	D013629
Entity: 10704919	99	108	hemolysis	Disease	D006461
Relation: 10704919	CID	81	84	D013629	17	26	D006461	true
Relation: 10704919	CID	81	84	D013629	99	108	D006461	true

Sentence: The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM induced hemolysis is not related to oxidative membrane damage.
Entity: 10704919	4	13	hemolytic	Disease	D006461
Entity: 10704919	24	27	TAM	Chemical	D013629
Entity: 10704919	66	82	alpha-tocopherol	Chemical	D024502
Entity: 10704919	84	91	alpha-T	Chemical	D024502
Entity: 10704919	97	121	alpha-tocopherol acetate	Chemical	D024502
Entity: 10704919	123	132	alpha-TAc	Chemical	D024502
Entity: 10704919	158	166	hydroxyl	Chemical	D017665
Entity: 10704919	184	187	TAM	Chemical	D013629
Entity: 10704919	196	205	hemolysis	Disease	D006461
Relation: 10704919	CID	24	27	D013629	4	13	D006461	true
Relation: 10704919	CID	24	27	D013629	196	205	D006461	true
Relation: 10704919	CID	66	82	D024502	4	13	D006461	false
Relation: 10704919	CID	66	82	D024502	196	205	D006461	false
Relation: 10704919	CID	84	91	D024502	4	13	D006461	false
Relation: 10704919	CID	84	91	D024502	196	205	D006461	false
Relation: 10704919	CID	97	121	D024502	4	13	D006461	false
Relation: 10704919	CID	97	121	D024502	196	205	D006461	false
Relation: 10704919	CID	123	132	D024502	4	13	D006461	false
Relation: 10704919	CID	123	132	D024502	196	205	D006461	false
Relation: 10704919	CID	158	166	D017665	4	13	D006461	false
Relation: 10704919	CID	158	166	D017665	196	205	D006461	false
Relation: 10704919	CID	184	187	D013629	4	13	D006461	true
Relation: 10704919	CID	184	187	D013629	196	205	D006461	true

Sentence: This was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with TAM induced hemolysis.
Entity: 10704919	41	47	oxygen	Chemical	D010100
Entity: 10704919	118	121	TAM	Chemical	D013629
Entity: 10704919	130	139	hemolysis	Disease	D006461
Relation: 10704919	CID	41	47	D010100	130	139	D006461	false
Relation: 10704919	CID	118	121	D013629	130	139	D006461	true

Sentence: Hemolysis caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.
Entity: 10704919	0	9	Hemolysis	Disease	D006461
Entity: 10704919	20	23	TAM	Chemical	D013629
Entity: 10704919	59	60	K	Chemical	D011188
Entity: 10704919	131	140	hemolysis	Disease	D006461
Relation: 10704919	CID	20	23	D013629	0	9	D006461	true
Relation: 10704919	CID	20	23	D013629	131	140	D006461	true
Relation: 10704919	CID	59	60	D011188	0	9	D006461	false
Relation: 10704919	CID	59	60	D011188	131	140	D006461	false

Sentence: These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.
Entity: 10704919	47	56	hemolysis	Disease	D006461
Entity: 10704919	60	71	tocopherols	Chemical	D024505
Entity: 10704919	98	101	TAM	Chemical	D013629
Relation: 10704919	CID	60	71	D024505	47	56	D006461	false
Relation: 10704919	CID	98	101	D013629	47	56	D006461	true

Sentence: Therefore, TAM induced hemolysis results from a structural perturbation of red cell membrane, leading to changes in the framework of the erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane.
Entity: 10704919	11	14	TAM	Chemical	D013629
Entity: 10704919	23	32	hemolysis	Disease	D006461
Relation: 10704919	CID	11	14	D013629	23	32	D006461	true

Sentence: These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM, resulting in hemolytic anemia.
Entity: 10704919	100	103	TAM	Chemical	D013629
Entity: 10704919	118	134	hemolytic anemia	Disease	D000743
Relation: 10704919	CID	100	103	D013629	118	134	D000743	true

Sentence: Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.
Entity: 10706004	11	17	sodium	Chemical	D012964
Entity: 10706004	22	25	ATP	Chemical	D000255
Entity: 10706004	53	55	Na	Chemical	D012964
Entity: 10706004	56	57	K	Chemical	D011188
Entity: 10706004	83	95	nitric oxide	Chemical	D009569
Entity: 10706004	106	118	hypertension	Disease	D006973
Relation: 10706004	CID	11	17	D012964	106	118	D006973	false
Relation: 10706004	CID	22	25	D000255	106	118	D006973	false
Relation: 10706004	CID	53	55	D012964	106	118	D006973	false
Relation: 10706004	CID	56	57	D011188	106	118	D006973	false
Relation: 10706004	CID	83	95	D009569	106	118	D006973	true

Sentence: Inhibition of NO synthesis induces sustained hypertension.
Entity: 10706004	14	16	NO	Chemical	D009569
Entity: 10706004	45	57	hypertension	Disease	D006973
Relation: 10706004	CID	14	16	D009569	45	57	D006973	true

Sentence: In several models of hypertension, elevation of intracellular sodium level was documented in cardiac tissue.
Entity: 10706004	21	33	hypertension	Disease	D006973
Entity: 10706004	62	68	sodium	Chemical	D012964
Relation: 10706004	CID	62	68	D012964	21	33	D006973	false

Sentence: To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient hypertension induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.
Entity: 10706004	79	81	Na	Chemical	D012964
Entity: 10706004	120	122	Na	Chemical	D012964
Entity: 10706004	123	124	K	Chemical	D011188
Entity: 10706004	136	138	NO	Chemical	D009569
Entity: 10706004	149	161	hypertension	Disease	D006973
Entity: 10706004	181	183	NO	Chemical	D009569
Entity: 10706004	222	256	N(G)-nitro-L-arginine methyl ester	Chemical	D019331
Entity: 10706004	258	264	L-NAME	Chemical	D019331
Relation: 10706004	CID	79	81	D012964	149	161	D006973	false
Relation: 10706004	CID	120	122	D012964	149	161	D006973	false
Relation: 10706004	CID	123	124	D011188	149	161	D006973	false
Relation: 10706004	CID	136	138	D009569	149	161	D006973	true
Relation: 10706004	CID	181	183	D009569	149	161	D006973	true
Relation: 10706004	CID	222	256	D019331	149	161	D006973	false
Relation: 10706004	CID	258	264	D019331	149	161	D006973	false

Sentence: After recovery from hypertension, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.
Entity: 10706004	20	32	hypertension	Disease	D006973
Entity: 10706004	51	53	Na	Chemical	D012964
Entity: 10706004	54	55	K	Chemical	D011188
Entity: 10706004	105	108	ATP	Chemical	D000255
Entity: 10706004	165	168	ATP	Chemical	D000255
Relation: 10706004	CID	51	53	D012964	20	32	D006973	false
Relation: 10706004	CID	54	55	D011188	20	32	D006973	false
Relation: 10706004	CID	105	108	D000255	20	32	D006973	false
Relation: 10706004	CID	165	168	D000255	20	32	D006973	false

Sentence: Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.
Entity: 10706004	14	16	NO	Chemical	D009569
Entity: 10706004	47	59	hypertension	Disease	D006973
Entity: 10706004	75	84	depressed	Disease	D003866
Entity: 10706004	85	87	Na	Chemical	D012964
Entity: 10706004	151	153	Na	Chemical	D012964
Entity: 10706004	182	184	Na	Chemical	D012964
Entity: 10706004	185	186	K	Chemical	D011188
Relation: 10706004	CID	14	16	D009569	47	59	D006973	true
Relation: 10706004	CID	14	16	D009569	75	84	D003866	false
Relation: 10706004	CID	85	87	D012964	47	59	D006973	false
Relation: 10706004	CID	85	87	D012964	75	84	D003866	false
Relation: 10706004	CID	151	153	D012964	47	59	D006973	false
Relation: 10706004	CID	151	153	D012964	75	84	D003866	false
Relation: 10706004	CID	182	184	D012964	47	59	D006973	false
Relation: 10706004	CID	182	184	D012964	75	84	D003866	false
Relation: 10706004	CID	185	186	D011188	47	59	D006973	false
Relation: 10706004	CID	185	186	D011188	75	84	D003866	false

Sentence: Effects of long-term pretreatment with isoproterenol on bromocriptine induced tachycardia in conscious rats.
Entity: 10721819	39	52	isoproterenol	Chemical	D007545
Entity: 10721819	56	69	bromocriptine	Chemical	D001971
Entity: 10721819	78	89	tachycardia	Disease	D013610
Relation: 10721819	CID	39	52	D007545	78	89	D013610	false
Relation: 10721819	CID	56	69	D001971	78	89	D013610	true

Sentence: It has been shown that bromocriptine induced tachycardia, which persisted after adrenalectomy, is (i) mediated by central dopamine D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart.
Entity: 10721819	23	36	bromocriptine	Chemical	D001971
Entity: 10721819	45	56	tachycardia	Disease	D013610
Entity: 10721819	122	130	dopamine	Chemical	D004298
Entity: 10721819	180	193	isoproterenol	Chemical	D007545
Relation: 10721819	CID	23	36	D001971	45	56	D013610	true
Relation: 10721819	CID	122	130	D004298	45	56	D013610	false
Relation: 10721819	CID	180	193	D007545	45	56	D013610	false

Sentence: This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish bromocriptine induced tachycardia in conscious rats.
Entity: 10721819	72	85	isoproterenol	Chemical	D007545
Entity: 10721819	100	113	bromocriptine	Chemical	D001971
Entity: 10721819	122	133	tachycardia	Disease	D013610
Relation: 10721819	CID	72	85	D007545	122	133	D013610	false
Relation: 10721819	CID	100	113	D001971	122	133	D013610	true

Sentence: Isoproterenol pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate.
Entity: 10721819	0	13	Isoproterenol	Chemical	D007545
Entity: 10721819	46	65	cardiac hypertrophy	Disease	D006332
Relation: 10721819	CID	0	13	D007545	46	65	D006332	true

Sentence: In control rats, intravenous bromocriptine (150 microg/kg) induced significant hypotension and tachycardia.
Entity: 10721819	29	42	bromocriptine	Chemical	D001971
Entity: 10721819	79	90	hypotension	Disease	D007022
Entity: 10721819	95	106	tachycardia	Disease	D013610
Relation: 10721819	CID	29	42	D001971	79	90	D007022	true
Relation: 10721819	CID	29	42	D001971	95	106	D013610	true

Sentence: Bromocriptine induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v. domperidone (0.5 mg/kg).
Entity: 10721819	0	13	Bromocriptine	Chemical	D001971
Entity: 10721819	22	33	hypotension	Disease	D007022
Entity: 10721819	52	65	isoproterenol	Chemical	D007545
Entity: 10721819	86	97	tachycardia	Disease	D013610
Entity: 10721819	126	137	bradycardia	Disease	D001919
Entity: 10721819	181	192	domperidone	Chemical	D004294
Relation: 10721819	CID	0	13	D001971	22	33	D007022	true
Relation: 10721819	CID	0	13	D001971	86	97	D013610	true
Relation: 10721819	CID	0	13	D001971	126	137	D001919	false
Relation: 10721819	CID	52	65	D007545	22	33	D007022	false
Relation: 10721819	CID	52	65	D007545	86	97	D013610	false
Relation: 10721819	CID	52	65	D007545	126	137	D001919	true
Relation: 10721819	CID	181	192	D004294	22	33	D007022	false
Relation: 10721819	CID	181	192	D004294	86	97	D013610	false
Relation: 10721819	CID	181	192	D004294	126	137	D001919	true

Sentence: These results show that 15-day isoproterenol pretreatment not only abolished but reversed bromocriptine induced tachycardia to bradycardia, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.
Entity: 10721819	31	44	isoproterenol	Chemical	D007545
Entity: 10721819	90	103	bromocriptine	Chemical	D001971
Entity: 10721819	112	123	tachycardia	Disease	D013610
Entity: 10721819	127	138	bradycardia	Disease	D001919
Relation: 10721819	CID	31	44	D007545	112	123	D013610	false
Relation: 10721819	CID	31	44	D007545	127	138	D001919	true
Relation: 10721819	CID	90	103	D001971	112	123	D013610	true
Relation: 10721819	CID	90	103	D001971	127	138	D001919	false

Sentence: Given that sympathetic neural dominance exhibits a similar developmental pattern, and given that clonidine induces sympathetic withdrawal and bradycardia, we hypothesized that clonidine's developmental effects on cardiac rate and ultrasound production would mirror each other.
Entity: 10737864	97	106	clonidine	Chemical	D003000
Entity: 10737864	142	153	bradycardia	Disease	D001919
Entity: 10737864	176	185	clonidine	Chemical	D003000
Relation: 10737864	CID	97	106	D003000	142	153	D001919	true
Relation: 10737864	CID	176	185	D003000	142	153	D001919	true

Sentence: Age-related changes in ultrasound production corresponded with changes in cardiovascular variables, including baseline cardiac rate and clonidine induced bradycardia.
Entity: 10737864	136	145	clonidine	Chemical	D003000
Entity: 10737864	154	165	bradycardia	Disease	D001919
Relation: 10737864	CID	136	145	D003000	154	165	D001919	true

Sentence: Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans.
Entity: 10743446	50	58	ketamine	Chemical	D007649
Entity: 10743446	63	72	lidocaine	Chemical	D008012
Entity: 10743446	95	107	hyperalgesia	Disease	D006930
Entity: 10743446	131	140	capsaicin	Chemical	D002211
Relation: 10743446	CID	50	58	D007649	95	107	D006930	false
Relation: 10743446	CID	63	72	D008012	95	107	D006930	false
Relation: 10743446	CID	131	140	D002211	95	107	D006930	true

Sentence: We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.
Entity: 10743446	58	66	ketamine	Chemical	D007649
Entity: 10743446	71	80	lidocaine	Chemical	D008012
Entity: 10743446	107	111	pain	Disease	D010146
Entity: 10743446	141	153	hyperalgesia	Disease	D006930
Entity: 10743446	165	174	capsaicin	Chemical	D002211
Relation: 10743446	CID	58	66	D007649	107	111	D010146	false
Relation: 10743446	CID	58	66	D007649	141	153	D006930	false
Relation: 10743446	CID	71	80	D008012	107	111	D010146	false
Relation: 10743446	CID	71	80	D008012	141	153	D006930	false
Relation: 10743446	CID	165	174	D002211	107	111	D010146	true
Relation: 10743446	CID	165	174	D002211	141	153	D006930	true

Sentence: Ketamine reduced both the area of brush-evoked and punctate-evoked hyperalgesia significantly and it tended to reduce brush-evoked pain.
Entity: 10743446	0	8	Ketamine	Chemical	D007649
Entity: 10743446	67	79	hyperalgesia	Disease	D006930
Entity: 10743446	131	135	pain	Disease	D010146
Relation: 10743446	CID	0	8	D007649	67	79	D006930	false
Relation: 10743446	CID	0	8	D007649	131	135	D010146	false

Sentence: Lidocaine reduced the area of punctate-evoked hyperalgesia significantly.
Entity: 10743446	0	9	Lidocaine	Chemical	D008012
Entity: 10743446	46	58	hyperalgesia	Disease	D006930
Relation: 10743446	CID	0	9	D008012	46	58	D006930	false

Sentence: Cyclosporine and tacrolimus-associated thrombotic microangiopathy.
Entity: 11007689	0	12	Cyclosporine	Chemical	D016572
Entity: 11007689	17	27	tacrolimus	Chemical	D016559
Entity: 11007689	39	65	thrombotic microangiopathy	Disease	D057049
Relation: 11007689	CID	0	12	D016572	39	65	D057049	true
Relation: 11007689	CID	17	27	D016559	39	65	D057049	true

Sentence: The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.
Entity: 11007689	19	45	thrombotic microangiopathy	Disease	D057049
Entity: 11007689	47	50	TMA	Disease	D057049
Entity: 11007689	79	91	cyclosporine	Chemical	D016572
Relation: 11007689	CID	79	91	D016572	19	45	D057049	true
Relation: 11007689	CID	79	91	D016572	47	50	D057049	true

Sentence: As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine induced TMA.
Entity: 11007689	26	36	tacrolimus	Chemical	D016559
Entity: 11007689	107	119	cyclosporine	Chemical	D016572
Entity: 11007689	128	131	TMA	Disease	D057049
Relation: 11007689	CID	26	36	D016559	128	131	D057049	true
Relation: 11007689	CID	107	119	D016572	128	131	D057049	true

Sentence: With the more widespread application of tacrolimus in organ transplantation, tacrolimus-associated TMA has also been recognized.
Entity: 11007689	40	50	tacrolimus	Chemical	D016559
Entity: 11007689	77	87	tacrolimus	Chemical	D016559
Entity: 11007689	99	102	TMA	Disease	D057049
Relation: 11007689	CID	40	50	D016559	99	102	D057049	true
Relation: 11007689	CID	77	87	D016559	99	102	D057049	true

Sentence: However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.
Entity: 11007689	65	68	TMA	Disease	D057049
Entity: 11007689	105	117	cyclosporine	Chemical	D016572
Entity: 11007689	122	132	tacrolimus	Chemical	D016559
Relation: 11007689	CID	105	117	D016572	65	68	D057049	true
Relation: 11007689	CID	122	132	D016559	65	68	D057049	true

Sentence: We report a case of a living donor renal transplant recipient who developed cyclosporine induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy.
Entity: 11007689	76	88	cyclosporine	Chemical	D016572
Entity: 11007689	97	100	TMA	Disease	D057049
Entity: 11007689	137	149	cyclosporine	Chemical	D016572
Relation: 11007689	CID	76	88	D016572	97	100	D057049	true
Relation: 11007689	CID	137	149	D016572	97	100	D057049	true

Sentence: Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft.
Entity: 11007689	16	26	tacrolimus	Chemical	D016559
Entity: 11007689	99	102	TMA	Disease	D057049
Relation: 11007689	CID	16	26	D016559	99	102	D057049	true

Sentence: Repeated transient anuria following losartan administration in a patient with a solitary kidney.
Entity: 11256525	19	25	anuria	Disease	D001002
Entity: 11256525	36	44	losartan	Chemical	D019808
Relation: 11256525	CID	36	44	D019808	19	25	D001002	true

Sentence: We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.
Entity: 11256525	36	48	hypertensive	Disease	D006973
Entity: 11256525	80	107	chronic renal insufficiency	Disease	D051436
Entity: 11256525	148	154	anuria	Disease	D001002
Entity: 11256525	161	169	losartan	Chemical	D019808
Relation: 11256525	CID	161	169	D019808	36	48	D006973	false
Relation: 11256525	CID	161	169	D019808	80	107	D051436	false
Relation: 11256525	CID	161	169	D019808	148	154	D001002	true

Sentence: Due to severe systolic dysfunction losartan was prescribed.
Entity: 11256525	14	34	systolic dysfunction	Disease	D006331
Entity: 11256525	35	43	losartan	Chemical	D019808
Relation: 11256525	CID	35	43	D019808	14	34	D006331	false

Sentence: Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.
Entity: 11256525	41	49	losartan	Chemical	D019808
Entity: 11256525	71	77	anuria	Disease	D001002
Entity: 11256525	122	132	furosemide	Chemical	D005665
Entity: 11256525	137	142	amine	Chemical	D000588
Relation: 11256525	CID	41	49	D019808	71	77	D001002	true
Relation: 11256525	CID	122	132	D005665	71	77	D001002	false
Relation: 11256525	CID	137	142	D000588	71	77	D001002	false

Sentence: One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours.
Entity: 11256525	28	36	losartan	Chemical	D019808
Entity: 11256525	146	152	anuria	Disease	D001002
Relation: 11256525	CID	28	36	D019808	146	152	D001002	true

Sentence: In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).
Entity: 11256525	17	38	renal artery stenosis	Disease	D012078
Entity: 11256525	53	66	heart failure	Disease	D006333
Entity: 11256525	143	154	angiotensin	Chemical	D000809
Relation: 11256525	CID	143	154	D000809	17	38	D012078	false
Relation: 11256525	CID	143	154	D000809	53	66	D006333	false

Sentence: In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen induced nephrotoxicity, amiodarone induced lung toxicity and doxorubicin induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.
Entity: 11334364	58	66	necrotic	Disease	D009336
Entity: 11334364	86	99	acetaminophen	Chemical	D000082
Entity: 11334364	108	122	nephrotoxicity	Disease	D007674
Entity: 11334364	124	134	amiodarone	Chemical	D000638
Entity: 11334364	143	156	lung toxicity	Disease	D008171
Entity: 11334364	161	172	doxorubicin	Chemical	D004317
Entity: 11334364	181	195	cardiotoxicity	Disease	D066126
Entity: 11334364	207	248	IH636 grape seed proanthocyanidin extract	Chemical	C511402
Relation: 11334364	CID	86	99	D000082	58	66	D009336	true
Relation: 11334364	CID	86	99	D000082	108	122	D007674	true
Relation: 11334364	CID	86	99	D000082	143	156	D008171	false
Relation: 11334364	CID	86	99	D000082	181	195	D066126	false
Relation: 11334364	CID	124	134	D000638	58	66	D009336	true
Relation: 11334364	CID	124	134	D000638	108	122	D007674	false
Relation: 11334364	CID	124	134	D000638	143	156	D008171	true
Relation: 11334364	CID	124	134	D000638	181	195	D066126	false
Relation: 11334364	CID	161	172	D004317	58	66	D009336	true
Relation: 11334364	CID	161	172	D004317	108	122	D007674	false
Relation: 11334364	CID	161	172	D004317	143	156	D008171	false
Relation: 11334364	CID	161	172	D004317	181	195	D066126	true
Relation: 11334364	CID	207	248	C511402	58	66	D009336	false
Relation: 11334364	CID	207	248	C511402	108	122	D007674	false
Relation: 11334364	CID	207	248	C511402	143	156	D008171	false
Relation: 11334364	CID	207	248	C511402	181	195	D066126	false

Sentence: This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP) induced nephrotoxicity, amiodarone (AMI) induced lung toxicity, and doxorubicin (DOX) induced cardiotoxicity in mice.
Entity: 11334364	35	76	IH636 grape seed proanthocyanidin extract	Chemical	C511402
Entity: 11334364	78	82	GSPE	Chemical	C511402
Entity: 11334364	95	108	acetaminophen	Chemical	D000082
Entity: 11334364	110	113	AAP	Chemical	D000082
Entity: 11334364	123	137	nephrotoxicity	Disease	D007674
Entity: 11334364	139	149	amiodarone	Chemical	D000638
Entity: 11334364	151	154	AMI	Chemical	D000638
Entity: 11334364	164	177	lung toxicity	Disease	D008171
Entity: 11334364	183	194	doxorubicin	Chemical	D004317
Entity: 11334364	196	199	DOX	Chemical	D004317
Entity: 11334364	209	223	cardiotoxicity	Disease	D066126
Relation: 11334364	CID	35	76	C511402	123	137	D007674	false
Relation: 11334364	CID	35	76	C511402	164	177	D008171	false
Relation: 11334364	CID	35	76	C511402	209	223	D066126	false
Relation: 11334364	CID	78	82	C511402	123	137	D007674	false
Relation: 11334364	CID	78	82	C511402	164	177	D008171	false
Relation: 11334364	CID	78	82	C511402	209	223	D066126	false
Relation: 11334364	CID	95	108	D000082	123	137	D007674	true
Relation: 11334364	CID	95	108	D000082	164	177	D008171	false
Relation: 11334364	CID	95	108	D000082	209	223	D066126	false
Relation: 11334364	CID	110	113	D000082	123	137	D007674	true
Relation: 11334364	CID	110	113	D000082	164	177	D008171	false
Relation: 11334364	CID	110	113	D000082	209	223	D066126	false
Relation: 11334364	CID	139	149	D000638	123	137	D007674	false
Relation: 11334364	CID	139	149	D000638	164	177	D008171	true
Relation: 11334364	CID	139	149	D000638	209	223	D066126	false
Relation: 11334364	CID	151	154	D000638	123	137	D007674	false
Relation: 11334364	CID	151	154	D000638	164	177	D008171	true
Relation: 11334364	CID	151	154	D000638	209	223	D066126	false
Relation: 11334364	CID	183	194	D004317	123	137	D007674	false
Relation: 11334364	CID	183	194	D004317	164	177	D008171	false
Relation: 11334364	CID	183	194	D004317	209	223	D066126	true
Relation: 11334364	CID	196	199	D004317	123	137	D007674	false
Relation: 11334364	CID	196	199	D004317	164	177	D008171	false
Relation: 11334364	CID	196	199	D004317	209	223	D066126	true

Sentence: Histopathological examination of kidney, heart and lung sections revealed moderate to massive tissue damage with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence.
Entity: 11334364	94	107	tissue damage	Disease	D017695
Entity: 11334364	193	197	GSPE	Chemical	C511402
Relation: 11334364	CID	193	197	C511402	94	107	D017695	false

Sentence: Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.
Entity: 11334364	39	42	AAP	Chemical	D000082
Entity: 11334364	44	47	AMI	Chemical	D000638
Entity: 11334364	52	55	DOX	Chemical	D004317
Entity: 11334364	95	103	necrosis	Disease	D009336
Entity: 11334364	167	171	GSPE	Chemical	C511402
Relation: 11334364	CID	39	42	D000082	95	103	D009336	true
Relation: 11334364	CID	44	47	D000638	95	103	D009336	true
Relation: 11334364	CID	52	55	D004317	95	103	D009336	true
Relation: 11334364	CID	167	171	C511402	95	103	D009336	false

Sentence: Palpebral twitching in a depressed adolescent on citalopram.
Entity: 11642480	0	19	Palpebral twitching	Disease	D004409
Entity: 11642480	25	34	depressed	Disease	D003866
Entity: 11642480	49	59	citalopram	Chemical	D015283
Relation: 11642480	CID	49	59	D015283	0	19	D004409	true
Relation: 11642480	CID	49	59	D015283	25	34	D003866	false

Sentence: We report a favorable response to treatment with citalopram by a 15-year-old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment.
Entity: 11642480	49	59	citalopram	Chemical	D015283
Entity: 11642480	86	102	major depression	Disease	D003865
Entity: 11642480	117	136	palpebral twitching	Disease	D004409
Relation: 11642480	CID	49	59	D015283	86	102	D003865	false
Relation: 11642480	CID	49	59	D015283	117	136	D004409	true

Sentence: Metamizol potentiates morphine antinociception but not constipation after chronic treatment.
Entity: 12063090	0	9	Metamizol	Chemical	D004177
Entity: 12063090	22	30	morphine	Chemical	D009020
Entity: 12063090	55	67	constipation	Disease	D003248
Relation: 12063090	CID	0	9	D004177	55	67	D003248	false
Relation: 12063090	CID	22	30	D009020	55	67	D003248	true

Sentence: This work evaluates the antinociceptive and constipating effects of the combination of 3.2 mg/kg s.c. morphine with 177.8 mg/kg s.c. metamizol in acutely and chronically treated (once a day for 12 days) rats.
Entity: 12063090	44	56	constipating	Disease	D003248
Entity: 12063090	102	110	morphine	Chemical	D009020
Entity: 12063090	133	142	metamizol	Chemical	D004177
Relation: 12063090	CID	102	110	D009020	44	56	D003248	true
Relation: 12063090	CID	133	142	D004177	44	56	D003248	false

Sentence: On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, pain induced functional impairment model, and the charcoal meal test was used to evaluate the intestinal transit.
Entity: 12063090	98	102	pain	Disease	D010146
Entity: 12063090	148	156	charcoal	Chemical	D002606
Relation: 12063090	CID	148	156	D002606	98	102	D010146	false

Sentence: In independent groups, morphine inhibited the intestinal transit in 48+/-4% and 38+/-4% after acute and chronic treatment, respectively, suggesting that tolerance did not develop to the constipating effects.
Entity: 12063090	23	31	morphine	Chemical	D009020
Entity: 12063090	186	198	constipating	Disease	D003248
Relation: 12063090	CID	23	31	D009020	186	198	D003248	true

Sentence: The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine induced constipation.
Entity: 12063090	73	81	morphine	Chemical	D009020
Entity: 12063090	135	144	metamizol	Chemical	D004177
Entity: 12063090	164	172	morphine	Chemical	D009020
Entity: 12063090	181	193	constipation	Disease	D003248
Relation: 12063090	CID	73	81	D009020	181	193	D003248	true
Relation: 12063090	CID	135	144	D004177	181	193	D003248	false
Relation: 12063090	CID	164	172	D009020	181	193	D003248	true

Sentence: Ifosfamide encephalopathy presenting with asterixis.
Entity: 12084448	0	10	Ifosfamide	Chemical	D007069
Entity: 12084448	11	25	encephalopathy	Disease	D001927
Entity: 12084448	42	51	asterixis	Disease	D020820
Relation: 12084448	CID	0	10	D007069	11	25	D001927	true
Relation: 12084448	CID	0	10	D007069	42	51	D020820	false

Sentence: We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma.
Entity: 12084448	79	88	myoclonus	Disease	D009207
Entity: 12084448	146	156	ifosfamide	Chemical	D007069
Entity: 12084448	161	173	plasmacytoma	Disease	D010954
Relation: 12084448	CID	146	156	D007069	79	88	D009207	true
Relation: 12084448	CID	146	156	D007069	161	173	D010954	false

Sentence: The administration of ifosfamide was discontinued and within 12 h the asterixis resolved completely.
Entity: 12084448	22	32	ifosfamide	Chemical	D007069
Entity: 12084448	70	79	asterixis	Disease	D020820
Relation: 12084448	CID	22	32	D007069	70	79	D020820	false

Sentence: OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine induced increases in nucleus accumbens (NAcc) dopamine (DA).
Entity: 12684739	55	70	substance abuse	Disease	D019966
Entity: 12684739	97	117	visual field defects	Disease	D005128
Entity: 12684739	119	122	VFD	Disease	D005128
Entity: 12684739	218	221	GVG	Chemical	D020888
Entity: 12684739	225	232	cocaine	Chemical	D003042
Entity: 12684739	279	287	dopamine	Chemical	D004298
Entity: 12684739	289	291	DA	Chemical	D004298
Relation: 12684739	CID	218	221	D020888	55	70	D019966	false
Relation: 12684739	CID	218	221	D020888	97	117	D005128	true
Relation: 12684739	CID	218	221	D020888	119	122	D005128	true
Relation: 12684739	CID	225	232	D003042	55	70	D019966	false
Relation: 12684739	CID	225	232	D003042	97	117	D005128	false
Relation: 12684739	CID	225	232	D003042	119	122	D005128	false
Relation: 12684739	CID	279	287	D004298	55	70	D019966	false
Relation: 12684739	CID	279	287	D004298	97	117	D005128	false
Relation: 12684739	CID	279	287	D004298	119	122	D005128	false
Relation: 12684739	CID	289	291	D004298	55	70	D019966	false
Relation: 12684739	CID	289	291	D004298	97	117	D005128	false
Relation: 12684739	CID	289	291	D004298	119	122	D005128	false

Sentence: In ICH induction using 0.014-unit collagenase, heparin enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the bleeding 7.6-fold.
Entity: 12716030	3	6	ICH	Disease	D002543
Entity: 12716030	47	54	heparin	Chemical	D006493
Entity: 12716030	68	76	hematoma	Disease	D006406
Entity: 12716030	119	122	ICH	Disease	D002543
Entity: 12716030	139	147	bleeding	Disease	D006470
Relation: 12716030	CID	47	54	D006493	3	6	D002543	false
Relation: 12716030	CID	47	54	D006493	68	76	D006406	true
Relation: 12716030	CID	47	54	D006493	119	122	D002543	false
Relation: 12716030	CID	47	54	D006493	139	147	D006470	false

Sentence: Estradiol reduces seizure induced hippocampal injury in ovariectomized female but not in male rats.
Entity: 12757899	0	9	Estradiol	Chemical	D004958
Entity: 12757899	18	25	seizure	Disease	D012640
Entity: 12757899	34	52	hippocampal injury	Disease	D001930
Relation: 12757899	CID	0	9	D004958	18	25	D012640	false
Relation: 12757899	CID	0	9	D004958	34	52	D001930	false

Sentence: Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid induced status epilepticus (SE).
Entity: 12757899	43	61	hippocampal injury	Disease	D001930
Entity: 12757899	73	84	kainic acid	Chemical	D007608
Entity: 12757899	93	111	status epilepticus	Disease	D013226
Entity: 12757899	113	115	SE	Disease	D013226
Relation: 12757899	CID	73	84	D007608	43	61	D001930	false
Relation: 12757899	CID	73	84	D007608	93	111	D013226	false
Relation: 12757899	CID	73	84	D007608	113	115	D013226	false

Sentence: We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium-pilocarpine induced SE.
Entity: 12757899	27	43	17beta-estradiol	Chemical	D004958
Entity: 12757899	102	109	lithium	Chemical	D008094
Entity: 12757899	110	121	pilocarpine	Chemical	D010862
Entity: 12757899	130	132	SE	Disease	D013226
Relation: 12757899	CID	27	43	D004958	130	132	D013226	false
Relation: 12757899	CID	102	109	D008094	130	132	D013226	true
Relation: 12757899	CID	110	121	D010862	130	132	D013226	true

Sentence: The extent of silver-stained CA3 and CA1 hippocampal neurons was evaluated 2 days after SE. 17beta-Estradiol did not alter the onset of first clonus in ovariectomized rats but accelerated it in males. 17beta-Estradiol reduced the argyrophilic neurons in the CA1 and CA3-C sectors of ovariectomized rats.
Entity: 12757899	14	20	silver	Chemical	D012834
Entity: 12757899	88	90	SE	Disease	D013226
Entity: 12757899	92	108	17beta-Estradiol	Chemical	D004958
Entity: 12757899	201	217	17beta-Estradiol	Chemical	D004958
Relation: 12757899	CID	14	20	D012834	88	90	D013226	false
Relation: 12757899	CID	92	108	D004958	88	90	D013226	false
Relation: 12757899	CID	201	217	D004958	88	90	D013226	false

Sentence: Delirium during clozapine treatment: incidence and associated risk factors.
Entity: 12905102	0	8	Delirium	Disease	D003693
Entity: 12905102	16	25	clozapine	Chemical	D003024
Relation: 12905102	CID	16	25	D003024	0	8	D003693	true

Sentence: BACKGROUND: Incidence and risk factors for delirium during clozapine treatment require further clarification.
Entity: 12905102	43	51	delirium	Disease	D003693
Entity: 12905102	59	68	clozapine	Chemical	D003024
Relation: 12905102	CID	59	68	D003024	43	51	D003693	true

Sentence: METHODS: We used computerized pharmacy records to identify all adult psychiatric inpatients treated with clozapine (1995-96), reviewed their medical records to score incidence and severity of delirium, and tested associations with potential risk factors.
Entity: 12905102	69	80	psychiatric	Disease	D001523
Entity: 12905102	105	114	clozapine	Chemical	D003024
Entity: 12905102	192	200	delirium	Disease	D003693
Relation: 12905102	CID	105	114	D003024	69	80	D001523	false
Relation: 12905102	CID	105	114	D003024	192	200	D003693	true

Sentence: CONCLUSIONS: Delirium was found in 10 % of clozapine-treated inpatients, particularly in older patients exposed to other central anticholinergics.
Entity: 12905102	13	21	Delirium	Disease	D003693
Entity: 12905102	43	52	clozapine	Chemical	D003024
Relation: 12905102	CID	43	52	D003024	13	21	D003693	true

Sentence: Ketoconazole induced neurologic sequelae.
Entity: 14513889	0	12	Ketoconazole	Chemical	D007654
Entity: 14513889	21	40	neurologic sequelae	Disease	D009422
Relation: 14513889	CID	0	12	D007654	21	40	D009422	false

Sentence: A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.
Entity: 14513889	29	52	weakness of extremities	Disease	D018908
Entity: 14513889	54	68	legs paralysis	Disease	D010243
Entity: 14513889	70	80	dysarthria	Disease	D004401
Entity: 14513889	85	91	tremor	Disease	D014202
Entity: 14513889	122	134	ketoconazole	Chemical	D007654
Relation: 14513889	CID	122	134	D007654	29	52	D018908	true
Relation: 14513889	CID	122	134	D007654	54	68	D010243	true
Relation: 14513889	CID	122	134	D007654	70	80	D004401	true
Relation: 14513889	CID	122	134	D007654	85	91	D014202	true

Sentence: Capsaicin (0.01-1 mm) applied to oral or nasal mucosa induced increases in dural and cortical blood flow and provoked lacrimation.
Entity: 15009014	0	9	Capsaicin	Chemical	D002211
Entity: 15009014	62	104	increases in dural and cortical blood flow	Disease	D006940
Relation: 15009014	CID	0	9	D002211	62	104	D006940	true

Sentence: The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.
Entity: 15009014	11	40	increases in dural blood flow	Disease	D006940
Entity: 15009014	94	102	atropine	Chemical	D001285
Relation: 15009014	CID	94	102	D001285	11	40	D006940	false

Sentence: Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.
Entity: 15120741	26	37	pilocarpine	Chemical	D010862
Entity: 15120741	55	73	status epilepticus	Disease	D013226
Entity: 15120741	75	77	SE	Disease	D013226
Entity: 15120741	123	131	seizures	Disease	D012640
Relation: 15120741	CID	26	37	D010862	55	73	D013226	true
Relation: 15120741	CID	26	37	D010862	75	77	D013226	true
Relation: 15120741	CID	26	37	D010862	123	131	D012640	true

Sentence: In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE.
Entity: 15120741	3	5	Mg	Chemical	D008274
Entity: 15120741	41	52	bicuculline	Chemical	D001640
Entity: 15120741	227	238	pilocarpine	Chemical	D010862
Entity: 15120741	276	278	SE	Disease	D013226
Relation: 15120741	CID	3	5	D008274	276	278	D013226	false
Relation: 15120741	CID	41	52	D001640	276	278	D013226	false
Relation: 15120741	CID	227	238	D010862	276	278	D013226	true

Sentence: In SE survivors, similar stimulation resulted in a population spike followed, at a variable latency, by negative DC shifts and repetitive afterdischarges of 3-60 s duration, which were blocked by ionotropic glutamate receptor antagonists.
Entity: 15120741	3	5	SE	Disease	D013226
Entity: 15120741	207	216	glutamate	Chemical	D018698
Relation: 15120741	CID	207	216	D018698	3	5	D013226	false

Sentence: Focal glutamate photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1-30 s duration in slices from SE survivors but not other groups.
Entity: 15120741	6	15	glutamate	Chemical	D018698
Entity: 15120741	170	172	SE	Disease	D013226
Relation: 15120741	CID	6	15	D018698	170	172	D013226	false

Sentence: The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine induced seizures and hypolocomotion in mice.
Entity: 15275829	31	44	acetylcholine	Chemical	D000109
Entity: 15275829	81	89	nicotine	Chemical	D009538
Entity: 15275829	98	106	seizures	Disease	D012640
Entity: 15275829	111	125	hypolocomotion	Disease	D006948
Relation: 15275829	CID	31	44	D000109	98	106	D012640	false
Relation: 15275829	CID	31	44	D000109	111	125	D006948	false
Relation: 15275829	CID	81	89	D009538	98	106	D012640	true
Relation: 15275829	CID	81	89	D009538	111	125	D006948	false

Sentence: Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death. nAChRs are pentameric ion channels usually composed of alpha and beta subunits.
Entity: 15275829	11	19	nicotine	Chemical	D009538
Entity: 15275829	33	46	acetylcholine	Chemical	D000109
Entity: 15275829	159	166	tremors	Disease	D014202
Entity: 15275829	171	179	seizures	Disease	D012640
Entity: 15275829	184	189	death	Disease	D003643
Relation: 15275829	CID	11	19	D009538	159	166	D014202	false
Relation: 15275829	CID	11	19	D009538	171	179	D012640	true
Relation: 15275829	CID	11	19	D009538	184	189	D003643	false
Relation: 15275829	CID	33	46	D000109	159	166	D014202	false
Relation: 15275829	CID	33	46	D000109	171	179	D012640	false
Relation: 15275829	CID	33	46	D000109	184	189	D003643	false

Sentence: We examined the role of the beta4 subunits in nicotine induced seizures and hypolocomotion in beta4 homozygous null (beta4 -/-) and alpha3 heterozygous (+/-) mice. beta4 -/- mice were less sensitive to the effects of nicotine both at low doses, measured as decreased exploration in an open field, and at high doses, measured as sensitivity to nicotine induced seizures.
Entity: 15275829	46	54	nicotine	Chemical	D009538
Entity: 15275829	63	71	seizures	Disease	D012640
Entity: 15275829	76	90	hypolocomotion	Disease	D006948
Entity: 15275829	217	225	nicotine	Chemical	D009538
Entity: 15275829	343	351	nicotine	Chemical	D009538
Entity: 15275829	360	368	seizures	Disease	D012640
Relation: 15275829	CID	46	54	D009538	63	71	D012640	true
Relation: 15275829	CID	46	54	D009538	76	90	D006948	false
Relation: 15275829	CID	46	54	D009538	360	368	D012640	true
Relation: 15275829	CID	217	225	D009538	63	71	D012640	true
Relation: 15275829	CID	217	225	D009538	76	90	D006948	false
Relation: 15275829	CID	217	225	D009538	360	368	D012640	true
Relation: 15275829	CID	343	351	D009538	63	71	D012640	true
Relation: 15275829	CID	343	351	D009538	76	90	D006948	false
Relation: 15275829	CID	343	351	D009538	360	368	D012640	true

Sentence: Using in situ hybridization probes for the alpha3 and alpha5 subunits, we showed that alpha5 mRNA levels are unchanged, whereas alpha3 mRNA levels are selectively decreased in the mitral cell layer of the olfactory bulb, and the inferior and the superior colliculus of beta4 -/- brains. alpha3 +/- mice were partially resistant to nicotine induced seizures when compared to wild-type littermates. mRNA levels for the alpha5 and the beta4 subunits were unchanged in alpha3 +/- brains.
Entity: 15275829	331	339	nicotine	Chemical	D009538
Entity: 15275829	348	356	seizures	Disease	D012640
Relation: 15275829	CID	331	339	D009538	348	356	D012640	true

Sentence: Recurrent acute interstitial nephritis induced by azithromycin.
Entity: 15602202	16	38	interstitial nephritis	Disease	D009395
Entity: 15602202	50	62	azithromycin	Chemical	D017963
Relation: 15602202	CID	50	62	D017963	16	38	D009395	true

Sentence: A 14-year-old girl is reported with recurrent, azithromycin induced, acute interstitial nephritis.
Entity: 15602202	47	59	azithromycin	Chemical	D017963
Entity: 15602202	75	97	interstitial nephritis	Disease	D009395
Relation: 15602202	CID	47	59	D017963	75	97	D009395	true

Sentence: Valproate induced encephalopathy.
Entity: 16181582	0	9	Valproate	Chemical	D014635
Entity: 16181582	18	32	encephalopathy	Disease	D001927
Relation: 16181582	CID	0	9	D014635	18	32	D001927	true

Sentence: Valproate induced encephalopathy is a rare syndrome that may manifest in otherwise normal epileptic individuals.
Entity: 16181582	0	9	Valproate	Chemical	D014635
Entity: 16181582	18	32	encephalopathy	Disease	D001927
Entity: 16181582	90	99	epileptic	Disease	D004827
Relation: 16181582	CID	0	9	D014635	18	32	D001927	true
Relation: 16181582	CID	0	9	D014635	90	99	D004827	false

Sentence: Nitro-L-arginine methyl ester: a potential protector against gentamicin ototoxicity.
Entity: 16298782	0	29	Nitro-L-arginine methyl ester	Chemical	D019331
Entity: 16298782	61	71	gentamicin	Chemical	D005839
Entity: 16298782	72	83	ototoxicity	Disease	D006311
Relation: 16298782	CID	0	29	D019331	72	83	D006311	false
Relation: 16298782	CID	61	71	D005839	72	83	D006311	false

Sentence: The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.
Entity: 16298782	4	16	nitric oxide	Chemical	D009569
Entity: 16298782	18	20	NO	Chemical	D009569
Entity: 16298782	32	61	nitro-L-arginine methyl ester	Chemical	D019331
Entity: 16298782	63	69	L-NAME	Chemical	D019331
Entity: 16298782	107	134	high-frequency hearing loss	Disease	D006316
Entity: 16298782	145	155	gentamicin	Chemical	D005839
Relation: 16298782	CID	4	16	D009569	107	134	D006316	false
Relation: 16298782	CID	18	20	D009569	107	134	D006316	false
Relation: 16298782	CID	32	61	D019331	107	134	D006316	false
Relation: 16298782	CID	63	69	D019331	107	134	D006316	false
Relation: 16298782	CID	145	155	D005839	107	134	D006316	false

Sentence: Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside induced sensorineural hearing loss.
Entity: 16298782	6	17	ototoxicity	Disease	D006311
Entity: 16298782	60	68	ototoxic	Disease	D006311
Entity: 16298782	106	108	NO	Chemical	D009569
Entity: 16298782	139	141	NO	Chemical	D009569
Entity: 16298782	175	189	aminoglycoside	Chemical	D000617
Entity: 16298782	198	224	sensorineural hearing loss	Disease	D006319
Relation: 16298782	CID	106	108	D009569	6	17	D006311	false
Relation: 16298782	CID	106	108	D009569	60	68	D006311	false
Relation: 16298782	CID	106	108	D009569	198	224	D006319	false
Relation: 16298782	CID	139	141	D009569	6	17	D006311	false
Relation: 16298782	CID	139	141	D009569	60	68	D006311	false
Relation: 16298782	CID	139	141	D009569	198	224	D006319	false
Relation: 16298782	CID	175	189	D000617	6	17	D006311	false
Relation: 16298782	CID	175	189	D000617	60	68	D006311	false
Relation: 16298782	CID	175	189	D000617	198	224	D006319	false

Sentence: Cerebral vasculitis following oral methylphenidate intake in an adult: a case report.
Entity: 16428221	0	19	Cerebral vasculitis	Disease	D020293
Entity: 16428221	35	50	methylphenidate	Chemical	D008774
Relation: 16428221	CID	35	50	D008774	0	19	D020293	true

Sentence: Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.
Entity: 16428221	0	19	Cerebral vasculitis	Disease	D020293
Entity: 16428221	36	53	amphetamine abuse	Disease	D019969
Entity: 16428221	92	108	ischaemic stroke	Disease	D002544
Entity: 16428221	133	148	methylphenidate	Chemical	D008774
Relation: 16428221	CID	133	148	D008774	0	19	D020293	true
Relation: 16428221	CID	133	148	D008774	36	53	D019969	false
Relation: 16428221	CID	133	148	D008774	92	108	D002544	false

Sentence: We report the case of a 63-year-old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes.
Entity: 16428221	64	79	methylphenidate	Chemical	D008774
Entity: 16428221	87	100	hyperactivity	Disease	D006948
Entity: 16428221	128	145	ischaemic strokes	Disease	D002544
Relation: 16428221	CID	64	79	D008774	87	100	D006948	false
Relation: 16428221	CID	64	79	D008774	128	145	D002544	false

Sentence: We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy.
Entity: 16428221	17	32	methylphenidate	Chemical	D008774
Entity: 16428221	42	52	vasculitis	Disease	D014657
Entity: 16428221	130	145	methylphenidate	Chemical	D008774
Relation: 16428221	CID	17	32	D008774	42	52	D014657	false
Relation: 16428221	CID	130	145	D008774	42	52	D014657	false

Sentence: Cerebral haemorrhage induced by warfarin - the influence of drug-drug interactions.
Entity: 16858720	0	20	Cerebral haemorrhage	Disease	D002543
Entity: 16858720	32	40	warfarin	Chemical	D014859
Relation: 16858720	CID	32	40	D014859	0	20	D002543	true

Sentence: PURPOSE: To evaluate the frequency, severity and preventability of warfarin induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden.
Entity: 16858720	67	75	warfarin	Chemical	D014859
Entity: 16858720	84	105	cerebral haemorrhages	Disease	D002543
Entity: 16858720	113	121	warfarin	Chemical	D014859
Entity: 16858720	126	134	warfarin	Chemical	D014859
Relation: 16858720	CID	67	75	D014859	84	105	D002543	true
Relation: 16858720	CID	113	121	D014859	84	105	D002543	true
Relation: 16858720	CID	126	134	D014859	84	105	D002543	true

Sentence: Medical records were studied retrospectively to evaluate whether warfarin and warfarin-drug interactions could have caused the cerebral haemorrhage.
Entity: 16858720	65	73	warfarin	Chemical	D014859
Entity: 16858720	78	86	warfarin	Chemical	D014859
Entity: 16858720	127	147	cerebral haemorrhage	Disease	D002543
Relation: 16858720	CID	65	73	D014859	127	147	D002543	true
Relation: 16858720	CID	78	86	D014859	127	147	D002543	true

Sentence: RESULTS: Among 593 patients with cerebral haemorrhage, 59 (10%) were assessed as related to warfarin treatment.
Entity: 16858720	33	53	cerebral haemorrhage	Disease	D002543
Entity: 16858720	92	100	warfarin	Chemical	D014859
Relation: 16858720	CID	92	100	D014859	33	53	D002543	true

Sentence: A warfarin-drug interaction could have contributed to the haemorrhage in 24 (41%) of the warfarin patients and in 7 of these (12%) the bleeding complication was considered being possible to avoid.
Entity: 16858720	2	10	warfarin	Chemical	D014859
Entity: 16858720	58	69	haemorrhage	Disease	D006470
Entity: 16858720	89	97	warfarin	Chemical	D014859
Entity: 16858720	135	143	bleeding	Disease	D006470
Relation: 16858720	CID	2	10	D014859	58	69	D006470	false
Relation: 16858720	CID	2	10	D014859	135	143	D006470	false
Relation: 16858720	CID	89	97	D014859	58	69	D006470	false
Relation: 16858720	CID	89	97	D014859	135	143	D006470	false

Sentence: CONCLUSIONS: Warfarin induced cerebral haemorrhages are a major clinical problem with a high fatality rate.
Entity: 16858720	13	21	Warfarin	Chemical	D014859
Entity: 16858720	30	51	cerebral haemorrhages	Disease	D002543
Relation: 16858720	CID	13	21	D014859	30	51	D002543	true

Sentence: PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space at the end of routine cataract surgery.
Entity: 17466854	98	116	methylprednisolone	Chemical	D008775
Entity: 17466854	121	131	gentamicin	Chemical	D005839
Entity: 17466854	191	199	cataract	Disease	D002386
Relation: 17466854	CID	98	116	D008775	191	199	D002386	false
Relation: 17466854	CID	121	131	D005839	191	199	D002386	false

Sentence: METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.
Entity: 17562951	96	105	iopamidol	Chemical	D007479
Entity: 17562951	110	119	iodixanol	Chemical	C044834
Entity: 17562951	137	159	chronic kidney disease	Disease	D051436
Relation: 17562951	CID	96	105	D007479	137	159	D051436	false
Relation: 17562951	CID	110	119	C044834	137	159	D051436	false

Sentence: In 414 patients, contrast volume, presence of diabetes mellitus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups.
Entity: 17562951	46	63	diabetes mellitus	Disease	D003920
Entity: 17562951	72	88	N-acetylcysteine	Chemical	D000111
Relation: 17562951	CID	72	88	D000111	46	63	D003920	false

Sentence: In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).
Entity: 17562951	17	25	diabetes	Disease	D003920
Entity: 17562951	92	101	iopamidol	Chemical	D007479
Entity: 17562951	137	146	iodixanol	Chemical	C044834
Relation: 17562951	CID	92	101	D007479	17	25	D003920	false
Relation: 17562951	CID	137	146	C044834	17	25	D003920	false

Sentence: Mean post-SCr increases were significantly less with iopamidol (all patients: 0.07 versus 0.12 mg/dL, 6.2 versus 10.6 micromol/L, P=0.03; patients with diabetes: 0.07 versus 0.16 mg/dL, 6.2 versus 14.1 micromol/L, P=0.01).
Entity: 17562951	53	62	iopamidol	Chemical	D007479
Entity: 17562951	152	160	diabetes	Disease	D003920
Relation: 17562951	CID	53	62	D007479	152	160	D003920	false

Sentence: A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.
Entity: 17600377	18	38	maltolyl p-coumarate	Chemical	C524754
Entity: 17600377	51	69	cognitive deficits	Disease	D003072
Entity: 17600377	125	133	dementia	Disease	D003704
Relation: 17600377	CID	18	38	C524754	51	69	D003072	false
Relation: 17600377	CID	18	38	C524754	125	133	D003704	false

Sentence: In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.
Entity: 17600377	46	66	maltolyl p-coumarate	Chemical	C524754
Entity: 17600377	81	98	cognitive decline	Disease	D003072
Entity: 17600377	102	113	scopolamine	Chemical	D012601
Entity: 17600377	135	161	amyloid beta peptide(1-42)	Chemical	C544092
Relation: 17600377	CID	46	66	C524754	81	98	D003072	false
Relation: 17600377	CID	102	113	D012601	81	98	D003072	true
Relation: 17600377	CID	135	161	C544092	81	98	D003072	false

Sentence: Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.
Entity: 17600377	0	20	Maltolyl p-coumarate	Chemical	C524754
Entity: 17600377	44	62	cognitive deficits	Disease	D003072
Entity: 17600377	181	207	amyloid beta peptide(1-42)	Chemical	C544092
Relation: 17600377	CID	0	20	C524754	44	62	D003072	false
Relation: 17600377	CID	181	207	C544092	44	62	D003072	false

Sentence: We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin.
Entity: 17639754	29	37	bleeding	Disease	D006470
Entity: 17639754	108	116	warfarin	Chemical	D014859
Entity: 17639754	121	133	levofloxacin	Chemical	D064704
Relation: 17639754	CID	108	116	D014859	29	37	D006470	true
Relation: 17639754	CID	121	133	D064704	29	37	D006470	true

Sentence: Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Entity: 17854040	26	36	lamivudine	Chemical	D019259
Entity: 17854040	59	61	na	Chemical	D012964
Entity: 17854040	66	98	hepatitis B virus (HBV) infected	Disease	D006509
Entity: 17854040	125	141	HIV co-infection	Disease	D015658
Entity: 17854040	186	189	HBV	Disease	D006509
Entity: 17854040	194	197	HIV	Disease	D015658
Relation: 17854040	CID	26	36	D019259	66	98	D006509	false
Relation: 17854040	CID	26	36	D019259	125	141	D015658	false
Relation: 17854040	CID	26	36	D019259	186	189	D006509	false
Relation: 17854040	CID	26	36	D019259	194	197	D015658	false
Relation: 17854040	CID	59	61	D012964	66	98	D006509	false
Relation: 17854040	CID	59	61	D012964	125	141	D015658	false
Relation: 17854040	CID	59	61	D012964	186	189	D006509	false
Relation: 17854040	CID	59	61	D012964	194	197	D015658	false

Sentence: This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.
Entity: 17854040	45	55	lamivudine	Chemical	D019259
Entity: 17854040	66	77	hepatitis B	Disease	D006509
Entity: 17854040	110	120	lamivudine	Chemical	D019259
Entity: 17854040	121	123	na	Chemical	D012964
Entity: 17854040	158	205	human immunodeficiency virus (HIV) co-infection	Disease	D015658
Relation: 17854040	CID	45	55	D019259	66	77	D006509	false
Relation: 17854040	CID	45	55	D019259	158	205	D015658	false
Relation: 17854040	CID	110	120	D019259	66	77	D006509	false
Relation: 17854040	CID	110	120	D019259	158	205	D015658	false
Relation: 17854040	CID	121	123	D012964	66	77	D006509	false
Relation: 17854040	CID	121	123	D012964	158	205	D015658	false

Sentence: Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.
Entity: 17854040	12	22	lamivudine	Chemical	D019259
Entity: 17854040	23	25	na	Chemical	D012964
Entity: 17854040	30	42	HBV infected	Disease	D006509
Entity: 17854040	68	84	HIV co-infection	Disease	D015658
Entity: 17854040	110	127	HBV mono-infected	Disease	D006509
Entity: 17854040	144	147	HBV	Disease	D006509
Entity: 17854040	148	151	HIV	Disease	D015658
Relation: 17854040	CID	12	22	D019259	30	42	D006509	false
Relation: 17854040	CID	12	22	D019259	68	84	D015658	false
Relation: 17854040	CID	12	22	D019259	110	127	D006509	false
Relation: 17854040	CID	12	22	D019259	144	147	D006509	false
Relation: 17854040	CID	12	22	D019259	148	151	D015658	false
Relation: 17854040	CID	23	25	D012964	30	42	D006509	false
Relation: 17854040	CID	23	25	D012964	68	84	D015658	false
Relation: 17854040	CID	23	25	D012964	110	127	D006509	false
Relation: 17854040	CID	23	25	D012964	144	147	D006509	false
Relation: 17854040	CID	23	25	D012964	148	151	D015658	false

Sentence: HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients.
Entity: 17854040	4	14	lamivudine	Chemical	D019259
Entity: 17854040	80	91	hepatitis B	Disease	D006509
Entity: 17854040	114	117	HBV	Disease	D006509
Entity: 17854040	118	121	HIV	Disease	D015658
Relation: 17854040	CID	4	14	D019259	80	91	D006509	false
Relation: 17854040	CID	4	14	D019259	114	117	D006509	false
Relation: 17854040	CID	4	14	D019259	118	121	D015658	false

Sentence: To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-na  ve HBV-HIV co-infected patients.
Entity: 17854040	71	81	lamivudine	Chemical	D019259
Entity: 17854040	111	113	na	Chemical	D012964
Entity: 17854040	118	121	HBV	Disease	D006509
Entity: 17854040	122	125	HIV	Disease	D015658
Relation: 17854040	CID	71	81	D019259	118	121	D006509	false
Relation: 17854040	CID	71	81	D019259	122	125	D015658	false
Relation: 17854040	CID	111	113	D012964	118	121	D006509	false
Relation: 17854040	CID	111	113	D012964	122	125	D015658	false

Sentence: Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.
Entity: 18221780	19	23	NMDA	Chemical	D016202
Entity: 18221780	50	58	morphine	Chemical	D009020
Entity: 18221780	81	90	capsaicin	Chemical	D002211
Entity: 18221780	111	115	pain	Disease	D010146
Entity: 18221780	146	156	acute pain	Disease	D059787
Relation: 18221780	CID	19	23	D016202	111	115	D010146	false
Relation: 18221780	CID	19	23	D016202	146	156	D059787	false
Relation: 18221780	CID	50	58	D009020	111	115	D010146	false
Relation: 18221780	CID	50	58	D009020	146	156	D059787	false
Relation: 18221780	CID	81	90	D002211	111	115	D010146	false
Relation: 18221780	CID	81	90	D002211	146	156	D059787	false

Sentence: In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females.
Entity: 18221780	3	13	acute pain	Disease	D059787
Entity: 18221780	22	42	N-methyl-D-aspartate	Chemical	D016202
Entity: 18221780	44	48	NMDA	Chemical	D016202
Entity: 18221780	101	109	morphine	Chemical	D009020
Relation: 18221780	CID	22	42	D016202	3	13	D059787	false
Relation: 18221780	CID	44	48	D016202	3	13	D059787	false
Relation: 18221780	CID	101	109	D009020	3	13	D059787	false

Sentence: To this end, persistent hyperalgesia was induced by administration of capsaicin in the tail of gonadally intact F344 rats, following which the tail was immersed in a mildly noxious thermal stimulus, and tail-withdrawal latencies measured.
Entity: 18221780	24	36	hyperalgesia	Disease	D006930
Entity: 18221780	70	79	capsaicin	Chemical	D002211
Relation: 18221780	CID	70	79	D002211	24	36	D006930	true

Sentence: Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models, with the magnitude of this effect being greater in males.
Entity: 18221780	15	23	morphine	Chemical	D009020
Entity: 18221780	43	59	dextromethorphan	Chemical	D003915
Entity: 18221780	102	112	acute pain	Disease	D059787
Relation: 18221780	CID	15	23	D009020	102	112	D059787	false
Relation: 18221780	CID	43	59	D003915	102	112	D059787	false

Sentence: Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients.
Entity: 18261172	15	26	proteinuria	Disease	D011507
Entity: 18261172	43	52	sirolimus	Chemical	D020123
Relation: 18261172	CID	43	52	D020123	15	26	D011507	true

Sentence: The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.
Entity: 18261172	38	46	sirolmus	Chemical	D020123
Entity: 18261172	48	51	Srl	Chemical	D020123
Entity: 18261172	59	70	nephrotoxic	Disease	D007674
Entity: 18261172	89	100	proteinuria	Disease	D011507
Entity: 18261172	117	120	Srl	Chemical	D020123
Relation: 18261172	CID	38	46	D020123	59	70	D007674	false
Relation: 18261172	CID	38	46	D020123	89	100	D011507	true
Relation: 18261172	CID	48	51	D020123	59	70	D007674	false
Relation: 18261172	CID	48	51	D020123	89	100	D011507	true
Relation: 18261172	CID	117	120	D020123	59	70	D007674	false
Relation: 18261172	CID	117	120	D020123	89	100	D011507	true

Sentence: In cardiac transplantation, the incidence of proteinuria associated with Srl is unknown.
Entity: 18261172	45	56	proteinuria	Disease	D011507
Entity: 18261172	73	76	Srl	Chemical	D020123
Relation: 18261172	CID	73	76	D020123	45	56	D011507	true

Sentence: ACE inhibitor and angiotensin-releasing blocker (ARB) therapy reduced proteinuria development.
Entity: 18261172	0	13	ACE inhibitor	Chemical	D000806
Entity: 18261172	18	47	angiotensin-releasing blocker	Chemical	D057911
Entity: 18261172	49	52	ARB	Chemical	D057911
Entity: 18261172	70	81	proteinuria	Disease	D011507
Relation: 18261172	CID	0	13	D000806	70	81	D011507	false
Relation: 18261172	CID	18	47	D057911	70	81	D011507	false
Relation: 18261172	CID	49	52	D057911	70	81	D011507	false

Sentence: Thus, proteinuria may develop in cardiac transplant patients after switch to Srl, which may have an adverse effect on renal function in these patients.
Entity: 18261172	6	17	proteinuria	Disease	D011507
Entity: 18261172	77	80	Srl	Chemical	D020123
Relation: 18261172	CID	77	80	D020123	6	17	D011507	true

Sentence: Methamphetamine induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling.
Entity: 18410508	0	15	Methamphetamine	Chemical	D008694
Entity: 18410508	24	37	neurotoxicity	Disease	D020258
Relation: 18410508	CID	0	15	D008694	24	37	D020258	false

Sentence: Neurosci. 9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP induced neurodegeneration of DA neurons.
Entity: 18410508	127	131	MPTP	Chemical	D015632
Entity: 18410508	140	157	neurodegeneration	Disease	D009422
Entity: 18410508	161	163	DA	Chemical	D004298
Relation: 18410508	CID	127	131	D015632	140	157	D009422	true
Relation: 18410508	CID	161	163	D004298	140	157	D009422	false

Sentence: Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH induced neurotoxicity and microglial activation.
Entity: 18410508	12	22	CNS damage	Disease	D009422
Entity: 18410508	33	37	METH	Chemical	D008694
Entity: 18410508	42	46	MPTP	Chemical	D015632
Entity: 18410508	75	77	DA	Chemical	D004298
Entity: 18410508	113	126	neurotoxicity	Disease	D020258
Entity: 18410508	176	180	METH	Chemical	D008694
Entity: 18410508	189	202	neurotoxicity	Disease	D020258
Relation: 18410508	CID	33	37	D008694	12	22	D009422	true
Relation: 18410508	CID	33	37	D008694	113	126	D020258	false
Relation: 18410508	CID	33	37	D008694	189	202	D020258	false
Relation: 18410508	CID	42	46	D015632	12	22	D009422	true
Relation: 18410508	CID	42	46	D015632	113	126	D020258	false
Relation: 18410508	CID	42	46	D015632	189	202	D020258	false
Relation: 18410508	CID	75	77	D004298	12	22	D009422	false
Relation: 18410508	CID	75	77	D004298	113	126	D020258	false
Relation: 18410508	CID	75	77	D004298	189	202	D020258	false
Relation: 18410508	CID	176	180	D008694	12	22	D009422	true
Relation: 18410508	CID	176	180	D008694	113	126	D020258	false
Relation: 18410508	CID	176	180	D008694	189	202	D020258	false

Sentence: Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.
Entity: 18410508	141	145	METH	Chemical	D008694
Entity: 18410508	172	185	neurotoxicity	Disease	D020258
Relation: 18410508	CID	141	145	D008694	172	185	D020258	false

Sentence: We conclude from these studies that CX3CR1 signaling does not modulate METH neurotoxicity or microglial activation.
Entity: 18410508	71	75	METH	Chemical	D008694
Entity: 18410508	76	89	neurotoxicity	Disease	D020258
Relation: 18410508	CID	71	75	D008694	76	89	D020258	false

Sentence: Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.
Entity: 18503483	12	22	tacrolimus	Chemical	D016559
Entity: 18503483	34	51	brachial neuritis	Disease	D020968
Entity: 18503483	72	82	everolimus	Chemical	C107135
Relation: 18503483	CID	12	22	D016559	34	51	D020968	true
Relation: 18503483	CID	72	82	C107135	34	51	D020968	false

Sentence: Valvular heart disease in patients with Parkinson's disease treated with pergolide.
Entity: 18560792	0	22	Valvular heart disease	Disease	D006349
Entity: 18560792	40	59	Parkinson's disease	Disease	D010300
Entity: 18560792	73	82	pergolide	Chemical	D010479
Relation: 18560792	CID	73	82	D010479	0	22	D006349	false
Relation: 18560792	CID	73	82	D010479	40	59	D010300	false

Sentence: Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.
Entity: 18560792	0	28	Valvular heart abnormalities	Disease	D006349
Entity: 18560792	65	84	Parkinson's disease	Disease	D010300
Entity: 18560792	86	88	PD	Disease	D010300
Entity: 18560792	103	112	pergolide	Chemical	D010479
Relation: 18560792	CID	103	112	D010479	0	28	D006349	false
Relation: 18560792	CID	103	112	D010479	65	84	D010300	false
Relation: 18560792	CID	103	112	D010479	86	88	D010300	false

Sentence: METHODS: All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography.
Entity: 18560792	13	15	PD	Disease	D010300
Entity: 18560792	57	66	pergolide	Chemical	D010479
Relation: 18560792	CID	57	66	D010479	13	15	D010300	false

Sentence: A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.
Entity: 18560792	25	47	valvular regurgitation	Disease	D006349
Entity: 18560792	75	84	pergolide	Chemical	D010479
Entity: 18560792	142	155	heart failure	Disease	D006333
Relation: 18560792	CID	75	84	D010479	25	47	D006349	false
Relation: 18560792	CID	75	84	D010479	142	155	D006333	false

Sentence: Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.
Entity: 18560792	0	9	Pergolide	Chemical	D010479
Entity: 18560792	47	69	valvular heart disease	Disease	D006349
Entity: 18560792	192	205	heart failure	Disease	D006333
Relation: 18560792	CID	0	9	D010479	47	69	D006349	false
Relation: 18560792	CID	0	9	D010479	192	205	D006333	false

Sentence: BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations.
Entity: 18726058	12	36	Papaverine hydrochloride	Chemical	D010208
Entity: 18726058	83	92	vasospasm	Disease	D020301
Relation: 18726058	CID	12	36	D010208	83	92	D020301	false

Sentence: Transient cranial nerve dysfunction has been described in a few cases with topical papaverine.
Entity: 18726058	10	35	cranial nerve dysfunction	Disease	D003389
Entity: 18726058	83	93	papaverine	Chemical	D010208
Relation: 18726058	CID	83	93	D010208	10	35	D003389	false

Sentence: METHODS: We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical papaverine for vasospasm.
Entity: 18726058	150	160	papaverine	Chemical	D010208
Entity: 18726058	165	174	vasospasm	Disease	D020301
Relation: 18726058	CID	150	160	D010208	165	174	D020301	false

Sentence: Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients.
Entity: 18726058	8	18	papaverine	Chemical	D010208
Entity: 18726058	69	78	vasospasm	Disease	D020301
Relation: 18726058	CID	8	18	D010208	69	78	D020301	false

Sentence: CONCLUSIONS: Topical papaverine for the treatment of vasospasm was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway.
Entity: 18726058	21	31	papaverine	Chemical	D010208
Entity: 18726058	53	62	vasospasm	Disease	D020301
Relation: 18726058	CID	21	31	D010208	53	62	D020301	false

Sentence: Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.
Entity: 18754075	8	19	proteinuria	Disease	D011507
Entity: 18754075	24	43	acute renal failure	Disease	D058186
Entity: 18754075	55	69	bisphosphonate	Chemical	D004164
Entity: 18754075	71	82	alendronate	Chemical	D019386
Entity: 18754075	117	151	focal segmental glomerulosclerosis	Disease	D005923
Relation: 18754075	CID	55	69	D004164	8	19	D011507	false
Relation: 18754075	CID	55	69	D004164	24	43	D058186	false
Relation: 18754075	CID	55	69	D004164	117	151	D005923	false
Relation: 18754075	CID	71	82	D019386	8	19	D011507	true
Relation: 18754075	CID	71	82	D019386	24	43	D058186	true
Relation: 18754075	CID	71	82	D019386	117	151	D005923	false

Sentence: A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.
Entity: 18754075	32	50	nephrotic syndrome	Disease	D009404
Entity: 18754075	58	92	focal segmental glomerulosclerosis	Disease	D005923
Entity: 18754075	126	133	steroid	Chemical	D013256
Relation: 18754075	CID	126	133	D013256	32	50	D009404	false
Relation: 18754075	CID	126	133	D013256	58	92	D005923	false

Sentence: Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.
Entity: 18754075	27	41	bisphosphonate	Chemical	D004164
Entity: 18754075	43	61	alendronate sodium	Chemical	D019386
Entity: 18754075	151	170	acute renal failure	Disease	D058186
Relation: 18754075	CID	27	41	D004164	151	170	D058186	false
Relation: 18754075	CID	43	61	D019386	151	170	D058186	true

Sentence: Serum- and glucocorticoid-inducible kinase 1 in doxorubicin induced nephrotic syndrome.
Entity: 18768591	48	59	doxorubicin	Chemical	D004317
Entity: 18768591	68	86	nephrotic syndrome	Disease	D009404
Relation: 18768591	CID	48	59	D004317	68	86	D009404	true

Sentence: Doxorubicin induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.
Entity: 18768591	0	11	Doxorubicin	Chemical	D004317
Entity: 18768591	20	31	nephropathy	Disease	D007674
Entity: 18768591	52	58	sodium	Chemical	D012964
Entity: 18768591	84	100	volume retention	Disease	D016055
Entity: 18768591	111	119	fibrosis	Disease	D005355
Relation: 18768591	CID	0	11	D004317	20	31	D007674	false
Relation: 18768591	CID	0	11	D004317	84	100	D016055	false
Relation: 18768591	CID	0	11	D004317	111	119	D005355	false
Relation: 18768591	CID	52	58	D012964	20	31	D007674	false
Relation: 18768591	CID	52	58	D012964	84	100	D016055	false
Relation: 18768591	CID	52	58	D012964	111	119	D005355	false

Sentence: The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess.
Entity: 18768591	4	15	aldosterone	Chemical	D000450
Entity: 18768591	152	160	fibrosis	Disease	D005355
Relation: 18768591	CID	4	15	D000450	152	160	D005355	false

Sentence: Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.
Entity: 18768591	0	11	Doxorubicin	Chemical	D004317
Entity: 18768591	40	51	proteinuria	Disease	D011507
Entity: 18768591	146	164	nephrotic syndrome	Disease	D009404
Entity: 18768591	170	177	ascites	Disease	D001201
Entity: 18768591	179	188	lipidemia	Disease	D006949
Entity: 18768591	194	209	hypoalbuminemia	Disease	D034141
Relation: 18768591	CID	0	11	D004317	40	51	D011507	true
Relation: 18768591	CID	0	11	D004317	146	164	D009404	true
Relation: 18768591	CID	0	11	D004317	170	177	D001201	true
Relation: 18768591	CID	0	11	D004317	179	188	D006949	true
Relation: 18768591	CID	0	11	D004317	194	209	D034141	true

Sentence: Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.
Entity: 18768591	7	18	aldosterone	Chemical	D000450
Entity: 18768591	39	48	nephrotic	Disease	D009404
Relation: 18768591	CID	7	18	D000450	39	48	D009404	false

Sentence: Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).
Entity: 18768591	8	14	sodium	Chemical	D012964
Entity: 18768591	202	213	weight gain	Disease	D015430
Relation: 18768591	CID	8	14	D012964	202	213	D015430	false

Sentence: During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).
Entity: 18768591	21	39	nephrotic syndrome	Disease	D009404
Entity: 18768591	47	51	urea	Chemical	D014508
Entity: 18768591	150	156	uremia	Disease	D014511
Relation: 18768591	CID	47	51	D014508	21	39	D009404	false
Relation: 18768591	CID	47	51	D014508	150	156	D014511	false

Sentence: Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients--a report of two cases.
Entity: 19299179	24	35	cholestasis	Disease	D002779
Entity: 19299179	52	66	co-trimoxazole	Chemical	D015662
Entity: 19299179	81	103	Pneumocystis pneumonia	Disease	D011020
Entity: 19299179	107	119	HIV-infected	Disease	D015658
Relation: 19299179	CID	52	66	D015662	24	35	D002779	false
Relation: 19299179	CID	52	66	D015662	81	103	D011020	false
Relation: 19299179	CID	52	66	D015662	107	119	D015658	false

Sentence: Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.
Entity: 19299179	0	22	Pneumocystis pneumonia	Disease	D011020
Entity: 19299179	24	27	PCP	Disease	D011020
Entity: 19299179	39	62	opportunistic infection	Disease	D009894
Entity: 19299179	66	78	HIV-infected	Disease	D015658
Entity: 19299179	132	146	co-trimoxazole	Chemical	D015662
Relation: 19299179	CID	132	146	D015662	0	22	D011020	false
Relation: 19299179	CID	132	146	D015662	24	27	D011020	false
Relation: 19299179	CID	132	146	D015662	39	62	D009894	false
Relation: 19299179	CID	132	146	D015662	66	78	D015658	false

Sentence: Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.
Entity: 19299179	56	68	HIV-infected	Disease	D015658
Entity: 19299179	99	123	intrahepatic cholestasis	Disease	D002780
Entity: 19299179	162	175	liver abscess	Disease	D008100
Entity: 19299179	214	228	co-trimoxazole	Chemical	D015662
Entity: 19299179	243	246	PCP	Disease	D011020
Relation: 19299179	CID	214	228	D015662	56	68	D015658	false
Relation: 19299179	CID	214	228	D015662	99	123	D002780	true
Relation: 19299179	CID	214	228	D015662	162	175	D008100	false
Relation: 19299179	CID	214	228	D015662	243	246	D011020	false

Sentence: Clinically significant proteinuria following the administration of sirolimus to renal transplant recipients.
Entity: 19356053	23	34	proteinuria	Disease	D011507
Entity: 19356053	67	76	sirolimus	Chemical	D020123
Relation: 19356053	CID	67	76	D020123	23	34	D011507	true

Sentence: BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less nephrotoxicity than calcineurin inhibitor (CNI)-based regimens.
Entity: 19356053	12	21	Sirolimus	Chemical	D020123
Entity: 19356053	105	119	nephrotoxicity	Disease	D007674
Relation: 19356053	CID	12	21	D020123	105	119	D007674	false

Sentence: To date there has been little documentation of clinically significant proteinuria linked with the use of sirolimus.
Entity: 19356053	70	81	proteinuria	Disease	D011507
Entity: 19356053	105	114	sirolimus	Chemical	D020123
Relation: 19356053	CID	105	114	D020123	70	81	D011507	true

Sentence: We have encountered several patients who developed substantial proteinuria associated with sirolimus use.
Entity: 19356053	63	74	proteinuria	Disease	D011507
Entity: 19356053	91	100	sirolimus	Chemical	D020123
Relation: 19356053	CID	91	100	D020123	63	74	D011507	true

Sentence: In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria.
Entity: 19356053	76	85	sirolimus	Chemical	D020123
Entity: 19356053	98	109	proteinuria	Disease	D011507
Entity: 19356053	121	130	sirolimus	Chemical	D020123
Entity: 19356053	166	177	proteinuria	Disease	D011507
Relation: 19356053	CID	76	85	D020123	98	109	D011507	true
Relation: 19356053	CID	76	85	D020123	166	177	D011507	true
Relation: 19356053	CID	121	130	D020123	98	109	D011507	true
Relation: 19356053	CID	121	130	D020123	166	177	D011507	true

Sentence: In these patients, the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein:creatinine ratios, an estimate of grams of proteinuria/day.
Entity: 19356053	36	47	proteinuria	Disease	D011507
Entity: 19356053	139	149	creatinine	Chemical	D003404
Entity: 19356053	182	193	proteinuria	Disease	D011507
Relation: 19356053	CID	139	149	D003404	36	47	D011507	false
Relation: 19356053	CID	139	149	D003404	182	193	D011507	false

Sentence: In 7 of the 28 patients there was a striking temporal association between the initiation of sirolimus and the development of nephrotic-range proteinuria.
Entity: 19356053	92	101	sirolimus	Chemical	D020123
Entity: 19356053	125	134	nephrotic	Disease	D009404
Entity: 19356053	141	152	proteinuria	Disease	D011507
Relation: 19356053	CID	92	101	D020123	125	134	D009404	false
Relation: 19356053	CID	92	101	D020123	141	152	D011507	true

Sentence: Proteinuria correlated most strongly with sirolimus therapy when compared to other demographic and clinical variables.
Entity: 19356053	0	11	Proteinuria	Disease	D011507
Entity: 19356053	42	51	sirolimus	Chemical	D020123
Relation: 19356053	CID	42	51	D020123	0	11	D011507	true

Sentence: In most patients, discontinuation of sirolimus resulted in a decrease, but not resolution, of proteinuria.
Entity: 19356053	37	46	sirolimus	Chemical	D020123
Entity: 19356053	94	105	proteinuria	Disease	D011507
Relation: 19356053	CID	37	46	D020123	94	105	D011507	true

Sentence: CONCLUSIONS: Sirolimus induces or aggravates pre-existing proteinuria in an unpredictable subset of renal allograft recipients.
Entity: 19356053	13	22	Sirolimus	Chemical	D020123
Entity: 19356053	58	69	proteinuria	Disease	D011507
Relation: 19356053	CID	13	22	D020123	58	69	D011507	true

Sentence: This study measured the objective and subjective neurocognitive effects of a single 10-mg dose of immediate-release oxycodone in healthy, older (> 65 years), and middle-aged (35 to 55 years) adults who were not suffering from chronic or significant daily pain.
Entity: 19729346	116	125	oxycodone	Chemical	D010098
Entity: 19729346	255	259	pain	Disease	D010146
Relation: 19729346	CID	116	125	D010098	255	259	D010146	false

Sentence: This study suggests that for healthy older adults who are not suffering from chronic pain, neurocognitive and pharmacodynamic changes in response to a 10-mg dose of immediate-release oxycodone are similar to those observed for middle-aged adults.
Entity: 19729346	77	89	chronic pain	Disease	D059350
Entity: 19729346	183	192	oxycodone	Chemical	D010098
Relation: 19729346	CID	183	192	D010098	77	89	D059350	false

Sentence: OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.
Entity: 20080983	89	98	modafinil	Chemical	C048833
Entity: 20080983	112	130	daytime sleepiness	Disease	D012893
Entity: 20080983	142	149	cocaine	Chemical	D003042
Relation: 20080983	CID	89	98	C048833	112	130	D012893	false
Relation: 20080983	CID	142	149	D003042	112	130	D012893	true

Sentence: Modafinil was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective daytime sleepiness.
Entity: 20080983	0	9	Modafinil	Chemical	C048833
Entity: 20080983	159	177	daytime sleepiness	Disease	D012893
Relation: 20080983	CID	0	9	C048833	159	177	D012893	false

Sentence: CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.
Entity: 20080983	27	36	modafinil	Chemical	C048833
Entity: 20080983	108	126	daytime sleepiness	Disease	D012893
Entity: 20080983	140	147	cocaine	Chemical	D003042
Relation: 20080983	CID	27	36	C048833	108	126	D012893	false
Relation: 20080983	CID	140	147	D003042	108	126	D012893	true

Sentence: Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.
Entity: 20520283	23	32	asenapine	Chemical	C522667
Entity: 20520283	51	62	haloperidol	Chemical	D006220
Entity: 20520283	119	132	schizophrenia	Disease	D012559
Relation: 20520283	CID	23	32	C522667	119	132	D012559	false
Relation: 20520283	CID	51	62	D006220	119	132	D012559	false

Sentence: Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.
Entity: 20520283	0	9	Asenapine	Chemical	C522667
Entity: 20520283	92	105	schizophrenia	Disease	D012559
Entity: 20520283	112	117	manic	Disease	D001714
Entity: 20520283	152	170	bipolar I disorder	Disease	D001714
Entity: 20520283	187	196	psychotic	Disease	D011618
Relation: 20520283	CID	0	9	C522667	92	105	D012559	false
Relation: 20520283	CID	0	9	C522667	112	117	D001714	false
Relation: 20520283	CID	0	9	C522667	152	170	D001714	false
Relation: 20520283	CID	0	9	C522667	187	196	D011618	false

Sentence: In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).
Entity: 20520283	56	69	schizophrenia	Disease	D012559
Entity: 20520283	122	131	asenapine	Chemical	C522667
Entity: 20520283	159	168	asenapine	Chemical	C522667
Entity: 20520283	195	206	haloperidol	Chemical	D006220
Relation: 20520283	CID	122	131	C522667	56	69	D012559	false
Relation: 20520283	CID	159	168	C522667	56	69	D012559	false
Relation: 20520283	CID	195	206	D006220	56	69	D012559	false

Sentence: Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.
Entity: 20520283	0	23	Extrapyramidal symptoms	Disease	D001480
Entity: 20520283	85	94	asenapine	Chemical	C522667
Entity: 20520283	115	126	haloperidol	Chemical	D006220
Relation: 20520283	CID	85	94	C522667	0	23	D001480	true
Relation: 20520283	CID	115	126	D006220	0	23	D001480	true

Sentence: Permeability, ultrastructural changes, and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis.
Entity: 20588063	109	134	puromycin aminonucleoside	Chemical	D011692
Entity: 20588063	135	144	nephrosis	Disease	D009401
Relation: 20588063	CID	109	134	D011692	135	144	D009401	true

Sentence: Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.
Entity: 20588063	6	31	puromycin aminonucleoside	Chemical	D011692
Entity: 20588063	32	41	nephrosis	Disease	D009401
Relation: 20588063	CID	6	31	D011692	32	41	D009401	true

Sentence: Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy.
Entity: 19820426	27	43	cardiac toxicity	Disease	D066126
Entity: 19820426	55	74	lopinavir/ritonavir	Chemical	C558899
Relation: 19820426	CID	55	74	C558899	27	43	D066126	false

Sentence: One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.
Entity: 19820426	36	47	heart block	Disease	D006327
Entity: 19820426	52	74	dilated cardiomyopathy	Disease	D002311
Entity: 19820426	86	105	lopinavir/ritonavir	Chemical	C558899
Entity: 19820426	187	198	bradycardia	Disease	D001919
Relation: 19820426	CID	86	105	C558899	36	47	D006327	true
Relation: 19820426	CID	86	105	C558899	52	74	D002311	true
Relation: 19820426	CID	86	105	C558899	187	198	D001919	true

Sentence: Learning of rats under amnesia caused by pentobarbital.
Entity: 1616457	23	30	amnesia	Disease	D000647
Entity: 1616457	41	54	pentobarbital	Chemical	D010424
Relation: 1616457	CID	41	54	D010424	23	30	D000647	true

Sentence: Dissociated learning of rats in the normal state and the state of amnesia produced by pentobarbital (15 mg/kg, ip) was carried out.
Entity: 1616457	66	73	amnesia	Disease	D000647
Entity: 1616457	86	99	pentobarbital	Chemical	D010424
Relation: 1616457	CID	86	99	D010424	66	73	D000647	true

Sentence: Angiosarcoma of the liver associated with diethylstilbestrol.
Entity: 567256	0	12	Angiosarcoma	Disease	D006394
Entity: 567256	0	12	Angiosarcoma	Disease	D008113
Entity: 567256	42	60	diethylstilbestrol	Chemical	D004054
Relation: 567256	CID	42	60	D004054	0	12	D006394	true
Relation: 567256	CID	42	60	D004054	0	12	D008113	true

Sentence: Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years.
Entity: 567256	0	12	Angiosarcoma	Disease	D006394
Entity: 567256	0	12	Angiosarcoma	Disease	D008113
Entity: 567256	103	117	adenocarcinoma	Disease	D000230
Entity: 567256	103	117	adenocarcinoma	Disease	D008113
Entity: 567256	136	154	diethylstilbestrol	Chemical	D004054
Relation: 567256	CID	136	154	D004054	0	12	D006394	true
Relation: 567256	CID	136	154	D004054	0	12	D008113	true
Relation: 567256	CID	136	154	D004054	103	117	D000230	false
Relation: 567256	CID	136	154	D004054	103	117	D008113	true

Sentence: Role of xanthine oxidase in dexamethasone induced hypertension in rats. 1.
Entity: 17439425	8	16	xanthine	Chemical	D019820
Entity: 17439425	28	41	dexamethasone	Chemical	D003907
Entity: 17439425	50	62	hypertension	Disease	D006973
Relation: 17439425	CID	8	16	D019820	50	62	D006973	false
Relation: 17439425	CID	28	41	D003907	50	62	D006973	true

Sentence: Glucocorticoid induced hypertension (GC-HT) in the rat is associated with nitric oxide-redox imbalance. 2.
Entity: 17439425	23	35	hypertension	Disease	D006973
Entity: 17439425	40	42	HT	Disease	D006973
Entity: 17439425	74	86	nitric oxide	Chemical	D009569
Relation: 17439425	CID	74	86	D009569	23	35	D006973	false
Relation: 17439425	CID	74	86	D009569	40	42	D006973	false

Sentence: We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone induced hypertension (dex-HT). 3.
Entity: 17439425	23	31	xanthine	Chemical	D019820
Entity: 17439425	115	128	dexamethasone	Chemical	D003907
Entity: 17439425	137	149	hypertension	Disease	D006973
Entity: 17439425	151	154	dex	Chemical	D003907
Entity: 17439425	155	157	HT	Disease	D006973
Relation: 17439425	CID	23	31	D019820	137	149	D006973	false
Relation: 17439425	CID	23	31	D019820	155	157	D006973	false
Relation: 17439425	CID	115	128	D003907	137	149	D006973	true
Relation: 17439425	CID	115	128	D003907	155	157	D006973	true
Relation: 17439425	CID	151	154	D003907	137	149	D006973	true
Relation: 17439425	CID	151	154	D003907	155	157	D006973	true

Sentence: Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P" < 0.01).
Entity: 17439425	0	3	Dex	Chemical	D003907
Entity: 17439425	4	17	increased SBP	Disease	D006973
Entity: 17439425	60	104	decreased thymus (P < 0.001) and bodyweights	Disease	D015431
Relation: 17439425	CID	0	3	D003907	4	17	D006973	true
Relation: 17439425	CID	0	3	D003907	60	104	D015431	true

Sentence: Allopurinol did not prevent dex-HT.
Entity: 17439425	0	11	Allopurinol	Chemical	D000493
Entity: 17439425	28	31	dex	Chemical	D003907
Entity: 17439425	32	34	HT	Disease	D006973
Relation: 17439425	CID	0	11	D000493	32	34	D006973	false
Relation: 17439425	CID	28	31	D003907	32	34	D006973	true

Sentence: Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics.
Entity: 9351491	45	56	risperidone	Chemical	D018967
Entity: 9351491	124	142	psychotic symptoms	Disease	D011618
Relation: 9351491	CID	45	56	D018967	124	142	D011618	false

Sentence: Drug induced parkinsonism was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%.
Entity: 9351491	0	25	Drug-induced parkinsonism	Disease	D010302
Entity: 9351491	64	75	risperidone	Chemical	D018967
Entity: 9351491	86	97	haloperidol	Chemical	D006220
Relation: 9351491	CID	64	75	D018967	0	25	D010302	true
Relation: 9351491	CID	86	97	D006220	0	25	D010302	true

Sentence: Simvastatin-ezetimibe induced hepatic failure necessitating liver transplantation.
Entity: 18752389	0	21	Simvastatin-ezetimibe	Chemical	C492458
Entity: 18752389	30	45	hepatic failure	Disease	D017093
Relation: 18752389	CID	0	21	C492458	30	45	D017093	false

Sentence: However, hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe.
Entity: 18752389	9	20	hepatotoxic	Disease	D056486
Entity: 18752389	64	73	ezetimibe	Chemical	C108606
Entity: 18752389	99	120	simvastatin-ezetimibe	Chemical	C492458
Relation: 18752389	CID	64	73	C108606	9	20	D056486	false
Relation: 18752389	CID	99	120	C492458	9	20	D056486	true

Sentence: We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.
Entity: 18752389	55	80	fulminant hepatic failure	Disease	D017114
Entity: 18752389	148	159	simvastatin	Chemical	D019821
Entity: 18752389	173	206	simvastatin 10 mg-ezetimibe 40 mg	Chemical	C492458
Relation: 18752389	CID	148	159	D019821	55	80	D017114	false
Relation: 18752389	CID	173	206	C492458	55	80	D017114	true

Sentence: The patient's lipid panel had been maintained with simvastatin for 18 months before the conversion without evidence of hepatotoxicity.
Entity: 18752389	51	62	simvastatin	Chemical	D019821
Entity: 18752389	119	133	hepatotoxicity	Disease	D056486
Relation: 18752389	CID	51	62	D019821	119	133	D056486	false

Sentence: Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.
Entity: 18752389	0	20	Simvastatinezetimibe	Chemical	C492458
Entity: 18752389	25	37	escitalopram	Chemical	D015283
Entity: 18752389	64	74	depression	Disease	D003866
Entity: 18752389	125	139	hepatotoxicity	Disease	D056486
Relation: 18752389	CID	0	20	C492458	64	74	D003866	false
Relation: 18752389	CID	0	20	C492458	125	139	D056486	true
Relation: 18752389	CID	25	37	D015283	64	74	D003866	false
Relation: 18752389	CID	25	37	D015283	125	139	D056486	false

Sentence: Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.
Entity: 18752389	0	9	Ezetimibe	Chemical	C108606
Entity: 18752389	49	68	uridine diphosphate	Chemical	D014530
Entity: 18752389	173	197	simvastatin hydroxy acid	Chemical	C532833
Entity: 18752389	222	233	simvastatin	Chemical	D019821
Entity: 18752389	258	272	hepatotoxicity	Disease	D056486
Relation: 18752389	CID	0	9	C108606	258	272	D056486	false
Relation: 18752389	CID	49	68	D014530	258	272	D056486	false
Relation: 18752389	CID	173	197	C532833	258	272	D056486	false
Relation: 18752389	CID	222	233	D019821	258	272	D056486	false

Sentence: To our knowledge, this is the first case report of simvastatin-ezetimibe induced liver failure that resulted in liver transplantation.
Entity: 18752389	51	72	simvastatin-ezetimibe	Chemical	C492458
Entity: 18752389	81	94	liver failure	Disease	D017093
Relation: 18752389	CID	51	72	C492458	81	94	D017093	false

Sentence: We postulate that the mechanism of the simvastatinezetimibe induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.
Entity: 18752389	39	59	simvastatinezetimibe	Chemical	C492458
Entity: 18752389	68	82	hepatotoxicity	Disease	D056486
Entity: 18752389	100	111	simvastatin	Chemical	D019821
Entity: 18752389	124	133	ezetimibe	Chemical	C108606
Relation: 18752389	CID	39	59	C492458	68	82	D056486	true
Relation: 18752389	CID	100	111	D019821	68	82	D056486	false
Relation: 18752389	CID	124	133	C108606	68	82	D056486	false

Sentence: BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.
Entity: 20098969	12	27	Methamphetamine	Chemical	D008694
Entity: 20098969	155	175	cardiac dysrhythmias	Disease	D001145
Entity: 20098969	177	189	hypertension	Disease	D006973
Entity: 20098969	191	205	hallucinations	Disease	D006212
Entity: 20098969	211	227	violent behavior	Disease	D001523
Relation: 20098969	CID	12	27	D008694	155	175	D001145	false
Relation: 20098969	CID	12	27	D008694	177	189	D006973	false
Relation: 20098969	CID	12	27	D008694	191	205	D006212	false
Relation: 20098969	CID	12	27	D008694	211	227	D001523	false

Sentence: Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries ("meth mouth"), and excessive tooth wear.
Entity: 20098969	24	39	methamphetamine	Chemical	D008694
Entity: 20098969	76	86	xerostomia	Disease	D014987
Entity: 20098969	96	102	caries	Disease	D003731
Entity: 20098969	105	115	meth mouth	Disease	-1
Entity: 20098969	133	143	tooth wear	Disease	D057085
Relation: 20098969	CID	24	39	D008694	76	86	D014987	false
Relation: 20098969	CID	24	39	D008694	96	102	D003731	true
Relation: 20098969	CID	24	39	D008694	105	115	-1	false
Relation: 20098969	CID	24	39	D008694	133	143	D057085	false

Sentence: She reported her use of methamphetamine for five years and had not experienced any major carious episodes before she started using the drug.
Entity: 20098969	24	39	methamphetamine	Chemical	D008694
Entity: 20098969	89	105	carious episodes	Disease	D003731
Relation: 20098969	CID	24	39	D008694	89	105	D003731	true

Sentence: Thyroxine abuse: an unusual case of thyrotoxicosis in pregnancy.
Entity: 9653867	0	9	Thyroxine	Chemical	D013974
Entity: 9653867	36	50	thyrotoxicosis	Disease	D013971
Relation: 9653867	CID	0	9	D013974	36	50	D013971	true

Sentence: Attenuation of methamphetamine induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment.
Entity: 17608141	15	30	methamphetamine	Chemical	D008694
Entity: 17608141	66	79	neurotoxicity	Disease	D020258
Entity: 17608141	91	109	lipopolysaccharide	Chemical	D008070
Relation: 17608141	CID	15	30	D008694	66	79	D020258	false
Relation: 17608141	CID	91	109	D008070	66	79	D020258	false

Sentence: Immunological activation has been proposed to play a role in methamphetamine induced dopaminergic terminal damage.
Entity: 17608141	61	76	methamphetamine	Chemical	D008694
Entity: 17608141	85	113	dopaminergic terminal damage	Disease	D009422
Relation: 17608141	CID	61	76	D008694	85	113	D009422	false

Sentence: In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine induced nigrostriatal dopamine neurotoxicity.
Entity: 17608141	40	58	lipopolysaccharide	Chemical	D008070
Entity: 17608141	132	147	methamphetamine	Chemical	D008694
Entity: 17608141	170	178	dopamine	Chemical	D004298
Entity: 17608141	179	192	neurotoxicity	Disease	D020258
Relation: 17608141	CID	40	58	D008070	179	192	D020258	false
Relation: 17608141	CID	132	147	D008694	179	192	D020258	false
Relation: 17608141	CID	170	178	D004298	179	192	D020258	false

Sentence: Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited hyperthermia three days later.
Entity: 17608141	0	18	Lipopolysaccharide	Chemical	D008070
Entity: 17608141	77	92	methamphetamine	Chemical	D008694
Entity: 17608141	102	114	hyperthermia	Disease	D005334
Relation: 17608141	CID	0	18	D008070	102	114	D005334	false
Relation: 17608141	CID	77	92	D008694	102	114	D005334	true

Sentence: Effect of converting enzyme inhibition on the course of adriamycin induced nephropathy.
Entity: 2559236	56	66	adriamycin	Chemical	D004317
Entity: 2559236	75	86	nephropathy	Disease	D007674
Relation: 2559236	CID	56	66	D004317	75	86	D007674	false

Sentence: The effect of the converting enzyme inhibitor (CEI) enalapril was assessed in Munich-Wistar rats with established adriamycin nephrosis.
Entity: 2559236	52	61	enalapril	Chemical	D004656
Entity: 2559236	114	124	adriamycin	Chemical	D004317
Entity: 2559236	125	134	nephrosis	Disease	D009401
Relation: 2559236	CID	52	61	D004656	125	134	D009401	false
Relation: 2559236	CID	114	124	D004317	125	134	D009401	true

Sentence: Rats were given a single dose of adriamycin and one month later divided into four groups matched for albuminuria, blood pressure, and plasma albumin concentration.
Entity: 2559236	33	43	adriamycin	Chemical	D004317
Entity: 2559236	101	112	albuminuria	Disease	D000419
Relation: 2559236	CID	33	43	D004317	101	112	D000419	true

Sentence: These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).
Entity: 2559236	37	46	enalapril	Chemical	D004656
Entity: 2559236	243	254	albuminuria	Disease	D000419
Relation: 2559236	CID	37	46	D004656	243	254	D000419	false

Sentence: Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.
Entity: 2559236	78	87	enalapril	Chemical	D004656
Entity: 2559236	106	118	renal injury	Disease	D007674
Entity: 2559236	122	132	adriamycin	Chemical	D004317
Entity: 2559236	133	142	nephrosis	Disease	D009401
Relation: 2559236	CID	78	87	D004656	106	118	D007674	false
Relation: 2559236	CID	78	87	D004656	133	142	D009401	false
Relation: 2559236	CID	122	132	D004317	106	118	D007674	false
Relation: 2559236	CID	122	132	D004317	133	142	D009401	true

Sentence: Chronic enalapril treatment reduced blood pressure without reducing albuminuria in group 4.
Entity: 2559236	8	17	enalapril	Chemical	D004656
Entity: 2559236	68	79	albuminuria	Disease	D000419
Relation: 2559236	CID	8	17	D004656	68	79	D000419	false

Sentence: Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy.
Entity: 21029050	64	69	apnea	Disease	D001049
Entity: 21029050	76	91	succinylcholine	Chemical	D013390
Relation: 21029050	CID	76	91	D013390	64	69	D001049	true

Sentence: Ketamine sedation for the reduction of children's fractures in the emergency department.
Entity: 10901305	0	8	Ketamine	Chemical	D007649
Entity: 10901305	50	59	fractures	Disease	D050723
Relation: 10901305	CID	0	8	D007649	50	59	D050723	false

Sentence: The purpose of the present study was to examine the safety and efficacy of ketamine for sedation in the treatment of children's fractures in the emergency department.
Entity: 10901305	75	83	ketamine	Chemical	D007649
Entity: 10901305	128	137	fractures	Disease	D050723
Relation: 10901305	CID	75	83	D007649	128	137	D050723	false

Sentence: RESULTS: The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes).
Entity: 10901305	61	69	ketamine	Chemical	D007649
Entity: 10901305	93	101	fracture	Disease	D050723
Entity: 10901305	105	116	dislocation	Disease	D004204
Relation: 10901305	CID	61	69	D007649	93	101	D050723	false
Relation: 10901305	CID	61	69	D007649	105	116	D004204	false

Sentence: CONCLUSIONS: Ketamine reliably, safely, and quickly provided adequate sedation to effectively facilitate the reduction of children's fractures in the emergency department at our institution.
Entity: 10901305	13	21	Ketamine	Chemical	D007649
Entity: 10901305	133	142	fractures	Disease	D050723
Relation: 10901305	CID	13	21	D007649	133	142	D050723	false

Sentence: Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders.
Entity: 19037603	20	30	lamivudine	Chemical	D019259
Entity: 19037603	74	97	rheumatologic disorders	Disease	D012216
Relation: 19037603	CID	20	30	D019259	74	97	D012216	false

Sentence: The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.
Entity: 19037603	124	134	lamivudine	Chemical	D019259
Entity: 19037603	138	171	hepatitis B virus surface antigen	Chemical	D006514
Entity: 19037603	173	179	HBs Ag	Chemical	D006514
Entity: 19037603	204	225	rheumatologic disease	Disease	D012216
Relation: 19037603	CID	124	134	D019259	204	225	D012216	false
Relation: 19037603	CID	138	171	D006514	204	225	D012216	false
Relation: 19037603	CID	173	179	D006514	204	225	D012216	false

Sentence: From June 2004 to October 2006, 11 HBs Ag positive patients with rheumatologic diseases, who were on both immunosuppressive and prophylactic lamivudine therapies, were retrospectively assessed.
Entity: 19037603	35	41	HBs Ag	Chemical	D006514
Entity: 19037603	65	87	rheumatologic diseases	Disease	D012216
Entity: 19037603	141	151	lamivudine	Chemical	D019259
Relation: 19037603	CID	35	41	D006514	65	87	D012216	false
Relation: 19037603	CID	141	151	D019259	65	87	D012216	false

Sentence: Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.
Entity: 20084309	100	106	stroke	Disease	D020521
Entity: 20084309	108	122	myocardiopathy	Disease	D009202
Entity: 20084309	124	126	MP	Disease	D009202
Entity: 20084309	151	171	mitral regurgitation	Disease	D008944
Entity: 20084309	173	175	MR	Disease	D008944
Entity: 20084309	185	187	MZ	Chemical	D008874
Relation: 20084309	CID	185	187	D008874	100	106	D020521	false
Relation: 20084309	CID	185	187	D008874	108	122	D009202	false
Relation: 20084309	CID	185	187	D008874	124	126	D009202	false
Relation: 20084309	CID	185	187	D008874	151	171	D008944	false
Relation: 20084309	CID	185	187	D008874	173	175	D008944	false

Sentence: Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.
Entity: 20084309	5	12	hypoxia	Disease	D000860
Entity: 20084309	100	107	hypoxia	Disease	D000860
Entity: 20084309	121	139	airway obstruction	Disease	D000402
Entity: 20084309	182	189	hypoxia	Disease	D000860
Entity: 20084309	200	202	MZ	Chemical	D008874
Relation: 20084309	CID	200	202	D008874	5	12	D000860	true
Relation: 20084309	CID	200	202	D008874	100	107	D000860	true
Relation: 20084309	CID	200	202	D008874	121	139	D000402	false
Relation: 20084309	CID	200	202	D008874	182	189	D000860	true

Sentence: The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).
Entity: 20084309	45	47	MR	Disease	D008944
Entity: 20084309	49	51	MP	Disease	D009202
Entity: 20084309	79	81	MZ	Chemical	D008874
Relation: 20084309	CID	79	81	D008874	45	47	D008944	false
Relation: 20084309	CID	79	81	D008874	49	51	D009202	false

Sentence: Effects of calcium channel blockers on bupivacaine induced toxicity.
Entity: 8231633	11	18	calcium	Chemical	D002118
Entity: 8231633	39	50	bupivacaine	Chemical	D002045
Entity: 8231633	59	67	toxicity	Disease	D064420
Relation: 8231633	CID	11	18	D002118	59	67	D064420	false
Relation: 8231633	CID	39	50	D002045	59	67	D064420	false

Sentence: The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine induced acute toxicity.
Entity: 8231633	62	69	calcium	Chemical	D002118
Entity: 8231633	90	101	bupivacaine	Chemical	D002045
Entity: 8231633	116	124	toxicity	Disease	D064420
Relation: 8231633	CID	62	69	D002118	116	124	D064420	false
Relation: 8231633	CID	90	101	D002045	116	124	D064420	false

Sentence: Selegiline induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.
Entity: 10091617	0	10	Selegiline	Chemical	D012642
Entity: 10091617	19	39	postural hypotension	Disease	D007024
Entity: 10091617	43	62	Parkinson's disease	Disease	D010300
Relation: 10091617	CID	0	10	D012642	19	39	D007024	true
Relation: 10091617	CID	0	10	D012642	43	62	D010300	false

Sentence: OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.
Entity: 10091617	31	50	Parkinson's Disease	Disease	D010300
Entity: 10091617	127	146	Parkinson's disease	Disease	D010300
Entity: 10091617	148	150	PD	Disease	D010300
Entity: 10091617	180	190	selegiline	Chemical	D012642
Entity: 10091617	203	209	L-dopa	Chemical	D007980
Entity: 10091617	237	243	L-dopa	Chemical	D007980
Relation: 10091617	CID	180	190	D012642	31	50	D010300	false
Relation: 10091617	CID	180	190	D012642	127	146	D010300	false
Relation: 10091617	CID	180	190	D012642	148	150	D010300	false
Relation: 10091617	CID	203	209	D007980	31	50	D010300	false
Relation: 10091617	CID	203	209	D007980	127	146	D010300	false
Relation: 10091617	CID	203	209	D007980	148	150	D010300	false
Relation: 10091617	CID	237	243	D007980	31	50	D010300	false
Relation: 10091617	CID	237	243	D007980	127	146	D010300	false
Relation: 10091617	CID	237	243	D007980	148	150	D010300	false

Sentence: Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.
Entity: 10091617	37	47	selegiline	Chemical	D012642
Entity: 10091617	52	58	L-dopa	Chemical	D007980
Entity: 10091617	89	121	systolic orthostatic hypotension	Disease	D007024
Entity: 10091617	159	169	selegiline	Chemical	D012642
Relation: 10091617	CID	37	47	D012642	89	121	D007024	true
Relation: 10091617	CID	52	58	D007980	89	121	D007024	false
Relation: 10091617	CID	159	169	D012642	89	121	D007024	true

Sentence: The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension.
Entity: 10091617	174	184	selegiline	Chemical	D012642
Entity: 10091617	274	297	orthostatic hypotension	Disease	D007024
Relation: 10091617	CID	174	184	D012642	274	297	D007024	true

Sentence: METHODS: The cardiovascular responses to standing and head-up tilt were studied repeatedly in PD patients receiving selegiline and as the drug was withdrawn.
Entity: 10091617	94	96	PD	Disease	D010300
Entity: 10091617	116	126	selegiline	Chemical	D012642
Relation: 10091617	CID	116	126	D012642	94	96	D010300	false

Sentence: RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.
Entity: 10091617	29	61	systolic orthostatic hypotension	Disease	D007024
Entity: 10091617	92	94	PD	Disease	D010300
Entity: 10091617	107	117	selegiline	Chemical	D012642
Relation: 10091617	CID	107	117	D012642	29	61	D007024	true
Relation: 10091617	CID	107	117	D012642	92	94	D010300	false

Sentence: Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug.
Entity: 10091617	0	23	Orthostatic hypotension	Disease	D007024
Entity: 10091617	67	77	selegiline	Chemical	D012642
Relation: 10091617	CID	67	77	D012642	0	23	D007024	true

Sentence: Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action.
Entity: 10091617	9	19	selegiline	Chemical	D012642
Entity: 10091617	39	96	reduced the supine systolic and diastolic blood pressures	Disease	D007024
Relation: 10091617	CID	9	19	D012642	39	96	D007024	true

Sentence: CONCLUSION: This study confirms our previous finding that selegiline in combination with L-dopa is associated with selective orthostatic hypotension.
Entity: 10091617	58	68	selegiline	Chemical	D012642
Entity: 10091617	89	95	L-dopa	Chemical	D007980
Entity: 10091617	125	148	orthostatic hypotension	Disease	D007024
Relation: 10091617	CID	58	68	D012642	125	148	D007024	true
Relation: 10091617	CID	89	95	D007980	125	148	D007024	false

Sentence: Explicit episodic memory for sensory-discriminative components of capsaicin induced pain: immediate and delayed ratings.
Entity: 19269743	66	75	capsaicin	Chemical	D002211
Entity: 19269743	84	88	pain	Disease	D010146
Relation: 19269743	CID	66	75	D002211	84	88	D010146	true

Sentence: In order to address long-term pain memory, nine healthy male volunteers received intradermal injections of three doses of capsaicin (0.05, 1 and 20 microg, separated by 15 min breaks), each given three times in a balanced design across three sessions at one week intervals.
Entity: 19269743	30	34	pain	Disease	D010146
Entity: 19269743	122	131	capsaicin	Chemical	D002211
Relation: 19269743	CID	122	131	D002211	30	34	D010146	true

Sentence: Subjects were able to reliably discriminate pain magnitude and duration across capsaicin doses (both p<0.001), regardless of whether first-time ratings were requested immediately, after one hour or after one day.
Entity: 19269743	44	48	pain	Disease	D010146
Entity: 19269743	79	88	capsaicin	Chemical	D002211
Relation: 19269743	CID	79	88	D002211	44	48	D010146	true

Sentence: Reversibility of captopril induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension.
Entity: 3070035	17	26	captopril	Chemical	D002216
Entity: 3070035	35	54	renal insufficiency	Disease	D051437
Entity: 3070035	97	122	renovascular hypertension	Disease	D006978
Relation: 3070035	CID	17	26	D002216	35	54	D051437	false
Relation: 3070035	CID	17	26	D002216	97	122	D006978	false

Sentence: We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.
Entity: 3070035	27	39	hypertension	Disease	D006973
Entity: 3070035	106	144	sudden deterioration of renal function	Disease	D058186
Entity: 3070035	170	179	captopril	Chemical	D002216
Relation: 3070035	CID	170	179	D002216	27	39	D006973	false
Relation: 3070035	CID	170	179	D002216	106	144	D058186	true

Sentence: Liver disease caused by propylthiouracil.
Entity: 1147734	0	13	Liver disease	Disease	D008107
Entity: 1147734	24	40	propylthiouracil	Chemical	D011441
Relation: 1147734	CID	24	40	D011441	0	13	D008107	false

Sentence: This report presents the clinical, laboratory, and light and electron microscopic observations on a patient with chronic active (aggressive) hepatitis caused by the administration of propylthiouracil.
Entity: 1147734	113	150	chronic active (aggressive) hepatitis	Disease	D006521
Entity: 1147734	183	199	propylthiouracil	Chemical	D011441
Relation: 1147734	CID	183	199	D011441	113	150	D006521	true

Sentence: Capsaicin induced muscle pain alters the excitability of the human jaw-stretch reflex.
Entity: 12202650	0	9	Capsaicin	Chemical	D002211
Entity: 12202650	18	29	muscle pain	Disease	D063806
Relation: 12202650	CID	0	9	D002211	18	29	D063806	false

Sentence: Capsaicin (10 micro g) was injected into the masseter muscle to induce pain in 11 healthy volunteers.
Entity: 12202650	0	9	Capsaicin	Chemical	D002211
Entity: 12202650	71	75	pain	Disease	D010146
Relation: 12202650	CID	0	9	D002211	71	75	D010146	true

Sentence: Repetitive transcranial magnetic stimulation for levodopa induced dyskinesias in Parkinson's disease.
Entity: 18951540	49	57	levodopa	Chemical	D007980
Entity: 18951540	66	77	dyskinesias	Disease	D004409
Entity: 18951540	81	100	Parkinson's disease	Disease	D010300
Relation: 18951540	CID	49	57	D007980	66	77	D004409	true
Relation: 18951540	CID	49	57	D007980	81	100	D010300	false

Sentence: In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and dyspnea.
Entity: 19657887	43	50	alcohol	Chemical	D000431
Entity: 19657887	78	98	flushing of the face	Disease	D005483
Entity: 19657887	100	111	tachycardia	Disease	D013610
Entity: 19657887	117	124	dyspnea	Disease	D004417
Relation: 19657887	CID	43	50	D000431	78	98	D005483	true
Relation: 19657887	CID	43	50	D000431	100	111	D013610	true
Relation: 19657887	CID	43	50	D000431	117	124	D004417	true

Sentence: Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and arterial hypotension after consuming three glasses of wine.
Entity: 19657887	40	50	disulfiram	Chemical	D004221
Entity: 19657887	70	78	flushing	Disease	D005483
Entity: 19657887	80	91	tachycardia	Disease	D013610
Entity: 19657887	97	117	arterial hypotension	Disease	D007022
Relation: 19657887	CID	40	50	D004221	70	78	D005483	false
Relation: 19657887	CID	40	50	D004221	80	91	D013610	false
Relation: 19657887	CID	40	50	D004221	97	117	D007022	false

Sentence: In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.
Entity: 9660111	24	27	TRI	Chemical	D014299
Entity: 9660111	65	74	reserpine	Chemical	D012110
Entity: 9660111	75	86	hypothermia	Disease	D007035
Entity: 9660111	123	142	5-hydroxytryptophan	Chemical	D006916
Relation: 9660111	CID	24	27	D014299	75	86	D007035	false
Relation: 9660111	CID	65	74	D012110	75	86	D007035	true
Relation: 9660111	CID	123	142	D006916	75	86	D007035	false

Sentence: TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).
Entity: 9660111	0	3	TRI	Chemical	D014299
Entity: 9660111	53	66	hyperactivity	Disease	D006948
Entity: 9660111	78	91	d-amphetamine	Chemical	D003913
Entity: 9660111	93	103	quinpirole	Chemical	D019257
Entity: 9660111	146	154	dopamine	Chemical	D004298
Relation: 9660111	CID	0	3	D014299	53	66	D006948	true
Relation: 9660111	CID	78	91	D003913	53	66	D006948	true
Relation: 9660111	CID	93	103	D019257	53	66	D006948	true
Relation: 9660111	CID	146	154	D004298	53	66	D006948	false

Sentence: It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the aggressiveness evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor.
Entity: 9660111	49	62	phenylephrine	Chemical	D010656
Entity: 9660111	147	161	aggressiveness	Disease	D010554
Entity: 9660111	172	181	clonidine	Chemical	D003000
Relation: 9660111	CID	49	62	D010656	147	161	D010554	false
Relation: 9660111	CID	172	181	D003000	147	161	D010554	false

Sentence: Ranitidine induced acute interstitial nephritis in a cadaveric renal allograft.
Entity: 11431197	0	10	Ranitidine	Chemical	D011899
Entity: 11431197	25	47	interstitial nephritis	Disease	D009395
Relation: 11431197	CID	0	10	D011899	25	47	D009395	true

Sentence: Late, late doxorubicin cardiotoxicity.
Entity: 7449470	11	22	doxorubicin	Chemical	D004317
Entity: 7449470	23	37	cardiotoxicity	Disease	D066126
Relation: 7449470	CID	11	22	D004317	23	37	D066126	false

Sentence: Cardiac toxicity is a major complication which limits the use of adriamycin as a chemotherapeutic agent.
Entity: 7449470	0	16	Cardiac toxicity	Disease	D066126
Entity: 7449470	65	75	adriamycin	Chemical	D004317
Relation: 7449470	CID	65	75	D004317	0	16	D066126	false

Sentence: Acetazolamide induced nephrolithiasis: implications for treatment of neuromuscular disorders.
Entity: 8170551	0	13	Acetazolamide	Chemical	D000086
Entity: 8170551	22	37	nephrolithiasis	Disease	D053040
Entity: 8170551	69	92	neuromuscular disorders	Disease	D009468
Relation: 8170551	CID	0	13	D000086	22	37	D053040	false
Relation: 8170551	CID	0	13	D000086	69	92	D009468	false

Sentence: Three patients on acetazolamide (15%) developed renal calculi.
Entity: 8170551	18	31	acetazolamide	Chemical	D000086
Entity: 8170551	48	61	renal calculi	Disease	D007669
Relation: 8170551	CID	18	31	D000086	48	61	D007669	true

Sentence: Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.
Entity: 2476560	14	21	scabies	Disease	D012532
Entity: 2476560	83	90	lindane	Chemical	D001556
Entity: 2476560	92	118	gamma benzene hexachloride	Chemical	D001556
Relation: 2476560	CID	83	90	D001556	14	21	D012532	false
Relation: 2476560	CID	92	118	D001556	14	21	D012532	false

Sentence: Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia.
Entity: 2476560	30	37	lindane	Chemical	D001556
Entity: 2476560	45	80	toxic to the central nervous system	Disease	D002493
Entity: 2476560	108	124	aplastic anaemia	Disease	D000741
Relation: 2476560	CID	30	37	D001556	45	80	D002493	true
Relation: 2476560	CID	30	37	D001556	108	124	D000741	true

Sentence: Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).
Entity: 18821488	0	8	Toxicity	Disease	D064420
Entity: 18821488	59	75	8-aminoquinoline	Chemical	C080436
Entity: 18821488	76	152	8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline	Chemical	C068820
Entity: 18821488	154	162	WR242511	Chemical	C068820
Relation: 18821488	CID	59	75	C080436	0	8	D064420	false
Relation: 18821488	CID	76	152	C068820	0	8	D064420	false
Relation: 18821488	CID	154	162	C068820	0	8	D064420	false

Sentence: RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey.
Entity: 18821488	31	39	WR242511	Chemical	C068820
Entity: 18821488	68	85	methemoglobinemia	Disease	D008708
Relation: 18821488	CID	31	39	C068820	68	85	D008708	false

Sentence: Furthermore, transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 (3.5 or 7.0 mg/kg), and 2 lethalities occurred (one IV and one PO) following the 7.0 mg/kg dose.
Entity: 18821488	23	37	hemoglobinuria	Disease	D006456
Entity: 18821488	90	98	WR242511	Chemical	C068820
Relation: 18821488	CID	90	98	C068820	23	37	D006456	true

Sentence: Atypical sensations following the use of subcutaneous sumatriptan are common, but of uncertain origin.
Entity: 9195768	0	19	Atypical sensations	Disease	D010292
Entity: 9195768	54	65	sumatriptan	Chemical	D018170
Relation: 9195768	CID	54	65	D018170	0	19	D010292	true

Sentence: Tremor side effects of salbutamol, quantified by a laser pointer technique.
Entity: 15338796	0	6	Tremor	Disease	D014202
Entity: 15338796	23	33	salbutamol	Chemical	D000420
Relation: 15338796	CID	23	33	D000420	0	6	D014202	true

Sentence: OBJECTIVE: To study tremor side effects of salbutamol an easily applicable, quick and low-priced method is needed.
Entity: 15338796	20	26	tremor	Disease	D014202
Entity: 15338796	43	53	salbutamol	Chemical	D000420
Relation: 15338796	CID	43	53	D000420	20	26	D014202	true

Sentence: To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol.
Entity: 15338796	37	43	tremor	Disease	D014202
Entity: 15338796	64	88	obstructive lung disease	Disease	D008173
Entity: 15338796	133	143	salbutamol	Chemical	D000420
Relation: 15338796	CID	133	143	D000420	37	43	D014202	true
Relation: 15338796	CID	133	143	D000420	64	88	D008173	false

Sentence: RESULTS: Salbutamol significantly increased tremor severity in patients in a dose-dependent way.
Entity: 15338796	9	19	Salbutamol	Chemical	D000420
Entity: 15338796	44	50	tremor	Disease	D014202
Relation: 15338796	CID	9	19	D000420	44	50	D014202	true

Sentence: Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.
Entity: 12627929	23	45	venous thromboembolism	Disease	D054556
Entity: 12627929	70	79	docetaxel	Chemical	C067311
Entity: 12627929	84	95	thalidomide	Chemical	D013792
Entity: 12627929	145	160	prostate cancer	Disease	D011471
Relation: 12627929	CID	70	79	C067311	23	45	D054556	true
Relation: 12627929	CID	70	79	C067311	145	160	D011471	false
Relation: 12627929	CID	84	95	D013792	23	45	D054556	true
Relation: 12627929	CID	84	95	D013792	145	160	D011471	false

Sentence: STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.
Entity: 12627929	46	68	venous thromboembolism	Disease	D054556
Entity: 12627929	70	73	VTE	Disease	D054556
Entity: 12627929	122	137	prostate cancer	Disease	D011471
Entity: 12627929	160	169	docetaxel	Chemical	C067311
Entity: 12627929	199	210	thalidomide	Chemical	D013792
Relation: 12627929	CID	160	169	C067311	46	68	D054556	true
Relation: 12627929	CID	160	169	C067311	70	73	D054556	true
Relation: 12627929	CID	160	169	C067311	122	137	D011471	false
Relation: 12627929	CID	199	210	D013792	46	68	D054556	true
Relation: 12627929	CID	199	210	D013792	70	73	D054556	true
Relation: 12627929	CID	199	210	D013792	122	137	D011471	false

Sentence: MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).
Entity: 12627929	64	73	docetaxel	Chemical	C067311
Entity: 12627929	90	93	VTE	Disease	D054556
Entity: 12627929	139	148	docetaxel	Chemical	C067311
Entity: 12627929	154	165	thalidomide	Chemical	D013792
Entity: 12627929	176	179	VTE	Disease	D054556
Relation: 12627929	CID	64	73	C067311	90	93	D054556	true
Relation: 12627929	CID	64	73	C067311	176	179	D054556	true
Relation: 12627929	CID	139	148	C067311	90	93	D054556	true
Relation: 12627929	CID	139	148	C067311	176	179	D054556	true
Relation: 12627929	CID	154	165	D013792	90	93	D054556	true
Relation: 12627929	CID	154	165	D013792	176	179	D054556	true

Sentence: CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.
Entity: 12627929	28	39	thalidomide	Chemical	D013792
Entity: 12627929	43	52	docetaxel	Chemical	C067311
Entity: 12627929	73	88	prostate cancer	Disease	D011471
Entity: 12627929	130	133	VTE	Disease	D054556
Relation: 12627929	CID	28	39	D013792	73	88	D011471	false
Relation: 12627929	CID	28	39	D013792	130	133	D054556	true
Relation: 12627929	CID	43	52	C067311	73	88	D011471	false
Relation: 12627929	CID	43	52	C067311	130	133	D054556	true

Sentence: UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain induced ventricular tachycardias.
Entity: 6634932	0	6	UM-272	Chemical	C002616
Entity: 6634932	8	31	N,N-dimethylpropranolol	Chemical	C002616
Entity: 6634932	112	119	ouabain	Chemical	D010042
Entity: 6634932	128	152	ventricular tachycardias	Disease	D017180
Relation: 6634932	CID	0	6	C002616	128	152	D017180	false
Relation: 6634932	CID	8	31	C002616	128	152	D017180	false
Relation: 6634932	CID	112	119	D010042	128	152	D017180	true

Sentence: Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.
Entity: 18791946	7	23	thrombocytopenia	Disease	D013921
Entity: 18791946	28	46	haemolytic anaemia	Disease	D000743
Entity: 18791946	63	76	ciprofloxacin	Chemical	D002939
Relation: 18791946	CID	63	76	D002939	7	23	D013921	true
Relation: 18791946	CID	63	76	D002939	28	46	D000743	true

Sentence: A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.
Entity: 18791946	42	56	abdominal pain	Disease	D015746
Entity: 18791946	61	69	jaundice	Disease	D007565
Entity: 18791946	105	118	ciprofloxacin	Chemical	D002939
Entity: 18791946	136	159	urinary tract infection	Disease	D014552
Relation: 18791946	CID	105	118	D002939	42	56	D015746	true
Relation: 18791946	CID	105	118	D002939	61	69	D007565	true
Relation: 18791946	CID	105	118	D002939	136	159	D014552	false

Sentence: Simvastatin induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism.
Entity: 17344566	0	11	Simvastatin	Chemical	D019821
Entity: 17344566	34	54	compartment syndrome	Disease	D003161
Entity: 17344566	59	70	myonecrosis	Disease	D009135
Entity: 17344566	87	101	hypothyroidism	Disease	D007037
Relation: 17344566	CID	0	11	D019821	34	54	D003161	true
Relation: 17344566	CID	0	11	D019821	59	70	D009135	false
Relation: 17344566	CID	0	11	D019821	87	101	D007037	false

Sentence: A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.
Entity: 17344566	14	25	hypothyroid	Disease	D007037
Entity: 17344566	38	47	thyroxine	Chemical	D013974
Entity: 17344566	52	63	simvastatin	Chemical	D019821
Entity: 17344566	93	113	compartment syndrome	Disease	D003161
Entity: 17344566	118	129	myonecrosis	Disease	D009135
Relation: 17344566	CID	38	47	D013974	14	25	D007037	false
Relation: 17344566	CID	38	47	D013974	93	113	D003161	false
Relation: 17344566	CID	38	47	D013974	118	129	D009135	false
Relation: 17344566	CID	52	63	D019821	14	25	D007037	false
Relation: 17344566	CID	52	63	D019821	93	113	D003161	true
Relation: 17344566	CID	52	63	D019821	118	129	D009135	false

Sentence: Bile duct hamartoma occurring in association with long-term treatment with danazol.
Entity: 9293063	0	4	Bile	Disease	D001650
Entity: 9293063	10	19	hamartoma	Disease	D006222
Entity: 9293063	75	82	danazol	Chemical	D003613
Relation: 9293063	CID	75	82	D003613	0	4	D001650	true
Relation: 9293063	CID	75	82	D003613	10	19	D006222	true

Sentence: We report a case of bile duct hamartoma which developed in a patient who had been on long-term danazol treatment.
Entity: 9293063	20	24	bile	Disease	D001650
Entity: 9293063	30	39	hamartoma	Disease	D006222
Entity: 9293063	95	102	danazol	Chemical	D003613
Relation: 9293063	CID	95	102	D003613	20	24	D001650	true
Relation: 9293063	CID	95	102	D003613	30	39	D006222	true

Sentence: Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid.
Entity: 1728522	0	13	Granulomatous	Disease	D006099
Entity: 1728522	14	23	hepatitis	Disease	D056486
Entity: 1728522	31	77	combination of amoxicillin and clavulanic acid	Chemical	D019980
Relation: 1728522	CID	31	77	D019980	0	13	D006099	true
Relation: 1728522	CID	31	77	D019980	14	23	D056486	true

Sentence: We report the case of a patient with amoxicillin-clavulanic acid induced hepatitis with histologic multiple granulomas.
Entity: 1728522	37	64	amoxicillin-clavulanic acid	Chemical	D019980
Entity: 1728522	73	82	hepatitis	Disease	D056486
Entity: 1728522	108	118	granulomas	Disease	D006099
Relation: 1728522	CID	37	64	D019980	73	82	D056486	true
Relation: 1728522	CID	37	64	D019980	108	118	D006099	true

Sentence: METHODS: A review of admissions during a 6-year period revealed 14 patients with cocaine-related aneurysms.
Entity: 10807237	81	88	cocaine	Chemical	D003042
Entity: 10807237	97	106	aneurysms	Disease	D000783
Relation: 10807237	CID	81	88	D003042	97	106	D000783	false

Sentence: Hunt and Hess grade (P < 0.005) and age (P < 0.007) were significant predictors of outcome for the patients with cocaine-related aneurysms.
Entity: 10807237	113	120	cocaine	Chemical	D003042
Entity: 10807237	129	138	aneurysms	Disease	D000783
Relation: 10807237	CID	113	120	D003042	129	138	D000783	false

Sentence: The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.
Entity: 12536034	48	64	absence epilepsy	Disease	D004832
Entity: 12536034	89	102	carbamazepine	Chemical	D002220
Entity: 12536034	107	117	vigabatrin	Chemical	D020888
Relation: 12536034	CID	89	102	D002220	48	64	D004832	true
Relation: 12536034	CID	107	117	D020888	48	64	D004832	true

Sentence: The gamma-aminobutyric acid-transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy.
Entity: 12536034	4	27	gamma-aminobutyric acid	Chemical	D005680
Entity: 12536034	133	149	absence epilepsy	Disease	D004832
Relation: 12536034	CID	4	27	D005680	133	149	D004832	false

Sentence: Procainamide induced polymorphous ventricular tachycardia.
Entity: 7234705	0	12	Procainamide	Chemical	D011342
Entity: 7234705	34	57	ventricular tachycardia	Disease	D017180
Relation: 7234705	CID	0	12	D011342	34	57	D017180	true

Sentence: Seven cases of procainamide induced polymorphous ventricular tachycardia are presented.
Entity: 7234705	15	27	procainamide	Chemical	D011342
Entity: 7234705	49	72	ventricular tachycardia	Disease	D017180
Relation: 7234705	CID	15	27	D011342	49	72	D017180	true

Sentence: In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.
Entity: 7234705	31	54	ventricular tachycardia	Disease	D017180
Entity: 7234705	117	129	procainamide	Chemical	D011342
Entity: 7234705	161	184	ventricular tachycardia	Disease	D017180
Relation: 7234705	CID	117	129	D011342	31	54	D017180	true
Relation: 7234705	CID	117	129	D011342	161	184	D017180	true

Sentence: In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.
Entity: 7234705	33	45	procainamide	Chemical	D011342
Entity: 7234705	95	129	premature ventricular contractions	Disease	D018879
Entity: 7234705	133	147	atrial flutter	Disease	D001282
Relation: 7234705	CID	33	45	D011342	95	129	D018879	false
Relation: 7234705	CID	33	45	D011342	133	147	D001282	false

Sentence: In the seventh patient, a permanent ventricular pacemaker was inserted and, despite continuation of procainamide therapy, polymorphous ventricular tachycardia did not reoccur.
Entity: 7234705	100	112	procainamide	Chemical	D011342
Entity: 7234705	135	158	ventricular tachycardia	Disease	D017180
Relation: 7234705	CID	100	112	D011342	135	158	D017180	true

Sentence: Role of activation of bradykinin B2 receptors in disruption of the blood-brain barrier during acute hypertension.
Entity: 8955532	22	32	bradykinin	Chemical	D001920
Entity: 8955532	100	112	hypertension	Disease	D006973
Relation: 8955532	CID	22	32	D001920	100	112	D006973	false

Sentence: The goal of this study was to determine the role of synthesis/release of bradykinin to activate B2 receptors in disruption of the blood-brain barrier during acute hypertension.
Entity: 8955532	73	83	bradykinin	Chemical	D001920
Entity: 8955532	163	175	hypertension	Disease	D006973
Relation: 8955532	CID	73	83	D001920	163	175	D006973	false

Sentence: Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).
Entity: 8955532	92	99	dextran	Chemical	D003911
Entity: 8955532	118	131	phenylephrine	Chemical	D010656
Entity: 8955532	146	158	hypertension	Disease	D006973
Entity: 8955532	192	199	Hoe-140	Chemical	C065679
Relation: 8955532	CID	92	99	D003911	146	158	D006973	false
Relation: 8955532	CID	118	131	D010656	146	158	D006973	true
Relation: 8955532	CID	192	199	C065679	146	158	D006973	false

Sentence: 5-azacytidine potentiates initiation induced by carcinogens in rat liver.
Entity: 2578334	0	13	5-azacytidine	Chemical	D001374
Entity: 2578334	26	59	initiation induced by carcinogens	Disease	D011230
Relation: 2578334	CID	0	13	D001374	26	59	D011230	true

Sentence: To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).
Entity: 2578334	98	132	initiation of carcinogenic process	Disease	D011230
Entity: 2578334	134	147	5-azacytidine	Chemical	D001374
Entity: 2578334	149	154	5-AzC	Chemical	D001374
Entity: 2578334	290	305	benzo[a]-pyrene	Chemical	D001564
Entity: 2578334	319	341	N-methyl-N-nitrosourea	Chemical	D008770
Entity: 2578334	357	378	1,2-dimethylhydrazine	Chemical	D019813
Entity: 2578334	380	387	1,2-DMH	Chemical	D019813
Relation: 2578334	CID	134	147	D001374	98	132	D011230	true
Relation: 2578334	CID	149	154	D001374	98	132	D011230	true
Relation: 2578334	CID	290	305	D001564	98	132	D011230	true
Relation: 2578334	CID	319	341	D008770	98	132	D011230	true
Relation: 2578334	CID	357	378	D019813	98	132	D011230	true
Relation: 2578334	CID	380	387	D019813	98	132	D011230	true

Sentence: Withdrawal-emergent rabbit syndrome during dose reduction of risperidone.
Entity: 11532387	0	10	Withdrawal	Disease	D013375
Entity: 11532387	11	19	emergent	Disease	D001480
Entity: 11532387	61	72	risperidone	Chemical	D018967
Relation: 11532387	CID	61	72	D018967	0	10	D013375	true
Relation: 11532387	CID	61	72	D018967	11	19	D001480	true

Sentence: Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram.
Entity: 3173179	0	9	Verapamil	Chemical	D014700
Entity: 3173179	44	65	myocardial infarction	Disease	D009203
Entity: 3173179	71	83	hypertensive	Disease	D006973
Relation: 3173179	CID	0	9	D014700	44	65	D009203	true
Relation: 3173179	CID	0	9	D014700	71	83	D006973	false

Sentence: We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension.
Entity: 3173179	26	47	myocardial infarction	Disease	D009203
Entity: 3173179	83	92	captopril	Chemical	D002216
Entity: 3173179	115	124	verapamil	Chemical	D014700
Entity: 3173179	172	184	hypertension	Disease	D006973
Relation: 3173179	CID	83	92	D002216	26	47	D009203	false
Relation: 3173179	CID	83	92	D002216	172	184	D006973	false
Relation: 3173179	CID	115	124	D014700	26	47	D009203	true
Relation: 3173179	CID	115	124	D014700	172	184	D006973	false

Sentence: Remission induction of meningeal leukemia with high-dose intravenous methotrexate.
Entity: 3856631	23	41	meningeal leukemia	Disease	D008577
Entity: 3856631	69	81	methotrexate	Chemical	D008727
Relation: 3856631	CID	69	81	D008727	23	41	D008577	false

Sentence: Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.
Entity: 3856631	21	49	acute lymphoblastic leukemia	Disease	D054198
Entity: 3856631	64	81	meningeal disease	Disease	D002493
Entity: 3856631	124	136	methotrexate	Chemical	D008727
Entity: 3856631	191	203	methotrexate	Chemical	D008727
Relation: 3856631	CID	124	136	D008727	21	49	D054198	false
Relation: 3856631	CID	124	136	D008727	64	81	D002493	false
Relation: 3856631	CID	191	203	D008727	21	49	D054198	false
Relation: 3856631	CID	191	203	D008727	64	81	D002493	false

Sentence: The most common toxicities encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis.
Entity: 3856631	16	26	toxicities	Disease	D064420
Entity: 3856631	77	86	bilirubin	Chemical	D001663
Entity: 3856631	99	110	neutropenia	Disease	D009503
Entity: 3856631	116	125	mucositis	Disease	D052016
Relation: 3856631	CID	77	86	D001663	16	26	D064420	false
Relation: 3856631	CID	77	86	D001663	99	110	D009503	false
Relation: 3856631	CID	77	86	D001663	116	125	D052016	false

Sentence: Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.
Entity: 2522601	0	16	Hypersensitivity	Disease	D004342
Entity: 2522601	20	33	carbamazepine	Chemical	D002220
Entity: 2522601	52	70	leukemoid reaction	Disease	D007955
Entity: 2522601	72	84	eosinophilia	Disease	D004802
Entity: 2522601	86	98	erythroderma	Disease	D003873
Entity: 2522601	104	117	renal failure	Disease	D051437
Relation: 2522601	CID	20	33	D002220	0	16	D004342	true
Relation: 2522601	CID	20	33	D002220	52	70	D007955	true
Relation: 2522601	CID	20	33	D002220	72	84	D004802	false
Relation: 2522601	CID	20	33	D002220	86	98	D003873	true
Relation: 2522601	CID	20	33	D002220	104	117	D051437	true

Sentence: We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.
Entity: 2522601	28	44	hypersensitivity	Disease	D004342
Entity: 2522601	48	61	carbamazepine	Chemical	D002220
Entity: 2522601	89	101	erythroderma	Disease	D003873
Entity: 2522601	112	130	leukemoid reaction	Disease	D007955
Entity: 2522601	132	144	eosinophilia	Disease	D004802
Entity: 2522601	146	158	hyponatremia	Disease	D007010
Entity: 2522601	164	177	renal failure	Disease	D051437
Relation: 2522601	CID	48	61	D002220	28	44	D004342	true
Relation: 2522601	CID	48	61	D002220	89	101	D003873	true
Relation: 2522601	CID	48	61	D002220	112	130	D007955	true
Relation: 2522601	CID	48	61	D002220	132	144	D004802	false
Relation: 2522601	CID	48	61	D002220	146	158	D007010	true
Relation: 2522601	CID	48	61	D002220	164	177	D051437	true

Sentence: Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine induced hyperactivity, and raised spontaneous nocturnal activity.
Entity: 8741744	110	132	locomotor hypoactivity	Disease	D009069
Entity: 8741744	143	151	nicotine	Chemical	D009538
Entity: 8741744	207	215	nicotine	Chemical	D009538
Entity: 8741744	224	237	hyperactivity	Disease	D006948
Relation: 8741744	CID	143	151	D009538	110	132	D009069	false
Relation: 8741744	CID	143	151	D009538	224	237	D006948	true
Relation: 8741744	CID	207	215	D009538	110	132	D009069	false
Relation: 8741744	CID	207	215	D009538	224	237	D006948	true

Sentence: Assessment of a new non-invasive index of cardiac performance for detection of dobutamine induced myocardial ischemia.
Entity: 17491223	79	89	dobutamine	Chemical	D004280
Entity: 17491223	98	117	myocardial ischemia	Disease	D017202
Relation: 17491223	CID	79	89	D004280	98	117	D017202	true

Sentence: BACKGROUND: Electrocardiography has a very low sensitivity in detecting dobutamine induced myocardial ischemia.
Entity: 17491223	72	82	dobutamine	Chemical	D004280
Entity: 17491223	91	110	myocardial ischemia	Disease	D017202
Relation: 17491223	CID	72	82	D004280	91	110	D017202	true

Sentence: OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.
Entity: 17491223	198	208	dobutamine	Chemical	D004280
Entity: 17491223	217	236	myocardial ischemia	Disease	D017202
Entity: 17491223	244	259	Tc99m-Sestamibi	Chemical	D017256
Entity: 17491223	375	383	ischemia	Disease	D007511
Relation: 17491223	CID	198	208	D004280	217	236	D017202	true
Relation: 17491223	CID	198	208	D004280	375	383	D007511	false
Relation: 17491223	CID	244	259	D017256	217	236	D017202	false
Relation: 17491223	CID	244	259	D017256	375	383	D007511	false

Sentence: Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage.
Entity: 18004067	0	19	Acute liver failure	Disease	D017114
Entity: 18004067	49	56	alcohol	Chemical	D000431
Entity: 18004067	79	90	paracetamol	Chemical	D000082
Relation: 18004067	CID	49	56	D000431	0	19	D017114	false
Relation: 18004067	CID	79	90	D000082	0	19	D017114	false

Sentence: BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.
Entity: 18004067	33	40	alcohol	Chemical	D000431
Entity: 18004067	63	77	hepatotoxicity	Disease	D056486
Entity: 18004067	115	126	paracetamol	Chemical	D000082
Entity: 18004067	128	141	acetaminophen	Chemical	D000082
Relation: 18004067	CID	33	40	D000431	63	77	D056486	false
Relation: 18004067	CID	115	126	D000082	63	77	D056486	true
Relation: 18004067	CID	128	141	D000082	63	77	D056486	true

Sentence: CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.
Entity: 18004067	66	73	alcohol	Chemical	D000431
Entity: 18004067	92	105	liver failure	Disease	D017093
Entity: 18004067	157	164	alcohol	Chemical	D000431
Entity: 18004067	206	217	paracetamol	Chemical	D000082
Relation: 18004067	CID	66	73	D000431	92	105	D017093	false
Relation: 18004067	CID	157	164	D000431	92	105	D017093	false
Relation: 18004067	CID	206	217	D000082	92	105	D017093	true

Sentence: Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of paracetamol are discussed.
Entity: 18004067	45	59	hepatotoxicity	Disease	D056486
Entity: 18004067	106	117	paracetamol	Chemical	D000082
Relation: 18004067	CID	106	117	D000082	45	59	D056486	true

Sentence: CONCLUSION: In patients with risk factors, e.g. regular consumption of alcohol, liver failure is possible when therapeutic doses are ingested.
Entity: 18004067	71	78	alcohol	Chemical	D000431
Entity: 18004067	80	93	liver failure	Disease	D017093
Relation: 18004067	CID	71	78	D000431	80	93	D017093	false

Sentence: Cocaine related chest pain: are we seeing the tip of an iceberg.
Entity: 12443032	0	7	Cocaine	Chemical	D003042
Entity: 12443032	16	26	chest pain	Disease	D002637
Relation: 12443032	CID	0	7	D003042	16	26	D002637	true

Sentence: In particular, the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.
Entity: 12443032	31	38	cocaine	Chemical	D003042
Entity: 12443032	50	60	chest pain	Disease	D002637
Entity: 12443032	142	152	chest pain	Disease	D002637
Relation: 12443032	CID	31	38	D003042	50	60	D002637	true
Relation: 12443032	CID	31	38	D003042	142	152	D002637	true

Sentence: The mechanism of chest pain related to cocaine use is discussed and treatment dilemmas are discussed.
Entity: 12443032	17	27	chest pain	Disease	D002637
Entity: 12443032	39	46	cocaine	Chemical	D003042
Relation: 12443032	CID	39	46	D003042	17	27	D002637	true

Sentence: Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.
Entity: 17615423	7	21	rhabdomyolysis	Disease	D012206
Entity: 17615423	26	45	acute renal failure	Disease	D058186
Entity: 17615423	78	89	simvastatin	Chemical	D019821
Entity: 17615423	91	101	amiodarone	Chemical	D000638
Entity: 17615423	107	117	atazanavir	Chemical	C413408
Relation: 17615423	CID	78	89	D019821	7	21	D012206	true
Relation: 17615423	CID	78	89	D019821	26	45	D058186	true
Relation: 17615423	CID	91	101	D000638	7	21	D012206	true
Relation: 17615423	CID	91	101	D000638	26	45	D058186	true
Relation: 17615423	CID	107	117	C413408	7	21	D012206	true
Relation: 17615423	CID	107	117	C413408	26	45	D058186	true

Sentence: OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.
Entity: 17615423	60	71	simvastatin	Chemical	D019821
Entity: 17615423	73	83	amiodarone	Chemical	D000638
Entity: 17615423	89	99	atazanavir	Chemical	C413408
Entity: 17615423	113	127	rhabdomyolysis	Disease	D012206
Entity: 17615423	132	151	acute renal failure	Disease	D058186
Relation: 17615423	CID	60	71	D019821	113	127	D012206	true
Relation: 17615423	CID	60	71	D019821	132	151	D058186	true
Relation: 17615423	CID	73	83	D000638	113	127	D012206	true
Relation: 17615423	CID	73	83	D000638	132	151	D058186	true
Relation: 17615423	CID	89	99	C413408	113	127	D012206	true
Relation: 17615423	CID	89	99	C413408	132	151	D058186	true

Sentence: Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.
Entity: 17615423	0	11	Simvastatin	Chemical	D019821
Entity: 17615423	13	23	amiodarone	Chemical	D000638
Entity: 17615423	43	71	human immunodeficiency virus	Disease	D015658
Relation: 17615423	CID	0	11	D019821	43	71	D015658	false
Relation: 17615423	CID	13	23	D000638	43	71	D015658	false

Sentence: DISCUSSION: The risk of rhabdomyolysis is increased in the presence of concomitant drugs that inhibit simvastatin metabolism.
Entity: 17615423	24	38	rhabdomyolysis	Disease	D012206
Entity: 17615423	102	113	simvastatin	Chemical	D019821
Relation: 17615423	CID	102	113	D019821	24	38	D012206	true

Sentence: Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma.
Entity: 8558192	18	29	vinorelbine	Chemical	C030852
Entity: 8558192	44	78	squamous cell esophageal carcinoma	Disease	C562729
Relation: 8558192	CID	18	29	C030852	44	78	C562729	false

Sentence: PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma.
Entity: 8558192	60	71	vinorelbine	Chemical	C030852
Entity: 8558192	73	76	VNB	Chemical	C030852
Entity: 8558192	123	157	squamous cell esophageal carcinoma	Disease	C562729
Relation: 8558192	CID	60	71	C030852	123	157	C562729	false
Relation: 8558192	CID	73	76	C030852	123	157	C562729	false

Sentence: Thirty patients without prior chemotherapy and 16 pretreated with cisplatin-based chemotherapy were assessable for toxicity and response.
Entity: 8558192	66	75	cisplatin	Chemical	D002945
Entity: 8558192	115	123	toxicity	Disease	D064420
Relation: 8558192	CID	66	75	D002945	115	123	D064420	false

Sentence: VNB was well tolerated and zero instances of WHO grade 4 nonhematologic toxicity occurred.
Entity: 8558192	0	3	VNB	Chemical	C030852
Entity: 8558192	72	80	toxicity	Disease	D064420
Relation: 8558192	CID	0	3	C030852	72	80	D064420	false

Sentence: CONCLUSION: These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma.
Entity: 8558192	37	40	VNB	Chemical	C030852
Entity: 8558192	74	108	esophageal squamous cell carcinoma	Disease	C562729
Relation: 8558192	CID	37	40	C030852	74	108	C562729	false

Sentence: Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
Entity: 11135224	0	10	Paclitaxel	Chemical	D017239
Entity: 11135224	12	21	cisplatin	Chemical	D002945
Entity: 11135224	27	38	gemcitabine	Chemical	C056507
Entity: 11135224	126	154	nonsmall cell lung carcinoma	Disease	D002289
Relation: 11135224	CID	0	10	D017239	126	154	D002289	false
Relation: 11135224	CID	12	21	D002945	126	154	D002289	false
Relation: 11135224	CID	27	38	C056507	126	154	D002289	false

Sentence: BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC).
Entity: 11135224	12	21	Cisplatin	Chemical	D002945
Entity: 11135224	103	131	nonsmall cell lung carcinoma	Disease	D002289
Entity: 11135224	133	138	NSCLC	Disease	D002289
Relation: 11135224	CID	12	21	D002945	103	131	D002289	false
Relation: 11135224	CID	12	21	D002945	133	138	D002289	false

Sentence: METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.
Entity: 11135224	90	98	toxicity	Disease	D064420
Entity: 11135224	104	114	paclitaxel	Chemical	D017239
Entity: 11135224	116	125	cisplatin	Chemical	D002945
Entity: 11135224	131	142	gemcitabine	Chemical	C056507
Entity: 11135224	175	180	NSCLC	Disease	D002289
Relation: 11135224	CID	104	114	D017239	90	98	D064420	false
Relation: 11135224	CID	104	114	D017239	175	180	D002289	false
Relation: 11135224	CID	116	125	D002945	90	98	D064420	false
Relation: 11135224	CID	116	125	D002945	175	180	D002289	false
Relation: 11135224	CID	131	142	C056507	90	98	D064420	false
Relation: 11135224	CID	131	142	C056507	175	180	D002289	false

Sentence: Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.
Entity: 11135224	66	71	NSCLC	Disease	D002289
Entity: 11135224	175	185	paclitaxel	Chemical	D017239
Entity: 11135224	241	250	cisplatin	Chemical	D002945
Entity: 11135224	310	321	gemcitabine	Chemical	C056507
Relation: 11135224	CID	175	185	D017239	66	71	D002289	false
Relation: 11135224	CID	241	250	D002945	66	71	D002289	false
Relation: 11135224	CID	310	321	C056507	66	71	D002289	false

Sentence: CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.
Entity: 11135224	32	42	paclitaxel	Chemical	D017239
Entity: 11135224	44	53	cisplatin	Chemical	D002945
Entity: 11135224	59	70	gemcitabine	Chemical	C056507
Entity: 11135224	127	132	NSCLC	Disease	D002289
Relation: 11135224	CID	32	42	D017239	127	132	D002289	false
Relation: 11135224	CID	44	53	D002945	127	132	D002289	false
Relation: 11135224	CID	59	70	C056507	127	132	D002289	false

Sentence: The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.
Entity: 8590259	4	22	ocular hypotensive	Disease	D015814
Entity: 8590259	66	79	apraclonidine	Chemical	C016986
Entity: 8590259	224	237	apraclonidine	Chemical	C016986
Relation: 8590259	CID	66	79	C016986	4	22	D015814	true
Relation: 8590259	CID	224	237	C016986	4	22	D015814	true

Sentence: Carmofur induced organic mental disorders.
Entity: 2096243	0	8	Carmofur	Chemical	C017367
Entity: 2096243	17	41	organic mental disorders	Disease	D019965
Relation: 2096243	CID	0	8	C017367	17	41	D019965	true

Sentence: Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of carmofur induced leukoencephalopathy.
Entity: 2096243	0	23	Organic mental disorder	Disease	D019965
Entity: 2096243	105	113	carmofur	Chemical	C017367
Entity: 2096243	122	141	leukoencephalopathy	Disease	D056784
Relation: 2096243	CID	105	113	C017367	0	23	D019965	true
Relation: 2096243	CID	105	113	C017367	122	141	D056784	true

Sentence: Consequently, carmofur induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state.
Entity: 2096243	14	22	carmofur	Chemical	C017367
Entity: 2096243	31	50	leukoencephalopathy	Disease	D056784
Entity: 2096243	76	104	organic personality syndrome	Disease	D010554
Relation: 2096243	CID	14	22	C017367	31	50	D056784	true
Relation: 2096243	CID	14	22	C017367	76	104	D010554	false

Sentence: The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction.
Entity: 6209318	60	70	mexiletine	Chemical	D008801
Entity: 6209318	72	90	Mexitil-Perlongets	Chemical	D008801
Entity: 6209318	178	199	myocardial infarction	Disease	D009203
Relation: 6209318	CID	60	70	D008801	178	199	D009203	false
Relation: 6209318	CID	72	90	D008801	178	199	D009203	false

Sentence: There were more deaths in the mexiletine group (7.6%) than in the placebo group (4.8%); the difference was not statistically significant.
Entity: 6209318	16	22	deaths	Disease	D003643
Entity: 6209318	30	40	mexiletine	Chemical	D008801
Relation: 6209318	CID	30	40	D008801	16	22	D003643	false

Sentence: Regional localization of the antagonism of amphetamine induced hyperactivity by intracerebral calcitonin injections.
Entity: 3615541	43	54	amphetamine	Chemical	D000661
Entity: 3615541	63	76	hyperactivity	Disease	D006948
Entity: 3615541	94	104	calcitonin	Chemical	D002116
Relation: 3615541	CID	43	54	D000661	63	76	D006948	true
Relation: 3615541	CID	94	104	D002116	63	76	D006948	false

Sentence: Fatal intracranial bleeding associated with prehospital use of epinephrine.
Entity: 8953972	6	27	intracranial bleeding	Disease	D013345
Entity: 8953972	63	74	epinephrine	Chemical	D004837
Relation: 8953972	CID	63	74	D004837	6	27	D013345	true

Sentence: The sudden onset of respiratory distress, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine.
Entity: 8953972	20	40	respiratory distress	Disease	D012128
Entity: 8953972	42	46	rash	Disease	D005076
Entity: 8953972	143	154	epinephrine	Chemical	D004837
Relation: 8953972	CID	143	154	D004837	20	40	D012128	false
Relation: 8953972	CID	143	154	D004837	42	46	D005076	false

Sentence: A case of massive rhabdomyolysis following molindone administration.
Entity: 3782049	18	32	rhabdomyolysis	Disease	D012206
Entity: 3782049	43	52	molindone	Chemical	D008972
Relation: 3782049	CID	43	52	D008972	18	32	D012206	true

Sentence: The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.
Entity: 3782049	14	27	schizophrenic	Disease	D012559
Entity: 3782049	70	84	rhabdomyolysis	Disease	D012206
Entity: 3782049	100	119	acute renal failure	Disease	D058186
Entity: 3782049	130	139	molindone	Chemical	D008972
Relation: 3782049	CID	130	139	D008972	14	27	D012559	false
Relation: 3782049	CID	130	139	D008972	70	84	D012206	true
Relation: 3782049	CID	130	139	D008972	100	119	D058186	true

Sentence: Cardiovascular alterations in rat fetuses exposed to calcium channel blockers.
Entity: 9100294	0	26	Cardiovascular alterations	Disease	D018376
Entity: 9100294	53	60	calcium	Chemical	D002118
Relation: 9100294	CID	53	60	D002118	0	26	D018376	false

Sentence: Preclinical toxicologic investigation suggested that a new calcium channel blocker, Ro 40-5967, induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis.
Entity: 9100294	59	66	calcium	Chemical	D002118
Entity: 9100294	84	94	Ro 40-5967	Chemical	D020748
Entity: 9100294	104	130	cardiovascular alterations	Disease	D018376
Relation: 9100294	CID	59	66	D002118	104	130	D018376	false
Relation: 9100294	CID	84	94	D020748	104	130	D018376	true

Sentence: The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect.
Entity: 9100294	66	73	calcium	Chemical	D002118
Entity: 9100294	109	137	cardiovascular malformations	Disease	D018376
Relation: 9100294	CID	66	73	D002118	109	137	D018376	false

Sentence: Pregnant rats were administered one of these calcium channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for cardiovascular malformations.
Entity: 9100294	45	52	calcium	Chemical	D002118
Entity: 9100294	167	195	cardiovascular malformations	Disease	D018376
Relation: 9100294	CID	45	52	D002118	167	195	D018376	false

Sentence: A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.
Entity: 9100294	19	47	cardiovascular malformations	Disease	D018376
Entity: 9100294	96	103	calcium	Chemical	D002118
Entity: 9100294	180	189	verapamil	Chemical	D014700
Entity: 9100294	194	204	nifedipine	Chemical	D009543
Relation: 9100294	CID	96	103	D002118	19	47	D018376	false
Relation: 9100294	CID	180	189	D014700	19	47	D018376	true
Relation: 9100294	CID	194	204	D009543	19	47	D018376	true

Sentence: The effects of sevoflurane on lidocaine induced convulsions.
Entity: 15278670	15	26	sevoflurane	Chemical	C009250
Entity: 15278670	30	39	lidocaine	Chemical	D008012
Entity: 15278670	48	59	convulsions	Disease	D012640
Relation: 15278670	CID	15	26	C009250	48	59	D012640	false
Relation: 15278670	CID	30	39	D008012	48	59	D012640	true

Sentence: The influence of sevoflurane on lidocaine induced convulsions was studied in cats.
Entity: 15278670	17	28	sevoflurane	Chemical	C009250
Entity: 15278670	32	41	lidocaine	Chemical	D008012
Entity: 15278670	50	61	convulsions	Disease	D012640
Relation: 15278670	CID	17	28	C009250	50	61	D012640	false
Relation: 15278670	CID	32	41	D008012	50	61	D012640	true

Sentence: The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.
Entity: 15278670	4	14	convulsive	Disease	D012640
Entity: 15278670	71	80	lidocaine	Chemical	D008012
Entity: 15278670	201	212	sevoflurane	Chemical	C009250
Relation: 15278670	CID	71	80	D008012	4	14	D012640	true
Relation: 15278670	CID	201	212	C009250	4	14	D012640	false

Sentence: There was no significant difference in the convulsive threshold between sevoflurane and enflurane.
Entity: 15278670	43	53	convulsive	Disease	D012640
Entity: 15278670	72	83	sevoflurane	Chemical	C009250
Entity: 15278670	88	97	enflurane	Chemical	D004737
Relation: 15278670	CID	72	83	C009250	43	53	D012640	false
Relation: 15278670	CID	88	97	D004737	43	53	D012640	false

Sentence: The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.
Entity: 15278670	76	87	sevoflurane	Chemical	C009250
Entity: 15278670	91	100	enflurane	Chemical	D004737
Entity: 15278670	145	156	convulsions	Disease	D012640
Entity: 15278670	189	200	sevoflurane	Chemical	C009250
Entity: 15278670	223	232	enflurane	Chemical	D004737
Relation: 15278670	CID	76	87	C009250	145	156	D012640	false
Relation: 15278670	CID	91	100	D004737	145	156	D012640	false
Relation: 15278670	CID	189	200	C009250	145	156	D012640	false
Relation: 15278670	CID	223	232	D004737	145	156	D012640	false

Sentence: Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.
Entity: 15278670	0	6	Apamin	Chemical	D001030
Entity: 15278670	46	56	convulsive	Disease	D012640
Relation: 15278670	CID	0	6	D001030	46	56	D012640	false

Sentence: Anti-oxidant effects of atorvastatin in dexamethasone induced hypertension in the rat. 1.
Entity: 17042910	24	36	atorvastatin	Chemical	C065179
Entity: 17042910	40	53	dexamethasone	Chemical	D003907
Entity: 17042910	62	74	hypertension	Disease	D006973
Relation: 17042910	CID	24	36	C065179	62	74	D006973	false
Relation: 17042910	CID	40	53	D003907	62	74	D006973	true

Sentence: Dexamethasone (Dex) induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.
Entity: 17042910	0	13	Dexamethasone	Chemical	D003907
Entity: 17042910	15	18	Dex	Chemical	D003907
Entity: 17042910	28	40	hypertension	Disease	D006973
Entity: 17042910	101	113	nitric oxide	Chemical	D009569
Entity: 17042910	115	117	NO	Chemical	D009569
Entity: 17042910	144	154	superoxide	Chemical	D013481
Entity: 17042910	156	159	O2-	Chemical	D013481
Relation: 17042910	CID	0	13	D003907	28	40	D006973	true
Relation: 17042910	CID	15	18	D003907	28	40	D006973	true
Relation: 17042910	CID	101	113	D009569	28	40	D006973	false
Relation: 17042910	CID	115	117	D009569	28	40	D006973	false
Relation: 17042910	CID	144	154	D013481	28	40	D006973	false
Relation: 17042910	CID	156	159	D013481	28	40	D006973	false

Sentence: Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.
Entity: 17042910	0	12	Atorvastatin	Chemical	C065179
Entity: 17042910	14	17	Ato	Chemical	C065179
Entity: 17042910	142	144	NO	Chemical	D009569
Entity: 17042910	157	160	O2-	Chemical	D013481
Entity: 17042910	192	204	hypertension	Disease	D006973
Relation: 17042910	CID	0	12	C065179	192	204	D006973	false
Relation: 17042910	CID	14	17	C065179	192	204	D006973	false
Relation: 17042910	CID	142	144	D009569	192	204	D006973	false
Relation: 17042910	CID	157	160	D013481	192	204	D006973	false

Sentence: 99mTc-glucarate for detection of isoproterenol induced myocardial infarction in rats.
Entity: 11897407	0	15	99mTc-glucarate	Chemical	C067171
Entity: 11897407	33	46	isoproterenol	Chemical	D007545
Entity: 11897407	55	76	myocardial infarction	Disease	D009203
Relation: 11897407	CID	0	15	C067171	55	76	D009203	false
Relation: 11897407	CID	33	46	D007545	55	76	D009203	true

Sentence: The animal model used to produce infarction implies artery ligation but chemical induction can be easily obtained with isoproterenol.
Entity: 11897407	33	43	infarction	Disease	D007238
Entity: 11897407	119	132	isoproterenol	Chemical	D007545
Relation: 11897407	CID	119	132	D007545	33	43	D007238	false

Sentence: A new infarct-avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ. 99mTc-glucarate was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol induced acute myocardial infarction.
Entity: 11897407	6	13	infarct	Disease	D007238
Entity: 11897407	48	61	glucaric acid	Chemical	D005937
Entity: 11897407	121	136	99mTc-glucarate	Chemical	C067171
Entity: 11897407	229	242	isoproterenol	Chemical	D007545
Entity: 11897407	257	278	myocardial infarction	Disease	D009203
Relation: 11897407	CID	48	61	D005937	6	13	D007238	false
Relation: 11897407	CID	48	61	D005937	257	278	D009203	false
Relation: 11897407	CID	121	136	C067171	6	13	D007238	false
Relation: 11897407	CID	121	136	C067171	257	278	D009203	false
Relation: 11897407	CID	229	242	D007545	6	13	D007238	false
Relation: 11897407	CID	229	242	D007545	257	278	D009203	true

Sentence: Histological studies demonstrated that the rats developed an infarct 18 h after isoproterenol administration.
Entity: 11897407	61	68	infarct	Disease	D007238
Entity: 11897407	80	93	isoproterenol	Chemical	D007545
Relation: 11897407	CID	80	93	D007545	61	68	D007238	false

Sentence: A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.
Entity: 9812111	58	69	haloperidol	Chemical	D006220
Entity: 9812111	74	83	psychosis	Disease	D011618
Entity: 9812111	88	108	disruptive behaviors	Disease	D019958
Entity: 9812111	112	131	Alzheimer's disease	Disease	D000544
Relation: 9812111	CID	58	69	D006220	74	83	D011618	false
Relation: 9812111	CID	58	69	D006220	88	108	D019958	false
Relation: 9812111	CID	58	69	D006220	112	131	D000544	false

Sentence: OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.
Entity: 9812111	95	106	haloperidol	Chemical	D006220
Entity: 9812111	139	148	psychosis	Disease	D011618
Entity: 9812111	153	173	disruptive behaviors	Disease	D019958
Entity: 9812111	191	210	Alzheimer's disease	Disease	D000544
Relation: 9812111	CID	95	106	D006220	139	148	D011618	false
Relation: 9812111	CID	95	106	D006220	153	173	D019958	false
Relation: 9812111	CID	95	106	D006220	191	210	D000544	false

Sentence: METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.
Entity: 9812111	89	100	haloperidol	Chemical	D006220
Entity: 9812111	134	145	haloperidol	Chemical	D006220
Entity: 9812111	213	232	Alzheimer's disease	Disease	D000544
Relation: 9812111	CID	89	100	D006220	213	232	D000544	false
Relation: 9812111	CID	134	145	D006220	213	232	D000544	false

Sentence: RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.
Entity: 9812111	66	77	haloperidol	Chemical	D006220
Entity: 9812111	124	135	haloperidol	Chemical	D006220
Entity: 9812111	197	206	psychosis	Disease	D011618
Entity: 9812111	221	242	psychomotor agitation	Disease	D011595
Relation: 9812111	CID	66	77	D006220	197	206	D011618	false
Relation: 9812111	CID	66	77	D006220	221	242	D011595	false
Relation: 9812111	CID	124	135	D006220	197	206	D011618	false
Relation: 9812111	CID	124	135	D006220	221	242	D011595	false

Sentence: CONCLUSIONS: The results indicated a favorable therapeutic profile for haloperidol in doses of 2-3 mg/day, although a subgroup developed moderate to severe extrapyramidal signs.
Entity: 9812111	71	82	haloperidol	Chemical	D006220
Entity: 9812111	156	176	extrapyramidal signs	Disease	D001480
Relation: 9812111	CID	71	82	D006220	156	176	D001480	true

Sentence: Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin induced renal damage.
Entity: 15572383	87	97	adriamycin	Chemical	D004317
Entity: 15572383	106	118	renal damage	Disease	D007674
Relation: 15572383	CID	87	97	D004317	106	118	D007674	false

Sentence: Therefore, we studied the predictive effect of renal ACE activity for the severity of renal damage induced by a single injection of adriamycin in rats.
Entity: 15572383	86	98	renal damage	Disease	D007674
Entity: 15572383	132	142	adriamycin	Chemical	D004317
Relation: 15572383	CID	132	142	D004317	86	98	D007674	false

Sentence: After 1 week of recovery, proteinuria was induced by adriamycin [1.5 mg/kg intravenously (i.v.) n = 18; controls, saline i.v. n = 9].
Entity: 15572383	26	37	proteinuria	Disease	D011507
Entity: 15572383	53	63	adriamycin	Chemical	D004317
Relation: 15572383	CID	53	63	D004317	26	37	D011507	true

Sentence: RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.
Entity: 15572383	25	35	adriamycin	Chemical	D004317
Entity: 15572383	45	54	nephrotic	Disease	D009404
Entity: 15572383	61	72	proteinuria	Disease	D011507
Entity: 15572383	74	99	renal interstitial damage	Disease	D007674
Entity: 15572383	109	133	focal glomerulosclerosis	Disease	D005923
Relation: 15572383	CID	25	35	D004317	45	54	D009404	false
Relation: 15572383	CID	25	35	D004317	61	72	D011507	true
Relation: 15572383	CID	25	35	D004317	74	99	D007674	false
Relation: 15572383	CID	25	35	D004317	109	133	D005923	false

Sentence: Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).
Entity: 15572383	67	78	proteinuria	Disease	D011507
Entity: 15572383	85	95	adriamycin	Chemical	D004317
Relation: 15572383	CID	85	95	D004317	67	78	D011507	true

Sentence: CONCLUSION: Individual differences in renal ACE activity predict the severity of adriamycin induced renal damage in this outbred rat strain.
Entity: 15572383	81	91	adriamycin	Chemical	D004317
Entity: 15572383	100	112	renal damage	Disease	D007674
Relation: 15572383	CID	81	91	D004317	100	112	D007674	false

Sentence: Clinical nephrotoxicity of tobramycin and gentamicin.
Entity: 7420681	9	23	nephrotoxicity	Disease	D007674
Entity: 7420681	27	37	tobramycin	Chemical	D014031
Entity: 7420681	42	52	gentamicin	Chemical	D005839
Relation: 7420681	CID	27	37	D014031	9	23	D007674	false
Relation: 7420681	CID	42	52	D005839	9	23	D007674	false

Sentence: Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.
Entity: 7420681	0	18	Gentamicin sulfate	Chemical	D005839
Entity: 7420681	23	41	tobramycin sulfate	Chemical	D014031
Entity: 7420681	66	77	ototoxicity	Disease	D006311
Entity: 7420681	82	96	nephrotoxicity	Disease	D007674
Relation: 7420681	CID	0	18	D005839	66	77	D006311	false
Relation: 7420681	CID	0	18	D005839	82	96	D007674	false
Relation: 7420681	CID	23	41	D014031	66	77	D006311	false
Relation: 7420681	CID	23	41	D014031	82	96	D007674	false

Sentence: In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.
Entity: 7420681	109	127	gentamicin sulfate	Chemical	D005839
Entity: 7420681	131	149	tobramycin sulfate	Chemical	D014031
Entity: 7420681	232	246	aminoglycoside	Chemical	D000617
Entity: 7420681	255	268	renal failure	Disease	D051437
Relation: 7420681	CID	109	127	D005839	255	268	D051437	true
Relation: 7420681	CID	131	149	D014031	255	268	D051437	true
Relation: 7420681	CID	232	246	D000617	255	268	D051437	false

Sentence: Five of 33 (15%) of the tobramycin-treated patients and 16 of 29 (55.2%) of the gentamicin-treated patients had renal failure.
Entity: 7420681	24	34	tobramycin	Chemical	D014031
Entity: 7420681	80	90	gentamicin	Chemical	D005839
Entity: 7420681	112	125	renal failure	Disease	D051437
Relation: 7420681	CID	24	34	D014031	112	125	D051437	true
Relation: 7420681	CID	80	90	D005839	112	125	D051437	true

Sentence: Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.
Entity: 12907309	26	30	MPEP	Chemical	C121465
Entity: 12907309	66	81	methamphetamine	Chemical	D008694
Entity: 12907309	103	116	neurotoxicity	Disease	D020258
Entity: 12907309	150	158	dopamine	Chemical	D004298
Entity: 12907309	185	197	hyperthermia	Disease	D005334
Relation: 12907309	CID	26	30	C121465	103	116	D020258	false
Relation: 12907309	CID	26	30	C121465	185	197	D005334	false
Relation: 12907309	CID	66	81	D008694	103	116	D020258	false
Relation: 12907309	CID	66	81	D008694	185	197	D005334	true
Relation: 12907309	CID	150	158	D004298	103	116	D020258	false
Relation: 12907309	CID	150	158	D004298	185	197	D005334	false

Sentence: Moreover, it transiently diminished the methamphetamine (10 mg/kg sc) induced hyperthermia and reduced basal body temperature.
Entity: 12907309	40	55	methamphetamine	Chemical	D008694
Entity: 12907309	78	90	hyperthermia	Disease	D005334
Relation: 12907309	CID	40	55	D008694	78	90	D005334	true

Sentence: The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine induced toxicity.
Entity: 12907309	65	69	MPEP	Chemical	C121465
Entity: 12907309	112	127	methamphetamine	Chemical	D008694
Entity: 12907309	136	144	toxicity	Disease	D064420
Relation: 12907309	CID	65	69	C121465	136	144	D064420	false
Relation: 12907309	CID	112	127	D008694	136	144	D064420	false

Sentence: Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.
Entity: 16680561	64	75	desipramine	Chemical	D003891
Entity: 16680561	102	113	desipramine	Chemical	D003891
Entity: 16680561	119	129	cinacalcet	Chemical	C476217
Entity: 16680561	175	181	nausea	Disease	D009325
Entity: 16680561	186	194	headache	Disease	D006261
Entity: 16680561	248	259	desipramine	Chemical	D003891
Entity: 16680561	263	273	cinacalcet	Chemical	C476217
Relation: 16680561	CID	64	75	D003891	175	181	D009325	true
Relation: 16680561	CID	64	75	D003891	186	194	D006261	true
Relation: 16680561	CID	102	113	D003891	175	181	D009325	true
Relation: 16680561	CID	102	113	D003891	186	194	D006261	true
Relation: 16680561	CID	119	129	C476217	175	181	D009325	true
Relation: 16680561	CID	119	129	C476217	186	194	D006261	true
Relation: 16680561	CID	248	259	D003891	175	181	D009325	true
Relation: 16680561	CID	248	259	D003891	186	194	D006261	true
Relation: 16680561	CID	263	273	C476217	175	181	D009325	true
Relation: 16680561	CID	263	273	C476217	186	194	D006261	true

Sentence: Proteomic analysis of striatal proteins in the rat model of L-DOPA induced dyskinesia.
Entity: 17532790	60	66	L-DOPA	Chemical	D007980
Entity: 17532790	75	85	dyskinesia	Disease	D004409
Relation: 17532790	CID	60	66	D007980	75	85	D004409	true

Sentence: L-DOPA induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.
Entity: 17532790	0	6	L-DOPA	Chemical	D007980
Entity: 17532790	15	25	dyskinesia	Disease	D004409
Entity: 17532790	27	30	LID	Disease	D004409
Entity: 17532790	79	98	Parkinson's disease	Disease	D010300
Entity: 17532790	100	102	PD	Disease	D010300
Entity: 17532790	146	152	L-DOPA	Chemical	D007980
Relation: 17532790	CID	0	6	D007980	15	25	D004409	true
Relation: 17532790	CID	0	6	D007980	27	30	D004409	true
Relation: 17532790	CID	0	6	D007980	79	98	D010300	false
Relation: 17532790	CID	0	6	D007980	100	102	D010300	false
Relation: 17532790	CID	146	152	D007980	15	25	D004409	true
Relation: 17532790	CID	146	152	D007980	27	30	D004409	true
Relation: 17532790	CID	146	152	D007980	79	98	D010300	false
Relation: 17532790	CID	146	152	D007980	100	102	D010300	false

Sentence: In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).
Entity: 17532790	132	149	6-hydroxydopamine	Chemical	D016627
Entity: 17532790	170	172	PD	Disease	D010300
Entity: 17532790	194	200	L-DOPA	Chemical	D007980
Entity: 17532790	204	217	bromocriptine	Chemical	D001971
Relation: 17532790	CID	132	149	D016627	170	172	D010300	false
Relation: 17532790	CID	194	200	D007980	170	172	D010300	false
Relation: 17532790	CID	204	217	D001971	170	172	D010300	false

Sentence: Rats treated with L-DOPA were allocated to two groups based on the presence or absence of LID.
Entity: 17532790	18	24	L-DOPA	Chemical	D007980
Entity: 17532790	90	93	LID	Disease	D004409
Relation: 17532790	CID	18	24	D007980	90	93	D004409	true

Sentence: Pseudo-allergic reactions to corticosteroids: diagnosis and alternatives.
Entity: 7582165	7	25	allergic reactions	Disease	D004342
Entity: 7582165	29	44	corticosteroids	Chemical	D000305
Relation: 7582165	CID	29	44	D000305	7	25	D004342	false

Sentence: Corticosteroids different from paramethasone also produced hypersensitivity reactions in these patients; however, a few of them were tolerated.
Entity: 7582165	31	44	paramethasone	Chemical	D010248
Entity: 7582165	59	75	hypersensitivity	Disease	D004342
Relation: 7582165	CID	31	44	D010248	59	75	D004342	false

Sentence: Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.
Entity: 16787750	0	13	Valproic acid	Chemical	D014635
Entity: 16787750	22	36	encephalopathy	Disease	D001927
Entity: 16787750	109	112	VPA	Chemical	D014635
Relation: 16787750	CID	0	13	D014635	22	36	D001927	true
Relation: 16787750	CID	109	112	D014635	22	36	D001927	true

Sentence: Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA induced hepatotoxicity and VPA induced encephalopathy.
Entity: 16787750	78	90	pancreatitis	Disease	D010195
Entity: 16787750	92	115	bone marrow suppression	Disease	D001855
Entity: 16787750	117	120	VPA	Chemical	D014635
Entity: 16787750	129	143	hepatotoxicity	Disease	D056486
Entity: 16787750	148	151	VPA	Chemical	D014635
Entity: 16787750	160	174	encephalopathy	Disease	D001927
Relation: 16787750	CID	117	120	D014635	78	90	D010195	true
Relation: 16787750	CID	117	120	D014635	92	115	D001855	true
Relation: 16787750	CID	117	120	D014635	129	143	D056486	true
Relation: 16787750	CID	117	120	D014635	160	174	D001927	true
Relation: 16787750	CID	148	151	D014635	78	90	D010195	true
Relation: 16787750	CID	148	151	D014635	92	115	D001855	true
Relation: 16787750	CID	148	151	D014635	129	143	D056486	true
Relation: 16787750	CID	148	151	D014635	160	174	D001927	true

Sentence: The typical signs of VPA induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.
Entity: 16787750	21	24	VPA	Chemical	D014635
Entity: 16787750	33	47	encephalopathy	Disease	D001927
Entity: 16787750	52	74	impaired consciousness	Disease	D003244
Entity: 16787750	127	134	seizure	Disease	D012640
Entity: 16787750	162	176	hyperammonemia	Disease	D022124
Relation: 16787750	CID	21	24	D014635	33	47	D001927	true
Relation: 16787750	CID	21	24	D014635	52	74	D003244	true
Relation: 16787750	CID	21	24	D014635	127	134	D012640	false
Relation: 16787750	CID	21	24	D014635	162	176	D022124	false

Sentence: There is still no proof of causative effect of VPA in patients with encephalopathy, but only of an association with an assumed causal relation.
Entity: 16787750	47	50	VPA	Chemical	D014635
Entity: 16787750	68	82	encephalopathy	Disease	D001927
Relation: 16787750	CID	47	50	D014635	68	82	D001927	true

Sentence: Haemolytic-uraemic syndrome after treatment with metronidazole.
Entity: 3173180	0	27	Haemolytic-uraemic syndrome	Disease	D006463
Entity: 3173180	49	62	metronidazole	Chemical	D008795
Relation: 3173180	CID	49	62	D008795	0	27	D006463	true

Sentence: This paper describes the clinical features of six children who developed the haemolytic-uraemic syndrome after treatment with metronidazole.
Entity: 3173180	77	104	haemolytic-uraemic syndrome	Disease	D006463
Entity: 3173180	126	139	metronidazole	Chemical	D008795
Relation: 3173180	CID	126	139	D008795	77	104	D006463	true

Sentence: Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.
Entity: 8996652	0	11	Ototoxicity	Disease	D006311
Entity: 8996652	92	100	ototoxic	Disease	D006311
Entity: 8996652	121	136	aminoglycosides	Chemical	D000617
Entity: 8996652	141	151	furosemide	Chemical	D005665
Relation: 8996652	CID	121	136	D000617	0	11	D006311	false
Relation: 8996652	CID	121	136	D000617	92	100	D006311	false
Relation: 8996652	CID	141	151	D005665	0	11	D006311	false
Relation: 8996652	CID	141	151	D005665	92	100	D006311	false

Sentence: Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion. 15 cases of cimetidine-associated mental confusion have been reported.
Entity: 84204	54	64	cimetidine	Chemical	D002927
Entity: 84204	83	92	confusion	Disease	D003221
Entity: 84204	106	116	cimetidine	Chemical	D002927
Entity: 84204	135	144	confusion	Disease	D003221
Relation: 84204	CID	54	64	D002927	83	92	D003221	true
Relation: 84204	CID	54	64	D002927	135	144	D003221	true
Relation: 84204	CID	106	116	D002927	83	92	D003221	true
Relation: 84204	CID	106	116	D002927	135	144	D003221	true

Sentence: These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).
Entity: 84204	26	31	renal	Disease	D051437
Entity: 84204	36	41	liver	Disease	D008107
Entity: 84204	85	95	cimetidine	Chemical	D002927
Relation: 84204	CID	85	95	D002927	26	31	D051437	false
Relation: 84204	CID	85	95	D002927	36	41	D008107	false

Sentence: We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.
Entity: 9862868	22	46	intrahepatic cholestasis	Disease	D002780
Entity: 9862868	50	67	ethinyl estradiol	Chemical	D004997
Entity: 9862868	69	71	EE	Chemical	D004997
Entity: 9862868	87	111	extrahepatic cholestasis	Disease	D001651
Relation: 9862868	CID	50	67	D004997	22	46	D002780	true
Relation: 9862868	CID	50	67	D004997	87	111	D001651	false
Relation: 9862868	CID	69	71	D004997	22	46	D002780	true
Relation: 9862868	CID	69	71	D004997	87	111	D001651	false

Sentence: No ototoxic factor, other than DFO, was present in any of the patients.
Entity: 15515654	3	11	ototoxic	Disease	D006311
Entity: 15515654	31	34	DFO	Chemical	D003676
Relation: 15515654	CID	31	34	D003676	3	11	D006311	false

Sentence: Subjects with SNHL were submitted to DFO reduction or temporary withdrawal.
Entity: 15515654	14	18	SNHL	Disease	D006319
Entity: 15515654	37	40	DFO	Chemical	D003676
Relation: 15515654	CID	37	40	D003676	14	18	D006319	true

Sentence: CONCLUSION: The findings are indicative of DFO's contributing role in the development of hearing impairment.
Entity: 15515654	43	46	DFO	Chemical	D003676
Entity: 15515654	89	107	hearing impairment	Disease	D034381
Relation: 15515654	CID	43	46	D003676	89	107	D034381	false

Sentence: Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.
Entity: 2024540	51	60	enalapril	Chemical	D004656
Entity: 2024540	65	73	prazosin	Chemical	D011224
Entity: 2024540	122	146	congestive heart failure	Disease	D006333
Relation: 2024540	CID	51	60	D004656	122	146	D006333	false
Relation: 2024540	CID	65	73	D011224	122	146	D006333	false

Sentence: Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.
Entity: 2024540	26	72	angiotensin converting enzyme (ACE) inhibitors	Chemical	D000806
Entity: 2024540	120	144	congestive heart failure	Disease	D006333
Entity: 2024540	162	173	hypotension	Disease	D007022
Relation: 2024540	CID	26	72	D000806	120	144	D006333	false
Relation: 2024540	CID	26	72	D000806	162	173	D007022	true

Sentence: To assess the safety of the ACE inhibitor enalapril a multicenter, randomized, prazosin-controlled trial was designed that compared the incidence and severity of symptomatic hypotension on the first day of treatment.
Entity: 2024540	28	41	ACE inhibitor	Chemical	D000806
Entity: 2024540	42	51	enalapril	Chemical	D004656
Entity: 2024540	79	87	prazosin	Chemical	D011224
Entity: 2024540	174	185	hypotension	Disease	D007022
Relation: 2024540	CID	28	41	D000806	174	185	D007022	true
Relation: 2024540	CID	42	51	D004656	174	185	D007022	false
Relation: 2024540	CID	79	87	D011224	174	185	D007022	true

Sentence: Patients who received enalapril experienced clinically and statistically significantly less symptomatic hypotension (5.2%) than the patients who received prazosin (12.9%).
Entity: 2024540	22	31	enalapril	Chemical	D004656
Entity: 2024540	104	115	hypotension	Disease	D007022
Entity: 2024540	154	162	prazosin	Chemical	D011224
Relation: 2024540	CID	22	31	D004656	104	115	D007022	false
Relation: 2024540	CID	154	162	D011224	104	115	D007022	true

Sentence: Antagonism between interleukin 3 and erythropoietin in mice with azidothymidine induced anemia and in bone marrow endothelial cells.
Entity: 12090760	65	79	azidothymidine	Chemical	D015215
Entity: 12090760	88	94	anemia	Disease	D000740
Relation: 12090760	CID	65	79	D015215	88	94	D000740	true

Sentence: Azidothymidine (AZT) induced anemia in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).
Entity: 12090760	0	14	Azidothymidine	Chemical	D015215
Entity: 12090760	16	19	AZT	Chemical	D015215
Entity: 12090760	29	35	anemia	Disease	D000740
Relation: 12090760	CID	0	14	D015215	29	35	D000740	true
Relation: 12090760	CID	16	19	D015215	29	35	D000740	true

Sentence: Dose-dependent bradycardia induced by verapamil was potentiated by LNa, LCa, and HCa.
Entity: 7516729	15	26	bradycardia	Disease	D001919
Entity: 7516729	38	47	verapamil	Chemical	D014700
Relation: 7516729	CID	38	47	D014700	15	26	D001919	true

Sentence: Sodium status influences chronic amphotericin B nephrotoxicity in rats.
Entity: 2802551	0	6	Sodium	Chemical	D012964
Entity: 2802551	33	47	amphotericin B	Chemical	D000666
Entity: 2802551	48	62	nephrotoxicity	Disease	D007674
Relation: 2802551	CID	0	6	D012964	48	62	D007674	false
Relation: 2802551	CID	33	47	D000666	48	62	D007674	true

Sentence: The nephrotoxic potential of amphotericin B (5 mg/kg per day intraperitoneally for 3 weeks) has been investigated in salt-depleted, normal-salt, and salt-loaded rats.
Entity: 2802551	4	15	nephrotoxic	Disease	D007674
Entity: 2802551	29	43	amphotericin B	Chemical	D000666
Relation: 2802551	CID	29	43	D000666	4	15	D007674	true

Sentence: Reversible inferior colliculus lesion in metronidazole induced encephalopathy: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging.
Entity: 19346865	11	37	inferior colliculus lesion	Disease	D001927
Entity: 19346865	41	54	metronidazole	Chemical	D008795
Entity: 19346865	63	77	encephalopathy	Disease	D001927
Relation: 19346865	CID	41	54	D008795	11	37	D001927	true
Relation: 19346865	CID	41	54	D008795	63	77	D001927	true

Sentence: OBJECTIVE: This is to present reversible inferior colliculus lesions in metronidazole induced encephalopathy, to focus on the diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging.
Entity: 19346865	41	68	inferior colliculus lesions	Disease	D001927
Entity: 19346865	72	85	metronidazole	Chemical	D008795
Entity: 19346865	94	108	encephalopathy	Disease	D001927
Relation: 19346865	CID	72	85	D008795	41	68	D001927	true
Relation: 19346865	CID	72	85	D008795	94	108	D001927	true

Sentence: MATERIALS AND METHODS: From November 2005 to September 2007, 8 patients (5 men and 3 women) were diagnosed as having metronidazole induced encephalopathy (age range; 43-78 years).
Entity: 19346865	117	130	metronidazole	Chemical	D008795
Entity: 19346865	139	153	encephalopathy	Disease	D001927
Relation: 19346865	CID	117	130	D008795	139	153	D001927	true

Sentence: They had been taking metronidazole (total dosage, 45-120 g; duration, 30 days to 2 months) to treat the infection in various organs.
Entity: 19346865	21	34	metronidazole	Chemical	D008795
Entity: 19346865	104	113	infection	Disease	D007239
Relation: 19346865	CID	21	34	D008795	104	113	D007239	false

Sentence: The incidence of postoperative respiratory apnoea was compared between five patients receiving a continuous i.v. infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surgery.
Entity: 2334618	43	49	apnoea	Disease	D001049
Entity: 2334618	125	133	morphine	Chemical	D009020
Entity: 2334618	219	230	bupivacaine	Chemical	D002045
Relation: 2334618	CID	125	133	D009020	43	49	D001049	false
Relation: 2334618	CID	219	230	D002045	43	49	D001049	false

Sentence: Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion.
Entity: 2334618	5	16	obstructive	Disease	D020181
Entity: 2334618	40	47	central	Disease	D020182
Entity: 2334618	121	129	morphine	Chemical	D009020
Relation: 2334618	CID	121	129	D009020	5	16	D020181	true
Relation: 2334618	CID	121	129	D009020	40	47	D020182	true

Sentence: Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages.
Entity: 8864707	50	59	epileptic	Disease	D004827
Entity: 8864707	75	84	phenytoin	Chemical	D010672
Entity: 8864707	85	96	overdosages	Disease	D062787
Relation: 8864707	CID	75	84	D010672	50	59	D004827	false
Relation: 8864707	CID	75	84	D010672	85	96	D062787	true

Sentence: The aim of this study was to evaluate the relationship between phenytoin medication and cerebellar atrophy in patients who had experienced clinical intoxication.
Entity: 8864707	63	72	phenytoin	Chemical	D010672
Entity: 8864707	88	106	cerebellar atrophy	Disease	D002526
Relation: 8864707	CID	63	72	D010672	88	106	D002526	false

Sentence: Using linear regression we found that no correlation exists between seizure duration, elevation of phenytoin serum levels and cerebellar volume.
Entity: 8864707	68	75	seizure	Disease	D012640
Entity: 8864707	99	108	phenytoin	Chemical	D010672
Relation: 8864707	CID	99	108	D010672	68	75	D012640	false

Sentence: We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.
Entity: 8864707	17	26	phenytoin	Chemical	D010672
Entity: 8864707	27	37	overdosage	Disease	D062787
Entity: 8864707	69	87	cerebellar atrophy	Disease	D002526
Entity: 8864707	112	121	phenytoin	Chemical	D010672
Entity: 8864707	155	173	cerebellar atrophy	Disease	D002526
Relation: 8864707	CID	17	26	D010672	27	37	D062787	true
Relation: 8864707	CID	17	26	D010672	69	87	D002526	false
Relation: 8864707	CID	17	26	D010672	155	173	D002526	false
Relation: 8864707	CID	112	121	D010672	27	37	D062787	true
Relation: 8864707	CID	112	121	D010672	69	87	D002526	false
Relation: 8864707	CID	112	121	D010672	155	173	D002526	false

Sentence: Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings.
Entity: 12589964	60	77	myocardial damage	Disease	D009202
Entity: 12589964	81	92	doxorubicin	Chemical	D004317
Entity: 12589964	101	115	cardiomyopathy	Disease	D009202
Relation: 12589964	CID	81	92	D004317	60	77	D009202	true
Relation: 12589964	CID	81	92	D004317	101	115	D009202	true

Sentence: We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX) induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.
Entity: 12589964	75	92	myocardial damage	Disease	D009202
Entity: 12589964	111	122	doxorubicin	Chemical	D004317
Entity: 12589964	124	127	DOX	Chemical	D004317
Entity: 12589964	137	151	cardiomyopathy	Disease	D009202
Entity: 12589964	239	256	cardiac disorders	Disease	D006331
Relation: 12589964	CID	111	122	D004317	75	92	D009202	true
Relation: 12589964	CID	111	122	D004317	137	151	D009202	true
Relation: 12589964	CID	111	122	D004317	239	256	D006331	false
Relation: 12589964	CID	124	127	D004317	75	92	D009202	true
Relation: 12589964	CID	124	127	D004317	137	151	D009202	true
Relation: 12589964	CID	124	127	D004317	239	256	D006331	false

Sentence: RESULTS: Eighteen of the DOX rats died prematurely of general toxicity during the 9-week period.
Entity: 12589964	25	28	DOX	Chemical	D004317
Entity: 12589964	62	70	toxicity	Disease	D064420
Relation: 12589964	CID	25	28	D004317	62	70	D064420	false

Sentence: Histological evaluation of hearts from all rats given DOX revealed significant slight degrees of perivascular and interstitial fibrosis.
Entity: 12589964	54	57	DOX	Chemical	D004317
Entity: 12589964	127	135	fibrosis	Disease	D005355
Relation: 12589964	CID	54	57	D004317	127	135	D005355	false

Sentence: CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.
Entity: 12589964	30	45	ischemic injury	Disease	D017202
Entity: 12589964	52	55	DOX	Chemical	D004317
Entity: 12589964	108	125	myocardial damage	Disease	D009202
Relation: 12589964	CID	52	55	D004317	30	45	D017202	false
Relation: 12589964	CID	52	55	D004317	108	125	D009202	true

Sentence: The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.
Entity: 11263551	17	29	cyclosporine	Chemical	D016572
Entity: 11263551	34	44	tacrolimus	Chemical	D016559
Entity: 11263551	85	92	calcium	Chemical	D002118
Entity: 11263551	127	131	pain	Disease	D010146
Relation: 11263551	CID	17	29	D016572	127	131	D010146	true
Relation: 11263551	CID	34	44	D016559	127	131	D010146	true
Relation: 11263551	CID	85	92	D002118	127	131	D010146	false

Sentence: The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.
Entity: 11263551	34	38	Pain	Disease	D010146
Entity: 11263551	49	53	CIPS	Disease	-1
Entity: 11263551	91	103	cyclosporine	Chemical	D016572
Entity: 11263551	107	117	tacrolimus	Chemical	D016559
Relation: 11263551	CID	91	103	D016572	34	38	D010146	true
Relation: 11263551	CID	91	103	D016572	49	53	-1	false
Relation: 11263551	CID	107	117	D016559	34	38	D010146	true
Relation: 11263551	CID	107	117	D016559	49	53	-1	false

Sentence: We investigated the safety and efficacy of adding different doses of ephedrine to propofol in order to obtund the hypotensive response.
Entity: 10520387	69	78	ephedrine	Chemical	D004809
Entity: 10520387	82	90	propofol	Chemical	D015742
Entity: 10520387	114	125	hypotensive	Disease	D007022
Relation: 10520387	CID	69	78	D004809	114	125	D007022	false
Relation: 10520387	CID	82	90	D015742	114	125	D007022	true

Sentence: The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study.
Entity: 10520387	16	25	ephedrine	Chemical	D004809
Entity: 10520387	29	37	propofol	Chemical	D015742
Entity: 10520387	89	100	hypotensive	Disease	D007022
Entity: 10520387	113	121	propofol	Chemical	D015742
Relation: 10520387	CID	16	25	D004809	89	100	D007022	false
Relation: 10520387	CID	29	37	D015742	89	100	D007022	true
Relation: 10520387	CID	113	121	D015742	89	100	D007022	true

Sentence: However, marked tachycardia associated with the use of ephedrine in combination with propofol occurred in the majority of patients, occasionally reaching high levels in individual patients.
Entity: 10520387	16	27	tachycardia	Disease	D013610
Entity: 10520387	55	64	ephedrine	Chemical	D004809
Entity: 10520387	85	93	propofol	Chemical	D015742
Relation: 10520387	CID	55	64	D004809	16	27	D013610	true
Relation: 10520387	CID	85	93	D015742	16	27	D013610	true

Sentence: Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan.
Entity: 230316	0	13	Neurotoxicity	Disease	D020258
Entity: 230316	17	46	halogenated hydroxyquinolines	Chemical	D006912
Relation: 230316	CID	17	46	D006912	0	13	D020258	false

Sentence: An analysis is presented of 220 cases of possible neurotoxic reactions to halogenated hydroxyquinolines reported from outside Japan.
Entity: 230316	50	60	neurotoxic	Disease	D020258
Entity: 230316	74	103	halogenated hydroxyquinolines	Chemical	D006912
Relation: 230316	CID	74	103	D006912	50	60	D020258	false

Sentence: In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period.
Entity: 230316	33	57	neurological disturbance	Disease	D009422
Entity: 230316	91	105	encephalopathy	Disease	D001927
Entity: 230316	157	167	clioquinol	Chemical	D007464
Relation: 230316	CID	157	167	D007464	33	57	D009422	false
Relation: 230316	CID	157	167	D007464	91	105	D001927	true

Sentence: This was most frequently found in children, many of whom had received clioquinol as treatment for acrodermatitis enteropathica.
Entity: 230316	70	80	clioquinol	Chemical	D007464
Entity: 230316	98	126	acrodermatitis enteropathica	Disease	C538178
Relation: 230316	CID	70	80	D007464	98	126	C538178	false

Sentence: Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.
Entity: 11807648	0	18	Epileptic seizures	Disease	D004827
Entity: 11807648	80	95	tranexamic acid	Chemical	D014148
Relation: 11807648	CID	80	95	D014148	0	18	D004827	false

Sentence: However, tAMCA has been shown to cause epileptic seizures.
Entity: 11807648	9	14	tAMCA	Chemical	D014148
Entity: 11807648	39	57	epileptic seizures	Disease	D004827
Relation: 11807648	CID	9	14	D014148	39	57	D004827	false

Sentence: We wanted to study whether tAMCA retains its convulsive action if incorporated into a FS.
Entity: 11807648	27	32	tAMCA	Chemical	D014148
Entity: 11807648	45	55	convulsive	Disease	D012640
Relation: 11807648	CID	27	32	D014148	45	55	D012640	true

Sentence: FINDINGS: FS containing tAMCA caused paroxysmal brain activity which was associated with distinct convulsive behaviours.
Entity: 11807648	24	29	tAMCA	Chemical	D014148
Entity: 11807648	98	108	convulsive	Disease	D012640
Relation: 11807648	CID	24	29	D014148	98	108	D012640	true

Sentence: The degree of these seizures increased with increasing concentration of tAMCA.
Entity: 11807648	20	28	seizures	Disease	D012640
Entity: 11807648	72	77	tAMCA	Chemical	D014148
Relation: 11807648	CID	72	77	D014148	20	28	D012640	true

Sentence: Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.
Entity: 11807648	31	36	tAMCA	Chemical	D014148
Entity: 11807648	44	64	generalized seizures	Disease	D012640
Entity: 11807648	124	129	tAMCA	Chemical	D014148
Entity: 11807648	188	198	convulsive	Disease	D012640
Relation: 11807648	CID	31	36	D014148	44	64	D012640	true
Relation: 11807648	CID	31	36	D014148	188	198	D012640	true
Relation: 11807648	CID	124	129	D014148	44	64	D012640	true
Relation: 11807648	CID	124	129	D014148	188	198	D012640	true

Sentence: INTERPRETATION: Tranexamic acid retains its convulsive action within FS.
Entity: 11807648	16	31	Tranexamic acid	Chemical	D014148
Entity: 11807648	44	54	convulsive	Disease	D012640
Relation: 11807648	CID	16	31	D014148	44	54	D012640	true

Sentence: A diet promoting sugar dependency causes behavioral cross-sensitization to a low dose of amphetamine.
Entity: 14596845	17	33	sugar dependency	Disease	D019966
Entity: 14596845	41	71	behavioral cross-sensitization	Disease	D006948
Entity: 14596845	89	100	amphetamine	Chemical	D000661
Relation: 14596845	CID	89	100	D000661	17	33	D019966	false
Relation: 14596845	CID	89	100	D000661	41	71	D006948	true

Sentence: The present study examined whether female rats on various regimens of sugar access would show behavioral cross-sensitization to a low dose of amphetamine.
Entity: 14596845	94	124	behavioral cross-sensitization	Disease	D006948
Entity: 14596845	142	153	amphetamine	Chemical	D000661
Relation: 14596845	CID	142	153	D000661	94	124	D006948	true

Sentence: The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).
Entity: 14596845	40	47	sucrose	Chemical	D013395
Entity: 14596845	62	73	hyperactive	Disease	D006948
Entity: 14596845	89	100	amphetamine	Chemical	D000661
Entity: 14596845	151	158	sucrose	Chemical	D013395
Entity: 14596845	180	191	amphetamine	Chemical	D000661
Entity: 14596845	227	238	amphetamine	Chemical	D000661
Entity: 14596845	271	282	amphetamine	Chemical	D000661
Entity: 14596845	298	305	sucrose	Chemical	D013395
Relation: 14596845	CID	40	47	D013395	62	73	D006948	true
Relation: 14596845	CID	89	100	D000661	62	73	D006948	true
Relation: 14596845	CID	151	158	D013395	62	73	D006948	true
Relation: 14596845	CID	180	191	D000661	62	73	D006948	true
Relation: 14596845	CID	227	238	D000661	62	73	D006948	true
Relation: 14596845	CID	271	282	D000661	62	73	D006948	true
Relation: 14596845	CID	298	305	D013395	62	73	D006948	true

Sentence: D-penicillamine induced angiopathy in rats.
Entity: 6666578	0	15	D-penicillamine	Chemical	D010396
Entity: 6666578	24	34	angiopathy	Disease	D001018
Relation: 6666578	CID	0	15	D010396	24	34	D001018	true

Sentence: Brain natriuretic peptide is a predictor of anthracycline induced cardiotoxicity.
Entity: 11279304	44	57	anthracycline	Chemical	D018943
Entity: 11279304	66	80	cardiotoxicity	Disease	D066126
Relation: 11279304	CID	44	57	D018943	66	80	D066126	false

Sentence: Anthracyclines are effective antineoplastic drugs, but they frequently cause dose-related cardiotoxicity.
Entity: 11279304	0	14	Anthracyclines	Chemical	D018943
Entity: 11279304	90	104	cardiotoxicity	Disease	D066126
Relation: 11279304	CID	0	14	D018943	90	104	D066126	false

Sentence: The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction.
Entity: 11279304	4	18	cardiotoxicity	Disease	D066126
Entity: 11279304	35	48	anthracycline	Chemical	D018943
Entity: 11279304	149	168	cardiac dysfunction	Disease	D006331
Relation: 11279304	CID	35	48	D018943	4	18	D066126	false
Relation: 11279304	CID	35	48	D018943	149	168	D006331	false

Sentence: We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.
Entity: 11279304	137	150	anthracycline	Chemical	D018943
Entity: 11279304	159	173	cardiotoxicity	Disease	D066126
Entity: 11279304	191	205	acute leukemia	Disease	D015470
Entity: 11279304	221	233	daunorubicin	Chemical	D003630
Entity: 11279304	235	238	DNR	Chemical	D003630
Relation: 11279304	CID	137	150	D018943	159	173	D066126	false
Relation: 11279304	CID	137	150	D018943	191	205	D015470	false
Relation: 11279304	CID	221	233	D003630	159	173	D066126	false
Relation: 11279304	CID	221	233	D003630	191	205	D015470	false
Relation: 11279304	CID	235	238	D003630	159	173	D066126	false
Relation: 11279304	CID	235	238	D003630	191	205	D015470	false

Sentence: Thirteen patients with acute leukemia were treated with a DNR-containing regimen.
Entity: 11279304	23	37	acute leukemia	Disease	D015470
Entity: 11279304	58	61	DNR	Chemical	D003630
Relation: 11279304	CID	58	61	D003630	23	37	D015470	false

Sentence: On the other hand, BNP did not increase in the patients without heart failure given DNR, even at more than 700 mg/m(2).
Entity: 11279304	64	77	heart failure	Disease	D006333
Entity: 11279304	84	87	DNR	Chemical	D003630
Relation: 11279304	CID	84	87	D003630	64	77	D006333	true

Sentence: Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).
Entity: 19884587	0	12	Sulfonamides	Chemical	D013449
Entity: 19884587	34	45	anencephaly	Disease	D000757
Entity: 19884587	112	143	hypoplastic left heart syndrome	Disease	D018636
Entity: 19884587	174	198	coarctation of the aorta	Disease	D001017
Entity: 19884587	229	244	choanal atresia	Disease	D002754
Entity: 19884587	276	302	transverse limb deficiency	Disease	D017880
Entity: 19884587	337	357	diaphragmatic hernia	Disease	D006548
Relation: 19884587	CID	0	12	D013449	34	45	D000757	true
Relation: 19884587	CID	0	12	D013449	112	143	D018636	true
Relation: 19884587	CID	0	12	D013449	174	198	D001017	true
Relation: 19884587	CID	0	12	D013449	229	244	D002754	true
Relation: 19884587	CID	0	12	D013449	276	302	D017880	true
Relation: 19884587	CID	0	12	D013449	337	357	D006548	true

Sentence: Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).
Entity: 19884587	0	15	Nitrofurantoins	Chemical	D009582
Entity: 19884587	37	49	anophthalmia	Disease	D000853
Entity: 19884587	53	67	microphthalmos	Disease	D008850
Entity: 19884587	99	130	hypoplastic left heart syndrome	Disease	D018636
Entity: 19884587	161	182	atrial septal defects	Disease	D006344
Entity: 19884587	217	226	cleft lip	Disease	D002971
Entity: 19884587	232	244	cleft palate	Disease	D002972
Relation: 19884587	CID	0	15	D009582	37	49	D000853	true
Relation: 19884587	CID	0	15	D009582	53	67	D008850	true
Relation: 19884587	CID	0	15	D009582	99	130	D018636	true
Relation: 19884587	CID	0	15	D009582	161	182	D006344	true
Relation: 19884587	CID	0	15	D009582	217	226	D002971	true
Relation: 19884587	CID	0	15	D009582	232	244	D002972	true

Sentence: CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.
Entity: 19884587	27	38	penicillins	Chemical	D010406
Entity: 19884587	40	53	erythromycins	Chemical	D004917
Entity: 19884587	59	73	cephalosporins	Chemical	D002511
Entity: 19884587	147	160	birth defects	Disease	D000014
Relation: 19884587	CID	27	38	D010406	147	160	D000014	false
Relation: 19884587	CID	40	53	D004917	147	160	D000014	false
Relation: 19884587	CID	59	73	D002511	147	160	D000014	false

Sentence: Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.
Entity: 3970039	22	39	alkylating agents	Chemical	D000477
Entity: 3970039	81	110	acute nonlymphocytic leukemia	Disease	D015470
Entity: 3970039	121	138	alkylating agents	Chemical	D000477
Entity: 3970039	143	155	azathioprine	Chemical	D001379
Entity: 3970039	195	217	non-Hodgkin's lymphoma	Disease	D008228
Relation: 3970039	CID	22	39	D000477	81	110	D015470	true
Relation: 3970039	CID	22	39	D000477	195	217	D008228	true
Relation: 3970039	CID	121	138	D000477	81	110	D015470	true
Relation: 3970039	CID	121	138	D000477	195	217	D008228	true
Relation: 3970039	CID	143	155	D001379	81	110	D015470	false
Relation: 3970039	CID	143	155	D001379	195	217	D008228	true

Sentence: Cyclophosphamide therapy increases the risk of carcinoma of the bladder.
Entity: 3970039	0	16	Cyclophosphamide	Chemical	D003520
Entity: 3970039	47	56	carcinoma	Disease	D001749
Entity: 3970039	47	56	carcinoma	Disease	D002277
Relation: 3970039	CID	0	16	D003520	47	56	D001749	true
Relation: 3970039	CID	0	16	D003520	47	56	D002277	true

Sentence: There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.
Entity: 3970039	59	79	rheumatoid arthritis	Disease	D001172
Entity: 3970039	93	105	azathioprine	Chemical	D001379
Entity: 3970039	110	126	cyclophosphamide	Chemical	D003520
Entity: 3970039	167	174	cancers	Disease	D009369
Relation: 3970039	CID	93	105	D001379	59	79	D001172	false
Relation: 3970039	CID	93	105	D001379	167	174	D009369	false
Relation: 3970039	CID	110	126	D003520	59	79	D001172	false
Relation: 3970039	CID	110	126	D003520	167	174	D009369	false

Sentence: Patterns of hepatic injury induced by methyldopa.
Entity: 424937	12	26	hepatic injury	Disease	D056486
Entity: 424937	38	48	methyldopa	Chemical	D008750
Relation: 424937	CID	38	48	D008750	12	26	D056486	true

Sentence: Twelve patients with liver disease related to methyldopa were seen between 1967 and 1977.
Entity: 424937	21	34	liver disease	Disease	D008107
Entity: 424937	46	56	methyldopa	Chemical	D008750
Relation: 424937	CID	46	56	D008750	21	34	D008107	false

Sentence: One patient died, having presented in hepatic failure, and another, who had been taking methyldopa for 7 years, showed slower clinical and biochemical resolution over a period of several months.
Entity: 424937	38	53	hepatic failure	Disease	D017093
Entity: 424937	88	98	methyldopa	Chemical	D008750
Relation: 424937	CID	88	98	D008750	38	53	D017093	false

Sentence: The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa induced hepatitis.
Entity: 424937	46	65	fulminant hepatitis	Disease	D017114
Entity: 424937	141	151	methyldopa	Chemical	D008750
Entity: 424937	160	169	hepatitis	Disease	D056486
Relation: 424937	CID	141	151	D008750	46	65	D017114	false
Relation: 424937	CID	141	151	D008750	160	169	D056486	true

Sentence: A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Entity: 8643971	22	32	paclitaxel	Chemical	D017239
Entity: 8643971	38	47	cisplatin	Chemical	D002945
Entity: 8643971	74	95	head and neck cancers	Disease	D006258
Relation: 8643971	CID	22	32	D017239	74	95	D006258	false
Relation: 8643971	CID	38	47	D002945	74	95	D006258	false

Sentence: Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.
Entity: 8643971	83	93	paclitaxel	Chemical	D017239
Entity: 8643971	95	100	Taxol	Chemical	D017239
Entity: 8643971	193	213	head and neck cancer	Disease	D006258
Entity: 8643971	223	233	paclitaxel	Chemical	D017239
Entity: 8643971	234	243	cisplatin	Chemical	D002945
Entity: 8643971	342	356	ovarian cancer	Disease	D010051
Relation: 8643971	CID	83	93	D017239	193	213	D006258	false
Relation: 8643971	CID	83	93	D017239	342	356	D010051	false
Relation: 8643971	CID	95	100	D017239	193	213	D006258	false
Relation: 8643971	CID	95	100	D017239	342	356	D010051	false
Relation: 8643971	CID	223	233	D017239	193	213	D006258	false
Relation: 8643971	CID	223	233	D017239	342	356	D010051	false
Relation: 8643971	CID	234	243	D002945	193	213	D006258	false
Relation: 8643971	CID	234	243	D002945	342	356	D010051	false

Sentence: We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.
Entity: 8643971	62	70	toxicity	Disease	D064420
Entity: 8643971	85	95	paclitaxel	Chemical	D017239
Entity: 8643971	127	136	cisplatin	Chemical	D002945
Entity: 8643971	243	266	head and neck carcinoma	Disease	D006258
Relation: 8643971	CID	85	95	D017239	62	70	D064420	false
Relation: 8643971	CID	85	95	D017239	243	266	D006258	false
Relation: 8643971	CID	127	136	D002945	62	70	D064420	false
Relation: 8643971	CID	127	136	D002945	243	266	D006258	false

Sentence: The dose levels incorporate escalating paclitaxel doses, and intrapatient escalations within a given dose level are permitted if toxicity permits.
Entity: 8643971	39	49	paclitaxel	Chemical	D017239
Entity: 8643971	129	137	toxicity	Disease	D064420
Relation: 8643971	CID	39	49	D017239	129	137	D064420	false

Sentence: Paclitaxel/cisplatin is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted.
Entity: 8643971	0	10	Paclitaxel	Chemical	D017239
Entity: 8643971	11	20	cisplatin	Chemical	D002945
Entity: 8643971	84	104	head and neck cancer	Disease	D006258
Relation: 8643971	CID	0	10	D017239	84	104	D006258	false
Relation: 8643971	CID	11	20	D002945	84	104	D006258	false

Sentence: A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors.
Entity: 2224762	42	74	4'-0-tetrahydropyranyladriamycin	Chemical	C027260
Entity: 2224762	76	87	Pirarubicin	Chemical	C027260
Entity: 2224762	156	162	tumors	Disease	D009369
Relation: 2224762	CID	42	74	C027260	156	162	D009369	false
Relation: 2224762	CID	76	87	C027260	156	162	D009369	false

Sentence: Differential effects of gamma-hexachlorocyclohexane (lindane) on pharmacologically induced seizures.
Entity: 2440413	24	51	gamma-hexachlorocyclohexane	Chemical	D001556
Entity: 2440413	53	60	lindane	Chemical	D001556
Entity: 2440413	91	99	seizures	Disease	D012640
Relation: 2440413	CID	24	51	D001556	91	99	D012640	false
Relation: 2440413	CID	53	60	D001556	91	99	D012640	false

Sentence: Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).
Entity: 2440413	0	27	Gamma-hexachlorocyclohexane	Chemical	D001556
Entity: 2440413	29	38	gamma-HCH	Chemical	D001556
Entity: 2440413	82	89	lindane	Chemical	D001556
Entity: 2440413	118	125	seizure	Disease	D012640
Entity: 2440413	156	159	PTZ	Chemical	D010433
Entity: 2440413	183	192	gamma-HCH	Chemical	D001556
Entity: 2440413	230	233	PTZ	Chemical	D010433
Entity: 2440413	242	250	seizures	Disease	D012640
Entity: 2440413	274	283	gamma-HCH	Chemical	D001556
Relation: 2440413	CID	0	27	D001556	118	125	D012640	false
Relation: 2440413	CID	0	27	D001556	242	250	D012640	false
Relation: 2440413	CID	29	38	D001556	118	125	D012640	false
Relation: 2440413	CID	29	38	D001556	242	250	D012640	false
Relation: 2440413	CID	82	89	D001556	118	125	D012640	false
Relation: 2440413	CID	82	89	D001556	242	250	D012640	false
Relation: 2440413	CID	156	159	D010433	118	125	D012640	true
Relation: 2440413	CID	156	159	D010433	242	250	D012640	true
Relation: 2440413	CID	183	192	D001556	118	125	D012640	false
Relation: 2440413	CID	183	192	D001556	242	250	D012640	false
Relation: 2440413	CID	230	233	D010433	118	125	D012640	true
Relation: 2440413	CID	230	233	D010433	242	250	D012640	true
Relation: 2440413	CID	274	283	D001556	118	125	D012640	false
Relation: 2440413	CID	274	283	D001556	242	250	D012640	false

Sentence: In this study, the severity of response to other seizure-inducing agents was tested in mice 1 and 24 h after intraperitoneal administration of 80 mg/kg gamma-HCH.
Entity: 2440413	49	56	seizure	Disease	D012640
Entity: 2440413	152	161	gamma-HCH	Chemical	D001556
Relation: 2440413	CID	152	161	D001556	49	56	D012640	false

Sentence: One hour after the administration of gamma-HCH, the activity of seizure-inducing agents was increased, regardless of their mechanism, while 24 h after gamma-HCH a differential response was observed.
Entity: 2440413	37	46	gamma-HCH	Chemical	D001556
Entity: 2440413	64	71	seizure	Disease	D012640
Entity: 2440413	151	160	gamma-HCH	Chemical	D001556
Relation: 2440413	CID	37	46	D001556	64	71	D012640	false
Relation: 2440413	CID	151	160	D001556	64	71	D012640	false

Sentence: Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.
Entity: 2440413	0	7	Seizure	Disease	D012640
Entity: 2440413	24	27	PTZ	Chemical	D010433
Entity: 2440413	32	42	picrotoxin	Chemical	D010852
Entity: 2440413	44	47	PTX	Chemical	D010852
Entity: 2440413	87	94	seizure	Disease	D012640
Entity: 2440413	111	135	3-mercaptopropionic acid	Chemical	D015097
Entity: 2440413	137	140	MPA	Chemical	D015097
Entity: 2440413	143	154	bicuculline	Chemical	D001640
Entity: 2440413	156	159	BCC	Chemical	D001640
Entity: 2440413	162	216	methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate	Chemical	C034818
Entity: 2440413	218	222	DMCM	Chemical	C034818
Entity: 2440413	228	238	strychnine	Chemical	D013331
Entity: 2440413	240	243	STR	Chemical	D013331
Relation: 2440413	CID	24	27	D010433	0	7	D012640	true
Relation: 2440413	CID	24	27	D010433	87	94	D012640	true
Relation: 2440413	CID	32	42	D010852	0	7	D012640	true
Relation: 2440413	CID	32	42	D010852	87	94	D012640	true
Relation: 2440413	CID	44	47	D010852	0	7	D012640	true
Relation: 2440413	CID	44	47	D010852	87	94	D012640	true
Relation: 2440413	CID	111	135	D015097	0	7	D012640	true
Relation: 2440413	CID	111	135	D015097	87	94	D012640	true
Relation: 2440413	CID	137	140	D015097	0	7	D012640	true
Relation: 2440413	CID	137	140	D015097	87	94	D012640	true
Relation: 2440413	CID	143	154	D001640	0	7	D012640	true
Relation: 2440413	CID	143	154	D001640	87	94	D012640	true
Relation: 2440413	CID	156	159	D001640	0	7	D012640	true
Relation: 2440413	CID	156	159	D001640	87	94	D012640	true
Relation: 2440413	CID	162	216	C034818	0	7	D012640	true
Relation: 2440413	CID	162	216	C034818	87	94	D012640	true
Relation: 2440413	CID	218	222	C034818	0	7	D012640	true
Relation: 2440413	CID	218	222	C034818	87	94	D012640	true
Relation: 2440413	CID	228	238	D013331	0	7	D012640	true
Relation: 2440413	CID	228	238	D013331	87	94	D012640	true
Relation: 2440413	CID	240	243	D013331	0	7	D012640	true
Relation: 2440413	CID	240	243	D013331	87	94	D012640	true

Sentence: The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.
Entity: 2440413	71	78	seizure	Disease	D012640
Entity: 2440413	99	102	PTZ	Chemical	D010433
Entity: 2440413	107	110	PTX	Chemical	D010852
Entity: 2440413	122	131	gamma-HCH	Chemical	D001556
Entity: 2440413	170	177	seizure	Disease	D012640
Relation: 2440413	CID	99	102	D010433	71	78	D012640	true
Relation: 2440413	CID	99	102	D010433	170	177	D012640	true
Relation: 2440413	CID	107	110	D010852	71	78	D012640	true
Relation: 2440413	CID	107	110	D010852	170	177	D012640	true
Relation: 2440413	CID	122	131	D001556	71	78	D012640	false
Relation: 2440413	CID	122	131	D001556	170	177	D012640	false

Sentence: Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas.
Entity: 12483326	7	13	ocular	Disease	D005128
Entity: 12483326	18	25	orbital	Disease	D009916
Entity: 12483326	67	78	carboplatin	Chemical	D016190
Entity: 12483326	93	106	glioblastomas	Disease	D005909
Relation: 12483326	CID	67	78	D016190	7	13	D005128	false
Relation: 12483326	CID	67	78	D016190	18	25	D009916	true
Relation: 12483326	CID	67	78	D016190	93	106	D005909	false

Sentence: Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.
Entity: 12483326	11	22	carboplatin	Chemical	D016190
Entity: 12483326	64	73	cisplatin	Chemical	D002945
Entity: 12483326	81	87	ocular	Disease	D005128
Entity: 12483326	92	99	orbital	Disease	D009916
Relation: 12483326	CID	11	22	D016190	81	87	D005128	false
Relation: 12483326	CID	11	22	D016190	92	99	D009916	true
Relation: 12483326	CID	64	73	D002945	81	87	D005128	false
Relation: 12483326	CID	64	73	D002945	92	99	D009916	false

Sentence: However, we experienced a case of severe ocular and orbital toxicity after intracarotid injection of carboplatin, which is infrequently reported.
Entity: 12483326	41	47	ocular	Disease	D005128
Entity: 12483326	52	59	orbital	Disease	D009916
Entity: 12483326	101	112	carboplatin	Chemical	D016190
Relation: 12483326	CID	101	112	D016190	41	47	D005128	false
Relation: 12483326	CID	101	112	D016190	52	59	D009916	true

Sentence: CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe.
Entity: 12483326	62	73	carboplatin	Chemical	D016190
Entity: 12483326	88	101	glioblastomas	Disease	D005909
Relation: 12483326	CID	62	73	D016190	88	101	D005909	false

Sentence: Various ocular symptoms and findings caused by carboplatin toxicity were seen.
Entity: 12483326	47	58	carboplatin	Chemical	D016190
Entity: 12483326	59	67	toxicity	Disease	D064420
Relation: 12483326	CID	47	58	D016190	59	67	D064420	false

Sentence: Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.
Entity: 1664218	22	31	amsacrine	Chemical	D000677
Entity: 1664218	41	47	CI-921	Chemical	C042315
Entity: 1664218	49	59	NSC 343499	Chemical	C042315
Entity: 1664218	64	90	non-small cell lung cancer	Disease	D002289
Relation: 1664218	CID	22	31	D000677	64	90	D002289	false
Relation: 1664218	CID	41	47	C042315	64	90	D002289	false
Relation: 1664218	CID	49	59	C042315	64	90	D002289	false

Sentence: Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.
Entity: 18809400	0	17	Alpha-lipoic acid	Chemical	D008063
Entity: 18809400	27	47	mitochondrial damage	Disease	D028361
Entity: 18809400	52	65	neurotoxicity	Disease	D020258
Entity: 18809400	95	105	neuropathy	Disease	D009422
Relation: 18809400	CID	0	17	D008063	27	47	D028361	false
Relation: 18809400	CID	0	17	D008063	52	65	D020258	false
Relation: 18809400	CID	0	17	D008063	95	105	D009422	false

Sentence: The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.
Entity: 18809400	26	43	alpha-lipoic acid	Chemical	D008063
Entity: 18809400	92	105	neurotoxicity	Disease	D020258
Entity: 18809400	110	130	mitochondrial damage	Disease	D028361
Entity: 18809400	156	187	toxic neurodegenerative cascade	Disease	D009410
Entity: 18809400	223	240	alpha-lipoic acid	Chemical	D008063
Relation: 18809400	CID	26	43	D008063	92	105	D020258	false
Relation: 18809400	CID	26	43	D008063	110	130	D028361	false
Relation: 18809400	CID	26	43	D008063	156	187	D009410	false
Relation: 18809400	CID	223	240	D008063	92	105	D020258	false
Relation: 18809400	CID	223	240	D008063	110	130	D028361	false
Relation: 18809400	CID	223	240	D008063	156	187	D009410	false

Sentence: We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.
Entity: 18809400	50	71	peripheral neuropathy	Disease	D010523
Entity: 18809400	191	201	paclitaxel	Chemical	D017239
Entity: 18809400	206	215	cisplatin	Chemical	D002945
Relation: 18809400	CID	191	201	D017239	50	71	D010523	true
Relation: 18809400	CID	206	215	D002945	50	71	D010523	true

Sentence: This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.
Entity: 18809400	52	69	alpha-lipoic acid	Chemical	D008063
Entity: 18809400	84	97	axonal damage	Disease	D001480
Entity: 18809400	211	228	alpha-lipoic acid	Chemical	D008063
Relation: 18809400	CID	52	69	D008063	84	97	D001480	false
Relation: 18809400	CID	211	228	D008063	84	97	D001480	false

Sentence: Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.
Entity: 18809400	34	43	cisplatin	Chemical	D002945
Entity: 18809400	48	58	paclitaxel	Chemical	D017239
Entity: 18809400	71	95	mitochondrial impairment	Disease	D028361
Relation: 18809400	CID	34	43	D002945	71	95	D028361	false
Relation: 18809400	CID	48	58	D017239	71	95	D028361	false

Sentence: Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.
Entity: 18809400	0	17	Alpha-lipoic acid	Chemical	D008063
Entity: 18809400	78	91	neurotoxicity	Disease	D020258
Entity: 18809400	127	149	mitochondrial toxicity	Disease	D028361
Relation: 18809400	CID	0	17	D008063	78	91	D020258	false
Relation: 18809400	CID	0	17	D008063	127	149	D028361	false

Sentence: In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.
Entity: 18809400	14	36	mitochondrial toxicity	Disease	D028361
Entity: 18809400	70	80	paclitaxel	Chemical	D017239
Entity: 18809400	85	94	cisplatin	Chemical	D002945
Entity: 18809400	103	116	neurotoxicity	Disease	D020258
Relation: 18809400	CID	70	80	D017239	14	36	D028361	false
Relation: 18809400	CID	70	80	D017239	103	116	D020258	false
Relation: 18809400	CID	85	94	D002945	14	36	D028361	false
Relation: 18809400	CID	85	94	D002945	103	116	D020258	false

Sentence: Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of stroke by 62%, and that aspirin alone reduces the risk by 22%.
Entity: 17020434	88	96	warfarin	Chemical	D014859
Entity: 17020434	117	123	stroke	Disease	D020521
Entity: 17020434	141	148	aspirin	Chemical	D001241
Relation: 17020434	CID	88	96	D014859	117	123	D020521	false
Relation: 17020434	CID	141	148	D001241	117	123	D020521	false

Sentence: Overall, in high-risk patients, warfarin is superior to aspirin in preventing strokes, with a relative risk reduction of 36%.
Entity: 17020434	32	40	warfarin	Chemical	D014859
Entity: 17020434	56	63	aspirin	Chemical	D001241
Entity: 17020434	78	85	strokes	Disease	D020521
Relation: 17020434	CID	32	40	D014859	78	85	D020521	false
Relation: 17020434	CID	56	63	D001241	78	85	D020521	false

Sentence: Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.
Entity: 17020434	0	12	Ximelagatran	Chemical	C426686
Entity: 17020434	81	90	vitamin K	Chemical	D014812
Entity: 17020434	129	143	embolic events	Disease	D004617
Entity: 17020434	188	211	abnormal liver function	Disease	D056486
Relation: 17020434	CID	0	12	C426686	129	143	D004617	false
Relation: 17020434	CID	0	12	C426686	188	211	D056486	true
Relation: 17020434	CID	81	90	D014812	129	143	D004617	false
Relation: 17020434	CID	81	90	D014812	188	211	D056486	false

Sentence: The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.
Entity: 17020434	14	33	Atrial Fibrillation	Disease	D001281
Entity: 17020434	34	45	Clopidogrel	Chemical	C055162
Entity: 17020434	57	67	Irbesartan	Chemical	C081309
Entity: 17020434	131	139	warfarin	Chemical	D014859
Entity: 17020434	173	184	clopidogrel	Chemical	C055162
Entity: 17020434	190	197	aspirin	Chemical	D001241
Entity: 17020434	220	234	embolic events	Disease	D004617
Relation: 17020434	CID	34	45	C055162	14	33	D001281	false
Relation: 17020434	CID	34	45	C055162	220	234	D004617	false
Relation: 17020434	CID	57	67	C081309	14	33	D001281	false
Relation: 17020434	CID	57	67	C081309	220	234	D004617	false
Relation: 17020434	CID	131	139	D014859	14	33	D001281	false
Relation: 17020434	CID	131	139	D014859	220	234	D004617	false
Relation: 17020434	CID	173	184	C055162	14	33	D001281	false
Relation: 17020434	CID	173	184	C055162	220	234	D004617	false
Relation: 17020434	CID	190	197	D001241	14	33	D001281	false
Relation: 17020434	CID	190	197	D001241	220	234	D004617	false

Sentence: Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.
Entity: 17020434	0	11	Idraparinux	Chemical	C479958
Entity: 17020434	72	91	atrial fibrillation	Disease	D001281
Relation: 17020434	CID	0	11	C479958	72	91	D001281	false

Sentence: Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.
Entity: 17020434	0	11	Angiotensin	Chemical	D000809
Entity: 17020434	45	59	angiotensin II	Chemical	D000804
Entity: 17020434	100	119	atrial fibrillation	Disease	D001281
Entity: 17020434	128	147	cardiac remodelling	Disease	D020257
Relation: 17020434	CID	0	11	D000809	100	119	D001281	false
Relation: 17020434	CID	0	11	D000809	128	147	D020257	false
Relation: 17020434	CID	45	59	D000804	100	119	D001281	false
Relation: 17020434	CID	45	59	D000804	128	147	D020257	false

Sentence: A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.
Entity: 3865016	24	33	etoposide	Chemical	D005047
Entity: 3865016	38	51	cyclosporin A	Chemical	D016572
Entity: 3865016	83	111	acute T-lymphocytic leukemia	Disease	D054218
Relation: 3865016	CID	24	33	D005047	83	111	D054218	false
Relation: 3865016	CID	38	51	D016572	83	111	D054218	false

Sentence: The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.
Entity: 3865016	34	43	etoposide	Chemical	D005047
Entity: 3865016	48	61	cyclosporin A	Chemical	D016572
Entity: 3865016	109	130	leukemic infiltration	Disease	D017254
Relation: 3865016	CID	34	43	D005047	109	130	D017254	false
Relation: 3865016	CID	48	61	D016572	109	130	D017254	false

Sentence: The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.
Entity: 3629586	27	36	cefonicid	Chemical	D015790
Entity: 3629586	41	51	cefazedone	Chemical	C021341
Entity: 3629586	85	98	cephalosporin	Chemical	D002511
Entity: 3629586	99	113	hematotoxicity	Disease	D006402
Relation: 3629586	CID	27	36	D015790	99	113	D006402	false
Relation: 3629586	CID	41	51	C021341	99	113	D006402	false
Relation: 3629586	CID	85	98	D002511	99	113	D006402	false

Sentence: Cephalosporin antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized.
Entity: 3629586	0	13	Cephalosporin	Chemical	D002511
Entity: 3629586	45	69	hematologic disturbances	Disease	D006402
Relation: 3629586	CID	0	13	D002511	45	69	D006402	false

Sentence: In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.
Entity: 3629586	17	25	toxicity	Disease	D064420
Entity: 3629586	69	78	cefonicid	Chemical	D015790
Entity: 3629586	82	92	cefazedone	Chemical	C021341
Entity: 3629586	145	151	anemia	Disease	D000740
Entity: 3629586	153	164	neutropenia	Disease	D009503
Entity: 3629586	170	186	thrombocytopenia	Disease	D013921
Relation: 3629586	CID	69	78	D015790	17	25	D064420	false
Relation: 3629586	CID	69	78	D015790	145	151	D000740	true
Relation: 3629586	CID	69	78	D015790	153	164	D009503	true
Relation: 3629586	CID	69	78	D015790	170	186	D013921	true
Relation: 3629586	CID	82	92	C021341	17	25	D064420	false
Relation: 3629586	CID	82	92	C021341	145	151	D000740	true
Relation: 3629586	CID	82	92	C021341	153	164	D009503	true
Relation: 3629586	CID	82	92	C021341	170	186	D013921	true

Sentence: A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.
Entity: 3629586	18	24	anemia	Disease	D000740
Entity: 3629586	58	68	cytopenias	Disease	D006402
Entity: 3629586	135	144	cefonicid	Chemical	D015790
Entity: 3629586	162	172	cefazedone	Chemical	C021341
Relation: 3629586	CID	135	144	D015790	18	24	D000740	true
Relation: 3629586	CID	135	144	D015790	58	68	D006402	false
Relation: 3629586	CID	162	172	C021341	18	24	D000740	true
Relation: 3629586	CID	162	172	C021341	58	68	D006402	false

Sentence: Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).
Entity: 3629586	29	42	cephalosporin	Chemical	D002511
Entity: 3629586	48	68	hematologic syndrome	Disease	D006402
Entity: 3629586	105	114	cefonicid	Chemical	D015790
Entity: 3629586	124	134	cefazedone	Chemical	C021341
Relation: 3629586	CID	29	42	D002511	48	68	D006402	false
Relation: 3629586	CID	105	114	D015790	48	68	D006402	false
Relation: 3629586	CID	124	134	C021341	48	68	D006402	false

Sentence: A pyridoxine-dependent behavioral disorder unmasked by isoniazid.
Entity: 150790	2	12	pyridoxine	Chemical	D011736
Entity: 150790	23	42	behavioral disorder	Disease	D002653
Entity: 150790	55	64	isoniazid	Chemical	D007538
Relation: 150790	CID	2	12	D011736	23	42	D002653	false
Relation: 150790	CID	55	64	D007538	23	42	D002653	true

Sentence: A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.
Entity: 150790	22	46	behavioral deterioration	Disease	D002653
Entity: 150790	53	65	hyperkinesis	Disease	D006948
Entity: 150790	67	79	irritability	Disease	D001523
Entity: 150790	85	106	sleeping difficulties	Disease	D012893
Entity: 150790	147	156	isoniazid	Chemical	D007538
Relation: 150790	CID	147	156	D007538	22	46	D002653	true
Relation: 150790	CID	147	156	D007538	53	65	D006948	true
Relation: 150790	CID	147	156	D007538	67	79	D001523	false
Relation: 150790	CID	147	156	D007538	85	106	D012893	false

Sentence: Periodic withdrawal of pyridoxine was associated with return of the hyperkinesis.
Entity: 150790	23	33	pyridoxine	Chemical	D011736
Entity: 150790	68	80	hyperkinesis	Disease	D006948
Relation: 150790	CID	23	33	D011736	68	80	D006948	false

Sentence: NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.
Entity: 10579464	0	7	NRA0160	Chemical	C121249
Entity: 10579464	12	21	clozapine	Chemical	D003024
Entity: 10579464	44	57	hyperactivity	Disease	D006948
Entity: 10579464	69	84	methamphetamine	Chemical	D008694
Entity: 10579464	86	89	MAP	Chemical	D008694
Relation: 10579464	CID	0	7	C121249	44	57	D006948	false
Relation: 10579464	CID	12	21	D003024	44	57	D006948	false
Relation: 10579464	CID	69	84	D008694	44	57	D006948	true
Relation: 10579464	CID	86	89	D008694	44	57	D006948	true

Sentence: NRA0160 and clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given.
Entity: 10579464	0	7	NRA0160	Chemical	C121249
Entity: 10579464	12	21	clozapine	Chemical	D003024
Entity: 10579464	44	53	catalepsy	Disease	D002375
Relation: 10579464	CID	0	7	C121249	44	53	D002375	true
Relation: 10579464	CID	12	21	D003024	44	53	D002375	true

Sentence: Prolonged cholestasis after troleandomycin induced acute hepatitis.
Entity: 3496378	10	21	cholestasis	Disease	D002779
Entity: 3496378	28	42	troleandomycin	Chemical	D014217
Entity: 3496378	57	66	hepatitis	Disease	D056486
Relation: 3496378	CID	28	42	D014217	10	21	D002779	true
Relation: 3496378	CID	28	42	D014217	57	66	D056486	true

Sentence: We report the case of a patient in whom troleandomycin induced hepatitis was followed by prolonged anicteric cholestasis.
Entity: 3496378	40	54	troleandomycin	Chemical	D014217
Entity: 3496378	63	72	hepatitis	Disease	D056486
Entity: 3496378	109	120	cholestasis	Disease	D002779
Relation: 3496378	CID	40	54	D014217	63	72	D056486	true
Relation: 3496378	CID	40	54	D014217	109	120	D002779	true

Sentence: Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia.
Entity: 3496378	0	8	Jaundice	Disease	D007565
Entity: 3496378	42	56	troleandomycin	Chemical	D014217
Entity: 3496378	92	109	hypereosinophilia	Disease	D004802
Relation: 3496378	CID	42	56	D014217	0	8	D007565	true
Relation: 3496378	CID	42	56	D014217	92	109	D004802	true

Sentence: Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.
Entity: 3076126	0	8	Myopathy	Disease	D009135
Entity: 3076126	40	53	myoglobinuria	Disease	D009212
Entity: 3076126	85	98	renal failure	Disease	D051437
Entity: 3076126	130	140	lovastatin	Chemical	D008148
Entity: 3076126	192	203	cyclosporin	Chemical	D016572
Entity: 3076126	205	216	gemfibrozil	Chemical	D015248
Entity: 3076126	220	226	niacin	Chemical	D009525
Relation: 3076126	CID	130	140	D008148	0	8	D009135	false
Relation: 3076126	CID	130	140	D008148	40	53	D009212	true
Relation: 3076126	CID	130	140	D008148	85	98	D051437	true
Relation: 3076126	CID	192	203	D016572	0	8	D009135	true
Relation: 3076126	CID	192	203	D016572	40	53	D009212	false
Relation: 3076126	CID	192	203	D016572	85	98	D051437	false
Relation: 3076126	CID	205	216	D015248	0	8	D009135	true
Relation: 3076126	CID	205	216	D015248	40	53	D009212	false
Relation: 3076126	CID	205	216	D015248	85	98	D051437	false
Relation: 3076126	CID	220	226	D009525	0	8	D009135	true
Relation: 3076126	CID	220	226	D009525	40	53	D009212	false
Relation: 3076126	CID	220	226	D009525	85	98	D051437	false

Sentence: Sulfasalazine induced lupus erythematosus.
Entity: 2894766	0	13	Sulfasalazine	Chemical	D012460
Entity: 2894766	22	41	lupus erythematosus	Disease	D008180
Relation: 2894766	CID	0	13	D012460	22	41	D008180	true

Sentence: Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.
Entity: 2894766	0	11	Pneumonitis	Disease	D011014
Entity: 2894766	23	40	pleural effusions	Disease	D010996
Entity: 2894766	72	89	cardiac tamponade	Disease	D002305
Entity: 2894766	179	192	sulfasalazine	Chemical	D012460
Entity: 2894766	213	231	ulcerative colitis	Disease	D003093
Relation: 2894766	CID	179	192	D012460	0	11	D011014	true
Relation: 2894766	CID	179	192	D012460	23	40	D010996	true
Relation: 2894766	CID	179	192	D012460	72	89	D002305	true
Relation: 2894766	CID	179	192	D012460	213	231	D003093	false

Sentence: It is suggested that the patient had sulfasalazine induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.
Entity: 2894766	37	50	sulfasalazine	Chemical	D012460
Entity: 2894766	59	64	lupus	Disease	D008180
Entity: 2894766	88	97	serositis	Disease	D012700
Relation: 2894766	CID	37	50	D012460	59	64	D008180	true
Relation: 2894766	CID	37	50	D012460	88	97	D012700	false

Sentence: While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate carbidopa-levodopa to the point of "normality," which can lead to toxicity.
Entity: 1549199	51	59	levodopa	Chemical	D007980
Entity: 1549199	206	215	carbidopa	Chemical	D002230
Entity: 1549199	216	224	levodopa	Chemical	D007980
Entity: 1549199	272	280	toxicity	Disease	D064420
Relation: 1549199	CID	51	59	D007980	272	280	D064420	false
Relation: 1549199	CID	206	215	D002230	272	280	D064420	false
Relation: 1549199	CID	216	224	D007980	272	280	D064420	false

Sentence: Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.
Entity: 1549199	40	66	gastrointestinal disorders	Disease	D005767
Entity: 1549199	68	91	orthostatic hypotension	Disease	D007024
Entity: 1549199	93	101	levodopa	Chemical	D007980
Entity: 1549199	110	119	psychosis	Disease	D011618
Entity: 1549199	121	139	sleep disturbances	Disease	D012893
Entity: 1549199	143	154	parasomnias	Disease	D020447
Relation: 1549199	CID	93	101	D007980	40	66	D005767	true
Relation: 1549199	CID	93	101	D007980	68	91	D007024	true
Relation: 1549199	CID	93	101	D007980	110	119	D011618	false
Relation: 1549199	CID	93	101	D007980	121	139	D012893	false
Relation: 1549199	CID	93	101	D007980	143	154	D020447	true

Sentence: Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.
Entity: 88336	38	53	chlormethiazole	Chemical	D002719
Entity: 88336	58	65	alcohol	Chemical	D000431
Entity: 88336	66	85	withdrawal symptoms	Disease	D013375
Entity: 88336	111	119	overdose	Disease	D062787
Entity: 88336	123	133	nitrazepam	Chemical	D009567
Relation: 88336	CID	38	53	D002719	66	85	D013375	false
Relation: 88336	CID	38	53	D002719	111	119	D062787	false
Relation: 88336	CID	58	65	D000431	66	85	D013375	false
Relation: 88336	CID	58	65	D000431	111	119	D062787	false
Relation: 88336	CID	123	133	D009567	66	85	D013375	false
Relation: 88336	CID	123	133	D009567	111	119	D062787	true

Sentence: The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.
Entity: 88336	17	27	nitrazepam	Chemical	D009567
Entity: 88336	28	36	overdose	Disease	D062787
Entity: 88336	59	74	chlormethiazole	Chemical	D002719
Entity: 88336	124	128	coma	Disease	D003128
Relation: 88336	CID	17	27	D009567	28	36	D062787	true
Relation: 88336	CID	17	27	D009567	124	128	D003128	true
Relation: 88336	CID	59	74	D002719	28	36	D062787	false
Relation: 88336	CID	59	74	D002719	124	128	D003128	true

Sentence: Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.
Entity: 18544179	9	17	fentanyl	Chemical	D005283
Entity: 18544179	26	32	nausea	Disease	D009325
Entity: 18544179	37	45	vomiting	Disease	D014839
Entity: 18544179	66	70	pain	Disease	D010146
Entity: 18544179	78	89	sevoflurane	Chemical	C009250
Relation: 18544179	CID	9	17	D005283	26	32	D009325	false
Relation: 18544179	CID	9	17	D005283	37	45	D014839	false
Relation: 18544179	CID	9	17	D005283	66	70	D010146	false
Relation: 18544179	CID	78	89	C009250	26	32	D009325	false
Relation: 18544179	CID	78	89	C009250	37	45	D014839	false
Relation: 18544179	CID	78	89	C009250	66	70	D010146	false

Sentence: BACKGROUND AND OBJECTIVE: Despite advantages of induction and maintenance of anaesthesia with sevoflurane, postoperative nausea and vomiting occurs frequently.
Entity: 18544179	94	105	sevoflurane	Chemical	C009250
Entity: 18544179	107	140	postoperative nausea and vomiting	Disease	D020250
Relation: 18544179	CID	94	105	C009250	107	140	D020250	false

Sentence: METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.
Entity: 18544179	72	105	postoperative nausea and vomiting	Disease	D020250
Entity: 18544179	110	114	pain	Disease	D010146
Entity: 18544179	139	150	sevoflurane	Chemical	C009250
Relation: 18544179	CID	139	150	C009250	72	105	D020250	false
Relation: 18544179	CID	139	150	C009250	110	114	D010146	false

Sentence: RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).
Entity: 18544179	21	29	fentanyl	Chemical	D005283
Entity: 18544179	70	103	postoperative nausea and vomiting	Disease	D020250
Entity: 18544179	137	145	vomiting	Disease	D014839
Entity: 18544179	172	178	nausea	Disease	D009325
Entity: 18544179	220	228	fentanyl	Chemical	D005283
Entity: 18544179	233	241	fentanyl	Chemical	D005283
Entity: 18544179	242	255	dexamethasone	Chemical	D003907
Relation: 18544179	CID	21	29	D005283	70	103	D020250	true
Relation: 18544179	CID	21	29	D005283	137	145	D014839	false
Relation: 18544179	CID	21	29	D005283	172	178	D009325	false
Relation: 18544179	CID	220	228	D005283	70	103	D020250	true
Relation: 18544179	CID	220	228	D005283	137	145	D014839	false
Relation: 18544179	CID	220	228	D005283	172	178	D009325	false
Relation: 18544179	CID	233	241	D005283	70	103	D020250	true
Relation: 18544179	CID	233	241	D005283	137	145	D014839	false
Relation: 18544179	CID	233	241	D005283	172	178	D009325	false
Relation: 18544179	CID	242	255	D003907	70	103	D020250	false
Relation: 18544179	CID	242	255	D003907	137	145	D014839	false
Relation: 18544179	CID	242	255	D003907	172	178	D009325	false

Sentence: Dexamethasone had no significant effect on the incidence or severity of postoperative nausea and vomiting.
Entity: 18544179	0	13	Dexamethasone	Chemical	D003907
Entity: 18544179	72	105	postoperative nausea and vomiting	Disease	D020250
Relation: 18544179	CID	0	13	D003907	72	105	D020250	false

Sentence: Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).
Entity: 18544179	18	26	fentanyl	Chemical	D005283
Entity: 18544179	112	145	postoperative nausea and vomiting	Disease	D020250
Entity: 18544179	150	156	nausea	Disease	D009325
Entity: 18544179	255	261	nausea	Disease	D009325
Relation: 18544179	CID	18	26	D005283	112	145	D020250	true
Relation: 18544179	CID	18	26	D005283	150	156	D009325	false
Relation: 18544179	CID	18	26	D005283	255	261	D009325	false

Sentence: Pain severity and analgesic requirements were unaffected by the omission of fentanyl.
Entity: 18544179	0	4	Pain	Disease	D010146
Entity: 18544179	76	84	fentanyl	Chemical	D005283
Relation: 18544179	CID	76	84	D005283	0	4	D010146	false

Sentence: Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.
Entity: 18544179	0	8	Fentanyl	Chemical	D005283
Entity: 18544179	61	72	sevoflurane	Chemical	C009250
Entity: 18544179	102	124	respiratory depression	Disease	D012131
Entity: 18544179	126	137	hypotension	Disease	D007022
Entity: 18544179	142	153	bradycardia	Disease	D001919
Relation: 18544179	CID	0	8	D005283	102	124	D012131	true
Relation: 18544179	CID	0	8	D005283	126	137	D007022	true
Relation: 18544179	CID	0	8	D005283	142	153	D001919	true
Relation: 18544179	CID	61	72	C009250	102	124	D012131	false
Relation: 18544179	CID	61	72	C009250	126	137	D007022	false
Relation: 18544179	CID	61	72	C009250	142	153	D001919	false

Sentence: Lamivudine was added because of de nova hepatitis B infection during her follow-up.
Entity: 18186898	0	10	Lamivudine	Chemical	D019259
Entity: 18186898	40	61	hepatitis B infection	Disease	D006509
Relation: 18186898	CID	0	10	D019259	40	61	D006509	false

Sentence: Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.
Entity: 18186898	9	19	tacrolimus	Chemical	D016559
Entity: 18186898	80	88	acidosis	Disease	D000138
Entity: 18186898	109	118	sirolimus	Chemical	D020123
Entity: 18186898	120	128	acidosis	Disease	D000138
Relation: 18186898	CID	9	19	D016559	80	88	D000138	false
Relation: 18186898	CID	9	19	D016559	120	128	D000138	false
Relation: 18186898	CID	109	118	D020123	80	88	D000138	false
Relation: 18186898	CID	109	118	D020123	120	128	D000138	false

Sentence: The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic induced catalepsy, apomorphine induced climbing behavior and amphetamine induced locomotor activities in mice.
Entity: 16867021	54	63	histamine	Chemical	D006632
Entity: 16867021	109	118	catalepsy	Disease	D002375
Entity: 16867021	120	131	apomorphine	Chemical	D001058
Entity: 16867021	162	173	amphetamine	Chemical	D000661
Relation: 16867021	CID	54	63	D006632	109	118	D002375	false
Relation: 16867021	CID	120	131	D001058	109	118	D002375	false
Relation: 16867021	CID	162	173	D000661	109	118	D002375	false

Sentence: Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively.
Entity: 16867021	0	9	Catalepsy	Disease	D002375
Entity: 16867021	25	36	haloperidol	Chemical	D006220
Entity: 16867021	59	70	apomorphine	Chemical	D001058
Entity: 16867021	92	103	amphetamine	Chemical	D000661
Relation: 16867021	CID	25	36	D006220	0	9	D002375	true
Relation: 16867021	CID	59	70	D001058	0	9	D002375	false
Relation: 16867021	CID	92	103	D000661	0	9	D002375	false

Sentence: (R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.
Entity: 16867021	0	25	(R)-alpha-methylhistamine	Chemical	C069357
Entity: 16867021	27	31	RAMH	Chemical	C069357
Entity: 16867021	55	67	thioperamide	Chemical	C052075
Entity: 16867021	69	72	THP	Chemical	C052075
Entity: 16867021	112	121	catalepsy	Disease	D002375
Relation: 16867021	CID	0	25	C069357	112	121	D002375	false
Relation: 16867021	CID	27	31	C069357	112	121	D002375	false
Relation: 16867021	CID	55	67	C052075	112	121	D002375	true
Relation: 16867021	CID	69	72	C052075	112	121	D002375	true

Sentence: Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).
Entity: 16867021	18	21	THP	Chemical	C052075
Entity: 16867021	65	76	haloperidol	Chemical	D006220
Entity: 16867021	122	131	catalepsy	Disease	D002375
Relation: 16867021	CID	18	21	C052075	122	131	D002375	true
Relation: 16867021	CID	65	76	D006220	122	131	D002375	true

Sentence: On amphetamine induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).
Entity: 16867021	3	14	amphetamine	Chemical	D000661
Entity: 16867021	23	36	hyperactivity	Disease	D006948
Entity: 16867021	38	41	THP	Chemical	C052075
Relation: 16867021	CID	3	14	D000661	23	36	D006948	true
Relation: 16867021	CID	38	41	C052075	23	36	D006948	false

Sentence: THP exhibited an antipsychotic-like profile by potentiating haloperidol induced catalepsy, reducing amphetamine induced hyperactivity and reducing apomorphine induced climbing in mice.
Entity: 16867021	0	3	THP	Chemical	C052075
Entity: 16867021	60	71	haloperidol	Chemical	D006220
Entity: 16867021	80	89	catalepsy	Disease	D002375
Entity: 16867021	100	111	amphetamine	Chemical	D000661
Entity: 16867021	120	133	hyperactivity	Disease	D006948
Entity: 16867021	147	158	apomorphine	Chemical	D001058
Relation: 16867021	CID	0	3	C052075	80	89	D002375	true
Relation: 16867021	CID	0	3	C052075	120	133	D006948	false
Relation: 16867021	CID	60	71	D006220	80	89	D002375	true
Relation: 16867021	CID	60	71	D006220	120	133	D006948	false
Relation: 16867021	CID	100	111	D000661	80	89	D002375	false
Relation: 16867021	CID	100	111	D000661	120	133	D006948	true
Relation: 16867021	CID	147	158	D001058	80	89	D002375	false
Relation: 16867021	CID	147	158	D001058	120	133	D006948	false

Sentence: Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.
Entity: 14976857	10	45	platypnea-orthodeoxia-like syndrome	Disease	-1
Entity: 14976857	57	68	propafenone	Chemical	D011405
Entity: 14976857	69	77	overdose	Disease	D062787
Entity: 14976857	100	117	Ebstein's anomaly	Disease	D004437
Relation: 14976857	CID	57	68	D011405	10	45	-1	false
Relation: 14976857	CID	57	68	D011405	69	77	D062787	false
Relation: 14976857	CID	57	68	D011405	100	117	D004437	false

Sentence: This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure, and was probably precipitated by a propafenone overdose.
Entity: 14976857	26	46	patent foramen ovale	Disease	D054092
Entity: 14976857	146	157	propafenone	Chemical	D011405
Entity: 14976857	158	166	overdose	Disease	D062787
Relation: 14976857	CID	146	157	D011405	26	46	D054092	false
Relation: 14976857	CID	146	157	D011405	158	166	D062787	false

Sentence: A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).
Entity: 11745184	20	29	cisplatin	Chemical	D002945
Entity: 11745184	35	42	WR-2721	Chemical	D004999
Entity: 11745184	44	54	amifostine	Chemical	D004999
Entity: 11745184	71	87	breast carcinoma	Disease	D001943
Relation: 11745184	CID	20	29	D002945	71	87	D001943	false
Relation: 11745184	CID	35	42	D004999	71	87	D001943	false
Relation: 11745184	CID	44	54	D004999	71	87	D001943	false

Sentence: BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.
Entity: 11745184	12	21	Cisplatin	Chemical	D002945
Entity: 11745184	112	128	breast carcinoma	Disease	D001943
Relation: 11745184	CID	12	21	D002945	112	128	D001943	false

Sentence: Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.
Entity: 11745184	55	64	cisplatin	Chemical	D002945
Entity: 11745184	84	94	toxicities	Disease	D064420
Entity: 11745184	111	120	cisplatin	Chemical	D002945
Entity: 11745184	128	142	nephrotoxicity	Disease	D007674
Entity: 11745184	144	155	ototoxicity	Disease	D006311
Entity: 11745184	161	174	neurotoxicity	Disease	D020258
Entity: 11745184	216	232	breast carcinoma	Disease	D001943
Relation: 11745184	CID	55	64	D002945	84	94	D064420	false
Relation: 11745184	CID	55	64	D002945	128	142	D007674	true
Relation: 11745184	CID	55	64	D002945	144	155	D006311	true
Relation: 11745184	CID	55	64	D002945	161	174	D020258	false
Relation: 11745184	CID	55	64	D002945	216	232	D001943	false
Relation: 11745184	CID	111	120	D002945	84	94	D064420	false
Relation: 11745184	CID	111	120	D002945	128	142	D007674	true
Relation: 11745184	CID	111	120	D002945	144	155	D006311	true
Relation: 11745184	CID	111	120	D002945	161	174	D020258	false
Relation: 11745184	CID	111	120	D002945	216	232	D001943	false

Sentence: Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin induced nephrotoxicity, ototoxicity, and neuropathy were reduced.
Entity: 11745184	16	25	cisplatin	Chemical	D002945
Entity: 11745184	30	40	amifostine	Chemical	D004999
Entity: 11745184	91	100	cisplatin	Chemical	D002945
Entity: 11745184	109	123	nephrotoxicity	Disease	D007674
Entity: 11745184	125	136	ototoxicity	Disease	D006311
Entity: 11745184	142	152	neuropathy	Disease	D009422
Relation: 11745184	CID	16	25	D002945	109	123	D007674	true
Relation: 11745184	CID	16	25	D002945	125	136	D006311	true
Relation: 11745184	CID	16	25	D002945	142	152	D009422	true
Relation: 11745184	CID	30	40	D004999	109	123	D007674	false
Relation: 11745184	CID	30	40	D004999	125	136	D006311	false
Relation: 11745184	CID	30	40	D004999	142	152	D009422	false
Relation: 11745184	CID	91	100	D002945	109	123	D007674	true
Relation: 11745184	CID	91	100	D002945	125	136	D006311	true
Relation: 11745184	CID	91	100	D002945	142	152	D009422	true

Sentence: METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.
Entity: 11745184	48	57	cisplatin	Chemical	D002945
Entity: 11745184	63	73	amifostine	Chemical	D004999
Entity: 11745184	128	144	breast carcinoma	Disease	D001943
Relation: 11745184	CID	48	57	D002945	128	144	D001943	false
Relation: 11745184	CID	63	73	D004999	128	144	D001943	false

Sentence: Warfarin induced iliopsoas hemorrhage with subsequent femoral nerve palsy.
Entity: 3985451	0	8	Warfarin	Chemical	D014859
Entity: 3985451	27	37	hemorrhage	Disease	D006470
Entity: 3985451	54	73	femoral nerve palsy	Disease	D020428
Relation: 3985451	CID	0	8	D014859	27	37	D006470	false
Relation: 3985451	CID	0	8	D014859	54	73	D020428	true

Sentence: We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.
Entity: 3985451	52	60	warfarin	Chemical	D014859
Entity: 3985451	91	102	muscle tear	Disease	D009135
Entity: 3985451	128	132	pain	Disease	D010146
Entity: 3985451	147	158	contracture	Disease	D003286
Relation: 3985451	CID	52	60	D014859	91	102	D009135	true
Relation: 3985451	CID	52	60	D014859	128	132	D010146	false
Relation: 3985451	CID	52	60	D014859	147	158	D003286	false

Sentence: Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.
Entity: 3750012	0	17	Myasthenia gravis	Disease	D009157
Entity: 3750012	28	41	penicillamine	Chemical	D010396
Entity: 3750012	46	57	chloroquine	Chemical	D002738
Entity: 3750012	70	90	rheumatoid arthritis	Disease	D001172
Relation: 3750012	CID	28	41	D010396	0	17	D009157	true
Relation: 3750012	CID	28	41	D010396	70	90	D001172	false
Relation: 3750012	CID	46	57	D002738	0	17	D009157	true
Relation: 3750012	CID	46	57	D002738	70	90	D001172	false

Sentence: We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.
Entity: 3750012	71	88	myasthenia gravis	Disease	D009157
Entity: 3750012	95	108	penicillamine	Chemical	D010396
Entity: 3750012	113	124	chloroquine	Chemical	D002738
Entity: 3750012	137	157	rheumatoid arthritis	Disease	D001172
Relation: 3750012	CID	95	108	D010396	71	88	D009157	true
Relation: 3750012	CID	95	108	D010396	137	157	D001172	false
Relation: 3750012	CID	113	124	D002738	71	88	D009157	true
Relation: 3750012	CID	113	124	D002738	137	157	D001172	false

Sentence: Nephrotoxicity of combined cephalothin-gentamicin regimen.
Entity: 1130930	0	14	Nephrotoxicity	Disease	D007674
Entity: 1130930	27	38	cephalothin	Chemical	D002512
Entity: 1130930	39	49	gentamicin	Chemical	D005839
Relation: 1130930	CID	27	38	D002512	0	14	D007674	false
Relation: 1130930	CID	39	49	D005839	0	14	D007674	false

Sentence: Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.
Entity: 1130930	23	45	acute tubular necrosis	Disease	D007683
Entity: 1130930	81	89	oliguric	Disease	D009846
Entity: 1130930	90	95	renal	Disease	D051437
Entity: 1130930	148	166	cephalothin sodium	Chemical	D002512
Entity: 1130930	171	189	gentamicin sulfate	Chemical	D005839
Relation: 1130930	CID	148	166	D002512	23	45	D007683	true
Relation: 1130930	CID	148	166	D002512	81	89	D009846	true
Relation: 1130930	CID	148	166	D002512	90	95	D051437	false
Relation: 1130930	CID	171	189	D005839	23	45	D007683	true
Relation: 1130930	CID	171	189	D005839	81	89	D009846	true
Relation: 1130930	CID	171	189	D005839	90	95	D051437	false

Sentence: Components of lemon essential oil attenuate dementia induced by scopolamine.
Entity: 19356307	44	52	dementia	Disease	D003704
Entity: 19356307	64	75	scopolamine	Chemical	D012601
Relation: 19356307	CID	64	75	D012601	44	52	D003704	false

Sentence: The anti-dementia effects of s-limonene and s-perillyl alcohol were observed using the passive avoidance test (PA) and the open field habituation test (OFH).
Entity: 19356307	9	17	dementia	Disease	D003704
Entity: 19356307	29	39	s-limonene	Chemical	C008281
Entity: 19356307	44	62	s-perillyl alcohol	Chemical	C032208
Relation: 19356307	CID	29	39	C008281	9	17	D003704	false
Relation: 19356307	CID	44	62	C032208	9	17	D003704	false

Sentence: These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.
Entity: 19356307	60	75	memory impaired	Disease	D008569
Entity: 19356307	79	90	scopolamine	Chemical	D012601
Entity: 19356307	101	119	s-perillyl alcohol	Chemical	C032208
Entity: 19356307	133	162	deficit of associative memory	Disease	D008569
Relation: 19356307	CID	79	90	D012601	60	75	D008569	true
Relation: 19356307	CID	79	90	D012601	133	162	D008569	true
Relation: 19356307	CID	101	119	C032208	60	75	D008569	false
Relation: 19356307	CID	101	119	C032208	133	162	D008569	false

Sentence: The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.
Entity: 15957009	40	49	Ro4368554	Chemical	C507242
Entity: 15957009	120	137	memory deficiency	Disease	D008569
Relation: 15957009	CID	40	49	C507242	120	137	D008569	false

Sentence: Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).
Entity: 15957009	6	15	Ro4368554	Chemical	C507242
Entity: 15957009	63	74	metrifonate	Chemical	D014236
Entity: 15957009	115	130	memory deficits	Disease	D008569
Entity: 15957009	142	153	scopolamine	Chemical	D012601
Entity: 15957009	158	161	TRP	Chemical	D014364
Relation: 15957009	CID	6	15	C507242	115	130	D008569	false
Relation: 15957009	CID	63	74	D014236	115	130	D008569	false
Relation: 15957009	CID	142	153	D012601	115	130	D008569	true
Relation: 15957009	CID	158	161	D014364	115	130	D008569	false

Sentence: Lone atrial fibrillation associated with creatine monohydrate supplementation.
Entity: 15899738	5	24	atrial fibrillation	Disease	D001281
Entity: 15899738	41	49	creatine	Chemical	D003401
Relation: 15899738	CID	41	49	D003401	5	24	D001281	true

Sentence: Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study.
Entity: 15863244	28	36	toxicity	Disease	D064420
Entity: 15863244	125	128	DFU	Chemical	C106876
Entity: 15863244	133	142	piroxicam	Chemical	D010894
Relation: 15863244	CID	125	128	C106876	28	36	D064420	false
Relation: 15863244	CID	133	142	D010894	28	36	D064420	false

Sentence: The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.
Entity: 15863244	60	68	toxicity	Disease	D064420
Entity: 15863244	91	100	piroxicam	Chemical	D010894
Entity: 15863244	117	120	DFU	Chemical	C106876
Entity: 15863244	122	196	5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon	Chemical	C106876
Relation: 15863244	CID	91	100	D010894	60	68	D064420	false
Relation: 15863244	CID	117	120	C106876	60	68	D064420	false
Relation: 15863244	CID	122	196	C106876	60	68	D064420	false

Sentence: The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.
Entity: 15863244	36	47	ventricular	Disease	D006345
Entity: 15863244	65	72	midline	Disease	D009436
Entity: 15863244	127	136	piroxicam	Chemical	D010894
Relation: 15863244	CID	127	136	D010894	36	47	D006345	false
Relation: 15863244	CID	127	136	D010894	65	72	D009436	false

Sentence: RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.
Entity: 15863244	18	26	toxicity	Disease	D064420
Entity: 15863244	28	59	intrauterine growth retardation	Disease	D005317
Entity: 15863244	65	109	increase of external and skeletal variations	Disease	D009139
Entity: 15863244	162	171	piroxicam	Chemical	D010894
Relation: 15863244	CID	162	171	D010894	18	26	D064420	false
Relation: 15863244	CID	162	171	D010894	28	59	D005317	true
Relation: 15863244	CID	162	171	D010894	65	109	D009139	true

Sentence: Decrease of fetal length was the only signs of the DFU developmental toxicity observed in pups exposed to the highest compound dose.
Entity: 15863244	51	54	DFU	Chemical	C106876
Entity: 15863244	69	77	toxicity	Disease	D064420
Relation: 15863244	CID	51	54	C106876	69	77	D064420	false

Sentence: Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice.
Entity: 12921865	35	43	steroids	Chemical	D013256
Entity: 12921865	52	59	cocaine	Chemical	D003042
Entity: 12921865	68	76	seizures	Disease	D012640
Relation: 12921865	CID	35	43	D013256	68	76	D012640	false
Relation: 12921865	CID	52	59	D003042	68	76	D012640	true

Sentence: Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of neurological and psychiatric disorders.
Entity: 12921865	12	20	steroids	Chemical	D013256
Entity: 12921865	91	103	neurological	Disease	D009422
Entity: 12921865	108	119	psychiatric	Disease	D001523
Relation: 12921865	CID	12	20	D013256	91	103	D009422	false
Relation: 12921865	CID	12	20	D013256	108	119	D001523	false

Sentence: The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).
Entity: 12921865	88	95	steroid	Chemical	D013256
Entity: 12921865	125	148	gamma-aminobutyric acid	Chemical	D005680
Entity: 12921865	150	154	GABA	Chemical	D005680
Entity: 12921865	233	240	cocaine	Chemical	D003042
Entity: 12921865	264	271	cocaine	Chemical	D003042
Entity: 12921865	288	295	seizure	Disease	D012640
Relation: 12921865	CID	88	95	D013256	288	295	D012640	false
Relation: 12921865	CID	125	148	D005680	288	295	D012640	false
Relation: 12921865	CID	150	154	D005680	288	295	D012640	false
Relation: 12921865	CID	233	240	D003042	288	295	D012640	true
Relation: 12921865	CID	264	271	D003042	288	295	D012640	true

Sentence: Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.
Entity: 12921865	0	16	Allopregnanolone	Chemical	D011280
Entity: 12921865	18	54	3alpha-hydroxy-5alpha-pregnan-20-one	Chemical	D011280
Entity: 12921865	57	69	pregnanolone	Chemical	D011280
Entity: 12921865	71	106	3alpha-hydroxy-5beta-pregnan-20-one	Chemical	D011280
Entity: 12921865	112	122	ganaxolone	Chemical	C105051
Entity: 12921865	150	166	allopregnanolone	Chemical	D011280
Entity: 12921865	167	216	3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one	Chemical	C105051
Entity: 12921865	345	352	cocaine	Chemical	D003042
Entity: 12921865	361	369	seizures	Disease	D012640
Relation: 12921865	CID	0	16	D011280	361	369	D012640	false
Relation: 12921865	CID	18	54	D011280	361	369	D012640	false
Relation: 12921865	CID	57	69	D011280	361	369	D012640	false
Relation: 12921865	CID	71	106	D011280	361	369	D012640	false
Relation: 12921865	CID	112	122	C105051	361	369	D012640	false
Relation: 12921865	CID	150	166	D011280	361	369	D012640	false
Relation: 12921865	CID	167	216	C105051	361	369	D012640	false
Relation: 12921865	CID	345	352	D003042	361	369	D012640	true

Sentence: Kindled seizures were induced by daily administration of 60 mg/kg cocaine for 5 days.
Entity: 12921865	8	16	seizures	Disease	D012640
Entity: 12921865	66	73	cocaine	Chemical	D003042
Relation: 12921865	CID	66	73	D003042	8	16	D012640	true

Sentence: All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.
Entity: 12921865	22	26	GABA	Chemical	D005680
Entity: 12921865	78	86	seizures	Disease	D012640
Entity: 12921865	101	117	allopregnanolone	Chemical	D011280
Entity: 12921865	122	132	ganaxolone	Chemical	C105051
Relation: 12921865	CID	22	26	D005680	78	86	D012640	false
Relation: 12921865	CID	101	117	D011280	78	86	D012640	false
Relation: 12921865	CID	122	132	C105051	78	86	D012640	false

Sentence: These are nephrotoxic, but SRL seems to act differently displaying only minor nephrotoxic effects, although this question is still open.
Entity: 12584269	10	21	nephrotoxic	Disease	D007674
Entity: 12584269	27	30	SRL	Chemical	D020123
Entity: 12584269	78	89	nephrotoxic	Disease	D007674
Relation: 12584269	CID	27	30	D020123	10	21	D007674	true
Relation: 12584269	CID	27	30	D020123	78	89	D007674	true

Sentence: In a number of treatment protocols where SRL was combined with a calcineurin inhibitor indications of a synergistic nephrotoxic effect were described.
Entity: 12584269	41	44	SRL	Chemical	D020123
Entity: 12584269	116	127	nephrotoxic	Disease	D007674
Relation: 12584269	CID	41	44	D020123	116	127	D007674	true

Sentence: The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).
Entity: 12584269	80	83	CsA	Chemical	D016572
Entity: 12584269	89	92	SRL	Chemical	D020123
Entity: 12584269	165	173	fibrosis	Disease	D005355
Relation: 12584269	CID	80	83	D016572	165	173	D005355	false
Relation: 12584269	CID	89	92	D020123	165	173	D005355	false

Sentence: The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).
Entity: 12584269	4	9	FK506	Chemical	D016559
Entity: 12584269	15	18	SRL	Chemical	D020123
Entity: 12584269	73	81	fibrosis	Disease	D005355
Relation: 12584269	CID	4	9	D016559	73	81	D005355	false
Relation: 12584269	CID	15	18	D020123	73	81	D005355	false

Sentence: Effect of fucoidan treatment on collagenase induced intracerebral hemorrhage in rats.
Entity: 10406016	10	18	fucoidan	Chemical	C007789
Entity: 10406016	52	76	intracerebral hemorrhage	Disease	D002543
Relation: 10406016	CID	10	18	C007789	52	76	D002543	false

Sentence: We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.
Entity: 10406016	38	46	fucoidan	Chemical	C007789
Entity: 10406016	95	107	brain damage	Disease	D001925
Entity: 10406016	127	151	intracerebral hemorrhage	Disease	D002543
Relation: 10406016	CID	38	46	C007789	95	107	D001925	false
Relation: 10406016	CID	38	46	C007789	127	151	D002543	false

Sentence: Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.
Entity: 10406016	0	8	Fucoidan	Chemical	C007789
Entity: 10406016	44	67	impaired blood clotting	Disease	D020141
Entity: 10406016	72	84	hemodilution	Disease	D020141
Entity: 10406016	97	106	hematomas	Disease	D006406
Entity: 10406016	132	144	inflammation	Disease	D007249
Entity: 10406016	168	176	hematoma	Disease	D006406
Relation: 10406016	CID	0	8	C007789	44	67	D020141	true
Relation: 10406016	CID	0	8	C007789	72	84	D020141	true
Relation: 10406016	CID	0	8	C007789	97	106	D006406	false
Relation: 10406016	CID	0	8	C007789	132	144	D007249	false
Relation: 10406016	CID	0	8	C007789	168	176	D006406	false

Sentence: Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.
Entity: 3403780	0	11	Paracetamol	Chemical	D000082
Entity: 3403780	23	27	coma	Disease	D003128
Entity: 3403780	29	47	metabolic acidosis	Disease	D000138
Entity: 3403780	49	54	renal	Disease	D058186
Entity: 3403780	59	66	hepatic	Disease	D017093
Relation: 3403780	CID	0	11	D000082	23	27	D003128	false
Relation: 3403780	CID	0	11	D000082	29	47	D000138	true
Relation: 3403780	CID	0	11	D000082	49	54	D058186	true
Relation: 3403780	CID	0	11	D000082	59	66	D017093	false

Sentence: In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis.
Entity: 3101906	20	26	deaths	Disease	D003643
Entity: 3101906	52	64	ketoconazole	Chemical	D007654
Entity: 3101906	122	130	jaundice	Disease	D007565
Entity: 3101906	153	162	hepatitis	Disease	D056486
Relation: 3101906	CID	52	64	D007654	20	26	D003643	false
Relation: 3101906	CID	52	64	D007654	122	130	D007565	true
Relation: 3101906	CID	52	64	D007654	153	162	D056486	true

Sentence: Combined effects of prolonged prostaglandin E1 induced hypotension and haemodilution on human hepatic function.
Entity: 9088814	30	46	prostaglandin E1	Chemical	D000527
Entity: 9088814	55	66	hypotension	Disease	D007022
Entity: 9088814	71	84	haemodilution	Disease	D020141
Relation: 9088814	CID	30	46	D000527	55	66	D007022	true
Relation: 9088814	CID	30	46	D000527	71	84	D020141	false

Sentence: Combined effects of prolonged prostaglandin E1 (PGE1) induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.
Entity: 9088814	30	46	prostaglandin E1	Chemical	D000527
Entity: 9088814	48	52	PGE1	Chemical	D000527
Entity: 9088814	62	73	hypotension	Disease	D007022
Entity: 9088814	78	91	haemodilution	Disease	D020141
Relation: 9088814	CID	30	46	D000527	62	73	D007022	true
Relation: 9088814	CID	30	46	D000527	78	91	D020141	false
Relation: 9088814	CID	48	52	D000527	62	73	D007022	true
Relation: 9088814	CID	48	52	D000527	78	91	D020141	false

Sentence: Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution, and final haematocrit values were 21 or 22%.
Entity: 9088814	0	13	Haemodilution	Disease	D020141
Entity: 9088814	132	139	dextran	Chemical	D003911
Relation: 9088814	CID	132	139	D003911	0	13	D020141	false

Sentence: Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.
Entity: 9088814	11	22	hypotension	Disease	D007022
Entity: 9088814	58	62	PGE1	Chemical	D000527
Relation: 9088814	CID	58	62	D000527	11	22	D007022	true

Sentence: In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.
Entity: 9088814	106	117	hypotension	Disease	D007022
Entity: 9088814	201	210	bilirubin	Chemical	D001663
Relation: 9088814	CID	201	210	D001663	106	117	D007022	false

Sentence: Levodopa induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.
Entity: 20880751	0	8	Levodopa	Chemical	D007980
Entity: 20880751	17	28	dyskinesias	Disease	D004409
Entity: 20880751	46	65	Parkinson's disease	Disease	D010300
Relation: 20880751	CID	0	8	D007980	17	28	D004409	true
Relation: 20880751	CID	0	8	D007980	46	65	D010300	false

Sentence: Levodopa is the most effective drug for the treatment of Parkinson's disease.
Entity: 20880751	0	8	Levodopa	Chemical	D007980
Entity: 20880751	57	76	Parkinson's disease	Disease	D010300
Relation: 20880751	CID	0	8	D007980	57	76	D010300	false

Sentence: However, the long-term use of this dopamine precursor is complicated by highly disabling fluctuations and dyskinesias.
Entity: 20880751	35	43	dopamine	Chemical	D004298
Entity: 20880751	106	117	dyskinesias	Disease	D004409
Relation: 20880751	CID	35	43	D004298	106	117	D004409	false

Sentence: Although preclinical and clinical findings suggest pulsatile stimulation of striatal postsynaptic receptors as a key mechanism underlying levodopa induced dyskinesias, their pathogenesis is still unclear.
Entity: 20880751	138	146	levodopa	Chemical	D007980
Entity: 20880751	155	166	dyskinesias	Disease	D004409
Relation: 20880751	CID	138	146	D007980	155	166	D004409	true

Sentence: In this study, we investigated the therapeutic potential of bone marrow mononuclear cells (BMCs) in a model of epilepsy induced by pilocarpine in rats.
Entity: 20080419	111	119	epilepsy	Disease	D004827
Entity: 20080419	131	142	pilocarpine	Chemical	D010862
Relation: 20080419	CID	131	142	D010862	111	119	D004827	true

Sentence: Cardioprotective effect of salvianolic acid A on isoproterenol induced myocardial infarction in rats.
Entity: 19445921	27	45	salvianolic acid A	Chemical	C066201
Entity: 19445921	49	62	isoproterenol	Chemical	D007545
Entity: 19445921	71	92	myocardial infarction	Disease	D009203
Relation: 19445921	CID	27	45	C066201	71	92	D009203	false
Relation: 19445921	CID	49	62	D007545	71	92	D009203	true

Sentence: The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol induced myocardial infarction in rats.
Entity: 19445921	77	95	salvianolic acid A	Chemical	C066201
Entity: 19445921	99	112	isoproterenol	Chemical	D007545
Entity: 19445921	121	142	myocardial infarction	Disease	D009203
Relation: 19445921	CID	77	95	C066201	121	142	D009203	false
Relation: 19445921	CID	99	112	D007545	121	142	D009203	true

Sentence: In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats.
Entity: 19445921	27	50	respiratory dysfunction	Disease	D012131
Entity: 19445921	108	111	ADP	Chemical	D000244
Entity: 19445921	130	143	isoproterenol	Chemical	D007545
Relation: 19445921	CID	108	111	D000244	27	50	D012131	false
Relation: 19445921	CID	130	143	D007545	27	50	D012131	false

Sentence: Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.
Entity: 19445921	18	36	salvianolic acid A	Chemical	C066201
Entity: 19445921	85	98	isoproterenol	Chemical	D007545
Entity: 19445921	107	126	cardiac dysfunction	Disease	D006331
Entity: 19445921	131	148	myocardial injury	Disease	D009202
Relation: 19445921	CID	18	36	C066201	107	126	D006331	false
Relation: 19445921	CID	18	36	C066201	131	148	D009202	false
Relation: 19445921	CID	85	98	D007545	107	126	D006331	false
Relation: 19445921	CID	85	98	D007545	131	148	D009202	false

Sentence: The protective role of salvianolic acid A against isoproterenol induced myocardial damage was further confirmed by histopathological examination.
Entity: 19445921	23	41	salvianolic acid A	Chemical	C066201
Entity: 19445921	50	63	isoproterenol	Chemical	D007545
Entity: 19445921	72	89	myocardial damage	Disease	D009202
Relation: 19445921	CID	23	41	C066201	72	89	D009202	false
Relation: 19445921	CID	50	63	D007545	72	89	D009202	false

Sentence: Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine induced seizure in rats.
Entity: 18439803	17	42	N-(2-propylpentanoyl)urea	Chemical	C108761
Entity: 18439803	58	68	amino acid	Chemical	D000596
Entity: 18439803	90	101	pilocarpine	Chemical	D010862
Entity: 18439803	110	117	seizure	Disease	D012640
Relation: 18439803	CID	17	42	C108761	110	117	D012640	false
Relation: 18439803	CID	58	68	D000596	110	117	D012640	false
Relation: 18439803	CID	90	101	D010862	110	117	D012640	true

Sentence: VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine induced seizure whereas the corresponding value for VPA was 322 mg/kg.
Entity: 18439803	0	3	VPU	Chemical	C108761
Entity: 18439803	25	28	VPA	Chemical	D014635
Entity: 18439803	115	126	pilocarpine	Chemical	D010862
Entity: 18439803	135	142	seizure	Disease	D012640
Entity: 18439803	179	182	VPA	Chemical	D014635
Relation: 18439803	CID	0	3	C108761	135	142	D012640	false
Relation: 18439803	CID	25	28	D014635	135	142	D012640	false
Relation: 18439803	CID	115	126	D010862	135	142	D012640	true
Relation: 18439803	CID	179	182	D014635	135	142	D012640	false

Sentence: Based on the finding that VPU and VPA could protect the animals against pilocarpine induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.
Entity: 18439803	26	29	VPU	Chemical	C108761
Entity: 18439803	34	37	VPA	Chemical	D014635
Entity: 18439803	72	83	pilocarpine	Chemical	D010862
Entity: 18439803	92	99	seizure	Disease	D012640
Entity: 18439803	149	159	amino acid	Chemical	D000596
Entity: 18439803	242	251	glutamate	Chemical	D018698
Entity: 18439803	256	265	aspartate	Chemical	D001224
Relation: 18439803	CID	26	29	C108761	92	99	D012640	false
Relation: 18439803	CID	34	37	D014635	92	99	D012640	false
Relation: 18439803	CID	72	83	D010862	92	99	D012640	true
Relation: 18439803	CID	149	159	D000596	92	99	D012640	false
Relation: 18439803	CID	242	251	D018698	92	99	D012640	false
Relation: 18439803	CID	256	265	D001224	92	99	D012640	false

Sentence: Acute hepatitis attack after exposure to telithromycin.
Entity: 17919553	6	15	hepatitis	Disease	D056486
Entity: 17919553	41	54	telithromycin	Chemical	C106791
Relation: 17919553	CID	41	54	C106791	6	15	D056486	true

Sentence: He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior.
Entity: 17919553	23	36	telithromycin	Chemical	C106791
Entity: 17919553	61	94	upper respiratory tract infection	Disease	D012141
Relation: 17919553	CID	23	36	C106791	61	94	D012141	false

Sentence: The patient had suffered a previous episode of "acute hepatitis of unknown origin," that occurred after telithromycin usage.
Entity: 17919553	54	63	hepatitis	Disease	D056486
Entity: 17919553	104	117	telithromycin	Chemical	C106791
Relation: 17919553	CID	104	117	C106791	54	63	D056486	true

Sentence: Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug induced toxic hepatitis.
Entity: 17919553	37	58	adverse drug reaction	Disease	D064420
Entity: 17919553	78	91	telithromycin	Chemical	C106791
Entity: 17919553	124	133	hepatitis	Disease	D056486
Entity: 17919553	200	215	toxic hepatitis	Disease	D056486
Relation: 17919553	CID	78	91	C106791	37	58	D064420	false
Relation: 17919553	CID	78	91	C106791	124	133	D056486	true
Relation: 17919553	CID	78	91	C106791	200	215	D056486	true

Sentence: Recurrence of hepatitis attack might have been avoided if the initial incident had been communicated to the attending physician who prescribed telithromycin the second time.
Entity: 17919553	14	23	hepatitis	Disease	D056486
Entity: 17919553	143	156	telithromycin	Chemical	C106791
Relation: 17919553	CID	143	156	C106791	14	23	D056486	true

Sentence: Spironolactone induced renal insufficiency and hyperkalemia in patients with heart failure.
Entity: 15632880	0	14	Spironolactone	Chemical	D013148
Entity: 15632880	23	42	renal insufficiency	Disease	D051437
Entity: 15632880	47	59	hyperkalemia	Disease	D006947
Entity: 15632880	77	90	heart failure	Disease	D006333
Relation: 15632880	CID	0	14	D013148	23	42	D051437	true
Relation: 15632880	CID	0	14	D013148	47	59	D006947	true
Relation: 15632880	CID	0	14	D013148	77	90	D006333	false

Sentence: BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).
Entity: 15632880	73	87	spironolactone	Chemical	D013148
Entity: 15632880	91	104	heart failure	Disease	D006333
Entity: 15632880	137	149	hyperkalemia	Disease	D006947
Entity: 15632880	159	178	renal insufficiency	Disease	D051437
Relation: 15632880	CID	73	87	D013148	91	104	D006333	false
Relation: 15632880	CID	73	87	D013148	137	149	D006947	true
Relation: 15632880	CID	73	87	D013148	159	178	D051437	true

Sentence: Because treatments for heart failure have changed since the benefits of spironolactone were reported, the prevalence of these complications may differ in current clinical practice.
Entity: 15632880	23	36	heart failure	Disease	D006333
Entity: 15632880	72	86	spironolactone	Chemical	D013148
Relation: 15632880	CID	72	86	D013148	23	36	D006333	false

Sentence: We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.
Entity: 15632880	77	89	hyperkalemia	Disease	D006947
Entity: 15632880	94	113	renal insufficiency	Disease	D051437
Entity: 15632880	117	130	heart failure	Disease	D006333
Entity: 15632880	153	167	spironolactone	Chemical	D013148
Relation: 15632880	CID	153	167	D013148	77	89	D006947	true
Relation: 15632880	CID	153	167	D013148	94	113	D051437	true
Relation: 15632880	CID	153	167	D013148	117	130	D006333	false

Sentence: METHODS: We performed a case control study of heart failure patients treated with spironolactone in our clinical practice.
Entity: 15632880	46	59	heart failure	Disease	D006333
Entity: 15632880	82	96	spironolactone	Chemical	D013148
Relation: 15632880	CID	82	96	D013148	46	59	D006333	false

Sentence: Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.
Entity: 15632880	34	46	hyperkalemia	Disease	D006947
Entity: 15632880	48	49	K	Chemical	D011188
Entity: 15632880	68	87	renal insufficiency	Disease	D051437
Entity: 15632880	89	91	Cr	Chemical	D002857
Relation: 15632880	CID	48	49	D011188	34	46	D006947	false
Relation: 15632880	CID	48	49	D011188	68	87	D051437	false
Relation: 15632880	CID	89	91	D002857	34	46	D006947	false
Relation: 15632880	CID	89	91	D002857	68	87	D051437	false

Sentence: RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).
Entity: 15632880	72	86	spironolactone	Chemical	D013148
Entity: 15632880	94	106	hyperkalemia	Disease	D006947
Entity: 15632880	119	132	renal failure	Disease	D051437
Relation: 15632880	CID	72	86	D013148	94	106	D006947	true
Relation: 15632880	CID	72	86	D013148	119	132	D051437	true

Sentence: Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).
Entity: 15632880	23	35	hyperkalemia	Disease	D006947
Entity: 15632880	71	79	diabetes	Disease	D003920
Entity: 15632880	107	116	potassium	Chemical	D011188
Entity: 15632880	143	152	potassium	Chemical	D011188
Relation: 15632880	CID	107	116	D011188	23	35	D006947	false
Relation: 15632880	CID	107	116	D011188	71	79	D003920	false
Relation: 15632880	CID	143	152	D011188	23	35	D006947	false
Relation: 15632880	CID	143	152	D011188	71	79	D003920	false

Sentence: Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.
Entity: 15632880	23	42	renal insufficiency	Disease	D051437
Entity: 15632880	100	110	creatinine	Chemical	D003404
Entity: 15632880	193	201	thiazide	Chemical	D049971
Relation: 15632880	CID	100	110	D003404	23	42	D051437	false
Relation: 15632880	CID	193	201	D049971	23	42	D051437	false

Sentence: BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.
Entity: 11773892	39	51	cyclosporine	Chemical	D016572
Entity: 11773892	56	66	tacrolimus	Chemical	D016559
Entity: 11773892	88	99	nephrotoxic	Disease	D007674
Relation: 11773892	CID	39	51	D016572	88	99	D007674	true
Relation: 11773892	CID	56	66	D016559	88	99	D007674	true

Sentence: Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.
Entity: 11773892	54	57	CRF	Disease	D007676
Entity: 11773892	61	65	ESRD	Disease	D007676
Entity: 11773892	74	77	CRF	Disease	D007676
Entity: 11773892	95	105	creatinine	Chemical	D003404
Entity: 11773892	128	132	ESRD	Disease	D007676
Relation: 11773892	CID	95	105	D003404	54	57	D007676	false
Relation: 11773892	CID	95	105	D003404	61	65	D007676	false
Relation: 11773892	CID	95	105	D003404	74	77	D007676	false
Relation: 11773892	CID	95	105	D003404	128	132	D007676	false

Sentence: Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.
Entity: 11773892	32	35	CRF	Disease	D007676
Entity: 11773892	40	44	ESRD	Disease	D007676
Entity: 11773892	84	94	creatinine	Chemical	D003404
Entity: 11773892	141	161	hepatorenal syndrome	Disease	D006530
Entity: 11773892	271	281	creatinine	Chemical	D003404
Relation: 11773892	CID	84	94	D003404	32	35	D007676	false
Relation: 11773892	CID	84	94	D003404	40	44	D007676	false
Relation: 11773892	CID	84	94	D003404	141	161	D006530	false
Relation: 11773892	CID	271	281	D003404	32	35	D007676	false
Relation: 11773892	CID	271	281	D003404	40	44	D007676	false
Relation: 11773892	CID	271	281	D003404	141	161	D006530	false

Sentence: Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.
Entity: 11773892	135	145	creatinine	Chemical	D003404
Entity: 11773892	270	273	CRF	Disease	D007676
Entity: 11773892	277	281	ESRD	Disease	D007676
Relation: 11773892	CID	135	145	D003404	270	273	D007676	false
Relation: 11773892	CID	135	145	D003404	277	281	D007676	false

Sentence: Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.
Entity: 11773892	21	25	ESRD	Disease	D007676
Entity: 11773892	70	80	creatinine	Chemical	D003404
Entity: 11773892	109	129	hepatorenal syndrome	Disease	D006530
Relation: 11773892	CID	70	80	D003404	21	25	D007676	false
Relation: 11773892	CID	70	80	D003404	109	129	D006530	false

Sentence: Effect of intravenous nimodipine on blood pressure and outcome after acute stroke.
Entity: 10835440	22	32	nimodipine	Chemical	D009553
Entity: 10835440	69	81	acute stroke	Disease	D020521
Relation: 10835440	CID	22	32	D009553	69	81	D020521	false

Sentence: BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.
Entity: 10835440	40	50	Nimodipine	Chemical	D009553
Entity: 10835440	65	71	Stroke	Disease	D020521
Entity: 10835440	115	125	nimodipine	Chemical	D009553
Entity: 10835440	134	161	reduction in blood pressure	Disease	D007022
Entity: 10835440	197	209	acute stroke	Disease	D020521
Relation: 10835440	CID	40	50	D009553	65	71	D020521	false
Relation: 10835440	CID	40	50	D009553	134	161	D007022	true
Relation: 10835440	CID	40	50	D009553	197	209	D020521	false
Relation: 10835440	CID	115	125	D009553	65	71	D020521	false
Relation: 10835440	CID	115	125	D009553	134	161	D007022	true
Relation: 10835440	CID	115	125	D009553	197	209	D020521	false

Sentence: METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).
Entity: 10835440	47	62	ischemic stroke	Disease	D002544
Entity: 10835440	156	166	nimodipine	Chemical	D009553
Entity: 10835440	198	208	nimodipine	Chemical	D009553
Relation: 10835440	CID	156	166	D009553	47	62	D002544	false
Relation: 10835440	CID	198	208	D009553	47	62	D002544	false

Sentence: Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.
Entity: 10835440	0	10	Nimodipine	Chemical	D009553
Entity: 10835440	61	85	reduction in systolic BP	Disease	D007022
Relation: 10835440	CID	0	10	D009553	61	85	D007022	true

Sentence: CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose nimodipine after acute stroke.
Entity: 10835440	134	144	nimodipine	Chemical	D009553
Entity: 10835440	151	163	acute stroke	Disease	D020521
Relation: 10835440	CID	134	144	D009553	151	163	D020521	false

Sentence: Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.
Entity: 9523805	0	29	Transient neurologic symptoms	Disease	D009422
Entity: 9523805	78	88	prilocaine	Chemical	D011318
Entity: 9523805	93	104	bupivacaine	Chemical	D002045
Entity: 9523805	115	124	lidocaine	Chemical	D008012
Relation: 9523805	CID	78	88	D011318	0	29	D009422	true
Relation: 9523805	CID	93	104	D002045	0	29	D009422	false
Relation: 9523805	CID	115	124	D008012	0	29	D009422	true

Sentence: BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.
Entity: 9523805	42	71	transient neurologic symptoms	Disease	D009422
Entity: 9523805	73	77	TNSs	Disease	D009422
Entity: 9523805	97	106	lidocaine	Chemical	D008012
Entity: 9523805	149	160	bupivacaine	Chemical	D002045
Relation: 9523805	CID	97	106	D008012	42	71	D009422	true
Relation: 9523805	CID	97	106	D008012	73	77	D009422	true
Relation: 9523805	CID	149	160	D002045	42	71	D009422	false
Relation: 9523805	CID	149	160	D002045	73	77	D009422	false

Sentence: Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.
Entity: 9523805	66	76	prilocaine	Chemical	D011318
Entity: 9523805	82	91	lidocaine	Chemical	D008012
Entity: 9523805	96	107	bupivacaine	Chemical	D002045
Entity: 9523805	164	168	TNSs	Disease	D009422
Relation: 9523805	CID	66	76	D011318	164	168	D009422	true
Relation: 9523805	CID	82	91	D008012	164	168	D009422	true
Relation: 9523805	CID	96	107	D002045	164	168	D009422	false

Sentence: RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.
Entity: 9523805	39	48	lidocaine	Chemical	D008012
Entity: 9523805	61	65	TNSs	Disease	D009422
Entity: 9523805	94	104	prilocaine	Chemical	D011318
Entity: 9523805	160	171	bupivacaine	Chemical	D002045
Entity: 9523805	176	180	TNSs	Disease	D009422
Relation: 9523805	CID	39	48	D008012	61	65	D009422	true
Relation: 9523805	CID	39	48	D008012	176	180	D009422	true
Relation: 9523805	CID	94	104	D011318	61	65	D009422	true
Relation: 9523805	CID	94	104	D011318	176	180	D009422	true
Relation: 9523805	CID	160	171	D002045	61	65	D009422	false
Relation: 9523805	CID	160	171	D002045	176	180	D009422	false

Sentence: The role of nicotine in smoking-related cardiovascular disease.
Entity: 9245658	12	20	nicotine	Chemical	D009538
Entity: 9245658	40	62	cardiovascular disease	Disease	D002318
Relation: 9245658	CID	12	20	D009538	40	62	D002318	true

Sentence: Nicotine activates the sympathetic nervous system and in this way could contribute to cardiovascular disease.
Entity: 9245658	0	8	Nicotine	Chemical	D009538
Entity: 9245658	86	108	cardiovascular disease	Disease	D002318
Relation: 9245658	CID	0	8	D009538	86	108	D002318	true

Sentence: Animal studies and mechanistic studies indicate that nicotine could play a role in accelerating atherosclerosis, but evidence among humans is too inadequate to be definitive about such an effect.
Entity: 9245658	53	61	nicotine	Chemical	D009538
Entity: 9245658	96	111	atherosclerosis	Disease	D050197
Relation: 9245658	CID	53	61	D009538	96	111	D050197	true

Sentence: Nicotine does not appear to enhance thrombosis among humans.
Entity: 9245658	0	8	Nicotine	Chemical	D009538
Entity: 9245658	36	46	thrombosis	Disease	D013927
Relation: 9245658	CID	0	8	D009538	36	46	D013927	false

Sentence: Seizure resulting from a venlafaxine overdose.
Entity: 9034419	0	7	Seizure	Disease	D012640
Entity: 9034419	25	36	venlafaxine	Chemical	C047426
Entity: 9034419	37	45	overdose	Disease	D062787
Relation: 9034419	CID	25	36	C047426	0	7	D012640	true
Relation: 9034419	CID	25	36	C047426	37	45	D062787	true

Sentence: OBJECTIVE: To report a case of venlafaxine overdose.
Entity: 9034419	31	42	venlafaxine	Chemical	C047426
Entity: 9034419	43	51	overdose	Disease	D062787
Relation: 9034419	CID	31	42	C047426	43	51	D062787	true

Sentence: CASE SUMMARY: A 40-year-old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt.
Entity: 9034419	39	55	major depression	Disease	D003865
Entity: 9034419	64	72	overdose	Disease	D062787
Entity: 9034419	76	87	venlafaxine	Chemical	C047426
Relation: 9034419	CID	76	87	C047426	39	55	D003865	false
Relation: 9034419	CID	76	87	C047426	64	72	D062787	true

Sentence: After the ingestion of 26 venlafaxine 50-mg tablets, the patient experienced a witnessed generalized seizure.
Entity: 9034419	26	37	venlafaxine	Chemical	C047426
Entity: 9034419	101	108	seizure	Disease	D012640
Relation: 9034419	CID	26	37	C047426	101	108	D012640	true

Sentence: DISCUSSION: To our knowledge, this is the first reported case of venlafaxine overdose that resulted in a generalized seizure.
Entity: 9034419	65	76	venlafaxine	Chemical	C047426
Entity: 9034419	77	85	overdose	Disease	D062787
Entity: 9034419	117	124	seizure	Disease	D012640
Relation: 9034419	CID	65	76	C047426	77	85	D062787	true
Relation: 9034419	CID	65	76	C047426	117	124	D012640	true

Sentence: Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group comprising hypertensive patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine.
Entity: 8829025	33	43	tacrolimus	Chemical	D016559
Entity: 8829025	104	116	hypertensive	Disease	D006973
Entity: 8829025	145	155	nifedipine	Chemical	D009543
Entity: 8829025	221	231	nifedipine	Chemical	D009543
Relation: 8829025	CID	33	43	D016559	104	116	D006973	true
Relation: 8829025	CID	145	155	D009543	104	116	D006973	false
Relation: 8829025	CID	221	231	D009543	104	116	D006973	false

Sentence: Sinus arrest associated with continuous-infusion cimetidine.
Entity: 8437969	0	12	Sinus arrest	Disease	D054138
Entity: 8437969	49	59	cimetidine	Chemical	D002927
Relation: 8437969	CID	49	59	D002927	0	12	D054138	true

Sentence: The administration of intermittent intravenous infusions of cimetidine is infrequently associated with the development of bradyarrhythmias.
Entity: 8437969	60	70	cimetidine	Chemical	D002927
Entity: 8437969	122	138	bradyarrhythmias	Disease	D001919
Relation: 8437969	CID	60	70	D002927	122	138	D001919	true

Sentence: A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.
Entity: 8437969	23	31	leukemia	Disease	D007938
Entity: 8437969	50	65	cardiac disease	Disease	D006331
Entity: 8437969	114	126	sinus arrest	Disease	D054138
Entity: 8437969	163	173	cimetidine	Chemical	D002927
Relation: 8437969	CID	163	173	D002927	23	31	D007938	false
Relation: 8437969	CID	163	173	D002927	50	65	D006331	false
Relation: 8437969	CID	163	173	D002927	114	126	D054138	true

Sentence: The arrhythmias were temporally related to cimetidine administration, disappeared after dechallenge, and did not recur during ranitidine treatment.
Entity: 8437969	4	15	arrhythmias	Disease	D001145
Entity: 8437969	43	53	cimetidine	Chemical	D002927
Entity: 8437969	126	136	ranitidine	Chemical	D011899
Relation: 8437969	CID	43	53	D002927	4	15	D001145	false
Relation: 8437969	CID	126	136	D011899	4	15	D001145	false

Sentence: Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.
Entity: 7890216	15	34	gall bladder stones	Disease	D042882
Entity: 7890216	51	61	octreotide	Chemical	D015282
Entity: 7890216	80	100	ursodeoxycholic acid	Chemical	D014580
Relation: 7890216	CID	51	61	D015282	15	34	D042882	true
Relation: 7890216	CID	80	100	D014580	15	34	D042882	false

Sentence: Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients.
Entity: 7890216	0	10	Octreotide	Chemical	D015282
Entity: 7890216	39	49	acromegaly	Disease	D000172
Entity: 7890216	59	78	gall bladder stones	Disease	D042882
Relation: 7890216	CID	0	10	D015282	39	49	D000172	false
Relation: 7890216	CID	0	10	D015282	59	78	D042882	true

Sentence: Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.
Entity: 7890216	173	183	octreotide	Chemical	D015282
Entity: 7890216	192	203	acromegalic	Disease	D000172
Entity: 7890216	218	229	gall stones	Disease	D042882
Relation: 7890216	CID	173	183	D015282	192	203	D000172	false
Relation: 7890216	CID	173	183	D015282	218	229	D042882	true

Sentence: Chemical analysis of gall stones retrieved at cholecystectomy from two patients, showed that they contained 71% and 87% cholesterol by weight.
Entity: 7890216	21	32	gall stones	Disease	D042882
Entity: 7890216	120	131	cholesterol	Chemical	D002784
Relation: 7890216	CID	120	131	D002784	21	32	D042882	false

Sentence: After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.
Entity: 7890216	115	125	gall stone	Disease	D042882
Entity: 7890216	173	184	cholesterol	Chemical	D002784
Relation: 7890216	CID	173	184	D002784	115	125	D042882	false

Sentence: Cardiovascular complications associated with terbutaline treatment for preterm labor.
Entity: 7468724	0	28	Cardiovascular complications	Disease	D002318
Entity: 7468724	45	56	terbutaline	Chemical	D013726
Entity: 7468724	71	84	preterm labor	Disease	D007752
Relation: 7468724	CID	45	56	D013726	0	28	D002318	true
Relation: 7468724	CID	45	56	D013726	71	84	D007752	false

Sentence: Of the 20 animals that received subarachnoid injection of 2-chloroprocaine-CE seven (35%) developed hind-limb paralysis.
Entity: 7199841	58	77	2-chloroprocaine-CE	Chemical	C004616
Entity: 7199841	110	119	paralysis	Disease	D010243
Relation: 7199841	CID	58	77	C004616	110	119	D010243	true

Sentence: None of the animals that received bupivacaine, normal saline, or normal saline titrated to a pH 3.0 developed hind-limb paralysis.
Entity: 7199841	34	45	bupivacaine	Chemical	D002045
Entity: 7199841	120	129	paralysis	Disease	D010243
Relation: 7199841	CID	34	45	D002045	120	129	D010243	false

Sentence: Of the 15 spinal cords of the animals that received 2-chloroprocaine-CE, 13 showed subpial necrosis; the nerve roots and subarachnoid vessels were normal.
Entity: 7199841	52	71	2-chloroprocaine-CE	Chemical	C004616
Entity: 7199841	83	99	subpial necrosis	Disease	D013118
Relation: 7199841	CID	52	71	C004616	83	99	D013118	true

Sentence: Early adjuvant adriamycin in superficial bladder carcinoma.
Entity: 6640832	15	25	adriamycin	Chemical	D004317
Entity: 6640832	41	48	bladder	Disease	D001749
Entity: 6640832	49	58	carcinoma	Disease	D002277
Relation: 6640832	CID	15	25	D004317	41	48	D001749	false
Relation: 6640832	CID	15	25	D004317	49	58	D002277	false

Sentence: Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.
Entity: 6640832	0	10	Adriamycin	Chemical	D004317
Entity: 6640832	114	128	bladder tumors	Disease	D001749
Relation: 6640832	CID	0	10	D004317	114	128	D001749	false

Sentence: Hyperkalemia associated with sulindac therapy.
Entity: 3560096	0	12	Hyperkalemia	Disease	D006947
Entity: 3560096	29	37	sulindac	Chemical	D013467
Relation: 3560096	CID	29	37	D013467	0	12	D006947	true

Sentence: Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents (NSAID) such as indomethacin.
Entity: 3560096	0	12	Hyperkalemia	Disease	D006947
Entity: 3560096	116	128	indomethacin	Chemical	D007213
Relation: 3560096	CID	116	128	D007213	0	12	D006947	true

Sentence: We describe 4 patients in whom hyperkalemia ranging from 6.1 to 6.9 mEq/l developed within 3 to 8 days of sulindac administration.
Entity: 3560096	31	43	hyperkalemia	Disease	D006947
Entity: 3560096	106	114	sulindac	Chemical	D013467
Relation: 3560096	CID	106	114	D013467	31	43	D006947	true

Sentence: As no other medications known to effect serum potassium had been given concomitantly, this course of events is suggestive of a cause-and-effect relationship between sulindac and hyperkalemia.
Entity: 3560096	46	55	potassium	Chemical	D011188
Entity: 3560096	165	173	sulindac	Chemical	D013467
Entity: 3560096	178	190	hyperkalemia	Disease	D006947
Relation: 3560096	CID	46	55	D011188	178	190	D006947	false
Relation: 3560096	CID	165	173	D013467	178	190	D006947	true

Sentence: Ventricular tachyarrhythmias during cesarean section after ritodrine therapy: interaction with anesthetics.
Entity: 3358181	0	28	Ventricular tachyarrhythmias	Disease	D014693
Entity: 3358181	59	68	ritodrine	Chemical	D012312
Relation: 3358181	CID	59	68	D012312	0	28	D014693	true

Sentence: This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.
Entity: 3358181	46	55	ritodrine	Chemical	D012312
Entity: 3358181	60	73	preterm labor	Disease	D007752
Entity: 3358181	140	149	ritodrine	Chemical	D012312
Relation: 3358181	CID	46	55	D012312	60	73	D007752	false
Relation: 3358181	CID	140	149	D012312	60	73	D007752	false

Sentence: Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine.
Entity: 3358181	40	68	cardiovascular complications	Disease	D002318
Entity: 3358181	108	117	ritodrine	Chemical	D012312
Relation: 3358181	CID	108	117	D012312	40	68	D002318	false

Sentence: Immunohistochemical, electron microscopic and morphometric studies of estrogen induced rat prolactinomas after bromocriptine treatment.
Entity: 2887062	70	78	estrogen	Chemical	D004967
Entity: 2887062	91	104	prolactinomas	Disease	D015175
Entity: 2887062	111	124	bromocriptine	Chemical	D001971
Relation: 2887062	CID	70	78	D004967	91	104	D015175	true
Relation: 2887062	CID	111	124	D001971	91	104	D015175	false

Sentence: To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).
Entity: 2887062	26	39	bromocriptine	Chemical	D001971
Entity: 2887062	43	55	prolactinoma	Disease	D015175
Entity: 2887062	152	160	estrogen	Chemical	D004967
Entity: 2887062	173	185	prolactinoma	Disease	D015175
Entity: 2887062	223	236	bromocriptine	Chemical	D001971
Relation: 2887062	CID	26	39	D001971	43	55	D015175	false
Relation: 2887062	CID	26	39	D001971	173	185	D015175	false
Relation: 2887062	CID	152	160	D004967	43	55	D015175	true
Relation: 2887062	CID	152	160	D004967	173	185	D015175	true
Relation: 2887062	CID	223	236	D001971	43	55	D015175	false
Relation: 2887062	CID	223	236	D001971	173	185	D015175	false

Sentence: However, only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells.
Entity: 2887062	95	108	bromocriptine	Chemical	D001971
Entity: 2887062	126	133	adenoma	Disease	D000236
Relation: 2887062	CID	95	108	D001971	126	133	D000236	false

Sentence: Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.
Entity: 2425813	0	17	Liver enlargement	Disease	D006529
Entity: 2425813	22	36	muscle wastage	Disease	D009133
Entity: 2425813	106	118	prednisolone	Chemical	D011239
Relation: 2425813	CID	106	118	D011239	0	17	D006529	true
Relation: 2425813	CID	106	118	D011239	22	36	D009133	true

Sentence: Possible intramuscular midazolam-associated cardiorespiratory arrest and death.
Entity: 2375138	23	32	midazolam	Chemical	D008874
Entity: 2375138	44	68	cardiorespiratory arrest	Disease	D006323
Entity: 2375138	73	78	death	Disease	D003643
Relation: 2375138	CID	23	32	D008874	44	68	D006323	true
Relation: 2375138	CID	23	32	D008874	73	78	D003643	false

Sentence: This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of midazolam.
Entity: 2375138	50	74	cardiorespiratory arrest	Disease	D006323
Entity: 2375138	79	84	death	Disease	D003643
Entity: 2375138	133	142	midazolam	Chemical	D008874
Relation: 2375138	CID	133	142	D008874	50	74	D006323	true
Relation: 2375138	CID	133	142	D008874	79	84	D003643	false

Sentence: Serial epilepsy caused by levodopa/carbidopa administration in two patients on hemodialysis.
Entity: 2265898	7	15	epilepsy	Disease	D004827
Entity: 2265898	26	44	levodopa/carbidopa	Chemical	C009265
Relation: 2265898	CID	26	44	C009265	7	15	D004827	true

Sentence: Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.
Entity: 2265898	77	98	chronic renal failure	Disease	D007676
Entity: 2265898	201	219	carbidopa/levodopa	Chemical	C009265
Entity: 2265898	259	271	hallucinosis	Disease	D001523
Entity: 2265898	286	294	seizures	Disease	D012640
Relation: 2265898	CID	201	219	C009265	77	98	D007676	false
Relation: 2265898	CID	201	219	C009265	259	271	D001523	false
Relation: 2265898	CID	201	219	C009265	286	294	D012640	false

Sentence: Effect of L-alpha-glyceryl-phosphorylcholine on amnesia caused by scopolamine.
Entity: 2071257	10	44	L-alpha-glyceryl-phosphorylcholine	Chemical	D005997
Entity: 2071257	48	55	amnesia	Disease	D000647
Entity: 2071257	66	77	scopolamine	Chemical	D012601
Relation: 2071257	CID	10	44	D005997	48	55	D000647	false
Relation: 2071257	CID	66	77	D012601	48	55	D000647	false

Sentence: The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine (L-alpha-GFC) on memory impairment induced by scopolamine in man.
Entity: 2071257	57	90	L-alpha-glycerylphosphorylcholine	Chemical	D005997
Entity: 2071257	92	103	L-alpha-GFC	Chemical	D005997
Entity: 2071257	108	125	memory impairment	Disease	D008569
Entity: 2071257	137	148	scopolamine	Chemical	D012601
Relation: 2071257	CID	57	90	D005997	108	125	D008569	false
Relation: 2071257	CID	92	103	D005997	108	125	D008569	false
Relation: 2071257	CID	137	148	D012601	108	125	D008569	true

Sentence: Seizures induced by the cocaine metabolite benzoylecgonine in rats.
Entity: 1592014	0	8	Seizures	Disease	D012640
Entity: 1592014	24	31	cocaine	Chemical	D003042
Entity: 1592014	43	58	benzoylecgonine	Chemical	C005618
Relation: 1592014	CID	24	31	D003042	0	8	D012640	true
Relation: 1592014	CID	43	58	C005618	0	8	D012640	true

Sentence: The half-life (t1/2) of cocaine is relatively short, but some of the consequences of its use, such as seizures and strokes, can occur hours after exposure.
Entity: 1592014	24	31	cocaine	Chemical	D003042
Entity: 1592014	102	110	seizures	Disease	D012640
Entity: 1592014	115	122	strokes	Disease	D020521
Relation: 1592014	CID	24	31	D003042	102	110	D012640	true
Relation: 1592014	CID	24	31	D003042	115	122	D020521	false

Sentence: We evaluated the potential of the major metabolite of cocaine, benzoylecgonine (BE), to cause seizures.
Entity: 1592014	54	61	cocaine	Chemical	D003042
Entity: 1592014	63	78	benzoylecgonine	Chemical	C005618
Entity: 1592014	80	82	BE	Chemical	C005618
Entity: 1592014	94	102	seizures	Disease	D012640
Relation: 1592014	CID	54	61	D003042	94	102	D012640	true
Relation: 1592014	CID	63	78	C005618	94	102	D012640	true
Relation: 1592014	CID	80	82	C005618	94	102	D012640	true

Sentence: BE-Induced seizures occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of cocaine.
Entity: 1592014	0	2	BE	Chemical	C005618
Entity: 1592014	11	19	seizures	Disease	D012640
Entity: 1592014	127	134	cocaine	Chemical	D003042
Relation: 1592014	CID	0	2	C005618	11	19	D012640	true
Relation: 1592014	CID	127	134	D003042	11	19	D012640	true

Sentence: Whereas cocaine induced seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.
Entity: 1592014	8	15	cocaine	Chemical	D003042
Entity: 1592014	24	32	seizures	Disease	D012640
Entity: 1592014	106	111	death	Disease	D003643
Entity: 1592014	130	132	BE	Chemical	C005618
Entity: 1592014	206	211	death	Disease	D003643
Relation: 1592014	CID	8	15	D003042	24	32	D012640	true
Relation: 1592014	CID	8	15	D003042	106	111	D003643	false
Relation: 1592014	CID	8	15	D003042	206	211	D003643	false
Relation: 1592014	CID	130	132	C005618	24	32	D012640	true
Relation: 1592014	CID	130	132	C005618	106	111	D003643	false
Relation: 1592014	CID	130	132	C005618	206	211	D003643	false

Sentence: BE-Injected rats that did not have seizures had significantly more locomotor activity than cocaine-injected animals without seizures.
Entity: 1592014	0	2	BE	Chemical	C005618
Entity: 1592014	35	43	seizures	Disease	D012640
Entity: 1592014	91	98	cocaine	Chemical	D003042
Entity: 1592014	124	132	seizures	Disease	D012640
Relation: 1592014	CID	0	2	C005618	35	43	D012640	true
Relation: 1592014	CID	0	2	C005618	124	132	D012640	true
Relation: 1592014	CID	91	98	D003042	35	43	D012640	true
Relation: 1592014	CID	91	98	D003042	124	132	D012640	true

Sentence: Protection against amphetamine induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.
Entity: 1436384	19	30	amphetamine	Chemical	D000661
Entity: 1436384	39	52	neurotoxicity	Disease	D020258
Entity: 1436384	69	77	dopamine	Chemical	D004298
Entity: 1436384	100	108	LY274614	Chemical	C070935
Entity: 1436384	124	134	amino acid	Chemical	D000596
Relation: 1436384	CID	19	30	D000661	39	52	D020258	true
Relation: 1436384	CID	69	77	D004298	39	52	D020258	false
Relation: 1436384	CID	100	108	C070935	39	52	D020258	false
Relation: 1436384	CID	124	134	D000596	39	52	D020258	false

Sentence: Neonatal pyridoxine responsive convulsions due to isoniazid therapy.
Entity: 1085609	9	19	pyridoxine	Chemical	D011736
Entity: 1085609	31	42	convulsions	Disease	D012640
Entity: 1085609	50	59	isoniazid	Chemical	D007538
Relation: 1085609	CID	9	19	D011736	31	42	D012640	false
Relation: 1085609	CID	50	59	D007538	31	42	D012640	true

Sentence: A 17-day-old infant on isoniazid therapy 13 mg/kg daily from birth because of maternal tuberculosis was admitted after 4 days of clonic fits.
Entity: 1085609	23	32	isoniazid	Chemical	D007538
Entity: 1085609	87	99	tuberculosis	Disease	D014376
Entity: 1085609	129	140	clonic fits	Disease	D012640
Relation: 1085609	CID	23	32	D007538	87	99	D014376	false
Relation: 1085609	CID	23	32	D007538	129	140	D012640	true

Sentence: Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with acute myocardial infarction.
Entity: 809711	12	25	phenylephrine	Chemical	D010656
Entity: 809711	67	80	nitroglycerin	Chemical	D005996
Entity: 809711	98	125	acute myocardial infarction	Disease	D009203
Relation: 809711	CID	12	25	D010656	98	125	D009203	false
Relation: 809711	CID	67	80	D005996	98	125	D009203	false

Sentence: Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin induced hypotension.
Entity: 809711	0	13	Nitroglycerin	Chemical	D005996
Entity: 809711	67	94	acute myocardial infarction	Disease	D009203
Entity: 809711	152	165	nitroglycerin	Chemical	D005996
Entity: 809711	174	185	hypotension	Disease	D007022
Relation: 809711	CID	0	13	D005996	67	94	D009203	false
Relation: 809711	CID	0	13	D005996	174	185	D007022	true
Relation: 809711	CID	152	165	D005996	67	94	D009203	false
Relation: 809711	CID	152	165	D005996	174	185	D007022	true

Sentence: Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.
Entity: 809711	35	57	myocardial infarctions	Disease	D009203
Entity: 809711	79	92	nitroglycerin	Chemical	D005996
Relation: 809711	CID	79	92	D005996	35	57	D009203	false

Sentence: Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2 induced thoracic aortic aneurysm in a rat model.
Entity: 20621845	89	94	CaCl2	Chemical	D002122
Entity: 20621845	103	127	thoracic aortic aneurysm	Disease	D017545
Relation: 20621845	CID	89	94	D002122	103	127	D017545	true

Sentence: PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2)) induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.
Entity: 20621845	61	85	thoracic aortic aneurysm	Disease	D017545
Entity: 20621845	87	90	TAA	Disease	D017545
Entity: 20621845	95	111	calcium chloride	Chemical	D002122
Entity: 20621845	113	120	CaCl(2)	Chemical	D002122
Entity: 20621845	130	145	arterial injury	Disease	D014652
Entity: 20621845	303	306	TAA	Disease	D017545
Relation: 20621845	CID	95	111	D002122	61	85	D017545	true
Relation: 20621845	CID	95	111	D002122	87	90	D017545	true
Relation: 20621845	CID	95	111	D002122	130	145	D014652	false
Relation: 20621845	CID	95	111	D002122	303	306	D017545	true
Relation: 20621845	CID	113	120	D002122	61	85	D017545	true
Relation: 20621845	CID	113	120	D002122	87	90	D017545	true
Relation: 20621845	CID	113	120	D002122	130	145	D014652	false
Relation: 20621845	CID	113	120	D002122	303	306	D017545	true

Sentence: However, a bolus of epinephrine injected through an alternative catheter provoked a hypertensive crisis.
Entity: 19843802	20	31	epinephrine	Chemical	D004837
Entity: 19843802	84	96	hypertensive	Disease	D006973
Relation: 19843802	CID	20	31	D004837	84	96	D006973	true

Sentence: Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.
Entity: 19473225	10	19	glutamate	Chemical	D018698
Entity: 19473225	62	86	peripheral neurotoxicity	Disease	D010523
Entity: 19473225	90	100	paclitaxel	Chemical	D017239
Relation: 19473225	CID	10	19	D018698	62	86	D010523	false
Relation: 19473225	CID	90	100	D017239	62	86	D010523	true

Sentence: Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.
Entity: 19473225	6	27	peripheral neuropathy	Disease	D010523
Entity: 19473225	89	99	paclitaxel	Chemical	D017239
Entity: 19473225	101	104	PAC	Chemical	D017239
Entity: 19473225	116	125	glutamate	Chemical	D018698
Entity: 19473225	150	160	amino acid	Chemical	D000596
Entity: 19473225	161	170	glutamine	Chemical	D018698
Entity: 19473225	198	201	PAC	Chemical	D017239
Entity: 19473225	202	215	neurotoxicity	Disease	D020258
Relation: 19473225	CID	89	99	D017239	6	27	D010523	true
Relation: 19473225	CID	89	99	D017239	202	215	D020258	false
Relation: 19473225	CID	101	104	D017239	6	27	D010523	true
Relation: 19473225	CID	101	104	D017239	202	215	D020258	false
Relation: 19473225	CID	116	125	D018698	6	27	D010523	false
Relation: 19473225	CID	116	125	D018698	202	215	D020258	false
Relation: 19473225	CID	150	160	D000596	6	27	D010523	false
Relation: 19473225	CID	150	160	D000596	202	215	D020258	false
Relation: 19473225	CID	161	170	D018698	6	27	D010523	false
Relation: 19473225	CID	161	170	D018698	202	215	D020258	false
Relation: 19473225	CID	198	201	D017239	6	27	D010523	true
Relation: 19473225	CID	198	201	D017239	202	215	D020258	false

Sentence: This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC induced peripheral neuropathy in a randomized, placebo-controlled, double-blinded clinical and electro-diagnostic study.
Entity: 19473225	47	56	glutamate	Chemical	D018698
Entity: 19473225	88	91	PAC	Chemical	D017239
Entity: 19473225	100	121	peripheral neuropathy	Disease	D010523
Relation: 19473225	CID	47	56	D018698	100	121	D010523	false
Relation: 19473225	CID	88	91	D017239	100	121	D010523	true

Sentence: Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).
Entity: 19473225	12	26	ovarian cancer	Disease	D010051
Entity: 19473225	97	100	PAC	Chemical	D017239
Entity: 19473225	149	158	glutamate	Chemical	D018698
Relation: 19473225	CID	97	100	D017239	12	26	D010051	false
Relation: 19473225	CID	149	158	D018698	12	26	D010051	false

Sentence: Attentional modulation of perceived pain intensity in capsaicin induced secondary hyperalgesia.
Entity: 19387625	36	40	pain	Disease	D010146
Entity: 19387625	54	63	capsaicin	Chemical	D002211
Entity: 19387625	82	94	hyperalgesia	Disease	D006930
Relation: 19387625	CID	54	63	D002211	36	40	D010146	false
Relation: 19387625	CID	54	63	D002211	82	94	D006930	true

Sentence: However, it is not known that how pain intensity ratings are affected by attention in capsaicin induced secondary hyperalgesia.
Entity: 19387625	34	38	pain	Disease	D010146
Entity: 19387625	86	95	capsaicin	Chemical	D002211
Entity: 19387625	114	126	hyperalgesia	Disease	D006930
Relation: 19387625	CID	86	95	D002211	34	38	D010146	false
Relation: 19387625	CID	86	95	D002211	114	126	D006930	true

Sentence: Furthermore, it was found that the magnitude of attentional modulation in secondary hyperalgesia is very similar to that of capsaicin-untreated, control condition.
Entity: 19387625	84	96	hyperalgesia	Disease	D006930
Entity: 19387625	124	133	capsaicin	Chemical	D002211
Relation: 19387625	CID	124	133	D002211	84	96	D006930	true

Sentence: Testosterone-dependent hypertension and upregulation of intrarenal angiotensinogen in Dahl salt-sensitive rats.
Entity: 19211690	0	12	Testosterone	Chemical	D013739	
Entity: 19211690	23	35	hypertension	Disease	D006973	
Entity: 19211690	91	95	salt	Chemical	D017673	
Relation: 19211690	CID	0	12	D013739	23	35	D006973	false
Relation: 19211690	CID	91	95	D017673	23	35	D006973	false

Sentence: In this study, the hypothesis was tested that there is a sexual dimorphism in HS induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury.
Entity: 19211690	144	156	testosterone	Chemical	D013739	
Entity: 19211690	194	206	renal injury	Disease	D007674	
Relation: 19211690	CID	144	156	D013739	194	206	D007674	false

Sentence: Testosterone replacement in castrated DS rats increased BP, renal injury, and upregulation of renal angiotensinogen associated with HS diet.
Entity: 19211690	0	12	Testosterone	Chemical	D013739	
Entity: 19211690	60	72	renal injury	Disease	D007674	
Relation: 19211690	CID	0	12	D013739	60	72	D007674		false

Sentence: No changes in haloperidol induced catalepsy or MK-801 induced locomotion were seen following PD.
Entity: 18703024	14	25	haloperidol	Chemical	D006220
Entity: 18703024	34	43	catalepsy	Disease	D002375
Entity: 18703024	47	53	MK-801	Chemical	D016291
Relation: 18703024	CID	14	25	D006220	34	43	D002375	true
Relation: 18703024	CID	47	53	D016291	34	43	D002375	false

Sentence: Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.
Entity: 18631865	120	129	rapamycin	Chemical	D020123
Entity: 18631865	160	169	sirolimus	Chemical	D020123
Entity: 18631865	207	236	chronic allograft nephropathy	Disease	D051436
Relation: 18631865	CID	120	129	D020123	207	236	D051436	false
Relation: 18631865	CID	160	169	D020123	207	236	D051436	false

Sentence: Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.
Entity: 18631865	8	19	proteinuria	Disease	D011507
Entity: 18631865	31	40	sirolimus	Chemical	D020123
Entity: 18631865	135	146	proteinuria	Disease	D011507
Entity: 18631865	172	181	sirolimus	Chemical	D020123
Entity: 18631865	244	253	sirolimus	Chemical	D020123
Relation: 18631865	CID	31	40	D020123	8	19	D011507	true
Relation: 18631865	CID	31	40	D020123	135	146	D011507	true
Relation: 18631865	CID	172	181	D020123	8	19	D011507	true
Relation: 18631865	CID	172	181	D020123	135	146	D011507	true
Relation: 18631865	CID	244	253	D020123	8	19	D011507	true
Relation: 18631865	CID	244	253	D020123	135	146	D011507	true

Sentence: Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.
Entity: 18162529	42	58	ribonucleic acid	Chemical	D012313
Entity: 18162529	92	110	hyperprolactinemic	Disease	D006966
Entity: 18162529	182	191	estradiol	Chemical	D004958
Relation: 18162529	CID	42	58	D012313	92	110	D006966	false
Relation: 18162529	CID	182	191	D004958	92	110	D006966	false

Sentence: We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the estrogen induced LH surge.
Entity: 18162529	32	50	hyperprolactinemia	Disease	D006966
Entity: 18162529	154	162	estrogen	Chemical	D004967
Relation: 18162529	CID	154	162	D004967	32	50	D006966	false

Sentence: Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.
Entity: 18162529	8	26	hyperprolactinemia	Disease	D006966
Entity: 18162529	42	50	dopamine	Chemical	D004298
Entity: 18162529	62	71	sulpiride	Chemical	D013469
Entity: 18162529	188	197	estradiol	Chemical	D004958
Relation: 18162529	CID	42	50	D004298	8	26	D006966	false
Relation: 18162529	CID	62	71	D013469	8	26	D006966	true
Relation: 18162529	CID	188	197	D004958	8	26	D006966	false

Sentence: These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid-dependent manner.
Entity: 18162529	66	84	hyperprolactinemia	Disease	D006966
Entity: 18162529	90	97	steroid	Chemical	D013256
Relation: 18162529	CID	90	97	D013256	66	84	D006966	false

Sentence: We have previously demonstrated that ritonavir treatment increases atherosclerotic lesion formation in male mice to a greater extent than in female mice.
Entity: 17879945	37	46	ritonavir	Chemical	D019438
Entity: 17879945	67	89	atherosclerotic lesion	Disease	D050197
Relation: 17879945	CID	37	46	D019438	67	89	D050197	true

Sentence: A comparable overexpression of Pgp in the BBB was obtained after pilocarpine induced seizures in wild-type Wistar rats.
Entity: 17437408	65	76	pilocarpine	Chemical	D010862
Entity: 17437408	85	93	seizures	Disease	D012640
Relation: 17437408	CID	65	76	D010862	85	93	D012640	true

Sentence: QTLs for susceptibility to pilocarpine induced seizures, a model of temporal lobe epilepsy, have not been reported, and CSS have not previously been used to localize seizure susceptibility genes.
Entity: 17242861	27	38	pilocarpine	Chemical	D010862
Entity: 17242861	47	55	seizures	Disease	D012640
Entity: 17242861	68	90	temporal lobe epilepsy	Disease	D004833
Entity: 17242861	166	173	seizure	Disease	D012640
Relation: 17242861	CID	27	38	D010862	47	55	D012640	false
Relation: 17242861	CID	27	38	D010862	68	90	D004833	true
Relation: 17242861	CID	27	38	D010862	166	173	D012640	false

Sentence: We report QTLs identified using a B6 (host) x A/J (donor) CSS panel to localize genes involved in susceptibility to pilocarpine induced seizures.
Entity: 17242861	116	127	pilocarpine	Chemical	D010862
Entity: 17242861	136	144	seizures	Disease	D012640
Relation: 17242861	CID	116	127	D010862	136	144	D012640	false

Sentence: Three hundred fifty-five adult male CSS mice, 58 B6, and 39 A/J were tested for susceptibility to pilocarpine induced seizures.
Entity: 17242861	98	109	pilocarpine	Chemical	D010862
Entity: 17242861	118	126	seizures	Disease	D012640
Relation: 17242861	CID	98	109	D010862	118	126	D012640	false

Sentence: Investigation of mitochondrial involvement in the experimental model of epilepsy induced by pilocarpine.
Entity: 16337777	72	80	epilepsy	Disease	D004827
Entity: 16337777	92	103	pilocarpine	Chemical	D010862
Relation: 16337777	CID	92	103	D010862	72	80	D004827	false

Sentence: In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.
Entity: 16337777	73	91	status epilepticus	Disease	D013226
Entity: 16337777	277	288	pilocarpine	Chemical	D010862
Entity: 16337777	298	320	temporal lobe epilepsy	Disease	D004833
Relation: 16337777	CID	277	288	D010862	73	91	D013226	false
Relation: 16337777	CID	277	288	D010862	298	320	D004833	true

Sentence: Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.
Entity: 15859940	35	47	cyclosporine	Chemical	D016572
Entity: 15859940	49	59	tacrolimus	Chemical	D016559
Entity: 15859940	61	69	toxicity	Disease	D064420
Relation: 15859940	CID	35	47	D016572	61	69	D064420	false
Relation: 15859940	CID	49	59	D016559	61	69	D064420	false

Sentence: We found that the most-frequent cause of thrombotic microangiopathy was drug related, secondary mainly to cyclosporine.
Entity: 15859940	41	67	thrombotic microangiopathy	Disease	D057049
Entity: 15859940	106	118	cyclosporine	Chemical	D016572
Relation: 15859940	CID	106	118	D016572	41	67	D057049	true

Sentence: Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose.
Entity: 15188772	18	69	left ventricular systolic and diastolic dysfunction	Disease	D018487
Entity: 15188772	99	110	epinephrine	Chemical	D004837
Entity: 15188772	111	119	overdose	Disease	D062787
Relation: 15188772	CID	99	110	D004837	18	69	D018487	false
Relation: 15188772	CID	99	110	D004837	111	119	D062787	false

Sentence: Catecholamine induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon.
Entity: 15188772	0	13	Catecholamine	Chemical	D002395
Entity: 15188772	22	36	cardiomyopathy	Disease	D009202
Entity: 15188772	73	87	catecholamines	Chemical	D002395
Relation: 15188772	CID	0	13	D002395	22	36	D009202	false
Relation: 15188772	CID	73	87	D002395	22	36	D009202	false

Sentence: Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.
Entity: 15130900	0	22	Urinary bladder cancer	Disease	D001749
Entity: 15130900	26	50	Wegener's granulomatosis	Disease	D014890
Entity: 15130900	74	90	cyclophosphamide	Chemical	D003520
Relation: 15130900	CID	74	90	D003520	0	22	D001749	true
Relation: 15130900	CID	74	90	D003520	26	50	D014890	false

Sentence: OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.
Entity: 15130900	50	64	bladder cancer	Disease	D001749
Entity: 15130900	86	102	cyclophosphamide	Chemical	D003520
Entity: 15130900	121	145	Wegener's granulomatosis	Disease	D014890
Relation: 15130900	CID	86	102	D003520	50	64	D001749	true
Relation: 15130900	CID	86	102	D003520	121	145	D014890	false

Sentence: Nested within the cohort, a matched case-control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios (ORs) as relative risk.
Entity: 15130900	105	121	cyclophosphamide	Chemical	D003520
Entity: 15130900	126	140	bladder cancer	Disease	D001749
Relation: 15130900	CID	105	121	D003520	126	140	D001749	true

Sentence: The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide (OR = 2.0, 95% confidence interval (CI) 0.8 to 4.9).
Entity: 15130900	12	26	bladder cancer	Disease	D001749
Entity: 15130900	63	79	cyclophosphamide	Chemical	D003520
Relation: 15130900	CID	63	79	D003520	12	26	D001749	true

Sentence: L-arginine transport in humans with cortisol induced hypertension.
Entity: 12707296	0	10	L-arginine	Chemical	D001120
Entity: 12707296	36	44	cortisol	Chemical	D006854
Entity: 12707296	53	65	hypertension	Disease	D006973
Relation: 12707296	CID	0	10	D001120	53	65	D006973	false
Relation: 12707296	CID	36	44	D006854	53	65	D006973	false

Sentence: A deficient L-arginine-nitric oxide system is implicated in cortisol induced hypertension.
Entity: 12707296	12	22	L-arginine	Chemical	D001120
Entity: 12707296	23	35	nitric oxide	Chemical	D009569
Entity: 12707296	60	68	cortisol	Chemical	D006854
Entity: 12707296	77	89	hypertension	Disease	D006973
Relation: 12707296	CID	12	22	D001120	77	89	D006973	false
Relation: 12707296	CID	23	35	D009569	77	89	D006973	false
Relation: 12707296	CID	60	68	D006854	77	89	D006973	false

Sentence: MR imaging with quantitative diffusion mapping of tacrolimus induced neurotoxicity in organ transplant patients.
Entity: 12695819	50	60	tacrolimus	Chemical	D016559
Entity: 12695819	69	82	neurotoxicity	Disease	D020258
Relation: 12695819	CID	50	60	D016559	69	82	D020258	false

Sentence: Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications.
Entity: 12695819	111	121	tacrolimus	Chemical	D016559
Entity: 12695819	136	160	neurologic complications	Disease	D009422
Relation: 12695819	CID	111	121	D016559	136	160	D009422	false

Sentence: Octreotide induced hypoxemia and pulmonary hypertension in premature neonates.
Entity: 12596116	0	10	Octreotide	Chemical	D015282
Entity: 12596116	19	28	hypoxemia	Disease	D000860
Entity: 12596116	33	55	pulmonary hypertension	Disease	D006976
Relation: 12596116	CID	0	10	D015282	19	28	D000860	false
Relation: 12596116	CID	0	10	D015282	33	55	D006976	true

Sentence: We observed the exencephaly induced by 5-azacytidine at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5.
Entity: 11875660	16	27	exencephaly	Disease	D009436
Entity: 11875660	39	52	5-azacytidine	Chemical	D001374
Relation: 11875660	CID	39	52	D001374	16	27	D009436	false

Sentence: Acute cocaine induced seizures: differential sensitivity of six inbred mouse strains.
Entity: 11166519	6	13	cocaine	Chemical	D003042
Entity: 11166519	22	30	seizures	Disease	D012640
Relation: 11166519	CID	6	13	D003042	22	30	D012640	true

Sentence: Mature male and female mice from six inbred stains were tested for susceptibility to behavioral seizures induced by a single injection of cocaine.
Entity: 11166519	96	104	seizures	Disease	D012640
Entity: 11166519	138	145	cocaine	Chemical	D003042
Relation: 11166519	CID	138	145	D003042	96	104	D012640	true

Sentence: Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.
Entity: 8701950	0	33	Microangiopathic hemolytic anemia	Disease	D000743
Entity: 8701950	47	52	FK506	Chemical	D016559
Entity: 8701950	54	64	tacrolimus	Chemical	D016559
Relation: 8701950	CID	47	52	D016559	0	33	D000743	true
Relation: 8701950	CID	54	64	D016559	0	33	D000743	true

Sentence: We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.
Entity: 8701950	26	59	microangiopathic hemolytic anemia	Disease	D000743
Entity: 8701950	61	65	MAHA	Disease	D000743
Entity: 8701950	101	106	FK506	Chemical	D016559
Entity: 8701950	108	118	tacrolimus	Chemical	D016559
Relation: 8701950	CID	101	106	D016559	26	59	D000743	true
Relation: 8701950	CID	101	106	D016559	61	65	D000743	true
Relation: 8701950	CID	108	118	D016559	26	59	D000743	true
Relation: 8701950	CID	108	118	D016559	61	65	D000743	true

Sentence: In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.
Entity: 8701950	34	39	FK506	Chemical	D016559
Entity: 8701950	109	124	corticosteroids	Chemical	D000305
Entity: 8701950	126	133	aspirin	Chemical	D001241
Entity: 8701950	139	151	dipyridamole	Chemical	D004176
Entity: 8701950	173	177	MAHA	Disease	D000743
Relation: 8701950	CID	34	39	D016559	173	177	D000743	true
Relation: 8701950	CID	109	124	D000305	173	177	D000743	false
Relation: 8701950	CID	126	133	D001241	173	177	D000743	false
Relation: 8701950	CID	139	151	D004176	173	177	D000743	false

Sentence: In one patient, reintroduction of FK506 led to rapid recurrence of MAHA.
Entity: 8701950	34	39	FK506	Chemical	D016559
Entity: 8701950	67	71	MAHA	Disease	D000743
Relation: 8701950	CID	34	39	D016559	67	71	D000743	true

Sentence: FK506-associated MAHA is probably rare but physicians must be aware of this severe complication.
Entity: 8701950	0	5	FK506	Chemical	D016559
Entity: 8701950	17	21	MAHA	Disease	D000743
Relation: 8701950	CID	0	5	D016559	17	21	D000743	true

Sentence: Variant ventricular tachycardia in desipramine toxicity.
Entity: 7292072	8	31	ventricular tachycardia	Disease	D017180
Entity: 7292072	35	46	desipramine	Chemical	D003891
Entity: 7292072	47	55	toxicity	Disease	D064420
Relation: 7292072	CID	35	46	D003891	8	31	D017180	true
Relation: 7292072	CID	35	46	D003891	47	55	D064420	false

Sentence: We report a case of variant ventricular tachycardia induced by desipramine toxicity.
Entity: 7292072	28	51	ventricular tachycardia	Disease	D017180
Entity: 7292072	63	74	desipramine	Chemical	D003891
Entity: 7292072	75	83	toxicity	Disease	D064420
Relation: 7292072	CID	63	74	D003891	28	51	D017180	true
Relation: 7292072	CID	63	74	D003891	75	83	D064420	false

Sentence: Desipramine induced delirium at "subtherapeutic" concentrations: a case report.
Entity: 4027862	0	11	Desipramine	Chemical	D003891
Entity: 4027862	20	28	delirium	Disease	D003693
Relation: 4027862	CID	0	11	D003891	20	28	D003693	true

Sentence: An elderly patient treated with low dose Desipramine developed a delirium while her plasma level was in the "subtherapeutic" range.
Entity: 4027862	41	52	Desipramine	Chemical	D003891
Entity: 4027862	65	73	delirium	Disease	D003693
Relation: 4027862	CID	41	52	D003891	65	73	D003693	true

Sentence: The initial dose of amantadine depressed locomotor activity in all mouse strains studied with the BALB/C mice being the most sensitive.
Entity: 2484011	20	30	amantadine	Chemical	D000547
Entity: 2484011	31	40	depressed	Disease	D003866
Relation: 2484011	CID	20	30	D000547	31	40	D003866	false

Sentence: Readministration of amantadine, after a drug-free overnight period, increased motility from respective saline control in all strains with exception of the BALB/C mice where suppression of motility occurred.
Entity: 2484011	20	30	amantadine	Chemical	D000547
Entity: 2484011	173	196	suppression of motility	Disease	D011596
Relation: 2484011	CID	20	30	D000547	173	196	D011596	true

Sentence: No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.
Entity: 2396046	36	61	hepatocellular carcinomas	Disease	D006528
Entity: 2396046	94	101	choline	Chemical	D002794
Entity: 2396046	160	184	hepatocellular carcinoma	Disease	D006528
Entity: 2396046	236	249	phenobarbital	Chemical	D010634
Relation: 2396046	CID	94	101	D002794	36	61	D006528	true
Relation: 2396046	CID	94	101	D002794	160	184	D006528	true
Relation: 2396046	CID	236	249	D010634	36	61	D006528	false
Relation: 2396046	CID	236	249	D010634	160	184	D006528	false

Sentence: The incidence of preneoplastic nodules and of hepatocellular carcinomas was 10% and 37%, respectively, in rats fed the plain choline-devoid diet, and 17% and 30%, in rats fed the phenobarbital-containing choline-devoid diet.
Entity: 2396046	46	71	hepatocellular carcinomas	Disease	D006528
Entity: 2396046	125	132	choline	Chemical	D002794
Entity: 2396046	179	192	phenobarbital	Chemical	D010634
Entity: 2396046	204	211	choline	Chemical	D002794
Relation: 2396046	CID	125	132	D002794	46	71	D006528	true
Relation: 2396046	CID	179	192	D010634	46	71	D006528	false
Relation: 2396046	CID	204	211	D002794	46	71	D006528	true

Sentence: Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina.
Entity: 2008831	49	65	methylergonovine	Chemical	D008755
Entity: 2008831	95	109	variant angina	Disease	D000788
Relation: 2008831	CID	49	65	D008755	95	109	D000788	false

Sentence: The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).
Entity: 2008831	47	63	methylergonovine	Chemical	D008755
Entity: 2008831	97	111	variant angina	Disease	D000788
Entity: 2008831	142	152	chest pain	Disease	D002637
Entity: 2008831	175	190	angina pectoris	Disease	D000787
Relation: 2008831	CID	47	63	D008755	97	111	D000788	false
Relation: 2008831	CID	47	63	D008755	142	152	D002637	false
Relation: 2008831	CID	47	63	D008755	175	190	D000787	false

Sentence: Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer.
Entity: 1732369	0	10	Dobutamine	Chemical	D004280
Entity: 1732369	108	119	doxorubicin	Chemical	D004317
Entity: 1732369	161	167	cancer	Disease	D009369
Relation: 1732369	CID	0	10	D004280	161	167	D009369	false
Relation: 1732369	CID	108	119	D004317	161	167	D009369	false

Sentence: Doxorubicin is an effective anticancer chemotherapeutic agent known to cause acute and chronic cardiomyopathy.
Entity: 1732369	0	11	Doxorubicin	Chemical	D004317
Entity: 1732369	95	109	cardiomyopathy	Disease	D009202
Relation: 1732369	CID	0	11	D004317	95	109	D009202	true

Sentence: To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.
Entity: 1732369	65	79	cardiac damage	Disease	D006331
Entity: 1732369	87	98	doxorubicin	Chemical	D004317
Entity: 1732369	135	145	dobutamine	Chemical	D004280
Entity: 1732369	218	224	cancer	Disease	D009369
Entity: 1732369	238	249	doxorubicin	Chemical	D004317
Relation: 1732369	CID	87	98	D004317	65	79	D006331	false
Relation: 1732369	CID	87	98	D004317	218	224	D009369	false
Relation: 1732369	CID	135	145	D004280	65	79	D006331	false
Relation: 1732369	CID	135	145	D004280	218	224	D009369	false
Relation: 1732369	CID	238	249	D004317	65	79	D006331	false
Relation: 1732369	CID	238	249	D004317	218	224	D009369	false

Sentence: Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.
Entity: 234669	11	24	aminophylline	Chemical	D000628
Entity: 234669	57	81	ventricular fibrillation	Disease	D014693
Entity: 234669	89	108	respiratory failure	Disease	D012131
Relation: 234669	CID	11	24	D000628	57	81	D014693	true
Relation: 234669	CID	11	24	D000628	89	108	D012131	false

Sentence: The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.
Entity: 234669	15	28	aminophylline	Chemical	D000628
Entity: 234669	36	60	ventricular fibrillation	Disease	D014693
Entity: 234669	117	136	respiratory failure	Disease	D012131
Relation: 234669	CID	15	28	D000628	36	60	D014693	true
Relation: 234669	CID	15	28	D000628	117	136	D012131	false

Sentence: During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.
Entity: 234669	23	36	aminophylline	Chemical	D000628
Entity: 234669	42	66	ventricular fibrillation	Disease	D014693
Entity: 234669	157	163	oxygen	Chemical	D010100
Entity: 234669	165	168	PO2	Chemical	C093415
Entity: 234669	174	188	carbon dioxide	Chemical	D002245
Entity: 234669	190	193	CO2	Chemical	D002245
Relation: 234669	CID	23	36	D000628	42	66	D014693	true
Relation: 234669	CID	157	163	D010100	42	66	D014693	false
Relation: 234669	CID	165	168	C093415	42	66	D014693	false
Relation: 234669	CID	174	188	D002245	42	66	D014693	false
Relation: 234669	CID	190	193	D002245	42	66	D014693	false

Sentence: When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.
Entity: 234669	5	24	respiratory failure	Disease	D012131
Entity: 234669	41	56	hypoventilation	Disease	D007040
Entity: 234669	130	143	aminophylline	Chemical	D000628
Entity: 234669	184	208	ventricular fibrillation	Disease	D014693
Relation: 234669	CID	130	143	D000628	5	24	D012131	false
Relation: 234669	CID	130	143	D000628	41	56	D007040	false
Relation: 234669	CID	130	143	D000628	184	208	D014693	true

Sentence: Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.
Entity: 12464714	52	63	rizatriptan	Chemical	C093622
Entity: 12464714	77	87	ergotamine	Chemical	D004878
Entity: 12464714	88	96	caffeine	Chemical	D002110
Entity: 12464714	100	108	migraine	Disease	D008881
Relation: 12464714	CID	52	63	C093622	100	108	D008881	false
Relation: 12464714	CID	77	87	D004878	100	108	D008881	false
Relation: 12464714	CID	88	96	D002110	100	108	D008881	false

Sentence: Rizatriptan is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine.
Entity: 12464714	0	11	Rizatriptan	Chemical	C093622
Entity: 12464714	27	31	5-HT	Chemical	D012701
Entity: 12464714	135	143	migraine	Disease	D008881
Relation: 12464714	CID	0	11	C093622	135	143	D008881	false
Relation: 12464714	CID	27	31	D012701	135	143	D008881	false

Sentence: This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.
Entity: 12464714	87	98	rizatriptan	Chemical	C093622
Entity: 12464714	117	127	ergotamine	Chemical	D004878
Entity: 12464714	133	141	caffeine	Chemical	D002110
Entity: 12464714	191	199	migraine	Disease	D008881
Relation: 12464714	CID	87	98	C093622	191	199	D008881	false
Relation: 12464714	CID	117	127	D004878	191	199	D008881	false
Relation: 12464714	CID	133	141	D002110	191	199	D008881	false

Sentence: Faster relief of headache was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred ergotamine/caffeine.
Entity: 12464714	17	25	headache	Disease	D006261
Entity: 12464714	110	121	rizatriptan	Chemical	C093622
Entity: 12464714	158	168	ergotamine	Chemical	D004878
Entity: 12464714	169	177	caffeine	Chemical	D002110
Relation: 12464714	CID	110	121	C093622	17	25	D006261	false
Relation: 12464714	CID	158	168	D004878	17	25	D006261	false
Relation: 12464714	CID	169	177	D002110	17	25	D006261	false

Sentence: The co-primary endpoint of being pain free at 2 h was also in favor of rizatriptan.
Entity: 12464714	33	37	pain	Disease	D010146
Entity: 12464714	71	82	rizatriptan	Chemical	C093622
Relation: 12464714	CID	71	82	C093622	33	37	D010146	false

Sentence: Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.
Entity: 12464714	36	40	pain	Disease	D010146
Entity: 12464714	56	67	rizatriptan	Chemical	C093622
Entity: 12464714	102	112	ergotamine	Chemical	D004878
Entity: 12464714	113	121	caffeine	Chemical	D002110
Entity: 12464714	140	151	rizatriptan	Chemical	C093622
Relation: 12464714	CID	56	67	C093622	36	40	D010146	false
Relation: 12464714	CID	102	112	D004878	36	40	D010146	false
Relation: 12464714	CID	113	121	D002110	36	40	D010146	false
Relation: 12464714	CID	140	151	C093622	36	40	D010146	false

Sentence: Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.
Entity: 12464714	0	8	Headache	Disease	D006261
Entity: 12464714	37	48	rizatriptan	Chemical	C093622
Entity: 12464714	63	73	ergotamine	Chemical	D004878
Entity: 12464714	74	82	caffeine	Chemical	D002110
Entity: 12464714	106	117	rizatriptan	Chemical	C093622
Entity: 12464714	136	146	ergotamine	Chemical	D004878
Entity: 12464714	147	155	caffeine	Chemical	D002110
Relation: 12464714	CID	37	48	C093622	0	8	D006261	false
Relation: 12464714	CID	63	73	D004878	0	8	D006261	false
Relation: 12464714	CID	74	82	D002110	0	8	D006261	false
Relation: 12464714	CID	106	117	C093622	0	8	D006261	false
Relation: 12464714	CID	136	146	D004878	0	8	D006261	false
Relation: 12464714	CID	147	155	D002110	0	8	D006261	false

Sentence: Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).
Entity: 12464714	30	41	rizatriptan	Chemical	C093622
Entity: 12464714	47	51	pain	Disease	D010146
Entity: 12464714	164	174	ergotamine	Chemical	D004878
Entity: 12464714	175	183	caffeine	Chemical	D002110
Relation: 12464714	CID	30	41	C093622	47	51	D010146	false
Relation: 12464714	CID	164	174	D004878	47	51	D010146	false
Relation: 12464714	CID	175	183	D002110	47	51	D010146	false

Sentence: Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).
Entity: 12464714	0	11	Rizatriptan	Chemical	C093622
Entity: 12464714	33	43	ergotamine	Chemical	D004878
Entity: 12464714	44	52	caffeine	Chemical	D002110
Entity: 12464714	92	98	nausea	Disease	D009325
Entity: 12464714	100	108	vomiting	Disease	D014839
Entity: 12464714	110	121	phonophobia	Disease	D012001
Entity: 12464714	125	136	photophobia	Disease	D020795
Relation: 12464714	CID	0	11	C093622	92	98	D009325	true
Relation: 12464714	CID	0	11	C093622	100	108	D014839	false
Relation: 12464714	CID	0	11	C093622	110	121	D012001	false
Relation: 12464714	CID	0	11	C093622	125	136	D020795	false
Relation: 12464714	CID	33	43	D004878	92	98	D009325	false
Relation: 12464714	CID	33	43	D004878	100	108	D014839	false
Relation: 12464714	CID	33	43	D004878	110	121	D012001	false
Relation: 12464714	CID	33	43	D004878	125	136	D020795	false
Relation: 12464714	CID	44	52	D002110	92	98	D009325	false
Relation: 12464714	CID	44	52	D002110	100	108	D014839	false
Relation: 12464714	CID	44	52	D002110	110	121	D012001	false
Relation: 12464714	CID	44	52	D002110	125	136	D020795	false

Sentence: Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.
Entity: 6203452	19	28	carcinoma	Disease	D002277
Entity: 6203452	39	65	thrombotic microangiopathy	Disease	D057049
Entity: 6203452	84	103	renal insufficiency	Disease	D051437
Entity: 6203452	105	138	microangiopathic hemolytic anemia	Disease	D000743
Entity: 6203452	152	168	thrombocytopenia	Disease	D013921
Entity: 6203452	191	200	cisplatin	Chemical	D002945
Entity: 6203452	202	211	bleomycin	Chemical	D001761
Entity: 6203452	219	233	vinca alkaloid	Chemical	D014748
Relation: 6203452	CID	191	200	D002945	19	28	D002277	false
Relation: 6203452	CID	191	200	D002945	39	65	D057049	false
Relation: 6203452	CID	191	200	D002945	84	103	D051437	false
Relation: 6203452	CID	191	200	D002945	105	138	D000743	false
Relation: 6203452	CID	191	200	D002945	152	168	D013921	false
Relation: 6203452	CID	202	211	D001761	19	28	D002277	false
Relation: 6203452	CID	202	211	D001761	39	65	D057049	false
Relation: 6203452	CID	202	211	D001761	84	103	D051437	false
Relation: 6203452	CID	202	211	D001761	105	138	D000743	false
Relation: 6203452	CID	202	211	D001761	152	168	D013921	false
Relation: 6203452	CID	219	233	D014748	19	28	D002277	false
Relation: 6203452	CID	219	233	D014748	39	65	D057049	false
Relation: 6203452	CID	219	233	D014748	84	103	D051437	false
Relation: 6203452	CID	219	233	D014748	105	138	D000743	false
Relation: 6203452	CID	219	233	D014748	152	168	D013921	false

Sentence: Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.
Entity: 20528871	21	31	nelarabine	Chemical	C104457
Entity: 20528871	33	42	etoposide	Chemical	D005047
Entity: 20528871	48	64	cyclophosphamide	Chemical	D003520
Entity: 20528871	99	105	T-cell	Disease	D015458
Entity: 20528871	99	105	T-cell	Disease	D016399
Relation: 20528871	CID	21	31	C104457	99	105	D015458	false
Relation: 20528871	CID	21	31	C104457	99	105	D016399	false
Relation: 20528871	CID	33	42	D005047	99	105	D015458	false
Relation: 20528871	CID	33	42	D005047	99	105	D016399	false
Relation: 20528871	CID	48	64	D003520	99	105	D015458	false
Relation: 20528871	CID	48	64	D003520	99	105	D016399	false

Sentence: A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.
Entity: 20528871	24	34	nelarabine	Chemical	C104457
Entity: 20528871	36	40	AraG	Chemical	C104457
Entity: 20528871	54	63	etoposide	Chemical	D005047
Entity: 20528871	65	67	VP	Chemical	D005047
Entity: 20528871	73	89	cyclophosphamide	Chemical	D003520
Entity: 20528871	91	94	CPM	Chemical	D003520
Entity: 20528871	212	218	T-cell	Disease	D015458
Entity: 20528871	212	218	T-cell	Disease	D016399
Relation: 20528871	CID	24	34	C104457	212	218	D015458	false
Relation: 20528871	CID	24	34	C104457	212	218	D016399	false
Relation: 20528871	CID	36	40	C104457	212	218	D015458	false
Relation: 20528871	CID	36	40	C104457	212	218	D016399	false
Relation: 20528871	CID	54	63	D005047	212	218	D015458	false
Relation: 20528871	CID	54	63	D005047	212	218	D016399	false
Relation: 20528871	CID	65	67	D005047	212	218	D015458	false
Relation: 20528871	CID	65	67	D005047	212	218	D016399	false
Relation: 20528871	CID	73	89	D003520	212	218	D015458	false
Relation: 20528871	CID	73	89	D003520	212	218	D016399	false
Relation: 20528871	CID	91	94	D003520	212	218	D015458	false
Relation: 20528871	CID	91	94	D003520	212	218	D016399	false

Sentence: The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.
Entity: 20528871	49	53	AraG	Chemical	C104457
Entity: 20528871	95	105	neuropathy	Disease	D009422
Entity: 20528871	110	130	musculoskeletal pain	Disease	D059352
Relation: 20528871	CID	49	53	C104457	95	105	D009422	true
Relation: 20528871	CID	49	53	C104457	110	130	D059352	true

Sentence: Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies.
Entity: 20528871	0	23	Haematological toxicity	Disease	D006402
Entity: 20528871	61	65	AraG	Chemical	C104457
Relation: 20528871	CID	61	65	C104457	0	23	D006402	true

Sentence: A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.
Entity: 11672959	48	58	dermatitis	Disease	D003872
Entity: 11672959	60	65	fever	Disease	D005334
Entity: 11672959	67	82	lymphadenopathy	Disease	D008206
Entity: 11672959	87	96	hepatitis	Disease	D056486
Entity: 11672959	144	158	sulphasalazine	Chemical	D012460
Entity: 11672959	177	197	rheumatoid arthritis	Disease	D001172
Relation: 11672959	CID	144	158	D012460	48	58	D003872	true
Relation: 11672959	CID	144	158	D012460	60	65	D005334	true
Relation: 11672959	CID	144	158	D012460	67	82	D008206	true
Relation: 11672959	CID	144	158	D012460	87	96	D056486	true
Relation: 11672959	CID	144	158	D012460	177	197	D001172	false

Sentence: Bupropion (Zyban) toxicity.
Entity: 11928786	0	9	Bupropion	Chemical	D016642
Entity: 11928786	11	16	Zyban	Chemical	D016642
Entity: 11928786	18	26	toxicity	Disease	D064420
Relation: 11928786	CID	0	9	D016642	18	26	D064420	false
Relation: 11928786	CID	11	16	D016642	18	26	D064420	false

Sentence: Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine.
Entity: 11928786	10	18	seizures	Disease	D012640
Entity: 11928786	37	45	diazepam	Chemical	D003975
Entity: 11928786	64	75	tachycardia	Disease	D013610
Entity: 11928786	106	115	adenosine	Chemical	D000241
Relation: 11928786	CID	37	45	D003975	10	18	D012640	false
Relation: 11928786	CID	37	45	D003975	64	75	D013610	false
Relation: 11928786	CID	106	115	D000241	10	18	D012640	false
Relation: 11928786	CID	106	115	D000241	64	75	D013610	false

Sentence: Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.
Entity: 19300402	0	10	Bradykinin	Chemical	D001920
Entity: 19300402	37	49	nitric oxide	Chemical	D009569
Entity: 19300402	73	84	vincristine	Chemical	D014750
Entity: 19300402	89	103	streptozotocin	Chemical	D013311
Entity: 19300402	112	124	hyperalgesia	Disease	D006930
Entity: 19300402	145	164	diabetic neuropathy	Disease	D003929
Relation: 19300402	CID	0	10	D001920	112	124	D006930	false
Relation: 19300402	CID	0	10	D001920	145	164	D003929	false
Relation: 19300402	CID	37	49	D009569	112	124	D006930	false
Relation: 19300402	CID	37	49	D009569	145	164	D003929	false
Relation: 19300402	CID	73	84	D014750	112	124	D006930	true
Relation: 19300402	CID	73	84	D014750	145	164	D003929	false
Relation: 19300402	CID	89	103	D013311	112	124	D006930	true
Relation: 19300402	CID	89	103	D013311	145	164	D003929	true

Sentence: PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin induced) and toxic (vincristine induced) neuropathy was investigated.
Entity: 19300402	68	70	NO	Chemical	D009569
Entity: 19300402	151	153	NO	Chemical	D009569
Entity: 19300402	233	235	NO	Chemical	D009569
Entity: 19300402	373	383	bradykinin	Chemical	D001920
Entity: 19300402	385	392	HOE 140	Chemical	C065679
Entity: 19300402	412	429	des Arg10 HOE 140	Chemical	C078665
Entity: 19300402	472	480	diabetic	Disease	D003929
Entity: 19300402	510	515	toxic	Disease	D010523
Relation: 19300402	CID	68	70	D009569	472	480	D003929	false
Relation: 19300402	CID	68	70	D009569	510	515	D010523	false
Relation: 19300402	CID	151	153	D009569	472	480	D003929	false
Relation: 19300402	CID	151	153	D009569	510	515	D010523	false
Relation: 19300402	CID	233	235	D009569	472	480	D003929	false
Relation: 19300402	CID	233	235	D009569	510	515	D010523	false
Relation: 19300402	CID	373	383	D001920	472	480	D003929	false
Relation: 19300402	CID	373	383	D001920	510	515	D010523	false
Relation: 19300402	CID	385	392	C065679	472	480	D003929	false
Relation: 19300402	CID	385	392	C065679	510	515	D010523	false
Relation: 19300402	CID	412	429	C078665	472	480	D003929	false
Relation: 19300402	CID	412	429	C078665	510	515	D010523	false

Sentence: RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.
Entity: 19300402	62	72	bradykinin	Chemical	D001920
Entity: 19300402	97	99	NO	Chemical	D009569
Entity: 19300402	126	128	NO	Chemical	D009569
Entity: 19300402	155	176	diabetic hyperalgesia	Disease	D006930
Relation: 19300402	CID	62	72	D001920	155	176	D006930	false
Relation: 19300402	CID	97	99	D009569	155	176	D006930	false
Relation: 19300402	CID	126	128	D009569	155	176	D006930	false

Sentence: It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.
Entity: 19300402	50	52	NO	Chemical	D009569
Entity: 19300402	75	77	NO	Chemical	D009569
Entity: 19300402	109	119	bradykinin	Chemical	D001920
Entity: 19300402	136	148	hyperalgesia	Disease	D006930
Entity: 19300402	161	172	vincristine	Chemical	D014750
Relation: 19300402	CID	50	52	D009569	136	148	D006930	false
Relation: 19300402	CID	75	77	D009569	136	148	D006930	false
Relation: 19300402	CID	109	119	D001920	136	148	D006930	false
Relation: 19300402	CID	161	172	D014750	136	148	D006930	true

Sentence: Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.
Entity: 19300402	80	87	HOE 140	Chemical	C065679
Entity: 19300402	91	107	des-Arg10HOE 140	Chemical	C078665
Entity: 19300402	111	127	toxic neuropathy	Disease	D010523
Relation: 19300402	CID	80	87	C065679	111	127	D010523	false
Relation: 19300402	CID	91	107	C078665	111	127	D010523	false

Sentence: In streptozotocin induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.
Entity: 19300402	3	17	streptozotocin	Chemical	D013311
Entity: 19300402	26	38	hyperalgesia	Disease	D006930
Entity: 19300402	50	52	NO	Chemical	D009569
Entity: 19300402	105	115	bradykinin	Chemical	D001920
Entity: 19300402	128	139	vincristine	Chemical	D014750
Entity: 19300402	148	160	hyperalgesia	Disease	D006930
Entity: 19300402	161	171	bradykinin	Chemical	D001920
Entity: 19300402	200	202	NO	Chemical	D009569
Relation: 19300402	CID	3	17	D013311	26	38	D006930	true
Relation: 19300402	CID	3	17	D013311	148	160	D006930	true
Relation: 19300402	CID	50	52	D009569	26	38	D006930	false
Relation: 19300402	CID	50	52	D009569	148	160	D006930	false
Relation: 19300402	CID	105	115	D001920	26	38	D006930	false
Relation: 19300402	CID	105	115	D001920	148	160	D006930	false
Relation: 19300402	CID	128	139	D014750	26	38	D006930	true
Relation: 19300402	CID	128	139	D014750	148	160	D006930	true
Relation: 19300402	CID	161	171	D001920	26	38	D006930	false
Relation: 19300402	CID	161	171	D001920	148	160	D006930	false
Relation: 19300402	CID	200	202	D009569	26	38	D006930	false
Relation: 19300402	CID	200	202	D009569	148	160	D006930	false

Sentence: Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.
Entity: 15325671	0	16	Cardiac toxicity	Disease	D066126
Entity: 15325671	56	72	cyclophosphamide	Chemical	D003520
Entity: 15325671	107	120	breast cancer	Disease	D001943
Relation: 15325671	CID	56	72	D003520	0	16	D066126	false
Relation: 15325671	CID	56	72	D003520	107	120	D001943	false

Sentence: STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.
Entity: 15325671	26	36	paclitaxel	Chemical	D017239
Entity: 15325671	38	47	melphalan	Chemical	D008558
Entity: 15325671	62	78	cyclophosphamide	Chemical	D003520
Entity: 15325671	80	88	thiotepa	Chemical	D013852
Entity: 15325671	94	105	carboplatin	Chemical	D016190
Entity: 15325671	176	189	breast cancer	Disease	D001943
Relation: 15325671	CID	26	36	D017239	176	189	D001943	false
Relation: 15325671	CID	38	47	D008558	176	189	D001943	false
Relation: 15325671	CID	62	78	D003520	176	189	D001943	false
Relation: 15325671	CID	80	88	D013852	176	189	D001943	false
Relation: 15325671	CID	94	105	D016190	176	189	D001943	false

Sentence: Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.
Entity: 15325671	75	88	breast cancer	Disease	D001943
Entity: 15325671	115	131	cyclophosphamide	Chemical	D003520
Entity: 15325671	238	262	congestive heart failure	Disease	D006333
Entity: 15325671	264	267	CHF	Disease	D006333
Entity: 15325671	373	385	hypertension	Disease	D006973
Entity: 15325671	419	436	diabetes mellitus	Disease	D003920
Entity: 15325671	451	465	anthracyclines	Chemical	D018943
Relation: 15325671	CID	115	131	D003520	75	88	D001943	false
Relation: 15325671	CID	115	131	D003520	238	262	D006333	true
Relation: 15325671	CID	115	131	D003520	264	267	D006333	true
Relation: 15325671	CID	115	131	D003520	373	385	D006973	false
Relation: 15325671	CID	115	131	D003520	419	436	D003920	false
Relation: 15325671	CID	451	465	D018943	75	88	D001943	false
Relation: 15325671	CID	451	465	D018943	238	262	D006333	false
Relation: 15325671	CID	451	465	D018943	264	267	D006333	false
Relation: 15325671	CID	451	465	D018943	373	385	D006973	false
Relation: 15325671	CID	451	465	D018943	419	436	D003920	false

Sentence: RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31%.
Entity: 15325671	71	74	CHF	Disease	D006333
Entity: 15325671	96	112	cyclophosphamide	Chemical	D003520
Relation: 15325671	CID	96	112	D003520	71	74	D006333	true

Sentence: Incidence of transient cyclophosphamide-related cardiac toxicity (10%) is comparable to previous recorded literature.
Entity: 15325671	23	39	cyclophosphamide	Chemical	D003520
Entity: 15325671	48	64	cardiac toxicity	Disease	D066126
Relation: 15325671	CID	23	39	D003520	48	64	D066126	false

Sentence: Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.
Entity: 9746003	21	34	carbamazepine	Chemical	D002220
Entity: 9746003	39	49	vigabatrin	Chemical	D020888
Entity: 9746003	61	77	absence seizures	Disease	D004832
Relation: 9746003	CID	21	34	D002220	61	77	D004832	true
Relation: 9746003	CID	39	49	D020888	61	77	D004832	true

Sentence: Carbamazepine and vigabatrin are contraindicated in typical absence seizures.
Entity: 9746003	0	13	Carbamazepine	Chemical	D002220
Entity: 9746003	18	28	vigabatrin	Chemical	D020888
Entity: 9746003	60	76	absence seizures	Disease	D004832
Relation: 9746003	CID	0	13	D002220	60	76	D004832	true
Relation: 9746003	CID	18	28	D020888	60	76	D004832	true

Sentence: Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.
Entity: 9746003	62	75	carbamazepine	Chemical	D002220
Entity: 9746003	103	118	myoclonic jerks	Disease	D009207
Entity: 9746003	152	165	carbamazepine	Chemical	D002220
Relation: 9746003	CID	62	75	D002220	103	118	D009207	true
Relation: 9746003	CID	152	165	D002220	103	118	D009207	true

Sentence: Hemolytic anemia associated with the use of omeprazole.
Entity: 1992636	0	16	Hemolytic anemia	Disease	D000743
Entity: 1992636	44	54	omeprazole	Chemical	D009853
Relation: 1992636	CID	44	54	D009853	0	16	D000743	true

Sentence: We report the first case of a serious short-term adverse reaction with the use of omeprazole: hemolytic anemia.
Entity: 1992636	82	92	omeprazole	Chemical	D009853
Entity: 1992636	94	110	hemolytic anemia	Disease	D000743
Relation: 1992636	CID	82	92	D009853	94	110	D000743	true

Sentence: The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.
Entity: 1992636	32	40	lethargy	Disease	D053609
Entity: 1992636	46	65	shortness of breath	Disease	D004417
Entity: 1992636	101	111	omeprazole	Chemical	D009853
Relation: 1992636	CID	101	111	D009853	32	40	D053609	true
Relation: 1992636	CID	101	111	D009853	46	65	D004417	true

Sentence: The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT) One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day.
Entity: 8387218	12	20	toxicity	Disease	D064420
Entity: 8387218	24	34	didanosine	Chemical	D016049
Entity: 8387218	36	39	ddI	Chemical	D016049
Entity: 8387218	44	65	HIV antibody-positive	Disease	D015658
Entity: 8387218	92	102	zidovudine	Chemical	D015215
Entity: 8387218	104	107	AZT	Chemical	D015215
Entity: 8387218	158	168	zidovudine	Chemical	D015215
Entity: 8387218	170	173	AZT	Chemical	D015215
Entity: 8387218	184	194	didanosine	Chemical	D016049
Entity: 8387218	196	199	ddI	Chemical	D016049
Relation: 8387218	CID	24	34	D016049	12	20	D064420	false
Relation: 8387218	CID	24	34	D016049	44	65	D015658	false
Relation: 8387218	CID	36	39	D016049	12	20	D064420	false
Relation: 8387218	CID	36	39	D016049	44	65	D015658	false
Relation: 8387218	CID	92	102	D015215	12	20	D064420	false
Relation: 8387218	CID	92	102	D015215	44	65	D015658	false
Relation: 8387218	CID	104	107	D015215	12	20	D064420	false
Relation: 8387218	CID	104	107	D015215	44	65	D015658	false
Relation: 8387218	CID	158	168	D015215	12	20	D064420	false
Relation: 8387218	CID	158	168	D015215	44	65	D015658	false
Relation: 8387218	CID	170	173	D015215	12	20	D064420	false
Relation: 8387218	CID	170	173	D015215	44	65	D015658	false
Relation: 8387218	CID	184	194	D016049	12	20	D064420	false
Relation: 8387218	CID	184	194	D016049	44	65	D015658	false
Relation: 8387218	CID	196	199	D016049	12	20	D064420	false
Relation: 8387218	CID	196	199	D016049	44	65	D015658	false

Sentence: Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia.
Entity: 20698227	46	55	ribavirin	Chemical	D012254
Entity: 20698227	67	83	hemolytic anemia	Disease	D000743
Relation: 20698227	CID	46	55	D012254	67	83	D000743	false

Sentence: BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.
Entity: 20698227	26	35	ribavirin	Chemical	D012254
Entity: 20698227	123	132	sunitinib	Chemical	C473478
Entity: 20698227	137	146	sorafenib	Chemical	C471405
Entity: 20698227	178	187	hemolysis	Disease	D006461
Relation: 20698227	CID	26	35	D012254	178	187	D006461	false
Relation: 20698227	CID	123	132	C473478	178	187	D006461	true
Relation: 20698227	CID	137	146	C471405	178	187	D006461	true

Sentence: METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.
Entity: 20698227	27	70	chronically infected with hepatitis C virus	Disease	D019698
Entity: 20698227	87	116	pegylated interferon alpha 2a	Chemical	C100416
Entity: 20698227	121	130	ribavirin	Chemical	D012254
Relation: 20698227	CID	87	116	C100416	27	70	D019698	false
Relation: 20698227	CID	121	130	D012254	27	70	D019698	false

Sentence: CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with hepatitis C and we could not find any relation.
Entity: 20698227	116	125	ribavirin	Chemical	D012254
Entity: 20698227	134	140	anemia	Disease	D000740
Entity: 20698227	158	169	hepatitis C	Disease	D019698
Relation: 20698227	CID	116	125	D012254	134	140	D000740	false
Relation: 20698227	CID	116	125	D012254	158	169	D019698	false

Sentence: Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.
Entity: 20477932	0	7	Cocaine	Chemical	D003042
Entity: 20477932	15	21	memory	Disease	D008569
Entity: 20477932	26	34	learning	Disease	D007859
Entity: 20477932	134	144	topiramate	Chemical	C052342
Relation: 20477932	CID	0	7	D003042	15	21	D008569	true
Relation: 20477932	CID	0	7	D003042	26	34	D007859	true
Relation: 20477932	CID	134	144	C052342	15	21	D008569	false
Relation: 20477932	CID	134	144	C052342	26	34	D007859	false

Sentence: Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood.
Entity: 20477932	45	52	cocaine	Chemical	D003042
Entity: 20477932	53	61	toxicity	Disease	D064420
Entity: 20477932	166	173	cocaine	Chemical	D003042
Relation: 20477932	CID	45	52	D003042	53	61	D064420	false
Relation: 20477932	CID	166	173	D003042	53	61	D064420	false

Sentence: Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.
Entity: 20477932	56	68	nitric oxide	Chemical	D009569
Entity: 20477932	148	158	topiramate	Chemical	C052342
Entity: 20477932	194	211	cocaine addiction	Disease	D019970
Entity: 20477932	256	263	cocaine	Chemical	D003042
Relation: 20477932	CID	56	68	D009569	194	211	D019970	false
Relation: 20477932	CID	148	158	C052342	194	211	D019970	false
Relation: 20477932	CID	256	263	D003042	194	211	D019970	false

Sentence: (+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.
Entity: 9495837	6	10	PG-9	Chemical	C087567
Entity: 9495837	52	59	amnesia	Disease	D000647
Entity: 9495837	71	82	scopolamine	Chemical	D012601
Entity: 9495837	104	115	dicyclomine	Chemical	D004025
Relation: 9495837	CID	6	10	C087567	52	59	D000647	false
Relation: 9495837	CID	71	82	D012601	52	59	D000647	true
Relation: 9495837	CID	104	115	D004025	52	59	D000647	true

Sentence: Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.
Entity: 9495837	27	31	PG-9	Chemical	C087567
Entity: 9495837	336	343	amnesic	Disease	D000647
Entity: 9495837	368	372	PG-9	Chemical	C087567
Entity: 9495837	396	409	acetylcholine	Chemical	D000109
Relation: 9495837	CID	27	31	C087567	336	343	D000647	false
Relation: 9495837	CID	368	372	C087567	336	343	D000647	false
Relation: 9495837	CID	396	409	D000109	336	343	D000647	false

Sentence: Hyperbaric oxygen therapy for control of intractable cyclophosphamide induced hemorrhagic cystitis.
Entity: 1468485	11	17	oxygen	Chemical	D010100
Entity: 1468485	53	69	cyclophosphamide	Chemical	D003520
Entity: 1468485	78	89	hemorrhagic	Disease	D006470
Entity: 1468485	90	98	cystitis	Disease	D003556
Relation: 1468485	CID	11	17	D010100	78	89	D006470	false
Relation: 1468485	CID	11	17	D010100	90	98	D003556	false
Relation: 1468485	CID	53	69	D003520	78	89	D006470	true
Relation: 1468485	CID	53	69	D003520	90	98	D003556	true

Sentence: We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.
Entity: 1468485	32	43	hemorrhagic	Disease	D006470
Entity: 1468485	44	52	cystitis	Disease	D003556
Entity: 1468485	60	76	cyclophosphamide	Chemical	D003520
Entity: 1468485	89	113	Wegener's granulomatosis	Disease	D014890
Relation: 1468485	CID	60	76	D003520	32	43	D006470	true
Relation: 1468485	CID	60	76	D003520	44	52	D003556	true
Relation: 1468485	CID	60	76	D003520	89	113	D014890	false

Sentence: Conservative treatment, including bladder irrigation with physiological saline and instillation of prostaglandin F2 alpha, failed to totally control hemorrhage.
Entity: 1468485	99	121	prostaglandin F2 alpha	Chemical	D015237
Entity: 1468485	149	159	hemorrhage	Disease	D006470
Relation: 1468485	CID	99	121	D015237	149	159	D006470	false

Sentence: The results have shown that the degradation product p-choloroaniline is not a significant factor in chlorhexidine-digluconate associated erosive cystitis.
Entity: 1009330	52	68	p-choloroaniline	Chemical	C004658
Entity: 1009330	100	125	chlorhexidine-digluconate	Chemical	C010882
Entity: 1009330	145	153	cystitis	Disease	D003556
Relation: 1009330	CID	52	68	C004658	145	153	D003556	false
Relation: 1009330	CID	100	125	C010882	145	153	D003556	true

Sentence: A high percentage of kanamycin-colistin and povidone-iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage.
Entity: 1009330	21	30	kanamycin	Chemical	D007612
Entity: 1009330	31	39	colistin	Chemical	D003091
Entity: 1009330	44	59	povidone-iodine	Chemical	D011206
Entity: 1009330	101	109	cystitis	Disease	D003556
Relation: 1009330	CID	21	30	D007612	101	109	D003556	true
Relation: 1009330	CID	31	39	D003091	101	109	D003556	true
Relation: 1009330	CID	44	59	D011206	101	109	D003556	true

Sentence: In the double blind study with haloperidol, both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group.
Entity: 347884	31	42	haloperidol	Chemical	D006220
Entity: 347884	114	184	psychotic syndromes belonging predominantly to the schizophrenia group	Disease	D019967
Relation: 347884	CID	31	42	D006220	114	184	D019967	false

Sentence: Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.
Entity: 20667451	0	8	Curcumin	Chemical	D003474
Entity: 20667451	21	42	cognitive dysfunction	Disease	D003072
Entity: 20667451	67	81	phenobarbitone	Chemical	D010634
Entity: 20667451	86	99	carbamazepine	Chemical	D002220
Relation: 20667451	CID	0	8	D003474	21	42	D003072	false
Relation: 20667451	CID	67	81	D010634	21	42	D003072	true
Relation: 20667451	CID	86	99	D002220	21	42	D003072	true

Sentence: The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.
Entity: 20667451	25	39	phenobarbitone	Chemical	D010634
Entity: 20667451	44	57	carbamazepine	Chemical	D002220
Entity: 20667451	82	102	cognitive impairment	Disease	D003072
Relation: 20667451	CID	25	39	D010634	82	102	D003072	true
Relation: 20667451	CID	44	57	D002220	82	102	D003072	true

Sentence: Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine induced cognitive impairment and oxidative stress in rats.
Entity: 20667451	82	90	curcumin	Chemical	D003474
Entity: 20667451	109	123	phenobarbitone	Chemical	D010634
Entity: 20667451	129	142	carbamazepine	Chemical	D002220
Entity: 20667451	151	171	cognitive impairment	Disease	D003072
Relation: 20667451	CID	82	90	D003474	151	171	D003072	false
Relation: 20667451	CID	109	123	D010634	151	171	D003072	true
Relation: 20667451	CID	129	142	D002220	151	171	D003072	true

Sentence: The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.
Entity: 20667451	22	36	phenobarbitone	Chemical	D010634
Entity: 20667451	41	54	carbamazepine	Chemical	D002220
Entity: 20667451	87	120	impairment of learning and memory	Disease	D003072
Relation: 20667451	CID	22	36	D010634	87	120	D003072	true
Relation: 20667451	CID	41	54	D002220	87	120	D003072	true

Sentence: Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs.
Entity: 20667451	12	20	curcumin	Chemical	D003474
Entity: 20667451	50	70	cognitive impairment	Disease	D003072
Relation: 20667451	CID	12	20	D003474	50	70	D003072	false

Sentence: These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.
Entity: 20667451	24	32	curcumin	Chemical	D003474
Entity: 20667451	73	109	deterioration of cognitive functions	Disease	D003072
Entity: 20667451	152	166	phenobarbitone	Chemical	D010634
Entity: 20667451	171	184	carbamazepine	Chemical	D002220
Relation: 20667451	CID	24	32	D003474	73	109	D003072	false
Relation: 20667451	CID	152	166	D010634	73	109	D003072	true
Relation: 20667451	CID	171	184	D002220	73	109	D003072	true

Sentence: Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model.
Entity: 19767176	0	27	Pyrrolidine dithiocarbamate	Chemical	C020972
Entity: 19767176	64	75	pilocarpine	Chemical	D010862
Entity: 19767176	76	94	status epilepticus	Disease	D013226
Relation: 19767176	CID	0	27	C020972	76	94	D013226	false
Relation: 19767176	CID	64	75	D010862	76	94	D013226	true

Sentence: Both, production of reactive oxygen species as well as activation of NF-kappaB have been implicated in severe neuronal damage in different sub-regions of the hippocampus as well as in the surrounding cortices.
Entity: 19767176	29	35	oxygen	Chemical	D010100
Entity: 19767176	110	125	neuronal damage	Disease	D009410
Relation: 19767176	CID	29	35	D010100	110	125	D009410	false

Sentence: The effect of PDTC on status epilepticus-associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model.
Entity: 19767176	14	18	PDTC	Chemical	C020972
Entity: 19767176	22	40	status epilepticus	Disease	D013226
Entity: 19767176	139	150	pilocarpine	Chemical	D010862
Relation: 19767176	CID	14	18	C020972	22	40	D013226	false
Relation: 19767176	CID	139	150	D010862	22	40	D013226	true

Sentence: Treatment with 150 mg/kg PDTC before and following status epilepticus significantly increased the mortality rate to 100%.
Entity: 19767176	25	29	PDTC	Chemical	C020972
Entity: 19767176	51	69	status epilepticus	Disease	D013226
Relation: 19767176	CID	25	29	C020972	51	69	D013226	false

Sentence: Administration of 50 mg/kg PDTC (low-dose) did not exert major effects on the development of a status epilepticus or the mortality rate.
Entity: 19767176	27	31	PDTC	Chemical	C020972
Entity: 19767176	95	113	status epilepticus	Disease	D013226
Relation: 19767176	CID	27	31	C020972	95	113	D013226	false

Sentence: A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle- and PDTC-treated rats following status epilepticus.
Entity: 19767176	109	113	PDTC	Chemical	C020972
Entity: 19767176	137	155	status epilepticus	Disease	D013226
Relation: 19767176	CID	109	113	C020972	137	155	D013226	false

Sentence: In conclusion, the NF-kappaB inhibitor and antioxidant PDTC protected the piriform cortex, whereas it did not affect hilar neuronal loss.
Entity: 19767176	55	59	PDTC	Chemical	C020972
Entity: 19767176	123	136	neuronal loss	Disease	D009410
Relation: 19767176	CID	55	59	C020972	123	136	D009410	false

Sentence: These data might indicate that the generation of reactive oxygen species and activation of NF-kappaB plays a more central role in seizure-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus.
Entity: 19767176	58	64	oxygen	Chemical	D010100
Entity: 19767176	130	137	seizure	Disease	D012640
Entity: 19767176	149	164	neuronal damage	Disease	D009410
Relation: 19767176	CID	58	64	D010100	130	137	D012640	false
Relation: 19767176	CID	58	64	D010100	149	164	D009410	false

Sentence: Development of levodopa induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.
Entity: 14568327	15	23	levodopa	Chemical	D007980
Entity: 14568327	32	43	dyskinesias	Disease	D004409
Entity: 14568327	47	59	parkinsonian	Disease	D010300
Relation: 14568327	CID	15	23	D007980	32	43	D004409	true
Relation: 14568327	CID	15	23	D007980	47	59	D010300	false

Sentence: Levodopa induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.
Entity: 14568327	0	8	Levodopa	Chemical	D007980
Entity: 14568327	17	28	dyskinesias	Disease	D004409
Entity: 14568327	30	34	LIDs	Disease	D004409
Entity: 14568327	92	111	Parkinson's disease	Disease	D010300
Entity: 14568327	113	115	PD	Disease	D010300
Relation: 14568327	CID	0	8	D007980	17	28	D004409	true
Relation: 14568327	CID	0	8	D007980	30	34	D004409	true
Relation: 14568327	CID	0	8	D007980	92	111	D010300	false
Relation: 14568327	CID	0	8	D007980	113	115	D010300	false

Sentence: Using macaque monkeys with different types of MPTP induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.
Entity: 14568327	46	50	MPTP	Chemical	D015632
Entity: 14568327	59	71	parkinsonism	Disease	D010302
Entity: 14568327	200	208	levodopa	Chemical	D007980
Entity: 14568327	255	259	LIDs	Disease	D004409
Relation: 14568327	CID	46	50	D015632	59	71	D010302	true
Relation: 14568327	CID	46	50	D015632	255	259	D004409	false
Relation: 14568327	CID	200	208	D007980	59	71	D010302	false
Relation: 14568327	CID	200	208	D007980	255	259	D004409	true

Sentence: Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration.
Entity: 14568327	32	36	MPTP	Chemical	D015632
Entity: 14568327	117	125	levodopa	Chemical	D007980
Entity: 14568327	144	154	dyskinesia	Disease	D004409
Entity: 14568327	187	195	levodopa	Chemical	D007980
Relation: 14568327	CID	32	36	D015632	144	154	D004409	false
Relation: 14568327	CID	117	125	D007980	144	154	D004409	true
Relation: 14568327	CID	187	195	D007980	144	154	D004409	true

Sentence: In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).
Entity: 14568327	36	40	MPTP	Chemical	D015632
Entity: 14568327	128	136	levodopa	Chemical	D007980
Entity: 14568327	179	183	LIDs	Disease	D004409
Entity: 14568327	191	201	dyskinesia	Disease	D004409
Entity: 14568327	247	255	levodopa	Chemical	D007980
Relation: 14568327	CID	36	40	D015632	179	183	D004409	false
Relation: 14568327	CID	36	40	D015632	191	201	D004409	false
Relation: 14568327	CID	128	136	D007980	179	183	D004409	true
Relation: 14568327	CID	128	136	D007980	191	201	D004409	true
Relation: 14568327	CID	247	255	D007980	179	183	D004409	true
Relation: 14568327	CID	247	255	D007980	191	201	D004409	true

Sentence: Propylthiouracil induced perinuclear-staining antineutrophil cytoplasmic autoantibody-positive vasculitis in conjunction with pericarditis.
Entity: 11250767	0	16	Propylthiouracil	Chemical	D011441
Entity: 11250767	95	105	vasculitis	Disease	D014657
Entity: 11250767	126	138	pericarditis	Disease	D010493
Relation: 11250767	CID	0	16	D011441	95	105	D014657	false
Relation: 11250767	CID	0	16	D011441	126	138	D010493	true

Sentence: OBJECTIVE: To describe a case of propylthiouracil induced vasculitis manifesting with pericarditis.
Entity: 11250767	33	49	propylthiouracil	Chemical	D011441
Entity: 11250767	58	68	vasculitis	Disease	D014657
Entity: 11250767	86	98	pericarditis	Disease	D010493
Relation: 11250767	CID	33	49	D011441	58	68	D014657	false
Relation: 11250767	CID	33	49	D011441	86	98	D010493	true

Sentence: METHODS: We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis, fever, and glomerulonephritis developed.
Entity: 11250767	58	73	hyperthyroidism	Disease	D006980
Entity: 11250767	87	103	propylthiouracil	Chemical	D011441
Entity: 11250767	126	138	pericarditis	Disease	D010493
Entity: 11250767	140	145	fever	Disease	D005334
Entity: 11250767	151	169	glomerulonephritis	Disease	D005921
Relation: 11250767	CID	87	103	D011441	58	73	D006980	false
Relation: 11250767	CID	87	103	D011441	126	138	D010493	true
Relation: 11250767	CID	87	103	D011441	140	145	D005334	true
Relation: 11250767	CID	87	103	D011441	151	169	D005921	true

Sentence: A literature review revealed no prior reports of pericarditis in anti-MPO pANCA-positive vasculitis associated with propylthio- uracil therapy.
Entity: 11250767	49	61	pericarditis	Disease	D010493
Entity: 11250767	89	99	vasculitis	Disease	D014657
Entity: 11250767	116	134	propylthio- uracil	Chemical	D011441
Relation: 11250767	CID	116	134	D011441	49	61	D010493	true
Relation: 11250767	CID	116	134	D011441	89	99	D014657	false

Sentence: Two mouse lines selected for differential sensitivities to beta-carboline induced seizures are also differentially sensitive to various pharmacological effects of other GABA(A) receptor ligands.
Entity: 11206082	59	73	beta-carboline	Chemical	C036150
Entity: 11206082	82	90	seizures	Disease	D012640
Entity: 11206082	169	173	GABA	Chemical	D005680
Relation: 11206082	CID	59	73	C036150	82	90	D012640	true
Relation: 11206082	CID	169	173	D005680	82	90	D012640	false

Sentence: Two mouse lines were selectively bred according to their sensitivity (BS line) or resistance (BR line) to seizures induced by a single i.p. injection of methyl beta-carboline-3-carboxylate (beta-CCM), an inverse agonist of the GABA(A) receptor benzodiazepine site.
Entity: 11206082	106	114	seizures	Disease	D012640
Entity: 11206082	153	188	methyl beta-carboline-3-carboxylate	Chemical	C036150
Entity: 11206082	190	198	beta-CCM	Chemical	C036150
Entity: 11206082	227	231	GABA	Chemical	D005680
Entity: 11206082	244	258	benzodiazepine	Chemical	D001569
Relation: 11206082	CID	153	188	C036150	106	114	D012640	true
Relation: 11206082	CID	190	198	C036150	106	114	D012640	true
Relation: 11206082	CID	227	231	D005680	106	114	D012640	false
Relation: 11206082	CID	244	258	D001569	106	114	D012640	false

Sentence: We measured diazepam induced anxiolysis with the elevated plus-maze test, diazepam induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol induced seizures after i.p. injections.
Entity: 11206082	12	20	diazepam	Chemical	D003975
Entity: 11206082	74	82	diazepam	Chemical	D003975
Entity: 11206082	139	149	picrotoxin	Chemical	D010852
Entity: 11206082	155	172	pentylenetetrazol	Chemical	D010433
Entity: 11206082	181	189	seizures	Disease	D012640
Relation: 11206082	CID	12	20	D003975	181	189	D012640	false
Relation: 11206082	CID	74	82	D003975	181	189	D012640	false
Relation: 11206082	CID	139	149	D010852	181	189	D012640	true
Relation: 11206082	CID	155	172	D010433	181	189	D012640	true

Sentence: Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.
Entity: 11027905	32	40	ketamine	Chemical	D007649
Entity: 11027905	44	50	cancer	Disease	D009369
Entity: 11027905	63	71	morphine	Chemical	D009020
Relation: 11027905	CID	32	40	D007649	44	50	D009369	false
Relation: 11027905	CID	63	71	D009020	44	50	D009369	false

Sentence: Pain not responsive to morphine is often problematic.
Entity: 11027905	0	4	Pain	Disease	D010146
Entity: 11027905	23	31	morphine	Chemical	D009020
Relation: 11027905	CID	23	31	D009020	0	4	D010146	false

Sentence: Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.
Entity: 11027905	48	68	N-methyl-D-aspartate	Chemical	D016202
Entity: 11027905	70	74	NMDA	Chemical	D016202
Entity: 11027905	97	105	ketamine	Chemical	D007649
Entity: 11027905	167	171	pain	Disease	D010146
Entity: 11027905	191	207	neuropathic pain	Disease	D009437
Relation: 11027905	CID	48	68	D016202	167	171	D010146	false
Relation: 11027905	CID	48	68	D016202	191	207	D009437	false
Relation: 11027905	CID	70	74	D016202	167	171	D010146	false
Relation: 11027905	CID	70	74	D016202	191	207	D009437	false
Relation: 11027905	CID	97	105	D007649	167	171	D010146	false
Relation: 11027905	CID	97	105	D007649	191	207	D009437	false

Sentence: A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study.
Entity: 11027905	37	45	ketamine	Chemical	D007649
Entity: 11027905	89	95	cancer	Disease	D009369
Entity: 11027905	111	115	pain	Disease	D010146
Entity: 11027905	134	142	morphine	Chemical	D009020
Relation: 11027905	CID	37	45	D007649	89	95	D009369	false
Relation: 11027905	CID	37	45	D007649	111	115	D010146	false
Relation: 11027905	CID	134	142	D009020	89	95	D009369	false
Relation: 11027905	CID	134	142	D009020	111	115	D010146	false

Sentence: Ketamine, but not saline solution, significantly reduced the pain intensity in almost all the patients at both doses.
Entity: 11027905	0	8	Ketamine	Chemical	D007649
Entity: 11027905	61	65	pain	Disease	D010146
Relation: 11027905	CID	0	8	D007649	61	65	D010146	false

Sentence: Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.
Entity: 11027905	0	8	Ketamine	Chemical	D007649
Entity: 11027905	21	29	morphine	Chemical	D009020
Entity: 11027905	53	57	pain	Disease	D010146
Entity: 11027905	77	93	neuropathic pain	Disease	D009437
Relation: 11027905	CID	0	8	D007649	53	57	D010146	false
Relation: 11027905	CID	0	8	D007649	77	93	D009437	false
Relation: 11027905	CID	21	29	D009020	53	57	D010146	false
Relation: 11027905	CID	21	29	D009020	77	93	D009437	false

Sentence: PURPOSE: We reviewed the results of serum testosterone and prolactin determination in 1,022 patients referred because of erectile dysfunction and compared the data with history, results of physical examination, other etiological investigations and effects of endocrine therapy to refine the rules of cost-effective endocrine screening and to pinpoint actual responsibility for hormonal abnormalities.
Entity: 9334596	42	54	testosterone	Chemical	D013739
Entity: 9334596	121	141	erectile dysfunction	Disease	D007172
Relation: 9334596	CID	42	54	D013739	121	141	D007172	false

Sentence: Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or testosterone less than 4 ng./ml.
Entity: 9334596	31	43	testosterone	Chemical	D013739
Entity: 9334596	96	113	low sexual desire	Disease	D020018
Entity: 9334596	115	127	gynecomastia	Disease	D006177
Entity: 9334596	131	143	testosterone	Chemical	D013739
Relation: 9334596	CID	31	43	D013739	96	113	D020018	true
Relation: 9334596	CID	31	43	D013739	115	127	D006177	false
Relation: 9334596	CID	131	143	D013739	96	113	D020018	true
Relation: 9334596	CID	131	143	D013739	115	127	D006177	false

Sentence: Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.
Entity: 9334596	31	53	testosterone heptylate	Chemical	C004648
Entity: 9334596	90	102	hypogonadism	Disease	D007006
Entity: 9334596	107	120	bromocriptine	Chemical	D001971
Entity: 9334596	125	143	hyperprolactinemia	Disease	D006966
Relation: 9334596	CID	31	53	C004648	90	102	D007006	false
Relation: 9334596	CID	31	53	C004648	125	143	D006966	false
Relation: 9334596	CID	107	120	D001971	90	102	D007006	false
Relation: 9334596	CID	107	120	D001971	125	143	D006966	false

Sentence: Two pituitary tumors were discovered after testosterone determination.
Entity: 9334596	4	20	pituitary tumors	Disease	D010911
Entity: 9334596	43	55	testosterone	Chemical	D013739
Relation: 9334596	CID	43	55	D013739	4	20	D010911	false

Sentence: Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).
Entity: 9334596	22	34	testosterone	Chemical	D013739
Entity: 9334596	75	99	hypothalamic dysfunction	Disease	D007027
Entity: 9334596	191	211	erectile dysfunction	Disease	D007172
Relation: 9334596	CID	22	34	D013739	75	99	D007027	false
Relation: 9334596	CID	22	34	D013739	191	211	D007172	false

Sentence: Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40% of the cases with low testosterone, including 37% of those subsequently improved by androgen therapy.
Entity: 9334596	12	24	testosterone	Chemical	D013739
Entity: 9334596	42	59	low sexual desire	Disease	D020018
Entity: 9334596	137	149	testosterone	Chemical	D013739
Relation: 9334596	CID	12	24	D013739	42	59	D020018	true
Relation: 9334596	CID	137	149	D013739	42	59	D020018	true

Sentence: CONCLUSIONS: Low prevalences and effects of low testosterone and high prolactin in erectile dysfunction cannot justify their routine determination.
Entity: 9334596	48	60	testosterone	Chemical	D013739
Entity: 9334596	83	103	erectile dysfunction	Disease	D007172
Relation: 9334596	CID	48	60	D013739	83	103	D007172	false

Sentence: We now advocate that before age 50 years testosterone be determined only in cases of low sexual desire and abnormal physical examination but that it be measured in all men older than 50 years.
Entity: 9334596	41	53	testosterone	Chemical	D013739
Entity: 9334596	85	102	low sexual desire	Disease	D020018
Relation: 9334596	CID	41	53	D013739	85	102	D020018	true

Sentence: Thiopentone pretreatment for propofol injection pain in ambulatory patients.
Entity: 8595686	0	11	Thiopentone	Chemical	D013874
Entity: 8595686	29	37	propofol	Chemical	D015742
Entity: 8595686	48	52	pain	Disease	D010146
Relation: 8595686	CID	0	11	D013874	48	52	D010146	false
Relation: 8595686	CID	29	37	D015742	48	52	D010146	true

Sentence: This study investigated propofol injection pain in patients undergoing ambulatory anaesthesia.
Entity: 8595686	24	32	propofol	Chemical	D015742
Entity: 8595686	43	47	pain	Disease	D010146
Relation: 8595686	CID	24	32	D015742	43	47	D010146	true

Sentence: Comparison of i.v. glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.
Entity: 6466532	19	33	glycopyrrolate	Chemical	D006024
Entity: 6466532	38	46	atropine	Chemical	D001285
Entity: 6466532	68	79	bradycardia	Disease	D001919
Entity: 6466532	84	95	arrhythmias	Disease	D001145
Entity: 6466532	124	137	suxamethonium	Chemical	D013390
Relation: 6466532	CID	19	33	D006024	68	79	D001919	false
Relation: 6466532	CID	19	33	D006024	84	95	D001145	false
Relation: 6466532	CID	38	46	D001285	68	79	D001919	false
Relation: 6466532	CID	38	46	D001285	84	95	D001145	false
Relation: 6466532	CID	124	137	D013390	68	79	D001919	true
Relation: 6466532	CID	124	137	D013390	84	95	D001145	false

Sentence: The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v. immediately before the induction of anaesthesia, to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children, was studied.
Entity: 6466532	39	53	glycopyrrolate	Chemical	D006024
Entity: 6466532	83	91	atropine	Chemical	D001285
Entity: 6466532	183	193	arrhythmia	Disease	D001145
Entity: 6466532	198	209	bradycardia	Disease	D001919
Entity: 6466532	238	251	suxamethonium	Chemical	D013390
Relation: 6466532	CID	39	53	D006024	183	193	D001145	false
Relation: 6466532	CID	39	53	D006024	198	209	D001919	false
Relation: 6466532	CID	83	91	D001285	183	193	D001145	false
Relation: 6466532	CID	83	91	D001285	198	209	D001919	false
Relation: 6466532	CID	238	251	D013390	183	193	D001145	false
Relation: 6466532	CID	238	251	D013390	198	209	D001919	true

Sentence: Reduction in caffeine toxicity by acetaminophen.
Entity: 6308277	13	21	caffeine	Chemical	D002110
Entity: 6308277	22	30	toxicity	Disease	D064420
Entity: 6308277	34	47	acetaminophen	Chemical	D000082
Relation: 6308277	CID	13	21	D002110	22	30	D064420	false
Relation: 6308277	CID	34	47	D000082	22	30	D064420	false

Sentence: Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS toxicity of caffeine.
Entity: 6308277	77	85	caffeine	Chemical	D002110
Entity: 6308277	160	173	acetaminophen	Chemical	D000082
Entity: 6308277	209	217	toxicity	Disease	D064420
Entity: 6308277	221	229	caffeine	Chemical	D002110
Relation: 6308277	CID	77	85	D002110	209	217	D064420	false
Relation: 6308277	CID	160	173	D000082	209	217	D064420	false
Relation: 6308277	CID	221	229	D002110	209	217	D064420	false

Sentence: Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).
Entity: 6308277	57	70	acetaminophen	Chemical	D000082
Entity: 6308277	136	144	caffeine	Chemical	D002110
Entity: 6308277	190	201	convulsions	Disease	D012640
Entity: 6308277	253	266	acetaminophen	Chemical	D000082
Entity: 6308277	314	322	seizures	Disease	D012640
Entity: 6308277	351	359	caffeine	Chemical	D002110
Relation: 6308277	CID	57	70	D000082	190	201	D012640	false
Relation: 6308277	CID	57	70	D000082	314	322	D012640	false
Relation: 6308277	CID	136	144	D002110	190	201	D012640	true
Relation: 6308277	CID	136	144	D002110	314	322	D012640	true
Relation: 6308277	CID	253	266	D000082	190	201	D012640	false
Relation: 6308277	CID	253	266	D000082	314	322	D012640	false
Relation: 6308277	CID	351	359	D002110	190	201	D012640	true
Relation: 6308277	CID	351	359	D002110	314	322	D012640	true

Sentence: The frequency of sound induced seizures after 12.5 or 25 mg/kg caffeine was reduced from 50 to 5% by acetaminophen.
Entity: 6308277	31	39	seizures	Disease	D012640
Entity: 6308277	63	71	caffeine	Chemical	D002110
Entity: 6308277	101	114	acetaminophen	Chemical	D000082
Relation: 6308277	CID	63	71	D002110	31	39	D012640	true
Relation: 6308277	CID	101	114	D000082	31	39	D012640	false

Sentence: In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).
Entity: 6308277	18	26	caffeine	Chemical	D002110
Entity: 6308277	28	41	acetaminophen	Chemical	D000082
Entity: 6308277	79	87	seizures	Disease	D012640
Entity: 6308277	161	178	pentylenetetrezol	Chemical	D010433
Relation: 6308277	CID	18	26	D002110	79	87	D012640	true
Relation: 6308277	CID	28	41	D000082	79	87	D012640	false
Relation: 6308277	CID	161	178	D010433	79	87	D012640	true

Sentence: Flestolol produced a dose-dependent attenuation of isoproterenol induced tachycardia.
Entity: 2870085	0	9	Flestolol	Chemical	C047847
Entity: 2870085	51	64	isoproterenol	Chemical	D007545
Entity: 2870085	73	84	tachycardia	Disease	D013610
Relation: 2870085	CID	0	9	C047847	73	84	D013610	false
Relation: 2870085	CID	51	64	D007545	73	84	D013610	true

Sentence: Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia.
Entity: 2870085	0	9	Flestolol	Chemical	C047847
Entity: 2870085	58	90	supraventricular tachyarrhythmia	Disease	D013617
Relation: 2870085	CID	0	9	C047847	58	90	D013617	false

Sentence: In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.
Entity: 2870085	17	32	unstable angina	Disease	D000789
Entity: 2870085	34	43	flestolol	Chemical	C047847
Entity: 2870085	103	113	chest pain	Disease	D002637
Relation: 2870085	CID	34	43	C047847	17	32	D000789	false
Relation: 2870085	CID	34	43	C047847	103	113	D002637	false

Sentence: Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.
Entity: 1639466	22	29	calcium	Chemical	D002118
Entity: 1639466	46	58	nitrendipine	Chemical	D009568
Entity: 1639466	62	77	nephrosclerosis	Disease	D009400
Entity: 1639466	91	116	renovascular hypertension	Disease	D006978
Relation: 1639466	CID	22	29	D002118	62	77	D009400	false
Relation: 1639466	CID	22	29	D002118	91	116	D006978	false
Relation: 1639466	CID	46	58	D009568	62	77	D009400	true
Relation: 1639466	CID	46	58	D009568	91	116	D006978	false

Sentence: The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.
Entity: 1639466	42	49	calcium	Chemical	D002118
Entity: 1639466	66	78	nitrendipine	Chemical	D009568
Entity: 1639466	86	97	angiotensin	Chemical	D000809
Entity: 1639466	126	135	enalapril	Chemical	D004656
Entity: 1639466	155	166	albuminuria	Disease	D000419
Entity: 1639466	274	299	renovascular hypertension	Disease	D006978
Relation: 1639466	CID	42	49	D002118	155	166	D000419	false
Relation: 1639466	CID	42	49	D002118	274	299	D006978	false
Relation: 1639466	CID	66	78	D009568	155	166	D000419	true
Relation: 1639466	CID	66	78	D009568	274	299	D006978	false
Relation: 1639466	CID	86	97	D000809	155	166	D000419	false
Relation: 1639466	CID	86	97	D000809	274	299	D006978	false
Relation: 1639466	CID	126	135	D004656	155	166	D000419	false
Relation: 1639466	CID	126	135	D004656	274	299	D006978	false

Sentence: Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).
Entity: 1639466	46	58	hypertensive	Disease	D006973
Entity: 1639466	132	144	hypertensive	Disease	D006973
Entity: 1639466	163	172	enalapril	Chemical	D004656
Entity: 1639466	193	205	nitrendipine	Chemical	D009568
Relation: 1639466	CID	163	172	D004656	46	58	D006973	false
Relation: 1639466	CID	163	172	D004656	132	144	D006973	false
Relation: 1639466	CID	193	205	D009568	46	58	D006973	false
Relation: 1639466	CID	193	205	D009568	132	144	D006973	false

Sentence: Renal plasma flow increased, but albumin excretion and glomerulosclerosis did not change after enalapril treatment.
Entity: 1639466	55	73	glomerulosclerosis	Disease	D005921
Entity: 1639466	95	104	enalapril	Chemical	D004656
Relation: 1639466	CID	95	104	D004656	55	73	D005921	false

Sentence: In contrast, in the nitrendipine-treated group albuminuria increased from 12.8 +/- 2 progressively to 163 +/- 55 compared with 19.2 +/- 9 mg/24 hr in the hypertensive controls.
Entity: 1639466	20	32	nitrendipine	Chemical	D009568
Entity: 1639466	47	58	albuminuria	Disease	D000419
Entity: 1639466	154	166	hypertensive	Disease	D006973
Relation: 1639466	CID	20	32	D009568	47	58	D000419	true
Relation: 1639466	CID	20	32	D009568	154	166	D006973	false

Sentence: Furthermore, glomerulosclerosis index was significantly increased in the nitrendipine-treated group compared with the hypertensive controls (0.38 +/- 0.1 versus 0.13 +/- 0.04).
Entity: 1639466	13	31	glomerulosclerosis	Disease	D005921
Entity: 1639466	73	85	nitrendipine	Chemical	D009568
Entity: 1639466	118	130	hypertensive	Disease	D006973
Relation: 1639466	CID	73	85	D009568	13	31	D005921	false
Relation: 1639466	CID	73	85	D009568	118	130	D006973	false

Sentence: Treatment of tinnitus by intratympanic instillation of lignocaine (lidocaine) 2 per cent through ventilation tubes.
Entity: 1527456	13	21	tinnitus	Disease	D014012
Entity: 1527456	55	65	lignocaine	Chemical	D008012
Entity: 1527456	67	76	lidocaine	Chemical	D008012
Relation: 1527456	CID	55	65	D008012	13	21	D014012	false
Relation: 1527456	CID	67	76	D008012	13	21	D014012	false

Sentence: This paper presents the results of treating IST by intratympanic instillation of lignocaine (lidocaine) 2 per cent through a grommet, for five weekly courses.
Entity: 1527456	44	47	IST	Disease	D014012
Entity: 1527456	81	91	lignocaine	Chemical	D008012
Entity: 1527456	93	102	lidocaine	Chemical	D008012
Relation: 1527456	CID	81	91	D008012	44	47	D014012	false
Relation: 1527456	CID	93	102	D008012	44	47	D014012	false

Sentence: Perhexiline maleate and peripheral neuropathy.
Entity: 220563	0	19	Perhexiline maleate	Chemical	C023470
Entity: 220563	24	45	peripheral neuropathy	Disease	D010523
Relation: 220563	CID	0	19	C023470	24	45	D010523	true

Sentence: Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.
Entity: 220563	0	21	Peripheral neuropathy	Disease	D010523
Entity: 220563	71	90	perhexiline maleate	Chemical	C023470
Entity: 220563	201	216	angina pectoris	Disease	D000787
Relation: 220563	CID	71	90	C023470	0	21	D010523	true
Relation: 220563	CID	71	90	C023470	201	216	D000787	false

Sentence: Effect of humoral modulators of morphine induced increase in locomotor activity of mice.
Entity: 137340	32	40	morphine	Chemical	D009020
Entity: 137340	49	79	increase in locomotor activity	Disease	D006948
Relation: 137340	CID	32	40	D009020	49	79	D006948	true

Sentence: The effect of humoral modulators on the morphine induced increase in locomotor activity of mice was studied.
Entity: 137340	40	48	morphine	Chemical	D009020
Entity: 137340	57	87	increase in locomotor activity	Disease	D006948
Relation: 137340	CID	40	48	D009020	57	87	D006948	true

Sentence: The subcutaneous administration of 10 mg/kg of morphine-HC1 produced a marked increase in locomotor activity in mice.
Entity: 137340	47	55	morphine	Chemical	D009020
Entity: 137340	78	108	increase in locomotor activity	Disease	D006948
Relation: 137340	CID	47	55	D009020	78	108	D006948	true

Sentence: The morphine induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine.
Entity: 137340	4	12	morphine	Chemical	D009020
Entity: 137340	21	34	hyperactivity	Disease	D006948
Entity: 137340	54	65	scopolamine	Chemical	D012601
Entity: 137340	84	97	physostigmine	Chemical	D010830
Relation: 137340	CID	4	12	D009020	21	34	D006948	true
Relation: 137340	CID	54	65	D012601	21	34	D006948	true
Relation: 137340	CID	84	97	D010830	21	34	D006948	false

Sentence: In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.
Entity: 137340	18	33	methscopolamine	Chemical	D019832
Entity: 137340	38	49	neostigmine	Chemical	D009388
Entity: 137340	120	133	hyperactivity	Disease	D006948
Entity: 137340	146	154	morphine	Chemical	D009020
Relation: 137340	CID	18	33	D019832	120	133	D006948	false
Relation: 137340	CID	38	49	D009388	120	133	D006948	false
Relation: 137340	CID	146	154	D009020	120	133	D006948	true

Sentence: On the other hand, pretreatment with p-chlorophenylalamine (3 X 320 mg/kg i.p., 24 hr), a serotonin depletor, caused no significant change in the hyperactivity.
Entity: 137340	37	58	p-chlorophenylalamine	Chemical	D010134
Entity: 137340	90	99	serotonin	Chemical	D012701
Entity: 137340	146	159	hyperactivity	Disease	D006948
Relation: 137340	CID	37	58	D010134	146	159	D006948	false
Relation: 137340	CID	90	99	D012701	146	159	D006948	false

Sentence: Mechanisms of FK 506 induced hypertension in the rat. -Tacrolimus (FK 506) is a powerful, widely used immunosuppressant.
Entity: 9931093	14	20	FK 506	Chemical	D016559
Entity: 9931093	29	41	hypertension	Disease	D006973
Entity: 9931093	55	65	Tacrolimus	Chemical	D016559
Entity: 9931093	67	73	FK 506	Chemical	D016559
Relation: 9931093	CID	14	20	D016559	29	41	D006973	true
Relation: 9931093	CID	55	65	D016559	29	41	D006973	true
Relation: 9931093	CID	67	73	D016559	29	41	D006973	true

Sentence: The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity.
Entity: 9931093	24	30	FK 506	Chemical	D016559
Entity: 9931093	61	73	hypertension	Disease	D006973
Entity: 9931093	78	92	nephrotoxicity	Disease	D007674
Relation: 9931093	CID	24	30	D016559	61	73	D006973	true
Relation: 9931093	CID	24	30	D016559	78	92	D007674	false

Sentence: To clarify the mechanisms of FK 506 induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.
Entity: 9931093	29	35	FK 506	Chemical	D016559
Entity: 9931093	44	56	hypertension	Disease	D006973
Entity: 9931093	92	98	FK 506	Chemical	D016559
Entity: 9931093	231	243	nitric oxide	Chemical	D009569
Relation: 9931093	CID	29	35	D016559	44	56	D006973	true
Relation: 9931093	CID	92	98	D016559	44	56	D006973	true
Relation: 9931093	CID	231	243	D009569	44	56	D006973	false

Sentence: In addition, the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506 induced hypertension in rats was studied.
Entity: 9931093	78	87	FR 139317	Chemical	C079574
Entity: 9931093	91	97	FK 506	Chemical	D016559
Entity: 9931093	106	118	hypertension	Disease	D006973
Relation: 9931093	CID	78	87	C079574	106	118	D006973	false
Relation: 9931093	CID	91	97	D016559	106	118	D006973	true

Sentence: The administration of FR 139317 (10 mg. kg-1. d-1) prevented FK 506 induced hypertension in rats.
Entity: 9931093	22	31	FR 139317	Chemical	C079574
Entity: 9931093	61	67	FK 506	Chemical	D016559
Entity: 9931093	76	88	hypertension	Disease	D006973
Relation: 9931093	CID	22	31	C079574	76	88	D006973	false
Relation: 9931093	CID	61	67	D016559	76	88	D006973	true

Sentence: Suxamethonium induced prolonged apnea in a patient receiving electroconvulsive therapy.
Entity: 20633755	0	13	Suxamethonium	Chemical	D013390
Entity: 20633755	32	37	apnea	Disease	D001049
Relation: 20633755	CID	0	13	D013390	32	37	D001049	true

Sentence: Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.
Entity: 20633755	0	13	Suxamethonium	Chemical	D013390
Entity: 20633755	31	36	apnea	Disease	D001049
Entity: 20633755	105	134	organophosphorus (OP) poisons	Chemical	D009943
Relation: 20633755	CID	0	13	D013390	31	36	D001049	true
Relation: 20633755	CID	105	134	D009943	31	36	D001049	true

Sentence: The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.
Entity: 20067456	30	39	bupropion	Chemical	D016642
Entity: 20067456	48	66	sexual dysfunction	Disease	D012735
Entity: 20067456	80	118	selective serotonin reuptake inhibitor	Chemical	D017367
Relation: 20067456	CID	30	39	D016642	48	66	D012735	false
Relation: 20067456	CID	80	118	D017367	48	66	D012735	false

Sentence: OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.
Entity: 20067456	62	71	bupropion	Chemical	D016642
Entity: 20067456	103	121	sexual dysfunction	Disease	D012735
Entity: 20067456	123	125	SD	Disease	D012735
Entity: 20067456	140	178	selective serotonin reuptake inhibitor	Chemical	D017367
Entity: 20067456	180	184	SSRI	Chemical	D017367
Entity: 20067456	190	192	SD	Disease	D012735
Entity: 20067456	220	225	SSRIs	Chemical	D017367
Relation: 20067456	CID	62	71	D016642	103	121	D012735	false
Relation: 20067456	CID	62	71	D016642	123	125	D012735	false
Relation: 20067456	CID	62	71	D016642	190	192	D012735	false
Relation: 20067456	CID	140	178	D017367	103	121	D012735	false
Relation: 20067456	CID	140	178	D017367	123	125	D012735	false
Relation: 20067456	CID	140	178	D017367	190	192	D012735	false
Relation: 20067456	CID	180	184	D017367	103	121	D012735	false
Relation: 20067456	CID	180	184	D017367	123	125	D012735	false
Relation: 20067456	CID	180	184	D017367	190	192	D012735	false
Relation: 20067456	CID	220	225	D017367	103	121	D012735	false
Relation: 20067456	CID	220	225	D017367	123	125	D012735	false
Relation: 20067456	CID	220	225	D017367	190	192	D012735	false

Sentence: In linear regression analyses the CGI-SF score was not affected significantly by the duration of SD, type of SSRI used and age.
Entity: 20067456	97	99	SD	Disease	D012735
Entity: 20067456	109	113	SSRI	Chemical	D017367
Relation: 20067456	CID	109	113	D017367	97	99	D012735	false

Sentence: CONCLUSIONS: Bupropion is an effective treatment for male SD induced by SSRIs.
Entity: 20067456	13	22	Bupropion	Chemical	D016642
Entity: 20067456	58	60	SD	Disease	D012735
Entity: 20067456	72	77	SSRIs	Chemical	D017367
Relation: 20067456	CID	13	22	D016642	58	60	D012735	false
Relation: 20067456	CID	72	77	D017367	58	60	D012735	false

Sentence: Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.
Entity: 18464113	0	10	Lamivudine	Chemical	D019259
Entity: 18464113	33	44	hepatitis B	Disease	D006509
Entity: 18464113	67	94	hepatitis-B surface antigen	Chemical	D006514
Entity: 18464113	96	101	HBSAG	Chemical	D006514
Entity: 18464113	116	122	cancer	Disease	D009369
Relation: 18464113	CID	0	10	D019259	33	44	D006509	false
Relation: 18464113	CID	0	10	D019259	116	122	D009369	false
Relation: 18464113	CID	67	94	D006514	33	44	D006509	true
Relation: 18464113	CID	67	94	D006514	116	122	D009369	false
Relation: 18464113	CID	96	101	D006514	33	44	D006509	true
Relation: 18464113	CID	96	101	D006514	116	122	D009369	false

Sentence: In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.
Entity: 18464113	15	21	cancer	Disease	D009369
Entity: 18464113	50	76	hematological malignancies	Disease	D019337
Entity: 18464113	90	103	HBV infection	Disease	D006509
Entity: 18464113	133	143	lamivudine	Chemical	D019259
Entity: 18464113	223	233	lamivudine	Chemical	D019259
Relation: 18464113	CID	133	143	D019259	15	21	D009369	false
Relation: 18464113	CID	133	143	D019259	50	76	D019337	false
Relation: 18464113	CID	133	143	D019259	90	103	D006509	false
Relation: 18464113	CID	223	233	D019259	15	21	D009369	false
Relation: 18464113	CID	223	233	D019259	50	76	D019337	false
Relation: 18464113	CID	223	233	D019259	90	103	D006509	false

Sentence: In the prophylactic lamivudine group severe hepatitis were observed only in 1 patient (2.7%) of 37 patients (p < 0.006).
Entity: 18464113	20	30	lamivudine	Chemical	D019259
Entity: 18464113	44	53	hepatitis	Disease	D056486
Relation: 18464113	CID	20	30	D019259	44	53	D056486	false

Sentence: Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in cancer patients during and after immunosuppressive therapy.
Entity: 18464113	37	47	lamivudine	Chemical	D019259
Entity: 18464113	131	137	cancer	Disease	D009369
Relation: 18464113	CID	37	47	D019259	131	137	D009369	false

Sentence: Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.
Entity: 18308784	0	15	Ginsenoside Rg1	Chemical	C035054
Entity: 18308784	29	51	impairment of learning	Disease	D007859
Entity: 18308784	71	79	morphine	Chemical	D009020
Relation: 18308784	CID	0	15	C035054	29	51	D007859	false
Relation: 18308784	CID	71	79	D009020	29	51	D007859	true

Sentence: Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.
Entity: 18308784	0	3	Rg1	Chemical	C035054
Entity: 18308784	10	21	ginsenoside	Chemical	D036145
Entity: 18308784	77	96	learning impairment	Disease	D007859
Relation: 18308784	CID	0	3	C035054	77	96	D007859	false
Relation: 18308784	CID	10	21	D036145	77	96	D007859	false

Sentence: The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.
Entity: 18308784	55	58	Rg1	Chemical	C035054
Entity: 18308784	62	81	learning impairment	Disease	D007859
Entity: 18308784	93	101	morphine	Chemical	D009020
Relation: 18308784	CID	55	58	C035054	62	81	D007859	false
Relation: 18308784	CID	93	101	D009020	62	81	D007859	true

Sentence: A study on the effect of the duration of subcutaneous heparin injection on bruising and pain.
Entity: 17931375	54	61	heparin	Chemical	D006493
Entity: 17931375	75	83	bruising	Disease	D003288
Entity: 17931375	88	92	pain	Disease	D010146
Relation: 17931375	CID	54	61	D006493	75	83	D003288	true
Relation: 17931375	CID	54	61	D006493	88	92	D010146	true

Sentence: AIM: This study was carried out to determine the effect of injection duration on bruising and pain following the administration of the subcutaneous injection of heparin.
Entity: 17931375	81	89	bruising	Disease	D003288
Entity: 17931375	94	98	pain	Disease	D010146
Entity: 17931375	161	168	heparin	Chemical	D006493
Relation: 17931375	CID	161	168	D006493	81	89	D003288	true
Relation: 17931375	CID	161	168	D006493	94	98	D010146	true

Sentence: BACKGROUND: Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described, the effect of injection duration on the occurrence of bruising and pain is little documented.
Entity: 17931375	50	58	bruising	Disease	D003288
Entity: 17931375	63	67	pain	Disease	D010146
Entity: 17931375	108	115	heparin	Chemical	D006493
Entity: 17931375	210	218	bruising	Disease	D003288
Entity: 17931375	223	227	pain	Disease	D010146
Relation: 17931375	CID	108	115	D006493	50	58	D003288	true
Relation: 17931375	CID	108	115	D006493	63	67	D010146	true
Relation: 17931375	CID	108	115	D006493	210	218	D003288	true
Relation: 17931375	CID	108	115	D006493	223	227	D010146	true

Sentence: Dimensions of the bruising on the heparin applied areas were measured using transparent millimetric measuring paper.
Entity: 17931375	18	26	bruising	Disease	D003288
Entity: 17931375	34	41	heparin	Chemical	D006493
Relation: 17931375	CID	34	41	D006493	18	26	D003288	true

Sentence: CONCLUSIONS: It was determined that injection duration had an effect on bruising and pain following the subcutaneous administration of heparin.
Entity: 17931375	72	80	bruising	Disease	D003288
Entity: 17931375	85	89	pain	Disease	D010146
Entity: 17931375	135	142	heparin	Chemical	D006493
Relation: 17931375	CID	135	142	D006493	72	80	D003288	true
Relation: 17931375	CID	135	142	D006493	85	89	D010146	true

Sentence: Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.
Entity: 15649445	6	15	reserpine	Chemical	D012110
Entity: 15649445	31	42	haloperidol	Chemical	D006220
Entity: 15649445	80	89	glutamate	Chemical	D018698
Entity: 15649445	108	128	orofacial dyskinesia	Disease	D004409
Relation: 15649445	CID	6	15	D012110	108	128	D004409	true
Relation: 15649445	CID	31	42	D006220	108	128	D004409	true
Relation: 15649445	CID	80	89	D018698	108	128	D004409	false

Sentence: Reserpine- and haloperidol induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.
Entity: 15649445	0	9	Reserpine	Chemical	D012110
Entity: 15649445	15	26	haloperidol	Chemical	D006220
Entity: 15649445	35	55	orofacial dyskinesia	Disease	D004409
Entity: 15649445	86	104	tardive dyskinesia	Disease	D004409
Entity: 15649445	106	108	TD	Disease	D004409
Relation: 15649445	CID	0	9	D012110	35	55	D004409	true
Relation: 15649445	CID	0	9	D012110	86	104	D004409	true
Relation: 15649445	CID	0	9	D012110	106	108	D004409	true
Relation: 15649445	CID	15	26	D006220	35	55	D004409	true
Relation: 15649445	CID	15	26	D006220	86	104	D004409	true
Relation: 15649445	CID	15	26	D006220	106	108	D004409	true

Sentence: In the present study, the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats.
Entity: 15649445	42	62	orofacial dyskinesia	Disease	D004409
Entity: 15649445	72	81	reserpine	Chemical	D012110
Entity: 15649445	97	108	haloperidol	Chemical	D006220
Relation: 15649445	CID	72	81	D012110	42	62	D004409	true
Relation: 15649445	CID	97	108	D006220	42	62	D004409	true

Sentence: Importantly, a decrease in glutamate uptake correlates negatively with an increase in the incidence of orofacial diskinesia.
Entity: 15649445	27	36	glutamate	Chemical	D018698
Entity: 15649445	103	123	orofacial diskinesia	Disease	D004409
Relation: 15649445	CID	27	36	D018698	103	123	D004409	false

Sentence: Acute psychosis due to treatment with phenytoin in a nonepileptic patient.
Entity: 14698717	0	15	Acute psychosis	Disease	D011605
Entity: 14698717	38	47	phenytoin	Chemical	D010672
Relation: 14698717	CID	38	47	D010672	0	15	D011605	true

Sentence: The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.
Entity: 14698717	49	58	psychosis	Disease	D011605
Entity: 14698717	69	78	phenytoin	Chemical	D010672
Entity: 14698717	93	113	trigeminal neuralgia	Disease	D014277
Relation: 14698717	CID	69	78	D010672	49	58	D011605	true
Relation: 14698717	CID	69	78	D010672	93	113	D014277	false

Sentence: The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats: a preliminary study.
Entity: 12617329	29	39	gum Arabic	Chemical	D006170
Entity: 12617329	43	53	gentamicin	Chemical	D005839
Entity: 12617329	54	68	nephrotoxicity	Disease	D007674
Relation: 12617329	CID	29	39	D006170	54	68	D007674	false
Relation: 12617329	CID	43	53	D005839	54	68	D007674	false

Sentence: In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.
Entity: 12617329	69	79	gum Arabic	Chemical	D006170
Entity: 12617329	83	102	acute renal failure	Disease	D058186
Entity: 12617329	114	124	gentamicin	Chemical	D005839
Entity: 12617329	126	128	GM	Chemical	D005839
Entity: 12617329	130	144	nephrotoxicity	Disease	D007674
Relation: 12617329	CID	69	79	D006170	83	102	D058186	true
Relation: 12617329	CID	69	79	D006170	130	144	D007674	false
Relation: 12617329	CID	114	124	D005839	83	102	D058186	true
Relation: 12617329	CID	114	124	D005839	130	144	D007674	false
Relation: 12617329	CID	126	128	D005839	83	102	D058186	true
Relation: 12617329	CID	126	128	D005839	130	144	D007674	false

Sentence: Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.
Entity: 12617329	0	14	Nephrotoxicity	Disease	D007674
Entity: 12617329	63	73	creatinine	Chemical	D003404
Entity: 12617329	78	82	urea	Chemical	D014508
Entity: 12617329	109	120	glutathione	Chemical	D005978
Entity: 12617329	122	125	GSH	Chemical	D005978
Relation: 12617329	CID	63	73	D003404	0	14	D007674	false
Relation: 12617329	CID	78	82	D014508	0	14	D007674	false
Relation: 12617329	CID	109	120	D005978	0	14	D007674	false
Relation: 12617329	CID	122	125	D005978	0	14	D007674	false

Sentence: The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.
Entity: 12617329	54	64	gum Arabic	Chemical	D006170
Entity: 12617329	69	71	GM	Chemical	D005839
Entity: 12617329	96	106	creatinine	Chemical	D003404
Entity: 12617329	111	115	urea	Chemical	D014508
Entity: 12617329	228	230	GM	Chemical	D005839
Entity: 12617329	264	267	GSH	Chemical	D005978
Entity: 12617329	314	316	GM	Chemical	D005839
Entity: 12617329	328	330	GM	Chemical	D005839
Entity: 12617329	348	364	tubular necrosis	Disease	D007683
Entity: 12617329	415	417	GM	Chemical	D005839
Entity: 12617329	432	442	gum Arabic	Chemical	D006170
Entity: 12617329	463	465	GM	Chemical	D005839
Relation: 12617329	CID	54	64	D006170	348	364	D007683	false
Relation: 12617329	CID	69	71	D005839	348	364	D007683	false
Relation: 12617329	CID	96	106	D003404	348	364	D007683	false
Relation: 12617329	CID	111	115	D014508	348	364	D007683	false
Relation: 12617329	CID	228	230	D005839	348	364	D007683	false
Relation: 12617329	CID	264	267	D005978	348	364	D007683	false
Relation: 12617329	CID	314	316	D005839	348	364	D007683	false
Relation: 12617329	CID	328	330	D005839	348	364	D007683	false
Relation: 12617329	CID	415	417	D005839	348	364	D007683	false
Relation: 12617329	CID	432	442	D006170	348	364	D007683	false
Relation: 12617329	CID	463	465	D005839	348	364	D007683	false

Sentence: It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity.
Entity: 12617329	26	36	gum Arabic	Chemical	D006170
Entity: 12617329	136	138	GM	Chemical	D005839
Entity: 12617329	139	153	nephrotoxicity	Disease	D007674
Relation: 12617329	CID	26	36	D006170	139	153	D007674	false
Relation: 12617329	CID	136	138	D005839	139	153	D007674	false

Sentence: Visual hallucinations associated with zonisamide.
Entity: 12523465	0	21	Visual hallucinations	Disease	D006212
Entity: 12523465	38	48	zonisamide	Chemical	C022189
Relation: 12523465	CID	38	48	C022189	0	21	D006212	true

Sentence: Zonisamide is a broad-spectrum antiepileptic drug used to treat various types of seizures.
Entity: 12523465	0	10	Zonisamide	Chemical	C022189
Entity: 12523465	81	89	seizures	Disease	D012640
Relation: 12523465	CID	0	10	C022189	81	89	D012640	false

Sentence: Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.
Entity: 12523465	9	30	visual hallucinations	Disease	D006212
Entity: 12523465	141	162	visual hallucinations	Disease	D006212
Entity: 12523465	195	205	zonisamide	Chemical	C022189
Relation: 12523465	CID	195	205	C022189	9	30	D006212	true
Relation: 12523465	CID	195	205	C022189	141	162	D006212	true

Sentence: GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis.
Entity: 11961407	16	24	tyrosine	Chemical	D014443
Entity: 11961407	52	55	PAN	Chemical	D011692
Entity: 11961407	56	65	nephrosis	Disease	D009401
Relation: 11961407	CID	16	24	D014443	56	65	D009401	false
Relation: 11961407	CID	52	55	D011692	56	65	D009401	true

Sentence: Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).
Entity: 11961407	0	25	Puromycin aminonucleoside	Chemical	D011692
Entity: 11961407	26	35	nephrosis	Disease	D009401
Entity: 11961407	87	112	puromycin aminonucleoside	Chemical	D011692
Entity: 11961407	114	117	PAN	Chemical	D011692
Relation: 11961407	CID	0	25	D011692	26	35	D009401	true
Relation: 11961407	CID	87	112	D011692	26	35	D009401	true
Relation: 11961407	CID	114	117	D011692	26	35	D009401	true

Sentence: Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).
Entity: 11961407	68	71	PAN	Chemical	D011692
Entity: 11961407	123	134	proteinuria	Disease	D011507
Entity: 11961407	212	223	proteinuria	Disease	D011507
Entity: 11961407	240	258	glomerulosclerosis	Disease	D005921
Relation: 11961407	CID	68	71	D011692	123	134	D011507	true
Relation: 11961407	CID	68	71	D011692	212	223	D011507	true
Relation: 11961407	CID	68	71	D011692	240	258	D005921	false

Sentence: Ticlopidine induced aplastic anemia: report of three Chinese patients and review of the literature.
Entity: 9401499	0	11	Ticlopidine	Chemical	D013988
Entity: 9401499	20	35	aplastic anemia	Disease	D000741
Relation: 9401499	CID	0	11	D013988	20	35	D000741	true

Sentence: In this study, three Chinese patients with ticlopidine induced aplastic anemia were reported and another 13 patients in the English literature were reviewed.
Entity: 9401499	43	54	ticlopidine	Chemical	D013988
Entity: 9401499	63	78	aplastic anemia	Disease	D000741
Relation: 9401499	CID	43	54	D013988	63	78	D000741	true

Sentence: Agranulocytosis occurred 3-20 weeks after initiation of ticlopidine, so frequent examination of white cell count during treatment is recommended.
Entity: 9401499	0	15	Agranulocytosis	Disease	D000380
Entity: 9401499	56	67	ticlopidine	Chemical	D013988
Relation: 9401499	CID	56	67	D013988	0	15	D000380	true

Sentence: Treatment for ticlopidine induced aplastic anemia with colony-stimulating factors seemed to have little effect.
Entity: 9401499	14	25	ticlopidine	Chemical	D013988
Entity: 9401499	34	49	aplastic anemia	Disease	D000741
Relation: 9401499	CID	14	25	D013988	34	49	D000741	true

Sentence: Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.
Entity: 2273650	0	7	Amnesia	Disease	D000647
Entity: 2273650	20	31	scopolamine	Chemical	D012601
Entity: 2273650	36	49	cycloheximide	Chemical	D003513
Entity: 2273650	67	75	morphine	Chemical	D009020
Entity: 2273650	136	144	morphine	Chemical	D009020
Entity: 2273650	211	219	naloxone	Chemical	D009270
Relation: 2273650	CID	20	31	D012601	0	7	D000647	true
Relation: 2273650	CID	36	49	D003513	0	7	D000647	true
Relation: 2273650	CID	67	75	D009020	0	7	D000647	false
Relation: 2273650	CID	136	144	D009020	0	7	D000647	false
Relation: 2273650	CID	211	219	D009270	0	7	D000647	false

Sentence: Similarly, pre-test scopolamine partially reversed the scopolamine induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide induced amnesia.
Entity: 2273650	20	31	scopolamine	Chemical	D012601
Entity: 2273650	55	66	scopolamine	Chemical	D012601
Entity: 2273650	75	82	amnesia	Disease	D000647
Entity: 2273650	120	133	cycloheximide	Chemical	D003513
Entity: 2273650	156	169	cycloheximide	Chemical	D003513
Entity: 2273650	178	185	amnesia	Disease	D000647
Relation: 2273650	CID	20	31	D012601	75	82	D000647	true
Relation: 2273650	CID	20	31	D012601	178	185	D000647	true
Relation: 2273650	CID	55	66	D012601	75	82	D000647	true
Relation: 2273650	CID	55	66	D012601	178	185	D000647	true
Relation: 2273650	CID	120	133	D003513	75	82	D000647	true
Relation: 2273650	CID	120	133	D003513	178	185	D000647	true
Relation: 2273650	CID	156	169	D003513	75	82	D000647	true
Relation: 2273650	CID	156	169	D003513	178	185	D000647	true

Sentence: Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to dopamine turnover in the rodent brain.
Entity: 10683478	0	11	Apomorphine	Chemical	D001058
Entity: 10683478	28	44	dopamine agonist	Chemical	D018491
Entity: 10683478	121	132	hypothermia	Disease	D007035
Entity: 10683478	169	177	dopamine	Chemical	D004298
Relation: 10683478	CID	0	11	D001058	121	132	D007035	true
Relation: 10683478	CID	28	44	D018491	121	132	D007035	false
Relation: 10683478	CID	169	177	D004298	121	132	D007035	false

Sentence: In rats, detection of apomorphine induced hyperactivity was facilitated by a period of acclimatization to the test conditions.
Entity: 10683478	22	33	apomorphine	Chemical	D001058
Entity: 10683478	42	55	hyperactivity	Disease	D006948
Relation: 10683478	CID	22	33	D001058	42	55	D006948	true

Sentence: Moreover, test conditions can impact upon other physiological responses to apomorphine such as drug induced hypothermia.
Entity: 10683478	75	86	apomorphine	Chemical	D001058
Entity: 10683478	108	119	hypothermia	Disease	D007035
Relation: 10683478	CID	75	86	D001058	108	119	D007035	true

Sentence: Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant.
Entity: 6794356	0	29	Tricuspid valve regurgitation	Disease	D014262
Entity: 6794356	34	51	lithium carbonate	Chemical	D016651
Entity: 6794356	52	60	toxicity	Disease	D064420
Relation: 6794356	CID	34	51	D016651	0	29	D014262	false
Relation: 6794356	CID	34	51	D016651	52	60	D064420	false

Sentence: A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.
Entity: 6794356	23	46	tricuspid regurgitation	Disease	D014262
Entity: 6794356	48	62	atrial flutter	Disease	D001282
Entity: 6794356	64	88	congestive heart failure	Disease	D006333
Entity: 6794356	107	114	lithium	Chemical	D008094
Relation: 6794356	CID	107	114	D008094	23	46	D014262	false
Relation: 6794356	CID	107	114	D008094	48	62	D001282	false
Relation: 6794356	CID	107	114	D008094	64	88	D006333	false

Sentence: This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.
Entity: 6794356	48	71	tricuspid regurgitation	Disease	D014262
Entity: 6794356	76	90	atrial flutter	Disease	D001282
Entity: 6794356	128	143	cardiac disease	Disease	D006331
Entity: 6794356	169	176	lithium	Chemical	D008094
Relation: 6794356	CID	169	176	D008094	48	71	D014262	false
Relation: 6794356	CID	169	176	D008094	76	90	D001282	false
Relation: 6794356	CID	169	176	D008094	128	143	D006331	false

Sentence: Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy.
Entity: 6794356	0	17	Lithium carbonate	Chemical	D016651
Entity: 6794356	65	89	congenital heart disease	Disease	D006331
Relation: 6794356	CID	0	17	D016651	65	89	D006331	false

Sentence: Phenobarbital induced dyskinesia in a neurologically-impaired child.
Entity: 6504332	0	13	Phenobarbital	Chemical	D010634
Entity: 6504332	22	32	dyskinesia	Disease	D004409
Entity: 6504332	38	61	neurologically-impaired	Disease	D009422
Relation: 6504332	CID	0	13	D010634	22	32	D004409	true
Relation: 6504332	CID	0	13	D010634	38	61	D009422	false

Sentence: A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures.
Entity: 6504332	30	51	neurologic impairment	Disease	D009422
Entity: 6504332	64	74	dyskinesia	Disease	D004409
Entity: 6504332	95	108	phenobarbital	Chemical	D010634
Entity: 6504332	121	129	seizures	Disease	D012640
Relation: 6504332	CID	95	108	D010634	30	51	D009422	false
Relation: 6504332	CID	95	108	D010634	64	74	D004409	true
Relation: 6504332	CID	95	108	D010634	121	129	D012640	false

Sentence: On repeat challenge with phenobarbital, the dyskinesia recurred.
Entity: 6504332	25	38	phenobarbital	Chemical	D010634
Entity: 6504332	44	54	dyskinesia	Disease	D004409
Relation: 6504332	CID	25	38	D010634	44	54	D004409	true

Sentence: Valproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs.
Entity: 6436733	0	13	Valproic acid	Chemical	D014635
Entity: 6436733	15	18	VPA	Chemical	D014635
Entity: 6436733	36	45	epileptic	Disease	D004827
Relation: 6436733	CID	0	13	D014635	36	45	D004827	false
Relation: 6436733	CID	15	18	D014635	36	45	D004827	false

Sentence: Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.
Entity: 6436733	0	7	Ammonia	Chemical	D000641
Entity: 6436733	9	12	NH3	Chemical	D000641
Entity: 6436733	83	93	drowsiness	Disease	D006970
Entity: 6436733	167	170	VPA	Chemical	D014635
Relation: 6436733	CID	0	7	D000641	83	93	D006970	true
Relation: 6436733	CID	9	12	D000641	83	93	D006970	true
Relation: 6436733	CID	167	170	D014635	83	93	D006970	true

Sentence: Calcitonin injection resulted in a potentiation of haloperidol induced catalepsy and a partial prevention of apomorphine induced hyperactivity.
Entity: 6293644	51	62	haloperidol	Chemical	D006220
Entity: 6293644	71	80	catalepsy	Disease	D002375
Entity: 6293644	109	120	apomorphine	Chemical	D001058
Entity: 6293644	129	142	hyperactivity	Disease	D006948
Relation: 6293644	CID	51	62	D006220	71	80	D002375	true
Relation: 6293644	CID	51	62	D006220	129	142	D006948	false
Relation: 6293644	CID	109	120	D001058	71	80	D002375	false
Relation: 6293644	CID	109	120	D001058	129	142	D006948	true

Sentence: Development of isoproterenol induced cardiac hypertrophy.
Entity: 6203632	15	28	isoproterenol	Chemical	D007545
Entity: 6203632	37	56	cardiac hypertrophy	Disease	D006332
Relation: 6203632	CID	15	28	D007545	37	56	D006332	true

Sentence: The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).
Entity: 6203632	19	38	cardiac hypertrophy	Disease	D006332
Entity: 6203632	122	135	isoproterenol	Chemical	D007545
Entity: 6203632	137	140	ISO	Chemical	D007545
Relation: 6203632	CID	122	135	D007545	19	38	D006332	true
Relation: 6203632	CID	137	140	D007545	19	38	D006332	true

Sentence: These data indicate that the adaptive response to ISO shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA.
Entity: 6203632	50	53	ISO	Chemical	D007545
Entity: 6203632	69	81	hypertrophic	Disease	D006984
Relation: 6203632	CID	50	53	D007545	69	81	D006984	false

Sentence: Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.
Entity: 3131282	3	15	carcinogenic	Disease	D063646
Entity: 3131282	26	41	retinyl acetate	Chemical	C009166
Entity: 3131282	45	71	forestomach carcinogenesis	Disease	D013274
Entity: 3131282	103	127	butylated hydroxyanisole	Chemical	D002083
Relation: 3131282	CID	26	41	C009166	3	15	D063646	false
Relation: 3131282	CID	26	41	C009166	45	71	D013274	false
Relation: 3131282	CID	103	127	D002083	3	15	D063646	false
Relation: 3131282	CID	103	127	D002083	45	71	D013274	true

Sentence: The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA) induced rat forestomach tumorigenesis was examined.
Entity: 3131282	34	49	retinyl acetate	Chemical	C009166
Entity: 3131282	51	53	RA	Chemical	C009166
Entity: 3131282	58	82	butylated hydroxyanisole	Chemical	D002083
Entity: 3131282	84	87	BHA	Chemical	D002083
Entity: 3131282	101	126	forestomach tumorigenesis	Disease	D013274
Relation: 3131282	CID	34	49	C009166	101	126	D013274	false
Relation: 3131282	CID	51	53	C009166	101	126	D013274	false
Relation: 3131282	CID	58	82	D002083	101	126	D013274	true
Relation: 3131282	CID	84	87	D002083	101	126	D013274	true

Sentence: In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.
Entity: 3131282	19	22	BHA	Chemical	D002083
Entity: 3131282	148	150	RA	Chemical	C009166
Entity: 3131282	211	229	forestomach tumors	Disease	D013274
Entity: 3131282	231	254	squamous cell papilloma	Disease	D010212
Entity: 3131282	259	268	carcinoma	Disease	D002277
Entity: 3131282	296	305	carcinoma	Disease	D002277
Entity: 3131282	336	345	carcinoma	Disease	D002277
Entity: 3131282	366	368	RA	Chemical	C009166
Relation: 3131282	CID	19	22	D002083	211	229	D013274	true
Relation: 3131282	CID	19	22	D002083	231	254	D010212	false
Relation: 3131282	CID	19	22	D002083	259	268	D002277	false
Relation: 3131282	CID	19	22	D002083	296	305	D002277	false
Relation: 3131282	CID	19	22	D002083	336	345	D002277	false
Relation: 3131282	CID	148	150	C009166	211	229	D013274	false
Relation: 3131282	CID	148	150	C009166	231	254	D010212	false
Relation: 3131282	CID	148	150	C009166	259	268	D002277	false
Relation: 3131282	CID	148	150	C009166	296	305	D002277	false
Relation: 3131282	CID	148	150	C009166	336	345	D002277	false
Relation: 3131282	CID	366	368	C009166	211	229	D013274	false
Relation: 3131282	CID	366	368	C009166	231	254	D010212	false
Relation: 3131282	CID	366	368	C009166	259	268	D002277	false
Relation: 3131282	CID	366	368	C009166	296	305	D002277	false
Relation: 3131282	CID	366	368	C009166	336	345	D002277	false

Sentence: In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA induced epithelial hyperplasia.
Entity: 3131282	17	20	BHA	Chemical	D002083
Entity: 3131282	22	24	RA	Chemical	C009166
Entity: 3131282	145	148	BHA	Chemical	D002083
Entity: 3131282	157	179	epithelial hyperplasia	Disease	D017573
Relation: 3131282	CID	17	20	D002083	157	179	D017573	false
Relation: 3131282	CID	22	24	C009166	157	179	D017573	false
Relation: 3131282	CID	145	148	D002083	157	179	D017573	false

Sentence: Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% RA and in one rat (10%) with 0.05% RA co-administration.
Entity: 3131282	0	6	Tumors	Disease	D009369
Entity: 3131282	12	22	papillomas	Disease	D010212
Entity: 3131282	64	66	RA	Chemical	C009166
Entity: 3131282	99	101	RA	Chemical	C009166
Relation: 3131282	CID	64	66	C009166	0	6	D009369	false
Relation: 3131282	CID	64	66	C009166	12	22	D010212	false
Relation: 3131282	CID	99	101	C009166	0	6	D009369	false
Relation: 3131282	CID	99	101	C009166	12	22	D010212	false

Sentence: Ketanserin pretreatment reverses alfentanil induced muscle rigidity.
Entity: 3115150	0	10	Ketanserin	Chemical	D007650
Entity: 3115150	33	43	alfentanil	Chemical	D015760
Entity: 3115150	52	67	muscle rigidity	Disease	D009127
Relation: 3115150	CID	0	10	D007650	52	67	D009127	false
Relation: 3115150	CID	33	43	D015760	52	67	D009127	true

Sentence: Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.
Entity: 3115150	27	37	ketanserin	Chemical	D007650
Entity: 3115150	68	77	serotonin	Chemical	D012701
Entity: 3115150	128	143	muscle rigidity	Disease	D009127
Entity: 3115150	203	213	alfentanil	Chemical	D015760
Relation: 3115150	CID	27	37	D007650	128	143	D009127	false
Relation: 3115150	CID	68	77	D012701	128	143	D009127	false
Relation: 3115150	CID	203	213	D015760	128	143	D009127	true

Sentence: Chlordiazepoxide at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.
Entity: 3115150	0	16	Chlordiazepoxide	Chemical	D002707
Entity: 3115150	79	87	rigidity	Disease	D009127
Entity: 3115150	100	110	alfentanil	Chemical	D015760
Relation: 3115150	CID	0	16	D002707	79	87	D009127	false
Relation: 3115150	CID	100	110	D015760	79	87	D009127	true

Sentence: Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.
Entity: 3115150	23	31	rigidity	Disease	D009127
Entity: 3115150	55	65	ketanserin	Chemical	D007650
Entity: 3115150	109	119	alfentanil	Chemical	D015760
Entity: 3115150	214	224	alfentanil	Chemical	D015760
Relation: 3115150	CID	55	65	D007650	23	31	D009127	false
Relation: 3115150	CID	109	119	D015760	23	31	D009127	true
Relation: 3115150	CID	214	224	D015760	23	31	D009127	true

Sentence: Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.
Entity: 3115150	25	34	serotonin	Chemical	D012701
Entity: 3115150	102	110	rigidity	Disease	D009127
Relation: 3115150	CID	25	34	D012701	102	110	D009127	false

Sentence: Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium induced bradycardias.
Entity: 2917114	7	21	glycopyrronium	Chemical	D006024
Entity: 2917114	110	121	edrophonium	Chemical	D004491
Entity: 2917114	157	168	edrophonium	Chemical	D004491
Entity: 2917114	177	189	bradycardias	Disease	D001919
Relation: 2917114	CID	7	21	D006024	177	189	D001919	false
Relation: 2917114	CID	110	121	D004491	177	189	D001919	true
Relation: 2917114	CID	157	168	D004491	177	189	D001919	true

Sentence: Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl induced muscular rigidity in the rat.
Entity: 2564649	70	78	fentanyl	Chemical	D005283
Entity: 2564649	87	104	muscular rigidity	Disease	D009127
Relation: 2564649	CID	70	78	D005283	87	104	D009127	true

Sentence: Whereas muscular rigidity is a well-known side effect that is associated with high-dose fentanyl anesthesia, a paucity of information exists with regard to its underlying mechanism(s).
Entity: 2564649	8	25	muscular rigidity	Disease	D009127
Entity: 2564649	88	96	fentanyl	Chemical	D005283
Relation: 2564649	CID	88	96	D005283	8	25	D009127	true

Sentence: Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, prazosin.
Entity: 2564649	16	33	muscular rigidity	Disease	D009127
Entity: 2564649	208	216	prazosin	Chemical	D011224
Relation: 2564649	CID	208	216	D011224	16	33	D009127	false

Sentence: We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.
Entity: 2339463	55	63	sagittal	Disease	D020225
Entity: 2339463	68	72	left	Disease	D020227
Entity: 2339463	127	152	epsilon-aminocaproic acid	Chemical	D015119
Entity: 2339463	165	176	menorrhagia	Disease	D008595
Relation: 2339463	CID	127	152	D015119	55	63	D020225	true
Relation: 2339463	CID	127	152	D015119	68	72	D020227	false
Relation: 2339463	CID	127	152	D015119	165	176	D008595	false

Sentence: Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described.
Entity: 2339463	27	49	thromboembolic disease	Disease	D013923
Entity: 2339463	90	115	epsilon-aminocaproic acid	Chemical	D015119
Entity: 2339463	117	142	cerebral sinus thrombosis	Disease	D012851
Relation: 2339463	CID	90	115	D015119	27	49	D013923	false
Relation: 2339463	CID	90	115	D015119	117	142	D012851	false

Sentence: Hemorrhagic cystitis is a potentially serious complication of high-dose cyclophosphamide therapy administered before bone marrow transplantation.
Entity: 1545575	0	11	Hemorrhagic	Disease	D006470
Entity: 1545575	12	20	cystitis	Disease	D003556
Entity: 1545575	72	88	cyclophosphamide	Chemical	D003520
Relation: 1545575	CID	72	88	D003520	0	11	D006470	true
Relation: 1545575	CID	72	88	D003520	12	20	D003556	true

Sentence: In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.
Entity: 1545575	122	127	mesna	Chemical	D015080
Entity: 1545575	173	189	cyclophosphamide	Chemical	D003520
Entity: 1545575	202	213	hemorrhagic	Disease	D006470
Entity: 1545575	214	222	cystitis	Disease	D003556
Relation: 1545575	CID	122	127	D015080	202	213	D006470	false
Relation: 1545575	CID	122	127	D015080	214	222	D003556	false
Relation: 1545575	CID	173	189	D003520	202	213	D006470	true
Relation: 1545575	CID	173	189	D003520	214	222	D003556	true

Sentence: In contrast, two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks.
Entity: 1545575	59	64	mesna	Chemical	D015080
Entity: 1545575	137	148	hemorrhagic	Disease	D006470
Entity: 1545575	149	157	cystitis	Disease	D003556
Relation: 1545575	CID	59	64	D015080	137	148	D006470	false
Relation: 1545575	CID	59	64	D015080	149	157	D003556	false

Sentence: The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.
Entity: 1286498	37	43	nausea	Disease	D009325
Entity: 1286498	48	56	vomiting	Disease	D014839
Entity: 1286498	64	74	flumazenil	Chemical	D005442
Entity: 1286498	85	91	nausea	Disease	D009325
Entity: 1286498	111	115	pain	Disease	D010146
Relation: 1286498	CID	64	74	D005442	37	43	D009325	true
Relation: 1286498	CID	64	74	D005442	48	56	D014839	true
Relation: 1286498	CID	64	74	D005442	85	91	D009325	true
Relation: 1286498	CID	64	74	D005442	111	115	D010146	false

Sentence: Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.
Entity: 839274	8	16	adenomas	Disease	D000236
Entity: 839274	21	46	focal nodular hyperplasia	Disease	D020518
Entity: 839274	78	97	oral contraceptives	Chemical	D003276
Relation: 839274	CID	78	97	D003276	8	16	D000236	true
Relation: 839274	CID	78	97	D003276	21	46	D020518	true

Sentence: Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.
Entity: 839274	21	28	adenoma	Disease	D000236
Entity: 839274	40	65	focal nodular hyperplasia	Disease	D020518
Entity: 839274	104	123	oral contraceptives	Chemical	D003276
Relation: 839274	CID	104	123	D003276	21	28	D000236	true
Relation: 839274	CID	104	123	D003276	40	65	D020518	true

Sentence: Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin induced thrombocytopenia.
Entity: 591536	9	24	thromboembolism	Disease	D013923
Entity: 591536	56	63	heparin	Chemical	D006493
Entity: 591536	104	111	heparin	Chemical	D006493
Entity: 591536	120	136	thrombocytopenia	Disease	D013921
Relation: 591536	CID	56	63	D006493	9	24	D013923	false
Relation: 591536	CID	56	63	D006493	120	136	D013921	true
Relation: 591536	CID	104	111	D006493	9	24	D013923	false
Relation: 591536	CID	104	111	D006493	120	136	D013921	true

Sentence: Arterial thromboembolism is a recognized complication of systemic heparin therapy.
Entity: 591536	9	24	thromboembolism	Disease	D013923
Entity: 591536	66	73	heparin	Chemical	D006493
Relation: 591536	CID	66	73	D006493	9	24	D013923	false

Sentence: Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.
Entity: 591536	32	50	arterial occlusion	Disease	D001157
Entity: 591536	70	77	thrombi	Disease	D013927
Entity: 591536	90	98	ischemia	Disease	D007511
Entity: 591536	153	160	heparin	Chemical	D006493
Entity: 591536	191	207	thrombocytopenia	Disease	D013921
Relation: 591536	CID	153	160	D006493	32	50	D001157	true
Relation: 591536	CID	153	160	D006493	70	77	D013927	false
Relation: 591536	CID	153	160	D006493	90	98	D007511	false
Relation: 591536	CID	153	160	D006493	191	207	D013921	true

Sentence: The common factor relating thromboembolism and thrombocytopenia is heparin induced platelet aggregation.
Entity: 591536	27	42	thromboembolism	Disease	D013923
Entity: 591536	47	63	thrombocytopenia	Disease	D013921
Entity: 591536	67	74	heparin	Chemical	D006493
Entity: 591536	83	103	platelet aggregation	Disease	D001791
Relation: 591536	CID	67	74	D006493	27	42	D013923	false
Relation: 591536	CID	67	74	D006493	47	63	D013921	true
Relation: 591536	CID	67	74	D006493	83	103	D001791	false

Sentence: Long-term prognosis for transplant-free survivors of paracetamol induced acute liver failure.
Entity: 20735774	53	64	paracetamol	Chemical	D000082
Entity: 20735774	73	92	acute liver failure	Disease	D017114
Relation: 20735774	CID	53	64	D000082	73	92	D017114	true

Sentence: BACKGROUND: The prognosis for transplant-free survivors of paracetamol induced acute liver failure remains unknown.
Entity: 20735774	59	70	paracetamol	Chemical	D000082
Entity: 20735774	79	98	acute liver failure	Disease	D017114
Relation: 20735774	CID	59	70	D000082	79	98	D017114	true

Sentence: AIM: To examine whether paracetamol induced acute liver failure increases long-term mortality.
Entity: 20735774	24	35	paracetamol	Chemical	D000082
Entity: 20735774	44	63	acute liver failure	Disease	D017114
Relation: 20735774	CID	24	35	D000082	44	63	D017114	true

Sentence: METHODS: We followed up all transplant-free survivors of paracetamol induced acute liver injury, hospitalized in a Danish national referral centre during 1984-2004.
Entity: 20735774	57	68	paracetamol	Chemical	D000082
Entity: 20735774	77	95	acute liver injury	Disease	D056486
Relation: 20735774	CID	57	68	D000082	77	95	D056486	false

Sentence: On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.
Entity: 20735774	89	100	paracetamol	Chemical	D000082
Entity: 20735774	109	121	liver injury	Disease	D056486
Entity: 20735774	136	155	acute liver failure	Disease	D017114
Entity: 20735774	273	292	acute liver failure	Disease	D017114
Entity: 20735774	301	314	liver disease	Disease	D008107
Relation: 20735774	CID	89	100	D000082	109	121	D056486	false
Relation: 20735774	CID	89	100	D000082	136	155	D017114	true
Relation: 20735774	CID	89	100	D000082	273	292	D017114	true
Relation: 20735774	CID	89	100	D000082	301	314	D008107	false

Sentence: CONCLUSIONS: Paracetamol induced acute liver failure did not affect long-term mortality.
Entity: 20735774	13	24	Paracetamol	Chemical	D000082
Entity: 20735774	33	52	acute liver failure	Disease	D017114
Relation: 20735774	CID	13	24	D000082	33	52	D017114	true

Sentence: Serotonin 6 receptor gene is associated with methamphetamine induced psychosis in a Japanese population.
Entity: 20705401	0	9	Serotonin	Chemical	D012701
Entity: 20705401	45	60	methamphetamine	Chemical	D008694
Entity: 20705401	69	78	psychosis	Disease	D011605
Relation: 20705401	CID	0	9	D012701	69	78	D011605	false
Relation: 20705401	CID	45	60	D008694	69	78	D011605	true

Sentence: The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.
Entity: 20705401	4	13	serotonin	Chemical	D012701
Entity: 20705401	17	21	5-HT	Chemical	D012701
Entity: 20705401	114	123	clozapine	Chemical	D003024
Entity: 20705401	128	138	olanzapine	Chemical	C076029
Entity: 20705401	144	157	d-amphetamine	Chemical	D003913
Entity: 20705401	166	179	hyperactivity	Disease	D006948
Entity: 20705401	229	233	5-HT	Chemical	D012701
Relation: 20705401	CID	4	13	D012701	166	179	D006948	false
Relation: 20705401	CID	17	21	D012701	166	179	D006948	false
Relation: 20705401	CID	114	123	D003024	166	179	D006948	false
Relation: 20705401	CID	128	138	C076029	166	179	D006948	false
Relation: 20705401	CID	144	157	D003913	166	179	D006948	false
Relation: 20705401	CID	229	233	D012701	166	179	D006948	false

Sentence: These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.
Entity: 20705401	72	85	schizophrenia	Disease	D012559
Entity: 20705401	132	136	5-HT	Chemical	D012701
Entity: 20705401	187	206	psychotic disorders	Disease	D011605
Relation: 20705401	CID	132	136	D012701	72	85	D012559	false
Relation: 20705401	CID	132	136	D012701	187	206	D011605	false

Sentence: The symptoms of methamphetamine (METH) induced psychosis are similar to those of paranoid type schizophrenia.
Entity: 20705401	16	31	methamphetamine	Chemical	D008694
Entity: 20705401	33	37	METH	Chemical	D008694
Entity: 20705401	47	56	psychosis	Disease	D011605
Entity: 20705401	81	108	paranoid type schizophrenia	Disease	D012563
Relation: 20705401	CID	16	31	D008694	47	56	D011605	true
Relation: 20705401	CID	16	31	D008694	81	108	D012563	false
Relation: 20705401	CID	33	37	D008694	47	56	D011605	true
Relation: 20705401	CID	33	37	D008694	81	108	D012563	false

Sentence: Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with METH induced psychosis.
Entity: 20705401	62	66	5-HT	Chemical	D012701
Entity: 20705401	85	89	METH	Chemical	D008694
Entity: 20705401	98	107	psychosis	Disease	D011605
Relation: 20705401	CID	62	66	D012701	98	107	D011605	false
Relation: 20705401	CID	85	89	D008694	98	107	D011605	true

Sentence: METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH induced psychosis patients and 337 controls) in the Japanese population.
Entity: 20705401	165	169	METH	Chemical	D008694
Entity: 20705401	178	187	psychosis	Disease	D011605
Relation: 20705401	CID	165	169	D008694	178	187	D011605	true

Sentence: RESULTS: rs6693503 was associated with METH induced psychosis patients in the allele/genotype-wise analysis.
Entity: 20705401	39	43	METH	Chemical	D008694
Entity: 20705401	52	61	psychosis	Disease	D011605
Relation: 20705401	CID	39	43	D008694	52	61	D011605	true

Sentence: In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and METH induced psychosis patients, respectively.
Entity: 20705401	172	176	METH	Chemical	D008694
Entity: 20705401	185	194	psychosis	Disease	D011605
Relation: 20705401	CID	172	176	D008694	185	194	D011605	true

Sentence: Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride induced seizures in mice.
Entity: 19105845	55	78	bupropion hydrochloride	Chemical	D016642
Entity: 19105845	87	95	seizures	Disease	D012640
Relation: 19105845	CID	55	78	D016642	87	95	D012640	true

Sentence: BACKGROUND: It is not known if there is a relationship between input rate and incidence of bupropion induced seizures.
Entity: 19105845	91	100	bupropion	Chemical	D016642
Entity: 19105845	109	117	seizures	Disease	D012640
Relation: 19105845	CID	91	100	D016642	109	117	D012640	true

Sentence: METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion induced convulsions in the Swiss albino mice.
Entity: 19105845	85	98	bupropion HCl	Chemical	D016642
Entity: 19105845	118	128	convulsive	Disease	D012640
Entity: 19105845	178	187	bupropion	Chemical	D016642
Entity: 19105845	196	207	convulsions	Disease	D012640
Relation: 19105845	CID	85	98	D016642	118	128	D012640	true
Relation: 19105845	CID	85	98	D016642	196	207	D012640	true
Relation: 19105845	CID	178	187	D016642	118	128	D012640	true
Relation: 19105845	CID	178	187	D016642	196	207	D012640	true

Sentence: RESULTS: The results showed that IP administration of bupropion HCl 120 mg/kg by bolus injection induced convulsions in 6 out of 10 mice (60% of convulsing mice) in group 1.
Entity: 19105845	54	67	bupropion HCl	Chemical	D016642
Entity: 19105845	105	116	convulsions	Disease	D012640
Relation: 19105845	CID	54	67	D016642	105	116	D012640	true

Sentence: Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.
Entity: 19105845	145	158	bupropion HCl	Chemical	D016642
Entity: 19105845	211	222	convulsions	Disease	D012640
Relation: 19105845	CID	145	158	D016642	211	222	D012640	true

Sentence: Detailed spectral profile analysis of penicillin induced epileptiform activity in anesthetized rats.
Entity: 18657397	38	48	penicillin	Chemical	D010406
Entity: 18657397	57	78	epileptiform activity	Disease	D004827
Relation: 18657397	CID	38	48	D010406	57	78	D004827	false

Sentence: Penicillin model is a widely used experimental model for epilepsy research.
Entity: 18657397	0	10	Penicillin	Chemical	D010406
Entity: 18657397	57	65	epilepsy	Disease	D004827
Relation: 18657397	CID	0	10	D010406	57	65	D004827	false

Sentence: In the present study we aimed to portray a detailed spectral analysis of penicillin induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats.
Entity: 18657397	73	83	penicillin	Chemical	D010406
Entity: 18657397	92	113	epileptiform activity	Disease	D004827
Relation: 18657397	CID	73	83	D010406	92	113	D004827	false

Sentence: After a short period of basal activity recording, epileptic focus was induced by injecting 400IU/2 microl penicillin-G potassium into the left lateral ventricle while the cortical activity was continuously recorded.
Entity: 18657397	50	59	epileptic	Disease	D004827
Entity: 18657397	106	128	penicillin-G potassium	Chemical	D010400
Relation: 18657397	CID	106	128	D010400	50	59	D004827	true

Sentence: Basal activity, latent period and the penicillin induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis.
Entity: 18657397	38	48	penicillin	Chemical	D010406
Entity: 18657397	57	78	epileptiform activity	Disease	D004827
Relation: 18657397	CID	38	48	D010406	57	78	D004827	false

Sentence: Although dexmedetomidine sedation was associated with a 16% incidence of bradycardia, all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and oxygen saturations were 95% or higher.
Entity: 18363626	9	24	dexmedetomidine	Chemical	D020927
Entity: 18363626	73	84	bradycardia	Disease	D001919
Entity: 18363626	181	187	oxygen	Chemical	D010100
Relation: 18363626	CID	9	24	D020927	73	84	D001919	true
Relation: 18363626	CID	181	187	D010100	73	84	D001919	false

Sentence: Methamphetamine causes alterations in the MAP kinase-related pathways in the brains of mice that display increased aggressiveness.
Entity: 16192988	0	15	Methamphetamine	Chemical	D008694
Entity: 16192988	115	129	aggressiveness	Disease	D001523
Relation: 16192988	CID	0	15	D008694	115	129	D001523	true

Sentence: Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.
Entity: 16192988	0	20	Aggressive behaviors	Disease	D001523
Entity: 16192988	73	94	psychiatric disorders	Disease	D001523
Entity: 16192988	114	129	methamphetamine	Chemical	D008694
Entity: 16192988	131	135	METH	Chemical	D008694
Relation: 16192988	CID	114	129	D008694	0	20	D001523	true
Relation: 16192988	CID	114	129	D008694	73	94	D001523	true
Relation: 16192988	CID	131	135	D008694	0	20	D001523	true
Relation: 16192988	CID	131	135	D008694	73	94	D001523	true

Sentence: Herein, we report that multiple (but not single) injections of METH significantly increased aggressiveness in male CD-1 mice.
Entity: 16192988	63	67	METH	Chemical	D008694
Entity: 16192988	92	106	aggressiveness	Disease	D001523
Relation: 16192988	CID	63	67	D008694	92	106	D001523	true

Sentence: This increase in aggressiveness was not secondary to METH induced hyperactivity.
Entity: 16192988	17	31	aggressiveness	Disease	D001523
Entity: 16192988	53	57	METH	Chemical	D008694
Entity: 16192988	66	79	hyperactivity	Disease	D006948
Relation: 16192988	CID	53	57	D008694	17	31	D001523	true
Relation: 16192988	CID	53	57	D008694	66	79	D006948	false

Sentence: Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.
Entity: 16157917	0	11	Lamotrigine	Chemical	C047781
Entity: 16157917	52	61	myoclonus	Disease	D009207
Entity: 16157917	65	98	idiopathic generalized epilepsies	Disease	C562694
Relation: 16157917	CID	0	11	C047781	52	61	D009207	true
Relation: 16157917	CID	0	11	C047781	65	98	C562694	false

Sentence: Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).
Entity: 16157917	19	52	idiopathic generalized epilepsies	Disease	C562694
Entity: 16157917	54	57	IGE	Disease	C562694
Entity: 16157917	72	83	lamotrigine	Chemical	C047781
Entity: 16157917	85	88	LTG	Chemical	C047781
Entity: 16157917	140	155	myoclonic jerks	Disease	D009207
Entity: 16157917	157	159	MJ	Disease	D009207
Relation: 16157917	CID	72	83	C047781	19	52	C562694	false
Relation: 16157917	CID	72	83	C047781	54	57	C562694	false
Relation: 16157917	CID	72	83	C047781	140	155	D009207	true
Relation: 16157917	CID	72	83	C047781	157	159	D009207	true
Relation: 16157917	CID	85	88	C047781	19	52	C562694	false
Relation: 16157917	CID	85	88	C047781	54	57	C562694	false
Relation: 16157917	CID	85	88	C047781	140	155	D009207	true
Relation: 16157917	CID	85	88	C047781	157	159	D009207	true

Sentence: In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.
Entity: 16157917	19	22	LTG	Chemical	C047781
Entity: 16157917	35	37	MJ	Disease	D009207
Relation: 16157917	CID	19	22	C047781	35	37	D009207	true

Sentence: MJ disappeared when LTG dose was decreased by 25 to 50%.
Entity: 16157917	0	2	MJ	Disease	D009207
Entity: 16157917	20	23	LTG	Chemical	C047781
Relation: 16157917	CID	20	23	C047781	0	2	D009207	true

Sentence: The neural mechanisms and circuitry involved in levodopa induced dyskinesia are unclear.
Entity: 16116131	48	56	levodopa	Chemical	D007980
Entity: 16116131	65	75	dyskinesia	Disease	D004409
Relation: 16116131	CID	48	56	D007980	65	75	D004409	true

Sentence: Assessment of the onset and persistence of amnesia during procedural sedation with propofol.
Entity: 15930398	43	50	amnesia	Disease	D000647
Entity: 15930398	83	91	propofol	Chemical	D015742
Relation: 15930398	CID	83	91	D015742	43	50	D000647	true

Sentence: Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.
Entity: 15867025	61	72	hepatitis B	Disease	D006509
Entity: 15867025	77	84	rubella	Disease	D012409
Entity: 15867025	108	119	hepatitis B	Disease	D006509
Entity: 15867025	173	184	hepatitis B	Disease	D006509
Entity: 15867025	229	256	hepatitis B surface antigen	Chemical	D006514
Entity: 15867025	275	282	rubella	Disease	D012409
Entity: 15867025	338	345	rubella	Disease	D012409
Entity: 15867025	357	364	rubella	Disease	D012409
Relation: 15867025	CID	229	256	D006514	61	72	D006509	true
Relation: 15867025	CID	229	256	D006514	77	84	D012409	false
Relation: 15867025	CID	229	256	D006514	108	119	D006509	true
Relation: 15867025	CID	229	256	D006514	173	184	D006509	true
Relation: 15867025	CID	229	256	D006514	275	282	D012409	false
Relation: 15867025	CID	229	256	D006514	338	345	D012409	false
Relation: 15867025	CID	229	256	D006514	357	364	D012409	false

Sentence: All infants who were born to hepatitis B surface antigen-positive mothers also received hepatitis B immune globulin.
Entity: 15867025	29	56	hepatitis B surface antigen	Chemical	D006514
Entity: 15867025	88	99	hepatitis B	Disease	D006509
Relation: 15867025	CID	29	56	D006514	88	99	D006509	true

Sentence: Doxorubicin is an anti-tumor agent that represses cardiac-specific gene expression and induces myocardial cell apoptosis.
Entity: 14975762	0	11	Doxorubicin	Chemical	D004317
Entity: 14975762	23	28	tumor	Disease	D009369
Relation: 14975762	CID	0	11	D004317	23	28	D009369	false

Sentence: Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis.
Entity: 14736955	70	81	doxorubicin	Chemical	D004317
Entity: 14736955	82	91	nephrosis	Disease	D009401
Relation: 14736955	CID	70	81	D004317	82	91	D009401	true

Sentence: BACKGROUND: Doxorubicin induces a self-perpetuating nephropathy characterized by early glomerular and late-onset tubular lesions in rats.
Entity: 14736955	12	23	Doxorubicin	Chemical	D004317
Entity: 14736955	52	63	nephropathy	Disease	D007674
Entity: 14736955	87	128	glomerular and late-onset tubular lesions	Disease	D007674
Relation: 14736955	CID	12	23	D004317	52	63	D007674	false
Relation: 14736955	CID	12	23	D004317	87	128	D007674	false

Sentence: RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.
Entity: 14736955	47	77	glomerular and tubular lesions	Disease	D007674
Entity: 14736955	181	188	citrate	Chemical	C102006
Relation: 14736955	CID	181	188	C102006	47	77	D007674	false

Sentence: Amphotericin B induced seizures in a patient with AIDS.
Entity: 11573852	0	14	Amphotericin B	Chemical	D000666
Entity: 11573852	23	31	seizures	Disease	D012640
Entity: 11573852	50	54	AIDS	Disease	D000163
Relation: 11573852	CID	0	14	D000666	23	31	D012640	true
Relation: 11573852	CID	0	14	D000666	50	54	D000163	false

Sentence: OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.
Entity: 11573852	52	59	seizure	Disease	D012640
Entity: 11573852	75	79	AIDS	Disease	D000163
Entity: 11573852	97	111	amphotericin B	Chemical	D000666
Relation: 11573852	CID	97	111	D000666	52	59	D012640	true
Relation: 11573852	CID	97	111	D000666	75	79	D000163	false

Sentence: CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.
Entity: 11573852	71	89	grand mal seizures	Disease	D004830
Entity: 11573852	121	135	amphotericin B	Chemical	D000666
Entity: 11573852	152	160	seizures	Disease	D012640
Relation: 11573852	CID	121	135	D000666	71	89	D004830	false
Relation: 11573852	CID	121	135	D000666	152	160	D012640	true

Sentence: Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.
Entity: 11573852	26	35	phenytoin	Chemical	D010672
Entity: 11573852	40	49	lorazepam	Chemical	D008140
Entity: 11573852	55	63	seizures	Disease	D012640
Entity: 11573852	99	112	amphotercin B	Chemical	D000666
Relation: 11573852	CID	26	35	D010672	55	63	D012640	false
Relation: 11573852	CID	40	49	D008140	55	63	D012640	false
Relation: 11573852	CID	99	112	D000666	55	63	D012640	true

Sentence: The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.
Entity: 11573852	29	42	alcohol abuse	Disease	D000437
Entity: 11573852	44	51	alcohol	Chemical	D000431
Entity: 11573852	96	104	seizures	Disease	D012640
Relation: 11573852	CID	44	51	D000431	29	42	D000437	false
Relation: 11573852	CID	44	51	D000431	96	104	D012640	false

Sentence: Didanosine also has a potential for inducing seizures.
Entity: 11573852	0	10	Didanosine	Chemical	D016049
Entity: 11573852	45	53	seizures	Disease	D012640
Relation: 11573852	CID	0	10	D016049	45	53	D012640	false

Sentence: The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.
Entity: 11573852	41	55	amphotericin B	Chemical	D000666
Entity: 11573852	77	85	seizures	Disease	D012640
Entity: 11573852	94	98	AIDS	Disease	D000163
Relation: 11573852	CID	41	55	D000666	77	85	D012640	true
Relation: 11573852	CID	41	55	D000666	94	98	D000163	false

Sentence: CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.
Entity: 11573852	13	27	Amphotericin B	Chemical	D000666
Entity: 11573852	66	74	seizures	Disease	D012640
Relation: 11573852	CID	13	27	D000666	66	74	D012640	true

Sentence: OBJECTIVE: To evaluate the effect of dosage regimen (once-daily vs. twice-daily) of tobramicyn on steady-state serum concentrations and toxicity.
Entity: 9875685	84	94	tobramicyn	Chemical	D014031
Entity: 9875685	136	144	toxicity	Disease	D064420
Relation: 9875685	CID	84	94	D014031	136	144	D064420	false

Sentence: Increased serum creatinine was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of nephrotoxicity.
Entity: 9875685	16	26	creatinine	Chemical	D003404
Entity: 9875685	115	129	nephrotoxicity	Disease	D007674
Relation: 9875685	CID	16	26	D003404	115	129	D007674	false

Sentence: Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin induced cardiomyopathy in beagle dogs.
Entity: 9848575	37	50	anthracycline	Chemical	D018943
Entity: 9848575	63	70	SM-5887	Chemical	C055866
Entity: 9848575	92	103	doxorubicin	Chemical	D004317
Entity: 9848575	112	126	cardiomyopathy	Disease	D009202
Relation: 9848575	CID	37	50	D018943	112	126	D009202	false
Relation: 9848575	CID	63	70	C055866	112	126	D009202	false
Relation: 9848575	CID	92	103	D004317	112	126	D009202	true

Sentence: This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre induced by doxorubicin in beagle dogs.
Entity: 9848575	51	62	cardiotoxic	Disease	D066126
Entity: 9848575	76	83	SM-5887	Chemical	C055866
Entity: 9848575	123	130	SM-5887	Chemical	C055866
Entity: 9848575	144	158	cardiotoxicity	Disease	D066126
Entity: 9848575	174	185	doxorubicin	Chemical	D004317
Relation: 9848575	CID	76	83	C055866	51	62	D066126	false
Relation: 9848575	CID	76	83	C055866	144	158	D066126	false
Relation: 9848575	CID	123	130	C055866	51	62	D066126	false
Relation: 9848575	CID	123	130	C055866	144	158	D066126	false
Relation: 9848575	CID	174	185	D004317	51	62	D066126	false
Relation: 9848575	CID	174	185	D004317	144	158	D066126	false

Sentence: Animals which received over six courses of doxorubicin demonstrated the electrocardiogram (ECG) changes, decrease of blood pressure and high-grade histopathological cardiomyopathy, while animals which were terminally sacrificed after the SM-5887 administration did not show any changes in ECG, blood pressure and histopathological examinations.
Entity: 9848575	43	54	doxorubicin	Chemical	D004317
Entity: 9848575	165	179	cardiomyopathy	Disease	D009202
Entity: 9848575	238	245	SM-5887	Chemical	C055866
Relation: 9848575	CID	43	54	D004317	165	179	D009202	true
Relation: 9848575	CID	238	245	C055866	165	179	D009202	false

Sentence: To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).
Entity: 9848575	36	47	cardiotoxic	Disease	D066126
Entity: 9848575	58	65	SM-5887	Chemical	C055866
Entity: 9848575	77	91	cardiomyopathy	Disease	D009202
Entity: 9848575	131	142	doxorubicin	Chemical	D004317
Relation: 9848575	CID	58	65	C055866	36	47	D066126	false
Relation: 9848575	CID	58	65	C055866	77	91	D009202	false
Relation: 9848575	CID	131	142	D004317	36	47	D066126	false
Relation: 9848575	CID	131	142	D004317	77	91	D009202	true

Sentence: The low-grade cardiotoxic changes were enhanced by the additional doxorubicin treatment.
Entity: 9848575	14	25	cardiotoxic	Disease	D066126
Entity: 9848575	66	77	doxorubicin	Chemical	D004317
Relation: 9848575	CID	66	77	D004317	14	25	D066126	false

Sentence: On the contrary, the SM-5887 treatment did not progress the grade of cardiomyopathy.
Entity: 9848575	21	28	SM-5887	Chemical	C055866
Entity: 9848575	69	83	cardiomyopathy	Disease	D009202
Relation: 9848575	CID	21	28	C055866	69	83	D009202	false

Sentence: Neuropeptide-Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy.
Entity: 9305828	39	50	pilocarpine	Chemical	D010862
Entity: 9305828	60	82	temporal lobe epilepsy	Disease	D004833
Relation: 9305828	CID	39	50	D010862	60	82	D004833	true

Sentence: The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.
Entity: 9305828	4	15	pilocarpine	Chemical	D010862
Entity: 9305828	17	21	PILO	Chemical	D010862
Entity: 9305828	32	40	epilepsy	Disease	D004827
Entity: 9305828	80	98	status epilepticus	Disease	D013226
Entity: 9305828	133	141	seizures	Disease	D012640
Entity: 9305828	154	166	brain damage	Disease	D001930
Relation: 9305828	CID	4	15	D010862	32	40	D004827	false
Relation: 9305828	CID	4	15	D010862	80	98	D013226	false
Relation: 9305828	CID	4	15	D010862	133	141	D012640	false
Relation: 9305828	CID	4	15	D010862	154	166	D001930	false
Relation: 9305828	CID	17	21	D010862	32	40	D004827	false
Relation: 9305828	CID	17	21	D010862	80	98	D013226	false
Relation: 9305828	CID	17	21	D010862	133	141	D012640	false
Relation: 9305828	CID	17	21	D010862	154	166	D001930	false

Sentence: During the follow-up, 3 patients (12%) developed steroid induced elevated intraocular pressure (IOP) that resolved after corticosteroid therapy was discontinued.
Entity: 9041081	49	56	steroid	Chemical	D013256
Entity: 9041081	65	94	elevated intraocular pressure	Disease	D009798
Entity: 9041081	121	135	corticosteroid	Chemical	D000305
Relation: 9041081	CID	49	56	D013256	65	94	D009798	false
Relation: 9041081	CID	121	135	D000305	65	94	D009798	true

Sentence: Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study.
Entity: 8305357	10	22	daunorubicin	Chemical	D003630
Entity: 8305357	35	51	Kaposi's sarcoma	Disease	D012514
Relation: 8305357	CID	10	22	D003630	35	51	D012514	false

Sentence: We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.
Entity: 8305357	98	110	daunorubicin	Chemical	D003630
Entity: 8305357	143	147	AIDS	Disease	D000163
Entity: 8305357	156	172	Kaposi's sarcoma	Disease	D012514
Relation: 8305357	CID	98	110	D003630	143	147	D000163	false
Relation: 8305357	CID	98	110	D003630	156	172	D012514	false

Sentence: Failure of ancrod in the treatment of heparin induced arterial thrombosis.
Entity: 8012887	38	45	heparin	Chemical	D006493
Entity: 8012887	63	73	thrombosis	Disease	D013927
Relation: 8012887	CID	38	45	D006493	63	73	D013927	true

Sentence: The morbidity and mortality associated with heparin induced thrombosis remain high despite numerous empirical therapies.
Entity: 8012887	44	51	heparin	Chemical	D006493
Entity: 8012887	60	70	thrombosis	Disease	D013927
Relation: 8012887	CID	44	51	D006493	60	70	D013927	true

Sentence: Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.
Entity: 8012887	73	83	thrombosis	Disease	D013927
Entity: 8012887	101	108	heparin	Chemical	D006493
Entity: 8012887	117	137	platelet aggregation	Disease	D001791
Entity: 8012887	170	177	heparin	Chemical	D006493
Entity: 8012887	230	240	thrombosis	Disease	D013927
Relation: 8012887	CID	101	108	D006493	73	83	D013927	true
Relation: 8012887	CID	101	108	D006493	117	137	D001791	false
Relation: 8012887	CID	101	108	D006493	230	240	D013927	true
Relation: 8012887	CID	170	177	D006493	73	83	D013927	true
Relation: 8012887	CID	170	177	D006493	117	137	D001791	false
Relation: 8012887	CID	170	177	D006493	230	240	D013927	true

Sentence: Seizure after flumazenil administration in a pediatric patient.
Entity: 7651879	0	7	Seizure	Disease	D012640
Entity: 7651879	14	24	flumazenil	Chemical	D005442
Relation: 7651879	CID	14	24	D005442	0	7	D012640	true

Sentence: Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.
Entity: 7651879	0	10	Flumazenil	Chemical	D005442
Entity: 7651879	16	30	benzodiazepine	Chemical	D001569
Entity: 7651879	80	102	respiratory depression	Disease	D012131
Entity: 7651879	114	129	benzodiazepines	Chemical	D001569
Relation: 7651879	CID	0	10	D005442	80	102	D012131	false
Relation: 7651879	CID	16	30	D001569	80	102	D012131	false
Relation: 7651879	CID	114	129	D001569	80	102	D012131	false

Sentence: Remodelling of nerve structure in experimental isoniazid neuropathy in the rat.
Entity: 3015327	47	56	isoniazid	Chemical	D007538
Entity: 3015327	57	67	neuropathy	Disease	D009422
Relation: 3015327	CID	47	56	D007538	57	67	D009422	true

Sentence: Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).
Entity: 2980315	15	39	ventricular fibrillation	Disease	D014693
Entity: 2980315	90	98	iopentol	Chemical	C053571
Entity: 2980315	108	115	iohexol	Chemical	D007472
Entity: 2980315	132	142	metrizoate	Chemical	D008794
Relation: 2980315	CID	90	98	C053571	15	39	D014693	false
Relation: 2980315	CID	108	115	D007472	15	39	D014693	false
Relation: 2980315	CID	132	142	D008794	15	39	D014693	true

Sentence: Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis: correlation with thallium-201 single-photon emission tomography.
Entity: 1564236	100	117	coronary stenosis	Disease	D023921
Entity: 1564236	136	144	thallium	Chemical	D013793
Relation: 1564236	CID	136	144	D013793	100	117	D023921	false

Sentence: During dipyridamole induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.
Entity: 1564236	7	19	dipyridamole	Chemical	D004176
Entity: 1564236	28	37	hyperemia	Disease	D006940
Entity: 1564236	72	89	coronary stenosis	Disease	D023921
Relation: 1564236	CID	7	19	D004176	28	37	D006940	true
Relation: 1564236	CID	7	19	D004176	72	89	D023921	false

Sentence: The four dogs without a perfusion defect had a stenosis that resulted in a mild (0% to 50%) reduction in dipyridamole induced hyperemia.
Entity: 1564236	105	117	dipyridamole	Chemical	D004176
Entity: 1564236	126	135	hyperemia	Disease	D006940
Relation: 1564236	CID	105	117	D004176	126	135	D006940	true

Sentence: Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).
Entity: 1564236	0	8	Thallium	Chemical	D013793
Entity: 1564236	82	94	dipyridamole	Chemical	D004176
Entity: 1564236	103	112	hyperemia	Disease	D006940
Relation: 1564236	CID	0	8	D013793	103	112	D006940	false
Relation: 1564236	CID	82	94	D004176	103	112	D006940	true

Sentence: Potential deleterious effect of furosemide in radiocontrast nephropathy.
Entity: 1300436	32	42	furosemide	Chemical	D005665
Entity: 1300436	60	71	nephropathy	Disease	D007674
Relation: 1300436	CID	32	42	D005665	60	71	D007674	false

Sentence: The purpose of the study was to determine the efficacy of furosemide in addition to intravenous fluids in the prevention of radiocontrast nephropathy. 18 patients, referred to a radiocontrast study, considered at risk because of preexisting renal insufficiency, were enrolled in a prospective, randomized, controlled trial, performed at the secondary care center of a 1,100-bed private university hospital.
Entity: 1300436	58	68	furosemide	Chemical	D005665
Entity: 1300436	138	149	nephropathy	Disease	D007674
Entity: 1300436	241	260	renal insufficiency	Disease	D051437
Relation: 1300436	CID	58	68	D005665	138	149	D007674	false
Relation: 1300436	CID	58	68	D005665	241	260	D051437	false

Sentence: Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).
Entity: 1300436	0	41	Renal function significantly deteriorated	Disease	D058186
Entity: 1300436	71	81	furosemide	Chemical	D005665
Entity: 1300436	125	135	creatinine	Chemical	D003404
Relation: 1300436	CID	71	81	D005665	0	41	D058186	true
Relation: 1300436	CID	125	135	D003404	0	41	D058186	false

Sentence: Renal failure was associated with weight loss in the furosemide-treated group.
Entity: 1300436	0	13	Renal failure	Disease	D051437
Entity: 1300436	34	45	weight loss	Disease	D015431
Entity: 1300436	53	63	furosemide	Chemical	D005665
Relation: 1300436	CID	53	63	D005665	0	13	D051437	false
Relation: 1300436	CID	53	63	D005665	34	45	D015431	false

Sentence: The renal pathology in a case of lithium induced diabetes insipidus.
Entity: 1141447	33	40	lithium	Chemical	D008094
Entity: 1141447	49	67	diabetes insipidus	Disease	D003919
Relation: 1141447	CID	33	40	D008094	49	67	D003919	true

Sentence: A case of lithium induced diabetes insipidus is reported.
Entity: 1141447	10	17	lithium	Chemical	D008094
Entity: 1141447	26	44	diabetes insipidus	Disease	D003919
Relation: 1141447	CID	10	17	D008094	26	44	D003919	true

Sentence: Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives.
Entity: 188339	41	53	liver tumors	Disease	D008113
Entity: 188339	70	89	oral contraceptives	Chemical	D003276
Relation: 188339	CID	70	89	D003276	41	53	D008113	true

Sentence: Within the last several years, previously rare liver tumors have been seen in young women using oral contraceptive steroids.
Entity: 188339	47	59	liver tumors	Disease	D008113
Entity: 188339	96	114	oral contraceptive	Chemical	D003276
Entity: 188339	115	123	steroids	Chemical	D013256
Relation: 188339	CID	96	114	D003276	47	59	D008113	true
Relation: 188339	CID	115	123	D013256	47	59	D008113	false

Sentence: The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.
Entity: 188339	17	29	Liver Tumors	Disease	D008113
Entity: 188339	46	65	Oral Contraceptives	Chemical	D003276
Relation: 188339	CID	46	65	D003276	17	29	D008113	true

Sentence: Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.
Entity: 19135948	0	25	Graft-versus-host disease	Disease	D006086
Entity: 19135948	43	53	everolimus	Chemical	C107135
Entity: 19135948	58	68	tacrolimus	Chemical	D016559
Entity: 19135948	108	139	sinusoidal obstruction syndrome	Disease	D006504
Entity: 19135948	144	159	microangiopathy	Disease	D014652
Relation: 19135948	CID	43	53	C107135	0	25	D006086	false
Relation: 19135948	CID	43	53	C107135	108	139	D006504	true
Relation: 19135948	CID	43	53	C107135	144	159	D014652	true
Relation: 19135948	CID	58	68	D016559	0	25	D006086	false
Relation: 19135948	CID	58	68	D016559	108	139	D006504	true
Relation: 19135948	CID	58	68	D016559	144	159	D014652	true

Sentence: A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).
Entity: 19135948	38	50	methotrexate	Chemical	D008727
Entity: 19135948	83	108	graft-versus-host disease	Disease	D006086
Entity: 19135948	110	114	GVHD	Disease	D006086
Relation: 19135948	CID	38	50	D008727	83	108	D006086	false
Relation: 19135948	CID	38	50	D008727	110	114	D006086	false

Sentence: We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.
Entity: 19135948	30	40	everolimus	Chemical	C107135
Entity: 19135948	45	55	tacrolimus	Chemical	D016559
Entity: 19135948	106	130	myelodysplastic syndrome	Disease	D009190
Entity: 19135948	132	135	MDS	Disease	D009190
Entity: 19135948	148	170	acute myeloid leukemia	Disease	D015470
Entity: 19135948	172	175	AML	Disease	D015470
Relation: 19135948	CID	30	40	C107135	106	130	D009190	false
Relation: 19135948	CID	30	40	C107135	132	135	D009190	false
Relation: 19135948	CID	30	40	C107135	148	170	D015470	false
Relation: 19135948	CID	30	40	C107135	172	175	D015470	false
Relation: 19135948	CID	45	55	D016559	106	130	D009190	false
Relation: 19135948	CID	45	55	D016559	132	135	D009190	false
Relation: 19135948	CID	45	55	D016559	148	170	D015470	false
Relation: 19135948	CID	45	55	D016559	172	175	D015470	false

Sentence: Loreclezole (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both seizure and afterdischarge durations.
Entity: 14704468	0	11	Loreclezole	Chemical	C066440
Entity: 14704468	102	109	seizure	Disease	D012640
Relation: 14704468	CID	0	11	C066440	102	109	D012640	false

Sentence: Acute liver failure with concurrent bupropion and carbimazole therapy.
Entity: 12549952	0	19	Acute liver failure	Disease	D017114
Entity: 12549952	36	45	bupropion	Chemical	D016642
Entity: 12549952	50	61	carbimazole	Chemical	D002231
Relation: 12549952	CID	36	45	D016642	0	19	D017114	true
Relation: 12549952	CID	50	61	D002231	0	19	D017114	true

Sentence: OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole.
Entity: 12549952	37	50	liver failure	Disease	D017093
Entity: 12549952	94	103	bupropion	Chemical	D016642
Entity: 12549952	108	119	carbimazole	Chemical	D002231
Relation: 12549952	CID	94	103	D016642	37	50	D017093	false
Relation: 12549952	CID	108	119	D002231	37	50	D017093	false

Sentence: CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.
Entity: 12549952	58	73	hyperthyroidism	Disease	D006980
Entity: 12549952	96	107	carbimazole	Chemical	D002231
Entity: 12549952	112	123	propranolol	Chemical	D011433
Relation: 12549952	CID	96	107	D002231	58	73	D006980	false
Relation: 12549952	CID	112	123	D011433	58	73	D006980	false

Sentence: The likelihood that bupropion induced hepatotoxicity in our patient was possible, based on the Naranjo probability scale.
Entity: 12549952	20	29	bupropion	Chemical	D016642
Entity: 12549952	38	52	hepatotoxicity	Disease	D056486
Relation: 12549952	CID	20	29	D016642	38	52	D056486	true

Sentence: DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.
Entity: 12549952	53	67	hepatotoxicity	Disease	D056486
Entity: 12549952	79	88	bupropion	Chemical	D016642
Entity: 12549952	155	174	acute liver failure	Disease	D017114
Entity: 12549952	198	207	bupropion	Chemical	D016642
Entity: 12549952	244	255	carbimazole	Chemical	D002231
Relation: 12549952	CID	79	88	D016642	53	67	D056486	true
Relation: 12549952	CID	79	88	D016642	155	174	D017114	true
Relation: 12549952	CID	198	207	D016642	53	67	D056486	true
Relation: 12549952	CID	198	207	D016642	155	174	D017114	true
Relation: 12549952	CID	244	255	D002231	53	67	D056486	true
Relation: 12549952	CID	244	255	D002231	155	174	D017114	true

Sentence: Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.
Entity: 19370593	10	19	oestrogen	Chemical	D004967
Entity: 19370593	64	87	venous thrombo-embolism	Disease	D054556
Entity: 19370593	89	95	stroke	Disease	D020521
Entity: 19370593	100	119	gallbladder disease	Disease	D005705
Entity: 19370593	240	253	breast cancer	Disease	D001943
Relation: 19370593	CID	10	19	D004967	64	87	D054556	true
Relation: 19370593	CID	10	19	D004967	89	95	D020521	true
Relation: 19370593	CID	10	19	D004967	100	119	D005705	true
Relation: 19370593	CID	10	19	D004967	240	253	D001943	false

Sentence: Passage of mannitol into the brain around gliomas: a potential cause of rebound phenomenon.
Entity: 17019386	11	19	mannitol	Chemical	D008353
Entity: 17019386	42	49	gliomas	Disease	D005910
Relation: 17019386	CID	11	19	D008353	42	49	D005910	false

Sentence: AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.
Entity: 17019386	23	31	mannitol	Chemical	D008353
Entity: 17019386	42	53	brain edema	Disease	D001929
Entity: 17019386	64	76	elevated ICP	Disease	D019586
Entity: 17019386	80	91	brain tumor	Disease	D001932
Relation: 17019386	CID	23	31	D008353	42	53	D001929	false
Relation: 17019386	CID	23	31	D008353	64	76	D019586	true
Relation: 17019386	CID	23	31	D008353	80	91	D001932	false

Sentence: As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 brain tumor patients.
Entity: 17019386	79	87	mannitol	Chemical	D008353
Entity: 17019386	130	141	brain tumor	Disease	D001932
Relation: 17019386	CID	79	87	D008353	130	141	D001932	false

Sentence: METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.
Entity: 17019386	9	17	Mannitol	Chemical	D008353
Entity: 17019386	90	106	malignant glioma	Disease	D005910
Entity: 17019386	120	130	metastases	Disease	D009362
Entity: 17019386	140	150	meningioma	Disease	D008579
Relation: 17019386	CID	9	17	D008353	90	106	D005910	false
Relation: 17019386	CID	9	17	D008353	120	130	D009362	false
Relation: 17019386	CID	9	17	D008353	140	150	D008579	false

Sentence: RESULTS: In most glioma patients, mannitol concentrations in white matter were 2 to 6 times higher than in plasma (mean 3.5 times).
Entity: 17019386	17	23	glioma	Disease	D005910
Entity: 17019386	34	42	mannitol	Chemical	D008353
Relation: 17019386	CID	34	42	D008353	17	23	D005910	false

Sentence: In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.
Entity: 17019386	3	13	meningioma	Disease	D008579
Entity: 17019386	18	28	metastases	Disease	D009362
Entity: 17019386	63	71	mannitol	Chemical	D008353
Relation: 17019386	CID	63	71	D008353	3	13	D008579	false
Relation: 17019386	CID	63	71	D008353	18	28	D009362	false

Sentence: Can lidocaine reduce succinylcholine induced postoperative myalgia.
Entity: 12452237	4	13	lidocaine	Chemical	D008012
Entity: 12452237	21	36	succinylcholine	Chemical	D013390
Entity: 12452237	45	66	postoperative myalgia	Disease	D010149
Relation: 12452237	CID	4	13	D008012	45	66	D010149	false
Relation: 12452237	CID	21	36	D013390	45	66	D010149	true

Sentence: This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine induced myalgia in patients undergoing general anesthesia for gynecological surgery.
Entity: 12452237	53	62	lidocaine	Chemical	D008012
Entity: 12452237	92	107	succinylcholine	Chemical	D013390
Entity: 12452237	116	123	myalgia	Disease	D063806
Relation: 12452237	CID	53	62	D008012	116	123	D063806	false
Relation: 12452237	CID	92	107	D013390	116	123	D063806	false

Sentence: Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults.
Entity: 9564988	25	37	levofloxacin	Chemical	D064704
Entity: 9564988	75	84	sinusitis	Disease	D012852
Relation: 9564988	CID	25	37	D064704	75	84	D012852	false

Sentence: PURPOSE: To evaluate the efficacy and safety of levofloxacin (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial sinusitis.
Entity: 9564988	48	60	levofloxacin	Chemical	D064704
Entity: 9564988	157	166	sinusitis	Disease	D012852
Relation: 9564988	CID	48	60	D064704	157	166	D012852	false

Sentence: At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed.
Entity: 7596955	81	101	platelet aggregation	Disease	D001791
Entity: 7596955	137	141	cAMP	Chemical	D000242
Relation: 7596955	CID	137	141	D000242	81	101	D001791	false

Sentence: Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.
Entity: 7596955	37	45	headache	Disease	D006261
Entity: 7596955	79	91	facial flush	Disease	D005483
Entity: 7596955	103	109	nausea	Disease	D009325
Entity: 7596955	148	151	CLZ	Chemical	C045645
Relation: 7596955	CID	148	151	C045645	37	45	D006261	true
Relation: 7596955	CID	148	151	C045645	79	91	D005483	true
Relation: 7596955	CID	148	151	C045645	103	109	D009325	true

Sentence: Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).
Entity: 17965424	33	43	etoricoxib	Chemical	C422649
Entity: 17965424	47	67	rheumatoid arthritis	Disease	D001172
Entity: 17965424	93	103	etoricoxib	Chemical	C422649
Entity: 17965424	107	124	diclofenac sodium	Chemical	D004008
Relation: 17965424	CID	33	43	C422649	47	67	D001172	false
Relation: 17965424	CID	93	103	C422649	47	67	D001172	false
Relation: 17965424	CID	107	124	D004008	47	67	D001172	false

Sentence: OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).
Entity: 17965424	118	128	etoricoxib	Chemical	C422649
Entity: 17965424	133	143	diclofenac	Chemical	D004008
Entity: 17965424	161	181	rheumatoid arthritis	Disease	D001172
Entity: 17965424	183	185	RA	Disease	D001172
Relation: 17965424	CID	118	128	C422649	161	181	D001172	false
Relation: 17965424	CID	118	128	C422649	183	185	D001172	false
Relation: 17965424	CID	133	143	D004008	161	181	D001172	false
Relation: 17965424	CID	133	143	D004008	183	185	D001172	false

Sentence: PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).
Entity: 17965424	84	86	RA	Disease	D001172
Entity: 17965424	114	124	etoricoxib	Chemical	C422649
Entity: 17965424	151	161	diclofenac	Chemical	D004008
Relation: 17965424	CID	114	124	C422649	84	86	D001172	false
Relation: 17965424	CID	151	161	D004008	84	86	D001172	false

Sentence: The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).
Entity: 17965424	43	49	GI AEs	Disease	D005767
Entity: 17965424	79	89	etoricoxib	Chemical	C422649
Entity: 17965424	95	105	diclofenac	Chemical	D004008
Relation: 17965424	CID	79	89	C422649	43	49	D005767	false
Relation: 17965424	CID	95	105	D004008	43	49	D005767	true

Sentence: The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).
Entity: 17965424	38	50	hypertension	Disease	D006973
Entity: 17965424	63	69	oedema	Disease	D004487
Entity: 17965424	113	123	etoricoxib	Chemical	C422649
Entity: 17965424	167	177	diclofenac	Chemical	D004008
Entity: 17965424	219	231	hypertension	Disease	D006973
Entity: 17965424	247	253	oedema	Disease	D004487
Relation: 17965424	CID	113	123	C422649	38	50	D006973	true
Relation: 17965424	CID	113	123	C422649	63	69	D004487	true
Relation: 17965424	CID	113	123	C422649	219	231	D006973	true
Relation: 17965424	CID	113	123	C422649	247	253	D004487	true
Relation: 17965424	CID	167	177	D004008	38	50	D006973	false
Relation: 17965424	CID	167	177	D004008	63	69	D004487	false
Relation: 17965424	CID	167	177	D004008	219	231	D006973	false
Relation: 17965424	CID	167	177	D004008	247	253	D004487	false

Sentence: CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.
Entity: 17965424	13	23	Etoricoxib	Chemical	C422649
Entity: 17965424	105	111	GI AEs	Disease	D005767
Entity: 17965424	126	136	diclofenac	Chemical	D004008
Relation: 17965424	CID	13	23	C422649	105	111	D005767	false
Relation: 17965424	CID	126	136	D004008	105	111	D005767	true

Sentence: Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
Entity: 17042884	27	50	extrapyramidal symptoms	Disease	D001480
Entity: 17042884	52	55	EPS	Disease	D001480
Entity: 17042884	62	72	quetiapine	Chemical	C069541
Entity: 17042884	112	125	bipolar mania	Disease	D001714
Relation: 17042884	CID	62	72	C069541	27	50	D001480	false
Relation: 17042884	CID	62	72	C069541	52	55	D001480	false
Relation: 17042884	CID	62	72	C069541	112	125	D001714	false

Sentence: OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.
Entity: 17042884	24	47	extrapyramidal symptoms	Disease	D001480
Entity: 17042884	49	52	EPS	Disease	D001480
Entity: 17042884	65	74	akathisia	Disease	D017109
Entity: 17042884	81	91	quetiapine	Chemical	C069541
Entity: 17042884	109	122	bipolar mania	Disease	D001714
Relation: 17042884	CID	81	91	C069541	24	47	D001480	false
Relation: 17042884	CID	81	91	C069541	49	52	D001480	false
Relation: 17042884	CID	81	91	C069541	65	74	D017109	false
Relation: 17042884	CID	81	91	C069541	109	122	D001714	false

Sentence: RESULTS: The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).
Entity: 17042884	26	29	EPS	Disease	D001480
Entity: 17042884	64	73	akathisia	Disease	D017109
Entity: 17042884	97	107	quetiapine	Chemical	C069541
Relation: 17042884	CID	97	107	C069541	26	29	D001480	false
Relation: 17042884	CID	97	107	C069541	64	73	D017109	false

Sentence: Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).
Entity: 17042884	11	14	EPS	Disease	D001480
Entity: 17042884	43	46	QTP	Chemical	C069541
Entity: 17042884	49	51	Li	Chemical	D008094
Entity: 17042884	52	55	DVP	Chemical	D014635
Entity: 17042884	98	100	Li	Chemical	D008094
Entity: 17042884	101	104	DVP	Chemical	D014635
Relation: 17042884	CID	43	46	C069541	11	14	D001480	false
Relation: 17042884	CID	49	51	D008094	11	14	D001480	true
Relation: 17042884	CID	52	55	D014635	11	14	D001480	false
Relation: 17042884	CID	98	100	D008094	11	14	D001480	true
Relation: 17042884	CID	101	104	D014635	11	14	D001480	false

Sentence: Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.
Entity: 17042884	26	29	EPS	Disease	D001480
Entity: 17042884	73	84	haloperidol	Chemical	D006220
Entity: 17042884	146	153	lithium	Chemical	D008094
Entity: 17042884	213	216	EPS	Disease	D001480
Relation: 17042884	CID	73	84	D006220	26	29	D001480	true
Relation: 17042884	CID	73	84	D006220	213	216	D001480	true
Relation: 17042884	CID	146	153	D008094	26	29	D001480	true
Relation: 17042884	CID	146	153	D008094	213	216	D001480	true

Sentence: The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).
Entity: 17042884	17	26	akathisia	Disease	D017109
Entity: 17042884	52	62	quetiapine	Chemical	C069541
Entity: 17042884	111	114	QTP	Chemical	C069541
Entity: 17042884	117	119	Li	Chemical	D008094
Entity: 17042884	120	123	DVP	Chemical	D014635
Entity: 17042884	141	143	Li	Chemical	D008094
Entity: 17042884	144	147	DVP	Chemical	D014635
Relation: 17042884	CID	52	62	C069541	17	26	D017109	false
Relation: 17042884	CID	111	114	C069541	17	26	D017109	false
Relation: 17042884	CID	117	119	D008094	17	26	D017109	false
Relation: 17042884	CID	120	123	D014635	17	26	D017109	false
Relation: 17042884	CID	141	143	D008094	17	26	D017109	false
Relation: 17042884	CID	144	147	D014635	17	26	D017109	false

Sentence: Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.
Entity: 17042884	0	7	Lithium	Chemical	D008094
Entity: 17042884	75	81	tremor	Disease	D014202
Entity: 17042884	95	105	quetiapine	Chemical	C069541
Entity: 17042884	125	131	tremor	Disease	D014202
Entity: 17042884	168	175	lithium	Chemical	D008094
Entity: 17042884	222	228	tremor	Disease	D014202
Entity: 17042884	251	258	lithium	Chemical	D008094
Relation: 17042884	CID	0	7	D008094	75	81	D014202	true
Relation: 17042884	CID	0	7	D008094	125	131	D014202	true
Relation: 17042884	CID	0	7	D008094	222	228	D014202	true
Relation: 17042884	CID	95	105	C069541	75	81	D014202	false
Relation: 17042884	CID	95	105	C069541	125	131	D014202	false
Relation: 17042884	CID	95	105	C069541	222	228	D014202	false
Relation: 17042884	CID	168	175	D008094	75	81	D014202	true
Relation: 17042884	CID	168	175	D008094	125	131	D014202	true
Relation: 17042884	CID	168	175	D008094	222	228	D014202	true
Relation: 17042884	CID	251	258	D008094	75	81	D014202	true
Relation: 17042884	CID	251	258	D008094	125	131	D014202	true
Relation: 17042884	CID	251	258	D008094	222	228	D014202	true

Sentence: Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.
Entity: 17042884	0	11	Haloperidol	Chemical	D006220
Entity: 17042884	68	77	akathisia	Disease	D017109
Entity: 17042884	99	105	tremor	Disease	D014202
Entity: 17042884	131	154	extrapyramidal syndrome	Disease	D001480
Entity: 17042884	180	190	quetiapine	Chemical	C069541
Relation: 17042884	CID	0	11	D006220	68	77	D017109	true
Relation: 17042884	CID	0	11	D006220	99	105	D014202	true
Relation: 17042884	CID	0	11	D006220	131	154	D001480	true
Relation: 17042884	CID	180	190	C069541	68	77	D017109	false
Relation: 17042884	CID	180	190	C069541	99	105	D014202	false
Relation: 17042884	CID	180	190	C069541	131	154	D001480	false

Sentence: Contribution of the sympathetic nervous system to salt-sensitivity in lifetime captopril-treated spontaneously hypertensive rats.
Entity: 8586822	79	88	captopril	Chemical	D002216
Entity: 8586822	111	123	hypertensive	Disease	D006973
Relation: 8586822	CID	79	88	D002216	111	123	D006973	false

Sentence: OBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.
Entity: 8586822	52	61	captopril	Chemical	D002216
Entity: 8586822	84	96	hypertensive	Disease	D006973
Entity: 8586822	171	183	hypertensive	Disease	D006973
Entity: 8586822	194	217	dietary sodium chloride	Chemical	D017673
Relation: 8586822	CID	52	61	D002216	84	96	D006973	false
Relation: 8586822	CID	52	61	D002216	171	183	D006973	false
Relation: 8586822	CID	194	217	D017673	84	96	D006973	true
Relation: 8586822	CID	194	217	D017673	171	183	D006973	true

Sentence: Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride induced increase in MAP in both groups.
Entity: 8586822	47	60	hexamethonium	Chemical	D018738
Entity: 8586822	116	139	dietary sodium chloride	Chemical	D017673
Entity: 8586822	148	163	increase in MAP	Disease	D006973
Relation: 8586822	CID	47	60	D018738	148	163	D006973	false
Relation: 8586822	CID	116	139	D017673	148	163	D006973	true

Sentence: Dose-related beneficial and adverse effects of dietary corticosterone on organophosphorus induced delayed neuropathy in chickens.
Entity: 3961813	55	69	corticosterone	Chemical	D003345
Entity: 3961813	73	89	organophosphorus	Chemical	D010755
Entity: 3961813	106	116	neuropathy	Disease	D009422
Relation: 3961813	CID	55	69	D003345	106	116	D009422	false
Relation: 3961813	CID	73	89	D010755	106	116	D009422	false

Sentence: Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.
Entity: 3961813	62	76	corticosterone	Chemical	D003345
Entity: 3961813	103	107	TOTP	Chemical	C025541
Entity: 3961813	116	126	neuropathy	Disease	D009422
Entity: 3961813	213	217	TOTP	Chemical	C025541
Entity: 3961813	221	224	DFP	Chemical	D007531
Relation: 3961813	CID	62	76	D003345	116	126	D009422	false
Relation: 3961813	CID	103	107	C025541	116	126	D009422	true
Relation: 3961813	CID	213	217	C025541	116	126	D009422	true
Relation: 3961813	CID	221	224	D007531	116	126	D009422	true

Sentence: Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.
Entity: 3961813	0	10	Neurotoxic	Disease	D020258
Entity: 3961813	43	47	TOTP	Chemical	C025541
Entity: 3961813	51	54	DFP	Chemical	D007531
Entity: 3961813	115	132	organophosphorous	Chemical	D010755
Relation: 3961813	CID	43	47	C025541	0	10	D020258	false
Relation: 3961813	CID	51	54	D007531	0	10	D020258	false
Relation: 3961813	CID	115	132	D010755	0	10	D020258	false

Sentence: In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.
Entity: 20973483	35	71	adenosine A2A/A1 receptor antagonist	Chemical	D058915
Entity: 20973483	92	111	Parkinson's disease	Disease	D010300
Relation: 20973483	CID	35	71	D058915	92	111	D010300	false

Sentence: The in vivo characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Parkinson's disease is described.
Entity: 20973483	39	79	adenosine A(2A)/A(1) receptor antagonist	Chemical	D058915
Entity: 20973483	108	127	Parkinson's disease	Disease	D010300
Relation: 20973483	CID	39	79	D058915	108	127	D010300	false

Sentence: An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.
Entity: 17511042	26	48	delusional parasitosis	Disease	D063726
Entity: 17511042	54	73	chronic hepatitis C	Disease	D019698
Entity: 17511042	89	118	pegylated interferon alpha-2b	Chemical	C417083
Entity: 17511042	123	132	ribavirin	Chemical	D012254
Relation: 17511042	CID	89	118	C417083	26	48	D063726	true
Relation: 17511042	CID	89	118	C417083	54	73	D019698	false
Relation: 17511042	CID	123	132	D012254	26	48	D063726	true
Relation: 17511042	CID	123	132	D012254	54	73	D019698	false

Sentence: During treatment of chronic hepatitis C patients with interferon and ribavirin, a lot of side effects are described.
Entity: 17511042	20	39	chronic hepatitis C	Disease	D019698
Entity: 17511042	69	78	ribavirin	Chemical	D012254
Relation: 17511042	CID	69	78	D012254	20	39	D019698	false

Sentence: We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and ribavirin.
Entity: 17511042	47	69	delusional parasitosis	Disease	D063726
Entity: 17511042	92	121	pegylated interferon alpha-2b	Chemical	C417083
Entity: 17511042	133	142	ribavirin	Chemical	D012254
Relation: 17511042	CID	92	121	C417083	47	69	D063726	true
Relation: 17511042	CID	133	142	D012254	47	69	D063726	true

Sentence: Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.
Entity: 16720068	9	39	neuroleptic malignant syndrome	Disease	D009459
Entity: 16720068	78	88	paroxetine	Chemical	D017374
Entity: 16720068	93	103	alprazolam	Chemical	D000525
Relation: 16720068	CID	78	88	D017374	9	39	D009459	true
Relation: 16720068	CID	93	103	D000525	9	39	D009459	true

Sentence: On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.
Entity: 16720068	19	29	paroxetine	Chemical	D017374
Entity: 16720068	34	44	alprazolam	Chemical	D000525
Entity: 16720068	85	108	psychomotor retardation	Disease	D011596
Entity: 16720068	137	152	muscle rigidity	Disease	D009127
Entity: 16720068	158	165	tremors	Disease	D014202
Relation: 16720068	CID	19	29	D017374	85	108	D011596	false
Relation: 16720068	CID	19	29	D017374	137	152	D009127	false
Relation: 16720068	CID	19	29	D017374	158	165	D014202	false
Relation: 16720068	CID	34	44	D000525	85	108	D011596	false
Relation: 16720068	CID	34	44	D000525	137	152	D009127	false
Relation: 16720068	CID	34	44	D000525	158	165	D014202	false

Sentence: The patient received bromocriptine and diazepam to treat his symptoms. 7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).
Entity: 16720068	21	34	bromocriptine	Chemical	D001971
Entity: 16720068	39	47	diazepam	Chemical	D003975
Entity: 16720068	89	94	fever	Disease	D005334
Relation: 16720068	CID	21	34	D001971	89	94	D005334	false
Relation: 16720068	CID	39	47	D003975	89	94	D005334	false

Sentence: This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.
Entity: 16720068	40	70	neuroleptic malignant syndrome	Disease	D009459
Entity: 16720068	72	75	NMS	Disease	D009459
Entity: 16720068	102	105	NMS	Disease	D009459
Entity: 16720068	145	155	paroxetine	Chemical	D017374
Entity: 16720068	160	170	alprazolam	Chemical	D000525
Relation: 16720068	CID	145	155	D017374	40	70	D009459	true
Relation: 16720068	CID	145	155	D017374	72	75	D009459	true
Relation: 16720068	CID	145	155	D017374	102	105	D009459	true
Relation: 16720068	CID	160	170	D000525	40	70	D009459	true
Relation: 16720068	CID	160	170	D000525	72	75	D009459	true
Relation: 16720068	CID	160	170	D000525	102	105	D009459	true

Sentence: Pilocarpine seizures cause age-dependent impairment in auditory location discrimination.
Entity: 16596970	0	11	Pilocarpine	Chemical	D010862
Entity: 16596970	12	20	seizures	Disease	D012640
Entity: 16596970	41	87	impairment in auditory location discrimination	Disease	D001308
Relation: 16596970	CID	0	11	D010862	12	20	D012640	false
Relation: 16596970	CID	0	11	D010862	41	87	D001308	true

Sentence: Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.
Entity: 16596970	0	11	Pilocarpine	Chemical	D010862
Entity: 16596970	34	52	status epilepticus	Disease	D013226
Entity: 16596970	54	72	status epilepticus	Disease	D013226
Entity: 16596970	122	130	seizures	Disease	D012640
Entity: 16596970	181	189	seizures	Disease	D012640
Relation: 16596970	CID	0	11	D010862	34	52	D013226	true
Relation: 16596970	CID	0	11	D010862	54	72	D013226	true
Relation: 16596970	CID	0	11	D010862	122	130	D012640	false
Relation: 16596970	CID	0	11	D010862	181	189	D012640	false

Sentence: Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.
Entity: 16586083	85	106	myocardial infarction	Disease	D009203
Entity: 16586083	108	114	stroke	Disease	D020521
Entity: 16586083	116	128	hypertension	Disease	D006973
Entity: 16586083	133	146	heart failure	Disease	D006333
Entity: 16586083	169	194	cyclooxygenase inhibitors	Chemical	D016861
Relation: 16586083	CID	169	194	D016861	85	106	D009203	true
Relation: 16586083	CID	169	194	D016861	108	114	D020521	true
Relation: 16586083	CID	169	194	D016861	116	128	D006973	true
Relation: 16586083	CID	169	194	D016861	133	146	D006333	true

Sentence: Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD) BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.
Entity: 10539815	14	38	decreased renal function	Disease	D051437
Entity: 10539815	56	69	heart failure	Disease	D006333
Entity: 10539815	77	88	angiotensin	Chemical	D000809
Entity: 10539815	154	182	left ventricular dysfunction	Disease	D018487
Entity: 10539815	212	223	angiotensin	Chemical	D000809
Entity: 10539815	301	325	congestive heart failure	Disease	D006333
Entity: 10539815	327	330	CHF	Disease	D006333
Entity: 10539815	351	375	decreased renal function	Disease	D051437
Relation: 10539815	CID	77	88	D000809	14	38	D051437	false
Relation: 10539815	CID	77	88	D000809	56	69	D006333	false
Relation: 10539815	CID	77	88	D000809	154	182	D018487	false
Relation: 10539815	CID	77	88	D000809	301	325	D006333	false
Relation: 10539815	CID	77	88	D000809	327	330	D006333	false
Relation: 10539815	CID	77	88	D000809	351	375	D051437	false
Relation: 10539815	CID	212	223	D000809	14	38	D051437	false
Relation: 10539815	CID	212	223	D000809	56	69	D006333	false
Relation: 10539815	CID	212	223	D000809	154	182	D018487	false
Relation: 10539815	CID	212	223	D000809	301	325	D006333	false
Relation: 10539815	CID	212	223	D000809	327	330	D006333	false
Relation: 10539815	CID	212	223	D000809	351	375	D051437	false

Sentence: OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin-converting enzyme inhibitor therapy.
Entity: 10539815	55	82	reduction in renal function	Disease	D051437
Entity: 10539815	100	103	CHF	Disease	D006333
Entity: 10539815	123	134	angiotensin	Chemical	D000809
Relation: 10539815	CID	123	134	D000809	55	82	D051437	false
Relation: 10539815	CID	123	134	D000809	100	103	D006333	false

Sentence: METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.
Entity: 10539815	45	73	Left Ventricular Dysfunction	Disease	D018487
Entity: 10539815	139	148	enalapril	Chemical	D004656
Entity: 10539815	170	173	CHF	Disease	D006333
Relation: 10539815	CID	139	148	D004656	45	73	D018487	false
Relation: 10539815	CID	139	148	D004656	170	173	D006333	false

Sentence: Decreased renal function was defined as a rise in serum creatinine >/=0.5 mg/dL (44 micromol/L) from baseline.
Entity: 10539815	0	24	Decreased renal function	Disease	D051437
Entity: 10539815	56	66	creatinine	Chemical	D003404
Relation: 10539815	CID	56	66	D003404	0	24	D051437	false

Sentence: We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.
Entity: 10539815	146	156	creatinine	Chemical	D003404
Entity: 10539815	211	223	hypertension	Disease	D006973
Entity: 10539815	225	233	diabetes	Disease	D003920
Entity: 10539815	260	268	diuretic	Chemical	D004232
Relation: 10539815	CID	146	156	D003404	211	223	D006973	false
Relation: 10539815	CID	146	156	D003404	225	233	D003920	false
Relation: 10539815	CID	260	268	D004232	211	223	D006973	false
Relation: 10539815	CID	260	268	D004232	225	233	D003920	false

Sentence: RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).
Entity: 10539815	39	48	enalapril	Chemical	D004656
Entity: 10539815	81	105	decreased renal function	Disease	D051437
Relation: 10539815	CID	39	48	D004656	81	105	D051437	true

Sentence: By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.
Entity: 10539815	50	59	enalapril	Chemical	D004656
Entity: 10539815	78	86	diuretic	Chemical	D004232
Entity: 10539815	100	108	diabetes	Disease	D003920
Entity: 10539815	130	154	decreased renal function	Disease	D051437
Relation: 10539815	CID	50	59	D004656	100	108	D003920	false
Relation: 10539815	CID	50	59	D004656	130	154	D051437	true
Relation: 10539815	CID	78	86	D004232	100	108	D003920	false
Relation: 10539815	CID	78	86	D004232	130	154	D051437	true

Sentence: Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).
Entity: 10539815	59	83	decreased renal function	Disease	D051437
Entity: 10539815	133	142	enalapril	Chemical	D004656
Entity: 10539815	150	159	enalapril	Chemical	D004656
Entity: 10539815	240	249	enalapril	Chemical	D004656
Relation: 10539815	CID	133	142	D004656	59	83	D051437	true
Relation: 10539815	CID	150	159	D004656	59	83	D051437	true
Relation: 10539815	CID	240	249	D004656	59	83	D051437	true

Sentence: Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).
Entity: 10539815	0	8	Diuretic	Chemical	D004232
Entity: 10539815	64	88	decreased renal function	Disease	D051437
Entity: 10539815	96	105	enalapril	Chemical	D004656
Relation: 10539815	CID	0	8	D004232	64	88	D051437	true
Relation: 10539815	CID	96	105	D004656	64	88	D051437	true

Sentence: Conversely, enalapril had a relative renoprotective effect (RR 1.33, 95% CI 1.13-1.53) compared with placebo (RR 1.96, 95% CI 1.57-2.44) in patients with diabetes.
Entity: 10539815	12	21	enalapril	Chemical	D004656
Entity: 10539815	154	162	diabetes	Disease	D003920
Relation: 10539815	CID	12	21	D004656	154	162	D003920	false

Sentence: CONCLUSIONS: Enalapril use caused a 33% increase in the risk of decreased renal function in patients with CHF.
Entity: 10539815	13	22	Enalapril	Chemical	D004656
Entity: 10539815	64	88	decreased renal function	Disease	D051437
Entity: 10539815	106	109	CHF	Disease	D006333
Relation: 10539815	CID	13	22	D004656	64	88	D051437	true
Relation: 10539815	CID	13	22	D004656	106	109	D006333	false

Sentence: Pemoline induced acute choreoathetosis: case report and review of the literature.
Entity: 9022662	0	8	Pemoline	Chemical	D010389
Entity: 9022662	23	38	choreoathetosis	Disease	D002819
Entity: 9022662	23	38	choreoathetosis	Disease	D001264
Relation: 9022662	CID	0	8	D010389	23	38	D002819	true
Relation: 9022662	CID	0	8	D010389	23	38	D001264	true

Sentence: BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.
Entity: 9022662	12	20	Pemoline	Chemical	D010389
Entity: 9022662	27	38	oxazolidine	Chemical	C064210
Entity: 9022662	86	98	amphetamines	Chemical	D000662
Entity: 9022662	128	154	attention deficit disorder	Disease	D001289
Relation: 9022662	CID	12	20	D010389	128	154	D001289	false
Relation: 9022662	CID	27	38	C064210	128	154	D001289	false
Relation: 9022662	CID	86	98	D000662	128	154	D001289	false

Sentence: Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.
Entity: 9022662	0	8	Pemoline	Chemical	D010389
Entity: 9022662	80	98	movement disorders	Disease	D009069
Relation: 9022662	CID	0	8	D010389	80	98	D009069	false

Sentence: The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis.
Entity: 9022662	64	72	pemoline	Chemical	D010389
Entity: 9022662	98	113	choreoathetosis	Disease	D002819
Entity: 9022662	98	113	choreoathetosis	Disease	D001264
Relation: 9022662	CID	64	72	D010389	98	113	D002819	true
Relation: 9022662	CID	64	72	D010389	98	113	D001264	true

Sentence: The children had a medical history significant for attention deficit disorder previously treated with methylphenidate without success.
Entity: 9022662	51	77	attention deficit disorder	Disease	D001289
Entity: 9022662	102	117	methylphenidate	Chemical	D008774
Relation: 9022662	CID	102	117	D008774	51	77	D001289	false

Sentence: The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the choreoathetoid movements.
Entity: 9022662	85	100	benzodiazepines	Chemical	D001569
Entity: 9022662	130	144	choreoathetoid	Disease	D002819
Entity: 9022662	130	144	choreoathetoid	Disease	D001264
Relation: 9022662	CID	85	100	D001569	130	144	D002819	false
Relation: 9022662	CID	85	100	D001569	130	144	D001264	false

Sentence: CONCLUSION: Pemoline associated movement disorder has been rarely reported in the acute toxicology literature.
Entity: 9022662	12	20	Pemoline	Chemical	D010389
Entity: 9022662	32	49	movement disorder	Disease	D009069
Relation: 9022662	CID	12	20	D010389	32	49	D009069	false

Sentence: Continuous subcutaneous administration of mesna to prevent ifosfamide induced hemorrhagic cystitis.
Entity: 8677458	42	47	mesna	Chemical	D015080
Entity: 8677458	59	69	ifosfamide	Chemical	D007069
Entity: 8677458	78	89	hemorrhagic	Disease	D006470
Entity: 8677458	90	98	cystitis	Disease	D003556
Relation: 8677458	CID	42	47	D015080	78	89	D006470	true
Relation: 8677458	CID	42	47	D015080	90	98	D003556	true
Relation: 8677458	CID	59	69	D007069	78	89	D006470	true
Relation: 8677458	CID	59	69	D007069	90	98	D003556	true

Sentence: Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.
Entity: 8677458	0	11	Hemorrhagic	Disease	D006470
Entity: 8677458	12	20	cystitis	Disease	D003556
Entity: 8677458	42	50	toxicity	Disease	D064420
Entity: 8677458	54	64	ifosfamide	Chemical	D007069
Entity: 8677458	104	109	mesna	Chemical	D015080
Relation: 8677458	CID	54	64	D007069	0	11	D006470	true
Relation: 8677458	CID	54	64	D007069	12	20	D003556	true
Relation: 8677458	CID	54	64	D007069	42	50	D064420	false
Relation: 8677458	CID	104	109	D015080	0	11	D006470	true
Relation: 8677458	CID	104	109	D015080	12	20	D003556	true
Relation: 8677458	CID	104	109	D015080	42	50	D064420	false

Sentence: In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide induced emesis and is unable to absorb the drug.
Entity: 8677458	120	125	mesna	Chemical	D015080
Entity: 8677458	175	180	mesna	Chemical	D015080
Entity: 8677458	204	214	ifosfamide	Chemical	D007069
Entity: 8677458	223	229	emesis	Disease	D014839
Relation: 8677458	CID	120	125	D015080	223	229	D014839	false
Relation: 8677458	CID	175	180	D015080	223	229	D014839	false
Relation: 8677458	CID	204	214	D007069	223	229	D014839	false

Sentence: Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.
Entity: 6323692	18	34	ammonium acetate	Chemical	C018824
Entity: 6323692	36	41	NH4Ac	Chemical	C018824
Entity: 6323692	91	99	morphine	Chemical	D009020
Entity: 6323692	172	186	incoordination	Disease	D001259
Entity: 6323692	190	198	diazepam	Chemical	D003975
Entity: 6323692	204	209	NH4Ac	Chemical	C018824
Relation: 6323692	CID	18	34	C018824	172	186	D001259	true
Relation: 6323692	CID	36	41	C018824	172	186	D001259	true
Relation: 6323692	CID	91	99	D009020	172	186	D001259	false
Relation: 6323692	CID	190	198	D003975	172	186	D001259	true
Relation: 6323692	CID	204	209	C018824	172	186	D001259	true

Sentence: Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.
Entity: 6323692	19	26	calcium	Chemical	D002118
Entity: 6323692	40	50	depression	Disease	D003866
Entity: 6323692	72	79	calcium	Chemical	D002118
Entity: 6323692	92	105	catecholamine	Chemical	D002395
Entity: 6323692	117	129	acetaldehyde	Chemical	D000079
Entity: 6323692	149	154	NH4Ac	Chemical	C018824
Relation: 6323692	CID	19	26	D002118	40	50	D003866	false
Relation: 6323692	CID	72	79	D002118	40	50	D003866	false
Relation: 6323692	CID	92	105	D002395	40	50	D003866	false
Relation: 6323692	CID	117	129	D000079	40	50	D003866	false
Relation: 6323692	CID	149	154	C018824	40	50	D003866	false

Sentence: Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam induced muscular incoordination and antagonized amphetamine induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.
Entity: 6323692	5	14	verapamil	Chemical	D014700
Entity: 6323692	35	40	NH4Ac	Chemical	C018824
Entity: 6323692	63	71	morphine	Chemical	D009020
Entity: 6323692	72	81	analgesia	Disease	D000699
Entity: 6323692	87	95	diazepam	Chemical	D003975
Entity: 6323692	113	127	incoordination	Disease	D001259
Entity: 6323692	144	155	amphetamine	Chemical	D000661
Entity: 6323692	192	201	verapamil	Chemical	D014700
Entity: 6323692	206	211	NH4Ac	Chemical	C018824
Entity: 6323692	246	254	metrazol	Chemical	D010433
Relation: 6323692	CID	5	14	D014700	72	81	D000699	false
Relation: 6323692	CID	5	14	D014700	113	127	D001259	false
Relation: 6323692	CID	35	40	C018824	72	81	D000699	false
Relation: 6323692	CID	35	40	C018824	113	127	D001259	true
Relation: 6323692	CID	63	71	D009020	72	81	D000699	false
Relation: 6323692	CID	63	71	D009020	113	127	D001259	false
Relation: 6323692	CID	87	95	D003975	72	81	D000699	false
Relation: 6323692	CID	87	95	D003975	113	127	D001259	true
Relation: 6323692	CID	144	155	D000661	72	81	D000699	false
Relation: 6323692	CID	144	155	D000661	113	127	D001259	false
Relation: 6323692	CID	192	201	D014700	72	81	D000699	false
Relation: 6323692	CID	192	201	D014700	113	127	D001259	false
Relation: 6323692	CID	206	211	C018824	72	81	D000699	false
Relation: 6323692	CID	206	211	C018824	113	127	D001259	true
Relation: 6323692	CID	246	254	D010433	72	81	D000699	false
Relation: 6323692	CID	246	254	D010433	113	127	D001259	false

Sentence: Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study.
Entity: 20195852	8	19	nephropathy	Disease	D007674
Entity: 20195852	50	64	contrast media	Chemical	D003287
Relation: 20195852	CID	50	64	D003287	8	19	D007674	true

Sentence: Despite increasing reports on nonionic contrast media induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.
Entity: 20195852	39	53	contrast media	Chemical	D003287
Entity: 20195852	62	73	nephropathy	Disease	D007674
Entity: 20195852	75	78	CIN	Disease	D007674
Relation: 20195852	CID	39	53	D003287	62	73	D007674	true
Relation: 20195852	CID	39	53	D003287	75	78	D007674	true

Sentence: This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.
Entity: 20195852	51	54	CIN	Disease	D007674
Entity: 20195852	72	86	contrast media	Chemical	D003287
Entity: 20195852	88	90	CM	Chemical	D003287
Entity: 20195852	93	102	iopromide	Chemical	C038192
Entity: 20195852	107	114	iohexol	Chemical	D007472
Entity: 20195852	239	241	CM	Chemical	D003287
Entity: 20195852	262	270	cyanosis	Disease	D003490
Relation: 20195852	CID	72	86	D003287	51	54	D007674	true
Relation: 20195852	CID	72	86	D003287	262	270	D003490	false
Relation: 20195852	CID	88	90	D003287	51	54	D007674	true
Relation: 20195852	CID	88	90	D003287	262	270	D003490	false
Relation: 20195852	CID	93	102	C038192	51	54	D007674	true
Relation: 20195852	CID	93	102	C038192	262	270	D003490	false
Relation: 20195852	CID	107	114	D007472	51	54	D007674	true
Relation: 20195852	CID	107	114	D007472	262	270	D003490	false
Relation: 20195852	CID	239	241	D003287	51	54	D007674	true
Relation: 20195852	CID	239	241	D003287	262	270	D003490	false

Sentence: Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).
Entity: 20195852	35	38	CIN	Disease	D007674
Entity: 20195852	90	92	CM	Chemical	D003287
Entity: 20195852	217	220	CIN	Disease	D007674
Entity: 20195852	257	259	CM	Chemical	D003287
Relation: 20195852	CID	90	92	D003287	35	38	D007674	true
Relation: 20195852	CID	90	92	D003287	217	220	D007674	true
Relation: 20195852	CID	257	259	D003287	35	38	D007674	true
Relation: 20195852	CID	257	259	D003287	217	220	D007674	true

Sentence: A case of ventricular tachycardia related to caffeine pretreatment.
Entity: 18997632	10	33	ventricular tachycardia	Disease	D017180
Entity: 18997632	45	53	caffeine	Chemical	D002110
Relation: 18997632	CID	45	53	D002110	10	33	D017180	true

Sentence: Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.
Entity: 18997632	12	20	caffeine	Chemical	D002110
Entity: 18997632	49	56	seizure	Disease	D012640
Entity: 18997632	178	196	ventricular ectopy	Disease	D018879
Relation: 18997632	CID	12	20	D002110	49	56	D012640	true
Relation: 18997632	CID	12	20	D002110	178	196	D018879	true

Sentence: We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.
Entity: 18997632	50	65	cardiac disease	Disease	D006331
Entity: 18997632	69	79	arrhythmia	Disease	D001145
Entity: 18997632	133	156	ventricular tachycardia	Disease	D017180
Entity: 18997632	163	171	caffeine	Chemical	D002110
Relation: 18997632	CID	163	171	D002110	50	65	D006331	false
Relation: 18997632	CID	163	171	D002110	69	79	D001145	false
Relation: 18997632	CID	163	171	D002110	133	156	D017180	true

Sentence: Optical coherence tomography can measure axonal loss in patients with ethambutol induced optic neuropathy.
Entity: 15565293	70	80	ethambutol	Chemical	D004977
Entity: 15565293	89	105	optic neuropathy	Disease	D009901
Relation: 15565293	CID	70	80	D004977	89	105	D009901	true

Sentence: PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol induced optic neuropathy using optical coherence tomography (OCT).
Entity: 15565293	54	73	axonal degeneration	Disease	D009410
Entity: 15565293	77	87	ethambutol	Chemical	D004977
Entity: 15565293	96	112	optic neuropathy	Disease	D009901
Relation: 15565293	CID	77	87	D004977	54	73	D009410	false
Relation: 15565293	CID	77	87	D004977	96	112	D009901	true

Sentence: Ethambutol is an antimycobacterial agent often used to treat tuberculosis.
Entity: 15565293	0	10	Ethambutol	Chemical	D004977
Entity: 15565293	61	73	tuberculosis	Disease	D014376
Relation: 15565293	CID	0	10	D004977	61	73	D014376	false

Sentence: A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.
Entity: 15565293	26	36	ethambutol	Chemical	D004977
Entity: 15565293	43	59	optic neuropathy	Disease	D009901
Relation: 15565293	CID	26	36	D004977	43	59	D009901	true

Sentence: METHODS: Three subjects with a history of ethambutol (EMB) induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.
Entity: 15565293	42	52	ethambutol	Chemical	D004977
Entity: 15565293	54	57	EMB	Chemical	D004977
Entity: 15565293	67	83	optic neuropathy	Disease	D009901
Entity: 15565293	124	139	visual deficits	Disease	D014786
Relation: 15565293	CID	42	52	D004977	67	83	D009901	true
Relation: 15565293	CID	42	52	D004977	124	139	D014786	true
Relation: 15565293	CID	54	57	D004977	67	83	D009901	true
Relation: 15565293	CID	54	57	D004977	124	139	D014786	true

Sentence: In all subjects with history of EMB induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.
Entity: 15565293	32	35	EMB	Chemical	D004977
Entity: 15565293	44	60	optic neuropathy	Disease	D009901
Entity: 15565293	247	262	visual deficits	Disease	D014786
Entity: 15565293	298	313	visual deficits	Disease	D014786
Relation: 15565293	CID	32	35	D004977	44	60	D009901	true
Relation: 15565293	CID	32	35	D004977	247	262	D014786	true
Relation: 15565293	CID	32	35	D004977	298	313	D014786	true

Sentence: CONCLUSIONS: The OCT results in these patients with EMB induced optic neuropathy show considerable loss especially of the temporal fibers.
Entity: 15565293	52	55	EMB	Chemical	D004977
Entity: 15565293	64	80	optic neuropathy	Disease	D009901
Relation: 15565293	CID	52	55	D004977	64	80	D009901	true

Sentence: Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.
Entity: 15266215	51	61	valdecoxib	Chemical	C406224
Entity: 15266215	136	146	thrombotic	Disease	D013927
Entity: 15266215	171	180	arthritis	Disease	D001168
Relation: 15266215	CID	51	61	C406224	136	146	D013927	false
Relation: 15266215	CID	51	61	C406224	171	180	D001168	false

Sentence: We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.
Entity: 15266215	43	53	valdecoxib	Chemical	C406224
Entity: 15266215	122	136	osteoarthritis	Disease	D010003
Entity: 15266215	141	161	rheumatoid arthritis	Disease	D001172
Relation: 15266215	CID	43	53	C406224	122	136	D010003	false
Relation: 15266215	CID	43	53	C406224	141	161	D001172	false

Sentence: The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.
Entity: 15266215	32	42	thrombotic	Disease	D013927
Entity: 15266215	113	123	thrombotic	Disease	D013927
Entity: 15266215	160	170	valdecoxib	Chemical	C406224
Entity: 15266215	209	219	diclofenac	Chemical	D004008
Entity: 15266215	231	240	ibuprofen	Chemical	D007052
Entity: 15266215	256	264	naproxen	Chemical	D009288
Entity: 15266215	313	327	osteoarthritis	Disease	D010003
Entity: 15266215	332	352	rheumatoid arthritis	Disease	D001172
Relation: 15266215	CID	160	170	C406224	32	42	D013927	false
Relation: 15266215	CID	160	170	C406224	113	123	D013927	false
Relation: 15266215	CID	160	170	C406224	313	327	D010003	false
Relation: 15266215	CID	160	170	C406224	332	352	D001172	false
Relation: 15266215	CID	209	219	D004008	32	42	D013927	false
Relation: 15266215	CID	209	219	D004008	113	123	D013927	false
Relation: 15266215	CID	209	219	D004008	313	327	D010003	false
Relation: 15266215	CID	209	219	D004008	332	352	D001172	false
Relation: 15266215	CID	231	240	D007052	32	42	D013927	false
Relation: 15266215	CID	231	240	D007052	113	123	D013927	false
Relation: 15266215	CID	231	240	D007052	313	327	D010003	false
Relation: 15266215	CID	231	240	D007052	332	352	D001172	false
Relation: 15266215	CID	256	264	D009288	32	42	D013927	false
Relation: 15266215	CID	256	264	D009288	113	123	D013927	false
Relation: 15266215	CID	256	264	D009288	313	327	D010003	false
Relation: 15266215	CID	256	264	D009288	332	352	D001172	false

Sentence: Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.
Entity: 15266215	42	52	thrombotic	Disease	D013927
Entity: 15266215	77	87	valdecoxib	Chemical	C406224
Relation: 15266215	CID	77	87	C406224	42	52	D013927	false

Sentence: The risk of serious thrombotic events was also similar for each valdecoxib dose.
Entity: 15266215	20	30	thrombotic	Disease	D013927
Entity: 15266215	64	74	valdecoxib	Chemical	C406224
Relation: 15266215	CID	64	74	C406224	20	30	D013927	false

Sentence: Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).
Entity: 15266215	0	10	Thrombotic	Disease	D013927
Entity: 15266215	53	60	aspirin	Chemical	D001241
Entity: 15266215	84	91	aspirin	Chemical	D001241
Entity: 15266215	115	125	valdecoxib	Chemical	C406224
Relation: 15266215	CID	53	60	D001241	0	10	D013927	true
Relation: 15266215	CID	84	91	D001241	0	10	D013927	true
Relation: 15266215	CID	115	125	C406224	0	10	D013927	false

Sentence: A randomized, placebo-controlled, crossover study of ephedrine for SSRI induced female sexual dysfunction.
Entity: 14742097	53	62	ephedrine	Chemical	D004809
Entity: 14742097	87	105	sexual dysfunction	Disease	D020018
Relation: 14742097	CID	53	62	D004809	87	105	D020018	false

Sentence: The objective of this study was to determine whether ephedrine, an alpha- and beta-adrenergic agonist previously shown to enhance genital blood flow in women, has beneficial effects in reversing antidepressant induced sexual dysfunction.
Entity: 14742097	53	62	ephedrine	Chemical	D004809
Entity: 14742097	218	236	sexual dysfunction	Disease	D020018
Relation: 14742097	CID	53	62	D004809	218	236	D020018	false

Sentence: Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.
Entity: 14742097	9	31	sexually dysfunctional	Disease	D020018
Entity: 14742097	55	65	fluoxetine	Chemical	D005473
Entity: 14742097	67	77	sertraline	Chemical	D020280
Entity: 14742097	82	92	paroxetine	Chemical	D017374
Entity: 14742097	193	202	ephedrine	Chemical	D004809
Relation: 14742097	CID	55	65	D005473	9	31	D020018	true
Relation: 14742097	CID	67	77	D020280	9	31	D020018	true
Relation: 14742097	CID	82	92	D017374	9	31	D020018	true
Relation: 14742097	CID	193	202	D004809	9	31	D020018	false

Sentence: Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
Entity: 9270571	43	51	dopamine	Chemical	D004298
Entity: 9270571	73	80	A-86929	Chemical	C095427
Entity: 9270571	100	112	parkinsonian	Disease	D020734
Entity: 9270571	113	121	levodopa	Chemical	D007980
Relation: 9270571	CID	43	51	D004298	100	112	D020734	false
Relation: 9270571	CID	73	80	C095427	100	112	D020734	false
Relation: 9270571	CID	113	121	D007980	100	112	D020734	false

Sentence: The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.
Entity: 9270571	24	32	dopamine	Chemical	D004298
Entity: 9270571	34	36	DA	Chemical	D004298
Entity: 9270571	79	98	Parkinson's disease	Disease	D010300
Entity: 9270571	100	102	PD	Disease	D010300
Relation: 9270571	CID	24	32	D004298	79	98	D010300	false
Relation: 9270571	CID	24	32	D004298	100	102	D010300	false
Relation: 9270571	CID	34	36	D004298	79	98	D010300	false
Relation: 9270571	CID	34	36	D004298	100	102	D010300	false

Sentence: We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.
Entity: 9270571	69	113	1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	Chemical	D015632
Entity: 9270571	115	119	MPTP	Chemical	D015632
Entity: 9270571	166	174	levodopa	Chemical	D007980
Entity: 9270571	183	194	dyskinesias	Disease	D004409
Entity: 9270571	225	235	dyskinetic	Disease	D004409
Entity: 9270571	301	308	A-86929	Chemical	C095427
Entity: 9270571	310	415	[-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol	Chemical	C095427
Entity: 9270571	439	441	DA	Chemical	D004298
Relation: 9270571	CID	69	113	D015632	183	194	D004409	false
Relation: 9270571	CID	69	113	D015632	225	235	D004409	false
Relation: 9270571	CID	115	119	D015632	183	194	D004409	false
Relation: 9270571	CID	115	119	D015632	225	235	D004409	false
Relation: 9270571	CID	166	174	D007980	183	194	D004409	true
Relation: 9270571	CID	166	174	D007980	225	235	D004409	true
Relation: 9270571	CID	301	308	C095427	183	194	D004409	false
Relation: 9270571	CID	301	308	C095427	225	235	D004409	false
Relation: 9270571	CID	310	415	C095427	183	194	D004409	false
Relation: 9270571	CID	310	415	C095427	225	235	D004409	false
Relation: 9270571	CID	439	441	D004298	183	194	D004409	false
Relation: 9270571	CID	439	441	D004298	225	235	D004409	false

Sentence: Acute administration of A-86929 was as efficacious in alleviating MPTP induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.
Entity: 9270571	24	31	A-86929	Chemical	C095427
Entity: 9270571	66	70	MPTP	Chemical	D015632
Entity: 9270571	79	91	parkinsonism	Disease	D020734
Entity: 9270571	95	103	levodopa	Chemical	D007980
Entity: 9270571	108	117	LY-171555	Chemical	C416545
Entity: 9270571	156	164	levodopa	Chemical	D007980
Entity: 9270571	173	184	dyskinesias	Disease	D004409
Entity: 9270571	219	228	LY-171555	Chemical	C416545
Entity: 9270571	256	264	levodopa	Chemical	D007980
Relation: 9270571	CID	24	31	C095427	79	91	D020734	false
Relation: 9270571	CID	24	31	C095427	173	184	D004409	false
Relation: 9270571	CID	66	70	D015632	79	91	D020734	true
Relation: 9270571	CID	66	70	D015632	173	184	D004409	false
Relation: 9270571	CID	95	103	D007980	79	91	D020734	false
Relation: 9270571	CID	95	103	D007980	173	184	D004409	true
Relation: 9270571	CID	108	117	C416545	79	91	D020734	false
Relation: 9270571	CID	108	117	C416545	173	184	D004409	false
Relation: 9270571	CID	156	164	D007980	79	91	D020734	false
Relation: 9270571	CID	156	164	D007980	173	184	D004409	true
Relation: 9270571	CID	219	228	C416545	79	91	D020734	false
Relation: 9270571	CID	219	228	C416545	173	184	D004409	false
Relation: 9270571	CID	256	264	D007980	79	91	D020734	false
Relation: 9270571	CID	256	264	D007980	173	184	D004409	true

Sentence: A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.
Entity: 7189975	41	52	convulsions	Disease	D012640
Entity: 7189975	89	100	bupivacaine	Chemical	D002045
Entity: 7189975	109	117	seizures	Disease	D012640
Entity: 7189975	133	147	chloroprocaine	Chemical	C004616
Entity: 7189975	172	181	lidocaine	Chemical	D008012
Relation: 7189975	CID	89	100	D002045	41	52	D012640	true
Relation: 7189975	CID	89	100	D002045	109	117	D012640	true
Relation: 7189975	CID	133	147	C004616	41	52	D012640	true
Relation: 7189975	CID	133	147	C004616	109	117	D012640	true
Relation: 7189975	CID	172	181	D008012	41	52	D012640	true
Relation: 7189975	CID	172	181	D008012	109	117	D012640	true

Sentence: Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children.
Entity: 6415512	0	9	Myoclonic	Disease	D004831
Entity: 6415512	23	30	absence	Disease	D004832
Entity: 6415512	65	78	carbamazepine	Chemical	D002220
Relation: 6415512	CID	65	78	D002220	0	9	D004831	true
Relation: 6415512	CID	65	78	D002220	23	30	D004832	true

Sentence: Five children, aged 3 to 11 years, treated with carbamazepine for epilepsy, had an acute aberrant reaction characterized by the onset of myoclonic, atypical absence and/or atonic (minor motor) seizures within a few days.
Entity: 6415512	48	61	carbamazepine	Chemical	D002220
Entity: 6415512	66	74	epilepsy	Disease	D004827
Relation: 6415512	CID	48	61	D002220	66	74	D004827	false

Sentence: Naloxone reversal of hypotension due to captopril overdose.
Entity: 1928887	0	8	Naloxone	Chemical	D009270
Entity: 1928887	21	32	hypotension	Disease	D007022
Entity: 1928887	40	49	captopril	Chemical	D002216
Entity: 1928887	50	58	overdose	Disease	D062787
Relation: 1928887	CID	0	8	D009270	21	32	D007022	false
Relation: 1928887	CID	0	8	D009270	50	58	D062787	false
Relation: 1928887	CID	40	49	D002216	21	32	D007022	false
Relation: 1928887	CID	40	49	D002216	50	58	D062787	false

Sentence: The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril.
Entity: 1928887	22	30	naloxone	Chemical	D009270
Entity: 1928887	70	81	hypotensive	Disease	D007022
Entity: 1928887	93	102	captopril	Chemical	D002216
Relation: 1928887	CID	22	30	D009270	70	81	D007022	false
Relation: 1928887	CID	93	102	D002216	70	81	D007022	false

Sentence: We report a case of an intentional captopril overdose, manifested by marked hypotension, that resolved promptly with the administration of naloxone.
Entity: 1928887	35	44	captopril	Chemical	D002216
Entity: 1928887	45	53	overdose	Disease	D062787
Entity: 1928887	76	87	hypotension	Disease	D007022
Entity: 1928887	139	147	naloxone	Chemical	D009270
Relation: 1928887	CID	35	44	D002216	45	53	D062787	false
Relation: 1928887	CID	35	44	D002216	76	87	D007022	false
Relation: 1928887	CID	139	147	D009270	45	53	D062787	false
Relation: 1928887	CID	139	147	D009270	76	87	D007022	false

Sentence: To our knowledge, this is the first reported case of captopril induced hypotension treated with naloxone.
Entity: 1928887	53	62	captopril	Chemical	D002216
Entity: 1928887	71	82	hypotension	Disease	D007022
Entity: 1928887	96	104	naloxone	Chemical	D009270
Relation: 1928887	CID	53	62	D002216	71	82	D007022	false
Relation: 1928887	CID	96	104	D009270	71	82	D007022	false

Sentence: Carbamazepine induced cardiac dysfunction.
Entity: 1728915	0	13	Carbamazepine	Chemical	D002220
Entity: 1728915	22	41	cardiac dysfunction	Disease	D006331
Relation: 1728915	CID	0	13	D002220	22	41	D006331	false

Sentence: A patient with sinus bradycardia and atrioventricular block, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.
Entity: 1728915	21	32	bradycardia	Disease	D001919
Entity: 1728915	37	59	atrioventricular block	Disease	D054537
Entity: 1728915	72	85	carbamazepine	Chemical	D002220
Relation: 1728915	CID	72	85	D002220	21	32	D001919	true
Relation: 1728915	CID	72	85	D002220	37	59	D054537	true

Sentence: From the analysis of these cases, two distinct forms of carbamazepine-associated cardiac dysfunction emerged.
Entity: 1728915	56	69	carbamazepine	Chemical	D002220
Entity: 1728915	81	100	cardiac dysfunction	Disease	D006331
Relation: 1728915	CID	56	69	D002220	81	100	D006331	false

Sentence: One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.
Entity: 1728915	28	46	sinus tachycardias	Disease	D013616
Entity: 1728915	75	88	carbamazepine	Chemical	D002220
Entity: 1728915	89	97	overdose	Disease	D062787
Relation: 1728915	CID	75	88	D002220	28	46	D013616	true
Relation: 1728915	CID	75	88	D002220	89	97	D062787	false

Sentence: The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.
Entity: 1728915	106	122	bradyarrhythmias	Disease	D001919
Entity: 1728915	126	159	atrioventricular conduction delay	Disease	D054537
Entity: 1728915	217	230	carbamazepine	Chemical	D002220
Relation: 1728915	CID	217	230	D002220	106	122	D001919	true
Relation: 1728915	CID	217	230	D002220	126	159	D054537	true

Sentence: Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol induced catalepsy.
Entity: 20558148	44	48	NMDA	Chemical	D016202
Entity: 20558148	99	110	haloperidol	Chemical	D006220
Entity: 20558148	119	128	catalepsy	Disease	D002375
Relation: 20558148	CID	44	48	D016202	119	128	D002375	false
Relation: 20558148	CID	99	110	D006220	119	128	D002375	true

Sentence: The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.
Entity: 20558148	55	65	amino acid	Chemical	D000596
Entity: 20558148	103	112	catalepsy	Disease	D002375
Entity: 20558148	128	136	dopamine	Chemical	D004298
Entity: 20558148	154	165	haloperidol	Chemical	D006220
Relation: 20558148	CID	55	65	D000596	103	112	D002375	false
Relation: 20558148	CID	128	136	D004298	103	112	D002375	false
Relation: 20558148	CID	154	165	D006220	103	112	D002375	true

Sentence: Haloperidol induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).
Entity: 20558148	0	11	Haloperidol	Chemical	D006220
Entity: 20558148	20	29	catalepsy	Disease	D002375
Entity: 20558148	91	100	glutamate	Chemical	D018698
Entity: 20558148	101	105	NMDA	Chemical	D016202
Entity: 20558148	128	134	MK-801	Chemical	D016291
Entity: 20558148	166	169	AP7	Chemical	C031231
Entity: 20558148	208	212	NMDA	Chemical	D016202
Entity: 20558148	230	250	N-methyl-d-aspartate	Chemical	D016202
Entity: 20558148	252	256	NMDA	Chemical	D016202
Relation: 20558148	CID	0	11	D006220	20	29	D002375	true
Relation: 20558148	CID	91	100	D018698	20	29	D002375	false
Relation: 20558148	CID	101	105	D016202	20	29	D002375	false
Relation: 20558148	CID	128	134	D016291	20	29	D002375	false
Relation: 20558148	CID	166	169	C031231	20	29	D002375	false
Relation: 20558148	CID	208	212	D016202	20	29	D002375	false
Relation: 20558148	CID	230	250	D016202	20	29	D002375	false
Relation: 20558148	CID	252	256	D016202	20	29	D002375	false

Sentence: The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.
Entity: 20558148	58	64	MK-801	Chemical	D016291
Entity: 20558148	69	72	AP7	Chemical	C031231
Entity: 20558148	108	119	haloperidol	Chemical	D006220
Entity: 20558148	149	158	catalepsy	Disease	D002375
Relation: 20558148	CID	58	64	D016291	149	158	D002375	false
Relation: 20558148	CID	69	72	C031231	149	158	D002375	false
Relation: 20558148	CID	108	119	D006220	149	158	D002375	true

Sentence: Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.
Entity: 19940105	13	22	glutamate	Chemical	D018698
Entity: 19940105	87	106	Parkinson's disease	Disease	D010300
Relation: 19940105	CID	13	22	D018698	87	106	D010300	false

Sentence: Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).
Entity: 19940105	13	22	glutamate	Chemical	D018698
Entity: 19940105	174	193	Parkinson's disease	Disease	D010300
Entity: 19940105	195	197	PD	Disease	D010300
Relation: 19940105	CID	13	22	D018698	174	193	D010300	false
Relation: 19940105	CID	13	22	D018698	195	197	D010300	false

Sentence: The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.
Entity: 19940105	15	66	N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride	Chemical	C507346
Entity: 19940105	68	74	AMN082	Chemical	C507346
Entity: 19940105	185	187	PD	Disease	D010300
Relation: 19940105	CID	15	66	C507346	185	187	D010300	false
Relation: 19940105	CID	68	74	C507346	185	187	D010300	false

Sentence: Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses haloperidol induced catalepsy in rats.
Entity: 19940105	88	94	AMN082	Chemical	C507346
Entity: 19940105	104	115	haloperidol	Chemical	D006220
Entity: 19940105	124	133	catalepsy	Disease	D002375
Relation: 19940105	CID	88	94	C507346	124	133	D002375	false
Relation: 19940105	CID	104	115	D006220	124	133	D002375	true

Sentence: In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.
Entity: 19940105	55	63	akinetic	Disease	D018476
Entity: 19940105	76	78	PD	Disease	D010300
Entity: 19940105	97	103	AMN082	Chemical	C507346
Entity: 19940105	174	180	6-OHDA	Chemical	D016627
Relation: 19940105	CID	97	103	C507346	55	63	D018476	false
Relation: 19940105	CID	97	103	C507346	76	78	D010300	false
Relation: 19940105	CID	174	180	D016627	55	63	D018476	false
Relation: 19940105	CID	174	180	D016627	76	78	D010300	false

Sentence: In addition, AMN082 reduces the duration of haloperidol induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.
Entity: 19940105	13	19	AMN082	Chemical	C507346
Entity: 19940105	44	55	haloperidol	Chemical	D006220
Entity: 19940105	64	73	catalepsy	Disease	D002375
Relation: 19940105	CID	13	19	C507346	64	73	D002375	false
Relation: 19940105	CID	44	55	D006220	64	73	D002375	true

Sentence: Higher doses of AMN082 (10 and 20 mg/kg p.o.) have no effect on the same models of PD.
Entity: 19940105	16	22	AMN082	Chemical	C507346
Entity: 19940105	83	85	PD	Disease	D010300
Relation: 19940105	CID	16	22	C507346	83	85	D010300	false

Sentence: Nimodipine prevents memory impairment caused by nitroglycerin induced hypotension in adult mice.
Entity: 19923525	0	10	Nimodipine	Chemical	D009553
Entity: 19923525	20	37	memory impairment	Disease	D008569
Entity: 19923525	48	61	nitroglycerin	Chemical	D005996
Entity: 19923525	70	81	hypotension	Disease	D007022
Relation: 19923525	CID	0	10	D009553	20	37	D008569	false
Relation: 19923525	CID	0	10	D009553	70	81	D007022	false
Relation: 19923525	CID	48	61	D005996	20	37	D008569	true
Relation: 19923525	CID	48	61	D005996	70	81	D007022	true

Sentence: We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG) induced hypotension would preserve long-term associative memory.
Entity: 19923525	30	40	nimodipine	Chemical	D009553
Entity: 19923525	42	46	NIMO	Chemical	D009553
Entity: 19923525	77	90	nitroglycerin	Chemical	D005996
Entity: 19923525	92	95	NTG	Chemical	D005996
Entity: 19923525	105	116	hypotension	Disease	D007022
Relation: 19923525	CID	30	40	D009553	105	116	D007022	false
Relation: 19923525	CID	42	46	D009553	105	116	D007022	false
Relation: 19923525	CID	77	90	D005996	105	116	D007022	true
Relation: 19923525	CID	92	95	D005996	105	116	D007022	true

Sentence: Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).
Entity: 19923525	18	29	hypotensive	Disease	D007022
Entity: 19923525	143	146	NTG	Chemical	D005996
Entity: 19923525	149	153	NIMO	Chemical	D009553
Entity: 19923525	166	169	NTG	Chemical	D005996
Relation: 19923525	CID	143	146	D005996	18	29	D007022	true
Relation: 19923525	CID	149	153	D009553	18	29	D007022	false
Relation: 19923525	CID	166	169	D005996	18	29	D007022	true

Sentence: CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect.
Entity: 19923525	57	60	NTG	Chemical	D005996
Entity: 19923525	187	198	hypotension	Disease	D007022
Relation: 19923525	CID	57	60	D005996	187	198	D007022	true

Sentence: NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.
Entity: 19923525	0	4	NIMO	Chemical	D009553
Entity: 19923525	78	81	NTG	Chemical	D005996
Entity: 19923525	128	139	hypotension	Disease	D007022
Relation: 19923525	CID	0	4	D009553	128	139	D007022	false
Relation: 19923525	CID	78	81	D005996	128	139	D007022	true

Sentence: Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.
Entity: 19058474	6	22	haemopericardium	Disease	D010490
Entity: 19058474	27	55	gastrointestinal haemorrhage	Disease	D006471
Entity: 19058474	108	116	warfarin	Chemical	D014859
Relation: 19058474	CID	108	116	D014859	6	22	D010490	false
Relation: 19058474	CID	108	116	D014859	27	55	D006471	true

Sentence: We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin.
Entity: 19058474	35	46	haemorrhage	Disease	D006470
Entity: 19058474	151	159	warfarin	Chemical	D014859
Relation: 19058474	CID	151	159	D014859	35	46	D006470	false

Sentence: Isoproterenol induces primary loss of dystrophin in rat hearts: correlation with myocardial injury.
Entity: 18808529	0	13	Isoproterenol	Chemical	D007545
Entity: 18808529	81	98	myocardial injury	Disease	D009202
Relation: 18808529	CID	0	13	D007545	81	98	D009202	true

Sentence: The mechanism of isoproterenol induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.
Entity: 18808529	17	30	isoproterenol	Chemical	D007545
Entity: 18808529	39	56	myocardial damage	Disease	D009202
Entity: 18808529	87	93	oxygen	Chemical	D010100
Entity: 18808529	131	142	hypotension	Disease	D007022
Entity: 18808529	147	171	myocardial hyperactivity	Disease	D009202
Relation: 18808529	CID	17	30	D007545	39	56	D009202	true
Relation: 18808529	CID	17	30	D007545	131	142	D007022	false
Relation: 18808529	CID	17	30	D007545	147	171	D009202	true
Relation: 18808529	CID	87	93	D010100	39	56	D009202	false
Relation: 18808529	CID	87	93	D010100	131	142	D007022	false
Relation: 18808529	CID	87	93	D010100	147	171	D009202	false

Sentence: High fat diet-fed obese rats are highly sensitive to doxorubicin induced cardiotoxicity.
Entity: 18674790	5	8	fat	Chemical	D004041
Entity: 18674790	18	23	obese	Disease	D009765
Entity: 18674790	53	64	doxorubicin	Chemical	D004317
Entity: 18674790	73	87	cardiotoxicity	Disease	D066126
Relation: 18674790	CID	5	8	D004041	18	23	D009765	true
Relation: 18674790	CID	5	8	D004041	73	87	D066126	false
Relation: 18674790	CID	53	64	D004317	18	23	D009765	false
Relation: 18674790	CID	53	64	D004317	73	87	D066126	false

Sentence: Often, chemotherapy by doxorubicin (Adriamycin) is limited due to life threatening cardiotoxicity in patients during and posttherapy.
Entity: 18674790	23	34	doxorubicin	Chemical	D004317
Entity: 18674790	36	46	Adriamycin	Chemical	D004317
Entity: 18674790	83	97	cardiotoxicity	Disease	D066126
Relation: 18674790	CID	23	34	D004317	83	97	D066126	false
Relation: 18674790	CID	36	46	D004317	83	97	D066126	false

Sentence: Recently, we have shown that moderate diet restriction remarkably protects against doxorubicin induced cardiotoxicity.
Entity: 18674790	83	94	doxorubicin	Chemical	D004317
Entity: 18674790	103	117	cardiotoxicity	Disease	D066126
Relation: 18674790	CID	83	94	D004317	103	117	D066126	false

Sentence: In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin induced cardiotoxicity.
Entity: 18674790	95	98	fat	Chemical	D004041
Entity: 18674790	125	132	obesity	Disease	D009765
Entity: 18674790	188	199	doxorubicin	Chemical	D004317
Entity: 18674790	208	222	cardiotoxicity	Disease	D066126
Relation: 18674790	CID	95	98	D004041	125	132	D009765	true
Relation: 18674790	CID	95	98	D004041	208	222	D066126	false
Relation: 18674790	CID	188	199	D004317	125	132	D009765	false
Relation: 18674790	CID	188	199	D004317	208	222	D066126	false

Sentence: A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.
Entity: 18674790	20	31	doxorubicin	Chemical	D004317
Entity: 18674790	104	118	cardiotoxicity	Disease	D066126
Entity: 18674790	120	139	cardiac dysfunction	Disease	D006331
Entity: 18674790	186	191	obese	Disease	D009765
Entity: 18674790	193	195	OB	Disease	D009765
Entity: 18674790	236	241	renal	Disease	D007674
Entity: 18674790	245	252	hepatic	Disease	D056486
Relation: 18674790	CID	20	31	D004317	104	118	D066126	false
Relation: 18674790	CID	20	31	D004317	120	139	D006331	true
Relation: 18674790	CID	20	31	D004317	186	191	D009765	false
Relation: 18674790	CID	20	31	D004317	193	195	D009765	false
Relation: 18674790	CID	20	31	D004317	236	241	D007674	false
Relation: 18674790	CID	20	31	D004317	245	252	D056486	false

Sentence: Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.
Entity: 18674790	0	11	Doxorubicin	Chemical	D004317
Entity: 18674790	73	84	doxorubicin	Chemical	D004317
Entity: 18674790	89	102	doxorubicinol	Chemical	C010013
Entity: 18674790	154	156	OB	Disease	D009765
Relation: 18674790	CID	0	11	D004317	154	156	D009765	false
Relation: 18674790	CID	73	84	D004317	154	156	D009765	false
Relation: 18674790	CID	89	102	C010013	154	156	D009765	false

Sentence: Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.
Entity: 18674790	34	36	OB	Disease	D009765
Entity: 18674790	392	394	OB	Disease	D009765
Entity: 18674790	425	428	AMP	Chemical	D000249
Entity: 18674790	480	483	ATP	Chemical	D000255
Entity: 18674790	516	519	ATP	Chemical	D000255
Entity: 18674790	520	523	ADP	Chemical	D000244
Entity: 18674790	536	547	doxorubicin	Chemical	D004317
Relation: 18674790	CID	425	428	D000249	34	36	D009765	false
Relation: 18674790	CID	425	428	D000249	392	394	D009765	false
Relation: 18674790	CID	480	483	D000255	34	36	D009765	false
Relation: 18674790	CID	480	483	D000255	392	394	D009765	false
Relation: 18674790	CID	516	519	D000255	34	36	D009765	false
Relation: 18674790	CID	516	519	D000255	392	394	D009765	false
Relation: 18674790	CID	520	523	D000244	34	36	D009765	false
Relation: 18674790	CID	520	523	D000244	392	394	D009765	false
Relation: 18674790	CID	536	547	D004317	34	36	D009765	false
Relation: 18674790	CID	536	547	D004317	392	394	D009765	false

Sentence: Complete atrioventricular block secondary to lithium therapy.
Entity: 18441470	9	31	atrioventricular block	Disease	D054537
Entity: 18441470	45	52	lithium	Chemical	D008094
Relation: 18441470	CID	45	52	D008094	9	31	D054537	true

Sentence: Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium.
Entity: 18441470	0	22	Sinus node dysfunction	Disease	D012804
Entity: 18441470	101	108	lithium	Chemical	D008094
Relation: 18441470	CID	101	108	D008094	0	22	D012804	true

Sentence: In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.
Entity: 18441470	30	57	atrioventricular (AV) block	Disease	D054537
Entity: 18441470	63	79	syncopal attacks	Disease	D013575
Entity: 18441470	103	110	lithium	Chemical	D008094
Relation: 18441470	CID	103	110	D008094	30	57	D054537	true
Relation: 18441470	CID	103	110	D008094	63	79	D013575	false

Sentence: Serum lithium levels remained under or within the therapeutic range during the syncopal attacks.
Entity: 18441470	6	13	lithium	Chemical	D008094
Entity: 18441470	79	95	syncopal attacks	Disease	D013575
Relation: 18441470	CID	6	13	D008094	79	95	D013575	false

Sentence: Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.
Entity: 17366349	0	30	Neuroleptic malignant syndrome	Disease	D009459
Entity: 17366349	42	53	ziprasidone	Chemical	C092292
Relation: 17366349	CID	42	53	C092292	0	30	D009459	true

Sentence: We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.
Entity: 17366349	22	52	neuroleptic malignant syndrome	Disease	D009459
Entity: 17366349	54	57	NMS	Disease	D009459
Entity: 17366349	86	97	ziprasidone	Chemical	C092292
Relation: 17366349	CID	86	97	C092292	22	52	D009459	true
Relation: 17366349	CID	86	97	C092292	54	57	D009459	true

Sentence: Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.
Entity: 17366349	71	74	NMS	Disease	D009459
Entity: 17366349	110	121	ziprasidone	Chemical	C092292
Relation: 17366349	CID	110	121	C092292	71	74	D009459	true

Sentence: The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.
Entity: 17366349	52	65	schizophrenia	Disease	D012559
Entity: 17366349	102	105	NMS	Disease	D009459
Entity: 17366349	179	190	ziprasidone	Chemical	C092292
Relation: 17366349	CID	179	190	C092292	52	65	D012559	false
Relation: 17366349	CID	179	190	C092292	102	105	D009459	true

Sentence: Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol induced myocardial infarction in rats.
Entity: 16584858	8	18	mangiferin	Chemical	C013592
Entity: 16584858	72	85	isoproterenol	Chemical	D007545
Entity: 16584858	94	115	myocardial infarction	Disease	D009203
Relation: 16584858	CID	8	18	C013592	94	115	D009203	false
Relation: 16584858	CID	72	85	D007545	94	115	D009203	true

Sentence: (Anacardiaceae), on isoproterenol (ISPH) induced myocardial infarction (MI) in rats through its antioxidative mechanism.
Entity: 16584858	20	33	isoproterenol	Chemical	D007545
Entity: 16584858	35	39	ISPH	Chemical	D007545
Entity: 16584858	49	70	myocardial infarction	Disease	D009203
Entity: 16584858	72	74	MI	Disease	D009203
Relation: 16584858	CID	20	33	D007545	49	70	D009203	true
Relation: 16584858	CID	20	33	D007545	72	74	D009203	true
Relation: 16584858	CID	35	39	D007545	49	70	D009203	true
Relation: 16584858	CID	35	39	D007545	72	74	D009203	true

Sentence: Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.
Entity: 16584858	26	30	ISPH	Chemical	D007545
Entity: 16584858	108	125	myocardial damage	Disease	D009202
Entity: 16584858	196	203	lactate	Chemical	D019344
Entity: 16584858	228	236	creatine	Chemical	D003401
Entity: 16584858	281	290	uric acid	Chemical	D014527
Entity: 16584858	316	320	iron	Chemical	D007501
Relation: 16584858	CID	26	30	D007545	108	125	D009202	false
Relation: 16584858	CID	196	203	D019344	108	125	D009202	false
Relation: 16584858	CID	228	236	D003401	108	125	D009202	false
Relation: 16584858	CID	281	290	D014527	108	125	D009202	false
Relation: 16584858	CID	316	320	D007501	108	125	D009202	false

Sentence: The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.
Entity: 16584858	23	33	mangiferin	Chemical	C013592
Entity: 16584858	50	80	triphenyl tetrazolium chloride	Chemical	C009591
Entity: 16584858	82	85	TTC	Chemical	C009591
Entity: 16584858	141	160	ischemic myocardium	Disease	D017202
Relation: 16584858	CID	23	33	C013592	141	160	D017202	false
Relation: 16584858	CID	50	80	C009591	141	160	D017202	false
Relation: 16584858	CID	82	85	C009591	141	160	D017202	false

Sentence: The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.
Entity: 16584858	45	55	superoxide	Chemical	D013481
Entity: 16584858	77	88	glutathione	Chemical	D005978
Entity: 16584858	101	112	glutathione	Chemical	D005978
Entity: 16584858	129	140	glutathione	Chemical	D005978
Entity: 16584858	212	221	Vitamin C	Chemical	D001205
Entity: 16584858	223	232	Vitamin E	Chemical	D014810
Entity: 16584858	237	248	glutathione	Chemical	D005978
Entity: 16584858	272	274	MI	Disease	D009203
Relation: 16584858	CID	45	55	D013481	272	274	D009203	false
Relation: 16584858	CID	77	88	D005978	272	274	D009203	false
Relation: 16584858	CID	101	112	D005978	272	274	D009203	false
Relation: 16584858	CID	129	140	D005978	272	274	D009203	false
Relation: 16584858	CID	212	221	D001205	272	274	D009203	false
Relation: 16584858	CID	223	232	D014810	272	274	D009203	false
Relation: 16584858	CID	237	248	D005978	272	274	D009203	false

Sentence: Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.
Entity: 16584858	23	33	mangiferin	Chemical	C013592
Entity: 16584858	78	97	dimethyl sulphoxide	Chemical	D004121
Entity: 16584858	138	140	MI	Disease	D009203
Relation: 16584858	CID	23	33	C013592	138	140	D009203	false
Relation: 16584858	CID	78	97	D004121	138	140	D009203	false

Sentence: Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH induced MI rats.
Entity: 16584858	114	124	mangiferin	Chemical	C013592
Entity: 16584858	155	159	ISPH	Chemical	D007545
Entity: 16584858	168	170	MI	Disease	D009203
Relation: 16584858	CID	114	124	C013592	168	170	D009203	false
Relation: 16584858	CID	155	159	D007545	168	170	D009203	true

Sentence: Remifentanil pretreatment reduces myoclonus after etomidate.
Entity: 16563323	0	12	Remifentanil	Chemical	C071741
Entity: 16563323	34	43	myoclonus	Disease	D009207
Entity: 16563323	50	59	etomidate	Chemical	D005045
Relation: 16563323	CID	0	12	C071741	34	43	D009207	false
Relation: 16563323	CID	50	59	D005045	34	43	D009207	true

Sentence: STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate.
Entity: 16563323	85	97	remifentanil	Chemical	C071741
Entity: 16563323	155	164	myoclonus	Disease	D009207
Entity: 16563323	197	206	etomidate	Chemical	D005045
Relation: 16563323	CID	85	97	C071741	155	164	D009207	false
Relation: 16563323	CID	197	206	D005045	155	164	D009207	true

Sentence: MAIN RESULTS: The incidence of myoclonus was significantly lower in the remifentanil group (6.7%) than in the placebo group (70%) (P < 0.001).
Entity: 16563323	31	40	myoclonus	Disease	D009207
Entity: 16563323	72	84	remifentanil	Chemical	C071741
Relation: 16563323	CID	72	84	C071741	31	40	D009207	false

Sentence: In the placebo group, male patients were associated with significantly increased incidence of myoclonus after etomidate administration.
Entity: 16563323	94	103	myoclonus	Disease	D009207
Entity: 16563323	110	119	etomidate	Chemical	D005045
Relation: 16563323	CID	110	119	D005045	94	103	D009207	true

Sentence: CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.
Entity: 16563323	30	42	remifentanil	Chemical	C071741
Entity: 16563323	63	72	myoclonus	Disease	D009207
Entity: 16563323	79	88	etomidate	Chemical	D005045
Entity: 16563323	138	143	apnea	Disease	D001049
Entity: 16563323	145	151	nausea	Disease	D009325
Entity: 16563323	156	164	pruritus	Disease	D011537
Relation: 16563323	CID	30	42	C071741	63	72	D009207	false
Relation: 16563323	CID	30	42	C071741	138	143	D001049	false
Relation: 16563323	CID	30	42	C071741	145	151	D009325	false
Relation: 16563323	CID	30	42	C071741	156	164	D011537	false
Relation: 16563323	CID	79	88	D005045	63	72	D009207	true
Relation: 16563323	CID	79	88	D005045	138	143	D001049	false
Relation: 16563323	CID	79	88	D005045	145	151	D009325	false
Relation: 16563323	CID	79	88	D005045	156	164	D011537	false

Sentence: Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug induced amnesia.
Entity: 16428827	0	8	Daidzein	Chemical	C004742
Entity: 16428827	19	26	choline	Chemical	D002794
Entity: 16428827	89	96	amnesia	Disease	D000647
Relation: 16428827	CID	0	8	C004742	89	96	D000647	false
Relation: 16428827	CID	19	26	D002794	89	96	D000647	false

Sentence: The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).
Entity: 16428827	4	11	choline	Chemical	D002794
Entity: 16428827	139	152	acetylcholine	Chemical	D000109
Entity: 16428827	154	157	ACh	Chemical	D000109
Entity: 16428827	203	222	Alzheimer's disease	Disease	D000544
Entity: 16428827	224	226	AD	Disease	D000544
Relation: 16428827	CID	4	11	D002794	203	222	D000544	false
Relation: 16428827	CID	4	11	D002794	224	226	D000544	false
Relation: 16428827	CID	139	152	D000109	203	222	D000544	false
Relation: 16428827	CID	139	152	D000109	224	226	D000544	false
Relation: 16428827	CID	154	157	D000109	203	222	D000544	false
Relation: 16428827	CID	154	157	D000109	224	226	D000544	false

Sentence: In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine induced impairments of learning and memory, we conducted a series of in vivo tests.
Entity: 16428827	39	47	daidzein	Chemical	C004742
Entity: 16428827	78	89	scopolamine	Chemical	D012601
Entity: 16428827	98	109	impairments	Disease	D007859
Entity: 16428827	98	109	impairments	Disease	D008569
Relation: 16428827	CID	39	47	C004742	98	109	D007859	false
Relation: 16428827	CID	39	47	C004742	98	109	D008569	false
Relation: 16428827	CID	78	89	D012601	98	109	D007859	false
Relation: 16428827	CID	78	89	D012601	98	109	D008569	false

Sentence: Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine induced amnesia, according to the results of a Y-maze test.
Entity: 16428827	18	26	daidzein	Chemical	C004742
Entity: 16428827	94	105	scopolamine	Chemical	D012601
Entity: 16428827	114	121	amnesia	Disease	D000647
Relation: 16428827	CID	18	26	C004742	114	121	D000647	false
Relation: 16428827	CID	94	105	D012601	114	121	D000647	true

Sentence: Possible azithromycin-associated hiccups.
Entity: 15985056	9	21	azithromycin	Chemical	D017963
Entity: 15985056	33	40	hiccups	Disease	D006606
Relation: 15985056	CID	9	21	D017963	33	40	D006606	true

Sentence: OBJECTIVE: To report a case of persistent hiccups associated by azithromycin therapy.
Entity: 15985056	42	49	hiccups	Disease	D006606
Entity: 15985056	64	76	azithromycin	Chemical	D017963
Relation: 15985056	CID	64	76	D017963	42	49	D006606	true

Sentence: CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis.
Entity: 15985056	58	65	hiccups	Disease	D006606
Entity: 15985056	82	94	azithromycin	Chemical	D017963
Entity: 15985056	116	127	pharyngitis	Disease	D010612
Relation: 15985056	CID	82	94	D017963	58	65	D006606	true
Relation: 15985056	CID	82	94	D017963	116	127	D010612	false

Sentence: Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups.
Entity: 15985056	19	31	azithromycin	Chemical	D017963
Entity: 15985056	49	57	baclofen	Chemical	D001418
Entity: 15985056	75	82	hiccups	Disease	D006606
Relation: 15985056	CID	19	31	D017963	75	82	D006606	true
Relation: 15985056	CID	49	57	D001418	75	82	D006606	true

Sentence: Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.
Entity: 15985056	17	30	dexamethasone	Chemical	D003907
Entity: 15985056	35	53	methylprednisolone	Chemical	D008775
Entity: 15985056	56	71	benzodiazepines	Chemical	D001569
Entity: 15985056	73	82	midazolam	Chemical	D008874
Entity: 15985056	226	233	hiccups	Disease	D006606
Relation: 15985056	CID	17	30	D003907	226	233	D006606	false
Relation: 15985056	CID	35	53	D008775	226	233	D006606	false
Relation: 15985056	CID	56	71	D001569	226	233	D006606	false
Relation: 15985056	CID	73	82	D008874	226	233	D006606	false

Sentence: Few cases of drug induced hiccups have been reported related to macrolide antimicrobials.
Entity: 15985056	26	33	hiccups	Disease	D006606
Entity: 15985056	64	73	macrolide	Chemical	D018942
Relation: 15985056	CID	64	73	D018942	26	33	D006606	false

Sentence: Using the Naranjo adverse effect reaction probability scale this event could be classified as possible (score 5 points), mostly because of the close temporal sequence, previous reports on this reaction with other macrolides and the absence of any alternative explanation for hiccups.
Entity: 15985056	213	223	macrolides	Chemical	D018942
Entity: 15985056	275	282	hiccups	Disease	D006606
Relation: 15985056	CID	213	223	D018942	275	282	D006606	false

Sentence: Our hypothesis is that a vagal mechanism mediated by azithromycin could be the pathogenesis of hiccups in our patient.
Entity: 15985056	53	65	azithromycin	Chemical	D017963
Entity: 15985056	95	102	hiccups	Disease	D006606
Relation: 15985056	CID	53	65	D017963	95	102	D006606	true

Sentence: Time trends in warfarin-associated hemorrhage.
Entity: 15276120	15	23	warfarin	Chemical	D014859
Entity: 15276120	35	45	hemorrhage	Disease	D006470
Relation: 15276120	CID	15	23	D014859	35	45	D006470	true

Sentence: The annual incidence of warfarin-related bleeding at Brigham and Women's Hospital increased from 0.97/1,000 patient admissions in the first time period (January 1995 to October 1998) to 1.19/1,000 patient admissions in the second time period (November 1998 to August 2002) of this study.
Entity: 15276120	24	32	warfarin	Chemical	D014859
Entity: 15276120	41	49	bleeding	Disease	D006470
Relation: 15276120	CID	24	32	D014859	41	49	D006470	true

Sentence: Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.
Entity: 11271907	6	18	haemorrhagic	Disease	D006470
Entity: 11271907	19	30	myocarditis	Disease	D009205
Entity: 11271907	44	60	cyclophosphamide	Chemical	D003520
Relation: 11271907	CID	44	60	D003520	6	18	D006470	true
Relation: 11271907	CID	44	60	D003520	19	30	D009205	true

Sentence: Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.
Entity: 10524660	0	19	Glyceryl trinitrate	Chemical	D005996
Entity: 10524660	39	60	migraine without aura	Disease	D020326
Entity: 10524660	77	95	migraine with aura	Disease	D020325
Relation: 10524660	CID	0	19	D005996	39	60	D020326	true
Relation: 10524660	CID	0	19	D005996	77	95	D020325	false

Sentence: In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.
Entity: 10524660	79	91	nitric oxide	Chemical	D009569
Entity: 10524660	93	95	NO	Chemical	D009569
Entity: 10524660	112	116	pain	Disease	D010146
Entity: 10524660	131	152	migraine without aura	Disease	D020326
Relation: 10524660	CID	79	91	D009569	112	116	D010146	false
Relation: 10524660	CID	79	91	D009569	131	152	D020326	true
Relation: 10524660	CID	93	95	D009569	112	116	D010146	false
Relation: 10524660	CID	93	95	D009569	131	152	D020326	true

Sentence: In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.
Entity: 10524660	49	67	migraine with aura	Disease	D020325
Entity: 10524660	106	114	headache	Disease	D006261
Entity: 10524660	151	170	glyceryl trinitrate	Chemical	D005996
Entity: 10524660	172	175	GTN	Chemical	D005996
Entity: 10524660	227	245	migraine with aura	Disease	D020325
Relation: 10524660	CID	151	170	D005996	49	67	D020325	false
Relation: 10524660	CID	151	170	D005996	106	114	D006261	false
Relation: 10524660	CID	151	170	D005996	227	245	D020325	false
Relation: 10524660	CID	172	175	D005996	49	67	D020325	false
Relation: 10524660	CID	172	175	D005996	106	114	D006261	false
Relation: 10524660	CID	172	175	D005996	227	245	D020325	false

Sentence: Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).
Entity: 10524660	0	8	Headache	Disease	D006261
Entity: 10524660	28	39	migraineurs	Disease	D008881
Entity: 10524660	90	93	GTN	Chemical	D005996
Relation: 10524660	CID	90	93	D005996	0	8	D006261	false
Relation: 10524660	CID	90	93	D005996	28	39	D008881	false

Sentence: In the controls, the GTN induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.
Entity: 10524660	21	24	GTN	Chemical	D005996
Entity: 10524660	33	41	headache	Disease	D006261
Entity: 10524660	76	87	migraineurs	Disease	D008881
Entity: 10524660	93	101	headache	Disease	D006261
Relation: 10524660	CID	21	24	D005996	33	41	D006261	false
Relation: 10524660	CID	21	24	D005996	76	87	D008881	false
Relation: 10524660	CID	21	24	D005996	93	101	D006261	false

Sentence: The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.
Entity: 10524660	35	37	NO	Chemical	D009569
Entity: 10524660	57	61	pain	Disease	D010146
Entity: 10524660	76	94	migraine with aura	Disease	D020325
Relation: 10524660	CID	35	37	D009569	57	61	D010146	false
Relation: 10524660	CID	35	37	D009569	76	94	D020325	false

Sentence: Stroke and cocaine or amphetamine use.
Entity: 9799166	0	6	Stroke	Disease	D020521
Entity: 9799166	11	18	cocaine	Chemical	D003042
Entity: 9799166	22	33	amphetamine	Chemical	D000661
Relation: 9799166	CID	11	18	D003042	0	6	D020521	true
Relation: 9799166	CID	22	33	D000661	0	6	D020521	true

Sentence: The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series.
Entity: 9799166	19	26	cocaine	Chemical	D003042
Entity: 9799166	31	42	amphetamine	Chemical	D000661
Entity: 9799166	68	76	ischemic	Disease	D007511
Entity: 9799166	77	83	stroke	Disease	D020521
Relation: 9799166	CID	19	26	D003042	68	76	D007511	false
Relation: 9799166	CID	19	26	D003042	77	83	D020521	true
Relation: 9799166	CID	31	42	D000661	68	76	D007511	false
Relation: 9799166	CID	31	42	D000661	77	83	D020521	true

Sentence: The limited number of epidemiologic studies of stroke and use of cocaine and/or amphetamine have been done in settings that serve mostly the poor and/or minorities.
Entity: 9799166	47	53	stroke	Disease	D020521
Entity: 9799166	65	72	cocaine	Chemical	D003042
Entity: 9799166	80	91	amphetamine	Chemical	D000661
Relation: 9799166	CID	65	72	D003042	47	53	D020521	true
Relation: 9799166	CID	80	91	D000661	47	53	D020521	true

Sentence: The univariate matched odds ratio for stroke in women who admitted to using cocaine and/or amphetamine was 8.5 (95% confidence interval = 3.6-20.0).
Entity: 9799166	38	44	stroke	Disease	D020521
Entity: 9799166	76	83	cocaine	Chemical	D003042
Entity: 9799166	91	102	amphetamine	Chemical	D000661
Relation: 9799166	CID	76	83	D003042	38	44	D020521	true
Relation: 9799166	CID	91	102	D000661	38	44	D020521	true

Sentence: Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women.
Entity: 9672273	14	27	breast cancer	Disease	D001943
Entity: 9672273	33	42	tamoxifen	Chemical	D013629
Relation: 9672273	CID	33	42	D013629	14	27	D001943	false

Sentence: BACKGROUND: Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of endometrial cancer.
Entity: 9672273	12	21	Tamoxifen	Chemical	D013629
Entity: 9672273	62	75	breast cancer	Disease	D001943
Entity: 9672273	137	155	endometrial cancer	Disease	D016889
Relation: 9672273	CID	12	21	D013629	62	75	D001943	false
Relation: 9672273	CID	12	21	D013629	137	155	D016889	false

Sentence: METHODS: In October, 1992, we started a double-blind placebo-controlled, randomised trial of tamoxifen in women (mainly in Italy) who did not have breast cancer and who had had a hysterectomy.
Entity: 9672273	93	102	tamoxifen	Chemical	D013629
Entity: 9672273	147	160	breast cancer	Disease	D001943
Relation: 9672273	CID	93	102	D013629	147	160	D001943	false

Sentence: There is no difference in breast-cancer frequency between the placebo (22 cases) and tamoxifen (19) arms.
Entity: 9672273	26	39	breast-cancer	Disease	D001943
Entity: 9672273	85	94	tamoxifen	Chemical	D013629
Relation: 9672273	CID	85	94	D013629	26	39	D001943	false

Sentence: There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.
Entity: 9672273	50	63	breast cancer	Disease	D001943
Entity: 9672273	86	95	tamoxifen	Chemical	D013629
Entity: 9672273	238	251	breast cancer	Disease	D001943
Entity: 9672273	304	313	tamoxifen	Chemical	D013629
Relation: 9672273	CID	86	95	D013629	50	63	D001943	false
Relation: 9672273	CID	86	95	D013629	238	251	D001943	false
Relation: 9672273	CID	304	313	D013629	50	63	D001943	false
Relation: 9672273	CID	304	313	D013629	238	251	D001943	false

Sentence: Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen.
Entity: 9672273	77	92	vascular events	Disease	D014652
Entity: 9672273	97	118	hypertriglyceridaemia	Disease	D015228
Entity: 9672273	134	143	tamoxifen	Chemical	D013629
Relation: 9672273	CID	134	143	D013629	77	92	D014652	true
Relation: 9672273	CID	134	143	D013629	97	118	D015228	true

Sentence: INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent.
Entity: 9672273	115	128	breast cancer	Disease	D001943
Entity: 9672273	167	176	tamoxifen	Chemical	D013629
Relation: 9672273	CID	167	176	D013629	115	128	D001943	false

Sentence: A measure of pupillary oscillation as a marker of cocaine induced paranoia.
Entity: 8854309	13	34	pupillary oscillation	Disease	D011681
Entity: 8854309	50	57	cocaine	Chemical	D003042
Entity: 8854309	66	74	paranoia	Disease	D010259
Relation: 8854309	CID	50	57	D003042	13	34	D011681	true
Relation: 8854309	CID	50	57	D003042	66	74	D010259	true

Sentence: Cocaine induced paranoia (CIP) remains an important drug induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.
Entity: 8854309	0	7	Cocaine	Chemical	D003042
Entity: 8854309	16	24	paranoia	Disease	D010259
Entity: 8854309	26	29	CIP	Disease	D010259
Entity: 8854309	85	93	paranoia	Disease	D010259
Relation: 8854309	CID	0	7	D003042	16	24	D010259	true
Relation: 8854309	CID	0	7	D003042	26	29	D010259	true
Relation: 8854309	CID	0	7	D003042	85	93	D010259	true

Sentence: Seizures induced by combined levomepromazine-fluvoxamine treatment.
Entity: 8473723	0	8	Seizures	Disease	D012640
Entity: 8473723	29	44	levomepromazine	Chemical	D008728
Entity: 8473723	45	56	fluvoxamine	Chemical	D016666
Relation: 8473723	CID	29	44	D008728	0	8	D012640	true
Relation: 8473723	CID	45	56	D016666	0	8	D012640	true

Sentence: We report a case of combined levomepromazine-fluvoxamine treatment induced seizures.
Entity: 8473723	29	44	levomepromazine	Chemical	D008728
Entity: 8473723	45	56	fluvoxamine	Chemical	D016666
Entity: 8473723	75	83	seizures	Disease	D012640
Relation: 8473723	CID	29	44	D008728	75	83	D012640	true
Relation: 8473723	CID	45	56	D016666	75	83	D012640	true

Sentence: Why may epsilon-aminocaproic acid (EACA) induce myopathy in man.
Entity: 6674249	8	33	epsilon-aminocaproic acid	Chemical	D015119
Entity: 6674249	35	39	EACA	Chemical	D015119
Entity: 6674249	48	56	myopathy	Disease	D009135
Relation: 6674249	CID	8	33	D015119	48	56	D009135	true
Relation: 6674249	CID	35	39	D015119	48	56	D009135	true

Sentence: Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.
Entity: 6150641	55	64	impotence	Disease	D007172
Entity: 6150641	78	88	cimetidine	Chemical	D002927
Entity: 6150641	137	147	cimetidine	Chemical	D002927
Entity: 6150641	164	174	ranitidine	Chemical	D011899
Relation: 6150641	CID	78	88	D002927	55	64	D007172	true
Relation: 6150641	CID	137	147	D002927	55	64	D007172	true
Relation: 6150641	CID	164	174	D011899	55	64	D007172	false

Sentence: Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.
Entity: 6150641	29	39	cimetidine	Chemical	D002927
Entity: 6150641	81	91	ranitidine	Chemical	D011899
Entity: 6150641	154	161	hepatic	Disease	D056486
Entity: 6150641	165	176	hematologic	Disease	D006402
Entity: 6150641	238	248	ranitidine	Chemical	D011899
Entity: 6150641	305	315	creatinine	Chemical	D003404
Entity: 6150641	337	347	cimetidine	Chemical	D002927
Relation: 6150641	CID	29	39	D002927	154	161	D056486	false
Relation: 6150641	CID	29	39	D002927	165	176	D006402	false
Relation: 6150641	CID	81	91	D011899	154	161	D056486	false
Relation: 6150641	CID	81	91	D011899	165	176	D006402	false
Relation: 6150641	CID	238	248	D011899	154	161	D056486	false
Relation: 6150641	CID	238	248	D011899	165	176	D006402	false
Relation: 6150641	CID	305	315	D003404	154	161	D056486	false
Relation: 6150641	CID	305	315	D003404	165	176	D006402	false
Relation: 6150641	CID	337	347	D002927	154	161	D056486	false
Relation: 6150641	CID	337	347	D002927	165	176	D006402	false

Sentence: Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol.
Entity: 2826064	29	40	hypokalemia	Disease	D007008
Entity: 2826064	64	74	oxprenolol	Chemical	D010096
Relation: 2826064	CID	64	74	D010096	29	40	D007008	false

Sentence: The time course and concentration-effect relationship of terbutaline induced hypokalemia was studied, using computer-aided pharmacokinetic-dynamic modeling.
Entity: 2826064	57	68	terbutaline	Chemical	D013726
Entity: 2826064	77	88	hypokalemia	Disease	D007008
Relation: 2826064	CID	57	68	D013726	77	88	D007008	true

Sentence: Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia, together with the pharmacokinetic interaction between both drugs.
Entity: 2826064	45	55	oxprenolol	Chemical	D010096
Entity: 2826064	77	88	hypokalemia	Disease	D007008
Relation: 2826064	CID	45	55	D010096	77	88	D007008	false

Sentence: Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa.
Entity: 2422478	11	20	serotonin	Chemical	D012701
Entity: 2422478	59	70	hypotensive	Disease	D007022
Entity: 2422478	81	91	methyldopa	Chemical	D008750
Relation: 2422478	CID	11	20	D012701	59	70	D007022	false
Relation: 2422478	CID	81	91	D008750	59	70	D007022	true

Sentence: Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord.
Entity: 2422478	74	84	methyldopa	Chemical	D008750
Entity: 2422478	124	133	serotonin	Chemical	D012701
Entity: 2422478	167	178	hypotensive	Disease	D007022
Relation: 2422478	CID	74	84	D008750	167	178	D007022	true
Relation: 2422478	CID	124	133	D012701	167	178	D007022	false

Sentence: In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.
Entity: 2422478	17	29	hypertensive	Disease	D006973
Entity: 2422478	31	37	stroke	Disease	D020521
Entity: 2422478	68	78	methyldopa	Chemical	D008750
Entity: 2422478	111	120	serotonin	Chemical	D012701
Entity: 2422478	171	182	hypotension	Disease	D007022
Entity: 2422478	269	278	serotonin	Chemical	D012701
Entity: 2422478	290	313	5,7-dihydroxytryptamine	Chemical	D015116
Entity: 2422478	315	322	5,7-DHT	Chemical	D015116
Relation: 2422478	CID	68	78	D008750	17	29	D006973	false
Relation: 2422478	CID	68	78	D008750	31	37	D020521	false
Relation: 2422478	CID	68	78	D008750	171	182	D007022	true
Relation: 2422478	CID	111	120	D012701	17	29	D006973	false
Relation: 2422478	CID	111	120	D012701	31	37	D020521	false
Relation: 2422478	CID	111	120	D012701	171	182	D007022	false
Relation: 2422478	CID	269	278	D012701	17	29	D006973	false
Relation: 2422478	CID	269	278	D012701	31	37	D020521	false
Relation: 2422478	CID	269	278	D012701	171	182	D007022	false
Relation: 2422478	CID	290	313	D015116	17	29	D006973	false
Relation: 2422478	CID	290	313	D015116	31	37	D020521	false
Relation: 2422478	CID	290	313	D015116	171	182	D007022	false
Relation: 2422478	CID	315	322	D015116	17	29	D006973	false
Relation: 2422478	CID	315	322	D015116	31	37	D020521	false
Relation: 2422478	CID	315	322	D015116	171	182	D007022	false

Sentence: However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.
Entity: 2422478	34	41	5,7-DHT	Chemical	D015116
Entity: 2422478	96	105	serotonin	Chemical	D012701
Entity: 2422478	157	168	hypotension	Disease	D007022
Relation: 2422478	CID	34	41	D015116	157	168	D007022	false
Relation: 2422478	CID	96	105	D012701	157	168	D007022	false

Sentence: Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers.
Entity: 1535072	0	9	Yohimbine	Chemical	D015016
Entity: 1535072	23	42	sexual side effects	Disease	D020018
Entity: 1535072	54	63	serotonin	Chemical	D012701
Relation: 1535072	CID	0	9	D015016	23	42	D020018	false
Relation: 1535072	CID	54	63	D012701	23	42	D020018	false

Sentence: BACKGROUND: Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of male impotence.
Entity: 1535072	58	67	yohimbine	Chemical	D015016
Entity: 1535072	135	149	male impotence	Disease	D007172
Relation: 1535072	CID	58	67	D015016	135	149	D007172	false

Sentence: A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.
Entity: 1535072	35	44	yohimbine	Chemical	D015016
Entity: 1535072	70	89	sexual side effects	Disease	D020018
Entity: 1535072	93	105	clomipramine	Chemical	D002997
Relation: 1535072	CID	35	44	D015016	70	89	D020018	false
Relation: 1535072	CID	93	105	D002997	70	89	D020018	true

Sentence: This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.
Entity: 1535072	21	30	yohimbine	Chemical	D015016
Entity: 1535072	54	73	sexual side effects	Disease	D020018
Entity: 1535072	84	93	serotonin	Chemical	D012701
Relation: 1535072	CID	21	30	D015016	54	73	D020018	false
Relation: 1535072	CID	84	93	D012701	54	73	D020018	false

Sentence: METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n. basis in an open clinical trial.
Entity: 1535072	33	62	obsessive compulsive disorder	Disease	D009771
Entity: 1535072	64	80	trichotillomania	Disease	D014256
Entity: 1535072	82	89	anxiety	Disease	D001008
Entity: 1535072	94	113	affective disorders	Disease	D019964
Entity: 1535072	127	146	sexual side effects	Disease	D020018
Entity: 1535072	168	177	serotonin	Chemical	D012701
Entity: 1535072	207	216	yohimbine	Chemical	D015016
Relation: 1535072	CID	168	177	D012701	33	62	D009771	false
Relation: 1535072	CID	168	177	D012701	64	80	D014256	false
Relation: 1535072	CID	168	177	D012701	82	89	D001008	false
Relation: 1535072	CID	168	177	D012701	94	113	D019964	false
Relation: 1535072	CID	168	177	D012701	127	146	D020018	false
Relation: 1535072	CID	207	216	D015016	33	62	D009771	false
Relation: 1535072	CID	207	216	D015016	64	80	D014256	false
Relation: 1535072	CID	207	216	D015016	82	89	D001008	false
Relation: 1535072	CID	207	216	D015016	94	113	D019964	false
Relation: 1535072	CID	207	216	D015016	127	146	D020018	false

Sentence: Side effects of yohimbine included excessive sweating, increased anxiety, and a wound-up feeling in some patients.
Entity: 1535072	16	25	yohimbine	Chemical	D015016
Entity: 1535072	65	72	anxiety	Disease	D001008
Relation: 1535072	CID	16	25	D015016	65	72	D001008	false

Sentence: CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers.
Entity: 1535072	52	61	yohimbine	Chemical	D015016
Entity: 1535072	100	119	sexual side effects	Disease	D020018
Entity: 1535072	130	139	serotonin	Chemical	D012701
Relation: 1535072	CID	52	61	D015016	100	119	D020018	false
Relation: 1535072	CID	130	139	D012701	100	119	D020018	false

Sentence: Hypersensitivity immune reaction as a mechanism for dilevalol-associated hepatitis.
Entity: 1504402	0	16	Hypersensitivity	Disease	D004342
Entity: 1504402	52	61	dilevalol	Chemical	D007741
Entity: 1504402	73	82	hepatitis	Disease	D056486
Relation: 1504402	CID	52	61	D007741	0	16	D004342	true
Relation: 1504402	CID	52	61	D007741	73	82	D056486	true

Sentence: OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol induced liver injury.
Entity: 1504402	46	55	dilevalol	Chemical	D007741
Entity: 1504402	97	106	dilevalol	Chemical	D007741
Entity: 1504402	144	153	dilevalol	Chemical	D007741
Entity: 1504402	162	174	liver injury	Disease	D056486
Relation: 1504402	CID	46	55	D007741	162	174	D056486	true
Relation: 1504402	CID	97	106	D007741	162	174	D056486	true
Relation: 1504402	CID	144	153	D007741	162	174	D056486	true

Sentence: PATIENT: A 58-year-old woman with a clinical diagnosis of dilevalol induced liver injury.
Entity: 1504402	58	67	dilevalol	Chemical	D007741
Entity: 1504402	76	88	liver injury	Disease	D056486
Relation: 1504402	CID	58	67	D007741	76	88	D056486	true

Sentence: Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report.
Entity: 19917396	11	33	myocardial hypertrophy	Disease	D006332
Entity: 19917396	45	55	tacrolimus	Chemical	D016559
Relation: 19917396	CID	45	55	D016559	11	33	D006332	true

Sentence: Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation.
Entity: 19917396	29	51	myocardial hypertrophy	Disease	D006332
Entity: 19917396	63	73	tacrolimus	Chemical	D016559
Relation: 19917396	CID	63	73	D016559	29	51	D006332	true

Sentence: Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur, as confirmed at echocardiography and myocardial biopsy.
Entity: 19917396	0	22	Myocardial hypertrophy	Disease	D006332
Entity: 19917396	85	95	tacrolimus	Chemical	D016559
Relation: 19917396	CID	85	95	D016559	0	22	D006332	true

Sentence: Thus, we conclude that tacrolimus induces reversible myocardial hypertrophy.
Entity: 19917396	23	33	tacrolimus	Chemical	D016559
Entity: 19917396	53	75	myocardial hypertrophy	Disease	D006332
Relation: 19917396	CID	23	33	D016559	53	75	D006332	true

Sentence: Ten consecutive patients (mean age, 58.4 +/- 6.8 years; 7 men, 3 women) with similar characteristics at the duration of disease (mean disease time, 8.4 +/- 3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and levodopa induced dyskinesias were selected.
Entity: 19234905	245	253	levodopa	Chemical	D007980
Entity: 19234905	262	273	dyskinesias	Disease	D004409
Relation: 19234905	CID	245	253	D007980	262	273	D004409	true

Sentence: Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.
Entity: 19234905	60	82	homonymous hemianopsia	Disease	D006423
Entity: 19234905	226	235	Valproate	Chemical	D014635
Relation: 19234905	CID	226	235	D014635	60	82	D006423	false

Sentence: Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.
Entity: 18541230	38	63	puromycin aminonucleoside	Chemical	D011692
Entity: 18541230	64	73	nephrosis	Disease	D009401
Relation: 18541230	CID	38	63	D011692	64	73	D009401	true

Sentence: We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside induced nephrosis, which is an experimental model of human nephrotic syndrome.
Entity: 18541230	101	126	puromycin aminonucleoside	Chemical	D011692
Entity: 18541230	135	144	nephrosis	Disease	D009401
Entity: 18541230	186	204	nephrotic syndrome	Disease	D009404
Relation: 18541230	CID	101	126	D011692	135	144	D009401	true
Relation: 18541230	CID	101	126	D011692	186	204	D009404	false

Sentence: Treatment with antithrombin attenuated the puromycin aminonucleoside induced hematological abnormalities.
Entity: 18541230	43	68	puromycin aminonucleoside	Chemical	D011692
Entity: 18541230	77	104	hematological abnormalities	Disease	D006402
Relation: 18541230	CID	43	68	D011692	77	104	D006402	false

Sentence: Puromycin aminonucleoside induced renal dysfunction and hyperlipidemia were also suppressed.
Entity: 18541230	0	25	Puromycin aminonucleoside	Chemical	D011692
Entity: 18541230	34	51	renal dysfunction	Disease	D007674
Entity: 18541230	56	70	hyperlipidemia	Disease	D006949
Relation: 18541230	CID	0	25	D011692	34	51	D007674	false
Relation: 18541230	CID	0	25	D011692	56	70	D006949	false

Sentence: These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside induced nephrotic syndrome.
Entity: 18541230	84	109	puromycin aminonucleoside	Chemical	D011692
Entity: 18541230	118	136	nephrotic syndrome	Disease	D009404
Relation: 18541230	CID	84	109	D011692	118	136	D009404	false

Sentence: Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use.
Entity: 18177388	20	63	left ventricular apical ballooning syndrome	Disease	D054549
Entity: 18177388	73	97	Takotsubo cardiomyopathy	Disease	D054549
Entity: 18177388	134	145	amphetamine	Chemical	D000661
Relation: 18177388	CID	134	145	D000661	20	63	D054549	true
Relation: 18177388	CID	134	145	D000661	73	97	D054549	true

Sentence: Amphetamine induced locomotor hyperactivity was similar in all groups.
Entity: 17490864	0	11	Amphetamine	Chemical	D000661
Entity: 17490864	20	43	locomotor hyperactivity	Disease	D006948
Relation: 17490864	CID	0	11	D000661	20	43	D006948	true

Sentence: Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra.
Entity: 17490790	11	23	iron dextran	Chemical	D007505
Entity: 17490790	32	68	degeneration of dopaminergic neurons	Disease	D009410
Relation: 17490790	CID	11	23	D007505	32	68	D009410	true

Sentence: Iron accumulation is considered to be involved in the pathogenesis of Parkinson's disease.
Entity: 17490790	0	4	Iron	Chemical	D007501
Entity: 17490790	70	89	Parkinson's disease	Disease	D010300
Relation: 17490790	CID	0	4	D007501	70	89	D010300	false

Sentence: To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.
Entity: 17490790	51	55	iron	Chemical	D007501
Entity: 17490790	178	186	tyrosine	Chemical	D014443
Entity: 17490790	233	237	iron	Chemical	D007501
Entity: 17490790	330	366	degeneration of dopaminergic neurons	Disease	D009410
Entity: 17490790	381	385	iron	Chemical	D007501
Entity: 17490790	407	419	iron dextran	Chemical	D007505
Relation: 17490790	CID	51	55	D007501	330	366	D009410	false
Relation: 17490790	CID	178	186	D014443	330	366	D009410	false
Relation: 17490790	CID	233	237	D007501	330	366	D009410	false
Relation: 17490790	CID	381	385	D007501	330	366	D009410	false
Relation: 17490790	CID	407	419	D007505	330	366	D009410	true

Sentence: These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.
Entity: 17490790	38	50	iron dextran	Chemical	D007505
Entity: 17490790	68	72	iron	Chemical	D007501
Entity: 17490790	106	110	iron	Chemical	D007501
Entity: 17490790	122	158	degeneration of dopaminergic neurons	Disease	D009410
Relation: 17490790	CID	38	50	D007505	122	158	D009410	true
Relation: 17490790	CID	68	72	D007501	122	158	D009410	false
Relation: 17490790	CID	106	110	D007501	122	158	D009410	false

Sentence: Warfarin induced leukocytoclastic vasculitis.
Entity: 16047871	0	8	Warfarin	Chemical	D014859
Entity: 16047871	17	44	leukocytoclastic vasculitis	Disease	C535509
Relation: 16047871	CID	0	8	D014859	17	44	C535509	false

Sentence: We report 4 patients with late-onset LV probably due to warfarin.
Entity: 16047871	37	39	LV	Disease	C535509
Entity: 16047871	56	64	warfarin	Chemical	D014859
Relation: 16047871	CID	56	64	D014859	37	39	C535509	false

Sentence: All 4 patients presented with skin eruptions that developed after receiving warfarin for several years.
Entity: 16047871	30	44	skin eruptions	Disease	D012871
Entity: 16047871	76	84	warfarin	Chemical	D014859
Relation: 16047871	CID	76	84	D014859	30	44	D012871	false

Sentence: The results of skin lesion biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued.
Entity: 16047871	15	26	skin lesion	Disease	D012871
Entity: 16047871	77	97	LV Cutaneous lesions	Disease	D018366
Entity: 16047871	129	137	warfarin	Chemical	D014859
Relation: 16047871	CID	129	137	D014859	15	26	D012871	false
Relation: 16047871	CID	129	137	D014859	77	97	D018366	true

Sentence: The activation of spinal N-methyl-D-aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia.
Entity: 15673851	25	45	N-methyl-D-aspartate	Chemical	D016202
Entity: 15673851	132	140	morphine	Chemical	D009020
Entity: 15673851	174	194	spinal cord ischemia	Disease	D020760
Relation: 15673851	CID	25	45	D016202	174	194	D020760	false
Relation: 15673851	CID	132	140	D009020	174	194	D020760	false

Sentence: We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats.
Entity: 15673851	100	120	N-methyl-d-aspartate	Chemical	D016202
Entity: 15673851	122	126	NMDA	Chemical	D016202
Entity: 15673851	154	162	morphine	Chemical	D009020
Entity: 15673851	200	216	aortic occlusion	Disease	D001157
Relation: 15673851	CID	100	120	D016202	200	216	D001157	false
Relation: 15673851	CID	122	126	D016202	200	216	D001157	false
Relation: 15673851	CID	154	162	D009020	200	216	D001157	false

Sentence: Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine induced spastic paraparesis.
Entity: 15673851	41	47	MK-801	Chemical	D016291
Entity: 15673851	113	121	morphine	Chemical	D009020
Entity: 15673851	130	149	spastic paraparesis	Disease	D020336
Relation: 15673851	CID	41	47	D016291	130	149	D020336	false
Relation: 15673851	CID	113	121	D009020	130	149	D020336	true

Sentence: IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after morphine induced spastic paraparesis compared with the saline group.
Entity: 15673851	3	9	MK-801	Chemical	D016291
Entity: 15673851	83	91	morphine	Chemical	D009020
Entity: 15673851	100	119	spastic paraparesis	Disease	D020336
Relation: 15673851	CID	3	9	D016291	100	119	D020336	false
Relation: 15673851	CID	83	91	D009020	100	119	D020336	true

Sentence: These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.
Entity: 15673851	28	36	morphine	Chemical	D009020
Entity: 15673851	45	64	spastic paraparesis	Disease	D020336
Entity: 15673851	100	109	glutamate	Chemical	D018698
Entity: 15673851	132	136	NMDA	Chemical	D016202
Relation: 15673851	CID	28	36	D009020	45	64	D020336	true
Relation: 15673851	CID	100	109	D018698	45	64	D020336	false
Relation: 15673851	CID	132	136	D016202	45	64	D020336	false

Sentence: Reduced sodium channel density, altered voltage dependence of inactivation, and increased susceptibility to seizures in mice lacking sodium channel beta 2-subunits.
Entity: 12481039	8	14	sodium	Chemical	D012964
Entity: 12481039	108	116	seizures	Disease	D012640
Entity: 12481039	133	139	sodium	Chemical	D012964
Relation: 12481039	CID	8	14	D012964	108	116	D012640	false
Relation: 12481039	CID	133	139	D012964	108	116	D012640	false

Sentence: In contrast, the conduction velocity, the number and size of axons in the optic nerve, and the specific localization of Na(v)1.6 channels in the nodes of Ranvier were unchanged. beta2(-/-) mice displayed increased susceptibility to seizures, as indicated by reduced latency and threshold for pilocarpine induced seizures, but seemed normal in other neurological tests.
Entity: 12481039	120	122	Na	Chemical	D012964
Entity: 12481039	232	240	seizures	Disease	D012640
Entity: 12481039	292	303	pilocarpine	Chemical	D010862
Entity: 12481039	312	320	seizures	Disease	D012640
Relation: 12481039	CID	120	122	D012964	232	240	D012640	false
Relation: 12481039	CID	120	122	D012964	312	320	D012640	false
Relation: 12481039	CID	292	303	D010862	232	240	D012640	true
Relation: 12481039	CID	292	303	D010862	312	320	D012640	true

Sentence: OBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients.
Entity: 11185967	109	116	cocaine	Chemical	D003042
Entity: 11185967	120	131	amphetamine	Chemical	D000661
Entity: 11185967	162	169	seizure	Disease	D012640
Relation: 11185967	CID	109	116	D003042	162	169	D012640	false
Relation: 11185967	CID	120	131	D000661	162	169	D012640	false

Sentence: Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.
Entity: 11185967	52	59	alcohol	Chemical	D000431
Entity: 11185967	68	75	seizure	Disease	D012640
Entity: 11185967	106	113	seizure	Disease	D012640
Entity: 11185967	160	167	cocaine	Disease	D019970
Entity: 11185967	171	182	amphetamine	Disease	D019969
Relation: 11185967	CID	52	59	D000431	68	75	D012640	false
Relation: 11185967	CID	52	59	D000431	106	113	D012640	false
Relation: 11185967	CID	52	59	D000431	160	167	D019970	false
Relation: 11185967	CID	52	59	D000431	171	182	D019969	false

Sentence: CONCLUSIONS: During this study period, routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield.
Entity: 11185967	68	75	cocaine	Chemical	D003042
Entity: 11185967	80	92	amphetamines	Chemical	D000662
Entity: 11185967	102	109	seizure	Disease	D012640
Relation: 11185967	CID	68	75	D003042	102	109	D012640	false
Relation: 11185967	CID	80	92	D000662	102	109	D012640	false

Sentence: The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa induced dyskinesias (LID).
Entity: 11099450	157	169	parkinsonian	Disease	D010300
Entity: 11099450	186	194	levodopa	Chemical	D007980
Entity: 11099450	203	214	dyskinesias	Disease	D004409
Entity: 11099450	216	219	LID	Disease	D004409
Relation: 11099450	CID	186	194	D007980	157	169	D010300	false
Relation: 11099450	CID	186	194	D007980	203	214	D004409	true
Relation: 11099450	CID	186	194	D007980	216	219	D004409	true

Sentence: We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests (Core Assessment Program for Intracerebral Transplantations) in the contralateral limbs and the improvement in these scores after surgery, whereas there was no correlation with the improvement in LID.
Entity: 11099450	68	76	levodopa	Chemical	D007980
Entity: 11099450	115	123	levodopa	Chemical	D007980
Entity: 11099450	360	363	LID	Disease	D004409
Relation: 11099450	CID	68	76	D007980	360	363	D004409	true
Relation: 11099450	CID	115	123	D007980	360	363	D004409	true

Sentence: The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.
Entity: 11099450	37	45	levodopa	Chemical	D007980
Entity: 11099450	80	92	parkinsonian	Disease	D010300
Entity: 11099450	109	112	LID	Disease	D004409
Entity: 11099450	174	185	dyskinesias	Disease	D004409
Entity: 11099450	190	202	parkinsonian	Disease	D010300
Entity: 11099450	324	336	parkinsonian	Disease	D010300
Entity: 11099450	353	364	dyskinesias	Disease	D004409
Relation: 11099450	CID	37	45	D007980	80	92	D010300	false
Relation: 11099450	CID	37	45	D007980	109	112	D004409	true
Relation: 11099450	CID	37	45	D007980	174	185	D004409	true
Relation: 11099450	CID	37	45	D007980	190	202	D010300	false
Relation: 11099450	CID	37	45	D007980	324	336	D010300	false
Relation: 11099450	CID	37	45	D007980	353	364	D004409	true

Sentence: Pain responses in methadone-maintained opioid abusers.
Entity: 11027904	0	4	Pain	Disease	D010146
Entity: 11027904	18	27	methadone	Chemical	D008691
Relation: 11027904	CID	18	27	D008691	0	4	D010146	false

Sentence: This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).
Entity: 11027904	36	40	pain	Disease	D010146
Entity: 11027904	89	103	opioid addicts	Disease	D009293
Entity: 11027904	118	127	methadone	Chemical	D008691
Relation: 11027904	CID	118	127	D008691	36	40	D010146	false
Relation: 11027904	CID	118	127	D008691	89	103	D009293	false

Sentence: By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.
Entity: 11027904	88	92	pain	Disease	D010146
Entity: 11027904	188	201	hydromorphone	Chemical	D004091
Entity: 11027904	244	253	ketorolac	Chemical	D020910
Relation: 11027904	CID	188	201	D004091	88	92	D010146	false
Relation: 11027904	CID	244	253	D020910	88	92	D010146	false

Sentence: METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.
Entity: 10193809	9	34	Puromycin aminonucleoside	Chemical	D011692
Entity: 10193809	36	39	PAN	Chemical	D011692
Entity: 10193809	91	102	proteinuria	Disease	D011507
Relation: 10193809	CID	9	34	D011692	91	102	D011507	true
Relation: 10193809	CID	36	39	D011692	91	102	D011507	true

Sentence: Over expression of vascular endothelial growth factor and its receptor during the development of estrogen induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.
Entity: 9214597	97	105	estrogen	Chemical	D004967
Entity: 9214597	118	134	pituitary tumors	Disease	D010911
Entity: 9214597	147	155	estrogen	Chemical	D004967
Entity: 9214597	166	171	tumor	Disease	D009369
Relation: 9214597	CID	97	105	D004967	118	134	D010911	false
Relation: 9214597	CID	97	105	D004967	166	171	D009369	false
Relation: 9214597	CID	147	155	D004967	118	134	D010911	false
Relation: 9214597	CID	147	155	D004967	166	171	D009369	false

Sentence: Estrogens, which have been associated with several types of human and animal cancers, can induce tumor angiogenesis in the pituitary of Fischer 344 rats.
Entity: 9214597	0	9	Estrogens	Chemical	D004967
Entity: 9214597	77	84	cancers	Disease	D009369
Entity: 9214597	97	102	tumor	Disease	D009369
Relation: 9214597	CID	0	9	D004967	77	84	D009369	false
Relation: 9214597	CID	0	9	D004967	97	102	D009369	false

Sentence: The mechanistic details of tumor angiogenesis induction, during estrogen carcinogenesis, are still unknown.
Entity: 9214597	27	32	tumor	Disease	D009369
Entity: 9214597	64	72	estrogen	Chemical	D004967
Entity: 9214597	73	87	carcinogenesis	Disease	D063646
Relation: 9214597	CID	64	72	D004967	27	32	D009369	false
Relation: 9214597	CID	64	72	D004967	73	87	D063646	false

Sentence: To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.
Entity: 9214597	25	33	estrogen	Chemical	D004967
Entity: 9214597	55	60	tumor	Disease	D009369
Relation: 9214597	CID	25	33	D004967	55	60	D009369	false

Sentence: The high tumor angiogenic potential was associated with an elevated VEGF/VPF protein expression in the E2 exposed pituitary of ovariectomized (OVEX) rats.
Entity: 9214597	9	14	tumor	Disease	D009369
Entity: 9214597	103	105	E2	Chemical	D004958
Relation: 9214597	CID	103	105	D004958	9	14	D009369	false

Sentence: Pravastatin-associated myopathy.
Entity: 7604176	0	11	Pravastatin	Chemical	D017035
Entity: 7604176	23	31	myopathy	Disease	D009135
Relation: 7604176	CID	0	11	D017035	23	31	D009135	false

Sentence: A case of acute inflammatory myopathy associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.
Entity: 7604176	16	37	inflammatory myopathy	Disease	D009220
Entity: 7604176	65	76	pravastatin	Chemical	D017035
Relation: 7604176	CID	65	76	D017035	16	37	D009220	true

Sentence: He assumed pravastatin (20 mg/day) because of hypercholesterolemia.
Entity: 7604176	11	22	pravastatin	Chemical	D017035
Entity: 7604176	46	66	hypercholesterolemia	Disease	D006937
Relation: 7604176	CID	11	22	D017035	46	66	D006937	false

Sentence: He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation.
Entity: 7604176	27	35	myopathy	Disease	D009135
Entity: 7604176	90	101	pravastatin	Chemical	D017035
Relation: 7604176	CID	90	101	D017035	27	35	D009135	false

Sentence: Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.
Entity: 7282516	52	63	doxorubicin	Chemical	D004317
Entity: 7282516	64	78	cardiomyopathy	Disease	D009202
Relation: 7282516	CID	52	63	D004317	64	78	D009202	true

Sentence: The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.
Entity: 7282516	4	18	cardiomyopathy	Disease	D009202
Entity: 7282516	20	22	CM	Disease	D009202
Entity: 7282516	56	67	doxorubicin	Chemical	D004317
Entity: 7282516	69	72	DXR	Chemical	D004317
Entity: 7282516	75	85	Adriamycin	Chemical	D004317
Entity: 7282516	199	217	myocardial disease	Disease	D009202
Relation: 7282516	CID	56	67	D004317	4	18	D009202	true
Relation: 7282516	CID	56	67	D004317	20	22	D009202	true
Relation: 7282516	CID	56	67	D004317	199	217	D009202	true
Relation: 7282516	CID	69	72	D004317	4	18	D009202	true
Relation: 7282516	CID	69	72	D004317	20	22	D009202	true
Relation: 7282516	CID	69	72	D004317	199	217	D009202	true
Relation: 7282516	CID	75	85	D004317	4	18	D009202	true
Relation: 7282516	CID	75	85	D004317	20	22	D009202	true
Relation: 7282516	CID	75	85	D004317	199	217	D009202	true

Sentence: Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol.
Entity: 7072798	6	21	aplastic anemia	Disease	D000741
Entity: 7072798	69	84	chloramphenicol	Chemical	D002701
Relation: 7072798	CID	69	84	D002701	6	21	D000741	true

Sentence: A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.
Entity: 7072798	28	43	aplastic anemia	Disease	D000741
Entity: 7072798	82	90	cataract	Disease	D002386
Entity: 7072798	137	152	chloramphenicol	Chemical	D002701
Relation: 7072798	CID	137	152	D002701	28	43	D000741	true
Relation: 7072798	CID	137	152	D002701	82	90	D002386	false

Sentence: The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol.
Entity: 7072798	19	34	aplastic anemia	Disease	D000741
Entity: 7072798	84	99	chloramphenicol	Chemical	D002701
Relation: 7072798	CID	84	99	D002701	19	34	D000741	true

Sentence: This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.
Entity: 7072798	36	51	aplastic anemia	Disease	D000741
Entity: 7072798	81	96	chloramphenicol	Chemical	D002701
Entity: 7072798	153	175	bone marrow hypoplasia	Disease	D001855
Relation: 7072798	CID	81	96	D002701	36	51	D000741	true
Relation: 7072798	CID	81	96	D002701	153	175	D001855	false

Sentence: Bradycardia due to trihexyphenidyl hydrochloride.
Entity: 3769769	0	11	Bradycardia	Disease	D001919
Entity: 3769769	19	48	trihexyphenidyl hydrochloride	Chemical	D014282
Relation: 3769769	CID	19	48	D014282	0	11	D001919	true

Sentence: A chronic schizophrenic patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride.
Entity: 3769769	10	23	schizophrenic	Disease	D012559
Entity: 3769769	74	103	trihexyphenidyl hydrochloride	Chemical	D014282
Relation: 3769769	CID	74	103	D014282	10	23	D012559	false

Sentence: Experimental cyclosporine nephrotoxicity: risk of concomitant chemotherapy.
Entity: 3708922	13	25	cyclosporine	Chemical	D016572
Entity: 3708922	26	40	nephrotoxicity	Disease	D007674
Relation: 3708922	CID	13	25	D016572	26	40	D007674	true

Sentence: The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.
Entity: 3708922	12	24	cyclosporine	Chemical	D016572
Entity: 3708922	26	29	CSA	Chemical	D016572
Entity: 3708922	108	122	renal toxicity	Disease	D007674
Relation: 3708922	CID	12	24	D016572	108	122	D007674	true
Relation: 3708922	CID	26	29	D016572	108	122	D007674	true

Sentence: The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.
Entity: 3708922	31	34	CSA	Chemical	D016572
Entity: 3708922	77	88	nephrotoxic	Disease	D007674
Entity: 3708922	108	118	gentamicin	Chemical	D005839
Entity: 3708922	143	158	amphothericin B	Chemical	D000666
Entity: 3708922	163	175	ketoconazole	Chemical	D007654
Entity: 3708922	255	258	CSA	Chemical	D016572
Entity: 3708922	267	275	toxicity	Disease	D064420
Relation: 3708922	CID	31	34	D016572	77	88	D007674	true
Relation: 3708922	CID	31	34	D016572	267	275	D064420	false
Relation: 3708922	CID	108	118	D005839	77	88	D007674	false
Relation: 3708922	CID	108	118	D005839	267	275	D064420	false
Relation: 3708922	CID	143	158	D000666	77	88	D007674	false
Relation: 3708922	CID	143	158	D000666	267	275	D064420	false
Relation: 3708922	CID	163	175	D007654	77	88	D007674	false
Relation: 3708922	CID	163	175	D007654	267	275	D064420	false
Relation: 3708922	CID	255	258	D016572	77	88	D007674	true
Relation: 3708922	CID	255	258	D016572	267	275	D064420	false

Sentence: Gentamicin at toxic doses, however, increased CSA nephrotoxicity.
Entity: 3708922	0	10	Gentamicin	Chemical	D005839
Entity: 3708922	46	49	CSA	Chemical	D016572
Entity: 3708922	50	64	nephrotoxicity	Disease	D007674
Relation: 3708922	CID	0	10	D005839	50	64	D007674	false
Relation: 3708922	CID	46	49	D016572	50	64	D007674	true

Sentence: Receptor mechanisms of nicotine induced locomotor hyperactivity in chronic nicotine-treated rats.
Entity: 3220106	23	31	nicotine	Chemical	D009538
Entity: 3220106	40	63	locomotor hyperactivity	Disease	D006948
Entity: 3220106	75	83	nicotine	Chemical	D009538
Relation: 3220106	CID	23	31	D009538	40	63	D006948	true
Relation: 3220106	CID	75	83	D009538	40	63	D006948	true

Sentence: Hydrocortisone induced hypertension in humans: pressor responsiveness and sympathetic function.
Entity: 2722224	0	14	Hydrocortisone	Chemical	D006854
Entity: 2722224	23	35	hypertension	Disease	D006973
Relation: 2722224	CID	0	14	D006854	23	35	D006973	true

Sentence: Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects, the mechanism of damage remains unclear.
Entity: 1636026	9	17	suprofen	Chemical	D013496
Entity: 1636026	62	81	acute renal failure	Disease	D058186
Relation: 1636026	CID	9	17	D013496	62	81	D058186	true

Sentence: The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.
Entity: 1636026	11	22	nephrotoxic	Disease	D007674
Entity: 1636026	60	68	suprofen	Chemical	D013496
Entity: 1636026	198	207	uric acid	Chemical	D014527
Relation: 1636026	CID	60	68	D013496	11	22	D007674	false
Relation: 1636026	CID	198	207	D014527	11	22	D007674	false

Sentence: Cocaine induced brainstem seizures and behavior.
Entity: 1610717	0	7	Cocaine	Chemical	D003042
Entity: 1610717	26	34	seizures	Disease	D012640
Relation: 1610717	CID	0	7	D003042	26	34	D012640	true

Sentence: Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol induced cholestasis in rats.
Entity: 873132	58	74	deoxycholic acid	Chemical	D003840
Entity: 873132	78	95	ethinyl estradiol	Chemical	D004997
Entity: 873132	104	115	cholestasis	Disease	D002779
Relation: 873132	CID	58	74	D003840	104	115	D002779	false
Relation: 873132	CID	78	95	D004997	104	115	D002779	true

Sentence: Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease.
Entity: 783197	11	18	ouabain	Chemical	D010042
Entity: 783197	33	39	oxygen	Chemical	D010100
Entity: 783197	83	106	coronary artery disease	Disease	D003324
Relation: 783197	CID	11	18	D010042	83	106	D003324	false
Relation: 783197	CID	33	39	D010100	83	106	D003324	false

Sentence: The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.
Entity: 783197	15	35	digitalis glycosides	Chemical	D004071
Entity: 783197	50	56	oxygen	Chemical	D010100
Entity: 783197	133	156	coronary artery disease	Disease	D003324
Relation: 783197	CID	15	35	D004071	133	156	D003324	false
Relation: 783197	CID	50	56	D010100	133	156	D003324	false

Sentence: We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.
Entity: 783197	27	34	ouabain	Chemical	D010042
Entity: 783197	149	172	coronary artery disease	Disease	D003324
Entity: 783197	190	214	congestive heart failure	Disease	D006333
Relation: 783197	CID	27	34	D010042	149	172	D003324	false
Relation: 783197	CID	27	34	D010042	190	214	D006333	false

Sentence: We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.
Entity: 783197	42	65	coronary artery disease	Disease	D003324
Entity: 783197	90	114	congestive heart failure	Disease	D006333
Entity: 783197	115	158	left ventricular end-diastolic volume falls	Disease	D002303
Entity: 783197	165	172	ouabain	Chemical	D010042
Relation: 783197	CID	165	172	D010042	42	65	D003324	false
Relation: 783197	CID	165	172	D010042	90	114	D006333	false
Relation: 783197	CID	165	172	D010042	115	158	D002303	true

Sentence: Prolongation of the QT interval related to cisapride-diltiazem interaction.
Entity: 9545159	0	31	Prolongation of the QT interval	Disease	D008133
Entity: 9545159	43	52	cisapride	Chemical	D020117
Entity: 9545159	53	62	diltiazem	Chemical	D004110
Relation: 9545159	CID	43	52	D020117	0	31	D008133	true
Relation: 9545159	CID	53	62	D004110	0	31	D008133	true

Sentence: Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders.
Entity: 9545159	0	9	Cisapride	Chemical	D020117
Entity: 9545159	95	130	gastrointestinal motility disorders	Disease	D015835
Relation: 9545159	CID	0	9	D020117	95	130	D015835	false

Sentence: Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.
Entity: 9545159	0	27	Prolongation of QT interval	Disease	D008133
Entity: 9545159	29	48	torsades de pointes	Disease	D016171
Entity: 9545159	54	74	sudden cardiac death	Disease	D016757
Entity: 9545159	132	144	erythromycin	Chemical	D004917
Entity: 9545159	148	153	azole	Chemical	D001393
Relation: 9545159	CID	132	144	D004917	0	27	D008133	true
Relation: 9545159	CID	132	144	D004917	29	48	D016171	true
Relation: 9545159	CID	132	144	D004917	54	74	D016757	true
Relation: 9545159	CID	148	153	D001393	0	27	D008133	true
Relation: 9545159	CID	148	153	D001393	29	48	D016171	true
Relation: 9545159	CID	148	153	D001393	54	74	D016757	true

Sentence: A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.
Entity: 9545159	75	84	cisapride	Chemical	D020117
Entity: 9545159	89	121	gastroesophageal reflux disorder	Disease	D005764
Entity: 9545159	126	135	diltiazem	Chemical	D004110
Entity: 9545159	188	200	hypertension	Disease	D006973
Relation: 9545159	CID	75	84	D020117	89	121	D005764	false
Relation: 9545159	CID	75	84	D020117	188	200	D006973	false
Relation: 9545159	CID	126	135	D004110	89	121	D005764	false
Relation: 9545159	CID	126	135	D004110	188	200	D006973	false

Sentence: Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.
Entity: 8643973	0	10	Paclitaxel	Chemical	D017239
Entity: 8643973	25	36	carboplatin	Chemical	D016190
Entity: 8643973	77	91	ovarian cancer	Disease	D010051
Relation: 8643973	CID	0	10	D017239	77	91	D010051	false
Relation: 8643973	CID	25	36	D016190	77	91	D010051	false

Sentence: In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.
Entity: 8643973	62	72	paclitaxel	Chemical	D017239
Entity: 8643973	74	79	Taxol	Chemical	D017239
Entity: 8643973	173	184	carboplatin	Chemical	D016190
Entity: 8643973	235	249	ovarian cancer	Disease	D010051
Entity: 8643973	251	261	paclitaxel	Chemical	D017239
Relation: 8643973	CID	62	72	D017239	235	249	D010051	false
Relation: 8643973	CID	74	79	D017239	235	249	D010051	false
Relation: 8643973	CID	173	184	D016190	235	249	D010051	false
Relation: 8643973	CID	251	261	D017239	235	249	D010051	false

Sentence: Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients.
Entity: 3535719	22	30	toxicity	Disease	D064420
Entity: 3535719	34	44	netilmicin	Chemical	D009428
Entity: 3535719	49	59	tobramycin	Chemical	D014031
Relation: 3535719	CID	34	44	D009428	22	30	D064420	false
Relation: 3535719	CID	49	59	D014031	22	30	D064420	false

Sentence: We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.
Entity: 3535719	53	71	netilmicin sulfate	Chemical	D009428
Entity: 3535719	75	93	tobramycin sulfate	Chemical	D014031
Entity: 3535719	114	133	piperacillin sodium	Chemical	D010878
Entity: 3535719	189	199	infections	Disease	D007239
Relation: 3535719	CID	53	71	D009428	189	199	D007239	false
Relation: 3535719	CID	75	93	D014031	189	199	D007239	false
Relation: 3535719	CID	114	133	D010878	189	199	D007239	false

Sentence: Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).
Entity: 3535719	0	14	Nephrotoxicity	Disease	D007674
Entity: 3535719	73	83	netilmicin	Chemical	D009428
Entity: 3535719	88	98	tobramycin	Chemical	D014031
Relation: 3535719	CID	73	83	D009428	0	14	D007674	true
Relation: 3535719	CID	88	98	D014031	0	14	D007674	true

Sentence: Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.
Entity: 3535719	0	11	Ototoxicity	Disease	D006311
Entity: 3535719	42	52	netilmicin	Chemical	D009428
Entity: 3535719	57	69	piperacillin	Chemical	D010878
Entity: 3535719	92	102	tobramycin	Chemical	D014031
Entity: 3535719	107	119	piperacillin	Chemical	D010878
Relation: 3535719	CID	42	52	D009428	0	11	D006311	true
Relation: 3535719	CID	57	69	D010878	0	11	D006311	true
Relation: 3535719	CID	92	102	D014031	0	11	D006311	true
Relation: 3535719	CID	107	119	D010878	0	11	D006311	true

Sentence: Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats.
Entity: 6433367	10	23	prostaglandin	Chemical	D011453
Entity: 6433367	72	83	convulsions	Disease	D012640
Relation: 6433367	CID	10	23	D011453	72	83	D012640	false

Sentence: To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.
Entity: 6433367	35	49	prostaglandins	Chemical	D011453
Entity: 6433367	51	54	PGs	Chemical	D011453
Entity: 6433367	59	66	seizure	Disease	D012640
Entity: 6433367	125	136	convulsions	Disease	D012640
Entity: 6433367	148	157	flurothyl	Chemical	D005481
Entity: 6433367	159	169	picrotoxin	Chemical	D010852
Entity: 6433367	171	182	pentetrazol	Chemical	D010433
Entity: 6433367	184	187	PTZ	Chemical	D010433
Entity: 6433367	206	217	bicuculline	Chemical	D001640
Relation: 6433367	CID	35	49	D011453	59	66	D012640	false
Relation: 6433367	CID	35	49	D011453	125	136	D012640	false
Relation: 6433367	CID	51	54	D011453	59	66	D012640	false
Relation: 6433367	CID	51	54	D011453	125	136	D012640	false
Relation: 6433367	CID	148	157	D005481	59	66	D012640	true
Relation: 6433367	CID	148	157	D005481	125	136	D012640	true
Relation: 6433367	CID	159	169	D010852	59	66	D012640	true
Relation: 6433367	CID	159	169	D010852	125	136	D012640	true
Relation: 6433367	CID	171	182	D010433	59	66	D012640	true
Relation: 6433367	CID	171	182	D010433	125	136	D012640	true
Relation: 6433367	CID	184	187	D010433	59	66	D012640	true
Relation: 6433367	CID	184	187	D010433	125	136	D012640	true
Relation: 6433367	CID	206	217	D001640	59	66	D012640	true
Relation: 6433367	CID	206	217	D001640	125	136	D012640	true

Sentence: This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of amlodipine/benazapril 10/5 mg.
Entity: 17285209	84	96	hypertension	Disease	D006973
Entity: 17285209	139	149	amlodipine	Chemical	D017311
Entity: 17285209	150	160	benazapril	Chemical	C044946
Relation: 17285209	CID	139	149	D017311	84	96	D006973	false
Relation: 17285209	CID	150	160	C044946	84	96	D006973	false

Sentence: Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.
Entity: 15858223	0	13	Valproic acid	Chemical	D014635
Entity: 15858223	63	77	liver toxicity	Disease	D056486
Entity: 15858223	83	96	valproic acid	Chemical	D014635
Relation: 15858223	CID	0	13	D014635	63	77	D056486	true
Relation: 15858223	CID	83	96	D014635	63	77	D056486	true

Sentence: To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.
Entity: 15858223	63	66	VPA	Chemical	D014635
Entity: 15858223	99	113	hepatotoxicity	Disease	D056486
Entity: 15858223	167	170	VPA	Chemical	D014635
Relation: 15858223	CID	63	66	D014635	99	113	D056486	true
Relation: 15858223	CID	167	170	D014635	99	113	D056486	true

Sentence: Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.
Entity: 15858223	0	14	Liver toxicity	Disease	D056486
Entity: 15858223	60	71	glutathione	Chemical	D005978
Relation: 15858223	CID	60	71	D005978	0	14	D056486	false

Sentence: Pheochromocytoma unmasked by amisulpride and tiapride.
Entity: 15811908	0	16	Pheochromocytoma	Disease	D010673
Entity: 15811908	29	40	amisulpride	Chemical	C012052
Entity: 15811908	45	53	tiapride	Chemical	D063325
Relation: 15811908	CID	29	40	C012052	0	16	D010673	false
Relation: 15811908	CID	45	53	D063325	0	16	D010673	false

Sentence: OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.
Entity: 15811908	40	56	pheochromocytoma	Disease	D010673
Entity: 15811908	83	94	amisulpride	Chemical	C012052
Entity: 15811908	99	107	tiapride	Chemical	D063325
Relation: 15811908	CID	83	94	C012052	40	56	D010673	false
Relation: 15811908	CID	99	107	D063325	40	56	D010673	false

Sentence: CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.
Entity: 15811908	54	66	hypertension	Disease	D006973
Entity: 15811908	79	87	headache	Disease	D006261
Entity: 15811908	92	100	vomiting	Disease	D014839
Entity: 15811908	134	145	amisulpride	Chemical	C012052
Entity: 15811908	157	165	tiapride	Chemical	D063325
Relation: 15811908	CID	134	145	C012052	54	66	D006973	true
Relation: 15811908	CID	134	145	C012052	79	87	D006261	true
Relation: 15811908	CID	134	145	C012052	92	100	D014839	true
Relation: 15811908	CID	157	165	D063325	54	66	D006973	true
Relation: 15811908	CID	157	165	D063325	79	87	D006261	true
Relation: 15811908	CID	157	165	D063325	92	100	D014839	true

Sentence: DISCUSSION: Drug induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs, but the underlying mechanism is unknown.
Entity: 15811908	37	53	pheochromocytoma	Disease	D010673
Entity: 15811908	103	112	benzamide	Chemical	C037689
Relation: 15811908	CID	103	112	C037689	37	53	D010673	false

Sentence: In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.
Entity: 15811908	96	108	hypertensive	Disease	D006973
Entity: 15811908	120	131	amisulpride	Chemical	C012052
Entity: 15811908	136	144	tiapride	Chemical	D063325
Relation: 15811908	CID	120	131	C012052	96	108	D006973	true
Relation: 15811908	CID	136	144	D063325	96	108	D006973	true

Sentence: CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and tiapride induced hypertensive crisis in a patient with pheochromocytoma.
Entity: 15811908	70	81	amisulpride	Chemical	C012052
Entity: 15811908	87	95	tiapride	Chemical	D063325
Entity: 15811908	104	116	hypertensive	Disease	D006973
Entity: 15811908	142	158	pheochromocytoma	Disease	D010673
Relation: 15811908	CID	70	81	C012052	104	116	D006973	true
Relation: 15811908	CID	70	81	C012052	142	158	D010673	false
Relation: 15811908	CID	87	95	D063325	104	116	D006973	true
Relation: 15811908	CID	87	95	D063325	142	158	D010673	false

Sentence: Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.
Entity: 15764424	38	47	psychosis	Disease	D011605
Entity: 15764424	83	97	catecholamines	Chemical	D002395
Entity: 15764424	102	114	hyperkinesia	Disease	D006948
Relation: 15764424	CID	83	97	D002395	38	47	D011605	false
Relation: 15764424	CID	83	97	D002395	102	114	D006948	false

Sentence: To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.
Entity: 15764424	72	86	catecholamines	Chemical	D002395
Entity: 15764424	92	110	psychotic symptoms	Disease	D011605
Entity: 15764424	135	146	psychiatric	Disease	D001523
Entity: 15764424	185	196	amphetamine	Chemical	D000661
Entity: 15764424	201	208	cocaine	Chemical	D003042
Entity: 15764424	217	226	psychosis	Disease	D011605
Entity: 15764424	327	340	catecholamine	Chemical	D002395
Relation: 15764424	CID	72	86	D002395	92	110	D011605	false
Relation: 15764424	CID	72	86	D002395	135	146	D001523	false
Relation: 15764424	CID	72	86	D002395	217	226	D011605	false
Relation: 15764424	CID	185	196	D000661	92	110	D011605	true
Relation: 15764424	CID	185	196	D000661	135	146	D001523	false
Relation: 15764424	CID	185	196	D000661	217	226	D011605	true
Relation: 15764424	CID	201	208	D003042	92	110	D011605	true
Relation: 15764424	CID	201	208	D003042	135	146	D001523	false
Relation: 15764424	CID	201	208	D003042	217	226	D011605	true
Relation: 15764424	CID	327	340	D002395	92	110	D011605	false
Relation: 15764424	CID	327	340	D002395	135	146	D001523	false
Relation: 15764424	CID	327	340	D002395	217	226	D011605	false

Sentence: Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.
Entity: 15764424	0	15	Methamphetamine	Chemical	D008694
Entity: 15764424	19	30	amphetamine	Chemical	D000661
Entity: 15764424	100	112	hyperkinesia	Disease	D006948
Relation: 15764424	CID	0	15	D008694	100	112	D006948	true
Relation: 15764424	CID	19	30	D000661	100	112	D006948	true

Sentence: Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.
Entity: 12101159	8	17	asystolic	Disease	D006323
Entity: 12101159	18	32	cardiac arrest	Disease	D006323
Entity: 12101159	39	48	diltiazem	Chemical	D004110
Entity: 12101159	49	57	overdose	Disease	D062787
Entity: 12101159	100	107	calcium	Chemical	D002118
Relation: 12101159	CID	39	48	D004110	8	17	D006323	true
Relation: 12101159	CID	39	48	D004110	18	32	D006323	true
Relation: 12101159	CID	39	48	D004110	49	57	D062787	true
Relation: 12101159	CID	100	107	D002118	8	17	D006323	false
Relation: 12101159	CID	100	107	D002118	18	32	D006323	false
Relation: 12101159	CID	100	107	D002118	49	57	D062787	false

Sentence: A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.
Entity: 12101159	31	39	overdose	Disease	D062787
Entity: 12101159	63	72	diltiazem	Chemical	D004110
Entity: 12101159	74	85	paracetamol	Chemical	D000082
Entity: 12101159	87	94	aspirin	Chemical	D001241
Entity: 12101159	96	106	isosorbide	Chemical	D007547
Entity: 12101159	107	114	nitrate	Chemical	D009566
Entity: 12101159	120	127	alcohol	Chemical	D000431
Relation: 12101159	CID	63	72	D004110	31	39	D062787	true
Relation: 12101159	CID	74	85	D000082	31	39	D062787	false
Relation: 12101159	CID	87	94	D001241	31	39	D062787	false
Relation: 12101159	CID	96	106	D007547	31	39	D062787	false
Relation: 12101159	CID	107	114	D009566	31	39	D062787	false
Relation: 12101159	CID	120	127	D000431	31	39	D062787	false

Sentence: This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose, particularly with the onset of asystole.
Entity: 12101159	72	79	calcium	Chemical	D002118
Entity: 12101159	98	107	diltiazem	Chemical	D004110
Entity: 12101159	108	116	overdose	Disease	D062787
Entity: 12101159	149	157	asystole	Disease	D006323
Relation: 12101159	CID	72	79	D002118	108	116	D062787	false
Relation: 12101159	CID	72	79	D002118	149	157	D006323	false
Relation: 12101159	CID	98	107	D004110	108	116	D062787	true
Relation: 12101159	CID	98	107	D004110	149	157	D006323	true

Sentence: It should be considered early in cases of cardiac arrest after diltiazem overdose.
Entity: 12101159	42	56	cardiac arrest	Disease	D006323
Entity: 12101159	63	72	diltiazem	Chemical	D004110
Entity: 12101159	73	81	overdose	Disease	D062787
Relation: 12101159	CID	63	72	D004110	42	56	D006323	true
Relation: 12101159	CID	63	72	D004110	73	81	D062787	true

Sentence: Renal papillary necrosis due to naproxen.
Entity: 6699841	0	24	Renal papillary necrosis	Disease	D007681
Entity: 6699841	32	40	naproxen	Chemical	D009288
Relation: 6699841	CID	32	40	D009288	0	24	D007681	true

Sentence: A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.
Entity: 6699841	23	43	rheumatoid arthritis	Disease	D001172
Entity: 6699841	82	90	sulindac	Chemical	D013467
Entity: 6699841	92	110	fenoprofen calcium	Chemical	D005279
Entity: 6699841	122	133	salicylates	Chemical	D012459
Entity: 6699841	138	142	gold	Chemical	D006046
Entity: 6699841	160	184	renal papillary necrosis	Disease	D007681
Entity: 6699841	186	189	RPN	Disease	D007681
Entity: 6699841	221	229	naproxen	Chemical	D009288
Relation: 6699841	CID	82	90	D013467	23	43	D001172	false
Relation: 6699841	CID	82	90	D013467	160	184	D007681	false
Relation: 6699841	CID	82	90	D013467	186	189	D007681	false
Relation: 6699841	CID	92	110	D005279	23	43	D001172	false
Relation: 6699841	CID	92	110	D005279	160	184	D007681	false
Relation: 6699841	CID	92	110	D005279	186	189	D007681	false
Relation: 6699841	CID	122	133	D012459	23	43	D001172	false
Relation: 6699841	CID	122	133	D012459	160	184	D007681	false
Relation: 6699841	CID	122	133	D012459	186	189	D007681	false
Relation: 6699841	CID	138	142	D006046	23	43	D001172	false
Relation: 6699841	CID	138	142	D006046	160	184	D007681	false
Relation: 6699841	CID	138	142	D006046	186	189	D007681	false
Relation: 6699841	CID	221	229	D009288	23	43	D001172	false
Relation: 6699841	CID	221	229	D009288	160	184	D007681	true
Relation: 6699841	CID	221	229	D009288	186	189	D007681	true

Sentence: Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.
Entity: 6127992	20	43	ischaemic heart disease	Disease	D017202
Entity: 6127992	63	78	cardiac failure	Disease	D006333
Entity: 6127992	80	91	hypotension	Disease	D007022
Entity: 6127992	96	107	bradycardia	Disease	D001919
Entity: 6127992	137	146	verapamil	Chemical	D014700
Entity: 6127992	151	181	beta-adrenergic blocking drugs	Chemical	D000319
Relation: 6127992	CID	137	146	D014700	20	43	D017202	false
Relation: 6127992	CID	137	146	D014700	63	78	D006333	true
Relation: 6127992	CID	137	146	D014700	80	91	D007022	true
Relation: 6127992	CID	137	146	D014700	96	107	D001919	true
Relation: 6127992	CID	151	181	D000319	20	43	D017202	false
Relation: 6127992	CID	151	181	D000319	63	78	D006333	true
Relation: 6127992	CID	151	181	D000319	80	91	D007022	true
Relation: 6127992	CID	151	181	D000319	96	107	D001919	true

Sentence: Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.
Entity: 6115999	21	35	bendrofluazide	Chemical	D001539
Entity: 6115999	40	51	propranolol	Chemical	D011433
Entity: 6115999	78	90	hypertension	Disease	D006973
Relation: 6115999	CID	21	35	D001539	78	90	D006973	false
Relation: 6115999	CID	40	51	D011433	78	90	D006973	false

Sentence: Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.
Entity: 6115999	70	82	hypertension	Disease	D006973
Entity: 6115999	139	153	bendrofluazide	Chemical	D001539
Entity: 6115999	155	166	propranolol	Chemical	D011433
Relation: 6115999	CID	139	153	D001539	70	82	D006973	false
Relation: 6115999	CID	155	166	D011433	70	82	D006973	false

Sentence: The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.
Entity: 6115999	40	54	bendrofluazide	Chemical	D001539
Entity: 6115999	69	78	impotence	Disease	D007172
Entity: 6115999	84	93	impotence	Disease	D007172
Entity: 6115999	143	154	propranolol	Chemical	D011433
Relation: 6115999	CID	40	54	D001539	69	78	D007172	true
Relation: 6115999	CID	40	54	D001539	84	93	D007172	true
Relation: 6115999	CID	143	154	D011433	69	78	D007172	true
Relation: 6115999	CID	143	154	D011433	84	93	D007172	true

Sentence: Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.
Entity: 6115999	71	97	impaired glucose tolerance	Disease	D018149
Entity: 6115999	119	123	gout	Disease	D006073
Entity: 6115999	148	162	bendrofluazide	Chemical	D001539
Entity: 6115999	178	198	Raynaud's phenomenon	Disease	D011928
Entity: 6115999	203	211	dyspnoea	Disease	D004417
Entity: 6115999	236	247	propranolol	Chemical	D011433
Relation: 6115999	CID	148	162	D001539	71	97	D018149	true
Relation: 6115999	CID	148	162	D001539	119	123	D006073	true
Relation: 6115999	CID	148	162	D001539	178	198	D011928	false
Relation: 6115999	CID	148	162	D001539	203	211	D004417	false
Relation: 6115999	CID	236	247	D011433	71	97	D018149	false
Relation: 6115999	CID	236	247	D011433	119	123	D006073	false
Relation: 6115999	CID	236	247	D011433	178	198	D011928	true
Relation: 6115999	CID	236	247	D011433	203	211	D004417	true

Sentence: No corneal disease is known to have occurred in the propranolol group.
Entity: 6115999	3	18	corneal disease	Disease	D003316
Entity: 6115999	52	63	propranolol	Chemical	D011433
Relation: 6115999	CID	52	63	D011433	3	18	D003316	false

Sentence: Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).
Entity: 18086064	0	15	Dexmedetomidine	Chemical	D020927
Entity: 18086064	148	169	myocardial infarction	Disease	D009203
Entity: 18086064	213	233	myocardial ischaemia	Disease	D017202
Relation: 18086064	CID	0	15	D020927	148	169	D009203	false
Relation: 18086064	CID	0	15	D020927	213	233	D017202	false

Sentence: Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.
Entity: 12739036	37	45	creatine	Chemical	D003401
Entity: 12739036	63	91	systemic lupus erythematosus	Disease	D008180
Relation: 12739036	CID	37	45	D003401	63	91	D008180	false

Sentence: We report the clinical and bioptic findings for a 57-year-old woman with severe chloroquine induced myopathy.
Entity: 12739036	80	91	chloroquine	Chemical	D002738
Entity: 12739036	100	108	myopathy	Disease	D009135
Relation: 12739036	CID	80	91	D002738	100	108	D009135	false

Sentence: Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.
Entity: 12739036	40	68	systemic lupus erythematosus	Disease	D008180
Entity: 12739036	70	73	SLE	Disease	D008180
Entity: 12739036	80	97	renal involvement	Disease	D007674
Entity: 12739036	138	150	azathioprine	Chemical	D001379
Entity: 12739036	155	171	cyclophosphamide	Chemical	D003520
Relation: 12739036	CID	138	150	D001379	40	68	D008180	false
Relation: 12739036	CID	138	150	D001379	70	73	D008180	false
Relation: 12739036	CID	138	150	D001379	80	97	D007674	false
Relation: 12739036	CID	155	171	D003520	40	68	D008180	false
Relation: 12739036	CID	155	171	D003520	70	73	D008180	false
Relation: 12739036	CID	155	171	D003520	80	97	D007674	false

Sentence: Additional therapy with chloroquine (CQ) was started because of arthralgia.
Entity: 12739036	24	35	chloroquine	Chemical	D002738
Entity: 12739036	37	39	CQ	Chemical	D002738
Entity: 12739036	64	74	arthralgia	Disease	D018771
Relation: 12739036	CID	24	35	D002738	64	74	D018771	false
Relation: 12739036	CID	37	39	D002738	64	74	D018771	false

Sentence: Myositis was suspected, and the patient was treated with steroids.
Entity: 12739036	0	8	Myositis	Disease	D009220
Entity: 12739036	57	65	steroids	Chemical	D013256
Relation: 12739036	CID	57	65	D013256	0	8	D009220	false

Sentence: As it revealed chloroquine induced myopathy, medication was stopped.
Entity: 12739036	15	26	chloroquine	Chemical	D002738
Entity: 12739036	35	43	myopathy	Disease	D009135
Relation: 12739036	CID	15	26	D002738	35	43	D009135	false

Sentence: Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children.
Entity: 12093990	12	21	ribavirin	Chemical	D012254
Entity: 12093990	43	61	adenovirus disease	Disease	D000257
Relation: 12093990	CID	12	21	D012254	43	61	D000257	false

Sentence: Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C.
Entity: 12093990	0	9	Ribavirin	Chemical	D012254
Entity: 12093990	59	96	respiratory syncytial virus infection	Disease	D018357
Entity: 12093990	149	160	hepatitis C	Disease	D006526
Relation: 12093990	CID	0	9	D012254	59	96	D018357	false
Relation: 12093990	CID	0	9	D012254	149	160	D006526	false

Sentence: Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.
Entity: 12093990	12	21	ribavirin	Chemical	D012254
Entity: 12093990	53	93	infection with hemorrhagic fever viruses	Disease	D006482
Relation: 12093990	CID	12	21	D012254	53	93	D006482	false

Sentence: The most common adverse effect of intravenous ribavirin is reversible mild anemia.
Entity: 12093990	46	55	ribavirin	Chemical	D012254
Entity: 12093990	75	81	anemia	Disease	D000740
Relation: 12093990	CID	46	55	D012254	75	81	D000740	false

Sentence: The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.
Entity: 12093990	11	20	cidofovir	Chemical	C059262
Entity: 12093990	31	51	adenovirus infection	Disease	D000257
Entity: 12093990	122	136	nephrotoxicity	Disease	D007674
Relation: 12093990	CID	11	20	C059262	31	51	D000257	false
Relation: 12093990	CID	11	20	C059262	122	136	D007674	false

Sentence: OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.
Entity: 12093990	53	62	ribavirin	Chemical	D012254
Entity: 12093990	82	100	adenovirus disease	Disease	D000257
Relation: 12093990	CID	53	62	D012254	82	100	D000257	false

Sentence: DESIGN/METHODS: We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease.
Entity: 12093990	103	112	ribavirin	Chemical	D012254
Entity: 12093990	135	153	adenovirus disease	Disease	D000257
Relation: 12093990	CID	103	112	D012254	135	153	D000257	false

Sentence: Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia.
Entity: 12093990	7	16	cidofovir	Chemical	C059262
Entity: 12093990	48	73	progressive renal failure	Disease	D058186
Entity: 12093990	78	89	neutropenia	Disease	D009503
Relation: 12093990	CID	7	16	C059262	48	73	D058186	true
Relation: 12093990	CID	7	16	C059262	78	89	D009503	true

Sentence: Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection.
Entity: 12093990	21	30	ribavirin	Chemical	D012254
Entity: 12093990	78	96	adenovirus disease	Disease	D000257
Entity: 12093990	206	215	infection	Disease	D007239
Relation: 12093990	CID	21	30	D012254	78	96	D000257	false
Relation: 12093990	CID	21	30	D012254	206	215	D007239	false

Sentence: CONCLUSIONS: Two of 5 children with severe adenovirus disease treated with intravenous ribavirin recovered.
Entity: 12093990	43	61	adenovirus disease	Disease	D000257
Entity: 12093990	87	96	ribavirin	Chemical	D012254
Relation: 12093990	CID	87	96	D012254	43	61	D000257	false

Sentence: Hepatotoxicity of amiodarone.
Entity: 3962737	0	14	Hepatotoxicity	Disease	D056486
Entity: 3962737	18	28	amiodarone	Chemical	D000638
Relation: 3962737	CID	18	28	D000638	0	14	D056486	true

Sentence: Amiodarone has proved very effective in the treatment of otherwise resistant cardiac tachyarrhythmias.
Entity: 3962737	0	10	Amiodarone	Chemical	D000638
Entity: 3962737	85	101	tachyarrhythmias	Disease	D013610
Relation: 3962737	CID	0	10	D000638	85	101	D013610	false

Sentence: A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.
Entity: 3962737	15	26	cholestatic	Disease	D002779
Entity: 3962737	27	36	hepatitis	Disease	D056486
Entity: 3962737	44	54	amiodarone	Chemical	D000638
Entity: 3962737	104	118	hepatotoxicity	Disease	D056486
Entity: 3962737	122	132	amiodarone	Chemical	D000638
Relation: 3962737	CID	44	54	D000638	15	26	D002779	true
Relation: 3962737	CID	44	54	D000638	27	36	D056486	true
Relation: 3962737	CID	44	54	D000638	104	118	D056486	true
Relation: 3962737	CID	122	132	D000638	15	26	D002779	true
Relation: 3962737	CID	122	132	D000638	27	36	D056486	true
Relation: 3962737	CID	122	132	D000638	104	118	D056486	true

Sentence: It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.
Entity: 3962737	46	60	hepatic injury	Disease	D056486
Entity: 3962737	68	78	amiodarone	Chemical	D000638
Entity: 3962737	100	109	steatosis	Disease	D005234
Entity: 3962737	134	153	alcoholic hepatitis	Disease	D006519
Entity: 3962737	155	166	cholestatic	Disease	D002779
Entity: 3962737	167	176	hepatitis	Disease	D056486
Entity: 3962737	194	216	cirrhosis of the liver	Disease	D008103
Relation: 3962737	CID	68	78	D000638	46	60	D056486	true
Relation: 3962737	CID	68	78	D000638	100	109	D005234	true
Relation: 3962737	CID	68	78	D000638	134	153	D006519	false
Relation: 3962737	CID	68	78	D000638	155	166	D002779	true
Relation: 3962737	CID	68	78	D000638	167	176	D056486	true
Relation: 3962737	CID	68	78	D000638	194	216	D008103	true

Sentence: Catalepsy induced by combinations of ketamine and morphine: potentiation, antagonism, tolerance and cross-tolerance in the rat.
Entity: 2716967	0	9	Catalepsy	Disease	D002375
Entity: 2716967	37	45	ketamine	Chemical	D007649
Entity: 2716967	50	58	morphine	Chemical	D009020
Relation: 2716967	CID	37	45	D007649	0	9	D002375	true
Relation: 2716967	CID	50	58	D009020	0	9	D002375	true

Sentence: Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat.
Entity: 2716967	40	48	ketamine	Chemical	D007649
Entity: 2716967	53	61	morphine	Chemical	D009020
Entity: 2716967	70	79	analgesia	Disease	D000699
Entity: 2716967	84	93	catalepsy	Disease	D002375
Relation: 2716967	CID	40	48	D007649	70	79	D000699	false
Relation: 2716967	CID	40	48	D007649	84	93	D002375	true
Relation: 2716967	CID	53	61	D009020	70	79	D000699	false
Relation: 2716967	CID	53	61	D009020	84	93	D002375	true

Sentence: Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.
Entity: 2716967	19	27	ketamine	Chemical	D007649
Entity: 2716967	56	64	morphine	Chemical	D009020
Entity: 2716967	92	100	morphine	Chemical	D009020
Entity: 2716967	135	143	ketamine	Chemical	D007649
Entity: 2716967	169	179	cataleptic	Disease	D002375
Entity: 2716967	235	243	morphine	Chemical	D009020
Relation: 2716967	CID	19	27	D007649	169	179	D002375	true
Relation: 2716967	CID	56	64	D009020	169	179	D002375	true
Relation: 2716967	CID	92	100	D009020	169	179	D002375	true
Relation: 2716967	CID	135	143	D007649	169	179	D002375	true
Relation: 2716967	CID	235	243	D009020	169	179	D002375	true

Sentence: Latency to the loss of righting reflex, rigidity and behavior on recovery, reflected the relative predominance of ketamine or morphine in each combination.
Entity: 2716967	40	48	rigidity	Disease	D009127
Entity: 2716967	114	122	ketamine	Chemical	D007649
Entity: 2716967	126	134	morphine	Chemical	D009020
Relation: 2716967	CID	114	122	D007649	40	48	D009127	false
Relation: 2716967	CID	126	134	D009020	40	48	D009127	false

Sentence: Naloxone inhibited the induced cataleptic effects.
Entity: 2716967	0	8	Naloxone	Chemical	D009270
Entity: 2716967	31	41	cataleptic	Disease	D002375
Relation: 2716967	CID	0	8	D009270	31	41	D002375	false

Sentence: Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.
Entity: 19642243	0	19	Acute renal failure	Disease	D058186
Entity: 19642243	37	41	AIDS	Disease	D000163
Entity: 19642243	45	54	tenofovir	Chemical	C096918
Entity: 19642243	81	91	vancomycin	Chemical	D014640
Entity: 19642243	103	116	osteomyelitis	Disease	D010019
Relation: 19642243	CID	45	54	C096918	0	19	D058186	false
Relation: 19642243	CID	45	54	C096918	37	41	D000163	false
Relation: 19642243	CID	45	54	C096918	103	116	D010019	false
Relation: 19642243	CID	81	91	D014640	0	19	D058186	true
Relation: 19642243	CID	81	91	D014640	37	41	D000163	false
Relation: 19642243	CID	81	91	D014640	103	116	D010019	false

Sentence: Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.
Entity: 19642243	0	13	Renal failure	Disease	D051437
Entity: 19642243	52	62	vancomycin	Chemical	D014640
Entity: 19642243	104	133	tenofovir disoproxil fumarate	Chemical	C418563
Relation: 19642243	CID	52	62	D014640	0	13	D051437	false
Relation: 19642243	CID	104	133	C418563	0	13	D051437	false

Sentence: Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.
Entity: 19642243	0	9	Tenofovir	Chemical	C096918
Entity: 19642243	52	68	Fanconi syndrome	Disease	D005198
Entity: 19642243	73	92	renal insufficiency	Disease	D051437
Relation: 19642243	CID	0	9	C096918	52	68	D005198	false
Relation: 19642243	CID	0	9	C096918	73	92	D051437	false

Sentence: Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent.
Entity: 19642243	0	10	Vancomycin	Chemical	D014640
Entity: 19642243	11	25	nephrotoxicity	Disease	D007674
Entity: 19642243	84	95	nephrotoxic	Disease	D007674
Relation: 19642243	CID	0	10	D014640	11	25	D007674	false
Relation: 19642243	CID	0	10	D014640	84	95	D007674	false

Sentence: BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.
Entity: 17682013	24	43	leukoencephalopathy	Disease	D056784
Entity: 17682013	54	78	cerebrovascular accident	Disease	D002544
Entity: 17682013	176	188	methotrexate	Chemical	D008727
Entity: 17682013	203	212	leukaemia	Disease	D007938
Relation: 17682013	CID	176	188	D008727	24	43	D056784	true
Relation: 17682013	CID	176	188	D008727	54	78	D002544	false
Relation: 17682013	CID	176	188	D008727	203	212	D007938	false

Sentence: RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.
Entity: 17682013	43	62	leukoencephalopathy	Disease	D056784
Entity: 17682013	88	100	methotrexate	Chemical	D008727
Entity: 17682013	126	140	5-fluorouracil	Chemical	D005472
Entity: 17682013	160	168	carmofur	Chemical	C017367
Entity: 17682013	174	186	capecitabine	Chemical	C110904
Relation: 17682013	CID	88	100	D008727	43	62	D056784	true
Relation: 17682013	CID	126	140	D005472	43	62	D056784	true
Relation: 17682013	CID	160	168	C017367	43	62	D056784	true
Relation: 17682013	CID	174	186	C110904	43	62	D056784	true

Sentence: Down-regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics induced convulsions and the counteraction by co-administration with local anesthetics.
Entity: 16725121	19	33	norepinephrine	Chemical	D009638
Entity: 16725121	92	103	desipramine	Chemical	D003891
Entity: 16725121	174	185	convulsions	Disease	D012640
Relation: 16725121	CID	19	33	D009638	174	185	D012640	false
Relation: 16725121	CID	92	103	D003891	174	185	D012640	false

Sentence: Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.
Entity: 16725121	15	29	norepinephrine	Chemical	D009638
Entity: 16725121	118	126	seizures	Disease	D012640
Entity: 16725121	137	144	cocaine	Chemical	D003042
Relation: 16725121	CID	15	29	D009638	118	126	D012640	false
Relation: 16725121	CID	137	144	D003042	118	126	D012640	true

Sentence: Daily administration of desipramine increased the incidence of appearance of lidocaine induced convulsions and decreased that of cocaine induced convulsions.
Entity: 16725121	24	35	desipramine	Chemical	D003891
Entity: 16725121	77	86	lidocaine	Chemical	D008012
Entity: 16725121	95	106	convulsions	Disease	D012640
Entity: 16725121	129	136	cocaine	Chemical	D003042
Entity: 16725121	145	156	convulsions	Disease	D012640
Relation: 16725121	CID	24	35	D003891	95	106	D012640	false
Relation: 16725121	CID	24	35	D003891	145	156	D012640	false
Relation: 16725121	CID	77	86	D008012	95	106	D012640	true
Relation: 16725121	CID	77	86	D008012	145	156	D012640	true
Relation: 16725121	CID	129	136	D003042	95	106	D012640	true
Relation: 16725121	CID	129	136	D003042	145	156	D012640	true

Sentence: Co-administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine.
Entity: 16725121	21	30	lidocaine	Chemical	D008012
Entity: 16725121	36	47	desipramine	Chemical	D003891
Entity: 16725121	72	82	convulsive	Disease	D012640
Entity: 16725121	95	104	lidocaine	Chemical	D008012
Entity: 16725121	109	116	cocaine	Chemical	D003042
Entity: 16725121	155	166	desipramine	Chemical	D003891
Relation: 16725121	CID	21	30	D008012	72	82	D012640	true
Relation: 16725121	CID	36	47	D003891	72	82	D012640	false
Relation: 16725121	CID	95	104	D008012	72	82	D012640	true
Relation: 16725121	CID	109	116	D003042	72	82	D012640	true
Relation: 16725121	CID	155	166	D003891	72	82	D012640	false

Sentence: These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine induced sensitization of lidocaine convulsions.
Entity: 16725121	99	110	desipramine	Chemical	D003891
Entity: 16725121	130	141	desipramine	Chemical	D003891
Entity: 16725121	167	176	lidocaine	Chemical	D008012
Entity: 16725121	177	188	convulsions	Disease	D012640
Relation: 16725121	CID	99	110	D003891	177	188	D012640	false
Relation: 16725121	CID	130	141	D003891	177	188	D012640	false
Relation: 16725121	CID	167	176	D008012	177	188	D012640	true

Sentence: The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin.
Entity: 16629641	31	44	HCV infection	Disease	D006526
Entity: 16629641	83	93	interferon	Chemical	D007372
Entity: 16629641	98	107	ribavirin	Chemical	D012254
Relation: 16629641	CID	83	93	D007372	31	44	D006526	false
Relation: 16629641	CID	98	107	D012254	31	44	D006526	false

Sentence: Hemoglobin concentrations decrease mainly as a result of ribavirin induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.
Entity: 16629641	57	66	ribavirin	Chemical	D012254
Entity: 16629641	75	84	hemolysis	Disease	D006461
Entity: 16629641	95	101	anemia	Disease	D000740
Entity: 16629641	138	151	HCV infection	Disease	D006526
Entity: 16629641	188	193	renal	Disease	D007674
Entity: 16629641	197	211	cardiovascular	Disease	D002318
Relation: 16629641	CID	57	66	D012254	75	84	D006461	false
Relation: 16629641	CID	57	66	D012254	95	101	D000740	false
Relation: 16629641	CID	57	66	D012254	138	151	D006526	false
Relation: 16629641	CID	57	66	D012254	188	193	D007674	false
Relation: 16629641	CID	57	66	D012254	197	211	D002318	false

Sentence: Although ribavirin-associated anemia can be reversed by dose reduction or discontinuation, this approach compromises outcomes by significantly decreasing SVR rates.
Entity: 16629641	9	18	ribavirin	Chemical	D012254
Entity: 16629641	30	36	anemia	Disease	D000740
Relation: 16629641	CID	9	18	D012254	30	36	D000740	false

Sentence: Recombinant human erythropoietin has been used to manage ribavirin-associated anemia but has other potential disadvantages.
Entity: 16629641	57	66	ribavirin	Chemical	D012254
Entity: 16629641	78	84	anemia	Disease	D000740
Relation: 16629641	CID	57	66	D012254	78	84	D000740	false

Sentence: Calcium carbonate toxicity: the updated milk-alkali syndrome; report of 3 cases and review of the literature.
Entity: 16006300	0	17	Calcium carbonate	Chemical	D002119
Entity: 16006300	18	26	toxicity	Disease	D064420
Entity: 16006300	40	60	milk-alkali syndrome	Disease	D006934
Relation: 16006300	CID	0	17	D002119	18	26	D064420	false
Relation: 16006300	CID	0	17	D002119	40	60	D006934	true

Sentence: OBJECTIVE: To describe 3 patients with calcium carbonate induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome.
Entity: 16006300	39	56	calcium carbonate	Chemical	D002119
Entity: 16006300	65	78	hypercalcemia	Disease	D006934
Entity: 16006300	134	154	milk-alkali syndrome	Disease	D006934
Relation: 16006300	CID	39	56	D002119	65	78	D006934	true
Relation: 16006300	CID	39	56	D002119	134	154	D006934	true

Sentence: METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome.
Entity: 16006300	92	105	hypercalcemia	Disease	D006934
Entity: 16006300	123	130	calcium	Chemical	D002118
Entity: 16006300	187	207	milk-alkali syndrome	Disease	D006934
Relation: 16006300	CID	123	130	D002118	92	105	D006934	false
Relation: 16006300	CID	123	130	D002118	187	207	D006934	false

Sentence: RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.
Entity: 16006300	28	53	acute renal insufficiency	Disease	D058186
Entity: 16006300	64	83	metabolic alkalosis	Disease	D000471
Entity: 16006300	145	168	1,25-dihydroxyvitamin D	Chemical	C097949
Relation: 16006300	CID	145	168	C097949	28	53	D058186	false
Relation: 16006300	CID	145	168	C097949	64	83	D000471	false

Sentence: The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia.
Entity: 16006300	37	44	calcium	Chemical	D002118
Entity: 16006300	69	80	pamidronate	Chemical	C019248
Entity: 16006300	145	157	hypocalcemia	Disease	D006996
Relation: 16006300	CID	37	44	D002118	145	157	D006996	false
Relation: 16006300	CID	69	80	C019248	145	157	D006996	true

Sentence: CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons.
Entity: 16006300	12	32	Milk-alkali syndrome	Disease	D006934
Entity: 16006300	70	83	hypercalcemia	Disease	D006934
Entity: 16006300	144	161	calcium carbonate	Chemical	D002119
Relation: 16006300	CID	144	161	D002119	12	32	D006934	true
Relation: 16006300	CID	144	161	D002119	70	83	D006934	true

Sentence: Management strategies for ribavirin induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.
Entity: 11705128	26	35	ribavirin	Chemical	D012254
Entity: 11705128	44	60	hemolytic anemia	Disease	D000743
Entity: 11705128	81	92	hepatitis C	Disease	D006526
Relation: 11705128	CID	26	35	D012254	44	60	D000743	true
Relation: 11705128	CID	26	35	D012254	81	92	D006526	false

Sentence: OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).
Entity: 11705128	151	160	ribavirin	Chemical	D012254
Entity: 11705128	175	191	interferon-alpha	Chemical	D016898
Entity: 11705128	224	243	chronic hepatitis C	Disease	D019698
Entity: 11705128	245	248	CHC	Disease	D019698
Relation: 11705128	CID	151	160	D012254	224	243	D019698	false
Relation: 11705128	CID	151	160	D012254	245	248	D019698	false
Relation: 11705128	CID	175	191	D016898	224	243	D019698	false
Relation: 11705128	CID	175	191	D016898	245	248	D019698	false

Sentence: Combination therapy is associated with a clinically important adverse effect: ribavirin induced hemolytic anemia (RIHA).
Entity: 11705128	78	87	ribavirin	Chemical	D012254
Entity: 11705128	96	112	hemolytic anemia	Disease	D000743
Entity: 11705128	114	118	RIHA	Disease	D000743
Relation: 11705128	CID	78	87	D012254	96	112	D000743	true
Relation: 11705128	CID	78	87	D012254	114	118	D000743	true

Sentence: The standard of care for management of RIHA is reduction or discontinuation of the ribavirin dosage.
Entity: 11705128	39	43	RIHA	Disease	D000743
Entity: 11705128	83	92	ribavirin	Chemical	D012254
Relation: 11705128	CID	83	92	D012254	39	43	D000743	true

Sentence: Questions remain about the optimal dose of ribavirin and the incidence of RIHA in a real-world population.
Entity: 11705128	43	52	ribavirin	Chemical	D012254
Entity: 11705128	74	78	RIHA	Disease	D000743
Relation: 11705128	CID	43	52	D012254	74	78	D000743	true

Sentence: Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals.
Entity: 6540303	11	16	amine	Chemical	D000588
Entity: 6540303	33	41	ketamine	Chemical	D007649
Entity: 6540303	42	51	catatonia	Disease	D002389
Relation: 6540303	CID	11	16	D000588	42	51	D002389	false
Relation: 6540303	CID	33	41	D007649	42	51	D002389	true

Sentence: The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.
Entity: 6540303	57	71	catecholamines	Chemical	D002395
Entity: 6540303	97	105	ketamine	Chemical	D007649
Entity: 6540303	114	123	catatonia	Disease	D002389
Relation: 6540303	CID	57	71	D002395	114	123	D002389	false
Relation: 6540303	CID	97	105	D007649	114	123	D002389	true

Sentence: In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.
Entity: 6540303	48	56	dopamine	Chemical	D004298
Entity: 6540303	83	92	catatonia	Disease	D002389
Entity: 6540303	105	113	ketamine	Chemical	D007649
Entity: 6540303	137	151	norepinephrine	Chemical	D009638
Relation: 6540303	CID	48	56	D004298	83	92	D002389	true
Relation: 6540303	CID	105	113	D007649	83	92	D002389	true
Relation: 6540303	CID	137	151	D009638	83	92	D002389	false

Sentence: Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.
Entity: 3057041	87	97	azelastine	Chemical	C020976
Entity: 3057041	99	115	chlorpheniramine	Chemical	D002744
Entity: 3057041	149	173	spring allergic rhinitis	Disease	D006255
Relation: 3057041	CID	87	97	C020976	149	173	D006255	false
Relation: 3057041	CID	99	115	D002744	149	173	D006255	false

Sentence: Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.
Entity: 3057041	0	10	Azelastine	Chemical	C020976
Entity: 3057041	63	87	chlorpheniramine maleate	Chemical	D002744
Entity: 3057041	144	168	spring allergic rhinitis	Disease	D006255
Relation: 3057041	CID	0	10	C020976	144	168	D006255	false
Relation: 3057041	CID	63	87	D002744	144	168	D006255	false

Sentence: Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.
Entity: 3057041	0	10	Drowsiness	Disease	D006970
Entity: 3057041	15	39	altered taste perception	Disease	D013651
Entity: 3057041	104	114	azelastine	Chemical	C020976
Relation: 3057041	CID	104	114	C020976	0	10	D006970	true
Relation: 3057041	CID	104	114	C020976	15	39	D013651	true

Sentence: Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids.
Entity: 7910951	10	19	paralysis	Disease	D010243
Entity: 7910951	27	72	nondepolarizing neuromuscular blocking agents	Chemical	D003473
Entity: 7910951	77	92	corticosteroids	Chemical	D000305
Relation: 7910951	CID	27	72	D003473	10	19	D010243	false
Relation: 7910951	CID	77	92	D000305	10	19	D010243	false

Sentence: The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.
Entity: 7910951	21	66	nondepolarizing neuromuscular blocking agents	Chemical	D003473
Entity: 7910951	68	75	ND-NMBA	Chemical	D003473
Entity: 7910951	130	145	muscle weakness	Disease	D018908
Relation: 7910951	CID	21	66	D003473	130	145	D018908	true
Relation: 7910951	CID	68	75	D003473	130	145	D018908	true

Sentence: We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND-NMBAs.
Entity: 7910951	50	75	respiratory insufficiency	Disease	D012131
Entity: 7910951	100	108	weakness	Disease	D018908
Entity: 7910951	142	150	ND-NMBAs	Chemical	D003473
Relation: 7910951	CID	142	150	D003473	50	75	D012131	false
Relation: 7910951	CID	142	150	D003473	100	108	D018908	true

Sentence: The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).
Entity: 7910951	4	12	weakness	Disease	D018908
Entity: 7910951	41	85	pathology at both the neuromuscular junction	Disease	D009468
Entity: 7910951	106	113	ND-NMBA	Chemical	D003473
Entity: 7910951	146	161	corticosteroids	Chemical	D000305
Relation: 7910951	CID	106	113	D003473	4	12	D018908	true
Relation: 7910951	CID	106	113	D003473	41	85	D009468	true
Relation: 7910951	CID	146	161	D000305	4	12	D018908	false
Relation: 7910951	CID	146	161	D000305	41	85	D009468	false

Sentence: Prostaglandin E2 induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins.
Entity: 7752389	0	16	Prostaglandin E2	Chemical	D015232
Entity: 7752389	25	46	bladder hyperactivity	Disease	D053201
Entity: 7752389	89	100	tachykinins	Chemical	D015320
Relation: 7752389	CID	0	16	D015232	25	46	D053201	true
Relation: 7752389	CID	89	100	D015320	25	46	D053201	false

Sentence: Thiazide diuretics, hypokalemia and cardiac arrhythmias.
Entity: 6942642	0	8	Thiazide	Chemical	D049971
Entity: 6942642	20	31	hypokalemia	Disease	D007008
Entity: 6942642	36	55	cardiac arrhythmias	Disease	D001145
Relation: 6942642	CID	0	8	D049971	20	31	D007008	false
Relation: 6942642	CID	0	8	D049971	36	55	D001145	false

Sentence: Hypokalemia is a commonly encountered metabolic consequence of chronic thiazide therapy.
Entity: 6942642	0	11	Hypokalemia	Disease	D007008
Entity: 6942642	71	79	thiazide	Chemical	D049971
Relation: 6942642	CID	71	79	D049971	0	11	D007008	false

Sentence: We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (HCTC) administered on a twice daily schedule.
Entity: 6942642	69	91	diastolic hypertension	Disease	C563897
Entity: 6942642	97	116	hydrochlorothiazide	Chemical	D006852
Entity: 6942642	118	122	HCTC	Chemical	D006852
Relation: 6942642	CID	97	116	D006852	69	91	C563897	false
Relation: 6942642	CID	118	122	D006852	69	91	C563897	false

Sentence: In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium.
Entity: 6942642	28	36	thiazide	Chemical	D049971
Entity: 6942642	53	64	hypokalemia	Disease	D007008
Entity: 6942642	87	96	potassium	Chemical	D011188
Relation: 6942642	CID	28	36	D049971	53	64	D007008	false
Relation: 6942642	CID	87	96	D011188	53	64	D007008	false

Sentence: Diuretics, potassium and arrhythmias in hypertensive coronary disease.
Entity: 3732088	11	20	potassium	Chemical	D011188
Entity: 3732088	25	36	arrhythmias	Disease	D001145
Entity: 3732088	40	52	hypertensive	Disease	D006973
Entity: 3732088	53	69	coronary disease	Disease	D003327
Relation: 3732088	CID	11	20	D011188	25	36	D001145	false
Relation: 3732088	CID	11	20	D011188	40	52	D006973	false
Relation: 3732088	CID	11	20	D011188	53	69	D003327	false

Sentence: It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias.
Entity: 3732088	51	60	potassium	Chemical	D011188
Entity: 3732088	92	111	cardiac arrhythmias	Disease	D001145
Relation: 3732088	CID	51	60	D011188	92	111	D001145	false

Sentence: Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.
Entity: 3732088	86	98	hypertension	Disease	D006973
Entity: 3732088	109	132	coronary artery disease	Disease	D003324
Entity: 3732088	167	176	potassium	Chemical	D011188
Entity: 3732088	198	207	amiloride	Chemical	D000584
Entity: 3732088	235	244	potassium	Chemical	D011188
Entity: 3732088	262	276	chlorthalidone	Chemical	D002752
Relation: 3732088	CID	167	176	D011188	86	98	D006973	false
Relation: 3732088	CID	167	176	D011188	109	132	D003324	false
Relation: 3732088	CID	198	207	D000584	86	98	D006973	false
Relation: 3732088	CID	198	207	D000584	109	132	D003324	false
Relation: 3732088	CID	235	244	D011188	86	98	D006973	false
Relation: 3732088	CID	235	244	D011188	109	132	D003324	false
Relation: 3732088	CID	262	276	D002752	86	98	D006973	false
Relation: 3732088	CID	262	276	D002752	109	132	D003324	false

Sentence: Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.
Entity: 3732088	12	21	amiloride	Chemical	D000584
Entity: 3732088	37	51	chlorthalidone	Chemical	D002752
Entity: 3732088	104	129	ventricular ectopic beats	Disease	D018879
Relation: 3732088	CID	12	21	D000584	104	129	D018879	false
Relation: 3732088	CID	37	51	D002752	104	129	D018879	true

Sentence: GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.
Entity: 2893236	0	4	GABA	Chemical	D005680
Entity: 2893236	20	28	naloxone	Chemical	D009270
Entity: 2893236	49	70	respiratory paralysis	Disease	D012133
Entity: 2893236	83	93	thiopental	Chemical	D013874
Relation: 2893236	CID	0	4	D005680	49	70	D012133	false
Relation: 2893236	CID	20	28	D009270	49	70	D012133	false
Relation: 2893236	CID	83	93	D013874	49	70	D012133	true

Sentence: In this study naloxone reversed respiratory paralysis induced by thiopental in rats. 25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.
Entity: 2893236	14	22	naloxone	Chemical	D009270
Entity: 2893236	32	53	respiratory paralysis	Disease	D012133
Entity: 2893236	65	75	thiopental	Chemical	D013874
Entity: 2893236	100	110	thiopental	Chemical	D013874
Entity: 2893236	176	180	GABA	Chemical	D005680
Entity: 2893236	192	201	glutamate	Chemical	D018698
Entity: 2893236	224	233	aspartate	Chemical	D001224
Entity: 2893236	237	244	glycine	Chemical	D005998
Relation: 2893236	CID	14	22	D009270	32	53	D012133	false
Relation: 2893236	CID	65	75	D013874	32	53	D012133	true
Relation: 2893236	CID	100	110	D013874	32	53	D012133	true
Relation: 2893236	CID	176	180	D005680	32	53	D012133	false
Relation: 2893236	CID	192	201	D018698	32	53	D012133	false
Relation: 2893236	CID	224	233	D001224	32	53	D012133	false
Relation: 2893236	CID	237	244	D005998	32	53	D012133	false

Sentence: Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental. 50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.
Entity: 2893236	26	43	thiosemicarbazide	Chemical	C005151
Entity: 2893236	139	149	thiopental	Chemical	D013874
Entity: 2893236	166	176	thiopental	Chemical	D013874
Entity: 2893236	186	204	respiratory arrest	Disease	D012131
Entity: 2893236	230	234	GABA	Chemical	D005680
Entity: 2893236	251	260	glutamate	Chemical	D018698
Entity: 2893236	321	332	amino acids	Chemical	D000596
Relation: 2893236	CID	26	43	C005151	186	204	D012131	false
Relation: 2893236	CID	139	149	D013874	186	204	D012131	false
Relation: 2893236	CID	166	176	D013874	186	204	D012131	false
Relation: 2893236	CID	230	234	D005680	186	204	D012131	false
Relation: 2893236	CID	251	260	D018698	186	204	D012131	false
Relation: 2893236	CID	321	332	D000596	186	204	D012131	false

Sentence: Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.
Entity: 2893236	0	8	Naloxone	Chemical	D009270
Entity: 2893236	36	57	respiratory paralysis	Disease	D012133
Entity: 2893236	59	68	glutamate	Chemical	D018698
Entity: 2893236	73	77	GABA	Chemical	D005680
Relation: 2893236	CID	0	8	D009270	36	57	D012133	false
Relation: 2893236	CID	59	68	D018698	36	57	D012133	false
Relation: 2893236	CID	73	77	D005680	36	57	D012133	false

Sentence: These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine.
Entity: 2533791	49	60	hepatitis B	Disease	D006509
Entity: 2533791	132	151	hepatitis B vaccine	Chemical	D017325
Relation: 2533791	CID	132	151	D017325	49	60	D006509	false

Sentence: The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests.
Entity: 2322844	45	59	prostaglandins	Chemical	D011453
Entity: 2322844	63	67	pain	Disease	D010146
Entity: 2322844	134	145	acetic acid	Chemical	D019342
Relation: 2322844	CID	45	59	D011453	63	67	D010146	false
Relation: 2322844	CID	134	145	D019342	63	67	D010146	false

Sentence: Prostaglandin D2 (0.5-3 ng/mouse) had a hyperalgesic action on the response to a hot plate during a 3-60 min period after injection.
Entity: 2322844	0	16	Prostaglandin D2	Chemical	D015230
Entity: 2322844	40	52	hyperalgesic	Disease	D006930
Relation: 2322844	CID	0	16	D015230	40	52	D006930	true

Sentence: Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.
Entity: 2322844	0	16	Prostaglandin E2	Chemical	D015232
Entity: 2322844	26	38	hyperalgesic	Disease	D006930
Entity: 2322844	60	62	pg	Chemical	D011453
Entity: 2322844	133	149	prostaglandin D2	Chemical	D015230
Relation: 2322844	CID	0	16	D015232	26	38	D006930	true
Relation: 2322844	CID	60	62	D011453	26	38	D006930	false
Relation: 2322844	CID	133	149	D015230	26	38	D006930	true

Sentence: The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.
Entity: 2322844	4	16	hyperalgesic	Disease	D006930
Entity: 2322844	27	43	prostaglandin D2	Chemical	D015230
Entity: 2322844	155	161	AH6809	Chemical	C053876
Relation: 2322844	CID	27	43	D015230	4	16	D006930	true
Relation: 2322844	CID	155	161	C053876	4	16	D006930	false

Sentence: Conversely, prostaglandin E2 induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.
Entity: 2322844	12	28	prostaglandin E2	Chemical	D015232
Entity: 2322844	37	49	hyperalgesia	Disease	D006930
Entity: 2322844	65	71	AH6809	Chemical	C053876
Relation: 2322844	CID	12	28	D015232	37	49	D006930	true
Relation: 2322844	CID	65	71	C053876	37	49	D006930	false

Sentence: Prostaglandin F2 alpha had little effect on pain responses.
Entity: 2322844	0	22	Prostaglandin F2 alpha	Chemical	D015237
Entity: 2322844	44	48	pain	Disease	D010146
Relation: 2322844	CID	0	22	D015237	44	48	D010146	false

Sentence: Swallowing induced atrial tachyarrhythmia triggered by salbutamol: case report and review of the literature.
Entity: 20552622	19	41	atrial tachyarrhythmia	Disease	D013617
Entity: 20552622	55	65	salbutamol	Chemical	D000420
Relation: 20552622	CID	55	65	D000420	19	41	D013617	true

Sentence: The arrhythmia resolved after therapy with atenolol, but recurred a year later.
Entity: 20552622	4	14	arrhythmia	Disease	D001145
Entity: 20552622	43	51	atenolol	Chemical	D001262
Relation: 20552622	CID	43	51	D001262	4	14	D001145	false

Sentence: After stopping the beta-agonist, and after a week with the atenolol, the arrhythmia disappeared.
Entity: 20552622	59	67	atenolol	Chemical	D001262
Entity: 20552622	73	83	arrhythmia	Disease	D001145
Relation: 20552622	CID	59	67	D001262	73	83	D001145	false

Sentence: CONCLUSION: Salbutamol is presented here as a possible trigger for SIAT.
Entity: 20552622	12	22	Salbutamol	Chemical	D000420
Entity: 20552622	67	71	SIAT	Disease	D013617
Relation: 20552622	CID	12	22	D000420	67	71	D013617	true

Sentence: Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice.
Entity: 20510337	0	12	Coenzyme Q10	Chemical	C024989
Entity: 20510337	41	50	cisplatin	Chemical	D002945
Entity: 20510337	51	65	nephrotoxicity	Disease	D007674
Relation: 20510337	CID	0	12	C024989	51	65	D007674	false
Relation: 20510337	CID	41	50	D002945	51	65	D007674	false

Sentence: The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p. injection of cisplatin (5 mg/kg).
Entity: 20510337	31	43	coenzyme Q10	Chemical	C024989
Entity: 20510337	74	92	acute renal injury	Disease	D058186
Entity: 20510337	131	140	cisplatin	Chemical	D002945
Relation: 20510337	CID	31	43	C024989	74	92	D058186	false
Relation: 20510337	CID	131	140	D002945	74	92	D058186	true

Sentence: Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.
Entity: 20510337	0	12	Coenzyme Q10	Chemical	C024989
Entity: 20510337	87	106	reduced glutathione	Chemical	D005978
Entity: 20510337	117	127	superoxide	Chemical	D013481
Entity: 20510337	208	213	tumor	Disease	D009369
Entity: 20510337	214	222	necrosis	Disease	D009336
Entity: 20510337	237	249	nitric oxide	Chemical	D009569
Entity: 20510337	254	262	platinum	Chemical	D010984
Entity: 20510337	315	323	selenium	Chemical	D012643
Entity: 20510337	328	332	zinc	Chemical	D015032
Entity: 20510337	368	377	cisplatin	Chemical	D002945
Relation: 20510337	CID	0	12	C024989	208	213	D009369	false
Relation: 20510337	CID	0	12	C024989	214	222	D009336	false
Relation: 20510337	CID	87	106	D005978	208	213	D009369	false
Relation: 20510337	CID	87	106	D005978	214	222	D009336	false
Relation: 20510337	CID	117	127	D013481	208	213	D009369	false
Relation: 20510337	CID	117	127	D013481	214	222	D009336	false
Relation: 20510337	CID	237	249	D009569	208	213	D009369	false
Relation: 20510337	CID	237	249	D009569	214	222	D009336	false
Relation: 20510337	CID	254	262	D010984	208	213	D009369	false
Relation: 20510337	CID	254	262	D010984	214	222	D009336	false
Relation: 20510337	CID	315	323	D012643	208	213	D009369	false
Relation: 20510337	CID	315	323	D012643	214	222	D009336	false
Relation: 20510337	CID	328	332	D015032	208	213	D009369	false
Relation: 20510337	CID	328	332	D015032	214	222	D009336	false
Relation: 20510337	CID	368	377	D002945	208	213	D009369	false
Relation: 20510337	CID	368	377	D002945	214	222	D009336	false

Sentence: Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.
Entity: 20510337	24	43	renal tissue damage	Disease	D007674
Entity: 20510337	56	65	cisplatin	Chemical	D002945
Entity: 20510337	85	97	coenzyme Q10	Chemical	C024989
Relation: 20510337	CID	56	65	D002945	24	43	D007674	false
Relation: 20510337	CID	85	97	C024989	24	43	D007674	false

Sentence: Metformin prevents experimental gentamicin induced nephropathy by a mitochondria-dependent pathway.
Entity: 20164825	0	9	Metformin	Chemical	D008687
Entity: 20164825	32	42	gentamicin	Chemical	D005839
Entity: 20164825	51	62	nephropathy	Disease	D007674
Relation: 20164825	CID	0	9	D008687	51	62	D007674	false
Relation: 20164825	CID	32	42	D005839	51	62	D007674	false

Sentence: The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients.
Entity: 20164825	22	31	metformin	Chemical	D008687
Entity: 20164825	116	136	vascular dysfunction	Disease	D014652
Relation: 20164825	CID	22	31	D008687	116	136	D014652	false

Sentence: Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity.
Entity: 20164825	68	78	gentamicin	Chemical	D005839
Entity: 20164825	79	87	toxicity	Disease	D064420
Relation: 20164825	CID	68	78	D005839	79	87	D064420	false

Sentence: Metformin treatment fully blocked gentamicin-mediated acute renal failure.
Entity: 20164825	0	9	Metformin	Chemical	D008687
Entity: 20164825	34	44	gentamicin	Chemical	D005839
Entity: 20164825	54	73	acute renal failure	Disease	D058186
Relation: 20164825	CID	0	9	D008687	54	73	D058186	false
Relation: 20164825	CID	34	44	D005839	54	73	D058186	true

Sentence: These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function.
Entity: 20164825	25	43	kidney dysfunction	Disease	D007674
Entity: 20164825	68	77	metformin	Chemical	D008687
Relation: 20164825	CID	68	77	D008687	25	43	D007674	false

Sentence: PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.
Entity: 20042557	165	173	delirium	Disease	D003693
Entity: 20042557	184	192	dementia	Disease	D003704
Entity: 20042557	207	219	hip fracture	Disease	D006620
Entity: 20042557	256	264	propofol	Chemical	D015742
Relation: 20042557	CID	256	264	D015742	165	173	D003693	true
Relation: 20042557	CID	256	264	D015742	184	192	D003704	false
Relation: 20042557	CID	256	264	D015742	207	219	D006620	false

Sentence: CONCLUSION: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation.
Entity: 20042557	29	37	propofol	Chemical	D015742
Entity: 20042557	75	88	postoperative	Disease	D011183
Entity: 20042557	89	97	delirium	Disease	D003693
Relation: 20042557	CID	29	37	D015742	75	88	D011183	true
Relation: 20042557	CID	29	37	D015742	89	97	D003693	true

Sentence: Sorafenib induced acute myocardial infarction due to coronary artery spasm.
Entity: 19944333	0	9	Sorafenib	Chemical	C471405
Entity: 19944333	24	45	myocardial infarction	Disease	D009203
Entity: 19944333	53	74	coronary artery spasm	Disease	D003329
Relation: 19944333	CID	0	9	C471405	24	45	D009203	false
Relation: 19944333	CID	0	9	C471405	53	74	D003329	true

Sentence: Addition of oral nicorandil reduced his symptoms and maintained stable angina status.
Entity: 19944333	17	27	nicorandil	Chemical	D020108
Entity: 19944333	64	77	stable angina	Disease	D060050
Relation: 19944333	CID	17	27	D020108	64	77	D060050	false

Sentence: We report the first case of sorafenib induced coronary artery spasm.
Entity: 19944333	28	37	sorafenib	Chemical	C471405
Entity: 19944333	46	67	coronary artery spasm	Disease	D003329
Relation: 19944333	CID	28	37	C471405	46	67	D003329	true

Sentence: RESULTS: The results indicate that ciprofloxacin- and norfloxacin-treated rats showed anxious behaviour in comparison to control rats in all the parameters studied.
Entity: 17975693	35	48	ciprofloxacin	Chemical	D002939
Entity: 17975693	54	65	norfloxacin	Chemical	D009643
Entity: 17975693	86	103	anxious behaviour	Disease	D001008
Relation: 17975693	CID	35	48	D002939	86	103	D001008	true
Relation: 17975693	CID	54	65	D009643	86	103	D001008	true

Sentence: Myocardial Fas ligand expression increases susceptibility to AZT induced cardiomyopathy.
Entity: 17943461	61	64	AZT	Chemical	D015215
Entity: 17943461	73	87	cardiomyopathy	Disease	D009202
Relation: 17943461	CID	61	64	D015215	73	87	D009202	true

Sentence: METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).
Entity: 17943461	73	83	zidovudine	Chemical	D015215
Entity: 17943461	85	114	3'-azido-2',3'-deoxythymidine	Chemical	D015215
Entity: 17943461	116	119	AZT	Chemical	D015215
Entity: 17943461	222	225	DCM	Disease	D002311
Entity: 17943461	395	398	AZT	Chemical	D015215
Relation: 17943461	CID	73	83	D015215	222	225	D002311	true
Relation: 17943461	CID	85	114	D015215	222	225	D002311	true
Relation: 17943461	CID	116	119	D015215	222	225	D002311	true
Relation: 17943461	CID	395	398	D015215	222	225	D002311	true

Sentence: In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.
Entity: 17943461	13	16	AZT	Chemical	D015215
Entity: 17943461	48	64	cardiac dilation	Disease	D002311
Relation: 17943461	CID	13	16	D015215	48	64	D002311	true

Sentence: Valproate induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.
Entity: 17074608	0	9	Valproate	Chemical	D014635
Entity: 17074608	18	24	chorea	Disease	D002819
Entity: 17074608	29	43	encephalopathy	Disease	D001927
Entity: 17074608	56	82	nonketotic hyperglycinemia	Disease	D020158
Relation: 17074608	CID	0	9	D014635	18	24	D002819	true
Relation: 17074608	CID	0	9	D014635	29	43	D001927	true
Relation: 17074608	CID	0	9	D014635	56	82	D020158	false

Sentence: Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.
Entity: 17074608	0	26	Nonketotic hyperglycinemia	Disease	D020158
Entity: 17074608	32	65	disorder of amino acid metabolism	Disease	D000592
Entity: 17074608	91	98	glycine	Chemical	D005998
Entity: 17074608	143	150	glycine	Chemical	D005998
Relation: 17074608	CID	91	98	D005998	0	26	D020158	false
Relation: 17074608	CID	91	98	D005998	32	65	D000592	false
Relation: 17074608	CID	143	150	D005998	0	26	D020158	false
Relation: 17074608	CID	143	150	D005998	32	65	D000592	false

Sentence: Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine induced amnesia in adult male rats.
Entity: 16364460	18	28	ritanserin	Chemical	D016713
Entity: 16364460	73	84	scopolamine	Chemical	D012601
Entity: 16364460	93	100	amnesia	Disease	D000647
Relation: 16364460	CID	18	28	D016713	93	100	D000647	false
Relation: 16364460	CID	73	84	D012601	93	100	D000647	true

Sentence: The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist) induced amnesia in Morris water maze (MWM) was investigated.
Entity: 16364460	14	24	ritanserin	Chemical	D016713
Entity: 16364460	47	58	scopolamine	Chemical	D012601
Entity: 16364460	103	110	amnesia	Disease	D000647
Relation: 16364460	CID	14	24	D016713	103	110	D000647	false
Relation: 16364460	CID	47	58	D012601	103	110	D000647	true

Sentence: With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.
Entity: 15579441	59	66	hypoxia	Disease	D000860
Entity: 15579441	74	99	puromycin aminonucleoside	Chemical	D011692
Entity: 15579441	108	126	nephrotic syndrome	Disease	D009404
Entity: 15579441	151	158	hypoxia	Disease	D000860
Relation: 15579441	CID	74	99	D011692	59	66	D000860	true
Relation: 15579441	CID	74	99	D011692	108	126	D009404	true
Relation: 15579441	CID	74	99	D011692	151	158	D000860	true

Sentence: Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.
Entity: 15579441	18	25	hypoxia	Disease	D000860
Entity: 15579441	128	153	puromycin aminonucleoside	Chemical	D011692
Relation: 15579441	CID	128	153	D011692	18	25	D000860	true

Sentence: However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.
Entity: 15517007	34	50	cyclophosphamide	Chemical	D003520
Entity: 15517007	54	68	anthracyclines	Chemical	D018943
Entity: 15517007	77	89	mitoxantrone	Chemical	D008942
Entity: 15517007	138	150	heart damage	Disease	D006331
Entity: 15517007	165	183	systemic sclerosis	Disease	D012595
Relation: 15517007	CID	34	50	D003520	138	150	D006331	true
Relation: 15517007	CID	34	50	D003520	165	183	D012595	false
Relation: 15517007	CID	54	68	D018943	138	150	D006331	false
Relation: 15517007	CID	54	68	D018943	165	183	D012595	false
Relation: 15517007	CID	77	89	D008942	138	150	D006331	true
Relation: 15517007	CID	77	89	D008942	165	183	D012595	false

Sentence: Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.
Entity: 12180796	47	59	nitric oxide	Chemical	D009569
Entity: 12180796	110	115	tumor	Disease	D009369
Entity: 12180796	151	160	arteritis	Disease	D001167
Entity: 12180796	180	190	fenoldopam	Chemical	D018818
Entity: 12180796	195	207	theophylline	Chemical	D013806
Relation: 12180796	CID	47	59	D009569	110	115	D009369	false
Relation: 12180796	CID	47	59	D009569	151	160	D001167	false
Relation: 12180796	CID	180	190	D018818	110	115	D009369	false
Relation: 12180796	CID	180	190	D018818	151	160	D001167	true
Relation: 12180796	CID	195	207	D013806	110	115	D009369	false
Relation: 12180796	CID	195	207	D013806	151	160	D001167	true

Sentence: Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).
Entity: 12180796	0	9	Arteritis	Disease	D001167
Entity: 12180796	43	53	fenoldopam	Chemical	D018818
Entity: 12180796	58	70	theophylline	Chemical	D013806
Entity: 12180796	144	156	nitric oxide	Chemical	D009569
Entity: 12180796	216	221	tumor	Disease	D009369
Relation: 12180796	CID	43	53	D018818	0	9	D001167	true
Relation: 12180796	CID	43	53	D018818	216	221	D009369	false
Relation: 12180796	CID	58	70	D013806	0	9	D001167	true
Relation: 12180796	CID	58	70	D013806	216	221	D009369	false
Relation: 12180796	CID	144	156	D009569	0	9	D001167	false
Relation: 12180796	CID	144	156	D009569	216	221	D009369	false

Sentence: Topiramate induced nephrolithiasis.
Entity: 12042105	0	10	Topiramate	Chemical	C052342
Entity: 12042105	19	34	nephrolithiasis	Disease	D053040
Relation: 12042105	CID	0	10	C052342	19	34	D053040	true

Sentence: Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures.
Entity: 12042105	0	10	Topiramate	Chemical	C052342
Entity: 12042105	136	155	refractory seizures	Disease	D004827
Relation: 12042105	CID	0	10	C052342	136	155	D004827	false

Sentence: These factors can lead to the development of calcium phosphate nephrolithiasis.
Entity: 12042105	45	62	calcium phosphate	Chemical	C020243
Entity: 12042105	63	78	nephrolithiasis	Disease	D053040
Relation: 12042105	CID	45	62	C020243	63	78	D053040	false

Sentence: Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients.
Entity: 11868798	0	14	Spironolactone	Chemical	D013148
Entity: 11868798	57	71	amphotericin B	Chemical	D000666
Entity: 11868798	80	91	hypokalemia	Disease	D007008
Entity: 11868798	95	101	cancer	Disease	D009369
Relation: 11868798	CID	0	14	D013148	80	91	D007008	false
Relation: 11868798	CID	0	14	D013148	95	101	D009369	false
Relation: 11868798	CID	57	71	D000666	80	91	D007008	true
Relation: 11868798	CID	57	71	D000666	95	101	D009369	false

Sentence: OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.
Entity: 11868798	11	25	Nephrotoxicity	Disease	D007674
Entity: 11868798	57	71	amphotericin B	Chemical	D000666
Entity: 11868798	73	76	AmB	Chemical	D000666
Relation: 11868798	CID	57	71	D000666	11	25	D007674	false
Relation: 11868798	CID	73	76	D000666	11	25	D007674	false

Sentence: Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB.
Entity: 11868798	36	44	toxicity	Disease	D064420
Entity: 11868798	86	95	potassium	Chemical	D011188
Entity: 11868798	159	162	AmB	Chemical	D000666
Relation: 11868798	CID	86	95	D011188	36	44	D064420	false
Relation: 11868798	CID	159	162	D000666	36	44	D064420	false

Sentence: Potassium depletion also potentiates the tubular toxicity of AmB.
Entity: 11868798	0	9	Potassium	Chemical	D011188
Entity: 11868798	49	57	toxicity	Disease	D064420
Entity: 11868798	61	64	AmB	Chemical	D000666
Relation: 11868798	CID	0	9	D011188	49	57	D064420	false
Relation: 11868798	CID	61	64	D000666	49	57	D064420	false

Sentence: This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.
Entity: 11868798	49	63	spironolactone	Chemical	D013148
Entity: 11868798	74	83	potassium	Chemical	D011188
Entity: 11868798	112	123	hypokalemia	Disease	D007008
Entity: 11868798	127	138	neutropenic	Disease	D009503
Entity: 11868798	151	154	AmB	Chemical	D000666
Relation: 11868798	CID	49	63	D013148	112	123	D007008	false
Relation: 11868798	CID	49	63	D013148	127	138	D009503	false
Relation: 11868798	CID	74	83	D011188	112	123	D007008	false
Relation: 11868798	CID	74	83	D011188	127	138	D009503	false
Relation: 11868798	CID	151	154	D000666	112	123	D007008	true
Relation: 11868798	CID	151	154	D000666	127	138	D009503	false

Sentence: METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.
Entity: 11868798	48	71	hematological disorders	Disease	D006402
Entity: 11868798	118	121	AmB	Chemical	D000666
Entity: 11868798	131	134	AmB	Chemical	D000666
Entity: 11868798	144	158	spironolactone	Chemical	D013148
Entity: 11868798	216	232	fungal infection	Disease	D009181
Relation: 11868798	CID	118	121	D000666	48	71	D006402	false
Relation: 11868798	CID	118	121	D000666	216	232	D009181	false
Relation: 11868798	CID	131	134	D000666	48	71	D006402	false
Relation: 11868798	CID	131	134	D000666	216	232	D009181	false
Relation: 11868798	CID	144	158	D013148	48	71	D006402	false
Relation: 11868798	CID	144	158	D013148	216	232	D009181	false

Sentence: Dopamine (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of epileptic seizures arising in the limbic system.
Entity: 11860278	0	8	Dopamine	Chemical	D004298
Entity: 11860278	10	12	DA	Chemical	D004298
Entity: 11860278	95	113	epileptic seizures	Disease	D004827
Relation: 11860278	CID	0	8	D004298	95	113	D004827	false
Relation: 11860278	CID	10	12	D004298	95	113	D004827	false

Sentence: In this respect, little is known about the role of DA receptors in the occurrence of epilepsy induced neuronal cell death.
Entity: 11860278	51	53	DA	Chemical	D004298
Entity: 11860278	85	93	epilepsy	Disease	D004827
Relation: 11860278	CID	51	53	D004298	85	93	D004827	false

Sentence: Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.
Entity: 11860278	34	42	seizures	Disease	D012640
Entity: 11860278	47	60	neurotoxicity	Disease	D020258
Entity: 11860278	114	125	pilocarpine	Chemical	D010862
Relation: 11860278	CID	114	125	D010862	34	42	D012640	true
Relation: 11860278	CID	114	125	D010862	47	60	D020258	false

Sentence: However, pilocarpine induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.
Entity: 11860278	9	20	pilocarpine	Chemical	D010862
Entity: 11860278	29	37	seizures	Disease	D012640
Entity: 11860278	128	130	KA	Chemical	D007608
Relation: 11860278	CID	9	20	D010862	29	37	D012640	true
Relation: 11860278	CID	128	130	D007608	29	37	D012640	true

Sentence: Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine.
Entity: 11860278	50	58	seizures	Disease	D012640
Entity: 11860278	75	84	glutamate	Chemical	D018698
Entity: 11860278	89	102	acetylcholine	Chemical	D000109
Relation: 11860278	CID	75	84	D018698	50	58	D012640	false
Relation: 11860278	CID	89	102	D000109	50	58	D012640	false

Sentence: Treatment of risperidone induced hyperprolactinemia with a dopamine agonist in children.
Entity: 11838826	13	24	risperidone	Chemical	D018967
Entity: 11838826	33	51	hyperprolactinemia	Disease	D006966
Entity: 11838826	59	67	dopamine	Chemical	D004298
Relation: 11838826	CID	13	24	D018967	33	51	D006966	true
Relation: 11838826	CID	59	67	D004298	33	51	D006966	false

Sentence: BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.
Entity: 11838826	12	23	Risperidone	Chemical	D018967
Entity: 11838826	123	141	hyperprolactinemia	Disease	D006966
Relation: 11838826	CID	12	23	D018967	123	141	D006966	true

Sentence: We report the successful treatment of risperidone induced hyperprolactinemia with cabergoline in youth.
Entity: 11838826	38	49	risperidone	Chemical	D018967
Entity: 11838826	58	76	hyperprolactinemia	Disease	D006966
Entity: 11838826	82	93	cabergoline	Chemical	C047047
Relation: 11838826	CID	38	49	D018967	58	76	D006966	true
Relation: 11838826	CID	82	93	C047047	58	76	D006966	false

Sentence: METHODS: We undertook a retrospective case review of four children with risperidone induced hyperprolactinemia treated with cabergoline.
Entity: 11838826	72	83	risperidone	Chemical	D018967
Entity: 11838826	92	110	hyperprolactinemia	Disease	D006966
Entity: 11838826	124	135	cabergoline	Chemical	C047047
Relation: 11838826	CID	72	83	D018967	92	110	D006966	true
Relation: 11838826	CID	124	135	C047047	92	110	D006966	false

Sentence: RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).
Entity: 11838826	79	95	Mental Disorders	Disease	D001523
Entity: 11838826	113	129	bipolar disorder	Disease	D001714
Entity: 11838826	133	142	psychoses	Disease	D011605
Entity: 11838826	149	160	risperidone	Chemical	D018967
Entity: 11838826	261	272	cabergoline	Chemical	C047047
Relation: 11838826	CID	149	160	D018967	79	95	D001523	false
Relation: 11838826	CID	149	160	D018967	113	129	D001714	false
Relation: 11838826	CID	149	160	D018967	133	142	D011605	false
Relation: 11838826	CID	261	272	C047047	79	95	D001523	false
Relation: 11838826	CID	261	272	C047047	113	129	D001714	false
Relation: 11838826	CID	261	272	C047047	133	142	D011605	false

Sentence: Cholestatic jaundice associated with the use of metformin.
Entity: 11467664	0	20	Cholestatic jaundice	Disease	D041781
Entity: 11467664	48	57	metformin	Chemical	D008687
Relation: 11467664	CID	48	57	D008687	0	20	D041781	true

Sentence: We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride.
Entity: 11467664	34	54	cholestatic jaundice	Disease	D041781
Entity: 11467664	98	121	metformin hydrochloride	Chemical	D008687
Relation: 11467664	CID	98	121	D008687	34	54	D041781	true

Sentence: Metformin hydrochloride was discontinued, and the patient's jaundice resolved slowly over a period of several months.
Entity: 11467664	0	23	Metformin hydrochloride	Chemical	D008687
Entity: 11467664	60	68	jaundice	Disease	D007565
Relation: 11467664	CID	0	23	D008687	60	68	D007565	false

Sentence: Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.
Entity: 11077455	120	130	vigabatrin	Chemical	D020888
Entity: 11077455	142	167	visual field constriction	Disease	D014786
Relation: 11077455	CID	120	130	D020888	142	167	D014786	true

Sentence: PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported.
Entity: 11077455	21	46	visual field constriction	Disease	D014786
Entity: 11077455	77	87	vigabatrin	Chemical	D020888
Relation: 11077455	CID	77	87	D020888	21	46	D014786	true

Sentence: The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin-attributed visual field loss, three of whom were reported previously.
Entity: 11077455	107	117	vigabatrin	Chemical	D020888
Entity: 11077455	129	146	visual field loss	Disease	D014786
Relation: 11077455	CID	107	117	D020888	129	146	D014786	true

Sentence: CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy.
Entity: 11077455	19	44	visual field constriction	Disease	D014786
Entity: 11077455	75	85	vigabatrin	Chemical	D020888
Relation: 11077455	CID	75	85	D020888	19	44	D014786	true

Sentence: BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.
Entity: 11063349	64	68	RAPA	Chemical	D020123
Entity: 11063349	103	115	cyclosporine	Chemical	D016572
Entity: 11063349	117	120	CsA	Chemical	D016572
Entity: 11063349	125	135	tacrolimus	Chemical	D016559
Entity: 11063349	137	140	Tac	Chemical	D016559
Entity: 11063349	142	150	toxicity	Disease	D064420
Relation: 11063349	CID	64	68	D020123	142	150	D064420	false
Relation: 11063349	CID	103	115	D016572	142	150	D064420	false
Relation: 11063349	CID	117	120	D016572	142	150	D064420	false
Relation: 11063349	CID	125	135	D016559	142	150	D064420	false
Relation: 11063349	CID	137	140	D016559	142	150	D064420	false

Sentence: The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.
Entity: 11063349	40	43	CsA	Chemical	D016572
Entity: 11063349	47	50	Tac	Chemical	D016559
Entity: 11063349	51	65	nephrotoxicity	Disease	D007674
Entity: 11063349	78	81	CsA	Chemical	D016572
Entity: 11063349	85	88	Tac	Chemical	D016559
Entity: 11063349	89	97	toxicity	Disease	D064420
Entity: 11063349	110	128	facial dysmorphism	Disease	-1
Entity: 11063349	134	177	posttransplant lymphoproliferative disorder	Disease	D008232
Entity: 11063349	179	183	PTLD	Disease	D008232
Entity: 11063349	207	221	hepatotoxicity	Disease	D056486
Relation: 11063349	CID	40	43	D016572	51	65	D007674	true
Relation: 11063349	CID	40	43	D016572	89	97	D064420	false
Relation: 11063349	CID	40	43	D016572	110	128	-1	false
Relation: 11063349	CID	40	43	D016572	134	177	D008232	false
Relation: 11063349	CID	40	43	D016572	179	183	D008232	false
Relation: 11063349	CID	40	43	D016572	207	221	D056486	false
Relation: 11063349	CID	47	50	D016559	51	65	D007674	true
Relation: 11063349	CID	47	50	D016559	89	97	D064420	false
Relation: 11063349	CID	47	50	D016559	110	128	-1	false
Relation: 11063349	CID	47	50	D016559	134	177	D008232	false
Relation: 11063349	CID	47	50	D016559	179	183	D008232	false
Relation: 11063349	CID	47	50	D016559	207	221	D056486	false
Relation: 11063349	CID	78	81	D016572	51	65	D007674	true
Relation: 11063349	CID	78	81	D016572	89	97	D064420	false
Relation: 11063349	CID	78	81	D016572	110	128	-1	false
Relation: 11063349	CID	78	81	D016572	134	177	D008232	false
Relation: 11063349	CID	78	81	D016572	179	183	D008232	false
Relation: 11063349	CID	78	81	D016572	207	221	D056486	false
Relation: 11063349	CID	85	88	D016559	51	65	D007674	true
Relation: 11063349	CID	85	88	D016559	89	97	D064420	false
Relation: 11063349	CID	85	88	D016559	110	128	-1	false
Relation: 11063349	CID	85	88	D016559	134	177	D008232	false
Relation: 11063349	CID	85	88	D016559	179	183	D008232	false
Relation: 11063349	CID	85	88	D016559	207	221	D056486	false

Sentence: RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].
Entity: 11063349	56	70	nephrotoxicity	Disease	D007674
Entity: 11063349	113	123	creatinine	Chemical	D003404
Relation: 11063349	CID	113	123	D003404	56	70	D007674	false

Sentence: RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.
Entity: 11063349	0	4	RAPA	Chemical	D020123
Entity: 11063349	51	60	pneumonia	Disease	D011014
Entity: 11063349	69	73	PTLD	Disease	D008232
Entity: 11063349	91	105	aphtous ulcers	Disease	D013281
Relation: 11063349	CID	0	4	D020123	51	60	D011014	false
Relation: 11063349	CID	0	4	D020123	69	73	D008232	false
Relation: 11063349	CID	0	4	D020123	91	105	D013281	false

Sentence: Worsening of levodopa induced dyskinesias by motor and mental tasks.
Entity: 10091616	13	21	levodopa	Chemical	D007980
Entity: 10091616	30	41	dyskinesias	Disease	D004409
Relation: 10091616	CID	13	21	D007980	30	41	D004409	true

Sentence: Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.
Entity: 10091616	21	40	Parkinson's disease	Disease	D010300
Entity: 10091616	56	66	dyskinesia	Disease	D004409
Entity: 10091616	312	322	dyskinesia	Disease	D004409
Entity: 10091616	379	390	apomorphine	Chemical	D001058
Relation: 10091616	CID	379	390	D001058	21	40	D010300	false
Relation: 10091616	CID	379	390	D001058	56	66	D004409	true
Relation: 10091616	CID	379	390	D001058	312	322	D004409	true

Sentence: Structural and functional impairment of mitochondria in adriamycin induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.
Entity: 9952311	0	52	Structural and functional impairment of mitochondria	Disease	D028361
Entity: 9952311	56	66	adriamycin	Chemical	D004317
Entity: 9952311	75	89	cardiomyopathy	Disease	D009202
Relation: 9952311	CID	56	66	D004317	0	52	D028361	true
Relation: 9952311	CID	56	66	D004317	75	89	D009202	false

Sentence: The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.
Entity: 9952311	11	21	adriamycin	Chemical	D004317
Entity: 9952311	23	26	ADR	Chemical	D004317
Entity: 9952311	31	37	cancer	Disease	D009369
Entity: 9952311	90	113	cardiovascular toxicity	Disease	D002318
Relation: 9952311	CID	11	21	D004317	31	37	D009369	false
Relation: 9952311	CID	11	21	D004317	90	113	D002318	false
Relation: 9952311	CID	23	26	D004317	31	37	D009369	false
Relation: 9952311	CID	23	26	D004317	90	113	D002318	false

Sentence: Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.
Entity: 9952311	53	56	ADR	Chemical	D004317
Entity: 9952311	64	90	cardiovascular arrhythmias	Disease	D001145
Entity: 9952311	108	119	bradycardia	Disease	D001919
Entity: 9952311	295	303	swelling	Disease	D004487
Relation: 9952311	CID	53	56	D004317	64	90	D001145	false
Relation: 9952311	CID	53	56	D004317	108	119	D001919	true
Relation: 9952311	CID	53	56	D004317	295	303	D004487	false

Sentence: Enhanced bradycardia induced by beta-adrenoceptor antagonists in rats pretreated with isoniazid.
Entity: 9915601	9	20	bradycardia	Disease	D001919
Entity: 9915601	86	95	isoniazid	Chemical	D007538
Relation: 9915601	CID	86	95	D007538	9	20	D001919	true

Sentence: High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).
Entity: 9915601	14	23	isoniazid	Chemical	D007538
Entity: 9915601	33	44	hypotension	Disease	D007022
Entity: 9915601	104	115	tachycardia	Disease	D013610
Entity: 9915601	119	130	bradycardia	Disease	D001919
Entity: 9915601	190	213	gamma-aminobutyric acid	Chemical	D005680
Entity: 9915601	215	219	GABA	Chemical	D005680
Relation: 9915601	CID	14	23	D007538	33	44	D007022	true
Relation: 9915601	CID	14	23	D007538	104	115	D013610	false
Relation: 9915601	CID	14	23	D007538	119	130	D001919	true
Relation: 9915601	CID	190	213	D005680	33	44	D007022	false
Relation: 9915601	CID	190	213	D005680	104	115	D013610	false
Relation: 9915601	CID	190	213	D005680	119	130	D001919	false
Relation: 9915601	CID	215	219	D005680	33	44	D007022	false
Relation: 9915601	CID	215	219	D005680	104	115	D013610	false
Relation: 9915601	CID	215	219	D005680	119	130	D001919	false

Sentence: In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.
Entity: 9915601	50	59	isoniazid	Chemical	D007538
Entity: 9915601	63	74	bradycardia	Disease	D001919
Entity: 9915601	158	168	chloralose	Chemical	D002698
Entity: 9915601	169	177	urethane	Chemical	D014520
Relation: 9915601	CID	50	59	D007538	63	74	D001919	true
Relation: 9915601	CID	158	168	D002698	63	74	D001919	false
Relation: 9915601	CID	169	177	D014520	63	74	D001919	false

Sentence: Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.
Entity: 9915601	0	9	Isoniazid	Chemical	D007538
Entity: 9915601	34	45	bradycardia	Disease	D001919
Entity: 9915601	52	63	propranolol	Chemical	D011433
Entity: 9915601	65	73	pindolol	Chemical	D010869
Entity: 9915601	75	84	labetalol	Chemical	D007741
Entity: 9915601	89	97	atenolol	Chemical	D001262
Entity: 9915601	116	125	clonidine	Chemical	D003000
Entity: 9915601	141	154	hexamethonium	Chemical	D018738
Entity: 9915601	158	167	carbachol	Chemical	D002217
Relation: 9915601	CID	0	9	D007538	34	45	D001919	true
Relation: 9915601	CID	52	63	D011433	34	45	D001919	false
Relation: 9915601	CID	65	73	D010869	34	45	D001919	false
Relation: 9915601	CID	75	84	D007741	34	45	D001919	false
Relation: 9915601	CID	89	97	D001262	34	45	D001919	false
Relation: 9915601	CID	116	125	D003000	34	45	D001919	false
Relation: 9915601	CID	141	154	D018738	34	45	D001919	false
Relation: 9915601	CID	158	167	D002217	34	45	D001919	false

Sentence: Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy) OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.
Entity: 9758264	26	36	folic acid	Chemical	D005492
Entity: 9758264	56	59	SLE	Disease	D008180
Entity: 9758264	61	71	folic acid	Chemical	D005492
Entity: 9758264	76	84	epilepsy	Disease	D004827
Entity: 9758264	120	130	folic acid	Chemical	D005492
Entity: 9758264	174	183	epileptic	Disease	D004827
Entity: 9758264	263	276	birth defects	Disease	D000014
Entity: 9758264	281	289	epilepsy	Disease	D004827
Relation: 9758264	CID	26	36	D005492	56	59	D008180	true
Relation: 9758264	CID	26	36	D005492	76	84	D004827	false
Relation: 9758264	CID	26	36	D005492	174	183	D004827	false
Relation: 9758264	CID	26	36	D005492	263	276	D000014	false
Relation: 9758264	CID	26	36	D005492	281	289	D004827	false
Relation: 9758264	CID	61	71	D005492	56	59	D008180	true
Relation: 9758264	CID	61	71	D005492	76	84	D004827	false
Relation: 9758264	CID	61	71	D005492	174	183	D004827	false
Relation: 9758264	CID	61	71	D005492	263	276	D000014	false
Relation: 9758264	CID	61	71	D005492	281	289	D004827	false
Relation: 9758264	CID	120	130	D005492	56	59	D008180	true
Relation: 9758264	CID	120	130	D005492	76	84	D004827	false
Relation: 9758264	CID	120	130	D005492	174	183	D004827	false
Relation: 9758264	CID	120	130	D005492	263	276	D000014	false
Relation: 9758264	CID	120	130	D005492	281	289	D004827	false

Sentence: RESULTS: Of 60 epileptic women with periconceptional folic acid (0.8 mg)-containing multivitamin supplementation, no one developed epilepsy-related side effects during the periconception period.
Entity: 9758264	15	24	epileptic	Disease	D004827
Entity: 9758264	53	63	folic acid	Chemical	D005492
Entity: 9758264	131	139	epilepsy	Disease	D004827
Relation: 9758264	CID	53	63	D005492	15	24	D004827	false
Relation: 9758264	CID	53	63	D005492	131	139	D004827	false

Sentence: This 22-year-old epileptic woman was treated continuously by carbamazepine and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.
Entity: 9758264	17	26	epileptic	Disease	D004827
Entity: 9758264	61	74	carbamazepine	Chemical	D002220
Entity: 9758264	81	91	folic acid	Chemical	D005492
Relation: 9758264	CID	61	74	D002220	17	26	D004827	false
Relation: 9758264	CID	81	91	D005492	17	26	D004827	false

Sentence: CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.
Entity: 9758264	17	26	epileptic	Disease	D004827
Entity: 9758264	46	64	autoimmune disease	Disease	D001327
Entity: 9758264	88	93	lupus	Disease	D008180
Entity: 9758264	180	190	folic acid	Chemical	D005492
Entity: 9758264	214	222	seizures	Disease	D012640
Relation: 9758264	CID	180	190	D005492	17	26	D004827	false
Relation: 9758264	CID	180	190	D005492	46	64	D001327	false
Relation: 9758264	CID	180	190	D005492	88	93	D008180	true
Relation: 9758264	CID	180	190	D005492	214	222	D012640	true

Sentence: Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.
Entity: 9669632	11	20	cisapride	Chemical	D020117
Entity: 9669632	91	115	irritable bowel syndrome	Disease	D043183
Relation: 9669632	CID	11	20	D020117	91	115	D043183	false

Sentence: Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).
Entity: 9669632	82	91	cisapride	Chemical	D020117
Entity: 9669632	146	170	irritable bowel syndrome	Disease	D043183
Entity: 9669632	172	175	IBS	Disease	D043183
Relation: 9669632	CID	82	91	D020117	146	170	D043183	false
Relation: 9669632	CID	82	91	D020117	172	175	D043183	false

Sentence: METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].
Entity: 9669632	36	39	IBS	Disease	D043183
Entity: 9669632	41	53	constipation	Disease	D003248
Entity: 9669632	75	84	diarrhoea	Disease	D003967
Entity: 9669632	188	197	cisapride	Chemical	D020117
Relation: 9669632	CID	188	197	D020117	36	39	D043183	false
Relation: 9669632	CID	188	197	D020117	41	53	D003248	false
Relation: 9669632	CID	188	197	D020117	75	84	D003967	false

Sentence: RESULTS: In diarrhoea-predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups.
Entity: 9669632	12	21	diarrhoea	Disease	D003967
Entity: 9669632	124	133	cisapride	Chemical	D020117
Relation: 9669632	CID	124	133	D020117	12	21	D003967	false

Sentence: In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.
Entity: 9669632	3	12	cisapride	Chemical	D020117
Entity: 9669632	21	30	diarrhoea	Disease	D003967
Entity: 9669632	135	144	cisapride	Chemical	D020117
Entity: 9669632	282	291	cisapride	Chemical	D020117
Entity: 9669632	436	445	cisapride	Chemical	D020117
Relation: 9669632	CID	3	12	D020117	21	30	D003967	false
Relation: 9669632	CID	135	144	D020117	21	30	D003967	false
Relation: 9669632	CID	282	291	D020117	21	30	D003967	false
Relation: 9669632	CID	436	445	D020117	21	30	D003967	false

Sentence: Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].
Entity: 9669632	43	55	constipation	Disease	D003248
Entity: 9669632	70	79	cisapride	Chemical	D020117
Entity: 9669632	88	100	constipation	Disease	D003248
Entity: 9669632	113	116	IBS	Disease	D043183
Entity: 9669632	164	173	cisapride	Chemical	D020117
Relation: 9669632	CID	70	79	D020117	43	55	D003248	false
Relation: 9669632	CID	70	79	D020117	88	100	D003248	false
Relation: 9669632	CID	70	79	D020117	113	116	D043183	false
Relation: 9669632	CID	164	173	D020117	43	55	D003248	false
Relation: 9669632	CID	164	173	D020117	88	100	D003248	false
Relation: 9669632	CID	164	173	D020117	113	116	D043183	false

Sentence: Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].
Entity: 9669632	0	9	Diarrhoea	Disease	D003967
Entity: 9669632	22	25	IBS	Disease	D043183
Entity: 9669632	48	52	pain	Disease	D010146
Entity: 9669632	65	74	cisapride	Chemical	D020117
Entity: 9669632	122	131	cisapride	Chemical	D020117
Relation: 9669632	CID	65	74	D020117	0	9	D003967	false
Relation: 9669632	CID	65	74	D020117	22	25	D043183	false
Relation: 9669632	CID	65	74	D020117	48	52	D010146	false
Relation: 9669632	CID	122	131	D020117	0	9	D003967	false
Relation: 9669632	CID	122	131	D020117	22	25	D043183	false
Relation: 9669632	CID	122	131	D020117	48	52	D010146	false

Sentence: Clarithromycin induced ventricular tachycardia.
Entity: 9326871	0	14	Clarithromycin	Chemical	D017291
Entity: 9326871	23	46	ventricular tachycardia	Disease	D017180
Relation: 9326871	CID	0	14	D017291	23	46	D017180	true

Sentence: Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.
Entity: 9326871	36	48	erythromycin	Chemical	D004917
Entity: 9326871	75	90	gastroenteritis	Disease	D005759
Entity: 9326871	205	215	macrolides	Chemical	D018942
Relation: 9326871	CID	36	48	D004917	75	90	D005759	true
Relation: 9326871	CID	205	215	D018942	75	90	D005759	false

Sentence: Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.
Entity: 9326871	0	14	Cardiotoxicity	Disease	D066126
Entity: 9326871	87	99	erythromycin	Chemical	D004917
Entity: 9326871	143	153	macrolides	Chemical	D018942
Relation: 9326871	CID	87	99	D004917	0	14	D066126	false
Relation: 9326871	CID	143	153	D018942	0	14	D066126	false

Sentence: We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin.
Entity: 9326871	20	44	ventricular dysrhythmias	Disease	D001145
Entity: 9326871	90	104	clarithromycin	Chemical	D017291
Relation: 9326871	CID	90	104	D017291	20	44	D001145	false

Sentence: Persistent nephrogenic diabetes insipidus following lithium therapy.
Entity: 9226773	11	41	nephrogenic diabetes insipidus	Disease	D018500
Entity: 9226773	52	59	lithium	Chemical	D008094
Relation: 9226773	CID	52	59	D008094	11	41	D018500	true

Sentence: Ten years previously he had been diagnosed to have lithium induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.
Entity: 9226773	51	58	lithium	Chemical	D008094
Entity: 9226773	67	97	nephrogenic diabetes insipidus	Disease	D018500
Entity: 9226773	103	110	lithium	Chemical	D008094
Relation: 9226773	CID	51	58	D008094	67	97	D018500	true
Relation: 9226773	CID	103	110	D008094	67	97	D018500	true

Sentence: He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.
Entity: 9226773	24	32	polyuric	Disease	D011141
Entity: 9226773	54	61	lithium	Chemical	D008094
Entity: 9226773	145	156	vasopressin	Chemical	D014667
Entity: 9226773	191	221	nephrogenic diabetes insipidus	Disease	D018500
Relation: 9226773	CID	54	61	D008094	24	32	D011141	true
Relation: 9226773	CID	54	61	D008094	191	221	D018500	true
Relation: 9226773	CID	145	156	D014667	24	32	D011141	false
Relation: 9226773	CID	145	156	D014667	191	221	D018500	false

Sentence: Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.
Entity: 9226773	0	7	Lithium	Chemical	D008094
Entity: 9226773	16	46	nephrogenic diabetes insipidus	Disease	D018500
Entity: 9226773	106	114	polyuria	Disease	D011141
Entity: 9226773	161	168	lithium	Chemical	D008094
Relation: 9226773	CID	0	7	D008094	16	46	D018500	true
Relation: 9226773	CID	0	7	D008094	106	114	D011141	true
Relation: 9226773	CID	161	168	D008094	16	46	D018500	true
Relation: 9226773	CID	161	168	D008094	106	114	D011141	true

Sentence: Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.
Entity: 8600333	66	77	bone tumors	Disease	D001859
Entity: 8600333	108	134	Rosen's T5 or T10 protocol	Chemical	C053519
Entity: 8600333	151	162	doxorubicin	Chemical	D004317
Relation: 8600333	CID	108	134	C053519	66	77	D001859	false
Relation: 8600333	CID	151	162	D004317	66	77	D001859	false

Sentence: The incidence of doxorubicin induced cardiotoxicity is high and increases with follow-up, irrespective of cumulative dose.
Entity: 8600333	17	28	doxorubicin	Chemical	D004317
Entity: 8600333	37	51	cardiotoxicity	Disease	D066126
Relation: 8600333	CID	17	28	D004317	37	51	D066126	false

Sentence: Venous complications of midazolam versus diazepam.
Entity: 8514073	0	20	Venous complications	Disease	D014652
Entity: 8514073	24	33	midazolam	Chemical	D008874
Entity: 8514073	41	49	diazepam	Chemical	D003975
Relation: 8514073	CID	24	33	D008874	0	20	D014652	true
Relation: 8514073	CID	41	49	D003975	0	20	D014652	true

Sentence: Although some studies have suggested fewer venous complications are associated with midazolam than with diazepam for endoscopic procedures, this variable has not been well documented.
Entity: 8514073	43	63	venous complications	Disease	D014652
Entity: 8514073	84	93	midazolam	Chemical	D008874
Entity: 8514073	104	112	diazepam	Chemical	D003975
Relation: 8514073	CID	84	93	D008874	43	63	D014652	true
Relation: 8514073	CID	104	112	D003975	43	63	D014652	true

Sentence: We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy.
Entity: 8514073	44	64	venous complications	Disease	D014652
Entity: 8514073	96	104	diazepam	Chemical	D003975
Entity: 8514073	108	117	midazolam	Chemical	D008874
Relation: 8514073	CID	96	104	D003975	44	64	D014652	true
Relation: 8514073	CID	108	117	D008874	44	64	D014652	true

Sentence: Overall, venous complications were more frequent with diazepam (22 of 62 patients) than with midazolam (4 of 60 patients) (p < 0.001).
Entity: 8514073	9	29	venous complications	Disease	D014652
Entity: 8514073	54	62	diazepam	Chemical	D003975
Entity: 8514073	93	102	midazolam	Chemical	D008874
Relation: 8514073	CID	54	62	D003975	9	29	D014652	true
Relation: 8514073	CID	93	102	D008874	9	29	D014652	true

Sentence: Pain at the injection site occurred in 35% (22 of 62) of patients in the diazepam group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001).
Entity: 8514073	0	4	Pain	Disease	D010146
Entity: 8514073	73	81	diazepam	Chemical	D003975
Entity: 8514073	131	140	midazolam	Chemical	D008874
Relation: 8514073	CID	73	81	D003975	0	4	D010146	false
Relation: 8514073	CID	131	140	D008874	0	4	D010146	false

Sentence: Tetany and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.
Entity: 8492347	0	6	Tetany	Disease	D013746
Entity: 8492347	11	25	rhabdomyolysis	Disease	D012206
Entity: 8492347	47	57	furosemide	Chemical	D005665
Entity: 8492347	73	82	magnesium	Chemical	D008274
Relation: 8492347	CID	47	57	D005665	0	6	D013746	true
Relation: 8492347	CID	47	57	D005665	11	25	D012206	true
Relation: 8492347	CID	73	82	D008274	0	6	D013746	false
Relation: 8492347	CID	73	82	D008274	11	25	D012206	false

Sentence: While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).
Entity: 8492347	13	24	hypokalemia	Disease	D007008
Entity: 8492347	35	50	muscle weakness	Disease	D018908
Entity: 8492347	59	73	hypomagnesemia	Disease	C537153
Entity: 8492347	93	106	muscle spasms	Disease	D013035
Entity: 8492347	111	117	tetany	Disease	D013746
Entity: 8492347	147	156	potassium	Chemical	D011188
Entity: 8492347	161	168	calcium	Chemical	D002118
Relation: 8492347	CID	147	156	D011188	13	24	D007008	false
Relation: 8492347	CID	147	156	D011188	35	50	D018908	false
Relation: 8492347	CID	147	156	D011188	59	73	C537153	false
Relation: 8492347	CID	147	156	D011188	93	106	D013035	false
Relation: 8492347	CID	147	156	D011188	111	117	D013746	false
Relation: 8492347	CID	161	168	D002118	13	24	D007008	false
Relation: 8492347	CID	161	168	D002118	35	50	D018908	false
Relation: 8492347	CID	161	168	D002118	59	73	C537153	false
Relation: 8492347	CID	161	168	D002118	93	106	D013035	false
Relation: 8492347	CID	161	168	D002118	111	117	D013746	false

Sentence: Loss of glutamate decarboxylase mRNA-containing neurons in the rat dentate gyrus following pilocarpine induced seizures.
Entity: 8410199	8	17	glutamate	Chemical	D018698
Entity: 8410199	91	102	pilocarpine	Chemical	D010862
Entity: 8410199	111	119	seizures	Disease	D012640
Relation: 8410199	CID	8	17	D018698	111	119	D012640	false
Relation: 8410199	CID	91	102	D010862	111	119	D012640	true

Sentence: In situ hybridization methods were used to determine if glutamic acid decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure induced damage in a model of chronic seizures.
Entity: 8410199	56	69	glutamic acid	Chemical	D018698
Entity: 8410199	170	177	seizure	Disease	D012640
Entity: 8410199	215	223	seizures	Disease	D012640
Relation: 8410199	CID	56	69	D018698	170	177	D012640	false
Relation: 8410199	CID	56	69	D018698	215	223	D012640	false

Sentence: Sprague-Dawley rats were injected intraperitoneally with pilocarpine, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine induced seizures.
Entity: 8410199	57	68	pilocarpine	Chemical	D010862
Entity: 8410199	166	177	pilocarpine	Chemical	D010862
Entity: 8410199	186	194	seizures	Disease	D012640
Relation: 8410199	CID	57	68	D010862	186	194	D012640	true
Relation: 8410199	CID	166	177	D010862	186	194	D012640	true

Sentence: Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.
Entity: 8410199	47	60	cresyl violet	Chemical	C028911
Entity: 8410199	71	92	neuronal degeneration	Disease	D009410
Entity: 8410199	257	270	neuronal loss	Disease	D009410
Relation: 8410199	CID	47	60	C028911	71	92	D009410	false
Relation: 8410199	CID	47	60	C028911	257	270	D009410	false

Sentence: Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients.
Entity: 7791169	21	32	misoprostol	Chemical	D016595
Entity: 7791169	36	48	indomethacin	Chemical	D007213
Entity: 7791169	57	74	renal dysfunction	Disease	D007674
Relation: 7791169	CID	21	32	D016595	57	74	D007674	false
Relation: 7791169	CID	36	48	D007213	57	74	D007674	true

Sentence: CONCLUSION: Hospitalized elderly patients are at risk for developing indomethacin related renal dysfunction.
Entity: 7791169	69	81	indomethacin	Chemical	D007213
Entity: 7791169	90	107	renal dysfunction	Disease	D007674
Relation: 7791169	CID	69	81	D007213	90	107	D007674	true

Sentence: Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation.
Entity: 6728084	0	11	Nephrotoxic	Disease	D007674
Entity: 6728084	23	37	aminoglycoside	Chemical	D000617
Relation: 6728084	CID	23	37	D000617	0	11	D007674	false

Sentence: Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.
Entity: 6111982	51	62	propranolol	Chemical	D011433
Entity: 6111982	67	75	pindolol	Chemical	D010869
Entity: 6111982	91	98	ouabain	Chemical	D010042
Entity: 6111982	99	109	arrhythmia	Disease	D001145
Relation: 6111982	CID	51	62	D011433	99	109	D001145	false
Relation: 6111982	CID	67	75	D010869	99	109	D001145	false
Relation: 6111982	CID	91	98	D010042	99	109	D001145	true

Sentence: Chorea associated with oral contraception.
Entity: 3123611	0	6	Chorea	Disease	D002819
Entity: 3123611	23	41	oral contraception	Chemical	D003276
Relation: 3123611	CID	23	41	D003276	0	6	D002819	true

Sentence: Three patients developed chorea while receiving oral contraceptives.
Entity: 3123611	25	31	chorea	Disease	D002819
Entity: 3123611	48	67	oral contraceptives	Chemical	D003276
Relation: 3123611	CID	48	67	D003276	25	31	D002819	true

Sentence: The third patient had acute amphetamine induced chorea after prolonged oral contraception.
Entity: 3123611	28	39	amphetamine	Chemical	D000661
Entity: 3123611	48	54	chorea	Disease	D002819
Entity: 3123611	71	89	oral contraception	Chemical	D003276
Relation: 3123611	CID	28	39	D000661	48	54	D002819	true
Relation: 3123611	CID	71	89	D003276	48	54	D002819	true

Sentence: Reversal of ammonia coma in rats by L-dopa: a peripheral effect.
Entity: 761833	12	19	ammonia	Chemical	D000641
Entity: 761833	20	24	coma	Disease	D003128
Entity: 761833	36	42	L-dopa	Chemical	D007980
Relation: 761833	CID	12	19	D000641	20	24	D003128	false
Relation: 761833	CID	36	42	D007980	20	24	D003128	false

Sentence: Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1.7 mmol NH4CL.
Entity: 761833	0	7	Ammonia	Chemical	D000641
Entity: 761833	8	12	coma	Disease	D003128
Entity: 761833	101	106	NH4CL	Chemical	D000643
Relation: 761833	CID	0	7	D000641	8	12	D003128	false
Relation: 761833	CID	101	106	D000643	8	12	D003128	true

Sentence: This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.
Entity: 761833	5	9	coma	Disease	D003128
Entity: 761833	39	45	L-dopa	Chemical	D007980
Entity: 761833	96	109	ammonium salt	Chemical	D064751
Relation: 761833	CID	39	45	D007980	5	9	D003128	false
Relation: 761833	CID	96	109	D064751	5	9	D003128	false

Sentence: Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations.
Entity: 761833	29	37	dopamine	Chemical	D004298
Entity: 761833	68	76	dopamine	Chemical	D004298
Entity: 761833	116	123	ammonia	Chemical	D000641
Entity: 761833	124	128	coma	Disease	D003128
Entity: 761833	160	167	ammonia	Chemical	D000641
Relation: 761833	CID	29	37	D004298	124	128	D003128	false
Relation: 761833	CID	68	76	D004298	124	128	D003128	false
Relation: 761833	CID	116	123	D000641	124	128	D003128	false
Relation: 761833	CID	160	167	D000641	124	128	D003128	false

Sentence: Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented.
Entity: 761833	58	64	L-dopa	Chemical	D007980
Entity: 761833	84	91	ammonia	Chemical	D000641
Entity: 761833	100	107	ammonia	Chemical	D000641
Entity: 761833	108	112	coma	Disease	D003128
Relation: 761833	CID	58	64	D007980	108	112	D003128	false
Relation: 761833	CID	84	91	D000641	108	112	D003128	false
Relation: 761833	CID	100	107	D000641	108	112	D003128	false

Sentence: Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.
Entity: 761833	39	46	ammonia	Chemical	D000641
Entity: 761833	69	76	ammonia	Chemical	D000641
Entity: 761833	77	81	coma	Disease	D003128
Entity: 761833	88	94	L-dopa	Chemical	D007980
Entity: 761833	145	153	dopamine	Chemical	D004298
Relation: 761833	CID	39	46	D000641	77	81	D003128	false
Relation: 761833	CID	69	76	D000641	77	81	D003128	false
Relation: 761833	CID	88	94	D007980	77	81	D003128	false
Relation: 761833	CID	145	153	D004298	77	81	D003128	false

Sentence: Heparin induced thrombocytopenia after liver transplantation.
Entity: 18589141	0	7	Heparin	Chemical	D006493
Entity: 18589141	16	32	thrombocytopenia	Disease	D013921
Relation: 18589141	CID	0	7	D006493	16	32	D013921	true

Sentence: BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.
Entity: 18589141	12	41	Unfractionated heparin sodium	Chemical	D006493
Entity: 18589141	43	46	UFH	Chemical	D006493
Entity: 18589141	51	79	low-molecular weight heparin	Chemical	D006495
Entity: 18589141	157	167	thrombosis	Disease	D013927
Relation: 18589141	CID	12	41	D006493	157	167	D013927	false
Relation: 18589141	CID	43	46	D006493	157	167	D013927	false
Relation: 18589141	CID	51	79	D006495	157	167	D013927	false

Sentence: Heparin induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.
Entity: 18589141	0	7	Heparin	Chemical	D006493
Entity: 18589141	16	32	thrombocytopenia	Disease	D013921
Entity: 18589141	34	37	HIT	Disease	D013921
Entity: 18589141	81	88	heparin	Chemical	D006493
Relation: 18589141	CID	0	7	D006493	16	32	D013921	true
Relation: 18589141	CID	0	7	D006493	34	37	D013921	true
Relation: 18589141	CID	81	88	D006493	16	32	D013921	true
Relation: 18589141	CID	81	88	D006493	34	37	D013921	true

Sentence: The frequencies of HIT after liver transplantation and platelet factor 4/heparin-reactive antibody (HIT antibody) positivity in liver transplantation patients, however, are unknown.
Entity: 18589141	19	22	HIT	Disease	D013921
Entity: 18589141	73	80	heparin	Chemical	D006493
Entity: 18589141	100	103	HIT	Disease	D013921
Relation: 18589141	CID	73	80	D006493	19	22	D013921	true
Relation: 18589141	CID	73	80	D006493	100	103	D013921	true

Sentence: The heparin induced platelet aggregation test was negative in these patients.
Entity: 18589141	4	11	heparin	Chemical	D006493
Entity: 18589141	20	40	platelet aggregation	Disease	D001791
Relation: 18589141	CID	4	11	D006493	20	40	D001791	false

Sentence: None of the subjects/patients developed UFH-related HIT.
Entity: 18589141	40	43	UFH	Chemical	D006493
Entity: 18589141	52	55	HIT	Disease	D013921
Relation: 18589141	CID	40	43	D006493	52	55	D013921	true

Sentence: PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.
Entity: 16418614	0	3	PTU	Chemical	D011441
Entity: 16418614	15	25	vasculitis	Disease	D014657
Entity: 16418614	41	56	Turner Syndrome	Disease	D014424
Entity: 16418614	61	76	Graves' disease	Disease	D006111
Relation: 16418614	CID	0	3	D011441	15	25	D014657	true
Relation: 16418614	CID	0	3	D011441	41	56	D014424	false
Relation: 16418614	CID	0	3	D011441	61	76	D006111	false

Sentence: The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.
Entity: 16418614	17	33	propylthiouracil	Chemical	D011441
Entity: 16418614	35	38	PTU	Chemical	D011441
Entity: 16418614	51	61	vasculitis	Disease	D014657
Entity: 16418614	245	248	PTU	Chemical	D011441
Relation: 16418614	CID	17	33	D011441	51	61	D014657	true
Relation: 16418614	CID	35	38	D011441	51	61	D014657	true
Relation: 16418614	CID	245	248	D011441	51	61	D014657	true

Sentence: Succinylcholine induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body.
Entity: 15893386	0	15	Succinylcholine	Chemical	D013390
Entity: 15893386	24	48	masseter muscle rigidity	Disease	D014313
Relation: 15893386	CID	0	15	D013390	24	48	D014313	true

Sentence: Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.
Entity: 15893386	35	59	masseter muscle rigidity	Disease	D014313
Entity: 15893386	61	73	jaw of steel	Disease	D014313
Entity: 15893386	81	96	succinylcholine	Chemical	D013390
Entity: 15893386	98	101	Sch	Chemical	D013390
Relation: 15893386	CID	81	96	D013390	35	59	D014313	true
Relation: 15893386	CID	81	96	D013390	61	73	D014313	true
Relation: 15893386	CID	98	101	D013390	35	59	D014313	true
Relation: 15893386	CID	98	101	D013390	61	73	D014313	true

Sentence: Minor neurological dysfunction, cognitive development, and somatic development at the age of 3 to 7 years after dexamethasone treatment in very-low birth-weight infants.
Entity: 15814210	6	30	neurological dysfunction	Disease	D009422
Entity: 15814210	112	125	dexamethasone	Chemical	D003907
Relation: 15814210	CID	112	125	D003907	6	30	D009422	true

Sentence: The objective of this study was to assess minor neurological dysfunction, cognitive development, and somatic development after dexamethasone therapy in very-low-birthweight infants.
Entity: 15814210	48	72	neurological dysfunction	Disease	D009422
Entity: 15814210	127	140	dexamethasone	Chemical	D003907
Relation: 15814210	CID	127	140	D003907	48	72	D009422	true

Sentence: After dexamethasone treatment, children showed a higher rate of minor neurological dysfunctions.
Entity: 15814210	6	19	dexamethasone	Chemical	D003907
Entity: 15814210	70	95	neurological dysfunctions	Disease	D009422
Relation: 15814210	CID	6	19	D003907	70	95	D009422	true

Sentence: Force overflow and levodopa induced dyskinesias in Parkinson's disease.
Entity: 11912119	19	27	levodopa	Chemical	D007980
Entity: 11912119	36	47	dyskinesias	Disease	D004409
Entity: 11912119	51	70	Parkinson's disease	Disease	D010300
Relation: 11912119	CID	19	27	D007980	36	47	D004409	true
Relation: 11912119	CID	19	27	D007980	51	70	D010300	false

Sentence: We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa induced dyskinesias (LID).
Entity: 11912119	46	65	Parkinson's disease	Disease	D010300
Entity: 11912119	113	121	levodopa	Chemical	D007980
Entity: 11912119	147	155	levodopa	Chemical	D007980
Entity: 11912119	164	175	dyskinesias	Disease	D004409
Entity: 11912119	177	180	LID	Disease	D004409
Relation: 11912119	CID	113	121	D007980	46	65	D010300	false
Relation: 11912119	CID	113	121	D007980	164	175	D004409	true
Relation: 11912119	CID	113	121	D007980	177	180	D004409	true
Relation: 11912119	CID	147	155	D007980	46	65	D010300	false
Relation: 11912119	CID	147	155	D007980	164	175	D004409	true
Relation: 11912119	CID	147	155	D007980	177	180	D004409	true

Sentence: We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.
Entity: 11912119	25	44	Parkinson's disease	Disease	D010300
Entity: 11912119	60	79	Parkinson's disease	Disease	D010300
Entity: 11912119	82	85	LID	Disease	D004409
Entity: 11912119	107	115	levodopa	Chemical	D007980
Entity: 11912119	124	135	dyskinesias	Disease	D004409
Entity: 11912119	137	156	Parkinson's disease	Disease	D010300
Entity: 11912119	159	162	LID	Disease	D004409
Relation: 11912119	CID	107	115	D007980	25	44	D010300	false
Relation: 11912119	CID	107	115	D007980	60	79	D010300	false
Relation: 11912119	CID	107	115	D007980	82	85	D004409	true
Relation: 11912119	CID	107	115	D007980	124	135	D004409	true
Relation: 11912119	CID	107	115	D007980	137	156	D010300	false
Relation: 11912119	CID	107	115	D007980	159	162	D004409	true

Sentence: The motor score of the Unified Parkinson's Disease Rating Scale, a dyskinesia score and force in a grip-lift paradigm were assessed ON and OFF levodopa.
Entity: 11912119	31	50	Parkinson's Disease	Disease	D010300
Entity: 11912119	67	77	dyskinesia	Disease	D004409
Entity: 11912119	143	151	levodopa	Chemical	D007980
Relation: 11912119	CID	143	151	D007980	31	50	D010300	false
Relation: 11912119	CID	143	151	D007980	67	77	D004409	true

Sentence: In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).
Entity: 11912119	3	22	Parkinson's disease	Disease	D010300
Entity: 11912119	25	28	LID	Disease	D004409
Entity: 11912119	123	131	levodopa	Chemical	D007980
Relation: 11912119	CID	123	131	D007980	3	22	D010300	false
Relation: 11912119	CID	123	131	D007980	25	28	D004409	true

Sentence: Postinfarction ventricular septal defect associated with long-term steroid therapy.
Entity: 9105126	15	40	ventricular septal defect	Disease	D018658
Entity: 9105126	67	74	steroid	Chemical	D013256
Relation: 9105126	CID	67	74	D013256	15	40	D018658	true

Sentence: Two cases of postinfarction ventricular septal rupture in patients on long-term steroid therapy are presented and the favourable outcome in both cases described.
Entity: 9105126	28	54	ventricular septal rupture	Disease	D018658
Entity: 9105126	80	87	steroid	Chemical	D013256
Relation: 9105126	CID	80	87	D013256	28	54	D018658	true

Sentence: Angioedema associated with droperidol administration.
Entity: 8599504	0	10	Angioedema	Disease	D000799
Entity: 8599504	27	37	droperidol	Chemical	D004329
Relation: 8599504	CID	27	37	D004329	0	10	D000799	true

Sentence: Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis.
Entity: 8546130	0	14	Clarithromycin	Chemical	D017291
Entity: 8546130	26	47	visual hallucinations	Disease	D006212
Entity: 8546130	66	87	chronic renal failure	Disease	D007676
Relation: 8546130	CID	0	14	D017291	26	47	D006212	true
Relation: 8546130	CID	0	14	D017291	66	87	D007676	false

Sentence: Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.
Entity: 8546130	32	53	visual hallucinations	Disease	D006212
Entity: 8546130	92	101	macrolide	Chemical	D018942
Entity: 8546130	114	128	clarithromycin	Chemical	D017291
Relation: 8546130	CID	92	101	D018942	32	53	D006212	false
Relation: 8546130	CID	114	128	D017291	32	53	D006212	true

Sentence: The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.
Entity: 8546130	45	59	clarithromycin	Chemical	D017291
Entity: 8546130	71	92	chronic renal failure	Disease	D007676
Entity: 8546130	145	153	aluminum	Chemical	D000535
Entity: 8546130	212	222	neurotoxic	Disease	D020258
Relation: 8546130	CID	45	59	D017291	71	92	D007676	false
Relation: 8546130	CID	45	59	D017291	212	222	D020258	false
Relation: 8546130	CID	145	153	D000535	71	92	D007676	false
Relation: 8546130	CID	145	153	D000535	212	222	D020258	false

Sentence: Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.
Entity: 7724492	6	20	renal toxicity	Disease	D007674
Entity: 7724492	24	35	doxorubicin	Chemical	D004317
Entity: 7724492	37	47	adriamycin	Chemical	D004317
Entity: 7724492	56	69	cyanoacrylate	Chemical	D003487
Relation: 7724492	CID	24	35	D004317	6	20	D007674	false
Relation: 7724492	CID	37	47	D004317	6	20	D007674	false
Relation: 7724492	CID	56	69	D003487	6	20	D007674	false

Sentence: Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.
Entity: 7724492	6	17	doxorubicin	Chemical	D004317
Entity: 7724492	45	59	renal toxicity	Disease	D007674
Entity: 7724492	120	138	glomerulonephritis	Disease	D005921
Relation: 7724492	CID	6	17	D004317	45	59	D007674	false
Relation: 7724492	CID	6	17	D004317	120	138	D005921	false

Sentence: A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX.
Entity: 7724492	17	28	proteinuria	Disease	D011507
Entity: 7724492	94	96	DX	Chemical	D004317
Relation: 7724492	CID	94	96	D004317	17	28	D011507	true

Sentence: In rats with immune experimental glomerulonephritis, 5/6 rats given DX died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived.
Entity: 7724492	33	51	glomerulonephritis	Disease	D005921
Entity: 7724492	68	70	DX	Chemical	D004317
Relation: 7724492	CID	68	70	D004317	33	51	D005921	false

Sentence: Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.
Entity: 7724492	0	11	Proteinuria	Disease	D011507
Entity: 7724492	99	110	doxorubicin	Chemical	D004317
Entity: 7724492	187	189	DX	Chemical	D004317
Relation: 7724492	CID	99	110	D004317	0	11	D011507	true
Relation: 7724492	CID	187	189	D004317	0	11	D011507	true

Sentence: These results demonstrate that, in these experimental conditions, DXNP killed less animals than free DX, despite of an enhanced renal toxicity of the former.
Entity: 7724492	101	103	DX	Chemical	D004317
Entity: 7724492	128	142	renal toxicity	Disease	D007674
Relation: 7724492	CID	101	103	D004317	128	142	D007674	false

Sentence: Etoposide-related myocardial infarction.
Entity: 7619765	0	9	Etoposide	Chemical	D005047
Entity: 7619765	18	39	myocardial infarction	Disease	D009203
Relation: 7619765	CID	0	9	D005047	18	39	D009203	true

Sentence: Subjective assessment of sexual dysfunction of patients on long-term administration of digoxin.
Entity: 7416947	25	43	sexual dysfunction	Disease	D020018
Entity: 7416947	87	94	digoxin	Chemical	D004077
Relation: 7416947	CID	87	94	D004077	25	43	D020018	true

Sentence: The patients of the study and control group (without digoxin) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the rheumatic heart disease patients.
Entity: 7416947	53	60	digoxin	Chemical	D004077
Entity: 7416947	164	187	rheumatic heart disease	Disease	D012214
Relation: 7416947	CID	53	60	D004077	164	187	D012214	false

Sentence: Fatal aplastic anemia due to indomethacin--lymphocyte transformation tests in vitro.
Entity: 7263204	6	21	aplastic anemia	Disease	D000741
Entity: 7263204	29	41	indomethacin	Chemical	D007213
Relation: 7263204	CID	29	41	D007213	6	21	D000741	true

Sentence: Although indomethacin has been implicated as a possible cause of aplastic anemia on the basis of a few clinical observations, its role has not been definitely established.
Entity: 7263204	9	21	indomethacin	Chemical	D007213
Entity: 7263204	65	80	aplastic anemia	Disease	D000741
Relation: 7263204	CID	9	21	D007213	65	80	D000741	true

Sentence: A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given.
Entity: 7263204	16	31	aplastic anemia	Disease	D000741
Entity: 7263204	74	85	allopurinol	Chemical	D000493
Entity: 7263204	90	102	indomethacin	Chemical	D007213
Relation: 7263204	CID	74	85	D000493	16	31	D000741	false
Relation: 7263204	CID	90	102	D007213	16	31	D000741	true

Sentence: Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside.
Entity: 7066357	69	87	nephrotic syndrome	Disease	D009404
Entity: 7066357	110	135	puromycin aminonucleoside	Chemical	D011692
Relation: 7066357	CID	110	135	D011692	69	87	D009404	true

Sentence: This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.
Entity: 7066357	95	113	nephrotic syndrome	Disease	D009404
Entity: 7066357	125	150	puromycin aminonucleoside	Chemical	D011692
Entity: 7066357	163	181	nephrotic syndrome	Disease	D009404
Entity: 7066357	219	234	aminonucleoside	Chemical	D011692
Relation: 7066357	CID	125	150	D011692	95	113	D009404	true
Relation: 7066357	CID	125	150	D011692	163	181	D009404	true
Relation: 7066357	CID	219	234	D011692	95	113	D009404	true
Relation: 7066357	CID	219	234	D011692	163	181	D009404	true

Sentence: The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside (20 mg/kg for 7 days) and the subsequent development of nephrotic syndrome.
Entity: 7066357	128	153	puromycin aminonucleoside	Chemical	D011692
Entity: 7066357	210	228	nephrotic syndrome	Disease	D009404
Relation: 7066357	CID	128	153	D011692	210	228	D009404	true

Sentence: In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.
Entity: 7066357	7	16	nephrotic	Disease	D009404
Entity: 7066357	43	54	fatty acids	Chemical	D005227
Entity: 7066357	56	71	triacylglycerol	Chemical	D014280
Entity: 7066357	119	137	cholesteryl esters	Chemical	D002788
Relation: 7066357	CID	43	54	D005227	7	16	D009404	false
Relation: 7066357	CID	56	71	D014280	7	16	D009404	false
Relation: 7066357	CID	119	137	D002788	7	16	D009404	false

Sentence: Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.
Entity: 7007443	128	153	fulminant hepatic failure	Disease	D017114
Entity: 7007443	160	171	paracetamol	Chemical	D000082
Entity: 7007443	172	180	overdose	Disease	D062787
Entity: 7007443	241	266	fulminant hepatic failure	Disease	D017114
Entity: 7007443	274	289	viral hepatitis	Disease	D006525
Relation: 7007443	CID	160	171	D000082	128	153	D017114	true
Relation: 7007443	CID	160	171	D000082	172	180	D062787	false
Relation: 7007443	CID	160	171	D000082	241	266	D017114	true
Relation: 7007443	CID	160	171	D000082	274	289	D006525	false

Sentence: Transketolase abnormality in tolazamide induced Wernicke's encephalopathy.
Entity: 3762968	29	39	tolazamide	Chemical	D014042
Entity: 3762968	48	73	Wernicke's encephalopathy	Disease	D014899
Relation: 3762968	CID	29	39	D014042	48	73	D014899	true

Sentence: We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.
Entity: 3762968	13	21	thiamine	Chemical	D013831
Entity: 3762968	77	85	diabetic	Disease	D003920
Entity: 3762968	108	133	Wernicke's encephalopathy	Disease	D014899
Entity: 3762968	152	162	tolazamide	Chemical	D014042
Entity: 3762968	250	272	thiamine pyrophosphate	Chemical	D013835
Entity: 3762968	274	277	TPP	Chemical	D013835
Entity: 3762968	321	348	Wernicke-Korsakoff syndrome	Disease	D020915
Relation: 3762968	CID	13	21	D013831	77	85	D003920	false
Relation: 3762968	CID	13	21	D013831	108	133	D014899	false
Relation: 3762968	CID	13	21	D013831	321	348	D020915	false
Relation: 3762968	CID	152	162	D014042	77	85	D003920	false
Relation: 3762968	CID	152	162	D014042	108	133	D014899	true
Relation: 3762968	CID	152	162	D014042	321	348	D020915	false
Relation: 3762968	CID	250	272	D013835	77	85	D003920	false
Relation: 3762968	CID	250	272	D013835	108	133	D014899	false
Relation: 3762968	CID	250	272	D013835	321	348	D020915	false
Relation: 3762968	CID	274	277	D013835	77	85	D003920	false
Relation: 3762968	CID	274	277	D013835	108	133	D014899	false
Relation: 3762968	CID	274	277	D013835	321	348	D020915	false

Sentence: We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.
Entity: 3762968	57	65	diabetic	Disease	D003920
Entity: 3762968	94	119	Wernicke's encephalopathy	Disease	D014899
Entity: 3762968	175	178	TPP	Chemical	D013835
Relation: 3762968	CID	175	178	D013835	57	65	D003920	false
Relation: 3762968	CID	175	178	D013835	94	119	D014899	false

Sentence: Mechanisms of myocardial ischemia induced by epinephrine: comparison with exercise induced ischemia.
Entity: 3413271	14	33	myocardial ischemia	Disease	D017202
Entity: 3413271	45	56	epinephrine	Chemical	D004837
Entity: 3413271	91	99	ischemia	Disease	D007511
Relation: 3413271	CID	45	56	D004837	14	33	D017202	true
Relation: 3413271	CID	45	56	D004837	91	99	D007511	false

Sentence: The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease.
Entity: 3413271	12	23	epinephrine	Chemical	D004837
Entity: 3413271	37	56	myocardial ischemia	Disease	D017202
Entity: 3413271	87	110	coronary artery disease	Disease	D003324
Relation: 3413271	CID	12	23	D004837	37	56	D017202	true
Relation: 3413271	CID	12	23	D004837	87	110	D003324	false

Sentence: Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise.
Entity: 3413271	19	27	ischemia	Disease	D007511
Entity: 3413271	62	68	oxygen	Chemical	D010100
Entity: 3413271	102	113	epinephrine	Chemical	D004837
Relation: 3413271	CID	62	68	D010100	19	27	D007511	false
Relation: 3413271	CID	102	113	D004837	19	27	D007511	false

Sentence: Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.
Entity: 3413271	5	16	epinephrine	Chemical	D004837
Entity: 3413271	39	58	myocardial ischemia	Disease	D017202
Entity: 3413271	86	96	depression	Disease	D003866
Entity: 3413271	101	107	angina	Disease	D000787
Relation: 3413271	CID	5	16	D004837	39	58	D017202	true
Relation: 3413271	CID	5	16	D004837	86	96	D003866	false
Relation: 3413271	CID	5	16	D004837	101	107	D000787	false

Sentence: However, the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise.
Entity: 3413271	27	46	myocardial ischemia	Disease	D017202
Entity: 3413271	58	69	epinephrine	Chemical	D004837
Relation: 3413271	CID	58	69	D004837	27	46	D017202	true

Sentence: Exercise induced myocardial ischemia was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while epinephrine induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.
Entity: 3413271	17	36	myocardial ischemia	Disease	D017202
Entity: 3413271	169	180	epinephrine	Chemical	D004837
Entity: 3413271	189	197	ischemia	Disease	D007511
Relation: 3413271	CID	169	180	D004837	17	36	D017202	true
Relation: 3413271	CID	169	180	D004837	189	197	D007511	false

Sentence: Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.
Entity: 3088349	10	32	contralateral rotation	Disease	D009069
Entity: 3088349	54	77	substantia nigra lesion	Disease	-1
Entity: 3088349	147	158	amphetamine	Chemical	D000661
Relation: 3088349	CID	147	158	D000661	10	32	D009069	true
Relation: 3088349	CID	147	158	D000661	54	77	-1	false

Sentence: Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.
Entity: 3088349	21	27	6-OHDA	Chemical	D016627
Entity: 3088349	36	45	SN lesion	Disease	-1
Entity: 3088349	69	91	contralateral rotation	Disease	D009069
Entity: 3088349	137	157	ipsilateral circling	Disease	D009069
Relation: 3088349	CID	21	27	D016627	36	45	-1	false
Relation: 3088349	CID	21	27	D016627	69	91	D009069	false
Relation: 3088349	CID	21	27	D016627	137	157	D009069	false

Sentence: In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion, on amphetamine induced rotational behavior.
Entity: 3088349	47	69	contralateral rotation	Disease	D009069
Entity: 3088349	149	160	amphetamine	Chemical	D000661
Entity: 3088349	169	188	rotational behavior	Disease	D009069
Relation: 3088349	CID	149	160	D000661	47	69	D009069	true
Relation: 3088349	CID	149	160	D000661	169	188	D009069	true

Sentence: A substantial degree of contralateral preference was still evident when amphetamine was administered for the first time 24 days after lesioning, indicating involvement of spared cells in the contralateral rotation.
Entity: 3088349	72	83	amphetamine	Chemical	D000661
Entity: 3088349	191	213	contralateral rotation	Disease	D009069
Relation: 3088349	CID	72	83	D000661	191	213	D009069	true

Sentence: However, regardless of the duration of recovery (and irrespective of either lesion volume, amphetamine dose, or post-lesion motor exercise), amphetamine induced rotation tended to become gradually more ipsilateral as the observation session progressed, and all rats circled ipsilaterally to the lesion in response to further amphetamine injections.
Entity: 3088349	91	102	amphetamine	Chemical	D000661
Entity: 3088349	141	152	amphetamine	Chemical	D000661
Entity: 3088349	161	169	rotation	Disease	D009069
Entity: 3088349	325	336	amphetamine	Chemical	D000661
Relation: 3088349	CID	91	102	D000661	161	169	D009069	true
Relation: 3088349	CID	141	152	D000661	161	169	D009069	true
Relation: 3088349	CID	325	336	D000661	161	169	D009069	true

Sentence: It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment.
Entity: 3001299	100	130	nephrogenic diabetes insipidus	Disease	D018500
Entity: 3001299	135	149	hypothyroidism	Disease	D007037
Entity: 3001299	157	164	lithium	Chemical	D008094
Relation: 3001299	CID	157	164	D008094	100	130	D018500	false
Relation: 3001299	CID	157	164	D008094	135	149	D007037	true

Sentence: Hypothyroidism developed in eight patients while they were taking lithium.
Entity: 3001299	0	14	Hypothyroidism	Disease	D007037
Entity: 3001299	66	73	lithium	Chemical	D008094
Relation: 3001299	CID	66	73	D008094	0	14	D007037	true

Sentence: Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice.
Entity: 2004015	66	80	azidothymidine	Chemical	D015215
Entity: 2004015	89	104	immunodeficient	Disease	C565469
Relation: 2004015	CID	66	80	D015215	89	104	C565469	false

Sentence: The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.
Entity: 2004015	4	11	anaemia	Disease	D000740
Entity: 2004015	23	50	3'-azido-3'dideoxythymidine	Chemical	D015215
Entity: 2004015	52	55	AZT	Chemical	D015215
Relation: 2004015	CID	23	50	D015215	4	11	D000740	true
Relation: 2004015	CID	52	55	D015215	4	11	D000740	true

Sentence: We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).
Entity: 2004015	31	35	AIDS	Disease	D000163
Entity: 2004015	37	46	infection	Disease	D007239
Entity: 2004015	89	98	leukaemia	Disease	D007938
Entity: 2004015	129	132	AZT	Chemical	D015215
Entity: 2004015	141	148	anaemia	Disease	D000740
Relation: 2004015	CID	129	132	D015215	31	35	D000163	false
Relation: 2004015	CID	129	132	D015215	37	46	D007239	false
Relation: 2004015	CID	129	132	D015215	89	98	D007938	false
Relation: 2004015	CID	129	132	D015215	141	148	D000740	true

Sentence: AZT produced anaemia in both groups, in a dose-dependent fashion.
Entity: 2004015	0	3	AZT	Chemical	D015215
Entity: 2004015	13	20	anaemia	Disease	D000740
Relation: 2004015	CID	0	3	D015215	13	20	D000740	true

Sentence: Despite the anaemia, the number of splenic and bone marrow BFU-e in AZT treated mice increased up to five-fold over levels observed in infected untreated animals after 15 d of treatment.
Entity: 2004015	12	19	anaemia	Disease	D000740
Entity: 2004015	68	71	AZT	Chemical	D015215
Relation: 2004015	CID	68	71	D015215	12	19	D000740	true

Sentence: The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.
Entity: 2004015	42	45	AZT	Chemical	D015215
Entity: 2004015	94	101	anaemia	Disease	D000740
Entity: 2004015	130	145	phenylhydrazine	Chemical	C030299
Entity: 2004015	147	150	PHZ	Chemical	C030299
Relation: 2004015	CID	42	45	D015215	94	101	D000740	true
Relation: 2004015	CID	130	145	C030299	94	101	D000740	false
Relation: 2004015	CID	147	150	C030299	94	101	D000740	false

Sentence: The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.
Entity: 2004015	97	100	AZT	Chemical	D015215
Entity: 2004015	105	108	PHZ	Chemical	C030299
Entity: 2004015	146	153	anaemia	Disease	D000740
Relation: 2004015	CID	97	100	D015215	146	153	D000740	true
Relation: 2004015	CID	105	108	C030299	146	153	D000740	false

Sentence: However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.
Entity: 2004015	9	24	reticulocytosis	Disease	D045262
Entity: 2004015	61	68	anaemia	Disease	D000740
Entity: 2004015	81	84	AZT	Chemical	D015215
Relation: 2004015	CID	81	84	D015215	9	24	D045262	false
Relation: 2004015	CID	81	84	D015215	61	68	D000740	true

Sentence: Detection of abnormal cardiac adrenergic neuron activity in adriamycin induced cardiomyopathy with iodine-125-metaiodobenzylguanidine.
Entity: 1732442	60	70	adriamycin	Chemical	D004317
Entity: 1732442	79	93	cardiomyopathy	Disease	D009202
Entity: 1732442	99	133	iodine-125-metaiodobenzylguanidine	Chemical	D019797
Relation: 1732442	CID	60	70	D004317	79	93	D009202	true
Relation: 1732442	CID	99	133	D019797	79	93	D009202	false

Sentence: Using a rat model of adriamycin induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.
Entity: 1732442	21	31	adriamycin	Chemical	D004317
Entity: 1732442	40	54	cardiomyopathy	Disease	D009202
Entity: 1732442	180	190	adriamycin	Chemical	D004317
Entity: 1732442	191	205	cardiomyopathy	Disease	D009202
Relation: 1732442	CID	21	31	D004317	40	54	D009202	true
Relation: 1732442	CID	21	31	D004317	191	205	D009202	true
Relation: 1732442	CID	180	190	D004317	40	54	D009202	true
Relation: 1732442	CID	180	190	D004317	191	205	D009202	true

Sentence: The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of adriamycin treatment (2 mg/kg, once a week).
Entity: 1732442	14	55	vacuolar degeneration of myocardial cells	Disease	C536522
Entity: 1732442	100	110	adriamycin	Chemical	D004317
Relation: 1732442	CID	100	110	D004317	14	55	C536522	false

Sentence: Amnestic syndrome associated with propranolol toxicity: a case report.
Entity: 1423339	0	17	Amnestic syndrome	Disease	D000647
Entity: 1423339	34	45	propranolol	Chemical	D011433
Entity: 1423339	46	54	toxicity	Disease	D064420
Relation: 1423339	CID	34	45	D011433	0	17	D000647	true
Relation: 1423339	CID	34	45	D011433	46	54	D064420	false

Sentence: An elderly woman developed an Alzheimer-like subacute dementia as a result of propranolol toxicity.
Entity: 1423339	30	39	Alzheimer	Disease	D000544
Entity: 1423339	54	62	dementia	Disease	D003704
Entity: 1423339	78	89	propranolol	Chemical	D011433
Entity: 1423339	90	98	toxicity	Disease	D064420
Relation: 1423339	CID	78	89	D011433	30	39	D000544	false
Relation: 1423339	CID	78	89	D011433	54	62	D003704	false
Relation: 1423339	CID	78	89	D011433	90	98	D064420	false

Sentence: Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a depression of the SA nodal activity by a direct action.
Entity: 921394	14	22	ketamine	Chemical	D007649
Entity: 921394	86	96	depression	Disease	D003866
Relation: 921394	CID	14	22	D007649	86	96	D003866	false

Sentence: Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ketamine induced tachycardia, while it was completely abolished in the reserpinized dogs or by a prior injection of a beta-blocking agent into the SA node artery.
Entity: 921394	123	131	ketamine	Chemical	D007649
Entity: 921394	140	151	tachycardia	Disease	D013610
Relation: 921394	CID	123	131	D007649	140	151	D013610	true

Sentence: The use of serum cholinesterase in succinylcholine apnoea.
Entity: 871943	35	50	succinylcholine	Chemical	D013390
Entity: 871943	51	57	apnoea	Disease	D001049
Relation: 871943	CID	35	50	D013390	51	57	D001049	true

Sentence: Fifteen patients demonstrating unexpected prolonged apnoea lasting several hours after succinylcholine have been treated by a new preparation of human serum cholinesterase.
Entity: 871943	52	58	apnoea	Disease	D001049
Entity: 871943	87	102	succinylcholine	Chemical	D013390
Relation: 871943	CID	87	102	D013390	52	58	D001049	true

Sentence: Orthostatic hypotension occurs following alpha 2-adrenoceptor blockade in chronic prazosin-pretreated conscious spontaneously hypertensive rats. 1.
Entity: 1355091	0	23	Orthostatic hypotension	Disease	D007024
Entity: 1355091	82	90	prazosin	Chemical	D011224
Entity: 1355091	126	138	hypertensive	Disease	D006973
Relation: 1355091	CID	82	90	D011224	0	23	D007024	true
Relation: 1355091	CID	82	90	D011224	126	138	D006973	false

Sentence: Studies were performed to evaluate whether chronic prazosin treatment alters the alpha 2-adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously hypertensive rats (SHR). 2.
Entity: 1355091	51	59	prazosin	Chemical	D011224
Entity: 1355091	189	201	hypertensive	Disease	D006973
Relation: 1355091	CID	51	59	D011224	189	201	D006973	false

Sentence: However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6). 3.
Entity: 1355091	34	57	orthostatic hypotension	Disease	D007024
Entity: 1355091	82	90	prazosin	Chemical	D011224
Entity: 1355091	142	153	rauwolscine	Chemical	D015016
Relation: 1355091	CID	82	90	D011224	34	57	D007024	true
Relation: 1355091	CID	142	153	D015016	34	57	D007024	false

Sentence: Head-up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).
Entity: 1355091	44	67	orthostatic hypotension	Disease	D007024
Entity: 1355091	124	132	prazosin	Chemical	D011224
Relation: 1355091	CID	124	132	D011224	44	67	D007024	true

Sentence: The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.
Entity: 1355091	26	37	bradycardia	Disease	D001919
Entity: 1355091	61	71	cirazoline	Chemical	C014282
Entity: 1355091	126	138	Abbott-53693	Chemical	C056299
Entity: 1355091	175	188	noradrenaline	Chemical	D009638
Entity: 1355091	282	290	prazosin	Chemical	D011224
Relation: 1355091	CID	61	71	C014282	26	37	D001919	true
Relation: 1355091	CID	126	138	C056299	26	37	D001919	true
Relation: 1355091	CID	175	188	D009638	26	37	D001919	true
Relation: 1355091	CID	282	290	D011224	26	37	D001919	false

Sentence: Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).
Entity: 1355091	21	32	bradycardia	Disease	D001919
Entity: 1355091	44	54	cirazoline	Chemical	C014282
Entity: 1355091	81	89	prazosin	Chemical	D011224
Relation: 1355091	CID	44	54	C014282	21	32	D001919	true
Relation: 1355091	CID	81	89	D011224	21	32	D001919	false

Sentence: On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.
Entity: 1355091	42	54	Abbott-53693	Chemical	C056299
Entity: 1355091	112	123	bradycardia	Disease	D001919
Entity: 1355091	156	164	prazosin	Chemical	D011224
Relation: 1355091	CID	42	54	C056299	112	123	D001919	true
Relation: 1355091	CID	156	164	D011224	112	123	D001919	false

Sentence: A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.
Entity: 8638876	51	59	headache	Disease	D006261
Entity: 8638876	61	67	nausea	Disease	D009325
Entity: 8638876	72	80	vomiting	Disease	D014839
Entity: 8638876	87	98	hemiparesis	Disease	D010291
Entity: 8638876	103	110	seizure	Disease	D012640
Entity: 8638876	144	156	progesterone	Chemical	D011374
Entity: 8638876	161	170	estradiol	Chemical	D004958
Relation: 8638876	CID	144	156	D011374	51	59	D006261	false
Relation: 8638876	CID	144	156	D011374	61	67	D009325	false
Relation: 8638876	CID	144	156	D011374	72	80	D014839	false
Relation: 8638876	CID	144	156	D011374	87	98	D010291	false
Relation: 8638876	CID	144	156	D011374	103	110	D012640	false
Relation: 8638876	CID	161	170	D004958	51	59	D006261	false
Relation: 8638876	CID	161	170	D004958	61	67	D009325	false
Relation: 8638876	CID	161	170	D004958	72	80	D014839	false
Relation: 8638876	CID	161	170	D004958	87	98	D010291	false
Relation: 8638876	CID	161	170	D004958	103	110	D012640	false

Sentence: Chloroquine related complete heart block with blindness: case report.
Entity: 1628552	0	11	Chloroquine	Chemical	D002738
Entity: 1628552	29	40	heart block	Disease	D006327
Entity: 1628552	46	55	blindness	Disease	D001766
Relation: 1628552	CID	0	11	D002738	29	40	D006327	false
Relation: 1628552	CID	0	11	D002738	46	55	D001766	true

Sentence: A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.
Entity: 1628552	52	63	chloroquine	Chemical	D002738
Entity: 1628552	101	124	deterioration of vision	Disease	D015354
Entity: 1628552	131	144	fatiguability	Disease	D005221
Entity: 1628552	146	154	dyspnoea	Disease	D004417
Entity: 1628552	156	165	dizziness	Disease	D004244
Entity: 1628552	181	197	syncopal attacks	Disease	D013575
Relation: 1628552	CID	52	63	D002738	101	124	D015354	false
Relation: 1628552	CID	52	63	D002738	131	144	D005221	true
Relation: 1628552	CID	52	63	D002738	146	154	D004417	true
Relation: 1628552	CID	52	63	D002738	156	165	D004244	true
Relation: 1628552	CID	52	63	D002738	181	197	D013575	true

Sentence: Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.
Entity: 1628552	49	60	chloroquine	Chemical	D002738
Entity: 1628552	61	72	retinopathy	Disease	D012164
Entity: 1628552	114	127	heart failure	Disease	D006333
Entity: 1628552	143	154	heart block	Disease	D006327
Entity: 1628552	160	185	right bundle branch block	Disease	D002037
Relation: 1628552	CID	49	60	D002738	61	72	D012164	true
Relation: 1628552	CID	49	60	D002738	114	127	D006333	true
Relation: 1628552	CID	49	60	D002738	143	154	D006327	false
Relation: 1628552	CID	49	60	D002738	160	185	D002037	true

Sentence: The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.
Entity: 1628552	4	15	heart block	Disease	D006327
Entity: 1628552	59	72	heart failure	Disease	D006333
Entity: 1628552	106	117	chloroquine	Chemical	D002738
Relation: 1628552	CID	106	117	D002738	4	15	D006327	false
Relation: 1628552	CID	106	117	D002738	59	72	D006333	true

Sentence: Systemic toxicity and resuscitation in bupivacaine-, levobupivacaine-, or ropivacaine-infused rats.
Entity: 11524350	9	17	toxicity	Disease	D064420
Entity: 11524350	39	50	bupivacaine	Chemical	D002045
Entity: 11524350	53	68	levobupivacaine	Chemical	C476513
Entity: 11524350	74	85	ropivacaine	Chemical	C037663
Relation: 11524350	CID	39	50	D002045	9	17	D064420	false
Relation: 11524350	CID	53	68	C476513	9	17	D064420	false
Relation: 11524350	CID	74	85	C037663	9	17	D064420	false

Sentence: We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.
Entity: 11524350	25	33	toxicity	Disease	D064420
Entity: 11524350	37	48	bupivacaine	Chemical	D002045
Entity: 11524350	50	65	levobupivacaine	Chemical	C476513
Entity: 11524350	71	82	ropivacaine	Chemical	C037663
Relation: 11524350	CID	37	48	D002045	25	33	D064420	false
Relation: 11524350	CID	50	65	C476513	25	33	D064420	false
Relation: 11524350	CID	71	82	C037663	25	33	D064420	false

Sentence: The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.
Entity: 11524350	24	39	levobupivacaine	Chemical	C476513
Entity: 11524350	44	55	ropivacaine	Chemical	C037663
Entity: 11524350	70	78	seizures	Disease	D012640
Entity: 11524350	122	133	bupivacaine	Chemical	D002045
Relation: 11524350	CID	24	39	C476513	70	78	D012640	true
Relation: 11524350	CID	44	55	C037663	70	78	D012640	true
Relation: 11524350	CID	122	133	D002045	70	78	D012640	false

Sentence: The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.
Entity: 11524350	24	39	levobupivacaine	Chemical	C476513
Entity: 11524350	54	66	dysrhythmias	Disease	D001145
Entity: 11524350	71	79	asystole	Disease	D006323
Entity: 11524350	125	136	ropivacaine	Chemical	C037663
Entity: 11524350	173	184	bupivacaine	Chemical	D002045
Relation: 11524350	CID	24	39	C476513	54	66	D001145	true
Relation: 11524350	CID	24	39	C476513	71	79	D006323	true
Relation: 11524350	CID	125	136	C037663	54	66	D001145	true
Relation: 11524350	CID	125	136	C037663	71	79	D006323	true
Relation: 11524350	CID	173	184	D002045	54	66	D001145	false
Relation: 11524350	CID	173	184	D002045	71	79	D006323	false

Sentence: 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
Entity: 10027919	0	16	22-oxacalcitriol	Chemical	C051883
Entity: 10027919	28	57	secondary hyperparathyroidism	Disease	D006962
Entity: 10027919	75	92	low bone turnover	Disease	D001851
Entity: 10027919	106	119	renal failure	Disease	D051437
Relation: 10027919	CID	0	16	C051883	28	57	D006962	false
Relation: 10027919	CID	0	16	C051883	75	92	D001851	false
Relation: 10027919	CID	0	16	C051883	106	119	D051437	false

Sentence: BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.
Entity: 10027919	12	22	Calcitriol	Chemical	D002117
Entity: 10027919	101	114	renal failure	Disease	D051437
Entity: 10027919	152	165	hypercalcemia	Disease	D006934
Entity: 10027919	180	208	suppression of bone turnover	Disease	D001851
Entity: 10027919	228	249	adynamic bone disease	Disease	D001851
Relation: 10027919	CID	12	22	D002117	101	114	D051437	false
Relation: 10027919	CID	12	22	D002117	152	165	D006934	true
Relation: 10027919	CID	12	22	D002117	180	208	D001851	true
Relation: 10027919	CID	12	22	D002117	228	249	D001851	true

Sentence: This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.
Entity: 10027919	54	57	OCT	Chemical	C051883
Entity: 10027919	119	142	impaired renal function	Disease	D007674
Relation: 10027919	CID	54	57	C051883	119	142	D007674	false

Sentence: RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.
Entity: 10027919	21	24	OCT	Chemical	C051883
Entity: 10027919	94	113	renal insufficiency	Disease	D051437
Relation: 10027919	CID	21	24	C051883	94	113	D051437	false

Sentence: In long-standing secondary hyperparathyroidism, OCT (0.03 microg/kg) stabilized serum PTH levels during the first months.
Entity: 10027919	17	46	secondary hyperparathyroidism	Disease	D006962
Entity: 10027919	48	51	OCT	Chemical	C051883
Relation: 10027919	CID	48	51	C051883	17	46	D006962	false

Sentence: In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.
Entity: 10027919	12	15	OCT	Chemical	C051883
Entity: 10027919	58	71	woven osteoid	Disease	-1
Entity: 10027919	76	84	fibrosis	Disease	D005355
Relation: 10027919	CID	12	15	C051883	58	71	-1	false
Relation: 10027919	CID	12	15	C051883	76	84	D005355	false

Sentence: Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.
Entity: 8643966	36	62	non-small cell lung cancer	Disease	D002289
Entity: 8643966	68	78	paclitaxel	Chemical	D017239
Relation: 8643966	CID	68	78	D017239	36	62	D002289	false

Sentence: Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.
Entity: 8643966	0	10	Paclitaxel	Chemical	D017239
Entity: 8643966	12	17	Taxol	Chemical	D017239
Entity: 8643966	135	140	tumor	Disease	D009369
Entity: 8643966	156	163	ovarian	Disease	D010051
Entity: 8643966	168	174	breast	Disease	D001943
Relation: 8643966	CID	0	10	D017239	135	140	D009369	false
Relation: 8643966	CID	0	10	D017239	156	163	D010051	false
Relation: 8643966	CID	0	10	D017239	168	174	D001943	false
Relation: 8643966	CID	12	17	D017239	135	140	D009369	false
Relation: 8643966	CID	12	17	D017239	156	163	D010051	false
Relation: 8643966	CID	12	17	D017239	168	174	D001943	false

Sentence: Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.
Entity: 8643966	31	41	paclitaxel	Chemical	D017239
Entity: 8643966	105	131	non-small cell lung cancer	Disease	D002289
Entity: 8643966	133	138	NSCLC	Disease	D002289
Relation: 8643966	CID	31	41	D017239	105	131	D002289	false
Relation: 8643966	CID	31	41	D017239	133	138	D002289	false

Sentence: We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.
Entity: 8643966	33	41	toxicity	Disease	D064420
Entity: 8643966	54	64	paclitaxel	Chemical	D017239
Entity: 8643966	139	144	NSCLC	Disease	D002289
Relation: 8643966	CID	54	64	D017239	33	41	D064420	false
Relation: 8643966	CID	54	64	D017239	139	144	D002289	false

Sentence: Paclitaxel is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity.
Entity: 8643966	0	10	Paclitaxel	Chemical	D017239
Entity: 8643966	217	225	toxicity	Disease	D064420
Relation: 8643966	CID	0	10	D017239	217	225	D064420	false

Sentence: Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine.
Entity: 6695415	0	19	Cerebral hemorrhage	Disease	D002543
Entity: 6695415	36	55	phenylpropanolamine	Chemical	D010665
Entity: 6695415	76	84	caffeine	Chemical	D002110
Relation: 6695415	CID	36	55	D010665	0	19	D002543	true
Relation: 6695415	CID	76	84	D002110	0	19	D002543	true

Sentence: Phenylpropanolamine (PPA) is a drug that has been associated with serious side effects including stroke.
Entity: 6695415	0	19	Phenylpropanolamine	Chemical	D010665
Entity: 6695415	21	24	PPA	Chemical	D010665
Entity: 6695415	97	103	stroke	Disease	D020521
Relation: 6695415	CID	0	19	D010665	97	103	D020521	true
Relation: 6695415	CID	21	24	D010665	97	103	D020521	true

Sentence: In order to determine if PPA/caffeine can lead to stroke in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.
Entity: 6695415	25	28	PPA	Chemical	D010665
Entity: 6695415	29	37	caffeine	Chemical	D002110
Entity: 6695415	50	56	stroke	Disease	D020521
Entity: 6695415	80	92	hypertensive	Disease	D006973
Relation: 6695415	CID	25	28	D010665	50	56	D020521	true
Relation: 6695415	CID	25	28	D010665	80	92	D006973	true
Relation: 6695415	CID	29	37	D002110	50	56	D020521	false
Relation: 6695415	CID	29	37	D002110	80	92	D006973	true

Sentence: A single PPA/caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals.
Entity: 6695415	9	12	PPA	Chemical	D010665
Entity: 6695415	13	21	caffeine	Chemical	D002110
Entity: 6695415	63	75	hypertension	Disease	D006973
Entity: 6695415	105	117	hypertensive	Disease	D006973
Relation: 6695415	CID	9	12	D010665	63	75	D006973	true
Relation: 6695415	CID	9	12	D010665	105	117	D006973	true
Relation: 6695415	CID	13	21	D002110	63	75	D006973	true
Relation: 6695415	CID	13	21	D002110	105	117	D006973	true

Sentence: Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.
Entity: 6637851	23	31	toxicity	Disease	D064420
Entity: 6637851	45	55	amiodarone	Chemical	D000638
Entity: 6637851	68	91	ventricular tachycardia	Disease	D017180
Entity: 6637851	95	119	ventricular fibrillation	Disease	D014693
Relation: 6637851	CID	45	55	D000638	23	31	D064420	false
Relation: 6637851	CID	45	55	D000638	68	91	D017180	false
Relation: 6637851	CID	45	55	D000638	95	119	D014693	false

Sentence: Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.
Entity: 6637851	0	10	Amiodarone	Chemical	D000638
Entity: 6637851	75	98	ventricular tachycardia	Disease	D017180
Entity: 6637851	100	102	VT	Disease	D017180
Entity: 6637851	119	133	cardiac arrest	Disease	D006323
Relation: 6637851	CID	0	10	D000638	75	98	D017180	false
Relation: 6637851	CID	0	10	D000638	100	102	D017180	false
Relation: 6637851	CID	0	10	D000638	119	133	D006323	false

Sentence: Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).
Entity: 6637851	56	66	amiodarone	Chemical	D000638
Entity: 6637851	104	106	VT	Disease	D017180
Entity: 6637851	110	134	ventricular fibrillation	Disease	D014693
Entity: 6637851	136	138	VF	Disease	D014693
Relation: 6637851	CID	56	66	D000638	104	106	D017180	false
Relation: 6637851	CID	56	66	D000638	110	134	D014693	false
Relation: 6637851	CID	56	66	D000638	136	138	D014693	false

Sentence: Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug.
Entity: 6637851	57	59	VT	Disease	D017180
Entity: 6637851	104	114	amiodarone	Chemical	D000638
Relation: 6637851	CID	104	114	D000638	57	59	D017180	false

Sentence: Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.
Entity: 6637851	20	30	amiodarone	Chemical	D000638
Entity: 6637851	81	83	VT	Disease	D017180
Entity: 6637851	87	89	VF	Disease	D014693
Entity: 6637851	161	169	toxicity	Disease	D064420
Relation: 6637851	CID	20	30	D000638	81	83	D017180	false
Relation: 6637851	CID	20	30	D000638	87	89	D014693	false
Relation: 6637851	CID	20	30	D000638	161	169	D064420	false

Sentence: Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.
Entity: 8800187	10	26	calcium chloride	Chemical	D002122
Entity: 8800187	31	46	4-aminopyridine	Chemical	D015761
Entity: 8800187	58	69	desipramine	Chemical	D003891
Entity: 8800187	70	78	toxicity	Disease	D064420
Relation: 8800187	CID	10	26	D002122	70	78	D064420	false
Relation: 8800187	CID	31	46	D015761	70	78	D064420	false
Relation: 8800187	CID	58	69	D003891	70	78	D064420	false

Sentence: This study addressed the potential role of calcium channel blockade in tricyclic antidepressant induced hypotension.
Entity: 8800187	43	50	calcium	Chemical	D002118
Entity: 8800187	104	115	hypotension	Disease	D007022
Relation: 8800187	CID	43	50	D002118	104	115	D007022	false

Sentence: METHODS: Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker overdose.
Entity: 8800187	103	110	calcium	Chemical	D002118
Entity: 8800187	127	135	overdose	Disease	D062787
Relation: 8800187	CID	103	110	D002118	127	135	D062787	false

Sentence: Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and bradycardia.
Entity: 8800187	56	67	desipramine	Chemical	D003891
Entity: 8800187	82	93	hypotension	Disease	D007022
Entity: 8800187	117	128	bradycardia	Disease	D001919
Relation: 8800187	CID	56	67	D003891	82	93	D007022	true
Relation: 8800187	CID	56	67	D003891	117	128	D001919	true

Sentence: RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation.
Entity: 8800187	9	15	NaHCO3	Chemical	D017693
Entity: 8800187	41	52	hypotension	Disease	D007022
Relation: 8800187	CID	9	15	D017693	41	52	D007022	false

Sentence: The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.
Entity: 8800187	17	40	ventricular arrhythmias	Disease	D001145
Entity: 8800187	57	65	seizures	Disease	D012640
Entity: 8800187	84	89	CaCl2	Chemical	D002122
Relation: 8800187	CID	84	89	D002122	17	40	D001145	true
Relation: 8800187	CID	84	89	D002122	57	65	D012640	false

Sentence: CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant induced hypotension in rats.
Entity: 8800187	34	39	CaCl2	Chemical	D002122
Entity: 8800187	43	58	4-aminopyridine	Chemical	D015761
Entity: 8800187	108	119	hypotension	Disease	D007022
Relation: 8800187	CID	34	39	D002122	108	119	D007022	false
Relation: 8800187	CID	43	58	D015761	108	119	D007022	false

Sentence: CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity.
Entity: 8800187	0	5	CaCl2	Chemical	D002122
Entity: 8800187	39	53	cardiovascular	Disease	D002318
Entity: 8800187	58	65	central	Disease	D002493
Relation: 8800187	CID	0	5	D002122	39	53	D002318	false
Relation: 8800187	CID	0	5	D002122	58	65	D002493	false

Sentence: Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.
Entity: 7707116	17	37	13-cis-retinoic acid	Chemical	D015474
Entity: 7707116	55	68	neuroblastoma	Disease	D009447
Relation: 7707116	CID	17	37	D015474	55	68	D009447	false

Sentence: PURPOSE: Treatment of neuroblastoma cell lines with 13-cis-retinoic acid (cis-RA) can cause sustained inhibition of proliferation.
Entity: 7707116	22	35	neuroblastoma	Disease	D009447
Entity: 7707116	52	72	13-cis-retinoic acid	Chemical	D015474
Entity: 7707116	74	80	cis-RA	Chemical	D015474
Relation: 7707116	CID	52	72	D015474	22	35	D009447	false
Relation: 7707116	CID	74	80	D015474	22	35	D009447	false

Sentence: Since cis-RA has demonstrated clinical responses in neuroblastoma patients, it may be effective in preventing relapse after cytotoxic therapy.
Entity: 7707116	6	12	cis-RA	Chemical	D015474
Entity: 7707116	52	65	neuroblastoma	Disease	D009447
Relation: 7707116	CID	6	12	D015474	52	65	D009447	false

Sentence: This phase I trial was designed to determine the maximal-tolerated dosage (MTD), toxicities, and pharmacokinetics of cis-RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation (BMT).
Entity: 7707116	81	91	toxicities	Disease	D064420
Entity: 7707116	117	123	cis-RA	Chemical	D015474
Entity: 7707116	182	195	neuroblastoma	Disease	D009447
Relation: 7707116	CID	117	123	D015474	81	91	D064420	false
Relation: 7707116	CID	117	123	D015474	182	195	D009447	false

Sentence: All toxicities resolved after cis-RA was discontinued.
Entity: 7707116	4	14	toxicities	Disease	D064420
Entity: 7707116	30	36	cis-RA	Chemical	D015474
Relation: 7707116	CID	30	36	D015474	4	14	D064420	false

Sentence: The DLT included hypercalcemia, and may be predicted by serum cis-RA levels.
Entity: 7707116	17	30	hypercalcemia	Disease	D006934
Entity: 7707116	62	68	cis-RA	Chemical	D015474
Relation: 7707116	CID	62	68	D015474	17	30	D006934	true

Sentence: The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.
Entity: 6892185	14	30	calcium chloride	Chemical	D002122
Entity: 6892185	233	242	mydriasis	Disease	D015878
Entity: 6892185	244	250	tremor	Disease	D014202
Entity: 6892185	255	279	clonic-tonic convulsions	Disease	D004830
Entity: 6892185	292	301	carbachol	Chemical	D002217
Entity: 6892185	306	313	eserine	Chemical	D010830
Relation: 6892185	CID	14	30	D002122	233	242	D015878	false
Relation: 6892185	CID	14	30	D002122	244	250	D014202	false
Relation: 6892185	CID	14	30	D002122	255	279	D004830	false
Relation: 6892185	CID	292	301	D002217	233	242	D015878	true
Relation: 6892185	CID	292	301	D002217	244	250	D014202	true
Relation: 6892185	CID	292	301	D002217	255	279	D004830	true
Relation: 6892185	CID	306	313	D010830	233	242	D015878	true
Relation: 6892185	CID	306	313	D010830	244	250	D014202	true
Relation: 6892185	CID	306	313	D010830	255	279	D004830	true

Sentence: On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.
Entity: 6892185	19	28	mydriasis	Disease	D015878
Entity: 6892185	30	36	tremor	Disease	D014202
Entity: 6892185	41	65	clonic-tonic convulsions	Disease	D004830
Entity: 6892185	76	85	carbachol	Chemical	D002217
Entity: 6892185	90	97	eserine	Chemical	D010830
Entity: 6892185	132	148	calcium chloride	Chemical	D002122
Relation: 6892185	CID	76	85	D002217	19	28	D015878	true
Relation: 6892185	CID	76	85	D002217	30	36	D014202	true
Relation: 6892185	CID	76	85	D002217	41	65	D004830	true
Relation: 6892185	CID	90	97	D010830	19	28	D015878	true
Relation: 6892185	CID	90	97	D010830	30	36	D014202	true
Relation: 6892185	CID	90	97	D010830	41	65	D004830	true
Relation: 6892185	CID	132	148	D002122	19	28	D015878	false
Relation: 6892185	CID	132	148	D002122	30	36	D014202	false
Relation: 6892185	CID	132	148	D002122	41	65	D004830	false

Sentence: It is apparent that calcium chloride can "dissociate" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.
Entity: 6892185	20	36	calcium chloride	Chemical	D002122
Entity: 6892185	123	132	mydriasis	Disease	D015878
Entity: 6892185	134	140	tremor	Disease	D014202
Entity: 6892185	145	169	clonic-tonic convulsions	Disease	D004830
Entity: 6892185	180	189	carbachol	Chemical	D002217
Entity: 6892185	194	201	eserine	Chemical	D010830
Relation: 6892185	CID	20	36	D002122	123	132	D015878	false
Relation: 6892185	CID	20	36	D002122	134	140	D014202	false
Relation: 6892185	CID	20	36	D002122	145	169	D004830	false
Relation: 6892185	CID	180	189	D002217	123	132	D015878	true
Relation: 6892185	CID	180	189	D002217	134	140	D014202	true
Relation: 6892185	CID	180	189	D002217	145	169	D004830	true
Relation: 6892185	CID	194	201	D010830	123	132	D015878	true
Relation: 6892185	CID	194	201	D010830	134	140	D014202	true
Relation: 6892185	CID	194	201	D010830	145	169	D004830	true

Sentence: Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis.
Entity: 6216862	25	38	penicillamine	Chemical	D010396
Entity: 6216862	67	87	rheumatoid arthritis	Disease	D001172
Relation: 6216862	CID	25	38	D010396	67	87	D001172	false

Sentence: Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.
Entity: 6216862	0	11	Skin rashes	Disease	D005076
Entity: 6216862	13	24	proteinuria	Disease	D011507
Entity: 6216862	26	54	systemic lupus erythematosus	Disease	D008180
Entity: 6216862	56	68	polymyositis	Disease	D017285
Entity: 6216862	73	90	myasthenia gravis	Disease	D009157
Entity: 6216862	134	147	penicillamine	Chemical	D010396
Entity: 6216862	173	193	rheumatoid arthritis	Disease	D001172
Relation: 6216862	CID	134	147	D010396	0	11	D005076	true
Relation: 6216862	CID	134	147	D010396	13	24	D011507	true
Relation: 6216862	CID	134	147	D010396	26	54	D008180	true
Relation: 6216862	CID	134	147	D010396	56	68	D017285	true
Relation: 6216862	CID	134	147	D010396	73	90	D009157	true
Relation: 6216862	CID	134	147	D010396	173	193	D001172	false

Sentence: Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.
Entity: 2004	53	61	Mellaril	Chemical	D013881
Entity: 2004	63	75	thioridazine	Chemical	D013881
Entity: 2004	122	145	ventricular tachycardia	Disease	D017180
Relation: 2004	CID	53	61	D013881	122	145	D017180	true
Relation: 2004	CID	63	75	D013881	122	145	D017180	true

Sentence: Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).
Entity: 2004	0	28	Supraventricular tachycardia	Disease	D013617
Entity: 2004	64	73	Thorazine	Chemical	D002746
Entity: 2004	75	89	chlorpromazine	Chemical	D002746
Relation: 2004	CID	64	73	D002746	0	28	D013617	false
Relation: 2004	CID	75	89	D002746	0	28	D013617	false

Sentence: Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.
Entity: 2004	0	7	Aventyl	Chemical	D009661
Entity: 2004	9	22	nortriptyline	Chemical	D009661
Entity: 2004	28	34	Elavil	Chemical	D000639
Entity: 2004	36	49	amitriptyline	Chemical	D000639
Entity: 2004	65	89	left bundle branch block	Disease	D002037
Relation: 2004	CID	0	7	D009661	65	89	D002037	true
Relation: 2004	CID	9	22	D009661	65	89	D002037	true
Relation: 2004	CID	28	34	D000639	65	89	D002037	true
Relation: 2004	CID	36	49	D000639	65	89	D002037	true

Sentence: The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.
Entity: 2004	4	27	ventricular arrhythmias	Disease	D001145
Entity: 2004	71	80	lidocaine	Chemical	D008012
Entity: 2004	203	214	propranolol	Chemical	D011433
Relation: 2004	CID	71	80	D008012	4	27	D001145	false
Relation: 2004	CID	203	214	D011433	4	27	D001145	false

Sentence: Serotonergic drugs, benzodiazepines and baclofen block muscimol induced myoclonic jerks in a strain of mice.
Entity: 6118280	20	35	benzodiazepines	Chemical	D001569
Entity: 6118280	40	48	baclofen	Chemical	D001418
Entity: 6118280	55	63	muscimol	Chemical	D009118
Entity: 6118280	72	87	myoclonic jerks	Disease	D009207
Relation: 6118280	CID	20	35	D001569	72	87	D009207	false
Relation: 6118280	CID	40	48	D001418	72	87	D009207	false
Relation: 6118280	CID	55	63	D009118	72	87	D009207	true

Sentence: In male Swiss mice, muscimol produced myoclonic jerks.
Entity: 6118280	20	28	muscimol	Chemical	D009118
Entity: 6118280	38	53	myoclonic jerks	Disease	D009207
Relation: 6118280	CID	20	28	D009118	38	53	D009207	true

Sentence: Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.
Entity: 6118280	7	22	benzodiazepines	Chemical	D001569
Entity: 6118280	24	34	clonazepam	Chemical	D002998
Entity: 6118280	97	105	diazepam	Chemical	D003975
Entity: 6118280	136	151	myoclonic jerks	Disease	D009207
Relation: 6118280	CID	7	22	D001569	136	151	D009207	false
Relation: 6118280	CID	24	34	D002998	136	151	D009207	false
Relation: 6118280	CID	97	105	D003975	136	151	D009207	false

Sentence: Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.
Entity: 6118280	26	31	5-HTP	Chemical	D006916
Entity: 6118280	40	55	benzodiazepines	Chemical	D001569
Entity: 6118280	119	128	myoclonus	Disease	D009207
Entity: 6118280	134	142	muscimol	Chemical	D009118
Entity: 6118280	151	160	myoclonus	Disease	D009207
Relation: 6118280	CID	26	31	D006916	119	128	D009207	false
Relation: 6118280	CID	26	31	D006916	151	160	D009207	false
Relation: 6118280	CID	40	55	D001569	119	128	D009207	false
Relation: 6118280	CID	40	55	D001569	151	160	D009207	false
Relation: 6118280	CID	134	142	D009118	119	128	D009207	true
Relation: 6118280	CID	134	142	D009118	151	160	D009207	true

Sentence: Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.
Entity: 3703509	33	43	prednisone	Chemical	D011241
Entity: 3703509	65	73	lethargy	Disease	D053609
Entity: 3703509	86	96	somnolence	Disease	D006970
Entity: 3703509	98	108	polydipsia	Disease	D059606
Entity: 3703509	110	120	polyphagia	Disease	D006963
Entity: 3703509	126	134	polyuria	Disease	D011141
Relation: 3703509	CID	33	43	D011241	65	73	D053609	false
Relation: 3703509	CID	33	43	D011241	86	96	D006970	false
Relation: 3703509	CID	33	43	D011241	98	108	D059606	false
Relation: 3703509	CID	33	43	D011241	110	120	D006963	false
Relation: 3703509	CID	33	43	D011241	126	134	D011141	false

Sentence: Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.
Entity: 3703509	11	26	lactic acidosis	Disease	D000140
Entity: 3703509	50	57	ketosis	Disease	D007662
Entity: 3703509	80	87	lactate	Chemical	D019344
Relation: 3703509	CID	80	87	D019344	11	26	D000140	false
Relation: 3703509	CID	80	87	D019344	50	57	D007662	false

Sentence: Effects of active constituents of Crocus sativus L., crocin on streptozocin induced model of sporadic Alzheimer's disease in male rats.
Entity: 20683499	53	59	crocin	Chemical	C029036
Entity: 20683499	63	75	streptozocin	Chemical	D013311
Entity: 20683499	102	121	Alzheimer's disease	Disease	D000544
Relation: 20683499	CID	53	59	C029036	102	121	D000544	false
Relation: 20683499	CID	63	75	D013311	102	121	D000544	true

Sentence: In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.
Entity: 20683499	36	43	crocins	Chemical	C029036
Entity: 20683499	56	75	Alzheimer's disease	Disease	D000544
Entity: 20683499	117	129	streptozocin	Chemical	D013311
Entity: 20683499	131	134	STZ	Chemical	D013311
Relation: 20683499	CID	36	43	C029036	56	75	D000544	false
Relation: 20683499	CID	117	129	D013311	56	75	D000544	true
Relation: 20683499	CID	131	134	D013311	56	75	D000544	true

Sentence: In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.
Entity: 20683499	3	22	Alzheimer's disease	Disease	D000544
Entity: 20683499	55	58	STZ	Chemical	D013311
Entity: 20683499	126	129	STZ	Chemical	D013311
Relation: 20683499	CID	55	58	D013311	3	22	D000544	true
Relation: 20683499	CID	126	129	D013311	3	22	D000544	true

Sentence: In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test.
Entity: 20683499	13	19	crocin	Chemical	C029036
Entity: 20683499	73	81	learning	Disease	D007859
Entity: 20683499	86	92	memory	Disease	D008569
Entity: 20683499	115	118	STZ	Chemical	D013311
Relation: 20683499	CID	13	19	C029036	73	81	D007859	false
Relation: 20683499	CID	13	19	C029036	86	92	D008569	false
Relation: 20683499	CID	115	118	D013311	73	81	D007859	false
Relation: 20683499	CID	115	118	D013311	86	92	D008569	false

Sentence: Rosaceiform dermatitis associated with topical tacrolimus treatment.
Entity: 20466178	12	22	dermatitis	Disease	D003872
Entity: 20466178	47	57	tacrolimus	Chemical	D016559
Relation: 20466178	CID	47	57	D016559	12	22	D003872	false

Sentence: We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.
Entity: 20466178	44	51	rosacea	Disease	D012393
Entity: 20466178	57	67	dermatitis	Disease	D003872
Entity: 20466178	68	77	eruptions	Disease	D003875
Entity: 20466178	104	114	tacrolimus	Chemical	D016559
Entity: 20466178	128	145	facial dermatitis	Disease	D005148
Relation: 20466178	CID	104	114	D016559	44	51	D012393	false
Relation: 20466178	CID	104	114	D016559	57	67	D003872	false
Relation: 20466178	CID	104	114	D016559	68	77	D003875	false
Relation: 20466178	CID	104	114	D016559	128	145	D005148	false

Sentence: Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.
Entity: 19944736	0	7	Tacrine	Chemical	D013619
Entity: 19944736	25	29	LiCl	Chemical	D018021
Entity: 19944736	78	86	seizures	Disease	D012640
Entity: 19944736	99	117	hippocampal damage	Disease	D001930
Relation: 19944736	CID	0	7	D013619	78	86	D012640	true
Relation: 19944736	CID	0	7	D013619	99	117	D001930	true
Relation: 19944736	CID	25	29	D018021	78	86	D012640	true
Relation: 19944736	CID	25	29	D018021	99	117	D001930	true

Sentence: All the animals treated with tacrine-loaded nanoparticles showed an earlier outcome of CNS adverse symptoms, i.e. epileptic onset, with respect to those animals treated with the free compound (10 min vs. 22 min respectively).
Entity: 19944736	29	36	tacrine	Chemical	D013619
Entity: 19944736	114	123	epileptic	Disease	D004827
Relation: 19944736	CID	29	36	D013619	114	123	D004827	false

Sentence: In addition, tacrine-loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.
Entity: 19944736	13	20	tacrine	Chemical	D013619
Entity: 19944736	65	89	damage of neuronal cells	Disease	D001930
Entity: 19944736	175	182	tacrine	Chemical	D013619
Relation: 19944736	CID	13	20	D013619	65	89	D001930	true
Relation: 19944736	CID	175	182	D013619	65	89	D001930	true

Sentence: This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine induced rat and ouabain induced guinea pig arrhythmia models.
Entity: 19721134	51	62	pilocarpine	Chemical	D010862
Entity: 19721134	118	127	aconitine	Chemical	D000157
Entity: 19721134	144	151	ouabain	Chemical	D010042
Entity: 19721134	171	181	arrhythmia	Disease	D001145
Relation: 19721134	CID	51	62	D010862	171	181	D001145	false
Relation: 19721134	CID	118	127	D000157	171	181	D001145	true
Relation: 19721134	CID	144	151	D010042	171	181	D001145	true

Sentence: The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.
Entity: 19721134	29	40	pilocarpine	Chemical	D010862
Entity: 19721134	72	83	arrhythmias	Disease	D001145
Entity: 19721134	114	125	ventricular	Disease	D017180
Entity: 19721134	114	125	ventricular	Disease	D014693
Entity: 19721134	164	174	arrhythmia	Disease	D001145
Entity: 19721134	217	227	arrhythmic	Disease	D001145
Entity: 19721134	251	253	Ca	Chemical	D002118
Entity: 19721134	282	291	aconitine	Chemical	D000157
Entity: 19721134	295	302	ouabain	Chemical	D010042
Entity: 19721134	352	363	pilocarpine	Chemical	D010862
Relation: 19721134	CID	29	40	D010862	72	83	D001145	false
Relation: 19721134	CID	29	40	D010862	114	125	D017180	false
Relation: 19721134	CID	29	40	D010862	114	125	D014693	false
Relation: 19721134	CID	29	40	D010862	164	174	D001145	false
Relation: 19721134	CID	29	40	D010862	217	227	D001145	false
Relation: 19721134	CID	251	253	D002118	72	83	D001145	false
Relation: 19721134	CID	251	253	D002118	114	125	D017180	false
Relation: 19721134	CID	251	253	D002118	114	125	D014693	false
Relation: 19721134	CID	251	253	D002118	164	174	D001145	false
Relation: 19721134	CID	251	253	D002118	217	227	D001145	false
Relation: 19721134	CID	282	291	D000157	72	83	D001145	true
Relation: 19721134	CID	282	291	D000157	114	125	D017180	false
Relation: 19721134	CID	282	291	D000157	114	125	D014693	false
Relation: 19721134	CID	282	291	D000157	164	174	D001145	true
Relation: 19721134	CID	282	291	D000157	217	227	D001145	true
Relation: 19721134	CID	295	302	D010042	72	83	D001145	true
Relation: 19721134	CID	295	302	D010042	114	125	D017180	false
Relation: 19721134	CID	295	302	D010042	114	125	D014693	false
Relation: 19721134	CID	295	302	D010042	164	174	D001145	true
Relation: 19721134	CID	295	302	D010042	217	227	D001145	true
Relation: 19721134	CID	352	363	D010862	72	83	D001145	false
Relation: 19721134	CID	352	363	D010862	114	125	D017180	false
Relation: 19721134	CID	352	363	D010862	114	125	D014693	false
Relation: 19721134	CID	352	363	D010862	164	174	D001145	false
Relation: 19721134	CID	352	363	D010862	217	227	D001145	false

Sentence: These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR.
Entity: 19721134	24	35	pilocarpine	Chemical	D010862
Entity: 19721134	71	81	arrhythmic	Disease	D001145
Entity: 19721134	119	128	aconitine	Chemical	D000157
Entity: 19721134	132	139	ouabain	Chemical	D010042
Relation: 19721134	CID	24	35	D010862	71	81	D001145	false
Relation: 19721134	CID	119	128	D000157	71	81	D001145	true
Relation: 19721134	CID	132	139	D010042	71	81	D001145	true

Sentence: Disulfiram induced transient optic and peripheral neuropathy: a case report.
Entity: 17786501	0	10	Disulfiram	Chemical	D004221
Entity: 17786501	29	34	optic	Disease	D009901
Entity: 17786501	39	49	peripheral	Disease	D010523
Relation: 17786501	CID	0	10	D004221	29	34	D009901	true
Relation: 17786501	CID	0	10	D004221	39	49	D010523	false

Sentence: AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.
Entity: 17786501	25	30	optic	Disease	D009901
Entity: 17786501	35	45	peripheral	Disease	D010523
Entity: 17786501	78	88	disulfiram	Chemical	D004221
Entity: 17786501	93	111	alcohol dependence	Disease	D000437
Relation: 17786501	CID	78	88	D004221	25	30	D009901	true
Relation: 17786501	CID	78	88	D004221	35	45	D010523	false
Relation: 17786501	CID	78	88	D004221	93	111	D000437	false

Sentence: He had been taking disulfiram for alcohol dependence for the preceding 3 years.
Entity: 17786501	19	29	disulfiram	Chemical	D004221
Entity: 17786501	34	52	alcohol dependence	Disease	D000437
Relation: 17786501	CID	19	29	D004221	34	52	D000437	false

Sentence: Sustained clinical improvement of a patient with decompensated hepatitis B virus-related cirrhosis after treatment with lamivudine monotherapy.
Entity: 16960342	63	74	hepatitis B	Disease	D006509
Entity: 16960342	89	98	cirrhosis	Disease	D005355
Entity: 16960342	120	130	lamivudine	Chemical	D019259
Relation: 16960342	CID	120	130	D019259	63	74	D006509	false
Relation: 16960342	CID	120	130	D019259	89	98	D005355	false

Sentence: Dual effects of melatonin on barbiturate induced narcosis in rats.
Entity: 11226639	16	25	melatonin	Chemical	D008550
Entity: 11226639	29	40	barbiturate	Chemical	C032232
Entity: 11226639	49	57	narcosis	Disease	D053608
Relation: 11226639	CID	16	25	D008550	49	57	D053608	true
Relation: 11226639	CID	29	40	C032232	49	57	D053608	false

Sentence: Melatonin affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug induced narcosis.
Entity: 11226639	0	9	Melatonin	Chemical	D008550
Entity: 11226639	108	116	narcosis	Disease	D053608
Relation: 11226639	CID	0	9	D008550	108	116	D053608	true

Sentence: Melatonin pre-treatment affected in a dual manner barbiturate narcosis, however, no dose-effect correlation was found.
Entity: 11226639	0	9	Melatonin	Chemical	D008550
Entity: 11226639	50	61	barbiturate	Chemical	C032232
Entity: 11226639	62	70	narcosis	Disease	D053608
Relation: 11226639	CID	0	9	D008550	62	70	D053608	true
Relation: 11226639	CID	50	61	C032232	62	70	D053608	false

Sentence: In particular, low doses reduced the latency to and prolonged the duration of barbiturate narcosis.
Entity: 11226639	78	89	barbiturate	Chemical	C032232
Entity: 11226639	90	98	narcosis	Disease	D053608
Relation: 11226639	CID	78	89	C032232	90	98	D053608	false

Sentence: In contrast, the highest dose of melatonin (50 mg/kg) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis, and a reduction in mortality rate.
Entity: 11226639	33	42	melatonin	Chemical	D008550
Entity: 11226639	153	161	narcosis	Disease	D053608
Relation: 11226639	CID	33	42	D008550	153	161	D053608	true

Sentence: Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam induced narcosis.
Entity: 11226639	0	9	Melatonin	Chemical	D008550
Entity: 11226639	73	81	ketamine	Chemical	D007649
Entity: 11226639	86	94	diazepam	Chemical	D003975
Entity: 11226639	103	111	narcosis	Disease	D053608
Relation: 11226639	CID	0	9	D008550	103	111	D053608	true
Relation: 11226639	CID	73	81	D007649	103	111	D053608	true
Relation: 11226639	CID	86	94	D003975	103	111	D053608	true

Sentence: Effects of NIK-247 on cholinesterase and scopolamine induced amnesia.
Entity: 9228650	11	18	NIK-247	Chemical	C049860
Entity: 9228650	41	52	scopolamine	Chemical	D012601
Entity: 9228650	61	68	amnesia	Disease	D000647
Relation: 9228650	CID	11	18	C049860	61	68	D000647	true
Relation: 9228650	CID	41	52	D012601	61	68	D000647	true

Sentence: The effects of NIK-247 on cholinesterase, scopolamine induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.
Entity: 9228650	15	22	NIK-247	Chemical	C049860
Entity: 9228650	42	53	scopolamine	Chemical	D012601
Entity: 9228650	62	69	amnesia	Disease	D000647
Entity: 9228650	177	184	tacrine	Chemical	D013619
Entity: 9228650	189	195	E-2020	Chemical	C076946
Relation: 9228650	CID	15	22	C049860	62	69	D000647	true
Relation: 9228650	CID	42	53	D012601	62	69	D000647	true
Relation: 9228650	CID	177	184	D013619	62	69	D000647	true
Relation: 9228650	CID	189	195	C076946	62	69	D000647	true

Sentence: All compounds at 0.1-1 mg/kg p.o. significantly improved the amnesia induced by scopolamine (0.5 mg/kg s.c.) in rats performing a passive avoidance task.
Entity: 9228650	61	68	amnesia	Disease	D000647
Entity: 9228650	80	91	scopolamine	Chemical	D012601
Relation: 9228650	CID	80	91	D012601	61	68	D000647	true

Sentence: These findings suggest that NIK-247 at a low dose (0.1-1 mg/kg p.o.) improves scopolamine induced amnesia but does not affect spontaneous movement.
Entity: 9228650	28	35	NIK-247	Chemical	C049860
Entity: 9228650	78	89	scopolamine	Chemical	D012601
Entity: 9228650	98	105	amnesia	Disease	D000647
Relation: 9228650	CID	28	35	C049860	98	105	D000647	true
Relation: 9228650	CID	78	89	D012601	98	105	D000647	true

Sentence: Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants.
Entity: 8766220	15	29	hallucinations	Disease	D006212
Entity: 8766220	56	64	tramadol	Chemical	D014147
Relation: 8766220	CID	56	64	D014147	15	29	D006212	true

Sentence: Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.
Entity: 8766220	0	8	Tramadol	Chemical	D014147
Entity: 8766220	110	116	cancer	Disease	D009369
Entity: 8766220	117	121	pain	Disease	D010146
Entity: 8766220	148	152	pain	Disease	D010146
Relation: 8766220	CID	0	8	D014147	110	116	D009369	false
Relation: 8766220	CID	0	8	D014147	117	121	D010146	false
Relation: 8766220	CID	0	8	D014147	148	152	D010146	false

Sentence: This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.
Entity: 8766220	44	54	paroxetine	Chemical	D017374
Entity: 8766220	59	83	dosulepine hydrochloride	Chemical	D004308
Entity: 8766220	89	101	tetraparetic	Disease	-1
Entity: 8766220	115	127	chronic pain	Disease	D059350
Relation: 8766220	CID	44	54	D017374	89	101	-1	false
Relation: 8766220	CID	44	54	D017374	115	127	D059350	false
Relation: 8766220	CID	59	83	D004308	89	101	-1	false
Relation: 8766220	CID	59	83	D004308	115	127	D059350	false

Sentence: Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and tramadol.
Entity: 8766220	71	85	hallucinations	Disease	D006212
Entity: 8766220	152	160	tramadol	Chemical	D014147
Relation: 8766220	CID	152	160	D014147	71	85	D006212	true

Sentence: BMT was used to treat severe aplastic anemia which was caused by gold in one case and D-penicillamine in the other.
Entity: 8441146	29	44	aplastic anemia	Disease	D000741
Entity: 8441146	65	69	gold	Chemical	D006046
Entity: 8441146	86	101	D-penicillamine	Chemical	D010396
Relation: 8441146	CID	65	69	D006046	29	44	D000741	true
Relation: 8441146	CID	86	101	D010396	29	44	D000741	true

Sentence: Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.
Entity: 3653576	0	41	Acute experimental models of renal damage	Disease	D058186
Entity: 3653576	147	171	hexachloro-1:3-butadiene	Chemical	C001335
Entity: 3653576	173	177	HCBD	Chemical	C001335
Entity: 3653576	180	205	puromycin aminonucleoside	Chemical	D011692
Entity: 3653576	207	210	PAN	Chemical	D011692
Entity: 3653576	217	234	2-bromoethylamine	Chemical	C004504
Entity: 3653576	236	239	BEA	Chemical	C004504
Relation: 3653576	CID	147	171	C001335	0	41	D058186	true
Relation: 3653576	CID	173	177	C001335	0	41	D058186	true
Relation: 3653576	CID	180	205	D011692	0	41	D058186	true
Relation: 3653576	CID	207	210	D011692	0	41	D058186	true
Relation: 3653576	CID	217	234	C004504	0	41	D058186	true
Relation: 3653576	CID	236	239	C004504	0	41	D058186	true

Sentence: Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.
Entity: 3653576	27	31	HCBD	Chemical	C001335
Entity: 3653576	35	38	BEA	Chemical	C004504
Entity: 3653576	100	117	glomerular damage	Disease	D007674
Entity: 3653576	130	133	PAN	Chemical	D011692
Relation: 3653576	CID	27	31	C001335	100	117	D007674	false
Relation: 3653576	CID	35	38	C004504	100	117	D007674	false
Relation: 3653576	CID	130	133	D011692	100	117	D007674	false

Sentence: Neuromuscular blockade with magnesium sulfate and nifedipine.
Entity: 2750819	0	22	Neuromuscular blockade	Disease	D020879
Entity: 2750819	28	45	magnesium sulfate	Chemical	D008278
Entity: 2750819	50	60	nifedipine	Chemical	D009543
Relation: 2750819	CID	28	45	D008278	0	22	D020879	true
Relation: 2750819	CID	50	60	D009543	0	22	D020879	true

Sentence: A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.
Entity: 2750819	38	48	nifedipine	Chemical	D009543
Entity: 2750819	59	81	neuromuscular blockade	Disease	D020879
Entity: 2750819	98	115	magnesium sulfate	Chemical	D008278
Relation: 2750819	CID	38	48	D009543	59	81	D020879	true
Relation: 2750819	CID	98	115	D008278	59	81	D020879	true

Sentence: The frequency and predictability of hematuria are not precise, and at least daily monitoring by urine Hematest is essential, adding Mesna to the infusate in patients with persistent hematuria.
Entity: 1899352	36	45	hematuria	Disease	D006417
Entity: 1899352	132	137	Mesna	Chemical	D015080
Entity: 1899352	182	191	hematuria	Disease	D006417
Relation: 1899352	CID	132	137	D015080	36	45	D006417	false
Relation: 1899352	CID	132	137	D015080	182	191	D006417	false

Sentence: Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction: a case report.
Entity: 18161408	0	21	Myocardial infarction	Disease	D009203
Entity: 18161408	51	69	clomiphene citrate	Chemical	D002996
Relation: 18161408	CID	51	69	D002996	0	21	D009203	true

Sentence: Thromboembolism is a rare but life-threatening complication that has been reported after ovulation induction with CC.
Entity: 18161408	0	15	Thromboembolism	Disease	D013923
Entity: 18161408	114	116	CC	Chemical	D002996
Relation: 18161408	CID	114	116	D002996	0	15	D013923	true

Sentence: CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.
Entity: 18161408	72	74	CC	Chemical	D002996
Entity: 18161408	118	128	chest pain	Disease	D002637
Relation: 18161408	CID	72	74	D002996	118	128	D002637	false

Sentence: CONCLUSION: This appears to be the first reported case documenting a possible association between CC and myocardial infarction.
Entity: 18161408	98	100	CC	Chemical	D002996
Entity: 18161408	105	126	myocardial infarction	Disease	D009203
Relation: 18161408	CID	98	100	D002996	105	126	D009203	true

Sentence: Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.
Entity: 17574447	0	14	Hepatonecrosis	Disease	-1
Entity: 17574447	19	30	cholangitis	Disease	D002761
Entity: 17574447	52	65	phenobarbital	Chemical	D010634
Relation: 17574447	CID	52	65	D010634	0	14	-1	false
Relation: 17574447	CID	52	65	D010634	19	30	D002761	true

Sentence: Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.
Entity: 17574447	0	13	Phenobarbital	Chemical	D010634
Entity: 17574447	15	17	PB	Chemical	D010634
Entity: 17574447	81	83	PB	Chemical	D010634
Entity: 17574447	201	214	liver disease	Disease	D008107
Relation: 17574447	CID	0	13	D010634	201	214	D008107	true
Relation: 17574447	CID	15	17	D010634	201	214	D008107	true
Relation: 17574447	CID	81	83	D010634	201	214	D008107	true

Sentence: Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.
Entity: 17574447	60	68	epilepsy	Disease	D004827
Entity: 17574447	82	84	PB	Chemical	D010634
Entity: 17574447	126	140	cardiac arrest	Disease	D006323
Entity: 17574447	161	177	bronchopneumonia	Disease	D001996
Relation: 17574447	CID	82	84	D010634	60	68	D004827	false
Relation: 17574447	CID	82	84	D010634	126	140	D006323	false
Relation: 17574447	CID	82	84	D010634	161	177	D001996	false

Sentence: Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.
Entity: 17574447	29	31	PB	Chemical	D010634
Entity: 17574447	63	75	liver damage	Disease	D008107
Relation: 17574447	CID	29	31	D010634	63	75	D008107	true

Sentence: Ethambutol-associated optic neuropathy.
Entity: 16710500	0	10	Ethambutol	Chemical	D004977
Entity: 16710500	22	38	optic neuropathy	Disease	D009901
Relation: 16710500	CID	0	10	D004977	22	38	D009901	true

Sentence: INTRODUCTION: Ethambutol is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.
Entity: 16710500	14	24	Ethambutol	Chemical	D004977
Entity: 16710500	53	65	tuberculosis	Disease	D014376
Entity: 16710500	148	159	visual loss	Disease	D014786
Relation: 16710500	CID	14	24	D004977	53	65	D014376	false
Relation: 16710500	CID	14	24	D004977	148	159	D014786	true

Sentence: CLINICAL PICTURE: Three patients with ethambutol-associated toxic optic neuropathy are described.
Entity: 16710500	38	48	ethambutol	Chemical	D004977
Entity: 16710500	66	82	optic neuropathy	Disease	D009901
Relation: 16710500	CID	38	48	D004977	66	82	D009901	true

Sentence: CONCLUSIONS: Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow-up.
Entity: 16710500	13	23	Ethambutol	Chemical	D004977
Entity: 16710500	59	70	visual loss	Disease	D014786
Relation: 16710500	CID	13	23	D004977	59	70	D014786	true

Sentence: Tolerability of nimesulide and paracetamol in patients with NSAID induced urticaria/angioedema.
Entity: 11694026	16	26	nimesulide	Chemical	C012655
Entity: 11694026	31	42	paracetamol	Chemical	D000082
Entity: 11694026	60	65	NSAID	Chemical	D000894
Entity: 11694026	74	83	urticaria	Disease	D014581
Entity: 11694026	84	94	angioedema	Disease	D000799
Relation: 11694026	CID	16	26	C012655	74	83	D014581	false
Relation: 11694026	CID	16	26	C012655	84	94	D000799	true
Relation: 11694026	CID	31	42	D000082	74	83	D014581	false
Relation: 11694026	CID	31	42	D000082	84	94	D000799	true
Relation: 11694026	CID	60	65	D000894	74	83	D014581	false
Relation: 11694026	CID	60	65	D000894	84	94	D000799	true

Sentence: In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID induced urticaria/angioedema.
Entity: 11694026	62	72	nimesulide	Chemical	C012655
Entity: 11694026	77	88	paracetamol	Chemical	D000082
Entity: 11694026	169	174	NSAID	Chemical	D000894
Entity: 11694026	183	192	urticaria	Disease	D014581
Entity: 11694026	193	203	angioedema	Disease	D000799
Relation: 11694026	CID	62	72	C012655	183	192	D014581	false
Relation: 11694026	CID	62	72	C012655	193	203	D000799	true
Relation: 11694026	CID	77	88	D000082	183	192	D014581	false
Relation: 11694026	CID	77	88	D000082	193	203	D000799	true
Relation: 11694026	CID	169	174	D000894	183	192	D014581	false
Relation: 11694026	CID	169	174	D000894	193	203	D000799	true

Sentence: A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID induced urticaria/angioedema.
Entity: 11694026	58	68	nimesulide	Chemical	C012655
Entity: 11694026	72	83	paracetamol	Chemical	D000082
Entity: 11694026	130	135	NSAID	Chemical	D000894
Entity: 11694026	144	153	urticaria	Disease	D014581
Entity: 11694026	154	164	angioedema	Disease	D000799
Relation: 11694026	CID	58	68	C012655	144	153	D014581	false
Relation: 11694026	CID	58	68	C012655	154	164	D000799	true
Relation: 11694026	CID	72	83	D000082	144	153	D014581	false
Relation: 11694026	CID	72	83	D000082	154	164	D000799	true
Relation: 11694026	CID	130	135	D000894	144	153	D014581	false
Relation: 11694026	CID	130	135	D000894	154	164	D000799	true

Sentence: Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of NSAID induced urticaria/angioedema or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.
Entity: 11694026	58	67	urticaria	Disease	D014581
Entity: 11694026	109	114	NSAID	Chemical	D000894
Entity: 11694026	123	132	urticaria	Disease	D014581
Entity: 11694026	133	143	angioedema	Disease	D000799
Entity: 11694026	147	157	angioedema	Disease	D000799
Entity: 11694026	189	198	urticaria	Disease	D014581
Relation: 11694026	CID	109	114	D000894	58	67	D014581	false
Relation: 11694026	CID	109	114	D000894	123	132	D014581	false
Relation: 11694026	CID	109	114	D000894	133	143	D000799	true
Relation: 11694026	CID	109	114	D000894	147	157	D000799	true
Relation: 11694026	CID	109	114	D000894	189	198	D014581	false

Sentence: Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.
Entity: 11694026	61	71	nimesulide	Chemical	C012655
Entity: 11694026	76	87	paracetamol	Chemical	D000082
Entity: 11694026	116	125	urticaria	Disease	D014581
Entity: 11694026	126	136	angioedema	Disease	D000799
Entity: 11694026	147	153	NSAIDs	Chemical	D000894
Relation: 11694026	CID	61	71	C012655	116	125	D014581	false
Relation: 11694026	CID	61	71	C012655	126	136	D000799	true
Relation: 11694026	CID	76	87	D000082	116	125	D014581	false
Relation: 11694026	CID	76	87	D000082	126	136	D000799	true
Relation: 11694026	CID	147	153	D000894	116	125	D014581	false
Relation: 11694026	CID	147	153	D000894	126	136	D000799	true

Sentence: Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs.
Entity: 11282081	11	20	verapamil	Chemical	D014700
Entity: 11282081	24	43	atrial fibrillation	Disease	D001281
Relation: 11282081	CID	11	20	D014700	24	43	D001281	true

Sentence: BACKGROUND: Atrial tachycardia induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.
Entity: 11282081	12	30	Atrial tachycardia	Disease	D013617
Entity: 11282081	93	112	atrial fibrillation	Disease	D001281
Entity: 11282081	114	116	AF	Disease	D001281
Entity: 11282081	139	141	Ca	Chemical	D002118
Relation: 11282081	CID	139	141	D002118	12	30	D013617	false
Relation: 11282081	CID	139	141	D002118	93	112	D001281	false
Relation: 11282081	CID	139	141	D002118	114	116	D001281	false

Sentence: There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.
Entity: 11282081	54	56	Ca	Chemical	D002118
Entity: 11282081	89	91	AF	Disease	D001281
Entity: 11282081	112	114	AF	Disease	D001281
Entity: 11282081	135	137	Ca	Chemical	D002118
Relation: 11282081	CID	54	56	D002118	89	91	D001281	false
Relation: 11282081	CID	54	56	D002118	112	114	D001281	false
Relation: 11282081	CID	135	137	D002118	89	91	D001281	false
Relation: 11282081	CID	135	137	D002118	112	114	D001281	false

Sentence: METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.
Entity: 11282081	49	51	AF	Disease	D001281
Entity: 11282081	65	67	Ca	Chemical	D002118
Entity: 11282081	106	115	verapamil	Chemical	D014700
Entity: 11282081	119	127	morphine	Chemical	D009020
Entity: 11282081	128	138	chloralose	Chemical	D002698
Relation: 11282081	CID	65	67	D002118	49	51	D001281	false
Relation: 11282081	CID	106	115	D014700	49	51	D001281	true
Relation: 11282081	CID	119	127	D009020	49	51	D001281	false
Relation: 11282081	CID	128	138	D002698	49	51	D001281	false

Sentence: RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.
Entity: 11282081	9	18	Verapamil	Chemical	D014700
Entity: 11282081	26	28	AF	Disease	D001281
Entity: 11282081	80	82	AF	Disease	D001281
Relation: 11282081	CID	9	18	D014700	26	28	D001281	true
Relation: 11282081	CID	9	18	D014700	80	82	D001281	true

Sentence: In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).
Entity: 11282081	22	31	verapamil	Chemical	D014700
Entity: 11282081	288	290	AF	Disease	D001281
Relation: 11282081	CID	22	31	D014700	288	290	D001281	true

Sentence: Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).
Entity: 11282081	0	9	Diltiazem	Chemical	D004110
Entity: 11282081	30	32	AF	Disease	D001281
Entity: 11282081	49	51	AF	Disease	D001281
Entity: 11282081	125	134	verapamil	Chemical	D014700
Relation: 11282081	CID	0	9	D004110	30	32	D001281	false
Relation: 11282081	CID	0	9	D004110	49	51	D001281	false
Relation: 11282081	CID	125	134	D014700	30	32	D001281	true
Relation: 11282081	CID	125	134	D014700	49	51	D001281	true

Sentence: In the presence of autonomic blockade, verapamil failed to promote AF and increased, rather than decreasing, refractoriness.
Entity: 11282081	39	48	verapamil	Chemical	D014700
Entity: 11282081	67	69	AF	Disease	D001281
Relation: 11282081	CID	39	48	D014700	67	69	D001281	true

Sentence: Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle.
Entity: 11282081	34	43	verapamil	Chemical	D014700
Entity: 11282081	53	55	AF	Disease	D001281
Relation: 11282081	CID	34	43	D014700	53	55	D001281	true

Sentence: Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.
Entity: 10074612	0	11	Hypotension	Disease	D007022
Entity: 10074612	13	24	bradycardia	Disease	D001919
Entity: 10074612	30	38	asystole	Disease	D006323
Entity: 10074612	67	85	methylprednisolone	Chemical	D008775
Relation: 10074612	CID	67	85	D008775	0	11	D007022	true
Relation: 10074612	CID	67	85	D008775	13	24	D001919	true
Relation: 10074612	CID	67	85	D008775	30	38	D006323	true

Sentence: We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.
Entity: 10074612	20	31	hypotension	Disease	D007022
Entity: 10074612	33	44	bradycardia	Disease	D001919
Entity: 10074612	50	58	asystole	Disease	D006323
Entity: 10074612	105	123	methylprednisolone	Chemical	D008775
Relation: 10074612	CID	105	123	D008775	20	31	D007022	true
Relation: 10074612	CID	105	123	D008775	33	44	D001919	true
Relation: 10074612	CID	105	123	D008775	50	58	D006323	true

Sentence: This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).
Entity: 10074612	54	66	sudden death	Disease	D003645
Entity: 10074612	100	118	methylprednisolone	Chemical	D008775
Entity: 10074612	120	124	IVMP	Chemical	D008775
Relation: 10074612	CID	100	118	D008775	54	66	D003645	false
Relation: 10074612	CID	120	124	D008775	54	66	D003645	false

Sentence: Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.
Entity: 9209318	32	46	azidothymidine	Chemical	D015215
Entity: 9209318	48	51	AZT	Chemical	D015215
Entity: 9209318	62	76	myelodysplasia	Disease	D009190
Relation: 9209318	CID	32	46	D015215	62	76	D009190	true
Relation: 9209318	CID	48	51	D015215	62	76	D009190	true

Sentence: AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.
Entity: 9209318	0	3	AZT	Chemical	D015215
Entity: 9209318	18	35	macrocytic anemia	Disease	D000748
Entity: 9209318	39	43	AIDS	Disease	D000163
Entity: 9209318	66	69	AZT	Chemical	D015215
Relation: 9209318	CID	0	3	D015215	18	35	D000748	true
Relation: 9209318	CID	0	3	D015215	39	43	D000163	false
Relation: 9209318	CID	66	69	D015215	18	35	D000748	true
Relation: 9209318	CID	66	69	D015215	39	43	D000163	false

Sentence: Influence of diet free of NAD-precursors on acetaminophen hepatotoxicity in mice.
Entity: 8742498	26	29	NAD	Chemical	D009243
Entity: 8742498	44	57	acetaminophen	Chemical	D000082
Entity: 8742498	58	72	hepatotoxicity	Disease	D056486
Relation: 8742498	CID	26	29	D009243	58	72	D056486	false
Relation: 8742498	CID	44	57	D000082	58	72	D056486	true

Sentence: Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP induced liver injury involves a step which depends on adenoribosylation.
Entity: 8742498	58	78	nicotinic acid amide	Chemical	D009536
Entity: 8742498	105	121	poly(ADP-ribose)	Chemical	D011064
Entity: 8742498	176	189	acetaminophen	Chemical	D000082
Entity: 8742498	191	194	AAP	Chemical	D000082
Entity: 8742498	196	205	hepatitis	Disease	D056486
Entity: 8742498	227	230	AAP	Chemical	D000082
Entity: 8742498	239	251	liver injury	Disease	D056486
Relation: 8742498	CID	58	78	D009536	196	205	D056486	false
Relation: 8742498	CID	58	78	D009536	239	251	D056486	false
Relation: 8742498	CID	105	121	D011064	196	205	D056486	false
Relation: 8742498	CID	105	121	D011064	239	251	D056486	false
Relation: 8742498	CID	176	189	D000082	196	205	D056486	true
Relation: 8742498	CID	176	189	D000082	239	251	D056486	true
Relation: 8742498	CID	191	194	D000082	196	205	D056486	true
Relation: 8742498	CID	191	194	D000082	239	251	D056486	true
Relation: 8742498	CID	227	230	D000082	196	205	D056486	true
Relation: 8742498	CID	227	230	D000082	239	251	D056486	true

Sentence: The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.
Entity: 8742498	75	78	NAD	Chemical	D009243
Entity: 8742498	139	142	AAP	Chemical	D000082
Entity: 8742498	143	152	hepatitis	Disease	D056486
Entity: 8742498	197	204	ethanol	Chemical	D000431
Relation: 8742498	CID	75	78	D009243	143	152	D056486	false
Relation: 8742498	CID	139	142	D000082	143	152	D056486	true
Relation: 8742498	CID	197	204	D000431	143	152	D056486	true

Sentence: Liver injuries were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT).
Entity: 8742498	0	14	Liver injuries	Disease	D056486
Entity: 8742498	54	63	glutamate	Chemical	D018698
Entity: 8742498	64	76	oxaloacetate	Chemical	D062907
Entity: 8742498	100	109	glutamate	Chemical	D018698
Entity: 8742498	110	118	pyruvate	Chemical	D019289
Relation: 8742498	CID	54	63	D018698	0	14	D056486	false
Relation: 8742498	CID	64	76	D062907	0	14	D056486	false
Relation: 8742498	CID	100	109	D018698	0	14	D056486	false
Relation: 8742498	CID	110	118	D019289	0	14	D056486	false

Sentence: In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by ethanol.
Entity: 8742498	105	108	AAP	Chemical	D000082
Entity: 8742498	148	155	ethanol	Chemical	D000431
Entity: 8742498	188	200	liver damage	Disease	D056486
Entity: 8742498	225	232	ethanol	Chemical	D000431
Relation: 8742498	CID	105	108	D000082	188	200	D056486	true
Relation: 8742498	CID	148	155	D000431	188	200	D056486	true
Relation: 8742498	CID	225	232	D000431	188	200	D056486	true

Sentence: A further 64% reduction of hepatitis was observed, when NAA was given to ethanol/AAP-mice.
Entity: 8742498	27	36	hepatitis	Disease	D056486
Entity: 8742498	56	59	NAA	Chemical	D009536
Entity: 8742498	73	80	ethanol	Chemical	D000431
Entity: 8742498	81	84	AAP	Chemical	D000082
Relation: 8742498	CID	56	59	D009536	27	36	D056486	false
Relation: 8742498	CID	73	80	D000431	27	36	D056486	true
Relation: 8742498	CID	81	84	D000082	27	36	D056486	true

Sentence: Our results provide evidence that the AAP induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.
Entity: 8742498	38	41	AAP	Chemical	D000082
Entity: 8742498	50	59	hepatitis	Disease	D056486
Entity: 8742498	84	91	ethanol	Chemical	D000431
Entity: 8742498	151	154	NAA	Chemical	D009536
Entity: 8742498	205	208	NAD	Chemical	D009243
Relation: 8742498	CID	38	41	D000082	50	59	D056486	true
Relation: 8742498	CID	84	91	D000431	50	59	D056486	true
Relation: 8742498	CID	151	154	D009536	50	59	D056486	false
Relation: 8742498	CID	205	208	D009243	50	59	D056486	false

Sentence: Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias.
Entity: 2435991	40	51	cibenzoline	Chemical	C032151
Entity: 2435991	62	85	ventricular arrhythmias	Disease	D001145
Relation: 2435991	CID	40	51	C032151	62	85	D001145	false

Sentence: Using two-stage coronary ligation-, digitalis-, and adrenaline induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.
Entity: 2435991	36	45	digitalis	Chemical	D004071
Entity: 2435991	52	62	adrenaline	Chemical	D004837
Entity: 2435991	78	101	ventricular arrhythmias	Disease	D001145
Entity: 2435991	129	140	cibenzoline	Chemical	C032151
Entity: 2435991	211	221	arrhythmia	Disease	D001145
Relation: 2435991	CID	36	45	D004071	78	101	D001145	true
Relation: 2435991	CID	36	45	D004071	211	221	D001145	true
Relation: 2435991	CID	52	62	D004837	78	101	D001145	true
Relation: 2435991	CID	52	62	D004837	211	221	D001145	true
Relation: 2435991	CID	129	140	C032151	78	101	D001145	false
Relation: 2435991	CID	129	140	C032151	211	221	D001145	false

Sentence: Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).
Entity: 2435991	0	11	Cibenzoline	Chemical	C032151
Entity: 2435991	31	42	arrhythmias	Disease	D001145
Entity: 2435991	96	107	arrhythmias	Disease	D001145
Entity: 2435991	167	176	digitalis	Chemical	D004071
Entity: 2435991	182	192	adrenaline	Chemical	D004837
Relation: 2435991	CID	0	11	C032151	31	42	D001145	false
Relation: 2435991	CID	0	11	C032151	96	107	D001145	false
Relation: 2435991	CID	167	176	D004071	31	42	D001145	true
Relation: 2435991	CID	167	176	D004071	96	107	D001145	true
Relation: 2435991	CID	182	192	D004837	31	42	D001145	true
Relation: 2435991	CID	182	192	D004837	96	107	D001145	true

Sentence: The concentration for adrenaline induced arrhythmia was significantly higher than those for the other types of arrhythmias.
Entity: 2435991	22	32	adrenaline	Chemical	D004837
Entity: 2435991	41	51	arrhythmia	Disease	D001145
Entity: 2435991	111	122	arrhythmias	Disease	D001145
Relation: 2435991	CID	22	32	D004837	41	51	D001145	true
Relation: 2435991	CID	22	32	D004837	111	122	D001145	true

Sentence: Immunopathology of penicillamine induced glomerular disease.
Entity: 950631	19	32	penicillamine	Chemical	D010396
Entity: 950631	41	59	glomerular disease	Disease	D007674
Relation: 950631	CID	19	32	D010396	41	59	D007674	true

Sentence: Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D-penicillamine.
Entity: 950631	19	39	rheumatoid arthritis	Disease	D001172
Entity: 950631	56	67	proteinuria	Disease	D011507
Entity: 950631	110	125	D-penicillamine	Chemical	D010396
Relation: 950631	CID	110	125	D010396	19	39	D001172	false
Relation: 950631	CID	110	125	D010396	56	67	D011507	true

Sentence: Ventricular fibrillation from diatrizoate with and without chelating agents.
Entity: 663266	0	24	Ventricular fibrillation	Disease	D014693
Entity: 663266	30	41	diatrizoate	Chemical	D003973
Relation: 663266	CID	30	41	D003973	0	24	D014693	false

Sentence: The toxicity of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs.
Entity: 663266	4	12	toxicity	Disease	D064420
Entity: 663266	16	30	Renografin 76%	Chemical	C027278
Entity: 663266	57	68	Hypaque 76%	Chemical	C027278
Relation: 663266	CID	16	30	C027278	4	12	D064420	false
Relation: 663266	CID	57	68	C027278	4	12	D064420	false

Sentence: Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.
Entity: 19319147	42	52	hemorrhage	Disease	D006470
Entity: 19319147	80	88	warfarin	Chemical	D014859
Entity: 19319147	100	124	intracerebral hemorrhage	Disease	D002543
Relation: 19319147	CID	80	88	D014859	42	52	D006470	false
Relation: 19319147	CID	80	88	D014859	100	124	D002543	true

Sentence: Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.
Entity: 19319147	0	8	Warfarin	Chemical	D014859
Entity: 19319147	20	44	intracerebral hemorrhage	Disease	D002543
Entity: 19319147	48	51	ICH	Disease	D002543
Entity: 19319147	73	79	stroke	Disease	D020521
Relation: 19319147	CID	0	8	D014859	20	44	D002543	true
Relation: 19319147	CID	0	8	D014859	48	51	D002543	true
Relation: 19319147	CID	0	8	D014859	73	79	D020521	false

Sentence: We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume.
Entity: 19319147	40	43	PCC	Chemical	C025667
Entity: 19319147	85	88	ICH	Disease	D002543
Relation: 19319147	CID	40	43	C025667	85	88	D002543	false

Sentence: This study examined the utility of biometry for detecting alcohol-related fetal growth impairment.
Entity: 16634859	58	65	alcohol	Chemical	D000431
Entity: 16634859	80	97	growth impairment	Disease	D006130
Relation: 16634859	CID	58	65	D000431	80	97	D006130	true

Sentence: Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.
Entity: 16634859	4	11	alcohol	Chemical	D000431
Entity: 16634859	87	112	reduced cerebellar growth	Disease	D006130
Entity: 16634859	124	156	decreased cranial to body growth	Disease	D006130
Relation: 16634859	CID	4	11	D000431	87	112	D006130	true
Relation: 16634859	CID	4	11	D000431	124	156	D006130	true

Sentence: Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.
Entity: 16471092	64	82	overactive bladder	Disease	D053201
Entity: 16471092	89	100	tolterodine	Chemical	C099041
Relation: 16471092	CID	89	100	C099041	64	82	D053201	false

Sentence: OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.
Entity: 16471092	89	107	overactive bladder	Disease	D053201
Entity: 16471092	109	112	OAB	Disease	D053201
Entity: 16471092	120	131	tolterodine	Chemical	C099041
Relation: 16471092	CID	120	131	C099041	89	107	D053201	false
Relation: 16471092	CID	120	131	C099041	109	112	D053201	false

Sentence: Absence of acute cerebral vasoconstriction after cocaine-associated subarachnoid hemorrhage.
Entity: 16174948	49	56	cocaine	Chemical	D003042
Entity: 16174948	68	91	subarachnoid hemorrhage	Disease	D013345
Relation: 16174948	CID	49	56	D003042	68	91	D013345	true

Sentence: INTRODUCTION: Cocaine use has been associated with neurovascular complications, including arterial vasoconstriction and vasculitis.
Entity: 16174948	14	21	Cocaine	Chemical	D003042
Entity: 16174948	51	78	neurovascular complications	Disease	D013901
Entity: 16174948	120	130	vasculitis	Disease	D014657
Relation: 16174948	CID	14	21	D003042	51	78	D013901	false
Relation: 16174948	CID	14	21	D003042	120	130	D014657	false

Sentence: Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.
Entity: 16174948	80	87	cocaine	Chemical	D003042
Entity: 16174948	99	122	subarachnoid hemorrhage	Disease	D013345
Entity: 16174948	124	127	SAH	Disease	D013345
Entity: 16174948	169	176	cocaine	Chemical	D003042
Relation: 16174948	CID	80	87	D003042	99	122	D013345	true
Relation: 16174948	CID	80	87	D003042	124	127	D013345	true
Relation: 16174948	CID	169	176	D003042	99	122	D013345	true
Relation: 16174948	CID	169	176	D003042	124	127	D013345	true

Sentence: METHODS: We screened patients with SAH retrospectively and identified those with positive urine toxicology for cocaine or its metabolites.
Entity: 16174948	35	38	SAH	Disease	D013345
Entity: 16174948	111	118	cocaine	Chemical	D003042
Relation: 16174948	CID	111	118	D003042	35	38	D013345	true

Sentence: The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.
Entity: 15042318	68	84	gastric lymphoma	Disease	C535648
Entity: 15042318	89	107	myotonic dystrophy	Disease	D009223
Entity: 15042318	139	157	muscular dystrophy	Disease	D009136
Entity: 15042318	170	189	atrial fibrillation	Disease	D001281
Entity: 15042318	213	224	doxorubicin	Chemical	D004317
Relation: 15042318	CID	213	224	D004317	68	84	C535648	false
Relation: 15042318	CID	213	224	D004317	89	107	D009223	false
Relation: 15042318	CID	213	224	D004317	139	157	D009136	false
Relation: 15042318	CID	213	224	D004317	170	189	D001281	true

Sentence: A phase II study of thalidomide in advanced metastatic renal cell carcinoma.
Entity: 12448656	20	31	thalidomide	Chemical	D013792
Entity: 12448656	55	75	renal cell carcinoma	Disease	D002292
Relation: 12448656	CID	20	31	D013792	55	75	D002292	false

Sentence: OBJECTIVES: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.
Entity: 12448656	28	36	toxicity	Disease	D064420
Entity: 12448656	53	64	thalidomide	Chemical	D013792
Entity: 12448656	102	119	renal cell cancer	Disease	D002292
Relation: 12448656	CID	53	64	D013792	28	36	D064420	false
Relation: 12448656	CID	53	64	D013792	102	119	D002292	false

Sentence: CONCLUSION: These results are consistent with a low level of activity of thalidomide in renal cell carcinoma.
Entity: 12448656	73	84	thalidomide	Chemical	D013792
Entity: 12448656	88	108	renal cell carcinoma	Disease	D002292
Relation: 12448656	CID	73	84	D013792	88	108	D002292	false

Sentence: Haloperidol (1 mg/kg ip) induced parkinsonian-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint.
Entity: 12231232	0	11	Haloperidol	Chemical	D006220
Entity: 12231232	33	45	parkinsonian	Disease	D010300
Entity: 12231232	51	66	muscle rigidity	Disease	D009127
Relation: 12231232	CID	0	11	D006220	33	45	D010300	false
Relation: 12231232	CID	0	11	D006220	51	66	D009127	true

Sentence: AIDA in doses of 7.5-15 microg/0.5 microl diminished the haloperidol induced muscle rigidity.
Entity: 12231232	0	4	AIDA	Chemical	C095756
Entity: 12231232	57	68	haloperidol	Chemical	D006220
Entity: 12231232	77	92	muscle rigidity	Disease	D009127
Relation: 12231232	CID	0	4	C095756	77	92	D009127	false
Relation: 12231232	CID	57	68	D006220	77	92	D009127	true

Sentence: Acute cholestatic hepatitis after exposure to isoflurane.
Entity: 11847945	6	17	cholestatic	Disease	D002779
Entity: 11847945	18	27	hepatitis	Disease	D056486
Entity: 11847945	46	56	isoflurane	Chemical	D007530
Relation: 11847945	CID	46	56	D007530	6	17	D002779	true
Relation: 11847945	CID	46	56	D007530	18	27	D056486	true

Sentence: OBJECTIVE: To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane.
Entity: 11847945	37	48	cholestatic	Disease	D002779
Entity: 11847945	49	58	hepatitis	Disease	D056486
Entity: 11847945	109	119	isoflurane	Chemical	D007530
Relation: 11847945	CID	109	119	D007530	37	48	D002779	true
Relation: 11847945	CID	109	119	D007530	49	58	D056486	true

Sentence: No other medications were involved except for dipyrone for analgesia.
Entity: 11847945	46	54	dipyrone	Chemical	D004177
Entity: 11847945	59	68	analgesia	Disease	D000699
Relation: 11847945	CID	46	54	D004177	59	68	D000699	false

Sentence: Calcitonin gene-related peptide levels during nitric oxide induced headache in patients with chronic tension-type headache.
Entity: 11284996	46	58	nitric oxide	Chemical	D009569
Entity: 11284996	67	75	headache	Disease	D006261
Entity: 11284996	101	122	tension-type headache	Disease	D018781
Relation: 11284996	CID	46	58	D009569	67	75	D006261	true
Relation: 11284996	CID	46	58	D009569	101	122	D018781	false

Sentence: It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).
Entity: 11284996	26	38	nitric oxide	Chemical	D009569
Entity: 11284996	40	42	NO	Chemical	D009569
Entity: 11284996	52	60	headache	Disease	D006261
Entity: 11284996	64	81	primary headaches	Disease	D051270
Relation: 11284996	CID	26	38	D009569	52	60	D006261	true
Relation: 11284996	CID	26	38	D009569	64	81	D051270	false
Relation: 11284996	CID	40	42	D009569	52	60	D006261	true
Relation: 11284996	CID	40	42	D009569	64	81	D051270	false

Sentence: In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.
Entity: 11284996	74	82	headache	Disease	D006261
Entity: 11284996	98	100	NO	Chemical	D009569
Entity: 11284996	107	126	glyceryl trinitrate	Chemical	D005996
Entity: 11284996	128	131	GTN	Chemical	D005996
Entity: 11284996	161	182	tension-type headache	Disease	D018781
Relation: 11284996	CID	98	100	D009569	74	82	D006261	true
Relation: 11284996	CID	98	100	D009569	161	182	D018781	false
Relation: 11284996	CID	107	126	D005996	74	82	D006261	true
Relation: 11284996	CID	107	126	D005996	161	182	D018781	false
Relation: 11284996	CID	128	131	D005996	74	82	D006261	true
Relation: 11284996	CID	128	131	D005996	161	182	D018781	false

Sentence: The subjects were randomly allocated to receive 0.5 microg/kg/min GTN or placebo over 20 min on two headache-free days.
Entity: 11284996	66	69	GTN	Chemical	D005996
Entity: 11284996	100	108	headache	Disease	D006261
Relation: 11284996	CID	66	69	D005996	100	108	D006261	true

Sentence: Both patients and controls developed significantly stronger immediate headache on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls.
Entity: 11284996	70	78	headache	Disease	D006261
Entity: 11284996	86	89	GTN	Chemical	D005996
Entity: 11284996	126	134	headache	Disease	D006261
Relation: 11284996	CID	86	89	D005996	70	78	D006261	true
Relation: 11284996	CID	86	89	D005996	126	134	D006261	true

Sentence: Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.
Entity: 11078231	0	19	Myocardial ischemia	Disease	D017202
Entity: 11078231	27	48	coronary artery spasm	Disease	D003329
Entity: 11078231	56	66	dobutamine	Chemical	D004280
Relation: 11078231	CID	56	66	D004280	0	19	D017202	false
Relation: 11078231	CID	56	66	D004280	27	48	D003329	true

Sentence: Dobutamine stress echocardiography (DSE) is a useful and safe provocation test for myocardial ischemia.
Entity: 11078231	0	10	Dobutamine	Chemical	D004280
Entity: 11078231	83	102	myocardial ischemia	Disease	D017202
Relation: 11078231	CID	0	10	D004280	83	102	D017202	false

Sentence: The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.
Entity: 11078231	51	70	myocardial ischemia	Disease	D017202
Entity: 11078231	78	92	coronary spasm	Disease	D003329
Entity: 11078231	107	117	dobutamine	Chemical	D004280
Relation: 11078231	CID	107	117	D004280	51	70	D017202	false
Relation: 11078231	CID	107	117	D004280	78	92	D003329	true

Sentence: Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.
Entity: 11078231	57	70	acetylcholine	Chemical	D000109
Entity: 11078231	85	109	coronary artery stenosis	Disease	D023921
Relation: 11078231	CID	57	70	D000109	85	109	D023921	false

Sentence: These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.
Entity: 11078231	29	39	dobutamine	Chemical	D004280
Entity: 11078231	52	66	coronary spasm	Disease	D003329
Entity: 11078231	89	112	coronary spastic angina	Disease	D000788
Relation: 11078231	CID	29	39	D004280	52	66	D003329	true
Relation: 11078231	CID	29	39	D004280	89	112	D000788	true

Sentence: Nitric oxide synthase expression in the course of lead induced hypertension.
Entity: 10523326	0	12	Nitric oxide	Chemical	D009569
Entity: 10523326	50	54	lead	Chemical	D007854
Entity: 10523326	63	75	hypertension	Disease	D006973
Relation: 10523326	CID	0	12	D009569	63	75	D006973	false
Relation: 10523326	CID	50	54	D007854	63	75	D006973	true

Sentence: We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead induced hypertension.
Entity: 10523326	37	43	oxygen	Chemical	D010100
Entity: 10523326	88	90	NO	Chemical	D009569
Entity: 10523326	124	126	NO	Chemical	D009569
Entity: 10523326	144	157	nitrotyrosine	Chemical	C002744
Entity: 10523326	190	194	lead	Chemical	D007854
Entity: 10523326	203	215	hypertension	Disease	D006973
Relation: 10523326	CID	37	43	D010100	203	215	D006973	false
Relation: 10523326	CID	88	90	D009569	203	215	D006973	false
Relation: 10523326	CID	124	126	D009569	203	215	D006973	false
Relation: 10523326	CID	144	157	C002744	203	215	D006973	false
Relation: 10523326	CID	190	194	D007854	203	215	D006973	true

Sentence: This study was designed to discern whether the reduction in urinary NOx in lead induced hypertension is, in part, due to depressed NO synthase (NOS) expression.
Entity: 10523326	75	79	lead	Chemical	D007854
Entity: 10523326	88	100	hypertension	Disease	D006973
Entity: 10523326	131	133	NO	Chemical	D009569
Relation: 10523326	CID	75	79	D007854	88	100	D006973	true
Relation: 10523326	CID	131	133	D009569	88	100	D006973	false

Sentence: Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.
Entity: 10523326	0	9	Vitamin E	Chemical	D014810
Entity: 10523326	38	50	hypertension	Disease	D006973
Entity: 10523326	67	70	MDA	Chemical	D008315
Relation: 10523326	CID	0	9	D014810	38	50	D006973	false
Relation: 10523326	CID	67	70	D008315	38	50	D006973	false

Sentence: In conclusion, lead induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression.
Entity: 10523326	15	19	lead	Chemical	D007854
Entity: 10523326	28	40	hypertension	Disease	D006973
Relation: 10523326	CID	15	19	D007854	28	40	D006973	true

Sentence: Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.
Entity: 9867728	9	31	valvular heart disease	Disease	D006349
Entity: 9867728	47	59	fenfluramine	Chemical	D005277
Entity: 9867728	64	79	dexfenfluramine	Chemical	D020372
Relation: 9867728	CID	47	59	D005277	9	31	D006349	false
Relation: 9867728	CID	64	79	D020372	9	31	D006349	false

Sentence: BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.
Entity: 9867728	103	115	fenfluramine	Chemical	D005277
Entity: 9867728	120	135	dexfenfluramine	Chemical	D020372
Entity: 9867728	140	156	valvular disease	Disease	D006349
Relation: 9867728	CID	103	115	D005277	140	156	D006349	false
Relation: 9867728	CID	120	135	D020372	140	156	D006349	false

Sentence: OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.
Entity: 9867728	54	76	valvular abnormalities	Disease	D006349
Entity: 9867728	92	104	fenfluramine	Chemical	D005277
Entity: 9867728	108	123	dexfenfluramine	Chemical	D020372
Relation: 9867728	CID	92	104	D005277	54	76	D006349	false
Relation: 9867728	CID	108	123	D020372	54	76	D006349	false

Sentence: RESULTS: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving fenfluramine-phentermine developed valvular heart disease.
Entity: 9867728	63	75	fenfluramine	Chemical	D005277
Entity: 9867728	76	87	phentermine	Chemical	D010645
Entity: 9867728	98	120	valvular heart disease	Disease	D006349
Relation: 9867728	CID	63	75	D005277	98	120	D006349	false
Relation: 9867728	CID	76	87	D010645	98	120	D006349	false

Sentence: BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.
Entity: 9636837	33	44	carboplatin	Chemical	D016190
Entity: 9636837	59	64	CBDCA	Chemical	D016190
Entity: 9636837	71	80	cisplatin	Chemical	D002945
Entity: 9636837	82	86	CDDP	Chemical	D002945
Entity: 9636837	120	130	neurotoxic	Disease	D020258
Relation: 9636837	CID	33	44	D016190	120	130	D020258	false
Relation: 9636837	CID	59	64	D016190	120	130	D020258	false
Relation: 9636837	CID	71	80	D002945	120	130	D020258	false
Relation: 9636837	CID	82	86	D002945	120	130	D020258	false

Sentence: However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.
Entity: 9636837	20	25	CBDCA	Chemical	D016190
Entity: 9636837	84	94	neurotoxic	Disease	D020258
Entity: 9636837	177	209	peripheral nervous system damage	Disease	D010523
Relation: 9636837	CID	20	25	D016190	84	94	D020258	false
Relation: 9636837	CID	20	25	D016190	177	209	D010523	true

Sentence: RESULTS: CBDCA administration induced dose-dependent peripheral neurotoxicity.
Entity: 9636837	9	14	CBDCA	Chemical	D016190
Entity: 9636837	53	77	peripheral neurotoxicity	Disease	D010523
Relation: 9636837	CID	9	14	D016190	53	77	D010523	true

Sentence: CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.
Entity: 9636837	13	18	CBDCA	Chemical	D016190
Entity: 9636837	22	32	neurotoxic	Disease	D020258
Entity: 9636837	137	141	CDDP	Chemical	D002945
Entity: 9636837	167	180	neurotoxicity	Disease	D020258
Relation: 9636837	CID	13	18	D016190	22	32	D020258	false
Relation: 9636837	CID	13	18	D016190	167	180	D020258	false
Relation: 9636837	CID	137	141	D002945	22	32	D020258	false
Relation: 9636837	CID	137	141	D002945	167	180	D020258	false

Sentence: Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.
Entity: 9579567	6	15	tamoxifen	Chemical	D013629
Entity: 9579567	34	47	breast cancer	Disease	D001943
Entity: 9579567	102	115	breast cancer	Disease	D001943
Relation: 9579567	CID	6	15	D013629	34	47	D001943	false
Relation: 9579567	CID	6	15	D013629	102	115	D001943	false

Sentence: We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case-control study.
Entity: 9579567	45	63	endometrial cancer	Disease	D016889
Entity: 9579567	68	77	tamoxifen	Chemical	D013629
Entity: 9579567	123	136	breast cancer	Disease	D001943
Relation: 9579567	CID	68	77	D013629	45	63	D016889	true
Relation: 9579567	CID	68	77	D013629	123	136	D001943	false

Sentence: Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not (crude relative risk = 4.9, p = 0.0001).
Entity: 9579567	23	32	tamoxifen	Chemical	D013629
Entity: 9579567	72	90	endometrial cancer	Disease	D016889
Relation: 9579567	CID	23	32	D013629	72	90	D016889	true

Sentence: Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.
Entity: 9579567	14	32	endometrial cancer	Disease	D016889
Entity: 9579567	50	59	tamoxifen	Chemical	D013629
Entity: 9579567	69	85	advanced disease	Disease	D020178
Entity: 9579567	123	141	endometrial cancer	Disease	D016889
Relation: 9579567	CID	50	59	D013629	14	32	D016889	true
Relation: 9579567	CID	50	59	D013629	69	85	D020178	false
Relation: 9579567	CID	50	59	D013629	123	141	D016889	true

Sentence: Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention.
Entity: 9579567	37	46	tamoxifen	Chemical	D013629
Entity: 9579567	50	68	endometrial cancer	Disease	D016889
Entity: 9579567	119	132	breast cancer	Disease	D001943
Relation: 9579567	CID	37	46	D013629	50	68	D016889	true
Relation: 9579567	CID	37	46	D013629	119	132	D001943	false

Sentence: Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis.
Entity: 9579567	0	19	Endometrial cancers	Disease	D016889
Entity: 9579567	52	61	tamoxifen	Chemical	D013629
Relation: 9579567	CID	52	61	D013629	0	19	D016889	true

Sentence: Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment.
Entity: 9579567	18	27	tamoxifen	Chemical	D013629
Entity: 9579567	32	45	breast cancer	Disease	D001943
Relation: 9579567	CID	18	27	D013629	32	45	D001943	false

Sentence: Granulosa cell tumor of the ovary associated with antecedent tamoxifen use.
Entity: 9205462	0	33	Granulosa cell tumor of the ovary	Disease	C537296
Entity: 9205462	61	70	tamoxifen	Chemical	D013629
Relation: 9205462	CID	61	70	D013629	0	33	C537296	true

Sentence: Review of the literature reveals an association between tamoxifen use and gynecologic tumors.
Entity: 9205462	56	65	tamoxifen	Chemical	D013629
Entity: 9205462	86	92	tumors	Disease	D009369
Relation: 9205462	CID	56	65	D013629	86	92	D009369	false

Sentence: CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.
Entity: 9205462	58	67	tamoxifen	Chemical	D013629
Entity: 9205462	81	89	estrogen	Chemical	D004967
Entity: 9205462	108	124	breast carcinoma	Disease	D001943
Relation: 9205462	CID	58	67	D013629	108	124	D001943	false
Relation: 9205462	CID	81	89	D004967	108	124	D001943	false

Sentence: A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.
Entity: 9098464	18	29	adenomyosis	Disease	D062788
Entity: 9098464	46	64	hyperprolactinemia	Disease	D006966
Entity: 9098464	76	100	fluoxetine hydrochloride	Chemical	D005473
Entity: 9098464	114	123	serotonin	Chemical	D012701
Entity: 9098464	147	158	adenomyosis	Disease	D062788
Relation: 9098464	CID	76	100	D005473	18	29	D062788	true
Relation: 9098464	CID	76	100	D005473	46	64	D006966	true
Relation: 9098464	CID	76	100	D005473	147	158	D062788	true
Relation: 9098464	CID	114	123	D012701	18	29	D062788	false
Relation: 9098464	CID	114	123	D012701	46	64	D006966	false
Relation: 9098464	CID	114	123	D012701	147	158	D062788	false

Sentence: OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis.
Entity: 9098464	60	70	fluoxetine	Chemical	D005473
Entity: 9098464	119	137	hyperprolactinemia	Disease	D006966
Entity: 9098464	170	181	adenomyosis	Disease	D062788
Relation: 9098464	CID	60	70	D005473	119	137	D006966	true
Relation: 9098464	CID	60	70	D005473	170	181	D062788	true

Sentence: DESIGN: Fluoxetine, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.
Entity: 9098464	8	18	Fluoxetine	Chemical	D005473
Entity: 9098464	22	31	serotonin	Chemical	D012701
Entity: 9098464	107	125	hyperprolactinemia	Disease	D006966
Relation: 9098464	CID	8	18	D005473	107	125	D006966	true
Relation: 9098464	CID	22	31	D012701	107	125	D006966	false

Sentence: Histological studies revealed 11 cases of adenomyosis, all within the noncastrated group receiving fluoxetine.
Entity: 9098464	42	53	adenomyosis	Disease	D062788
Entity: 9098464	99	109	fluoxetine	Chemical	D005473
Relation: 9098464	CID	99	109	D005473	42	53	D062788	true

Sentence: Effects of deliberate hypotension induced by labetalol with isoflurane on neuropsychological function.
Entity: 8424298	22	33	hypotension	Disease	D007022
Entity: 8424298	45	54	labetalol	Chemical	D007741
Entity: 8424298	60	70	isoflurane	Chemical	D007530
Relation: 8424298	CID	45	54	D007741	22	33	D007022	true
Relation: 8424298	CID	60	70	D007530	22	33	D007022	true

Sentence: Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by labetalol with isoflurane (hypotensive group).
Entity: 8424298	79	90	hypotension	Disease	D007022
Entity: 8424298	102	111	labetalol	Chemical	D007741
Entity: 8424298	117	127	isoflurane	Chemical	D007530
Entity: 8424298	129	140	hypotensive	Disease	D007022
Relation: 8424298	CID	102	111	D007741	79	90	D007022	true
Relation: 8424298	CID	102	111	D007741	129	140	D007022	true
Relation: 8424298	CID	117	127	D007530	79	90	D007022	true
Relation: 8424298	CID	117	127	D007530	129	140	D007022	true

Sentence: Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although apnoea occurred less often in the midazolam group it lasted longer.
Entity: 7102237	67	76	midazolam	Chemical	D008874
Entity: 7102237	98	104	apnoea	Disease	D001049
Entity: 7102237	132	141	midazolam	Chemical	D008874
Relation: 7102237	CID	67	76	D008874	98	104	D001049	true
Relation: 7102237	CID	132	141	D008874	98	104	D001049	true

Sentence: Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates. 10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg). 8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.
Entity: 6769133	0	11	Cardiotoxic	Disease	D066126
Entity: 6769133	49	59	adriamycin	Chemical	D004317
Entity: 6769133	113	123	adriamycin	Chemical	D004317
Entity: 6769133	211	235	congestive heart failure	Disease	D006333
Entity: 6769133	261	271	adriamycin	Chemical	D004317
Relation: 6769133	CID	49	59	D004317	0	11	D066126	false
Relation: 6769133	CID	49	59	D004317	211	235	D006333	true
Relation: 6769133	CID	113	123	D004317	0	11	D066126	false
Relation: 6769133	CID	113	123	D004317	211	235	D006333	true
Relation: 6769133	CID	261	271	D004317	0	11	D066126	false
Relation: 6769133	CID	261	271	D004317	211	235	D006333	true

Sentence: Histologically, the myocardial lesions resembled those found in human anthracycline induced cardiomyopathy. 1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.
Entity: 6769133	20	38	myocardial lesions	Disease	D001768
Entity: 6769133	70	83	anthracycline	Chemical	D018943
Entity: 6769133	92	106	cardiomyopathy	Disease	D009202
Entity: 6769133	138	165	acute myeloblastic leukemia	Disease	D015470
Entity: 6769133	195	205	adriamycin	Chemical	D004317
Relation: 6769133	CID	70	83	D018943	20	38	D001768	false
Relation: 6769133	CID	70	83	D018943	92	106	D009202	false
Relation: 6769133	CID	70	83	D018943	138	165	D015470	false
Relation: 6769133	CID	195	205	D004317	20	38	D001768	false
Relation: 6769133	CID	195	205	D004317	92	106	D009202	false
Relation: 6769133	CID	195	205	D004317	138	165	D015470	true

Sentence: Doxorubicin cardiomyopathy in children with left-sided Wilms tumor.
Entity: 6292680	0	11	Doxorubicin	Chemical	D004317
Entity: 6292680	12	26	cardiomyopathy	Disease	D009202
Entity: 6292680	55	66	Wilms tumor	Disease	D009396
Relation: 6292680	CID	0	11	D004317	12	26	D009202	true
Relation: 6292680	CID	0	11	D004317	55	66	D009396	false

Sentence: Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.
Entity: 6292680	18	29	Wilms tumor	Disease	D009396
Entity: 6292680	68	81	anthracycline	Chemical	D018943
Entity: 6292680	82	96	cardiomyopathy	Disease	D009202
Entity: 6292680	122	127	tumor	Disease	D009369
Entity: 6292680	159	170	doxorubicin	Chemical	D004317
Relation: 6292680	CID	68	81	D018943	18	29	D009396	false
Relation: 6292680	CID	68	81	D018943	82	96	D009202	false
Relation: 6292680	CID	68	81	D018943	122	127	D009369	false
Relation: 6292680	CID	159	170	D004317	18	29	D009396	false
Relation: 6292680	CID	159	170	D004317	82	96	D009202	true
Relation: 6292680	CID	159	170	D004317	122	127	D009369	false

Sentence: The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.
Entity: 6292680	4	18	cardiomyopathy	Disease	D009202
Entity: 6292680	79	90	Wilms tumor	Disease	D009396
Entity: 6292680	159	170	doxorubicin	Chemical	D004317
Relation: 6292680	CID	159	170	D004317	4	18	D009202	true
Relation: 6292680	CID	159	170	D004317	79	90	D009396	false

Sentence: Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats.
Entity: 3969369	23	35	testosterone	Chemical	D013739
Entity: 3969369	64	78	carcinogenesis	Disease	D063646
Relation: 3969369	CID	23	35	D013739	64	78	D063646	false

Sentence: Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.
Entity: 3969369	37	49	testosterone	Chemical	D013739
Entity: 3969369	99	114	prostate cancer	Disease	D011471
Entity: 3969369	179	185	tumors	Disease	D009369
Entity: 3969369	224	230	tumors	Disease	D009369
Relation: 3969369	CID	37	49	D013739	99	114	D011471	true
Relation: 3969369	CID	37	49	D013739	179	185	D009369	false
Relation: 3969369	CID	37	49	D013739	224	230	D009369	false

Sentence: Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.
Entity: 3969369	34	46	testosterone	Chemical	D013739
Entity: 3969369	154	169	prostate cancer	Disease	D011471
Relation: 3969369	CID	34	46	D013739	154	169	D011471	true

Sentence: Conventional SD rats fed diet L-485 and treated with testosterone developed only prostatitis.
Entity: 3969369	53	65	testosterone	Chemical	D013739
Entity: 3969369	81	92	prostatitis	Disease	D011472
Relation: 3969369	CID	53	65	D013739	81	92	D011472	true

Sentence: Mitomycin C associated hemolytic uremic syndrome.
Entity: 3108839	0	11	Mitomycin C	Chemical	D016685
Entity: 3108839	23	48	hemolytic uremic syndrome	Disease	D006463
Relation: 3108839	CID	0	11	D016685	23	48	D006463	true

Sentence: Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.
Entity: 3108839	0	11	Mitomycin C	Chemical	D016685
Entity: 3108839	23	48	Hemolytic Uremic Syndrome	Disease	D006463
Entity: 3108839	50	53	HUS	Disease	D006463
Relation: 3108839	CID	0	11	D016685	23	48	D006463	true
Relation: 3108839	CID	0	11	D016685	50	53	D006463	true

Sentence: It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.
Entity: 3108839	32	48	hemolytic anemia	Disease	D000743
Entity: 3108839	50	66	thrombocytopenia	Disease	D013921
Entity: 3108839	83	96	renal failure	Disease	D051437
Entity: 3108839	113	124	mitomycin C	Chemical	D016685
Relation: 3108839	CID	113	124	D016685	32	48	D000743	false
Relation: 3108839	CID	113	124	D016685	50	66	D013921	false
Relation: 3108839	CID	113	124	D016685	83	96	D051437	true

Sentence: The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.
Entity: 3108839	4	17	renal failure	Disease	D051437
Entity: 3108839	65	76	mitomycin C	Chemical	D016685
Entity: 3108839	131	144	renal failure	Disease	D051437
Entity: 3108839	148	163	pulmonary edema	Disease	D011654
Relation: 3108839	CID	65	76	D016685	4	17	D051437	true
Relation: 3108839	CID	65	76	D016685	131	144	D051437	true
Relation: 3108839	CID	65	76	D016685	148	163	D011654	false

Sentence: Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.
Entity: 2466960	46	62	cardiac toxicity	Disease	D066126
Entity: 2466960	79	91	fluorouracil	Chemical	D005472
Entity: 2466960	93	97	5-FU	Chemical	D005472
Relation: 2466960	CID	79	91	D005472	46	62	D066126	false
Relation: 2466960	CID	93	97	D005472	46	62	D066126	false

Sentence: We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.
Entity: 2466960	90	94	5-FU	Chemical	D005472
Entity: 2466960	127	133	tumors	Disease	D009369
Entity: 2466960	170	178	ischemic	Disease	D007511
Relation: 2466960	CID	90	94	D005472	127	133	D009369	false
Relation: 2466960	CID	90	94	D005472	170	178	D007511	true

Sentence: Anginal episodes were rare: only one patient had angina (during 5-FU infusion).
Entity: 2466960	0	7	Anginal	Disease	D000787
Entity: 2466960	49	55	angina	Disease	D000787
Entity: 2466960	64	68	5-FU	Chemical	D005472
Relation: 2466960	CID	64	68	D005472	0	7	D000787	true
Relation: 2466960	CID	64	68	D005472	49	55	D000787	true

Sentence: The incidence of ischemic episodes per patient per hour was 0.05 +/- 0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).
Entity: 2466960	17	25	ischemic	Disease	D007511
Entity: 2466960	83	87	5-FU	Chemical	D005472
Entity: 2466960	120	124	5-FU	Chemical	D005472
Entity: 2466960	234	238	5-FU	Chemical	D005472
Entity: 2466960	289	293	5-FU	Chemical	D005472
Relation: 2466960	CID	83	87	D005472	17	25	D007511	true
Relation: 2466960	CID	120	124	D005472	17	25	D007511	true
Relation: 2466960	CID	234	238	D005472	17	25	D007511	true
Relation: 2466960	CID	289	293	D005472	17	25	D007511	true

Sentence: Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.
Entity: 2320800	7	13	anuria	Disease	D001002
Entity: 2320800	37	47	ifosfamide	Chemical	D007069
Entity: 2320800	66	79	breast cancer	Disease	D001943
Entity: 2320800	96	119	impaired renal function	Disease	D007674
Relation: 2320800	CID	37	47	D007069	7	13	D001002	true
Relation: 2320800	CID	37	47	D007069	66	79	D001943	false
Relation: 2320800	CID	37	47	D007069	96	119	D007674	true

Sentence: A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.
Entity: 2320800	37	50	breast cancer	Disease	D001943
Entity: 2320800	76	85	cisplatin	Chemical	D002945
Entity: 2320800	120	133	renal failure	Disease	D051437
Entity: 2320800	139	145	anuria	Disease	D001002
Entity: 2320800	174	184	ifosfamide	Chemical	D007069
Relation: 2320800	CID	76	85	D002945	37	50	D001943	false
Relation: 2320800	CID	76	85	D002945	120	133	D051437	false
Relation: 2320800	CID	76	85	D002945	139	145	D001002	false
Relation: 2320800	CID	174	184	D007069	37	50	D001943	false
Relation: 2320800	CID	174	184	D007069	120	133	D051437	false
Relation: 2320800	CID	174	184	D007069	139	145	D001002	true

Sentence: Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.
Entity: 2320800	0	10	Ifosfamide	Chemical	D007069
Entity: 2320800	22	33	nephrotoxic	Disease	D007674
Entity: 2320800	57	70	tubulopathies	Disease	D007674
Relation: 2320800	CID	0	10	D007069	22	33	D007674	true
Relation: 2320800	CID	0	10	D007069	57	70	D007674	true

Sentence: We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.
Entity: 2320800	37	43	anuria	Disease	D001002
Entity: 2320800	62	72	ifosfamide	Chemical	D007069
Entity: 2320800	122	131	cisplatin	Chemical	D002945
Entity: 2320800	193	204	hypotension	Disease	D007022
Relation: 2320800	CID	62	72	D007069	37	43	D001002	true
Relation: 2320800	CID	62	72	D007069	193	204	D007022	false
Relation: 2320800	CID	122	131	D002945	37	43	D001002	false
Relation: 2320800	CID	122	131	D002945	193	204	D007022	false

Sentence: Central vein thrombosis and topical dipivalyl epinephrine.
Entity: 2220369	8	23	vein thrombosis	Disease	D020246
Entity: 2220369	36	57	dipivalyl epinephrine	Chemical	C015173
Relation: 2220369	CID	36	57	C015173	8	23	D020246	true

Sentence: Amelioration of bendrofluazide induced hypokalemia by timolol.
Entity: 326460	16	30	bendrofluazide	Chemical	D001539
Entity: 326460	39	50	hypokalemia	Disease	D007008
Entity: 326460	54	61	timolol	Chemical	D013999
Relation: 326460	CID	16	30	D001539	39	50	D007008	true
Relation: 326460	CID	54	61	D013999	39	50	D007008	false

Sentence: The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.
Entity: 326460	35	42	timolol	Chemical	D013999
Entity: 326460	66	77	hypokalemia	Disease	D007008
Entity: 326460	92	106	bendrofluazide	Chemical	D001539
Relation: 326460	CID	35	42	D013999	66	77	D007008	false
Relation: 326460	CID	92	106	D001539	66	77	D007008	true

Sentence: OBJECTIVE: The aim of the present study was to investigate the effect of risperidone induced hyperprolactinemia on trabecular bone mineral density (BMD) in children and adolescents.
Entity: 20331935	73	84	risperidone	Chemical	D018967
Entity: 20331935	93	111	hyperprolactinemia	Disease	D006966
Relation: 20331935	CID	73	84	D018967	93	111	D006966	true

Sentence: RESULTS: Hyperprolactinemia was present in 49% of 83 boys (n = 41) treated with risperidone for a mean of 2.9 years.
Entity: 20331935	9	27	Hyperprolactinemia	Disease	D006966
Entity: 20331935	80	91	risperidone	Chemical	D018967
Relation: 20331935	CID	80	91	D018967	9	27	D006966	true

Sentence: Serum testosterone concentration increased with pubertal status but was not affected by hyperprolactinemia.
Entity: 20331935	6	18	testosterone	Chemical	D013739
Entity: 20331935	88	106	hyperprolactinemia	Disease	D006966
Relation: 20331935	CID	6	18	D013739	88	106	D006966	false

Sentence: Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.
Entity: 20331935	17	26	fractures	Disease	D050723
Entity: 20331935	45	56	risperidone	Chemical	D018967
Entity: 20331935	116	134	hyperprolactinemia	Disease	D006966
Relation: 20331935	CID	45	56	D018967	17	26	D050723	false
Relation: 20331935	CID	45	56	D018967	116	134	D006966	true

Sentence: Seizures associated with levofloxacin: case presentation and literature review.
Entity: 19707748	0	8	Seizures	Disease	D012640
Entity: 19707748	25	37	levofloxacin	Chemical	D064704
Relation: 19707748	CID	25	37	D064704	0	8	D012640	true

Sentence: PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin induced seizures.
Entity: 19707748	54	62	seizures	Disease	D012640
Entity: 19707748	103	115	levofloxacin	Chemical	D064704
Entity: 19707748	267	279	levofloxacin	Chemical	D064704
Entity: 19707748	288	296	seizures	Disease	D012640
Relation: 19707748	CID	103	115	D064704	54	62	D012640	true
Relation: 19707748	CID	103	115	D064704	288	296	D012640	true
Relation: 19707748	CID	267	279	D064704	54	62	D012640	true
Relation: 19707748	CID	267	279	D064704	288	296	D012640	true

Sentence: RESULTS: Six cases of levofloxacin induced seizures have been reported in the literature.
Entity: 19707748	22	34	levofloxacin	Chemical	D064704
Entity: 19707748	43	51	seizures	Disease	D012640
Relation: 19707748	CID	22	34	D064704	43	51	D012640	true

Sentence: Mice lacking mPGES-1 are resistant to lithium induced polyuria.
Entity: 19692487	38	45	lithium	Chemical	D008094
Entity: 19692487	54	62	polyuria	Disease	D011141
Relation: 19692487	CID	38	45	D008094	54	62	D011141	false

Sentence: Cyclooxygenase-2 activity is required for the development of lithium induced polyuria.
Entity: 19692487	61	68	lithium	Chemical	D008094
Entity: 19692487	77	85	polyuria	Disease	D011141
Relation: 19692487	CID	61	68	D008094	77	85	D011141	false

Sentence: The present study was undertaken to assess lithium induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).
Entity: 19692487	43	50	lithium	Chemical	D008094
Entity: 19692487	59	67	polyuria	Disease	D011141
Entity: 19692487	100	115	prostaglandin E	Chemical	D011458
Relation: 19692487	CID	43	50	D008094	59	67	D011141	false
Relation: 19692487	CID	100	115	D011458	59	67	D011141	false

Sentence: A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.
Entity: 19692487	25	29	LiCl	Chemical	D018021
Entity: 19692487	93	101	polyuria	Disease	D011141
Relation: 19692487	CID	25	29	D018021	93	101	D011141	true

Sentence: In contrast, mPGES-1 -/- mice were largely resistant to lithium induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.
Entity: 19692487	56	63	lithium	Chemical	D008094
Entity: 19692487	72	80	polyuria	Disease	D011141
Entity: 19692487	169	175	PGE(2)	Chemical	D015232
Relation: 19692487	CID	56	63	D008094	72	80	D011141	false
Relation: 19692487	CID	169	175	D015232	72	80	D011141	false

Sentence: Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit a hypotensive response in pigs following a single high-dose infusion.
Entity: 19289093	41	48	heparin	Chemical	D006493
Entity: 19289093	109	128	chondroitin sulfate	Chemical	D002809
Entity: 19289093	167	178	hypotensive	Disease	D007022
Relation: 19289093	CID	41	48	D006493	167	178	D007022	false
Relation: 19289093	CID	109	128	D002809	167	178	D007022	true

Sentence: Using both contaminated heparin products and the synthetically produced derivative, we showed that the OSCS produces dose-dependent hypotension in pigs.
Entity: 19289093	24	31	heparin	Chemical	D006493
Entity: 19289093	132	143	hypotension	Disease	D007022
Relation: 19289093	CID	24	31	D006493	132	143	D007022	false

Sentence: Doxorubicin cardiomyopathy induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor.
Entity: 18627295	0	11	Doxorubicin	Chemical	D004317
Entity: 18627295	12	26	cardiomyopathy	Disease	D009202
Entity: 18627295	35	47	inflammation	Disease	D007249
Relation: 18627295	CID	0	11	D004317	12	26	D009202	true
Relation: 18627295	CID	0	11	D004317	35	47	D007249	false

Sentence: Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.
Entity: 18627295	20	33	anthracycline	Chemical	D018943
Entity: 18627295	34	45	doxorubicin	Chemical	D004317
Entity: 18627295	47	50	DOX	Chemical	D004317
Entity: 18627295	70	81	cardiotoxic	Disease	D066126
Relation: 18627295	CID	20	33	D018943	70	81	D066126	false
Relation: 18627295	CID	34	45	D004317	70	81	D066126	false
Relation: 18627295	CID	47	50	D004317	70	81	D066126	false

Sentence: To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX induced cardiomyopathy.
Entity: 18627295	88	91	DOX	Chemical	D004317
Entity: 18627295	92	106	cardiomyopathy	Disease	D009202
Entity: 18627295	173	185	inflammation	Disease	D007249
Entity: 18627295	219	222	DOX	Chemical	D004317
Entity: 18627295	231	245	cardiomyopathy	Disease	D009202
Relation: 18627295	CID	88	91	D004317	92	106	D009202	true
Relation: 18627295	CID	88	91	D004317	173	185	D007249	false
Relation: 18627295	CID	88	91	D004317	231	245	D009202	true
Relation: 18627295	CID	219	222	D004317	92	106	D009202	true
Relation: 18627295	CID	219	222	D004317	173	185	D007249	false
Relation: 18627295	CID	219	222	D004317	231	245	D009202	true

Sentence: DOX control mice showed cardiac dysfunction measured by pressure-volume loops in vivo.
Entity: 18627295	0	3	DOX	Chemical	D004317
Entity: 18627295	24	43	cardiac dysfunction	Disease	D006331
Relation: 18627295	CID	0	3	D004317	24	43	D006331	false

Sentence: In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.
Entity: 18627295	3	6	DOX	Chemical	D004317
Entity: 18627295	22	41	cardiac dysfunction	Disease	D006331
Entity: 18627295	67	70	DOX	Chemical	D004317
Relation: 18627295	CID	3	6	D004317	22	41	D006331	false
Relation: 18627295	CID	67	70	D004317	22	41	D006331	false

Sentence: These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis.
Entity: 18627295	50	53	DOX	Chemical	D004317
Entity: 18627295	54	68	cardiomyopathy	Disease	D009202
Relation: 18627295	CID	50	53	D004317	54	68	D009202	true

Sentence: Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.
Entity: 18405372	0	14	Hepatotoxicity	Disease	D056486
Entity: 18405372	31	44	sulfasalazine	Chemical	D012460
Entity: 18405372	61	70	arthritis	Disease	D001168
Relation: 18405372	CID	31	44	D012460	0	14	D056486	true
Relation: 18405372	CID	31	44	D012460	61	70	D001168	false

Sentence: Patients', who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR, were identified.
Entity: 18405372	19	33	hepatotoxicity	Disease	D056486
Entity: 18405372	37	50	sulfasalazine	Chemical	D012460
Relation: 18405372	CID	37	50	D012460	19	33	D056486	true

Sentence: The likely frequency of hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions.
Entity: 18405372	24	38	hepatotoxicity	Disease	D056486
Entity: 18405372	44	57	sulfasalazine	Chemical	D012460
Relation: 18405372	CID	44	57	D012460	24	38	D056486	true

Sentence: The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0.4% of treated patients.
Entity: 18405372	32	46	hepatotoxicity	Disease	D056486
Entity: 18405372	52	65	sulfasalazine	Chemical	D012460
Relation: 18405372	CID	52	65	D012460	32	46	D056486	true

Sentence: An evaluation of amikacin nephrotoxicity in the hematology/oncology population.
Entity: 18356633	17	25	amikacin	Chemical	D000583
Entity: 18356633	26	40	nephrotoxicity	Disease	D007674
Relation: 18356633	CID	17	25	D000583	26	40	D007674	true

Sentence: Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.
Entity: 18356633	0	8	Amikacin	Chemical	D000583
Entity: 18356633	15	29	aminoglycoside	Chemical	D000617
Entity: 18356633	100	119	febrile neutropenia	Disease	D009503
Entity: 18356633	140	150	infections	Disease	D007239
Relation: 18356633	CID	0	8	D000583	100	119	D009503	false
Relation: 18356633	CID	0	8	D000583	140	150	D007239	false
Relation: 18356633	CID	15	29	D000617	100	119	D009503	false
Relation: 18356633	CID	15	29	D000617	140	150	D007239	false

Sentence: To evaluate amikacin-associated nephrotoxicity in an adult hematology/oncology population, a prospective, randomized, open-label trial was conducted at a university-affiliated medical center.
Entity: 18356633	12	20	amikacin	Chemical	D000583
Entity: 18356633	32	46	nephrotoxicity	Disease	D007674
Relation: 18356633	CID	12	20	D000583	32	46	D007674	true

Sentence: Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.
Entity: 16574713	9	42	3,4-methylenedioxymethamphetamine	Chemical	D018817
Entity: 16574713	44	48	MDMA	Chemical	D018817
Entity: 16574713	52	59	ecstasy	Chemical	D018817
Entity: 16574713	92	101	serotonin	Chemical	D012701
Entity: 16574713	103	107	5-HT	Chemical	D012701
Entity: 16574713	201	205	MDMA	Chemical	D018817
Entity: 16574713	214	218	5-HT	Chemical	D012701
Entity: 16574713	219	237	neurotoxic lesions	Disease	D020258
Entity: 16574713	260	264	5-HT	Chemical	D012701
Relation: 16574713	CID	9	42	D018817	219	237	D020258	false
Relation: 16574713	CID	44	48	D018817	219	237	D020258	false
Relation: 16574713	CID	52	59	D018817	219	237	D020258	false
Relation: 16574713	CID	92	101	D012701	219	237	D020258	false
Relation: 16574713	CID	103	107	D012701	219	237	D020258	false
Relation: 16574713	CID	201	205	D018817	219	237	D020258	false
Relation: 16574713	CID	214	218	D012701	219	237	D020258	false
Relation: 16574713	CID	260	264	D012701	219	237	D020258	false

Sentence: In contrast, no evidence of memory impairment was observed in moderate MDMA users.
Entity: 16574713	28	45	memory impairment	Disease	D008569
Entity: 16574713	71	75	MDMA	Chemical	D018817
Relation: 16574713	CID	71	75	D018817	28	45	D008569	true

Sentence: While the use of MDMA in quantities that may be considered "moderate" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.
Entity: 16574713	17	21	MDMA	Chemical	D018817
Entity: 16574713	93	120	impaired memory functioning	Disease	D008569
Entity: 16574713	135	139	MDMA	Chemical	D018817
Entity: 16574713	169	187	memory impairments	Disease	D008569
Relation: 16574713	CID	17	21	D018817	93	120	D008569	true
Relation: 16574713	CID	17	21	D018817	169	187	D008569	true
Relation: 16574713	CID	135	139	D018817	93	120	D008569	true
Relation: 16574713	CID	135	139	D018817	169	187	D008569	true

Sentence: Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol.
Entity: 15638391	83	101	hyperprolactinemia	Disease	D006966
Entity: 15638391	113	124	haloperidol	Chemical	D006220
Relation: 15638391	CID	113	124	D006220	83	101	D006966	true

Sentence: The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.
Entity: 15638391	53	71	hyperprolactinemia	Disease	D006966
Entity: 15638391	84	95	haloperidol	Chemical	D006220
Entity: 15638391	97	100	HAL	Chemical	D006220
Relation: 15638391	CID	84	95	D006220	53	71	D006966	true
Relation: 15638391	CID	97	100	D006220	53	71	D006966	true

Sentence: Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes.
Entity: 15531665	18	27	vitamin C	Chemical	D001205
Entity: 15531665	37	59	cardiovascular disease	Disease	D002318
Entity: 15531665	79	87	diabetes	Disease	D003920
Relation: 15531665	CID	18	27	D001205	37	59	D002318	true
Relation: 15531665	CID	18	27	D001205	79	87	D003920	false

Sentence: These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote atherosclerosis.
Entity: 15531665	63	72	vitamin C	Chemical	D001205
Entity: 15531665	76	84	diabetic	Disease	D003920
Entity: 15531665	107	122	atherosclerosis	Disease	D050197
Relation: 15531665	CID	63	72	D001205	76	84	D003920	false
Relation: 15531665	CID	63	72	D001205	107	122	D050197	false

Sentence: OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.
Entity: 15531665	61	70	vitamin C	Chemical	D001205
Entity: 15531665	97	119	cardiovascular disease	Disease	D002318
Relation: 15531665	CID	61	70	D001205	97	119	D002318	true

Sentence: DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.
Entity: 15531665	40	49	vitamin C	Chemical	D001205
Entity: 15531665	82	104	cardiovascular disease	Disease	D002318
Entity: 15531665	116	139	coronary artery disease	Disease	D003324
Entity: 15531665	155	161	stroke	Disease	D020521
Entity: 15531665	219	227	diabetic	Disease	D003920
Relation: 15531665	CID	40	49	D001205	82	104	D002318	true
Relation: 15531665	CID	40	49	D001205	116	139	D003324	false
Relation: 15531665	CID	40	49	D001205	155	161	D020521	false
Relation: 15531665	CID	40	49	D001205	219	227	D003920	false

Sentence: RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.
Entity: 15531665	30	52	cardiovascular disease	Disease	D002318
Entity: 15531665	75	83	diabetes	Disease	D003920
Entity: 15531665	113	121	diabetes	Disease	D003920
Entity: 15531665	138	144	folate	Chemical	D005492
Entity: 15531665	146	155	vitamin E	Chemical	D014810
Entity: 15531665	161	174	beta-carotene	Chemical	D019207
Entity: 15531665	213	235	cardiovascular disease	Disease	D002318
Entity: 15531665	330	339	vitamin C	Chemical	D001205
Relation: 15531665	CID	138	144	D005492	30	52	D002318	false
Relation: 15531665	CID	138	144	D005492	75	83	D003920	false
Relation: 15531665	CID	138	144	D005492	113	121	D003920	false
Relation: 15531665	CID	138	144	D005492	213	235	D002318	false
Relation: 15531665	CID	146	155	D014810	30	52	D002318	false
Relation: 15531665	CID	146	155	D014810	75	83	D003920	false
Relation: 15531665	CID	146	155	D014810	113	121	D003920	false
Relation: 15531665	CID	146	155	D014810	213	235	D002318	false
Relation: 15531665	CID	161	174	D019207	30	52	D002318	false
Relation: 15531665	CID	161	174	D019207	75	83	D003920	false
Relation: 15531665	CID	161	174	D019207	113	121	D003920	false
Relation: 15531665	CID	161	174	D019207	213	235	D002318	false
Relation: 15531665	CID	330	339	D001205	30	52	D002318	true
Relation: 15531665	CID	330	339	D001205	75	83	D003920	false
Relation: 15531665	CID	330	339	D001205	113	121	D003920	false
Relation: 15531665	CID	330	339	D001205	213	235	D002318	true

Sentence: Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline.
Entity: 15531665	0	9	Vitamin C	Chemical	D001205
Entity: 15531665	49	71	cardiovascular disease	Disease	D002318
Relation: 15531665	CID	0	9	D001205	49	71	D002318	true

Sentence: Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.
Entity: 12851669	34	56	venous thromboembolism	Disease	D054556
Entity: 12851669	78	97	cyproterone acetate	Chemical	D017373
Entity: 12851669	102	118	ethinylestradiol	Chemical	D004997
Relation: 12851669	CID	78	97	D017373	34	56	D054556	false
Relation: 12851669	CID	102	118	D004997	34	56	D054556	false

Sentence: OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).
Entity: 12851669	49	71	venous thromboembolism	Disease	D054556
Entity: 12851669	73	76	VTE	Disease	D054556
Entity: 12851669	93	112	cyproterone acetate	Chemical	D017373
Entity: 12851669	118	134	ethinylestradiol	Chemical	D004997
Entity: 12851669	136	139	CPA	Chemical	D017373
Entity: 12851669	140	142	EE	Chemical	D004997
Entity: 12851669	164	192	combined oral contraceptives	Chemical	D003277
Entity: 12851669	194	198	COCs	Chemical	D003277
Relation: 12851669	CID	93	112	D017373	49	71	D054556	false
Relation: 12851669	CID	93	112	D017373	73	76	D054556	false
Relation: 12851669	CID	118	134	D004997	49	71	D054556	false
Relation: 12851669	CID	118	134	D004997	73	76	D054556	false
Relation: 12851669	CID	136	139	D017373	49	71	D054556	false
Relation: 12851669	CID	136	139	D017373	73	76	D054556	false
Relation: 12851669	CID	140	142	D004997	49	71	D054556	false
Relation: 12851669	CID	140	142	D004997	73	76	D054556	false
Relation: 12851669	CID	164	192	D003277	49	71	D054556	true
Relation: 12851669	CID	164	192	D003277	73	76	D054556	true
Relation: 12851669	CID	194	198	D003277	49	71	D054556	true
Relation: 12851669	CID	194	198	D003277	73	76	D054556	true

Sentence: RESULTS: During the time frame of the study, 330 women were found to have had VTE while on COCs.
Entity: 12851669	78	81	VTE	Disease	D054556
Entity: 12851669	91	95	COCs	Chemical	D003277
Relation: 12851669	CID	91	95	D003277	78	81	D054556	true

Sentence: The corresponding absolute risk of VTE was 3.4 (range, 3.1-3.8) per 10 000 women years among the women on COCs, 4.2 (range, 3.2-5.2) per 10 000 women years among women on levonorgestrel-containing COCs, and 3.1 (range, 1.3-4.9) per 10 000 women years among the women on CPA/EE.
Entity: 12851669	35	38	VTE	Disease	D054556
Entity: 12851669	106	110	COCs	Chemical	D003277
Entity: 12851669	171	185	levonorgestrel	Chemical	D016912
Entity: 12851669	197	201	COCs	Chemical	D003277
Entity: 12851669	270	273	CPA	Chemical	D017373
Entity: 12851669	274	276	EE	Chemical	D004997
Relation: 12851669	CID	106	110	D003277	35	38	D054556	true
Relation: 12851669	CID	171	185	D016912	35	38	D054556	false
Relation: 12851669	CID	197	201	D003277	35	38	D054556	true
Relation: 12851669	CID	270	273	D017373	35	38	D054556	false
Relation: 12851669	CID	274	276	D004997	35	38	D054556	false

Sentence: Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced neurotoxicity.
Entity: 12842176	10	17	lindane	Chemical	D001556
Entity: 12842176	92	99	lindane	Chemical	D001556
Entity: 12842176	108	121	neurotoxicity	Disease	D020258
Relation: 12842176	CID	10	17	D001556	108	121	D020258	false
Relation: 12842176	CID	92	99	D001556	108	121	D020258	false

Sentence: Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.
Entity: 12842176	64	84	3-methylcholanthrene	Chemical	D008748
Entity: 12842176	86	88	MC	Chemical	D008748
Entity: 12842176	177	184	lindane	Chemical	D001556
Entity: 12842176	193	204	convulsions	Disease	D012640
Entity: 12842176	224	237	phenobarbital	Chemical	D010634
Entity: 12842176	274	281	ethanol	Chemical	D000431
Entity: 12842176	368	375	lindane	Chemical	D001556
Entity: 12842176	384	395	convulsions	Disease	D012640
Relation: 12842176	CID	64	84	D008748	193	204	D012640	false
Relation: 12842176	CID	64	84	D008748	384	395	D012640	false
Relation: 12842176	CID	86	88	D008748	193	204	D012640	false
Relation: 12842176	CID	86	88	D008748	384	395	D012640	false
Relation: 12842176	CID	177	184	D001556	193	204	D012640	true
Relation: 12842176	CID	177	184	D001556	384	395	D012640	true
Relation: 12842176	CID	224	237	D010634	193	204	D012640	false
Relation: 12842176	CID	224	237	D010634	384	395	D012640	false
Relation: 12842176	CID	274	281	D000431	193	204	D012640	false
Relation: 12842176	CID	274	281	D000431	384	395	D012640	false
Relation: 12842176	CID	368	375	D001556	193	204	D012640	true
Relation: 12842176	CID	368	375	D001556	384	395	D012640	true

Sentence: Seizure associated with sleep deprivation and sustained-release bupropion.
Entity: 12745515	0	7	Seizure	Disease	D012640
Entity: 12745515	24	41	sleep deprivation	Disease	D012892
Entity: 12745515	64	73	bupropion	Chemical	D016642
Relation: 12745515	CID	64	73	D016642	0	7	D012640	true
Relation: 12745515	CID	64	73	D016642	24	41	D012892	false

Sentence: This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.
Entity: 12745515	41	48	seizure	Disease	D012640
Entity: 12745515	83	92	bupropion	Chemical	D016642
Entity: 12745515	101	118	sleep deprivation	Disease	D012892
Relation: 12745515	CID	83	92	D016642	41	48	D012640	true
Relation: 12745515	CID	83	92	D016642	101	118	D012892	false

Sentence: After 5 weeks of bupropion use, the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence.
Entity: 12745515	17	26	bupropion	Chemical	D016642
Entity: 12745515	83	90	seizure	Disease	D012640
Relation: 12745515	CID	17	26	D016642	83	90	D012640	true

Sentence: METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.
Entity: 12571256	95	106	nephrotoxic	Disease	D007674
Entity: 12571256	169	178	iodixanol	Chemical	C044834
Entity: 12571256	246	253	iohexol	Chemical	D007472
Relation: 12571256	CID	169	178	C044834	95	106	D007674	false
Relation: 12571256	CID	246	253	D007472	95	106	D007674	true

Sentence: The study involved 129 patients with diabetes with serum creatinine concentrations of 1.5 to 3.5 mg per deciliter who underwent coronary or aortofemoral angiography.
Entity: 12571256	37	45	diabetes	Disease	D003920
Entity: 12571256	57	67	creatinine	Chemical	D003404
Relation: 12571256	CID	57	67	D003404	37	45	D003920	false

Sentence: Experimental cranial pain elicited by capsaicin: a PET study.
Entity: 9514561	21	25	pain	Disease	D010146
Entity: 9514561	38	47	capsaicin	Chemical	D002211
Relation: 9514561	CID	38	47	D002211	21	25	D010146	true

Sentence: A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve.
Entity: 9514561	18	27	capsaicin	Chemical	D002211
Entity: 9514561	101	108	painful	Disease	D010146
Relation: 9514561	CID	18	27	D002211	101	108	D010146	true

Sentence: Neuroleptic malignant syndrome with risperidone.
Entity: 9165568	0	30	Neuroleptic malignant syndrome	Disease	D009459
Entity: 9165568	36	47	risperidone	Chemical	D018967
Relation: 9165568	CID	36	47	D018967	0	30	D009459	true

Sentence: Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia.
Entity: 9165568	0	30	Neuroleptic malignant syndrome	Disease	D009459
Entity: 9165568	60	68	dopamine	Chemical	D004298
Relation: 9165568	CID	60	68	D004298	0	30	D009459	false

Sentence: The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.
Entity: 9165568	58	81	extrapyramidal symptoms	Disease	D001480
Entity: 9165568	87	98	risperidone	Chemical	D018967
Relation: 9165568	CID	87	98	D018967	58	81	D001480	false

Sentence: A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone.
Entity: 9165568	30	60	neuroleptic malignant syndrome	Disease	D009459
Entity: 9165568	84	95	risperidone	Chemical	D018967
Relation: 9165568	CID	84	95	D018967	30	60	D009459	true

Sentence: Plasma concentration and urine excretion of the renin-angiotensin system proteins are altered in rats with nephrotic syndrome (NS).
Entity: 9154656	54	65	angiotensin	Chemical	D000809
Entity: 9154656	107	125	nephrotic syndrome	Disease	D009404
Entity: 9154656	127	129	NS	Disease	D009404
Relation: 9154656	CID	54	65	D000809	107	125	D009404	false
Relation: 9154656	CID	54	65	D000809	127	129	D009404	false

Sentence: NS was induced by a single injection of puromycin amino-nucleoside (PAN).
Entity: 9154656	0	2	NS	Disease	D009404
Entity: 9154656	40	66	puromycin amino-nucleoside	Chemical	D011692
Entity: 9154656	68	71	PAN	Chemical	D011692
Relation: 9154656	CID	40	66	D011692	0	2	D009404	true
Relation: 9154656	CID	68	71	D011692	0	2	D009404	true

Sentence: Although a great urinary excretion and half-normal plasma levels of Ao were observed on day 6 after PAN injection, when NS was clearly established, hepatic Ao mRNA levels did not change.
Entity: 9154656	100	103	PAN	Chemical	D011692
Entity: 9154656	120	122	NS	Disease	D009404
Relation: 9154656	CID	100	103	D011692	120	122	D009404	true

Sentence: Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases.
Entity: 8911359	0	16	Cyclophosphamide	Chemical	D003520
Entity: 8911359	28	42	bladder cancer	Disease	D001749
Relation: 8911359	CID	0	16	D003520	28	42	D001749	true

Sentence: PURPOSE: We gained knowledge of the etiology, treatment and prevention of cyclophosphamide associated urothelial cancer.
Entity: 8911359	74	90	cyclophosphamide	Chemical	D003520
Entity: 8911359	102	119	urothelial cancer	Disease	D014523
Relation: 8911359	CID	74	90	D003520	102	119	D014523	false

Sentence: MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with cyclophosphamide associated bladder cancer were reviewed.
Entity: 8911359	89	105	cyclophosphamide	Chemical	D003520
Entity: 8911359	117	131	bladder cancer	Disease	D001749
Relation: 8911359	CID	89	105	D003520	117	131	D001749	true

Sentence: CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease.
Entity: 8911359	13	29	Cyclophosphamide	Chemical	D003520
Entity: 8911359	41	54	bladder tumor	Disease	D001749
Relation: 8911359	CID	13	29	D003520	41	54	D001749	true

Sentence: Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine.
Entity: 8686832	0	17	Leg and back pain	Disease	D001416
Entity: 8686832	67	77	lignocaine	Chemical	D008012
Relation: 8686832	CID	67	77	D008012	0	17	D001416	true

Sentence: Five of the 13 patients (38%) with pain and seven of the 41 patients (17%) without pain admitted to a high alcohol intake, which might be a contributing factor.
Entity: 8686832	35	39	pain	Disease	D010146
Entity: 8686832	83	87	pain	Disease	D010146
Entity: 8686832	107	114	alcohol	Chemical	D000431
Relation: 8686832	CID	107	114	D000431	35	39	D010146	false
Relation: 8686832	CID	107	114	D000431	83	87	D010146	false

Sentence: Acute blood pressure elevations with caffeine in men with borderline systemic hypertension.
Entity: 8607407	37	45	caffeine	Chemical	D002110
Entity: 8607407	78	90	hypertension	Disease	D006973
Relation: 8607407	CID	37	45	D002110	78	90	D006973	true

Sentence: Whether the vasoconstrictive actions of caffeine are enhanced in hypertensive persons has not been demonstrated.
Entity: 8607407	40	48	caffeine	Chemical	D002110
Entity: 8607407	65	77	hypertensive	Disease	D006973
Relation: 8607407	CID	40	48	D002110	65	77	D006973	true

Sentence: Consequently, whereas all participants exhibited normotensive levels during the resting predrug baseline, 33% of borderline subjects achieved hypertensive BP levels after caffeine ingestion.
Entity: 8607407	142	154	hypertensive	Disease	D006973
Entity: 8607407	171	179	caffeine	Chemical	D002110
Relation: 8607407	CID	171	179	D002110	142	154	D006973	true

Sentence: Thus, in borderline hypertensive men, exaggerated responses to caffeine were: selective for diastolic BP, consistent with greater vasoconstriction, replicated in 2 protocols, and representative of nearly all borderline hypertensives.
Entity: 8607407	20	32	hypertensive	Disease	D006973
Entity: 8607407	63	71	caffeine	Chemical	D002110
Entity: 8607407	219	232	hypertensives	Disease	D006973
Relation: 8607407	CID	63	71	D002110	20	32	D006973	true
Relation: 8607407	CID	63	71	D002110	219	232	D006973	true

Sentence: Hallucinations and ifosfamide induced neurotoxicity.
Entity: 8111719	0	14	Hallucinations	Disease	D006212
Entity: 8111719	19	29	ifosfamide	Chemical	D007069
Entity: 8111719	38	51	neurotoxicity	Disease	D020258
Relation: 8111719	CID	19	29	D007069	0	14	D006212	true
Relation: 8111719	CID	19	29	D007069	38	51	D020258	false

Sentence: BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide.
Entity: 8111719	12	26	Hallucinations	Disease	D006212
Entity: 8111719	51	64	neurotoxicity	Disease	D020258
Entity: 8111719	113	123	ifosfamide	Chemical	D007069
Relation: 8111719	CID	113	123	D007069	12	26	D006212	true
Relation: 8111719	CID	113	123	D007069	51	64	D020258	false

Sentence: Most cases of ifosfamide induced hallucinations have been reported with other mental status changes.
Entity: 8111719	14	24	ifosfamide	Chemical	D007069
Entity: 8111719	33	47	hallucinations	Disease	D006212
Relation: 8111719	CID	14	24	D007069	33	47	D006212	true

Sentence: METHODS: The authors interviewed six persons with ifosfamide induced hallucinations in the presence of a clear sensorium.
Entity: 8111719	50	60	ifosfamide	Chemical	D007069
Entity: 8111719	69	83	hallucinations	Disease	D006212
Relation: 8111719	CID	50	60	D007069	69	83	D006212	true

Sentence: The clinician should be alerted for possible ifosfamide induced hallucinations, which may occur without other signs of neurotoxicity. "Eyes-closed" hallucinatory experiences appear to be an unusual feature of this presentation.
Entity: 8111719	45	55	ifosfamide	Chemical	D007069
Entity: 8111719	64	78	hallucinations	Disease	D006212
Entity: 8111719	119	132	neurotoxicity	Disease	D020258
Entity: 8111719	148	161	hallucinatory	Disease	D006212
Relation: 8111719	CID	45	55	D007069	64	78	D006212	true
Relation: 8111719	CID	45	55	D007069	119	132	D020258	false
Relation: 8111719	CID	45	55	D007069	148	161	D006212	true

Sentence: Chlorpropamide induced optic neuropathy.
Entity: 7059267	0	14	Chlorpropamide	Chemical	D002747
Entity: 7059267	23	39	optic neuropathy	Disease	D009901
Relation: 7059267	CID	0	14	D002747	23	39	D009901	true

Sentence: A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.
Entity: 7059267	25	45	adult-onset diabetes	Disease	D003924
Entity: 7059267	59	73	chlorpropamide	Chemical	D002747
Entity: 7059267	75	84	Diabenese	Chemical	D002747
Entity: 7059267	92	114	toxic optic neuropathy	Disease	D009901
Entity: 7059267	153	167	chlorpropamide	Chemical	D002747
Relation: 7059267	CID	59	73	D002747	25	45	D003924	false
Relation: 7059267	CID	59	73	D002747	92	114	D009901	true
Relation: 7059267	CID	75	84	D002747	25	45	D003924	false
Relation: 7059267	CID	75	84	D002747	92	114	D009901	true
Relation: 7059267	CID	153	167	D002747	25	45	D003924	false
Relation: 7059267	CID	153	167	D002747	92	114	D009901	true

Sentence: Levodopa induced dyskinesia and thalamotomy.
Entity: 6381653	0	8	Levodopa	Chemical	D007980
Entity: 6381653	17	27	dyskinesia	Disease	D004409
Relation: 6381653	CID	0	8	D007980	17	27	D004409	true

Sentence: Levodopa induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.
Entity: 6381653	0	8	Levodopa	Chemical	D007980
Entity: 6381653	17	27	dyskinesia	Disease	D004409
Entity: 6381653	62	74	Parkinsonism	Disease	D010302
Entity: 6381653	108	116	dystonic	Disease	D020821
Relation: 6381653	CID	0	8	D007980	17	27	D004409	true
Relation: 6381653	CID	0	8	D007980	62	74	D010302	false
Relation: 6381653	CID	0	8	D007980	108	116	D020821	false

Sentence: Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin.
Entity: 3950060	24	38	nephrotoxicity	Disease	D007674
Entity: 3950060	82	90	amikacin	Chemical	D000583
Relation: 3950060	CID	82	90	D000583	24	38	D007674	true

Sentence: Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity.
Entity: 3950060	35	43	amikacin	Chemical	D000583
Entity: 3950060	86	100	nephrotoxicity	Disease	D007674
Relation: 3950060	CID	35	43	D000583	86	100	D007674	true

Sentence: Group II also showed a significant decrease of chronic nephrotoxicity secondary to long-term therapy with cyclosporine.
Entity: 3311455	55	69	nephrotoxicity	Disease	D007674
Entity: 3311455	106	118	cyclosporine	Chemical	D016572
Relation: 3311455	CID	106	118	D016572	55	69	D007674	true

Sentence: Reversible cholestasis with bile duct injury following azathioprine therapy.
Entity: 2051906	11	22	cholestasis	Disease	D002779
Entity: 2051906	28	44	bile duct injury	Disease	D002779
Entity: 2051906	55	67	azathioprine	Chemical	D001379
Relation: 2051906	CID	55	67	D001379	11	22	D002779	true
Relation: 2051906	CID	55	67	D001379	28	44	D002779	true

Sentence: A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.
Entity: 2051906	36	48	polymyositis	Disease	D017285
Entity: 2051906	82	95	liver disease	Disease	D008107
Entity: 2051906	151	162	cholestasis	Disease	D002779
Entity: 2051906	192	204	azathioprine	Chemical	D001379
Relation: 2051906	CID	192	204	D001379	36	48	D017285	false
Relation: 2051906	CID	192	204	D001379	82	95	D008107	false
Relation: 2051906	CID	192	204	D001379	151	162	D002779	true

Sentence: Renal function and hemodynamics during prolonged isoflurane induced hypotension in humans.
Entity: 2021202	49	59	isoflurane	Chemical	D007530
Entity: 2021202	68	79	hypotension	Disease	D007022
Relation: 2021202	CID	49	59	D007530	68	79	D007022	true

Sentence: The effect of isoflurane induced hypotension on glomerular function and renal blood flow was investigated in 20 human subjects.
Entity: 2021202	14	24	isoflurane	Chemical	D007530
Entity: 2021202	33	44	hypotension	Disease	D007022
Relation: 2021202	CID	14	24	D007530	33	44	D007022	true

Sentence: Hypotension was induced for 236.9 +/- 15.1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59.8 +/- 0.4 mmHg.
Entity: 2021202	0	11	Hypotension	Disease	D007022
Entity: 2021202	65	75	isoflurane	Chemical	D007530
Relation: 2021202	CID	65	75	D007530	0	11	D007022	true

Sentence: The drug effect studied was the antagonism by metoprolol of terbutaline induced hypokalemia.
Entity: 1848636	46	56	metoprolol	Chemical	D008790
Entity: 1848636	60	71	terbutaline	Chemical	D013726
Entity: 1848636	80	91	hypokalemia	Disease	D007008
Relation: 1848636	CID	46	56	D008790	80	91	D007008	false
Relation: 1848636	CID	60	71	D013726	80	91	D007008	true

Sentence: Cefotetan induced immune hemolytic anemia.
Entity: 1445986	0	9	Cefotetan	Chemical	D015313
Entity: 1445986	25	41	hemolytic anemia	Disease	D000743
Relation: 1445986	CID	0	9	D015313	25	41	D000743	true

Sentence: Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation cephalosporins.
Entity: 1445986	7	23	hemolytic anemia	Disease	D000743
Entity: 1445986	110	121	penicillins	Chemical	D010406
Entity: 1445986	143	157	cephalosporins	Chemical	D002511
Relation: 1445986	CID	110	121	D010406	7	23	D000743	false
Relation: 1445986	CID	143	157	D002511	7	23	D000743	false

Sentence: We describe a patient who developed anemia while receiving intravenous cefotetan.
Entity: 1445986	36	42	anemia	Disease	D000740
Entity: 1445986	71	80	cefotetan	Chemical	D015313
Relation: 1445986	CID	71	80	D015313	36	42	D000740	false

Sentence: Acute renal failure subsequent to the administration of rifampicin.
Entity: 982002	0	19	Acute renal failure	Disease	D058186
Entity: 982002	56	66	rifampicin	Chemical	D012293
Relation: 982002	CID	56	66	D012293	0	19	D058186	true

Sentence: The patients had developed transient renal failure after the intermittent administration of rifampicin.
Entity: 982002	37	50	renal failure	Disease	D051437
Entity: 982002	92	102	rifampicin	Chemical	D012293
Relation: 982002	CID	92	102	D012293	37	50	D051437	false

Sentence: Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.
Entity: 343678	0	11	Hepatitis B	Disease	D006509
Entity: 343678	167	183	type B hepatitis	Disease	D006509
Entity: 343678	215	242	hepatitis B surface antigen	Chemical	D006514
Entity: 343678	244	249	HBsAG	Chemical	D006514
Relation: 343678	CID	215	242	D006514	0	11	D006509	false
Relation: 343678	CID	215	242	D006514	167	183	D006509	false
Relation: 343678	CID	244	249	D006514	0	11	D006509	false
Relation: 343678	CID	244	249	D006514	167	183	D006509	false

Sentence: Serotonin syndrome from venlafaxine-tranylcypromine interaction.
Entity: 8888541	0	18	Serotonin syndrome	Disease	D020230
Entity: 8888541	24	35	venlafaxine	Chemical	C047426
Entity: 8888541	36	51	tranylcypromine	Chemical	D014191
Relation: 8888541	CID	24	35	C047426	0	18	D020230	true
Relation: 8888541	CID	36	51	D014191	0	18	D020230	true

Sentence: Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.
Entity: 8888541	25	34	serotonin	Chemical	D012701
Entity: 8888541	72	81	serotonin	Chemical	D012701
Entity: 8888541	117	132	muscle rigidity	Disease	D009127
Entity: 8888541	134	144	salivation	Disease	D012798
Entity: 8888541	146	155	confusion	Disease	D003221
Entity: 8888541	157	166	agitation	Disease	D011595
Entity: 8888541	171	183	hyperthermia	Disease	D005334
Relation: 8888541	CID	25	34	D012701	117	132	D009127	false
Relation: 8888541	CID	25	34	D012701	134	144	D012798	false
Relation: 8888541	CID	25	34	D012701	146	155	D003221	false
Relation: 8888541	CID	25	34	D012701	157	166	D011595	false
Relation: 8888541	CID	25	34	D012701	171	183	D005334	false
Relation: 8888541	CID	72	81	D012701	117	132	D009127	false
Relation: 8888541	CID	72	81	D012701	134	144	D012798	false
Relation: 8888541	CID	72	81	D012701	146	155	D003221	false
Relation: 8888541	CID	72	81	D012701	157	166	D011595	false
Relation: 8888541	CID	72	81	D012701	171	183	D005334	false

Sentence: We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.
Entity: 8888541	12	23	venlafaxine	Chemical	C047426
Entity: 8888541	62	80	serotonin syndrome	Disease	D020230
Entity: 8888541	115	130	tranylcypromine	Chemical	D014191
Entity: 8888541	135	145	depression	Disease	D003866
Relation: 8888541	CID	12	23	C047426	62	80	D020230	true
Relation: 8888541	CID	12	23	C047426	135	145	D003866	false
Relation: 8888541	CID	115	130	D014191	62	80	D020230	true
Relation: 8888541	CID	115	130	D014191	135	145	D003866	false

Sentence: After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.
Entity: 8888541	16	24	diazepam	Chemical	D003975
Entity: 8888541	57	72	muscle rigidity	Disease	D009127
Relation: 8888541	CID	16	24	D003975	57	72	D009127	false

Sentence: Effect of nondopaminergic drugs on L-dopa induced dyskinesias in MPTP-treated monkeys.
Entity: 8106150	35	41	L-dopa	Chemical	D007980
Entity: 8106150	50	61	dyskinesias	Disease	D004409
Entity: 8106150	65	69	MPTP	Chemical	D015632
Relation: 8106150	CID	35	41	D007980	50	61	D004409	false
Relation: 8106150	CID	65	69	D015632	50	61	D004409	false

Sentence: A group of four monkeys was rendered parkinsonian with the toxin MPTP.
Entity: 8106150	37	49	parkinsonian	Disease	D020734
Entity: 8106150	65	69	MPTP	Chemical	D015632
Relation: 8106150	CID	65	69	D015632	37	49	D020734	true

Sentence: A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.
Entity: 8106150	68	76	dopamine	Chemical	D004298
Entity: 8106150	114	120	L-DOPA	Chemical	D007980
Entity: 8106150	135	145	dyskinetic	Disease	D004409
Relation: 8106150	CID	68	76	D004298	135	145	D004409	false
Relation: 8106150	CID	114	120	D007980	135	145	D004409	false

Sentence: Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.
Entity: 8106150	25	34	clonidine	Chemical	D003000
Entity: 8106150	36	49	physostigmine	Chemical	D010830
Entity: 8106150	51	63	methysergide	Chemical	D008784
Entity: 8106150	65	71	5-MDOT	Chemical	-1
Entity: 8106150	73	84	propranolol	Chemical	D011433
Entity: 8106150	90	96	MK-801	Chemical	D016291
Entity: 8106150	119	129	dyskinetic	Disease	D004409
Entity: 8106150	171	183	parkinsonian	Disease	D020734
Relation: 8106150	CID	25	34	D003000	119	129	D004409	false
Relation: 8106150	CID	25	34	D003000	171	183	D020734	false
Relation: 8106150	CID	36	49	D010830	119	129	D004409	false
Relation: 8106150	CID	36	49	D010830	171	183	D020734	false
Relation: 8106150	CID	51	63	D008784	119	129	D004409	false
Relation: 8106150	CID	51	63	D008784	171	183	D020734	false
Relation: 8106150	CID	65	71	-1	119	129	D004409	false
Relation: 8106150	CID	65	71	-1	171	183	D020734	false
Relation: 8106150	CID	73	84	D011433	119	129	D004409	false
Relation: 8106150	CID	73	84	D011433	171	183	D020734	false
Relation: 8106150	CID	90	96	D016291	119	129	D004409	false
Relation: 8106150	CID	90	96	D016291	171	183	D020734	false

Sentence: However, yohimbine and meperidine reduced predominantly the dyskinetic movements.
Entity: 8106150	9	18	yohimbine	Chemical	D015016
Entity: 8106150	23	33	meperidine	Chemical	D008614
Entity: 8106150	60	70	dyskinetic	Disease	D004409
Relation: 8106150	CID	9	18	D015016	60	70	D004409	false
Relation: 8106150	CID	23	33	D008614	60	70	D004409	false

Sentence: Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.
Entity: 8106150	0	8	Baclofen	Chemical	D001418
Entity: 8106150	54	62	dystonic	Disease	D020821
Entity: 8106150	71	81	dyskinesia	Disease	D004409
Relation: 8106150	CID	0	8	D001418	54	62	D020821	false
Relation: 8106150	CID	0	8	D001418	71	81	D004409	false

Sentence: CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).
Entity: 21418164	0	4	CCNU	Chemical	D008130
Entity: 21418164	6	15	lomustine	Chemical	D008130
Entity: 21418164	17	25	toxicity	Disease	D064420
Relation: 21418164	CID	0	4	D008130	17	25	D064420	false
Relation: 21418164	CID	6	15	D008130	17	25	D064420	false

Sentence: OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).
Entity: 21418164	40	102	haematological, renal, hepatic and gastrointestinal toxicities	Disease	D006402|D007674|D056486|D005767	haematological toxicities|renal toxicities|hepatic toxicities|gastrointestinal toxicities
Entity: 21418164	136	180	1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea	Chemical	D008130
Entity: 21418164	182	186	CCNU	Chemical	D008130
Relation: 21418164	CID	136	180	D008130	40	102	D006402|D007674|D056486|D005767	haematological toxicities|renal toxicities|hepatic toxicities|gastrointestinal toxicities	false
Relation: 21418164	CID	182	186	D008130	40	102	D006402|D007674|D056486|D005767	haematological toxicities|renal toxicities|hepatic toxicities|gastrointestinal toxicities	false

Sentence: RESULTS: Of the 206 dogs treated with CCNU, 185 met the inclusion criteria for at least one class of toxicity.
Entity: 21418164	38	42	CCNU	Chemical	D008130
Entity: 21418164	101	109	toxicity	Disease	D064420
Relation: 21418164	CID	38	42	D008130	101	109	D064420	false

Sentence: CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.
Entity: 21418164	0	4	CCNU	Chemical	D008130
Entity: 21418164	48	56	lymphoma	Disease	D008223
Entity: 21418164	58	74	mast cell tumour	Disease	D034801
Entity: 21418164	76	88	brain tumour	Disease	D001932
Entity: 21418164	90	109	histiocytic tumours	Disease	D015620
Entity: 21418164	114	138	epitheliotropic lymphoma	Disease	D008223
Relation: 21418164	CID	0	4	D008130	48	56	D008223	false
Relation: 21418164	CID	0	4	D008130	58	74	D034801	false
Relation: 21418164	CID	0	4	D008130	76	88	D001932	false
Relation: 21418164	CID	0	4	D008130	90	109	D015620	false
Relation: 21418164	CID	0	4	D008130	114	138	D008223	false

Sentence: Potential renal toxicity and elevated alanine transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively.
Entity: 21418164	16	24	toxicity	Disease	D064420
Entity: 21418164	38	45	alanine	Chemical	D000409
Relation: 21418164	CID	38	45	D000409	16	24	D064420	false

Sentence: Neuroactive steroids protect against pilocarpine- and kainic acid induced limbic seizures and status epilepticus in mice.
Entity: 9121607	12	20	steroids	Chemical	D013256
Entity: 9121607	37	48	pilocarpine	Chemical	D010862
Entity: 9121607	54	65	kainic acid	Chemical	D007608
Entity: 9121607	81	89	seizures	Disease	D012640
Entity: 9121607	94	112	status epilepticus	Disease	D013226
Relation: 9121607	CID	12	20	D013256	81	89	D012640	false
Relation: 9121607	CID	12	20	D013256	94	112	D013226	false
Relation: 9121607	CID	37	48	D010862	81	89	D012640	true
Relation: 9121607	CID	37	48	D010862	94	112	D013226	true
Relation: 9121607	CID	54	65	D007608	81	89	D012640	true
Relation: 9121607	CID	54	65	D007608	94	112	D013226	true

Sentence: Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA) induced seizures in mice.
Entity: 9121607	44	56	progesterone	Chemical	D011374
Entity: 9121607	58	90	3 alpha-hydroxy pregnane-20-ones	Chemical	D011374
Entity: 9121607	96	115	deoxycorticosterone	Chemical	D003900
Entity: 9121607	117	157	3 alpha-hydroxy pregnane-21-diol-20-ones	Chemical	D003900
Entity: 9121607	231	242	pilocarpine	Chemical	D010862
Entity: 9121607	245	256	kainic acid	Chemical	D007608
Entity: 9121607	262	282	N-methyl-D-aspartate	Chemical	D016202
Entity: 9121607	284	288	NMDA	Chemical	D016202
Entity: 9121607	298	306	seizures	Disease	D012640
Relation: 9121607	CID	44	56	D011374	298	306	D012640	false
Relation: 9121607	CID	58	90	D011374	298	306	D012640	false
Relation: 9121607	CID	96	115	D003900	298	306	D012640	false
Relation: 9121607	CID	117	157	D003900	298	306	D012640	false
Relation: 9121607	CID	231	242	D010862	298	306	D012640	true
Relation: 9121607	CID	245	256	D007608	298	306	D012640	true
Relation: 9121607	CID	262	282	D016202	298	306	D012640	false
Relation: 9121607	CID	284	288	D016202	298	306	D012640	false

Sentence: Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.) induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).
Entity: 9121607	0	8	Steroids	Chemical	D013256
Entity: 9121607	145	156	pilocarpine	Chemical	D010862
Entity: 9121607	196	204	seizures	Disease	D012640
Entity: 9121607	209	227	status epilepticus	Disease	D013226
Relation: 9121607	CID	0	8	D013256	196	204	D012640	false
Relation: 9121607	CID	0	8	D013256	209	227	D013226	false
Relation: 9121607	CID	145	156	D010862	196	204	D012640	true
Relation: 9121607	CID	145	156	D010862	209	227	D013226	true

Sentence: Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.
Entity: 9121607	25	33	steroids	Chemical	D013256
Entity: 9121607	73	87	benzodiazepine	Chemical	D001569
Entity: 9121607	88	98	clonazepam	Chemical	D002998
Entity: 9121607	121	132	pilocarpine	Chemical	D010862
Entity: 9121607	133	141	seizures	Disease	D012640
Entity: 9121607	143	151	steroids	Chemical	D013256
Entity: 9121607	287	294	seizure	Disease	D012640
Entity: 9121607	312	322	clonazepam	Chemical	D002998
Entity: 9121607	357	365	steroids	Chemical	D013256
Entity: 9121607	390	398	toxicity	Disease	D064420
Relation: 9121607	CID	25	33	D013256	133	141	D012640	false
Relation: 9121607	CID	25	33	D013256	287	294	D012640	false
Relation: 9121607	CID	25	33	D013256	390	398	D064420	false
Relation: 9121607	CID	73	87	D001569	133	141	D012640	false
Relation: 9121607	CID	73	87	D001569	287	294	D012640	false
Relation: 9121607	CID	73	87	D001569	390	398	D064420	false
Relation: 9121607	CID	88	98	D002998	133	141	D012640	false
Relation: 9121607	CID	88	98	D002998	287	294	D012640	false
Relation: 9121607	CID	88	98	D002998	390	398	D064420	false
Relation: 9121607	CID	121	132	D010862	133	141	D012640	true
Relation: 9121607	CID	121	132	D010862	287	294	D012640	true
Relation: 9121607	CID	121	132	D010862	390	398	D064420	false
Relation: 9121607	CID	143	151	D013256	133	141	D012640	false
Relation: 9121607	CID	143	151	D013256	287	294	D012640	false
Relation: 9121607	CID	143	151	D013256	390	398	D064420	false
Relation: 9121607	CID	312	322	D002998	133	141	D012640	false
Relation: 9121607	CID	312	322	D002998	287	294	D012640	false
Relation: 9121607	CID	312	322	D002998	390	398	D064420	false
Relation: 9121607	CID	357	365	D013256	133	141	D012640	false
Relation: 9121607	CID	357	365	D013256	287	294	D012640	false
Relation: 9121607	CID	357	365	D013256	390	398	D064420	false

Sentence: Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.
Entity: 9121607	0	8	Steroids	Chemical	D013256
Entity: 9121607	128	136	seizures	Disease	D012640
Entity: 9121607	148	159	kainic acid	Chemical	D007608
Entity: 9121607	221	229	seizures	Disease	D012640
Relation: 9121607	CID	0	8	D013256	128	136	D012640	false
Relation: 9121607	CID	0	8	D013256	221	229	D012640	false
Relation: 9121607	CID	148	159	D007608	128	136	D012640	true
Relation: 9121607	CID	148	159	D007608	221	229	D012640	true

Sentence: However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid induced limbic seizures and status epilepticus was obtained.
Entity: 9121607	35	42	steroid	Chemical	D013256
Entity: 9121607	116	127	kainic acid	Chemical	D007608
Entity: 9121607	143	151	seizures	Disease	D012640
Entity: 9121607	156	174	status epilepticus	Disease	D013226
Relation: 9121607	CID	35	42	D013256	143	151	D012640	false
Relation: 9121607	CID	35	42	D013256	156	174	D013226	false
Relation: 9121607	CID	116	127	D007608	143	151	D012640	true
Relation: 9121607	CID	116	127	D007608	156	174	D013226	true

Sentence: The steroids also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.) induced lethality, but did not completely protect against NMDA seizures or lethality.
Entity: 9121607	4	12	steroids	Chemical	D013256
Entity: 9121607	51	55	NMDA	Chemical	D016202
Entity: 9121607	132	136	NMDA	Chemical	D016202
Entity: 9121607	137	145	seizures	Disease	D012640
Relation: 9121607	CID	4	12	D013256	137	145	D012640	false
Relation: 9121607	CID	51	55	D016202	137	145	D012640	false
Relation: 9121607	CID	132	136	D016202	137	145	D012640	false

Sentence: The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.
Entity: 7905523	39	63	N-butyl-deoxynojirimycin	Chemical	C059896
Entity: 7905523	65	73	SC-48334	Chemical	C059896
Entity: 7905523	79	89	zidovudine	Chemical	D015215
Entity: 7905523	107	122	HIV-1 infection	Disease	D015658
Relation: 7905523	CID	39	63	C059896	107	122	D015658	false
Relation: 7905523	CID	65	73	C059896	107	122	D015658	false
Relation: 7905523	CID	79	89	D015215	107	122	D015658	false

Sentence: The mean SC-48334 steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).
Entity: 7905523	9	17	SC-48334	Chemical	C059896
Entity: 7905523	132	148	immunodeficiency	Disease	D007153
Relation: 7905523	CID	9	17	C059896	132	148	D007153	false

Sentence: CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.
Entity: 3431591	0	7	CB 3717	Chemical	C031662
Entity: 3431591	9	44	N10-propargyl-5,8-dideazafolic acid	Chemical	C031662
Entity: 3431591	110	122	cytotoxicity	Disease	D064420
Relation: 3431591	CID	0	7	C031662	110	122	D064420	false
Relation: 3431591	CID	9	44	C031662	110	122	D064420	false

Sentence: As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.
Entity: 3431591	130	137	CB 3717	Chemical	C031662
Entity: 3431591	220	227	CB 3717	Chemical	C031662
Entity: 3431591	228	240	cytotoxicity	Disease	D064420
Relation: 3431591	CID	130	137	C031662	228	240	D064420	false
Relation: 3431591	CID	220	227	C031662	228	240	D064420	false

Sentence: In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.
Entity: 3431591	31	38	CB 3717	Chemical	C031662
Entity: 3431591	66	79	breast cancer	Disease	D001943
Entity: 3431591	81	95	ovarian cancer	Disease	D010051
Entity: 3431591	97	105	hepatoma	Disease	D006528
Entity: 3431591	111	123	mesothelioma	Disease	D008654
Relation: 3431591	CID	31	38	C031662	66	79	D001943	false
Relation: 3431591	CID	31	38	C031662	81	95	D010051	false
Relation: 3431591	CID	31	38	C031662	97	105	D006528	false
Relation: 3431591	CID	31	38	C031662	111	123	D008654	false

Sentence: Ethopropazine and benztropine in neuroleptic induced parkinsonism.
Entity: 33969	0	13	Ethopropazine	Chemical	C084820
Entity: 33969	18	29	benztropine	Chemical	D001590
Entity: 33969	53	65	parkinsonism	Disease	D010302
Relation: 33969	CID	0	13	C084820	53	65	D010302	false
Relation: 33969	CID	18	29	D001590	53	65	D010302	false

Sentence: In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.
Entity: 33969	30	43	ethopropazine	Chemical	C084820
Entity: 33969	60	71	benztropine	Chemical	D001590
Entity: 33969	92	104	parkinsonism	Disease	D010302
Entity: 33969	116	138	fluphenazine enanthate	Chemical	C017610
Entity: 33969	145	158	schizophrenic	Disease	D012559
Relation: 33969	CID	30	43	C084820	92	104	D010302	false
Relation: 33969	CID	30	43	C084820	145	158	D012559	false
Relation: 33969	CID	60	71	D001590	92	104	D010302	false
Relation: 33969	CID	60	71	D001590	145	158	D012559	false
Relation: 33969	CID	116	138	C017610	92	104	D010302	true
Relation: 33969	CID	116	138	C017610	145	158	D012559	false

Sentence: Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.
Entity: 33969	0	13	Ethopropazine	Chemical	C084820
Entity: 33969	18	29	benztropine	Chemical	D001590
Entity: 33969	80	101	parkinsonian symptoms	Disease	D010302
Entity: 33969	129	141	procyclidine	Chemical	D011352
Relation: 33969	CID	0	13	C084820	80	101	D010302	false
Relation: 33969	CID	18	29	D001590	80	101	D010302	false
Relation: 33969	CID	129	141	D011352	80	101	D010302	false

Sentence: However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.
Entity: 33969	9	20	benztropine	Chemical	D001590
Entity: 33969	68	86	tardive dyskinesia	Disease	D004409
Entity: 33969	122	135	procyclindine	Chemical	D011352
Entity: 33969	170	177	anxiety	Disease	D001008
Entity: 33969	182	192	depression	Disease	D003866
Entity: 33969	198	211	ethopropazine	Chemical	C084820
Relation: 33969	CID	9	20	D001590	68	86	D004409	true
Relation: 33969	CID	9	20	D001590	170	177	D001008	true
Relation: 33969	CID	9	20	D001590	182	192	D003866	true
Relation: 33969	CID	122	135	D011352	68	86	D004409	false
Relation: 33969	CID	122	135	D011352	170	177	D001008	false
Relation: 33969	CID	122	135	D011352	182	192	D003866	false
Relation: 33969	CID	198	211	C084820	68	86	D004409	false
Relation: 33969	CID	198	211	C084820	170	177	D001008	false
Relation: 33969	CID	198	211	C084820	182	192	D003866	false

Sentence: Effect of alpha-tocopherol and deferoxamine on methamphetamine induced neurotoxicity.
Entity: 16844102	10	26	alpha-tocopherol	Chemical	D024502
Entity: 16844102	31	43	deferoxamine	Chemical	D003676
Entity: 16844102	47	62	methamphetamine	Chemical	D008694
Entity: 16844102	71	84	neurotoxicity	Disease	D020258
Relation: 16844102	CID	10	26	D024502	71	84	D020258	false
Relation: 16844102	CID	31	43	D003676	71	84	D020258	false
Relation: 16844102	CID	47	62	D008694	71	84	D020258	false

Sentence: Methamphetamine (MA) induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals.
Entity: 16844102	0	15	Methamphetamine	Chemical	D008694
Entity: 16844102	17	19	MA	Chemical	D008694
Entity: 16844102	42	55	neurotoxicity	Disease	D020258
Relation: 16844102	CID	0	15	D008694	42	55	D020258	false
Relation: 16844102	CID	17	19	D008694	42	55	D020258	false

Sentence: This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA induced neurotoxicity.
Entity: 16844102	34	50	alpha-tocopherol	Chemical	D024502
Entity: 16844102	52	60	alpha-TC	Chemical	D024502
Entity: 16844102	87	93	oxygen	Chemical	D010100
Entity: 16844102	107	119	deferoxamine	Chemical	D003676
Entity: 16844102	121	124	DFO	Chemical	D003676
Entity: 16844102	130	134	iron	Chemical	D007501
Entity: 16844102	152	154	MA	Chemical	D008694
Entity: 16844102	163	176	neurotoxicity	Disease	D020258
Relation: 16844102	CID	34	50	D024502	163	176	D020258	false
Relation: 16844102	CID	52	60	D024502	163	176	D020258	false
Relation: 16844102	CID	87	93	D010100	163	176	D020258	false
Relation: 16844102	CID	107	119	D003676	163	176	D020258	false
Relation: 16844102	CID	121	124	D003676	163	176	D020258	false
Relation: 16844102	CID	130	134	D007501	163	176	D020258	false
Relation: 16844102	CID	152	154	D008694	163	176	D020258	false

Sentence: The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment. alpha-TC and DFO attenuated the MA induced hyperthermia as well as the alterations in the locomotor activity.
Entity: 16844102	22	30	dopamine	Chemical	D004298
Entity: 16844102	32	34	DA	Chemical	D004298
Entity: 16844102	37	46	serotonin	Chemical	D012701
Entity: 16844102	99	101	MA	Chemical	D008694
Entity: 16844102	145	153	alpha-TC	Chemical	D024502
Entity: 16844102	158	161	DFO	Chemical	D003676
Entity: 16844102	176	184	alpha-TC	Chemical	D024502
Entity: 16844102	189	192	DFO	Chemical	D003676
Entity: 16844102	208	210	MA	Chemical	D008694
Entity: 16844102	219	231	hyperthermia	Disease	D005334
Relation: 16844102	CID	22	30	D004298	219	231	D005334	false
Relation: 16844102	CID	32	34	D004298	219	231	D005334	false
Relation: 16844102	CID	37	46	D012701	219	231	D005334	false
Relation: 16844102	CID	99	101	D008694	219	231	D005334	true
Relation: 16844102	CID	145	153	D024502	219	231	D005334	false
Relation: 16844102	CID	158	161	D003676	219	231	D005334	false
Relation: 16844102	CID	176	184	D024502	219	231	D005334	false
Relation: 16844102	CID	189	192	D003676	219	231	D005334	false
Relation: 16844102	CID	208	210	D008694	219	231	D005334	true

Sentence: Use of dexamethasone with mesna for the prevention of ifosfamide induced hemorrhagic cystitis.
Entity: 14633084	7	20	dexamethasone	Chemical	D003907
Entity: 14633084	26	31	mesna	Chemical	D015080
Entity: 14633084	54	64	ifosfamide	Chemical	D007069
Entity: 14633084	73	84	hemorrhagic	Disease	D006470
Entity: 14633084	85	93	cystitis	Disease	D003556
Relation: 14633084	CID	7	20	D003907	73	84	D006470	false
Relation: 14633084	CID	7	20	D003907	85	93	D003556	false
Relation: 14633084	CID	26	31	D015080	73	84	D006470	false
Relation: 14633084	CID	26	31	D015080	85	93	D003556	false
Relation: 14633084	CID	54	64	D007069	73	84	D006470	true
Relation: 14633084	CID	54	64	D007069	85	93	D003556	true

Sentence: AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).
Entity: 14633084	5	16	Hemorrhagic	Disease	D006470
Entity: 14633084	17	25	cystitis	Disease	D003556
Entity: 14633084	27	29	HC	Disease	D006470
Entity: 14633084	27	29	HC	Disease	D003556
Entity: 14633084	78	88	ifosfamide	Chemical	D007069
Entity: 14633084	90	93	IFS	Chemical	D007069
Relation: 14633084	CID	78	88	D007069	5	16	D006470	true
Relation: 14633084	CID	78	88	D007069	17	25	D003556	true
Relation: 14633084	CID	78	88	D007069	27	29	D006470	true
Relation: 14633084	CID	78	88	D007069	27	29	D003556	true
Relation: 14633084	CID	90	93	D007069	5	16	D006470	true
Relation: 14633084	CID	90	93	D007069	17	25	D003556	true
Relation: 14633084	CID	90	93	D007069	27	29	D006470	true
Relation: 14633084	CID	90	93	D007069	27	29	D003556	true

Sentence: In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS induced HC.
Entity: 14633084	56	69	dexamethasone	Chemical	D003907
Entity: 14633084	90	95	mesna	Chemical	D015080
Entity: 14633084	118	121	IFS	Chemical	D007069
Entity: 14633084	130	132	HC	Disease	D006470
Entity: 14633084	130	132	HC	Disease	D003556
Relation: 14633084	CID	56	69	D003907	130	132	D006470	false
Relation: 14633084	CID	56	69	D003907	130	132	D003556	false
Relation: 14633084	CID	90	95	D015080	130	132	D006470	false
Relation: 14633084	CID	90	95	D015080	130	132	D003556	false
Relation: 14633084	CID	118	121	D007069	130	132	D006470	true
Relation: 14633084	CID	118	121	D007069	130	132	D003556	true

Sentence: CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS induced HC.
Entity: 14633084	12	25	Dexamethasone	Chemical	D003907
Entity: 14633084	46	51	mesna	Chemical	D015080
Entity: 14633084	78	81	IFS	Chemical	D007069
Entity: 14633084	90	92	HC	Disease	D006470
Entity: 14633084	90	92	HC	Disease	D003556
Relation: 14633084	CID	12	25	D003907	90	92	D006470	false
Relation: 14633084	CID	12	25	D003907	90	92	D003556	false
Relation: 14633084	CID	46	51	D015080	90	92	D006470	false
Relation: 14633084	CID	46	51	D015080	90	92	D003556	false
Relation: 14633084	CID	78	81	D007069	90	92	D006470	true
Relation: 14633084	CID	78	81	D007069	90	92	D003556	true

Sentence: Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.
Entity: 11999899	0	9	Reserpine	Chemical	D012110
Entity: 11999899	89	109	orofacial dyskinesia	Disease	D009069
Entity: 11999899	188	206	tardive dyskinesia	Disease	D004409
Relation: 11999899	CID	0	9	D012110	89	109	D009069	false
Relation: 11999899	CID	0	9	D012110	188	206	D004409	true

Sentence: Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease.
Entity: 11999899	0	9	Reserpine	Chemical	D012110
Entity: 11999899	24	30	tremor	Disease	D014202
Entity: 11999899	35	44	catalepsy	Disease	D002375
Entity: 11999899	76	95	Parkinson's disease	Disease	D010300
Relation: 11999899	CID	0	9	D012110	24	30	D014202	true
Relation: 11999899	CID	0	9	D012110	35	44	D002375	true
Relation: 11999899	CID	0	9	D012110	76	95	D010300	false

Sentence: MK-801 (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and catalepsy induced by reserpine.
Entity: 11999899	0	6	MK-801	Chemical	D016291
Entity: 11999899	133	142	catalepsy	Disease	D002375
Entity: 11999899	154	163	reserpine	Chemical	D012110
Relation: 11999899	CID	0	6	D016291	133	142	D002375	false
Relation: 11999899	CID	154	163	D012110	133	142	D002375	true

Sentence: However, MK-801 injection produced a significant increase of tremor in reserpine-treated mice.
Entity: 11999899	9	15	MK-801	Chemical	D016291
Entity: 11999899	61	67	tremor	Disease	D014202
Entity: 11999899	71	80	reserpine	Chemical	D012110
Relation: 11999899	CID	9	15	D016291	61	67	D014202	false
Relation: 11999899	CID	71	80	D012110	61	67	D014202	true

Sentence: Reserpine (1 mg/kg), administered 90 min before the test and followed by apomophine injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.
Entity: 11999899	0	9	Reserpine	Chemical	D012110
Entity: 11999899	73	83	apomophine	Chemical	D001058
Entity: 11999899	145	160	oral dyskinesia	Disease	D009069
Relation: 11999899	CID	0	9	D012110	145	160	D009069	false
Relation: 11999899	CID	73	83	D001058	145	160	D009069	false

Sentence: On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice.
Entity: 11999899	19	28	reserpine	Chemical	D012110
Entity: 11999899	50	56	tremor	Disease	D014202
Entity: 11999899	61	70	catalepsy	Disease	D002375
Relation: 11999899	CID	19	28	D012110	50	56	D014202	true
Relation: 11999899	CID	19	28	D012110	61	70	D002375	true

Sentence: MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.
Entity: 11999899	0	6	MK-801	Chemical	D016291
Entity: 11999899	49	58	catalepsy	Disease	D002375
Entity: 11999899	63	69	tremor	Disease	D014202
Entity: 11999899	81	90	reserpine	Chemical	D012110
Relation: 11999899	CID	0	6	D016291	49	58	D002375	false
Relation: 11999899	CID	0	6	D016291	63	69	D014202	false
Relation: 11999899	CID	81	90	D012110	49	58	D002375	true
Relation: 11999899	CID	81	90	D012110	63	69	D014202	true

Sentence: Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.
Entity: 11999899	18	27	reserpine	Chemical	D012110
Entity: 11999899	166	172	tremor	Disease	D014202
Entity: 11999899	177	186	catalepsy	Disease	D002375
Entity: 11999899	196	202	MK-801	Chemical	D016291
Entity: 11999899	272	281	reserpine	Chemical	D012110
Relation: 11999899	CID	18	27	D012110	166	172	D014202	true
Relation: 11999899	CID	18	27	D012110	177	186	D002375	true
Relation: 11999899	CID	196	202	D016291	166	172	D014202	false
Relation: 11999899	CID	196	202	D016291	177	186	D002375	false
Relation: 11999899	CID	272	281	D012110	166	172	D014202	true
Relation: 11999899	CID	272	281	D012110	177	186	D002375	true

Sentence: These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.
Entity: 11999899	24	33	reserpine	Chemical	D012110
Entity: 11999899	57	75	abnormal movements	Disease	D004409
Entity: 11999899	150	162	parkinsonian	Disease	D010300
Entity: 11999899	172	190	tardive dsykinesia	Disease	D004409
Relation: 11999899	CID	24	33	D012110	57	75	D004409	true
Relation: 11999899	CID	24	33	D012110	150	162	D010300	false
Relation: 11999899	CID	24	33	D012110	172	190	D004409	true

Sentence: Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration.
Entity: 9431903	10	29	glyceryl trinitrate	Chemical	D005996
Entity: 9431903	37	46	sphincter	Disease	D046628
Entity: 9431903	55	60	spasm	Disease	D013035
Entity: 9431903	71	82	prostigmine	Chemical	D009388
Entity: 9431903	83	91	morphine	Chemical	D009020
Relation: 9431903	CID	10	29	D005996	37	46	D046628	false
Relation: 9431903	CID	10	29	D005996	55	60	D013035	false
Relation: 9431903	CID	71	82	D009388	37	46	D046628	true
Relation: 9431903	CID	71	82	D009388	55	60	D013035	true
Relation: 9431903	CID	83	91	D009020	37	46	D046628	true
Relation: 9431903	CID	83	91	D009020	55	60	D013035	true

Sentence: OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.
Entity: 9431903	39	58	glyceryl trinitrate	Chemical	D005996
Entity: 9431903	66	77	prostigmine	Chemical	D009388
Entity: 9431903	78	86	morphine	Chemical	D009020
Entity: 9431903	95	104	sphincter	Disease	D046628
Entity: 9431903	113	118	spasm	Disease	D013035
Entity: 9431903	162	190	sphincter of Oddi dyskinesia	Disease	D046628
Relation: 9431903	CID	39	58	D005996	95	104	D046628	false
Relation: 9431903	CID	39	58	D005996	113	118	D013035	false
Relation: 9431903	CID	39	58	D005996	162	190	D046628	false
Relation: 9431903	CID	66	77	D009388	95	104	D046628	true
Relation: 9431903	CID	66	77	D009388	113	118	D013035	true
Relation: 9431903	CID	66	77	D009388	162	190	D046628	true
Relation: 9431903	CID	78	86	D009020	95	104	D046628	true
Relation: 9431903	CID	78	86	D009020	113	118	D013035	true
Relation: 9431903	CID	78	86	D009020	162	190	D046628	true

Sentence: METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.
Entity: 9431903	8	17	Sphincter	Disease	D046628
Entity: 9431903	26	31	spasm	Disease	D013035
Entity: 9431903	47	58	prostigmine	Chemical	D009388
Entity: 9431903	59	67	morphine	Chemical	D009020
Entity: 9431903	91	102	prostigmine	Chemical	D009388
Entity: 9431903	129	137	morphine	Chemical	D009020
Relation: 9431903	CID	47	58	D009388	8	17	D046628	true
Relation: 9431903	CID	47	58	D009388	26	31	D013035	true
Relation: 9431903	CID	59	67	D009020	8	17	D046628	true
Relation: 9431903	CID	59	67	D009020	26	31	D013035	true
Relation: 9431903	CID	91	102	D009388	8	17	D046628	true
Relation: 9431903	CID	91	102	D009388	26	31	D013035	true
Relation: 9431903	CID	129	137	D009020	8	17	D046628	true
Relation: 9431903	CID	129	137	D009020	26	31	D013035	true

Sentence: RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.
Entity: 9431903	9	20	Prostigmine	Chemical	D009388
Entity: 9431903	21	29	morphine	Chemical	D009020
Entity: 9431903	453	458	spasm	Disease	D013035
Relation: 9431903	CID	9	20	D009388	453	458	D013035	true
Relation: 9431903	CID	21	29	D009020	453	458	D013035	true

Sentence: CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine induced sphincter of Oddi spasm in humans.
Entity: 9431903	77	96	glyceryl trinitrate	Chemical	D005996
Entity: 9431903	104	112	morphine	Chemical	D009020
Entity: 9431903	121	130	sphincter	Disease	D046628
Entity: 9431903	139	144	spasm	Disease	D013035
Relation: 9431903	CID	77	96	D005996	121	130	D046628	false
Relation: 9431903	CID	77	96	D005996	139	144	D013035	false
Relation: 9431903	CID	104	112	D009020	121	130	D046628	true
Relation: 9431903	CID	104	112	D009020	139	144	D013035	true

Sentence: Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of corticosteroids.
Entity: 8665051	46	54	myopathy	Disease	D009135
Entity: 8665051	107	122	corticosteroids	Chemical	D000305
Relation: 8665051	CID	107	122	D000305	46	54	D009135	false

Sentence: Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).
Entity: 8665051	71	95	reduction of food intake	Disease	D000855
Entity: 8665051	103	110	steroid	Chemical	D013256
Entity: 8665051	143	144	M	Chemical	D008775
Entity: 8665051	149	150	T	Chemical	D014221
Relation: 8665051	CID	103	110	D013256	71	95	D000855	false
Relation: 8665051	CID	143	144	D008775	71	95	D000855	true
Relation: 8665051	CID	149	150	D014221	71	95	D000855	true

Sentence: Half-relaxation time was prolonged in both steroid groups, and time to peak tension was longer with M, whereas tetanic tensions were similar.
Entity: 8665051	43	50	steroid	Chemical	D013256
Entity: 8665051	100	101	M	Chemical	D008775
Entity: 8665051	111	118	tetanic	Disease	D013746
Relation: 8665051	CID	43	50	D013256	111	118	D013746	false
Relation: 8665051	CID	100	101	D008775	111	118	D013746	false

Sentence: ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.
Entity: 8665051	91	98	atrophy	Disease	D009133
Entity: 8665051	106	113	steroid	Chemical	D013256
Entity: 8665051	153	160	atrophy	Disease	D009133
Entity: 8665051	166	167	T	Chemical	D014221
Entity: 8665051	252	260	necrosis	Disease	D009336
Relation: 8665051	CID	106	113	D013256	91	98	D009133	false
Relation: 8665051	CID	106	113	D013256	153	160	D009133	false
Relation: 8665051	CID	106	113	D013256	252	260	D009336	false
Relation: 8665051	CID	166	167	D014221	91	98	D009133	true
Relation: 8665051	CID	166	167	D014221	153	160	D009133	true
Relation: 8665051	CID	166	167	D014221	252	260	D009336	false

Sentence: Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals.
Entity: 8665051	57	58	T	Chemical	D014221
Entity: 8665051	81	95	muscle atrophy	Disease	D009133
Entity: 8665051	151	152	T	Chemical	D014221
Relation: 8665051	CID	57	58	D014221	81	95	D009133	true
Relation: 8665051	CID	151	152	D014221	81	95	D009133	true

Sentence: (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties.
Entity: 8665051	18	26	steroids	Chemical	D013256
Entity: 8665051	58	65	atrophy	Disease	D001284
Relation: 8665051	CID	18	26	D013256	58	65	D001284	false

Sentence: (3) neither steroid caused muscle necrosis.
Entity: 8665051	12	19	steroid	Chemical	D013256
Entity: 8665051	34	42	necrosis	Disease	D009336
Relation: 8665051	CID	12	19	D013256	34	42	D009336	false

Sentence: Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.
Entity: 7785794	11	28	cardiogenic shock	Disease	D012770
Entity: 7785794	42	53	heart block	Disease	D006327
Entity: 7785794	60	69	verapamil	Chemical	D014700
Entity: 7785794	77	87	metoprolol	Chemical	D008790
Relation: 7785794	CID	60	69	D014700	11	28	D012770	false
Relation: 7785794	CID	60	69	D014700	42	53	D006327	true
Relation: 7785794	CID	77	87	D008790	11	28	D012770	false
Relation: 7785794	CID	77	87	D008790	42	53	D006327	true

Sentence: A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.
Entity: 7785794	55	66	heart block	Disease	D006327
Entity: 7785794	82	93	hypotension	Disease	D007022
Entity: 7785794	149	158	verapamil	Chemical	D014700
Entity: 7785794	183	193	metoprolol	Chemical	D008790
Relation: 7785794	CID	149	158	D014700	55	66	D006327	true
Relation: 7785794	CID	149	158	D014700	82	93	D007022	true
Relation: 7785794	CID	183	193	D008790	55	66	D006327	true
Relation: 7785794	CID	183	193	D008790	82	93	D007022	true

Sentence: The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.
Entity: 7785794	32	43	hypotensive	Disease	D007022
Entity: 7785794	58	69	heart block	Disease	D006327
Entity: 7785794	110	118	atropine	Chemical	D001285
Entity: 7785794	167	175	dopamine	Chemical	D004298
Entity: 7785794	180	190	dobutamine	Chemical	D004280
Relation: 7785794	CID	110	118	D001285	32	43	D007022	false
Relation: 7785794	CID	110	118	D001285	58	69	D006327	false
Relation: 7785794	CID	167	175	D004298	32	43	D007022	false
Relation: 7785794	CID	167	175	D004298	58	69	D006327	false
Relation: 7785794	CID	180	190	D004280	32	43	D007022	false
Relation: 7785794	CID	180	190	D004280	58	69	D006327	false

Sentence: Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.
Entity: 8958188	65	75	lometrexol	Chemical	C045894
Entity: 8958188	97	104	tumours	Disease	D009369
Entity: 8958188	150	162	methotrexate	Chemical	D008727
Relation: 8958188	CID	65	75	C045894	97	104	D009369	false
Relation: 8958188	CID	150	162	D008727	97	104	D009369	false

Sentence: However, the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities.
Entity: 8958188	45	55	lometrexol	Chemical	C045894
Entity: 8958188	121	131	toxicities	Disease	D064420
Relation: 8958188	CID	45	55	C045894	121	131	D064420	false

Sentence: Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose.
Entity: 8958188	49	57	toxicity	Disease	D064420
Entity: 8958188	61	71	lometrexol	Chemical	C045894
Entity: 8958188	101	111	folic acid	Chemical	D005492
Relation: 8958188	CID	61	71	C045894	49	57	D064420	false
Relation: 8958188	CID	101	111	D005492	49	57	D064420	false

Sentence: This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.
Entity: 8958188	54	64	lometrexol	Chemical	C045894
Entity: 8958188	76	86	folic acid	Chemical	D005492
Entity: 8958188	132	140	toxicity	Disease	D064420
Entity: 8958188	144	154	lometrexol	Chemical	C045894
Entity: 8958188	182	192	folic acid	Chemical	D005492
Relation: 8958188	CID	54	64	C045894	132	140	D064420	false
Relation: 8958188	CID	76	86	D005492	132	140	D064420	false
Relation: 8958188	CID	144	154	C045894	132	140	D064420	false
Relation: 8958188	CID	182	192	D005492	132	140	D064420	false

Sentence: There was no clear relationship between clinical toxicity and the extent of plasma folate elevation.
Entity: 8958188	49	57	toxicity	Disease	D064420
Entity: 8958188	83	89	folate	Chemical	D005492
Relation: 8958188	CID	83	89	D005492	49	57	D064420	false

Sentence: Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.
Entity: 8958188	37	47	lometrexol	Chemical	C045894
Entity: 8958188	92	102	folic acid	Chemical	D005492
Entity: 8958188	172	180	toxicity	Disease	D064420
Entity: 8958188	194	204	lometrexol	Chemical	C045894
Relation: 8958188	CID	37	47	C045894	172	180	D064420	false
Relation: 8958188	CID	92	102	D005492	172	180	D064420	false
Relation: 8958188	CID	194	204	C045894	172	180	D064420	false

Sentence: Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2 induced hyperalgesia.
Entity: 2557556	116	132	prostaglandin E2	Chemical	D015232
Entity: 2557556	141	153	hyperalgesia	Disease	D006930
Relation: 2557556	CID	116	132	D015232	141	153	D006930	true

Sentence: Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.
Entity: 2557556	0	8	Morphine	Chemical	D009020
Entity: 2557556	37	49	hyperalgesia	Disease	D006930
Entity: 2557556	61	99	8-bromo cyclic adenosine monophosphate	Chemical	D015124
Relation: 2557556	CID	0	8	D009020	37	49	D006930	false
Relation: 2557556	CID	61	99	D015124	37	49	D006930	true

Sentence: Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.
Entity: 15580403	19	28	ribavirin	Chemical	D012254
Entity: 15580403	56	65	hemolysis	Disease	D006461
Entity: 15580403	96	106	interferon	Chemical	D007372
Entity: 15580403	111	120	ribavirin	Chemical	D012254
Entity: 15580403	125	144	chronic hepatitis C	Disease	D019698
Relation: 15580403	CID	19	28	D012254	56	65	D006461	false
Relation: 15580403	CID	19	28	D012254	125	144	D019698	false
Relation: 15580403	CID	96	106	D007372	56	65	D006461	false
Relation: 15580403	CID	96	106	D007372	125	144	D019698	false
Relation: 15580403	CID	111	120	D012254	56	65	D006461	false
Relation: 15580403	CID	111	120	D012254	125	144	D019698	false

Sentence: BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.
Entity: 15580403	12	28	Hemolytic anemia	Disease	D000743
Entity: 15580403	94	104	interferon	Chemical	D007372
Entity: 15580403	109	118	ribavirin	Chemical	D012254
Relation: 15580403	CID	94	104	D007372	12	28	D000743	true
Relation: 15580403	CID	109	118	D012254	12	28	D000743	true

Sentence: Because of ribavirin-related hemolytic anemia, dose reduction is a common event in this therapy.
Entity: 15580403	11	20	ribavirin	Chemical	D012254
Entity: 15580403	29	45	hemolytic anemia	Disease	D000743
Relation: 15580403	CID	11	20	D012254	29	45	D000743	true

Sentence: In this clinical retrospective cohort study we have examined the suitable timing of ribavirin reduction in patients with hemolysis during combination therapy.
Entity: 15580403	84	93	ribavirin	Chemical	D012254
Entity: 15580403	121	130	hemolysis	Disease	D006461
Relation: 15580403	CID	84	93	D012254	121	130	D006461	false

Sentence: However, 10 of 37 patients with reduction of ribavirin could not continue combination therapy because their <8.5 g/dl hemoglobin values decreased to or anemia-related severe side effects occurred (group B).
Entity: 15580403	45	54	ribavirin	Chemical	D012254
Entity: 15580403	152	158	anemia	Disease	D000740
Relation: 15580403	CID	45	54	D012254	152	158	D000740	false

Sentence: Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside induced nephrotic syndrome in rats.
Entity: 15075188	68	93	puromycin aminonucleoside	Chemical	D011692
Entity: 15075188	102	120	nephrotic syndrome	Disease	D009404
Relation: 15075188	CID	68	93	D011692	102	120	D009404	true

Sentence: Nephrotic syndrome is often accompanied by sodium retention and generalized edema.
Entity: 15075188	0	18	Nephrotic syndrome	Disease	D009404
Entity: 15075188	43	49	sodium	Chemical	D012964
Entity: 15075188	76	81	edema	Disease	D004487
Relation: 15075188	CID	43	49	D012964	0	18	D009404	false
Relation: 15075188	CID	43	49	D012964	76	81	D004487	false

Sentence: After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.
Entity: 15075188	14	17	PAN	Chemical	D011692
Entity: 15075188	48	59	proteinuria	Disease	D011507
Entity: 15075188	61	76	hypoalbuminemia	Disease	D034141
Entity: 15075188	96	102	sodium	Chemical	D012964
Entity: 15075188	128	135	ascites	Disease	D001201
Relation: 15075188	CID	14	17	D011692	48	59	D011507	true
Relation: 15075188	CID	14	17	D011692	61	76	D034141	true
Relation: 15075188	CID	14	17	D011692	128	135	D001201	true
Relation: 15075188	CID	96	102	D012964	48	59	D011507	false
Relation: 15075188	CID	96	102	D012964	61	76	D034141	false
Relation: 15075188	CID	96	102	D012964	128	135	D001201	false

Sentence: In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN induced nephrotic syndrome.
Entity: 15075188	196	202	sodium	Chemical	D012964
Entity: 15075188	229	232	PAN	Chemical	D011692
Entity: 15075188	241	259	nephrotic syndrome	Disease	D009404
Relation: 15075188	CID	196	202	D012964	241	259	D009404	false
Relation: 15075188	CID	229	232	D011692	241	259	D009404	true

Sentence: Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.
Entity: 14745746	48	59	anastrozole	Chemical	C090450
Entity: 14745746	61	70	tamoxifen	Chemical	D013629
Entity: 14745746	132	145	breast cancer	Disease	D001943
Relation: 14745746	CID	48	59	C090450	132	145	D001943	false
Relation: 14745746	CID	61	70	D013629	132	145	D001943	false

Sentence: Association of nitric oxide production and apoptosis in a model of experimental nephropathy.
Entity: 11208990	15	27	nitric oxide	Chemical	D009569
Entity: 11208990	80	91	nephropathy	Disease	D007674
Relation: 11208990	CID	15	27	D009569	80	91	D007674	false

Sentence: We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).
Entity: 11208990	28	30	NO	Chemical	D009569
Entity: 11208990	94	112	nephrotic syndrome	Disease	D009404
Entity: 11208990	146	156	adriamycin	Chemical	D004317
Entity: 11208990	158	161	ADR	Chemical	D004317
Relation: 11208990	CID	28	30	D009569	94	112	D009404	false
Relation: 11208990	CID	146	156	D004317	94	112	D009404	true
Relation: 11208990	CID	158	161	D004317	94	112	D009404	true

Sentence: Rats were stratified into control groups and ADR induced nephropathy groups.
Entity: 11208990	45	48	ADR	Chemical	D004317
Entity: 11208990	57	68	nephropathy	Disease	D007674
Relation: 11208990	CID	45	48	D004317	57	68	D007674	false

Sentence: RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.
Entity: 11208990	75	78	ADR	Chemical	D004317
Entity: 11208990	103	126	mesangial proliferation	Disease	C537346
Entity: 11208990	136	167	tubulointerstitial inflammation	Disease	D009395
Relation: 11208990	CID	75	78	D004317	103	126	C537346	false
Relation: 11208990	CID	75	78	D004317	136	167	D009395	false

Sentence: Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05).
Entity: 11208990	6	13	nitrite	Chemical	D009573
Entity: 11208990	57	60	ADR	Chemical	D004317
Entity: 11208990	61	72	nephropathy	Disease	D007674
Relation: 11208990	CID	6	13	D009573	61	72	D007674	false
Relation: 11208990	CID	57	60	D004317	61	72	D007674	false

Sentence: In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the ADR-nephropathy group.
Entity: 11208990	12	25	phenylephrine	Chemical	D010656
Entity: 11208990	30	43	acetylcholine	Chemical	D000109
Entity: 11208990	97	100	ADR	Chemical	D004317
Entity: 11208990	101	112	nephropathy	Disease	D007674
Relation: 11208990	CID	12	25	D010656	101	112	D007674	false
Relation: 11208990	CID	30	43	D000109	101	112	D007674	false
Relation: 11208990	CID	97	100	D004317	101	112	D007674	false

Sentence: However, in the ADR-nephropathy group, numerous apoptotic cells were identified in the tubulointerstitial areas.
Entity: 11208990	16	19	ADR	Chemical	D004317
Entity: 11208990	20	31	nephropathy	Disease	D007674
Relation: 11208990	CID	16	19	D004317	20	31	D007674	false

Sentence: The attenuating effect of carteolol hydrochloride, a beta-adrenoceptor antagonist, on neuroleptic induced catalepsy in rats.
Entity: 9201797	26	49	carteolol hydrochloride	Chemical	D002354
Entity: 9201797	106	115	catalepsy	Disease	D002375
Relation: 9201797	CID	26	49	D002354	106	115	D002375	false

Sentence: Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.
Entity: 9201797	26	35	carteolol	Chemical	D002354
Entity: 9201797	72	83	haloperidol	Chemical	D006220
Entity: 9201797	92	101	catalepsy	Disease	D002375
Entity: 9201797	163	174	propranolol	Chemical	D011433
Entity: 9201797	179	188	biperiden	Chemical	D001712
Relation: 9201797	CID	26	35	D002354	92	101	D002375	false
Relation: 9201797	CID	72	83	D006220	92	101	D002375	true
Relation: 9201797	CID	163	174	D011433	92	101	D002375	false
Relation: 9201797	CID	179	188	D001712	92	101	D002375	false

Sentence: Carteolol, as well as propranolol and biperiden, inhibited the haloperidol induced catalepsy.
Entity: 9201797	0	9	Carteolol	Chemical	D002354
Entity: 9201797	22	33	propranolol	Chemical	D011433
Entity: 9201797	38	47	biperiden	Chemical	D001712
Entity: 9201797	63	74	haloperidol	Chemical	D006220
Entity: 9201797	83	92	catalepsy	Disease	D002375
Relation: 9201797	CID	0	9	D002354	83	92	D002375	false
Relation: 9201797	CID	22	33	D011433	83	92	D002375	false
Relation: 9201797	CID	38	47	D001712	83	92	D002375	false
Relation: 9201797	CID	63	74	D006220	83	92	D002375	true

Sentence: Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.
Entity: 9201797	0	9	Carteolol	Chemical	D002354
Entity: 9201797	37	45	dopamine	Chemical	D004298
Entity: 9201797	107	122	hyperlocomotion	Disease	D009069
Relation: 9201797	CID	0	9	D002354	107	122	D009069	false
Relation: 9201797	CID	37	45	D004298	107	122	D009069	false

Sentence: Penicillamine induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis.
Entity: 8267029	0	13	Penicillamine	Chemical	D010396
Entity: 8267029	42	60	glomerulonephritis	Disease	D005921
Entity: 8267029	79	99	rheumatoid arthritis	Disease	D001172
Relation: 8267029	CID	0	13	D010396	42	60	D005921	true
Relation: 8267029	CID	0	13	D010396	79	99	D001172	false

Sentence: A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.
Entity: 8267029	25	45	rheumatoid arthritis	Disease	D001172
Entity: 8267029	76	94	glomerulonephritis	Disease	D005921
Entity: 8267029	96	100	RPGN	Disease	D005921
Entity: 8267029	120	135	D-penicillamine	Chemical	D010396
Relation: 8267029	CID	120	135	D010396	25	45	D001172	false
Relation: 8267029	CID	120	135	D010396	76	94	D005921	true
Relation: 8267029	CID	120	135	D010396	96	100	D005921	true

Sentence: This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients.
Entity: 8267029	17	21	RPGN	Disease	D005921
Entity: 8267029	39	54	D-penicillamine	Chemical	D010396
Entity: 8267029	166	177	proteinuria	Disease	D011507
Relation: 8267029	CID	39	54	D010396	17	21	D005921	true
Relation: 8267029	CID	39	54	D010396	166	177	D011507	false

Sentence: Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.
Entity: 384871	0	26	Bilateral optic neuropathy	Disease	D009901
Entity: 384871	43	53	ethambutol	Chemical	D004977
Entity: 384871	58	67	isoniazid	Chemical	D007538
Relation: 384871	CID	43	53	D004977	0	26	D009901	true
Relation: 384871	CID	58	67	D007538	0	26	D009901	true

Sentence: The hazards of optic nerve toxicity due to ethambutol are known.
Entity: 384871	27	35	toxicity	Disease	D064420
Entity: 384871	43	53	ethambutol	Chemical	D004977
Relation: 384871	CID	43	53	D004977	27	35	D064420	false

Sentence: Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.
Entity: 133615	0	14	Thromboembolic	Disease	D013923
Entity: 133615	42	60	oral contraceptive	Chemical	D003276
Entity: 133615	111	128	blood coagulation	Disease	D001778
Relation: 133615	CID	42	60	D003276	0	14	D013923	false
Relation: 133615	CID	42	60	D003276	111	128	D001778	true

Sentence: Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.
Entity: 17263743	0	14	Cardiac arrest	Disease	D006323
Entity: 17263743	31	45	cerebral palsy	Disease	D002547
Entity: 17263743	57	68	sevoflurane	Chemical	C009250
Entity: 17263743	112	121	clonidine	Chemical	D003000
Relation: 17263743	CID	57	68	C009250	0	14	D006323	false
Relation: 17263743	CID	57	68	C009250	31	45	D002547	false
Relation: 17263743	CID	112	121	D003000	0	14	D006323	true
Relation: 17263743	CID	112	121	D003000	31	45	D002547	false

Sentence: We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.
Entity: 17263743	45	59	cerebral palsy	Disease	D002547
Entity: 17263743	64	80	seizure disorder	Disease	D004827
Entity: 17263743	92	101	clonidine	Chemical	D003000
Entity: 17263743	106	118	restlessness	Disease	D011595
Entity: 17263743	153	161	baclofen	Chemical	D001418
Relation: 17263743	CID	92	101	D003000	45	59	D002547	false
Relation: 17263743	CID	92	101	D003000	64	80	D004827	false
Relation: 17263743	CID	92	101	D003000	106	118	D011595	false
Relation: 17263743	CID	153	161	D001418	45	59	D002547	false
Relation: 17263743	CID	153	161	D001418	64	80	D004827	false
Relation: 17263743	CID	153	161	D001418	106	118	D011595	false

Sentence: Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety.
Entity: 17263743	97	106	clonidine	Chemical	D003000
Entity: 17263743	166	173	anxiety	Disease	D001008
Relation: 17263743	CID	97	106	D003000	166	173	D001008	false

Sentence: Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the convulsive, lethal, locomotor stimulatory and rewarding actions of cocaine in mice.
Entity: 17241657	85	95	convulsive	Disease	D012640
Entity: 17241657	152	159	cocaine	Chemical	D003042
Relation: 17241657	CID	152	159	D003042	85	95	D012640	true

Sentence: In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)-SM 21 significantly attenuated cocaine induced convulsions and locomotor activity, but not lethality.
Entity: 17241657	63	68	UMB24	Chemical	C519696
Entity: 17241657	78	83	SM 21	Chemical	C107044
Entity: 17241657	109	116	cocaine	Chemical	D003042
Entity: 17241657	125	136	convulsions	Disease	D012640
Relation: 17241657	CID	63	68	C519696	125	136	D012640	false
Relation: 17241657	CID	78	83	C107044	125	136	D012640	false
Relation: 17241657	CID	109	116	D003042	125	136	D012640	true

Sentence: Methimazole induced cholestatic jaundice.
Entity: 14982270	0	11	Methimazole	Chemical	D008713
Entity: 14982270	20	40	cholestatic jaundice	Disease	D041781
Relation: 14982270	CID	0	11	D008713	20	40	D041781	true

Sentence: A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.
Entity: 14982270	31	39	jaundice	Disease	D007565
Entity: 14982270	44	51	itching	Disease	D011537
Entity: 14982270	76	87	methimazole	Chemical	D008713
Entity: 14982270	104	115	propranolol	Chemical	D011433
Entity: 14982270	145	160	hyperthyroidism	Disease	D006980
Relation: 14982270	CID	76	87	D008713	31	39	D007565	false
Relation: 14982270	CID	76	87	D008713	44	51	D011537	true
Relation: 14982270	CID	76	87	D008713	145	160	D006980	false
Relation: 14982270	CID	104	115	D011433	31	39	D007565	false
Relation: 14982270	CID	104	115	D011433	44	51	D011537	false
Relation: 14982270	CID	104	115	D011433	145	160	D006980	false

Sentence: Methimazole induced cholestasis was diagnosed, and propranolol therapy was resumed.
Entity: 14982270	0	11	Methimazole	Chemical	D008713
Entity: 14982270	20	31	cholestasis	Disease	D002779
Entity: 14982270	51	62	propranolol	Chemical	D011433
Relation: 14982270	CID	0	11	D008713	20	31	D002779	false
Relation: 14982270	CID	51	62	D011433	20	31	D002779	false

Sentence: Ciprofloxacin induced acute interstitial nephritis and autoimmune hemolytic anemia.
Entity: 12911170	0	13	Ciprofloxacin	Chemical	D002939
Entity: 12911170	28	50	interstitial nephritis	Disease	D009395
Entity: 12911170	55	82	autoimmune hemolytic anemia	Disease	D000744
Relation: 12911170	CID	0	13	D002939	28	50	D009395	true
Relation: 12911170	CID	0	13	D002939	55	82	D000744	false

Sentence: Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia.
Entity: 12911170	0	13	Ciprofloxacin	Chemical	D002939
Entity: 12911170	70	92	interstitial nephritis	Disease	D009395
Entity: 12911170	97	113	hemolytic anemia	Disease	D000743
Relation: 12911170	CID	0	13	D002939	70	92	D009395	true
Relation: 12911170	CID	0	13	D002939	97	113	D000743	true

Sentence: In this report, we describe a case of ciprofloxacin induced interstitial nephritis and autoimmune hemolytic anemia.
Entity: 12911170	38	51	ciprofloxacin	Chemical	D002939
Entity: 12911170	60	82	interstitial nephritis	Disease	D009395
Entity: 12911170	87	114	autoimmune hemolytic anemia	Disease	D000744
Relation: 12911170	CID	38	51	D002939	60	82	D009395	true
Relation: 12911170	CID	38	51	D002939	87	114	D000744	false

Sentence: Hemolytic anemia improved after stopping the drug and initiation of steroid therapy.
Entity: 12911170	0	16	Hemolytic anemia	Disease	D000743
Entity: 12911170	68	75	steroid	Chemical	D013256
Relation: 12911170	CID	68	75	D013256	0	16	D000743	false

Sentence: Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone.
Entity: 11195262	16	32	sodium valproate	Chemical	D014635
Entity: 11195262	40	99	syndrome of inappropriate secretion of antidiuretic hormone	Disease	D007177
Relation: 11195262	CID	16	32	D014635	40	99	D007177	true

Sentence: We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
Entity: 11195262	61	77	sodium valproate	Chemical	D014635
Entity: 11195262	79	82	VPA	Chemical	D014635
Entity: 11195262	119	178	syndrome of inappropriate secretion of antidiuretic hormone	Disease	D007177
Entity: 11195262	180	185	SIADH	Disease	D007177
Relation: 11195262	CID	61	77	D014635	119	178	D007177	true
Relation: 11195262	CID	61	77	D014635	180	185	D007177	true
Relation: 11195262	CID	79	82	D014635	119	178	D007177	true
Relation: 11195262	CID	79	82	D014635	180	185	D007177	true

Sentence: He had been taking VPA for treatment of idiopathic generalized tonic-clonic convulsions since he was 56 years old.
Entity: 11195262	19	22	VPA	Chemical	D014635
Entity: 11195262	63	87	tonic-clonic convulsions	Disease	D004830
Relation: 11195262	CID	19	22	D014635	63	87	D004830	false

Sentence: Vasopressin in the treatment of milrinone induced hypotension in severe heart failure.
Entity: 10728962	0	11	Vasopressin	Chemical	D014667
Entity: 10728962	32	41	milrinone	Chemical	D020105
Entity: 10728962	50	61	hypotension	Disease	D007022
Entity: 10728962	72	85	heart failure	Disease	D006333
Relation: 10728962	CID	0	11	D014667	50	61	D007022	true
Relation: 10728962	CID	0	11	D014667	72	85	D006333	false
Relation: 10728962	CID	32	41	D020105	50	61	D007022	true
Relation: 10728962	CID	32	41	D020105	72	85	D006333	false

Sentence: The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.
Entity: 10728962	48	57	milrinone	Chemical	D020105
Entity: 10728962	85	98	heart failure	Disease	D006333
Entity: 10728962	160	171	hypotension	Disease	D007022
Relation: 10728962	CID	48	57	D020105	85	98	D006333	false
Relation: 10728962	CID	48	57	D020105	160	171	D007022	true

Sentence: Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type hepatic injury both alone and following previous exposure to halothane.
Entity: 7647582	29	38	enflurane	Chemical	D004737
Entity: 7647582	43	53	isoflurane	Chemical	D007530
Entity: 7647582	98	112	hepatic injury	Disease	D056486
Entity: 7647582	159	168	halothane	Chemical	D006221
Relation: 7647582	CID	29	38	D004737	98	112	D056486	true
Relation: 7647582	CID	43	53	D007530	98	112	D056486	true
Relation: 7647582	CID	159	168	D006221	98	112	D056486	true

Sentence: Halothane hepatitis appears to involve an aberrant immune response.
Entity: 7647582	0	9	Halothane	Chemical	D006221
Entity: 7647582	10	19	hepatitis	Disease	D056486
Relation: 7647582	CID	0	9	D006221	10	19	D056486	true

Sentence: An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on halothane hepatitis patients.
Entity: 7647582	67	82	trifluoroacetyl	Chemical	D014269
Entity: 7647582	112	121	halothane	Chemical	D006221
Entity: 7647582	122	131	hepatitis	Disease	D056486
Relation: 7647582	CID	67	82	D014269	122	131	D056486	false
Relation: 7647582	CID	112	121	D006221	122	131	D056486	true

Sentence: This study was performed to determine cross-reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane.
Entity: 7647582	63	72	enflurane	Chemical	D004737
Entity: 7647582	77	87	isoflurane	Chemical	D007530
Entity: 7647582	97	113	hypersensitivity	Disease	D004342
Entity: 7647582	125	134	halothane	Chemical	D006221
Relation: 7647582	CID	63	72	D004737	97	113	D004342	false
Relation: 7647582	CID	77	87	D007530	97	113	D004342	false
Relation: 7647582	CID	125	134	D006221	97	113	D004342	false

Sentence: Induction by paracetamol of bladder and liver tumours in the rat.
Entity: 4090988	13	24	paracetamol	Chemical	D000082
Entity: 4090988	28	35	bladder	Disease	D001749
Entity: 4090988	40	45	liver	Disease	D008113
Relation: 4090988	CID	13	24	D000082	28	35	D001749	true
Relation: 4090988	CID	13	24	D000082	40	45	D008113	true

Sentence: Papillomas of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.
Entity: 4090988	0	10	Papillomas	Disease	D010212
Entity: 4090988	74	85	paracetamol	Chemical	D000082
Entity: 4090988	122	140	bladder carcinomas	Disease	D001749
Relation: 4090988	CID	74	85	D000082	0	10	D010212	false
Relation: 4090988	CID	74	85	D000082	122	140	D001749	true

Sentence: Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.
Entity: 4090988	27	38	paracetamol	Chemical	D000082
Entity: 4090988	62	73	hyperplasia	Disease	D006965
Entity: 4090988	147	162	bladder calculi	Disease	D001744
Relation: 4090988	CID	27	38	D000082	62	73	D006965	true
Relation: 4090988	CID	27	38	D000082	147	162	D001744	false

Sentence: A low yield of tumours at various other sites also arose following paracetamol feeding.
Entity: 4090988	15	22	tumours	Disease	D009369
Entity: 4090988	67	78	paracetamol	Chemical	D000082
Relation: 4090988	CID	67	78	D000082	15	22	D009369	false

Sentence: In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.
Entity: 4038130	15	28	muscle damage	Disease	D009135
Entity: 4038130	108	119	mepivacaine	Chemical	D008619
Entity: 4038130	124	133	lidocaine	Chemical	D008012
Entity: 4038130	139	150	epinephrine	Chemical	D004837
Relation: 4038130	CID	108	119	D008619	15	28	D009135	true
Relation: 4038130	CID	124	133	D008012	15	28	D009135	true
Relation: 4038130	CID	139	150	D004837	15	28	D009135	false

Sentence: Reversal of neuroleptic induced catalepsy by novel aryl-piperazine anxiolytic drugs.
Entity: 2907585	32	41	catalepsy	Disease	D002375
Entity: 2907585	51	66	aryl-piperazine	Chemical	-1
Relation: 2907585	CID	51	66	-1	32	41	D002375	false

Sentence: The novel anxiolytic drug, buspirone, reverses catalepsy induced by haloperidol.
Entity: 2907585	27	36	buspirone	Chemical	D002065
Entity: 2907585	47	56	catalepsy	Disease	D002375
Entity: 2907585	68	79	haloperidol	Chemical	D006220
Relation: 2907585	CID	27	36	D002065	47	56	D002375	false
Relation: 2907585	CID	68	79	D006220	47	56	D002375	true

Sentence: A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.
Entity: 2907585	12	27	aryl-piperazine	Chemical	-1
Entity: 2907585	41	50	buspirone	Chemical	D002065
Entity: 2907585	61	93	5-hydroxytryptaminergic agonists	Chemical	D058825
Entity: 2907585	135	146	haloperidol	Chemical	D006220
Entity: 2907585	155	164	catalepsy	Disease	D002375
Relation: 2907585	CID	12	27	-1	155	164	D002375	false
Relation: 2907585	CID	41	50	D002065	155	164	D002375	false
Relation: 2907585	CID	61	93	D058825	155	164	D002375	false
Relation: 2907585	CID	135	146	D006220	155	164	D002375	true

Sentence: Those drugs with strong affinity for 5-hydroxytryptamine1a receptors were able to reverse catalepsy.
Entity: 2907585	37	56	5-hydroxytryptamine	Chemical	D012701
Entity: 2907585	90	99	catalepsy	Disease	D002375
Relation: 2907585	CID	37	56	D012701	90	99	D002375	false

Sentence: Diazepam facilitates reflex bradycardia in conscious rats.
Entity: 2894433	0	8	Diazepam	Chemical	D003975
Entity: 2894433	28	39	bradycardia	Disease	D001919
Relation: 2894433	CID	0	8	D003975	28	39	D001919	true

Sentence: Also, reflex bradycardia was produced in rats by intravenous infusion of adrenaline (1.25-2.5 micrograms kg-1).
Entity: 2894433	13	24	bradycardia	Disease	D001919
Entity: 2894433	73	83	adrenaline	Chemical	D004837
Relation: 2894433	CID	73	83	D004837	13	24	D001919	true

Sentence: Intravenous pretreatment of the rats with diazepam, although causing no change in the adrenaline induced pressor effect, did enhance the adrenaline induced reflex bradycardia.
Entity: 2894433	42	50	diazepam	Chemical	D003975
Entity: 2894433	86	96	adrenaline	Chemical	D004837
Entity: 2894433	137	147	adrenaline	Chemical	D004837
Entity: 2894433	163	174	bradycardia	Disease	D001919
Relation: 2894433	CID	42	50	D003975	163	174	D001919	true
Relation: 2894433	CID	86	96	D004837	163	174	D001919	true
Relation: 2894433	CID	137	147	D004837	163	174	D001919	true

Sentence: However, the diazepam enhancement of adrenaline induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).
Entity: 2894433	13	21	diazepam	Chemical	D003975
Entity: 2894433	37	47	adrenaline	Chemical	D004837
Entity: 2894433	63	74	bradycardia	Disease	D001919
Entity: 2894433	143	153	picrotoxin	Chemical	D010852
Entity: 2894433	171	179	chloride	Chemical	D002712
Entity: 2894433	229	243	benzodiazepine	Chemical	D001569
Entity: 2894433	244	248	GABA	Chemical	D005680
Entity: 2894433	249	257	chloride	Chemical	D002712
Relation: 2894433	CID	13	21	D003975	63	74	D001919	true
Relation: 2894433	CID	37	47	D004837	63	74	D001919	true
Relation: 2894433	CID	143	153	D010852	63	74	D001919	false
Relation: 2894433	CID	171	179	D002712	63	74	D001919	false
Relation: 2894433	CID	229	243	D001569	63	74	D001919	false
Relation: 2894433	CID	244	248	D005680	63	74	D001919	false
Relation: 2894433	CID	249	257	D002712	63	74	D001919	false

Sentence: Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine.
Entity: 2790457	8	21	carbamazepine	Chemical	D002220
Entity: 2790457	67	75	seizures	Disease	D012640
Entity: 2790457	87	94	cocaine	Chemical	D003042
Entity: 2790457	99	108	lidocaine	Chemical	D008012
Relation: 2790457	CID	8	21	D002220	67	75	D012640	false
Relation: 2790457	CID	87	94	D003042	67	75	D012640	true
Relation: 2790457	CID	99	108	D008012	67	75	D012640	true

Sentence: The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.
Entity: 2790457	15	28	carbamazepine	Chemical	D002220
Entity: 2790457	30	33	CBZ	Chemical	D002220
Entity: 2790457	73	81	seizures	Disease	D012640
Entity: 2790457	186	189	CBZ	Chemical	D002220
Relation: 2790457	CID	15	28	D002220	73	81	D012640	false
Relation: 2790457	CID	30	33	D002220	73	81	D012640	false
Relation: 2790457	CID	186	189	D002220	73	81	D012640	false

Sentence: Chronic oral CBZ inhibited the development of both lidocaine- and cocaine induced seizures, but had little effect on the fully developed local anesthetic seizures.
Entity: 2790457	13	16	CBZ	Chemical	D002220
Entity: 2790457	51	60	lidocaine	Chemical	D008012
Entity: 2790457	66	73	cocaine	Chemical	D003042
Entity: 2790457	82	90	seizures	Disease	D012640
Entity: 2790457	154	162	seizures	Disease	D012640
Relation: 2790457	CID	13	16	D002220	82	90	D012640	false
Relation: 2790457	CID	13	16	D002220	154	162	D012640	false
Relation: 2790457	CID	51	60	D008012	82	90	D012640	true
Relation: 2790457	CID	51	60	D008012	154	162	D012640	true
Relation: 2790457	CID	66	73	D003042	82	90	D012640	true
Relation: 2790457	CID	66	73	D003042	154	162	D012640	true

Sentence: Chronic CBZ also decreased the incidence of seizure-related mortality in the cocaine-injected rats.
Entity: 2790457	8	11	CBZ	Chemical	D002220
Entity: 2790457	44	51	seizure	Disease	D012640
Entity: 2790457	77	84	cocaine	Chemical	D003042
Relation: 2790457	CID	8	11	D002220	44	51	D012640	false
Relation: 2790457	CID	77	84	D003042	44	51	D012640	true

Sentence: Acute CBZ over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine induced seizures.
Entity: 2790457	6	9	CBZ	Chemical	D002220
Entity: 2790457	73	82	lidocaine	Chemical	D008012
Entity: 2790457	100	107	cocaine	Chemical	D003042
Entity: 2790457	116	124	seizures	Disease	D012640
Relation: 2790457	CID	6	9	D002220	116	124	D012640	false
Relation: 2790457	CID	73	82	D008012	116	124	D012640	true
Relation: 2790457	CID	100	107	D003042	116	124	D012640	true

Sentence: Repeated i.p. injection of CBZ (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled seizures.
Entity: 2790457	27	30	CBZ	Chemical	D002220
Entity: 2790457	88	97	lidocaine	Chemical	D008012
Entity: 2790457	102	109	cocaine	Chemical	D003042
Entity: 2790457	118	126	seizures	Disease	D012640
Relation: 2790457	CID	27	30	D002220	118	126	D012640	false
Relation: 2790457	CID	88	97	D008012	118	126	D012640	true
Relation: 2790457	CID	102	109	D003042	118	126	D012640	true

Sentence: The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic-kindled seizures.
Entity: 2790457	28	31	CBZ	Chemical	D002220
Entity: 2790457	56	63	seizure	Disease	D012640
Entity: 2790457	181	189	seizures	Disease	D012640
Relation: 2790457	CID	28	31	D002220	56	63	D012640	false
Relation: 2790457	CID	28	31	D002220	181	189	D012640	false

Sentence: D-penicillamine in the treatment of localized scleroderma.
Entity: 2334179	0	15	D-penicillamine	Chemical	D010396
Entity: 2334179	36	57	localized scleroderma	Disease	D012594
Relation: 2334179	CID	0	15	D010396	36	57	D012594	false

Sentence: Case reports of 11 patients with severe, extensive localized scleroderma who were treated with D-penicillamine are summarized in this article.
Entity: 2334179	51	72	localized scleroderma	Disease	D012594
Entity: 2334179	95	110	D-penicillamine	Chemical	D010396
Relation: 2334179	CID	95	110	D010396	51	72	D012594	false

Sentence: D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.
Entity: 2334179	0	15	D-Penicillamine	Chemical	D010396
Entity: 2334179	23	41	nephrotic syndrome	Disease	D009404
Entity: 2334179	77	88	proteinuria	Disease	D011507
Entity: 2334179	125	144	renal insufficiency	Disease	D051437
Relation: 2334179	CID	0	15	D010396	23	41	D009404	true
Relation: 2334179	CID	0	15	D010396	77	88	D011507	true
Relation: 2334179	CID	0	15	D010396	125	144	D051437	false

Sentence: Preservation of renal blood flow during hypotension induced with fenoldopam in dogs.
Entity: 1969772	40	51	hypotension	Disease	D007022
Entity: 1969772	65	75	fenoldopam	Chemical	D018818
Relation: 1969772	CID	65	75	D018818	40	51	D007022	true

Sentence: The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested.
Entity: 1969772	20	30	fenoldopam	Chemical	D018818
Entity: 1969772	55	66	hypotension	Disease	D007022
Relation: 1969772	CID	20	30	D018818	55	66	D007022	true

Sentence: Renal blood flow (RBF) increased during fenoldopam induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside induced hypotension (P less than 0.01).
Entity: 1969772	40	50	fenoldopam	Chemical	D018818
Entity: 1969772	59	70	hypotension	Disease	D007022
Entity: 1969772	128	134	sodium	Chemical	D012964
Entity: 1969772	135	148	nitroprusside	Chemical	D009599
Entity: 1969772	157	168	hypotension	Disease	D007022
Relation: 1969772	CID	40	50	D018818	59	70	D007022	true
Relation: 1969772	CID	40	50	D018818	157	168	D007022	true
Relation: 1969772	CID	128	134	D012964	59	70	D007022	false
Relation: 1969772	CID	128	134	D012964	157	168	D007022	false
Relation: 1969772	CID	135	148	D009599	59	70	D007022	true
Relation: 1969772	CID	135	148	D009599	157	168	D007022	true

Sentence: Sodium nitroprusside is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension.
Entity: 1969772	7	20	nitroprusside	Chemical	D009599
Entity: 1969772	156	167	hypotension	Disease	D007022
Relation: 1969772	CID	7	20	D009599	156	167	D007022	true

Sentence: Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias.
Entity: 1700207	45	56	cibenzoline	Chemical	C032151
Entity: 1700207	67	90	ventricular arrhythmias	Disease	D001145
Relation: 1700207	CID	45	56	C032151	67	90	D001145	false

Sentence: Antiarrhythmic effects of (+)-cibenzoline and (-)-cibenzoline were examined using two canine ventricular arrhythmia models.
Entity: 1700207	30	41	cibenzoline	Chemical	C032151
Entity: 1700207	50	61	cibenzoline	Chemical	C032151
Entity: 1700207	93	115	ventricular arrhythmia	Disease	D001145
Relation: 1700207	CID	30	41	C032151	93	115	D001145	false
Relation: 1700207	CID	50	61	C032151	93	115	D001145	false

Sentence: Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.
Entity: 1700207	0	9	Digitalis	Chemical	D004070
Entity: 1700207	10	20	arrhythmia	Disease	D001145
Entity: 1700207	45	47	Na	Chemical	D012964
Entity: 1700207	126	133	ouabain	Chemical	D010042
Entity: 1700207	137	150	pentobarbital	Chemical	D010424
Relation: 1700207	CID	0	9	D004070	10	20	D001145	false
Relation: 1700207	CID	45	47	D012964	10	20	D001145	false
Relation: 1700207	CID	126	133	D010042	10	20	D001145	true
Relation: 1700207	CID	137	150	D010424	10	20	D001145	false

Sentence: Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.
Entity: 1700207	0	21	Adrenaline arrhythmia	Disease	D001145
Entity: 1700207	46	48	Ca	Chemical	D002118
Entity: 1700207	82	92	adrenaline	Chemical	D004837
Entity: 1700207	105	114	halothane	Chemical	D006221
Relation: 1700207	CID	46	48	D002118	0	21	D001145	false
Relation: 1700207	CID	82	92	D004837	0	21	D001145	true
Relation: 1700207	CID	105	114	D006221	0	21	D001145	false

Sentence: (+)-cibenzoline suppressed digitalis- and adrenaline induced arrhythmias, respectively.
Entity: 1700207	4	15	cibenzoline	Chemical	C032151
Entity: 1700207	27	36	digitalis	Chemical	D004070
Entity: 1700207	42	52	adrenaline	Chemical	D004837
Entity: 1700207	61	72	arrhythmias	Disease	D001145
Relation: 1700207	CID	4	15	C032151	61	72	D001145	false
Relation: 1700207	CID	27	36	D004070	61	72	D001145	false
Relation: 1700207	CID	42	52	D004837	61	72	D001145	true

Sentence: The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).
Entity: 1700207	51	62	cibenzoline	Chemical	C032151
Entity: 1700207	67	76	digitalis	Chemical	D004070
Entity: 1700207	82	92	adrenaline	Chemical	D004837
Entity: 1700207	101	112	arrhythmias	Disease	D001145
Relation: 1700207	CID	51	62	C032151	101	112	D001145	false
Relation: 1700207	CID	67	76	D004070	101	112	D001145	false
Relation: 1700207	CID	82	92	D004837	101	112	D001145	true

Sentence: A lower dose of 1 mg/kg i.v. of (-)-cibenzoline suppressed the digitalis induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress adrenaline induced arrhythmias.
Entity: 1700207	36	47	cibenzoline	Chemical	C032151
Entity: 1700207	63	72	digitalis	Chemical	D004070
Entity: 1700207	81	91	arrhythmia	Disease	D001145
Entity: 1700207	137	147	adrenaline	Chemical	D004837
Entity: 1700207	156	167	arrhythmias	Disease	D001145
Relation: 1700207	CID	36	47	C032151	81	91	D001145	false
Relation: 1700207	CID	36	47	C032151	156	167	D001145	false
Relation: 1700207	CID	63	72	D004070	81	91	D001145	false
Relation: 1700207	CID	63	72	D004070	156	167	D001145	false
Relation: 1700207	CID	137	147	D004837	81	91	D001145	true
Relation: 1700207	CID	137	147	D004837	156	167	D001145	true

Sentence: The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).
Entity: 1700207	51	62	cibenzoline	Chemical	C032151
Entity: 1700207	67	76	digitalis	Chemical	D004070
Entity: 1700207	82	92	adrenaline	Chemical	D004837
Entity: 1700207	101	111	arrhythmia	Disease	D001145
Relation: 1700207	CID	51	62	C032151	101	111	D001145	false
Relation: 1700207	CID	67	76	D004070	101	111	D001145	false
Relation: 1700207	CID	82	92	D004837	101	111	D001145	true

Sentence: Effect of methanolic extract of Hibiscus rosa sinensis (100-300 mg/kg) was studied on reserpine induced orofacial dyskinesia and neurochemical alterations.
Entity: 19761039	32	54	Hibiscus rosa sinensis	Chemical	D010936
Entity: 19761039	86	95	reserpine	Chemical	D012110
Entity: 19761039	114	124	dyskinesia	Disease	D004409
Relation: 19761039	CID	32	54	D010936	114	124	D004409	false
Relation: 19761039	CID	86	95	D012110	114	124	D004409	true

Sentence: Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma.
Entity: 11704023	44	51	timolol	Chemical	D013999
Entity: 11704023	129	137	glaucoma	Disease	D005901
Relation: 11704023	CID	44	51	D013999	129	137	D005901	false

Sentence: DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous timolol (timolol solution) and a 0.5% timolol suspension that forms a gel on application to the conjunctiva (timolol gellan) on the 24-hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate.
Entity: 11704023	65	72	timolol	Chemical	D013999
Entity: 11704023	74	81	timolol	Chemical	D013999
Entity: 11704023	103	110	timolol	Chemical	D013999
Entity: 11704023	174	181	timolol	Chemical	D013999
Entity: 11704023	256	264	glaucoma	Disease	D005901
Relation: 11704023	CID	65	72	D013999	256	264	D005901	false
Relation: 11704023	CID	74	81	D013999	256	264	D005901	false
Relation: 11704023	CID	103	110	D013999	256	264	D005901	false
Relation: 11704023	CID	174	181	D013999	256	264	D005901	false

Sentence: METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).
Entity: 11704023	53	72	open-angle glaucoma	Disease	D005902
Entity: 11704023	76	95	ocular hypertension	Disease	D009798
Entity: 11704023	271	278	timolol	Chemical	D013999
Entity: 11704023	327	334	timolol	Chemical	D013999
Relation: 11704023	CID	271	278	D013999	53	72	D005902	false
Relation: 11704023	CID	271	278	D013999	76	95	D009798	false
Relation: 11704023	CID	327	334	D013999	53	72	D005902	false
Relation: 11704023	CID	327	334	D013999	76	95	D009798	false

Sentence: 5 flourouracil induced apical ballooning syndrome: a case report.
Entity: 19300240	0	14	5 flourouracil	Chemical	D005472
Entity: 19300240	23	49	apical ballooning syndrome	Disease	D054549
Relation: 19300240	CID	0	14	D005472	23	49	D054549	true

Sentence: She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.
Entity: 19300240	39	51	fluorouracil	Chemical	D005472
Entity: 19300240	67	84	colorectal cancer	Disease	D015179
Relation: 19300240	CID	39	51	D005472	67	84	D015179	false

Sentence: Reduction of pain during induction with target-controlled propofol and remifentanil.
Entity: 18006530	13	17	pain	Disease	D010146
Entity: 18006530	58	66	propofol	Chemical	D015742
Entity: 18006530	71	83	remifentanil	Chemical	C071741
Relation: 18006530	CID	58	66	D015742	13	17	D010146	true
Relation: 18006530	CID	71	83	C071741	13	17	D010146	false

Sentence: BACKGROUND: Pain on injection of propofol is unpleasant.
Entity: 18006530	12	16	Pain	Disease	D010146
Entity: 18006530	33	41	propofol	Chemical	D015742
Relation: 18006530	CID	33	41	D015742	12	16	D010146	true

Sentence: We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.
Entity: 18006530	21	29	propofol	Chemical	D015742
Entity: 18006530	39	43	pain	Disease	D010146
Entity: 18006530	75	87	remifentanil	Chemical	C071741
Entity: 18006530	108	116	propofol	Chemical	D015742
Relation: 18006530	CID	21	29	D015742	39	43	D010146	true
Relation: 18006530	CID	75	87	C071741	39	43	D010146	false
Relation: 18006530	CID	108	116	D015742	39	43	D010146	true

Sentence: A prospective, randomized, double-blind, placebo-controlled trial was performed to determine the effect-site concentration (Ce) of remifentanil to prevent the pain without producing complications.
Entity: 18006530	131	143	remifentanil	Chemical	C071741
Entity: 18006530	159	163	pain	Disease	D010146
Relation: 18006530	CID	131	143	C071741	159	163	D010146	false

Sentence: Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.
Entity: 18006530	0	12	Remifentanil	Chemical	C071741
Entity: 18006530	60	72	remifentanil	Chemical	C071741
Entity: 18006530	87	91	pain	Disease	D010146
Entity: 18006530	102	110	propofol	Chemical	D015742
Entity: 18006530	161	169	propofol	Chemical	D015742
Relation: 18006530	CID	0	12	C071741	87	91	D010146	false
Relation: 18006530	CID	60	72	C071741	87	91	D010146	false
Relation: 18006530	CID	102	110	D015742	87	91	D010146	true
Relation: 18006530	CID	161	169	D015742	87	91	D010146	true

Sentence: Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat.
Entity: 17702969	21	31	fluoxetine	Chemical	D005473
Entity: 17702969	40	45	fetal	Disease	D005315
Entity: 17702969	46	55	pulmonary	Disease	D006976
Relation: 17702969	CID	21	31	D005473	40	45	D005315	true
Relation: 17702969	CID	21	31	D005473	46	55	D006976	true

Sentence: Epidemiological data suggest that fluoxetine exposure prenatally increases the prevalence of persistent pulmonary hypertension syndrome of the newborn.
Entity: 17702969	34	44	fluoxetine	Chemical	D005473
Entity: 17702969	104	135	pulmonary hypertension syndrome	Disease	D006976
Relation: 17702969	CID	34	44	D005473	104	135	D006976	true

Sentence: The mechanism responsible for this effect is unclear and paradoxical, considering the current evidence of a pulmonary hypertension protective fluoxetine effect in adult rodents.
Entity: 17702969	108	130	pulmonary hypertension	Disease	D006976
Entity: 17702969	142	152	fluoxetine	Chemical	D005473
Relation: 17702969	CID	142	152	D005473	108	130	D006976	true

Sentence: As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).
Entity: 17702969	27	37	fluoxetine	Chemical	D005473
Entity: 17702969	59	64	fetal	Disease	D005315
Entity: 17702969	65	74	pulmonary	Disease	D006976
Relation: 17702969	CID	27	37	D005473	59	64	D005315	true
Relation: 17702969	CID	27	37	D005473	65	74	D006976	true

Sentence: Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.
Entity: 17344330	0	7	Syncope	Disease	D013575
Entity: 17344330	12	27	QT prolongation	Disease	D008133
Entity: 17344330	56	65	methadone	Chemical	D008691
Entity: 17344330	70	76	heroin	Chemical	D003932
Relation: 17344330	CID	56	65	D008691	0	7	D013575	true
Relation: 17344330	CID	56	65	D008691	12	27	D008133	true
Relation: 17344330	CID	70	76	D003932	0	7	D013575	false
Relation: 17344330	CID	70	76	D003932	12	27	D008133	false

Sentence: Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.
Entity: 17344330	60	78	torsade de pointes	Disease	D016171
Entity: 17344330	80	83	TdP	Disease	D016171
Entity: 17344330	106	115	methadone	Chemical	D008691
Relation: 17344330	CID	106	115	D008691	60	78	D016171	false
Relation: 17344330	CID	106	115	D008691	80	83	D016171	false

Sentence: As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.
Entity: 17344330	3	9	heroin	Chemical	D003932
Entity: 17344330	106	113	syncope	Disease	D013575
Entity: 17344330	177	180	TdP	Disease	D016171
Entity: 17344330	306	315	methadone	Chemical	D008691
Relation: 17344330	CID	3	9	D003932	106	113	D013575	false
Relation: 17344330	CID	3	9	D003932	177	180	D016171	false
Relation: 17344330	CID	306	315	D008691	106	113	D013575	true
Relation: 17344330	CID	306	315	D008691	177	180	D016171	false

Sentence: The association between opioid dose and QT, and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression, respectively.
Entity: 17344330	48	57	methadone	Chemical	D008691
Entity: 17344330	80	87	syncope	Disease	D013575
Relation: 17344330	CID	48	57	D008691	80	87	D013575	true

Sentence: Among the subjects treated with methadone, 28% men and 32% women had prolonged QTc interval.
Entity: 17344330	32	41	methadone	Chemical	D008691
Entity: 17344330	69	91	prolonged QTc interval	Disease	D008133
Relation: 17344330	CID	32	41	D008691	69	91	D008133	true

Sentence: A 50 mg higher methadone dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for syncope.
Entity: 17344330	15	24	methadone	Chemical	D008691
Entity: 17344330	98	105	syncope	Disease	D013575
Relation: 17344330	CID	15	24	D008691	98	105	D013575	true

Sentence: Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.
Entity: 16826348	0	21	Peripheral neuropathy	Disease	D010523
Entity: 16826348	42	62	cytosine arabinoside	Chemical	D003561
Entity: 16826348	91	113	acute myeloid leukemia	Disease	D015470
Relation: 16826348	CID	42	62	D003561	0	21	D010523	true
Relation: 16826348	CID	42	62	D003561	91	113	D015470	false

Sentence: The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.
Entity: 16826348	27	35	toxicity	Disease	D064420
Entity: 16826348	49	69	cytosine arabinoside	Chemical	D003561
Entity: 16826348	98	106	toxicity	Disease	D064420
Entity: 16826348	110	130	cytosine arabinoside	Chemical	D003561
Relation: 16826348	CID	49	69	D003561	27	35	D064420	false
Relation: 16826348	CID	49	69	D003561	98	106	D064420	false
Relation: 16826348	CID	110	130	D003561	27	35	D064420	false
Relation: 16826348	CID	110	130	D003561	98	106	D064420	false

Sentence: The first course of high-dose cytosine arabinoside resulted in no unusual symptoms, but on day 21 of the second course of treatment, the patient complained of numbness in his right foot.
Entity: 16826348	30	50	cytosine arabinoside	Chemical	D003561
Entity: 16826348	159	167	numbness	Disease	D006987
Relation: 16826348	CID	30	50	D003561	159	167	D006987	false

Sentence: This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to methylprednisolone.
Entity: 16826348	5	15	neuropathy	Disease	D009422
Entity: 16826348	164	189	graft-versus-host disease	Disease	D006086
Entity: 16826348	234	252	methylprednisolone	Chemical	D008775
Relation: 16826348	CID	234	252	D008775	5	15	D009422	false
Relation: 16826348	CID	234	252	D008775	164	189	D006086	false

Sentence: Atorvastatin prevented and reversed dexamethasone induced hypertension in the rat.
Entity: 16820346	0	12	Atorvastatin	Chemical	C065179
Entity: 16820346	36	49	dexamethasone	Chemical	D003907
Entity: 16820346	58	70	hypertension	Disease	D006973
Relation: 16820346	CID	0	12	C065179	58	70	D006973	false
Relation: 16820346	CID	36	49	D003907	58	70	D006973	true

Sentence: To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex) induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.
Entity: 16820346	37	49	atorvastatin	Chemical	C065179
Entity: 16820346	51	57	atorva	Chemical	C065179
Entity: 16820346	62	75	dexamethasone	Chemical	D003907
Entity: 16820346	77	80	dex	Chemical	D003907
Entity: 16820346	90	102	hypertension	Disease	D006973
Entity: 16820346	150	156	atorva	Chemical	C065179
Relation: 16820346	CID	37	49	C065179	90	102	D006973	false
Relation: 16820346	CID	51	57	C065179	90	102	D006973	false
Relation: 16820346	CID	62	75	D003907	90	102	D006973	true
Relation: 16820346	CID	77	80	D003907	90	102	D006973	true
Relation: 16820346	CID	150	156	C065179	90	102	D006973	false

Sentence: Atorva reversed dex induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).
Entity: 16820346	0	6	Atorva	Chemical	C065179
Entity: 16820346	16	19	dex	Chemical	D003907
Entity: 16820346	28	40	hypertension	Disease	D006973
Entity: 16820346	113	123	superoxide	Chemical	D013481
Entity: 16820346	140	143	dex	Chemical	D003907
Entity: 16820346	160	166	atorva	Chemical	C065179
Entity: 16820346	169	172	dex	Chemical	D003907
Relation: 16820346	CID	0	6	C065179	28	40	D006973	false
Relation: 16820346	CID	16	19	D003907	28	40	D006973	true
Relation: 16820346	CID	113	123	D013481	28	40	D006973	false
Relation: 16820346	CID	140	143	D003907	28	40	D006973	true
Relation: 16820346	CID	160	166	C065179	28	40	D006973	false
Relation: 16820346	CID	169	172	D003907	28	40	D006973	true

Sentence: Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.
Entity: 15974569	43	50	kainate	Chemical	D007608
Entity: 15974569	106	110	pain	Disease	D010146
Relation: 15974569	CID	43	50	D007608	106	110	D010146	false

Sentence: Erythropoietin restores the anemia induced reduction in cyclophosphamide cytotoxicity in rat tumors.
Entity: 11245434	28	34	anemia	Disease	D000740
Entity: 11245434	56	72	cyclophosphamide	Chemical	D003520
Entity: 11245434	73	85	cytotoxicity	Disease	D064420
Entity: 11245434	93	99	tumors	Disease	D009369
Relation: 11245434	CID	56	72	D003520	28	34	D000740	false
Relation: 11245434	CID	56	72	D003520	73	85	D064420	false
Relation: 11245434	CID	56	72	D003520	93	99	D009369	false

Sentence: The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.
Entity: 11245434	51	57	anemia	Disease	D000740
Entity: 11245434	131	143	cytotoxicity	Disease	D064420
Entity: 11245434	147	163	cyclophosphamide	Chemical	D003520
Entity: 11245434	186	192	tumors	Disease	D009369
Relation: 11245434	CID	147	163	D003520	51	57	D000740	false
Relation: 11245434	CID	147	163	D003520	131	143	D064420	false
Relation: 11245434	CID	147	163	D003520	186	192	D009369	false

Sentence: Anemia was induced using a single dose of carboplatin (50 mg/kg i.v.) resulting in a long-lasting reduction (30%) of the hemoglobin concentration.
Entity: 11245434	0	6	Anemia	Disease	D000740
Entity: 11245434	42	53	carboplatin	Chemical	D016190
Relation: 11245434	CID	42	53	D016190	0	6	D000740	true

Sentence: In a second group, the development of anemia was prevented by rHuEPO (1000 IU/kg) administered s.c. three times/week starting 7 days before carboplatin application.
Entity: 11245434	38	44	anemia	Disease	D000740
Entity: 11245434	140	151	carboplatin	Chemical	D016190
Relation: 11245434	CID	140	151	D016190	38	44	D000740	true

Sentence: Four days after carboplatin treatment, tumors (DS-sarcoma of the rat) were implanted s.c. onto the hind food dorsum.
Entity: 11245434	16	27	carboplatin	Chemical	D016190
Entity: 11245434	39	45	tumors	Disease	D009369
Entity: 11245434	50	57	sarcoma	Disease	D012509
Relation: 11245434	CID	16	27	D016190	39	45	D009369	false
Relation: 11245434	CID	16	27	D016190	50	57	D012509	false

Sentence: Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.
Entity: 11245434	8	19	carboplatin	Chemical	D016190
Entity: 11245434	52	57	tumor	Disease	D009369
Relation: 11245434	CID	8	19	D016190	52	57	D009369	false

Sentence: When tumors were treated with a single dose of cyclophosphamide (60 mg/kg i.p.) 5 days after implantation, a growth delay with a subsequent regrowth of the tumors was observed.
Entity: 11245434	5	11	tumors	Disease	D009369
Entity: 11245434	47	63	cyclophosphamide	Chemical	D003520
Entity: 11245434	156	162	tumors	Disease	D009369
Relation: 11245434	CID	47	63	D003520	5	11	D009369	false
Relation: 11245434	CID	47	63	D003520	156	162	D009369	false

Sentence: The role of nitrergic system in lidocaine induced convulsion in the mouse.
Entity: 11243580	32	41	lidocaine	Chemical	D008012
Entity: 11243580	50	60	convulsion	Disease	D012640
Relation: 11243580	CID	32	41	D008012	50	60	D012640	true

Sentence: The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine induced convulsions.
Entity: 11243580	15	46	N-nitro-L-arginine-methyl ester	Chemical	D019331
Entity: 11243580	48	54	L-NAME	Chemical	D019331
Entity: 11243580	58	70	nitric oxide	Chemical	D009569
Entity: 11243580	72	74	NO	Chemical	D009569
Entity: 11243580	99	109	L-arginine	Chemical	D001120
Entity: 11243580	113	115	NO	Chemical	D009569
Entity: 11243580	148	157	lidocaine	Chemical	D008012
Entity: 11243580	166	177	convulsions	Disease	D012640
Relation: 11243580	CID	15	46	D019331	166	177	D012640	false
Relation: 11243580	CID	48	54	D019331	166	177	D012640	false
Relation: 11243580	CID	58	70	D009569	166	177	D012640	false
Relation: 11243580	CID	72	74	D009569	166	177	D012640	false
Relation: 11243580	CID	99	109	D001120	166	177	D012640	false
Relation: 11243580	CID	113	115	D009569	166	177	D012640	false
Relation: 11243580	CID	148	157	D008012	166	177	D012640	true

Sentence: L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg) induced convulsions.
Entity: 11243580	0	6	L-NAME	Chemical	D019331
Entity: 11243580	29	37	diazepam	Chemical	D003975
Entity: 11243580	89	98	lidocaine	Chemical	D008012
Entity: 11243580	118	129	convulsions	Disease	D012640
Relation: 11243580	CID	0	6	D019331	118	129	D012640	false
Relation: 11243580	CID	29	37	D003975	118	129	D012640	false
Relation: 11243580	CID	89	98	D008012	118	129	D012640	true

Sentence: In contrast, the L-arginine treatment increased the incidence of lidocaine (80 mg/kg, i.p.) induced convulsions significantly.
Entity: 11243580	17	27	L-arginine	Chemical	D001120
Entity: 11243580	65	74	lidocaine	Chemical	D008012
Entity: 11243580	100	111	convulsions	Disease	D012640
Relation: 11243580	CID	17	27	D001120	100	111	D012640	false
Relation: 11243580	CID	65	74	D008012	100	111	D012640	true

Sentence: Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine induced myocardial ischemia.
Entity: 11079278	22	32	metoprolol	Chemical	D008790
Entity: 11079278	48	58	metoprolol	Chemical	D008790
Entity: 11079278	76	86	dobutamine	Chemical	D004280
Entity: 11079278	95	114	myocardial ischemia	Disease	D017202
Relation: 11079278	CID	22	32	D008790	95	114	D017202	false
Relation: 11079278	CID	48	58	D008790	95	114	D017202	false
Relation: 11079278	CID	76	86	D004280	95	114	D017202	true

Sentence: Prednisolone induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression.
Entity: 10910842	0	12	Prednisolone	Chemical	D011239
Entity: 10910842	21	39	muscle dysfunction	Disease	D018908
Entity: 10910842	58	65	atrophy	Disease	D001284
Entity: 10910842	82	95	acetylcholine	Chemical	D000109
Relation: 10910842	CID	0	12	D011239	21	39	D018908	true
Relation: 10910842	CID	0	12	D011239	58	65	D001284	false
Relation: 10910842	CID	82	95	D000109	21	39	D018908	false
Relation: 10910842	CID	82	95	D000109	58	65	D001284	false

Sentence: On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.
Entity: 10910842	49	56	tetanic	Disease	D013746
Entity: 10910842	117	131	d-tubocurarine	Chemical	D014403
Relation: 10910842	CID	117	131	D014403	49	56	D013746	false

Sentence: Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.
Entity: 10910842	29	54	neuromuscular dysfunction	Disease	D009468
Entity: 10910842	61	73	prednisolone	Chemical	D011239
Entity: 10910842	120	134	muscle atrophy	Disease	D009133
Relation: 10910842	CID	61	73	D011239	29	54	D009468	false
Relation: 10910842	CID	61	73	D011239	120	134	D009133	true

Sentence: Rapid reversal of life-threatening diltiazem induced tetany with calcium chloride.
Entity: 10533019	35	44	diltiazem	Chemical	D004110
Entity: 10533019	53	59	tetany	Disease	D013746
Entity: 10533019	65	81	calcium chloride	Chemical	D002122
Relation: 10533019	CID	35	44	D004110	53	59	D013746	true
Relation: 10533019	CID	65	81	D002122	53	59	D013746	false

Sentence: We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem.
Entity: 10533019	36	42	tetany	Disease	D013746
Entity: 10533019	55	73	respiratory arrest	Disease	D012131
Entity: 10533019	108	117	diltiazem	Chemical	D004110
Relation: 10533019	CID	108	117	D004110	36	42	D013746	true
Relation: 10533019	CID	108	117	D004110	55	73	D012131	false

Sentence: The administration of calcium chloride rapidly resolved the patient's tetany with prompt recovery of respiratory function, averting the need for more aggressive airway management and ventilatory support.
Entity: 10533019	22	38	calcium chloride	Chemical	D002122
Entity: 10533019	70	76	tetany	Disease	D013746
Relation: 10533019	CID	22	38	D002122	70	76	D013746	false

Sentence: Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.
Entity: 10414674	14	48	aneurysmal subarachnoid hemorrhage	Disease	D013345
Entity: 10414674	50	53	SAH	Disease	D013345
Entity: 10414674	89	99	ketoprofen	Chemical	D007660
Entity: 10414674	128	138	ketoprofen	Chemical	D007660
Entity: 10414674	170	183	acetaminophen	Chemical	D000082
Entity: 10414674	209	222	acetaminophen	Chemical	D000082
Entity: 10414674	281	291	aneurysmal	Disease	D017542
Entity: 10414674	292	295	SAH	Disease	D013345
Relation: 10414674	CID	89	99	D007660	14	48	D013345	false
Relation: 10414674	CID	89	99	D007660	50	53	D013345	false
Relation: 10414674	CID	89	99	D007660	281	291	D017542	false
Relation: 10414674	CID	89	99	D007660	292	295	D013345	false
Relation: 10414674	CID	128	138	D007660	14	48	D013345	false
Relation: 10414674	CID	128	138	D007660	50	53	D013345	false
Relation: 10414674	CID	128	138	D007660	281	291	D017542	false
Relation: 10414674	CID	128	138	D007660	292	295	D013345	false
Relation: 10414674	CID	170	183	D000082	14	48	D013345	false
Relation: 10414674	CID	170	183	D000082	50	53	D013345	false
Relation: 10414674	CID	170	183	D000082	281	291	D017542	false
Relation: 10414674	CID	170	183	D000082	292	295	D013345	false
Relation: 10414674	CID	209	222	D000082	14	48	D013345	false
Relation: 10414674	CID	209	222	D000082	50	53	D013345	false
Relation: 10414674	CID	209	222	D000082	281	291	D017542	false
Relation: 10414674	CID	209	222	D000082	292	295	D013345	false

Sentence: Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.
Entity: 10414674	8	28	platelet aggregation	Disease	D001791
Entity: 10414674	52	73	adenosine diphosphate	Chemical	D000244
Entity: 10414674	108	118	ketoprofen	Chemical	D007660
Relation: 10414674	CID	52	73	D000244	8	28	D001791	false
Relation: 10414674	CID	108	118	D007660	8	28	D001791	true

Sentence: In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).
Entity: 10414674	21	41	platelet aggregation	Disease	D001791
Entity: 10414674	59	72	acetaminophen	Chemical	D000082
Entity: 10414674	144	164	platelet aggregation	Disease	D001791
Relation: 10414674	CID	59	72	D000082	21	41	D001791	false
Relation: 10414674	CID	59	72	D000082	144	164	D001791	false

Sentence: One patient in the ketoprofen group developed a postoperative intracranial hematoma.
Entity: 10414674	19	29	ketoprofen	Chemical	D007660
Entity: 10414674	75	83	hematoma	Disease	D006406
Relation: 10414674	CID	19	29	D007660	75	83	D006406	true

Sentence: Ketoprofen but not acetaminophen impaired platelet function in patients with SAH.
Entity: 10414674	0	10	Ketoprofen	Chemical	D007660
Entity: 10414674	19	32	acetaminophen	Chemical	D000082
Entity: 10414674	77	80	SAH	Disease	D013345
Relation: 10414674	CID	0	10	D007660	77	80	D013345	false
Relation: 10414674	CID	19	32	D000082	77	80	D013345	false

Sentence: Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.
Entity: 9523850	9	27	methylprednisolone	Chemical	D008775
Entity: 9523850	49	59	arthralgia	Disease	D018771
Entity: 9523850	60	67	myalgia	Disease	D063806
Entity: 9523850	120	132	iron dextran	Chemical	D007505
Relation: 9523850	CID	9	27	D008775	49	59	D018771	false
Relation: 9523850	CID	9	27	D008775	60	67	D063806	false
Relation: 9523850	CID	120	132	D007505	49	59	D018771	true
Relation: 9523850	CID	120	132	D007505	60	67	D063806	false

Sentence: These data demonstrate that administration of MP before and after TDI reduces the frequency and severity of the arthralgia-myalgia syndrome.
Entity: 9523850	46	48	MP	Chemical	D008775
Entity: 9523850	112	122	arthralgia	Disease	D018771
Entity: 9523850	123	130	myalgia	Disease	D063806
Relation: 9523850	CID	46	48	D008775	112	122	D018771	false
Relation: 9523850	CID	46	48	D008775	123	130	D063806	false

Sentence: Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.
Entity: 8384253	20	42	Non-Hodgkin's Lymphoma	Disease	D008228
Entity: 8384253	56	67	vincristine	Chemical	D014750
Entity: 8384253	193	204	vincristine	Chemical	D014750
Relation: 8384253	CID	56	67	D014750	20	42	D008228	false
Relation: 8384253	CID	193	204	D014750	20	42	D008228	false

Sentence: A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.
Entity: 8268147	10	22	polymyositis	Disease	D017285
Entity: 8268147	41	66	primary biliary cirrhosis	Disease	D008105
Entity: 8268147	80	95	D-penicillamine	Chemical	D010396
Relation: 8268147	CID	80	95	D010396	10	22	D017285	true
Relation: 8268147	CID	80	95	D010396	41	66	D008105	false

Sentence: Although D-penicillamine has been used for many rheumatologic diseases, toxicity limits its usefulness in many patients.
Entity: 8268147	9	24	D-penicillamine	Chemical	D010396
Entity: 8268147	48	70	rheumatologic diseases	Disease	D012216
Entity: 8268147	72	80	toxicity	Disease	D064420
Relation: 8268147	CID	9	24	D010396	48	70	D012216	false
Relation: 8268147	CID	9	24	D010396	72	80	D064420	false

Sentence: Polymyositis/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear.
Entity: 8268147	0	12	Polymyositis	Disease	D017285
Entity: 8268147	13	28	dermatomyositis	Disease	D003882
Entity: 8268147	83	98	D-penicillamine	Chemical	D010396
Relation: 8268147	CID	83	98	D010396	0	12	D017285	true
Relation: 8268147	CID	83	98	D010396	13	28	D003882	false

Sentence: We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy.
Entity: 8268147	25	50	primary biliary cirrhosis	Disease	D008105
Entity: 8268147	66	78	polymyositis	Disease	D017285
Entity: 8268147	95	110	D-penicillamine	Chemical	D010396
Relation: 8268147	CID	95	110	D010396	25	50	D008105	false
Relation: 8268147	CID	95	110	D010396	66	78	D017285	true

Sentence: Photodistributed nifedipine induced facial telangiectasia.
Entity: 8251368	17	27	nifedipine	Chemical	D009543
Entity: 8251368	43	57	telangiectasia	Disease	D013684
Relation: 8251368	CID	17	27	D009543	43	57	D013684	true

Sentence: Five months after starting nifedipine (Adalat), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.
Entity: 8251368	27	37	nifedipine	Chemical	D009543
Entity: 8251368	39	45	Adalat	Chemical	D009543
Entity: 8251368	95	109	telangiectasia	Disease	D013684
Relation: 8251368	CID	27	37	D009543	95	109	D013684	true
Relation: 8251368	CID	39	45	D009543	95	109	D013684	true

Sentence: One commenced the closely related drug amlodipine 3 years later, with recurrence of telangiectasia.
Entity: 8251368	39	49	amlodipine	Chemical	D017311
Entity: 8251368	84	98	telangiectasia	Disease	D013684
Relation: 8251368	CID	39	49	D017311	84	98	D013684	true

Sentence: Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.
Entity: 7542793	0	14	Nephrotoxicity	Disease	D007674
Entity: 7542793	18	31	cyclosporin A	Chemical	D016572
Entity: 7542793	36	41	FK506	Chemical	D016559
Relation: 7542793	CID	18	31	D016572	0	14	D007674	true
Relation: 7542793	CID	36	41	D016559	0	14	D007674	true

Sentence: Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.
Entity: 7542793	0	13	Cyclosporin A	Chemical	D016572
Entity: 7542793	15	18	CsA	Chemical	D016572
Entity: 7542793	34	44	Fujimycine	Chemical	D016559
Entity: 7542793	46	51	FK506	Chemical	D016559
Entity: 7542793	83	92	macrolide	Chemical	D018942
Entity: 7542793	111	120	rapamycin	Chemical	D020123
Entity: 7542793	239	250	hypertrophy	Disease	D006984
Relation: 7542793	CID	0	13	D016572	239	250	D006984	false
Relation: 7542793	CID	15	18	D016572	239	250	D006984	false
Relation: 7542793	CID	34	44	D016559	239	250	D006984	false
Relation: 7542793	CID	46	51	D016559	239	250	D006984	false
Relation: 7542793	CID	83	92	D018942	239	250	D006984	false
Relation: 7542793	CID	111	120	D020123	239	250	D006984	false

Sentence: The molecular mechanisms of CsA and FK506 toxicity were investigated.
Entity: 7542793	28	31	CsA	Chemical	D016572
Entity: 7542793	36	41	FK506	Chemical	D016559
Entity: 7542793	42	50	toxicity	Disease	D064420
Relation: 7542793	CID	28	31	D016572	42	50	D064420	false
Relation: 7542793	CID	36	41	D016559	42	50	D064420	false

Sentence: Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.
Entity: 7337133	8	22	cerebral edema	Disease	D001929
Entity: 7337133	49	64	hepatic failure	Disease	D017093
Entity: 7337133	68	81	acetaminophen	Chemical	D000082
Entity: 7337133	82	90	overdose	Disease	D062787
Relation: 7337133	CID	68	81	D000082	8	22	D001929	true
Relation: 7337133	CID	68	81	D000082	49	64	D017093	true
Relation: 7337133	CID	68	81	D000082	82	90	D062787	false

Sentence: Gentamicin nephropathy in a neonate.
Entity: 4069770	0	10	Gentamicin	Chemical	D005839
Entity: 4069770	11	22	nephropathy	Disease	D007674
Relation: 4069770	CID	0	10	D005839	11	22	D007674	false

Sentence: The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.
Entity: 4069770	66	85	acute renal failure	Disease	D058186
Entity: 4069770	105	115	gentamicin	Chemical	D005839
Entity: 4069770	134	144	penicillin	Chemical	D010406
Relation: 4069770	CID	105	115	D005839	66	85	D058186	true
Relation: 4069770	CID	134	144	D010406	66	85	D058186	false

Sentence: The serum gentamicin concentration had reached toxic levels when anuria developed.
Entity: 4069770	10	20	gentamicin	Chemical	D005839
Entity: 4069770	65	71	anuria	Disease	D001002
Relation: 4069770	CID	10	20	D005839	65	71	D001002	false

Sentence: Anti-carcinogenic action of phenobarbital given simultaneously with diethylnitrosamine in the rat.
Entity: 3780814	5	17	carcinogenic	Disease	D063646
Entity: 3780814	28	41	phenobarbital	Chemical	D010634
Entity: 3780814	68	86	diethylnitrosamine	Chemical	D004052
Relation: 3780814	CID	28	41	D010634	5	17	D063646	false
Relation: 3780814	CID	68	86	D004052	5	17	D063646	false

Sentence: The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).
Entity: 3780814	70	83	phenobarbital	Chemical	D010634
Entity: 3780814	85	87	PB	Chemical	D010634
Entity: 3780814	124	138	carcinogenesis	Disease	D063646
Entity: 3780814	183	201	diethylnitrosamine	Chemical	D004052
Entity: 3780814	203	206	DEN	Chemical	D004052
Relation: 3780814	CID	70	83	D010634	124	138	D063646	false
Relation: 3780814	CID	85	87	D010634	124	138	D063646	false
Relation: 3780814	CID	183	201	D004052	124	138	D063646	false
Relation: 3780814	CID	203	206	D004052	124	138	D063646	false

Sentence: Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.
Entity: 3780814	36	39	DEN	Chemical	D004052
Entity: 3780814	52	55	DEN	Chemical	D004052
Entity: 3780814	58	60	PB	Chemical	D010634
Entity: 3780814	115	135	hepatocarcinogenesis	Disease	D063646
Relation: 3780814	CID	36	39	D004052	115	135	D063646	false
Relation: 3780814	CID	52	55	D004052	115	135	D063646	false
Relation: 3780814	CID	58	60	D010634	115	135	D063646	false

Sentence: After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.
Entity: 3780814	80	98	preneoplastic foci	Disease	D011230
Entity: 3780814	130	132	PB	Chemical	D010634
Entity: 3780814	163	166	DEN	Chemical	D004052
Relation: 3780814	CID	130	132	D010634	80	98	D011230	false
Relation: 3780814	CID	163	166	D004052	80	98	D011230	true

Sentence: In DEN + PB treated rats, the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone.
Entity: 3780814	3	6	DEN	Chemical	D004052
Entity: 3780814	9	11	PB	Chemical	D010634
Entity: 3780814	61	66	tumor	Disease	D009369
Entity: 3780814	128	131	DEN	Chemical	D004052
Relation: 3780814	CID	3	6	D004052	61	66	D009369	false
Relation: 3780814	CID	9	11	D010634	61	66	D009369	false
Relation: 3780814	CID	128	131	D004052	61	66	D009369	false

Sentence: It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.
Entity: 3780814	21	23	PB	Chemical	D010634
Entity: 3780814	40	54	carcinogenesis	Disease	D063646
Entity: 3780814	83	86	DEN	Chemical	D004052
Entity: 3780814	159	162	DEN	Chemical	D004052
Relation: 3780814	CID	21	23	D010634	40	54	D063646	false
Relation: 3780814	CID	83	86	D004052	40	54	D063646	false
Relation: 3780814	CID	159	162	D004052	40	54	D063646	false

Sentence: Post-operative rigidity after fentanyl administration.
Entity: 3780697	15	23	rigidity	Disease	D009127
Entity: 3780697	30	38	fentanyl	Chemical	D005283
Relation: 3780697	CID	30	38	D005283	15	23	D009127	true

Sentence: A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.
Entity: 3780697	28	36	rigidity	Disease	D009127
Entity: 3780697	48	67	respiratory failure	Disease	D012131
Entity: 3780697	164	172	fentanyl	Chemical	D005283
Relation: 3780697	CID	164	172	D005283	28	36	D009127	true
Relation: 3780697	CID	164	172	D005283	48	67	D012131	false

Sentence: Postpartum psychosis induced by bromocriptine.
Entity: 3686155	11	20	psychosis	Disease	D011605
Entity: 3686155	32	45	bromocriptine	Chemical	D001971
Relation: 3686155	CID	32	45	D001971	11	20	D011605	true

Sentence: Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.
Entity: 3686155	40	51	psychiatric	Disease	D001523
Entity: 3686155	86	95	psychosis	Disease	D011605
Entity: 3686155	113	126	bromocriptine	Chemical	D001971
Entity: 3686155	131	154	inhibition of lactation	Disease	D007775
Relation: 3686155	CID	113	126	D001971	40	51	D001523	false
Relation: 3686155	CID	113	126	D001971	86	95	D011605	true
Relation: 3686155	CID	113	126	D001971	131	154	D007775	false

Sentence: Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.
Entity: 3686155	0	13	Bromocriptine	Chemical	D001971
Entity: 3686155	59	68	psychosis	Disease	D011605
Entity: 3686155	104	123	Parkinson's disease	Disease	D010300
Relation: 3686155	CID	0	13	D001971	59	68	D011605	true
Relation: 3686155	CID	0	13	D001971	104	123	D010300	false

Sentence: A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.
Entity: 3137399	46	60	cardiotoxicity	Disease	D066126
Entity: 3137399	72	83	mitomycin C	Chemical	D016685
Relation: 3137399	CID	72	83	D016685	46	60	D066126	false

Sentence: Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.
Entity: 3137399	11	22	mitomycin C	Chemical	D016685
Entity: 3137399	24	27	MMC	Chemical	D016685
Entity: 3137399	54	65	cardiotoxic	Disease	D066126
Entity: 3137399	116	127	doxorubicin	Chemical	D004317
Relation: 3137399	CID	11	22	D016685	54	65	D066126	false
Relation: 3137399	CID	24	27	D016685	54	65	D066126	false
Relation: 3137399	CID	116	127	D004317	54	65	D066126	false

Sentence: One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.
Entity: 3137399	30	45	cardiac failure	Disease	D006333
Entity: 3137399	62	65	MMC	Chemical	D016685
Entity: 3137399	86	97	doxorubicin	Chemical	D004317
Relation: 3137399	CID	62	65	D016685	30	45	D006333	true
Relation: 3137399	CID	86	97	D004317	30	45	D006333	true

Sentence: Phlorizin induced glycosuria does not prevent gentamicin nephrotoxicity in rats.
Entity: 2709684	0	9	Phlorizin	Chemical	D010695
Entity: 2709684	18	28	glycosuria	Disease	D006029
Entity: 2709684	46	56	gentamicin	Chemical	D005839
Entity: 2709684	57	71	nephrotoxicity	Disease	D007674
Relation: 2709684	CID	0	9	D010695	18	28	D006029	false
Relation: 2709684	CID	0	9	D010695	57	71	D007674	false
Relation: 2709684	CID	46	56	D005839	18	28	D006029	false
Relation: 2709684	CID	46	56	D005839	57	71	D007674	false

Sentence: Because rats with streptozotocin induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin induced acute renal failure (ARF).
Entity: 2709684	18	32	streptozotocin	Chemical	D013311
Entity: 2709684	41	58	diabetes mellitus	Disease	D003920
Entity: 2709684	60	62	DM	Disease	D003920
Entity: 2709684	93	103	glycosuria	Disease	D006029
Entity: 2709684	203	213	gentamicin	Chemical	D005839
Entity: 2709684	222	241	acute renal failure	Disease	D058186
Entity: 2709684	243	246	ARF	Disease	D058186
Relation: 2709684	CID	18	32	D013311	41	58	D003920	true
Relation: 2709684	CID	18	32	D013311	60	62	D003920	true
Relation: 2709684	CID	18	32	D013311	93	103	D006029	false
Relation: 2709684	CID	18	32	D013311	222	241	D058186	false
Relation: 2709684	CID	18	32	D013311	243	246	D058186	false
Relation: 2709684	CID	203	213	D005839	41	58	D003920	false
Relation: 2709684	CID	203	213	D005839	60	62	D003920	false
Relation: 2709684	CID	203	213	D005839	93	103	D006029	false
Relation: 2709684	CID	203	213	D005839	222	241	D058186	true
Relation: 2709684	CID	203	213	D005839	243	246	D058186	true

Sentence: The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).
Entity: 2709684	20	30	gentamicin	Chemical	D005839
Entity: 2709684	31	45	nephrotoxicity	Disease	D007674
Entity: 2709684	65	73	diabetic	Disease	D003920
Entity: 2709684	139	146	glucose	Chemical	D005947
Entity: 2709684	165	174	phlorizin	Chemical	D010695
Entity: 2709684	176	177	P	Chemical	D010695
Relation: 2709684	CID	20	30	D005839	31	45	D007674	false
Relation: 2709684	CID	20	30	D005839	65	73	D003920	false
Relation: 2709684	CID	139	146	D005947	31	45	D007674	false
Relation: 2709684	CID	139	146	D005947	65	73	D003920	false
Relation: 2709684	CID	165	174	D010695	31	45	D007674	false
Relation: 2709684	CID	165	174	D010695	65	73	D003920	false
Relation: 2709684	CID	176	177	D010695	31	45	D007674	false
Relation: 2709684	CID	176	177	D010695	65	73	D003920	false

Sentence: DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.
Entity: 2709684	0	2	DM	Disease	D003920
Entity: 2709684	18	28	glycosuria	Disease	D006029
Entity: 2709684	63	64	P	Chemical	D010695
Relation: 2709684	CID	63	64	D010695	0	2	D003920	false
Relation: 2709684	CID	63	64	D010695	18	28	D006029	false

Sentence: Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).
Entity: 2709684	9	10	P	Chemical	D010695
Entity: 2709684	27	28	P	Chemical	D010695
Entity: 2709684	65	66	P	Chemical	D010695
Entity: 2709684	69	79	gentamicin	Chemical	D005839
Entity: 2709684	93	103	gentamicin	Chemical	D005839
Entity: 2709684	130	132	DM	Disease	D003920
Entity: 2709684	135	145	gentamicin	Chemical	D005839
Relation: 2709684	CID	9	10	D010695	130	132	D003920	false
Relation: 2709684	CID	27	28	D010695	130	132	D003920	false
Relation: 2709684	CID	65	66	D010695	130	132	D003920	false
Relation: 2709684	CID	69	79	D005839	130	132	D003920	false
Relation: 2709684	CID	93	103	D005839	130	132	D003920	false
Relation: 2709684	CID	135	145	D005839	130	132	D003920	false

Sentence: Nephrotoxic doses (40 mg/kg body wt/day) of gentamicin were injected during the last nine days of study to the animals of groups II to IV.
Entity: 2709684	0	11	Nephrotoxic	Disease	D007674
Entity: 2709684	44	54	gentamicin	Chemical	D005839
Relation: 2709684	CID	44	54	D005839	0	11	D007674	false

Sentence: In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).
Entity: 2709684	12	13	P	Chemical	D010695
Entity: 2709684	44	54	glycosuria	Disease	D006029
Entity: 2709684	125	142	renal dysfunction	Disease	D007674
Entity: 2709684	214	230	tubular necrosis	Disease	D009956
Relation: 2709684	CID	12	13	D010695	44	54	D006029	false
Relation: 2709684	CID	12	13	D010695	125	142	D007674	false
Relation: 2709684	CID	12	13	D010695	214	230	D009956	false

Sentence: In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).
Entity: 2709684	13	14	P	Chemical	D010695
Entity: 2709684	31	41	gentamicin	Chemical	D005839
Entity: 2709684	42	45	ARF	Disease	D058186
Entity: 2709684	85	86	P	Chemical	D010695
Entity: 2709684	155	171	tubular necrosis	Disease	D009956
Relation: 2709684	CID	13	14	D010695	42	45	D058186	false
Relation: 2709684	CID	13	14	D010695	155	171	D009956	false
Relation: 2709684	CID	31	41	D005839	42	45	D058186	true
Relation: 2709684	CID	31	41	D005839	155	171	D009956	false
Relation: 2709684	CID	85	86	D010695	42	45	D058186	false
Relation: 2709684	CID	85	86	D010695	155	171	D009956	false

Sentence: Tiapride in levodopa induced involuntary movements.
Entity: 458486	0	8	Tiapride	Chemical	D063325
Entity: 458486	12	20	levodopa	Chemical	D007980
Entity: 458486	29	50	involuntary movements	Disease	D004409
Relation: 458486	CID	0	8	D063325	29	50	D004409	false
Relation: 458486	CID	12	20	D007980	29	50	D004409	true

Sentence: Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.
Entity: 458486	0	8	Tiapride	Chemical	D063325
Entity: 458486	24	33	benzamide	Chemical	C037689
Entity: 458486	64	78	metoclopramide	Chemical	D008787
Entity: 458486	88	96	levodopa	Chemical	D007980
Entity: 458486	115	136	involuntary movements	Disease	D004409
Entity: 458486	157	187	idiopathic Parkinson's disease	Disease	D010300
Relation: 458486	CID	0	8	D063325	115	136	D004409	false
Relation: 458486	CID	0	8	D063325	157	187	D010300	false
Relation: 458486	CID	24	33	C037689	115	136	D004409	false
Relation: 458486	CID	24	33	C037689	157	187	D010300	false
Relation: 458486	CID	64	78	D008787	115	136	D004409	false
Relation: 458486	CID	64	78	D008787	157	187	D010300	false
Relation: 458486	CID	88	96	D007980	115	136	D004409	true
Relation: 458486	CID	88	96	D007980	157	187	D010300	false

Sentence: Tiapride had no effect on levodopa induced early morning of "off-period" segmental dystonia.
Entity: 458486	0	8	Tiapride	Chemical	D063325
Entity: 458486	26	34	levodopa	Chemical	D007980
Entity: 458486	83	91	dystonia	Disease	D004421
Relation: 458486	CID	0	8	D063325	83	91	D004421	false
Relation: 458486	CID	26	34	D007980	83	91	D004421	false

Sentence: Effects of the hippocampal deep brain stimulation on cortical epileptic discharges in penicillin - induced epilepsy model in rats.
Entity: 21294084	62	71	epileptic	Disease	D004827
Entity: 21294084	86	96	penicillin	Chemical	D010406
Entity: 21294084	107	115	epilepsy	Disease	D004827
Relation: 21294084	CID	86	96	D010406	62	71	D004827	false
Relation: 21294084	CID	86	96	D010406	107	115	D004827	false

Sentence: The aim was to evaluate the effects of high frequency hippocampal stimulation on cortical epileptic activity in penicillin induced epilepsy model.
Entity: 21294084	90	99	epileptic	Disease	D004827
Entity: 21294084	112	122	penicillin	Chemical	D010406
Entity: 21294084	131	139	epilepsy	Disease	D004827
Relation: 21294084	CID	112	122	D010406	90	99	D004827	false
Relation: 21294084	CID	112	122	D010406	131	139	D004827	false

Sentence: RESULTS: High frequency hippocampal DBS suppressed the acute penicillin induced cortical epileptic activity independent from stimulus intensity.
Entity: 21294084	61	71	penicillin	Chemical	D010406
Entity: 21294084	89	98	epileptic	Disease	D004827
Relation: 21294084	CID	61	71	D010406	89	98	D004827	false

Sentence: Neural correlates of S-ketamine induced psychosis during overt continuous verbal fluency.
Entity: 20727411	21	31	S-ketamine	Chemical	-1
Entity: 20727411	40	49	psychosis	Disease	D011605
Relation: 20727411	CID	21	31	-1	40	49	D011605	false

Sentence: The glutamatergic N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia.
Entity: 20727411	18	38	N-methyl-D-aspartate	Chemical	D016202
Entity: 20727411	40	44	NMDA	Chemical	D016202
Entity: 20727411	101	114	schizophrenia	Disease	D012559
Relation: 20727411	CID	18	38	D016202	101	114	D012559	false
Relation: 20727411	CID	40	44	D016202	101	114	D012559	false

Sentence: Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia.
Entity: 20727411	80	84	NMDA	Chemical	D016202
Entity: 20727411	105	113	ketamine	Chemical	D007649
Entity: 20727411	180	193	schizophrenia	Disease	D012559
Relation: 20727411	CID	80	84	D016202	180	193	D012559	false
Relation: 20727411	CID	105	113	D007649	180	193	D012559	false

Sentence: In patients with schizophrenia, ketamine exacerbates the core symptoms of illness, supporting the hypothesis of a glutamatergic dysfunction.
Entity: 20727411	17	30	schizophrenia	Disease	D012559
Entity: 20727411	32	40	ketamine	Chemical	D007649
Entity: 20727411	114	139	glutamatergic dysfunction	Disease	D018754
Relation: 20727411	CID	32	40	D007649	17	30	D012559	false
Relation: 20727411	CID	32	40	D007649	114	139	D018754	false

Sentence: Ketamine elicited psychosis like psychopathology.
Entity: 20727411	0	8	Ketamine	Chemical	D007649
Entity: 20727411	18	27	psychosis	Disease	D011605
Relation: 20727411	CID	0	8	D007649	18	27	D011605	true

Sentence: Ketamine induces activation changes in healthy subjects similar to those observed in patients with schizophrenia, particularly in frontal and temporal brain regions.
Entity: 20727411	0	8	Ketamine	Chemical	D007649
Entity: 20727411	99	112	schizophrenia	Disease	D012559
Relation: 20727411	CID	0	8	D007649	99	112	D012559	false

Sentence: Dopamine is not essential for the development of methamphetamine induced neurotoxicity.
Entity: 20533999	0	8	Dopamine	Chemical	D004298
Entity: 20533999	49	64	methamphetamine	Chemical	D008694
Entity: 20533999	73	86	neurotoxicity	Disease	D020258
Relation: 20533999	CID	0	8	D004298	73	86	D020258	false
Relation: 20533999	CID	49	64	D008694	73	86	D020258	true

Sentence: It is widely believed that dopamine (DA) mediates methamphetamine (METH) induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.
Entity: 20533999	27	35	dopamine	Chemical	D004298
Entity: 20533999	37	39	DA	Chemical	D004298
Entity: 20533999	50	65	methamphetamine	Chemical	D008694
Entity: 20533999	67	71	METH	Chemical	D008694
Entity: 20533999	81	89	toxicity	Disease	D064420
Entity: 20533999	155	157	DA	Chemical	D004298
Entity: 20533999	185	193	toxicity	Disease	D064420
Entity: 20533999	223	225	DA	Chemical	D004298
Entity: 20533999	252	260	toxicity	Disease	D064420
Relation: 20533999	CID	27	35	D004298	81	89	D064420	false
Relation: 20533999	CID	27	35	D004298	185	193	D064420	false
Relation: 20533999	CID	27	35	D004298	252	260	D064420	false
Relation: 20533999	CID	37	39	D004298	81	89	D064420	false
Relation: 20533999	CID	37	39	D004298	185	193	D064420	false
Relation: 20533999	CID	37	39	D004298	252	260	D064420	false
Relation: 20533999	CID	50	65	D008694	81	89	D064420	false
Relation: 20533999	CID	50	65	D008694	185	193	D064420	false
Relation: 20533999	CID	50	65	D008694	252	260	D064420	false
Relation: 20533999	CID	67	71	D008694	81	89	D064420	false
Relation: 20533999	CID	67	71	D008694	185	193	D064420	false
Relation: 20533999	CID	67	71	D008694	252	260	D064420	false
Relation: 20533999	CID	155	157	D004298	81	89	D064420	false
Relation: 20533999	CID	155	157	D004298	185	193	D064420	false
Relation: 20533999	CID	155	157	D004298	252	260	D064420	false
Relation: 20533999	CID	223	225	D004298	81	89	D064420	false
Relation: 20533999	CID	223	225	D004298	185	193	D064420	false
Relation: 20533999	CID	223	225	D004298	252	260	D064420	false

Sentence: Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH induced DA neurotoxicity is also confounded by drug effects on body temperature.
Entity: 20533999	51	75	L-dihydroxyphenylalanine	Chemical	D007980
Entity: 20533999	112	138	alpha-methyl-para-tyrosine	Chemical	D019805
Entity: 20533999	142	146	METH	Chemical	D008694
Entity: 20533999	155	157	DA	Chemical	D004298
Entity: 20533999	158	171	neurotoxicity	Disease	D020258
Relation: 20533999	CID	51	75	D007980	158	171	D020258	false
Relation: 20533999	CID	112	138	D019805	158	171	D020258	false
Relation: 20533999	CID	142	146	D008694	158	171	D020258	true
Relation: 20533999	CID	155	157	D004298	158	171	D020258	false

Sentence: Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.
Entity: 20533999	75	77	DA	Chemical	D004298
Entity: 20533999	86	90	METH	Chemical	D008694
Entity: 20533999	91	104	neurotoxicity	Disease	D020258
Entity: 20533999	140	144	METH	Chemical	D008694
Relation: 20533999	CID	75	77	D004298	91	104	D020258	false
Relation: 20533999	CID	86	90	D008694	91	104	D020258	true
Relation: 20533999	CID	140	144	D008694	91	104	D020258	true

Sentence: In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.
Entity: 20533999	86	88	DA	Chemical	D004298
Entity: 20533999	106	110	METH	Chemical	D008694
Entity: 20533999	119	140	dopaminergic deficits	Disease	D009461
Relation: 20533999	CID	86	88	D004298	119	140	D009461	false
Relation: 20533999	CID	106	110	D008694	119	140	D009461	false

Sentence: Brainstem dysgenesis in an infant prenatally exposed to cocaine.
Entity: 20304337	0	20	Brainstem dysgenesis	Disease	-1
Entity: 20304337	56	63	cocaine	Chemical	D003042
Relation: 20304337	CID	56	63	D003042	0	20	-1	false

Sentence: The protective role of Nrf2 in streptozotocin induced diabetic nephropathy.
Entity: 20103708	31	45	streptozotocin	Chemical	D013311
Entity: 20103708	54	74	diabetic nephropathy	Disease	D003928
Relation: 20103708	CID	31	45	D013311	54	74	D003928	true

Sentence: OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).
Entity: 20103708	11	31	Diabetic nephropathy	Disease	D003928
Entity: 20103708	62	75	renal failure	Disease	D051437
Entity: 20103708	128	134	oxygen	Chemical	D010100
Relation: 20103708	CID	128	134	D010100	11	31	D003928	false
Relation: 20103708	CID	128	134	D010100	62	75	D051437	false

Sentence: RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.
Entity: 20103708	76	96	diabetic nephropathy	Disease	D003928
Entity: 20103708	136	156	diabetic nephropathy	Disease	D003928
Entity: 20103708	169	183	streptozotocin	Chemical	D013311
Entity: 20103708	192	212	diabetic nephropathy	Disease	D003928
Relation: 20103708	CID	169	183	D013311	76	96	D003928	true
Relation: 20103708	CID	169	183	D013311	136	156	D003928	true
Relation: 20103708	CID	169	183	D013311	192	212	D003928	true

Sentence: In the animal study, Nrf2 was demonstrated to be crucial in ameliorating streptozotocin induced renal damage.
Entity: 20103708	73	87	streptozotocin	Chemical	D013311
Entity: 20103708	96	108	renal damage	Disease	D058186
Relation: 20103708	CID	73	87	D013311	96	108	D058186	false

Sentence: High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.
Entity: 19996135	10	25	tranexamic Acid	Chemical	D014148
Entity: 19996135	66	74	seizures	Disease	D012640
Relation: 19996135	CID	10	25	D014148	66	74	D012640	true

Sentence: The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery.
Entity: 19996135	115	118	TXA	Chemical	D014148
Entity: 19996135	129	137	seizures	Disease	D012640
Relation: 19996135	CID	115	118	D014148	129	137	D012640	true

Sentence: All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures.
Entity: 19996135	21	29	seizures	Disease	D012640
Entity: 19996135	53	56	TXA	Chemical	D014148
Relation: 19996135	CID	53	56	D014148	21	29	D012640	true

Sentence: Recurrent dysosmia induced by pyrazinamide.
Entity: 19674115	10	18	dysosmia	Disease	D000857
Entity: 19674115	30	42	pyrazinamide	Chemical	D011718
Relation: 19674115	CID	30	42	D011718	10	18	D000857	true

Sentence: Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.
Entity: 19674115	0	12	Pyrazinamide	Chemical	D011718
Entity: 19674115	46	62	hepatic toxicity	Disease	D056486
Entity: 19674115	64	77	hyperuricemia	Disease	D033461
Relation: 19674115	CID	0	12	D011718	46	62	D056486	false
Relation: 19674115	CID	0	12	D011718	64	77	D033461	false

Sentence: We report a case of reversible olfactory disorder related to pyrazinamide in a woman, with a positive rechallenge.
Entity: 19674115	31	49	olfactory disorder	Disease	D000857
Entity: 19674115	61	73	pyrazinamide	Chemical	D011718
Relation: 19674115	CID	61	73	D011718	31	49	D000857	true

Sentence: Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.
Entity: 19139001	86	109	difluoromethylornithine	Chemical	D000518
Entity: 19139001	114	122	sulindac	Chemical	D013467
Entity: 19139001	150	169	colorectal adenomas	Disease	D015179
Relation: 19139001	CID	86	109	D000518	150	169	D015179	false
Relation: 19139001	CID	114	122	D013467	150	169	D015179	false

Sentence: A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.
Entity: 19139001	54	72	adenomatous polyps	Disease	D018256
Entity: 19139001	108	131	difluoromethylornithine	Chemical	D000518
Entity: 19139001	133	137	DFMO	Chemical	D000518
Entity: 19139001	144	152	sulindac	Chemical	D013467
Relation: 19139001	CID	108	131	D000518	54	72	D018256	false
Relation: 19139001	CID	133	137	D000518	54	72	D018256	false
Relation: 19139001	CID	144	152	D013467	54	72	D018256	false

Sentence: Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.
Entity: 19139001	10	22	hearing loss	Disease	D034381
Entity: 19139001	34	42	toxicity	Disease	D064420
Entity: 19139001	61	65	DFMO	Chemical	D000518
Relation: 19139001	CID	61	65	D000518	10	22	D034381	false
Relation: 19139001	CID	61	65	D000518	34	42	D064420	false

Sentence: There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group.
Entity: 19139001	73	77	DFMO	Chemical	D000518
Entity: 19139001	83	91	sulindac	Chemical	D013467
Entity: 19139001	137	149	hearing loss	Disease	D034381
Relation: 19139001	CID	73	77	D000518	137	149	D034381	false
Relation: 19139001	CID	83	91	D013467	137	149	D034381	true

Sentence: Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly.
Entity: 18239197	10	24	mental slowing	Disease	D003072
Entity: 18239197	72	87	trihexyphenidyl	Chemical	D014282
Relation: 18239197	CID	72	87	D014282	10	24	D003072	true

Sentence: OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl induced subjective effects and objective memory performance.
Entity: 18239197	122	137	trihexyphenidyl	Chemical	D014282
Entity: 18239197	174	183	confusion	Disease	D003221
Entity: 18239197	228	243	trihexyphenidyl	Chemical	D014282
Relation: 18239197	CID	122	137	D014282	174	183	D003221	false
Relation: 18239197	CID	228	243	D014282	174	183	D003221	false

Sentence: RESULTS: A 2.0-mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only.
Entity: 18239197	31	46	trihexyphenidyl	Chemical	D014282
Entity: 18239197	91	106	mental slowness	Disease	D003072
Relation: 18239197	CID	31	46	D014282	91	106	D003072	true

Sentence: Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.
Entity: 18239197	63	78	trihexyphenidyl	Chemical	D014282
Entity: 18239197	105	120	mental slowness	Disease	D003072
Relation: 18239197	CID	63	78	D014282	105	120	D003072	true

Sentence: Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.
Entity: 17194457	20	24	PCPA	Chemical	-1
Entity: 17194457	88	100	irritability	Disease	D001523
Entity: 17194457	162	172	aggression	Disease	D001523
Relation: 17194457	CID	20	24	-1	88	100	D001523	false
Relation: 17194457	CID	20	24	-1	162	172	D001523	false

Sentence: T alone had no effect on locomotion, irritability, or sexual behavior but increased partner preference and aggression.
Entity: 17194457	0	1	T	Chemical	D013739
Entity: 17194457	37	49	irritability	Disease	D001523
Entity: 17194457	107	117	aggression	Disease	D001523
Relation: 17194457	CID	0	1	D013739	37	49	D001523	true
Relation: 17194457	CID	0	1	D013739	107	117	D001523	true

Sentence: Intracavitary chemotherapy (paclitaxel/carboplatin liquid crystalline cubic phases) for recurrent glioblastoma -- clinical observations.
Entity: 16132524	28	38	paclitaxel	Chemical	D017239
Entity: 16132524	39	50	carboplatin	Chemical	D016190
Entity: 16132524	98	110	glioblastoma	Disease	D005909
Relation: 16132524	CID	28	38	D017239	98	110	D005909	false
Relation: 16132524	CID	39	50	D016190	98	110	D005909	false

Sentence: For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study.
Entity: 16132524	10	22	glioblastoma	Disease	D005909
Entity: 16132524	127	137	paclitaxel	Chemical	D017239
Entity: 16132524	142	153	carboplatin	Chemical	D016190
Relation: 16132524	CID	127	137	D017239	10	22	D005909	false
Relation: 16132524	CID	142	153	D016190	10	22	D005909	false

Sentence: A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.
Entity: 16132524	46	58	glioblastoma	Disease	D005909
Entity: 16132524	138	148	paclitaxel	Chemical	D017239
Entity: 16132524	153	164	carboplatin	Chemical	D016190
Relation: 16132524	CID	138	148	D017239	46	58	D005909	false
Relation: 16132524	CID	153	164	D016190	46	58	D005909	false

Sentence: Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.
Entity: 16132524	45	55	paclitaxel	Chemical	D017239
Entity: 16132524	93	104	brain edema	Disease	D001929
Entity: 16132524	166	176	paclitaxel	Chemical	D017239
Relation: 16132524	CID	45	55	D017239	93	104	D001929	true
Relation: 16132524	CID	166	176	D017239	93	104	D001929	true

Sentence: Methylphenidate induced obsessive-compulsive symptoms in an elderly man.
Entity: 12907924	0	15	Methylphenidate	Chemical	D008774
Entity: 12907924	24	53	obsessive-compulsive symptoms	Disease	D009771
Relation: 12907924	CID	0	15	D008774	24	53	D009771	true

Sentence: An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on methylphenidate.
Entity: 12907924	24	54	treatment-resistant depression	Disease	D061218
Entity: 12907924	65	84	Alzheimer's disease	Disease	D000544
Entity: 12907924	100	115	methylphenidate	Chemical	D008774
Relation: 12907924	CID	100	115	D008774	24	54	D061218	false
Relation: 12907924	CID	100	115	D008774	65	84	D000544	false

Sentence: Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.
Entity: 12907924	12	41	obsessive-compulsive behavior	Disease	D009771
Entity: 12907924	88	103	methylphenidate	Chemical	D008774
Entity: 12907924	120	131	fluvoxamine	Chemical	D016666
Relation: 12907924	CID	88	103	D008774	12	41	D009771	true
Relation: 12907924	CID	120	131	D016666	12	41	D009771	false

Sentence: Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.
Entity: 12139551	0	14	Cardiac arrest	Disease	D006323
Entity: 12139551	33	47	metoclopramide	Chemical	D008787
Entity: 12139551	88	102	metoclopramide	Chemical	D008787
Entity: 12139551	128	142	cardiac arrest	Disease	D006323
Relation: 12139551	CID	33	47	D008787	0	14	D006323	true
Relation: 12139551	CID	33	47	D008787	128	142	D006323	true
Relation: 12139551	CID	88	102	D008787	0	14	D006323	true
Relation: 12139551	CID	88	102	D008787	128	142	D006323	true

Sentence: We describe a patient where intravenous injection of metoclopramide was immediately followed by asystole repeatedly.
Entity: 12139551	53	67	metoclopramide	Chemical	D008787
Entity: 12139551	96	104	asystole	Disease	D006323
Relation: 12139551	CID	53	67	D008787	96	104	D006323	true

Sentence: After interviewing the attending nurses and reviewing the written documentation, it is clear that every administration of metoclopramide was immediately (within s) followed by asystole.
Entity: 12139551	122	136	metoclopramide	Chemical	D008787
Entity: 12139551	176	184	asystole	Disease	D006323
Relation: 12139551	CID	122	136	D008787	176	184	D006323	true

Sentence: We interpret this as episodes of cardiac arrest caused by metoclopramide.
Entity: 12139551	33	47	cardiac arrest	Disease	D006323
Entity: 12139551	58	72	metoclopramide	Chemical	D008787
Relation: 12139551	CID	58	72	D008787	33	47	D006323	true

Sentence: Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures.
Entity: 10411803	14	30	hemolytic anemia	Disease	D000743
Entity: 10411803	67	76	cefotetan	Chemical	D015313
Relation: 10411803	CID	67	76	D015313	14	30	D000743	true

Sentence: Second- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia.
Entity: 10411803	29	43	cephalosporins	Chemical	D002511
Entity: 10411803	56	65	cefotetan	Chemical	D015313
Entity: 10411803	131	147	hemolytic anemia	Disease	D000743
Relation: 10411803	CID	29	43	D002511	131	147	D000743	false
Relation: 10411803	CID	56	65	D015313	131	147	D000743	true

Sentence: We noticed that 10 of our 35 cases of cefotetan induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.
Entity: 10411803	38	47	cefotetan	Chemical	D015313
Entity: 10411803	56	73	hemolytic anemias	Disease	D000743
Entity: 10411803	108	117	cefotetan	Chemical	D015313
Relation: 10411803	CID	38	47	D015313	56	73	D000743	true
Relation: 10411803	CID	108	117	D015313	56	73	D000743	true

Sentence: Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.
Entity: 10225068	0	21	Cauda equina syndrome	Disease	D011128
Entity: 10225068	66	76	lignocaine	Chemical	D008012
Entity: 10225068	103	124	cauda equina syndrome	Disease	D011128
Relation: 10225068	CID	66	76	D008012	0	21	D011128	true
Relation: 10225068	CID	66	76	D008012	103	124	D011128	true

Sentence: Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5% lignocaine.
Entity: 10225068	53	66	neurotoxicity	Disease	D020258
Entity: 10225068	84	94	lignocaine	Chemical	D008012
Relation: 10225068	CID	84	94	D008012	53	66	D020258	false

Sentence: Cortical motor overactivation in parkinsonian patients with L-dopa induced peak-dose dyskinesia.
Entity: 9549528	33	45	parkinsonian	Disease	D020734
Entity: 9549528	60	66	L-dopa	Chemical	D007980
Entity: 9549528	85	95	dyskinesia	Disease	D004409
Relation: 9549528	CID	60	66	D007980	33	45	D020734	false
Relation: 9549528	CID	60	66	D007980	85	95	D004409	true

Sentence: We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.
Entity: 9549528	195	207	parkinsonian	Disease	D020734
Entity: 9549528	220	226	L-dopa	Chemical	D007980
Entity: 9549528	261	267	L-dopa	Chemical	D007980
Entity: 9549528	276	286	dyskinesia	Disease	D004409
Entity: 9549528	334	344	dyskinesia	Disease	D004409
Relation: 9549528	CID	220	226	D007980	195	207	D020734	false
Relation: 9549528	CID	220	226	D007980	276	286	D004409	true
Relation: 9549528	CID	220	226	D007980	334	344	D004409	true
Relation: 9549528	CID	261	267	D007980	195	207	D020734	false
Relation: 9549528	CID	261	267	D007980	276	286	D004409	true
Relation: 9549528	CID	261	267	D007980	334	344	D004409	true

Sentence: Dexamethasone induced ocular hypertension in perfusion-cultured human eyes.
Entity: 7843916	0	13	Dexamethasone	Chemical	D003907
Entity: 7843916	22	41	ocular hypertension	Disease	D009798
Relation: 7843916	CID	0	13	D003907	22	41	D009798	true

Sentence: In contrast, the dexamethasone-treated hypertensive eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.
Entity: 7843916	17	30	dexamethasone	Chemical	D003907
Entity: 7843916	39	56	hypertensive eyes	Disease	D009798
Relation: 7843916	CID	17	30	D003907	39	56	D009798	true

Sentence: CONCLUSION: Dexamethasone treatment of isolated, perfusion-cultured human eyes led to the generation of ocular hypertension in approximately 30% of the dexamethasone-treated eyes.
Entity: 7843916	12	25	Dexamethasone	Chemical	D003907
Entity: 7843916	104	123	ocular hypertension	Disease	D009798
Entity: 7843916	152	165	dexamethasone	Chemical	D003907
Relation: 7843916	CID	12	25	D003907	104	123	D009798	true
Relation: 7843916	CID	152	165	D003907	104	123	D009798	true

Sentence: Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.
Entity: 7843916	0	7	Steroid	Chemical	D013256
Entity: 7843916	107	130	corticosteroid glaucoma	Disease	D005901
Entity: 7843916	135	154	open angle glaucoma	Disease	D005902
Relation: 7843916	CID	0	7	D013256	107	130	D005901	false
Relation: 7843916	CID	0	7	D013256	135	154	D005902	false

Sentence: Cognitive deterioration from long-term abuse of dextromethorphan: a case report.
Entity: 7803371	0	23	Cognitive deterioration	Disease	D003072
Entity: 7803371	48	64	dextromethorphan	Chemical	D003915
Relation: 7803371	CID	48	64	D003915	0	23	D003072	true

Sentence: Complete heart block following a single dose of trazodone.
Entity: 6496797	9	20	heart block	Disease	D006327
Entity: 6496797	48	57	trazodone	Chemical	D014196
Relation: 6496797	CID	48	57	D014196	9	20	D006327	true

Sentence: Forty minutes after receiving a single starting dose of trazodone, a patient developed complete heart block.
Entity: 6496797	56	65	trazodone	Chemical	D014196
Entity: 6496797	96	107	heart block	Disease	D006327
Relation: 6496797	CID	56	65	D014196	96	107	D006327	true

Sentence: Quinidine phenylethylbarbiturate induced fulminant hepatitis in a pregnant woman.
Entity: 3411101	0	32	Quinidine phenylethylbarbiturate	Chemical	C033457
Entity: 3411101	51	60	hepatitis	Disease	D056486
Relation: 3411101	CID	0	32	C033457	51	60	D056486	true

Sentence: We report the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate.
Entity: 3411101	74	83	hepatitis	Disease	D056486
Entity: 3411101	162	194	quinidine phenylethylbarbiturate	Chemical	C033457
Relation: 3411101	CID	162	194	C033457	74	83	D056486	true

Sentence: The epidemiology of the acute flank pain syndrome from suprofen.
Entity: 2598570	30	40	flank pain	Disease	D021501
Entity: 2598570	55	63	suprofen	Chemical	D013496
Relation: 2598570	CID	55	63	D013496	30	40	D021501	true

Sentence: Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).
Entity: 2598570	107	116	hay fever	Disease	D006255
Entity: 2598570	121	127	asthma	Disease	D001249
Entity: 2598570	338	345	alcohol	Chemical	D000431
Relation: 2598570	CID	338	345	D000431	107	116	D006255	false
Relation: 2598570	CID	338	345	D000431	121	127	D001249	false

Sentence: Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.
Entity: 2598570	95	104	ibuprofen	Chemical	D007052
Entity: 2598570	119	132	renal disease	Disease	D007674
Entity: 2598570	147	160	kidney stones	Disease	D007669
Entity: 2598570	175	179	gout	Disease	D006073
Relation: 2598570	CID	95	104	D007052	119	132	D007674	false
Relation: 2598570	CID	95	104	D007052	147	160	D007669	false
Relation: 2598570	CID	95	104	D007052	175	179	D006073	false

Sentence: Hemolytic-uremic syndrome associated with ingestion of quinine.
Entity: 1415380	0	25	Hemolytic-uremic syndrome	Disease	D006463
Entity: 1415380	55	62	quinine	Chemical	D011803
Relation: 1415380	CID	55	62	D011803	0	25	D006463	true

Sentence: Hemolytic-uremic syndrome following quinine ingestion is a newly described phenomenon, with just two previous descriptions of 4 cases in the literature.
Entity: 1415380	0	25	Hemolytic-uremic syndrome	Disease	D006463
Entity: 1415380	36	43	quinine	Chemical	D011803
Relation: 1415380	CID	36	43	D011803	0	25	D006463	true

Sentence: Quinine-associated hemolytic-uremic syndrome probably occurs more often than is recognized.
Entity: 1415380	0	7	Quinine	Chemical	D011803
Entity: 1415380	19	44	hemolytic-uremic syndrome	Disease	D006463
Relation: 1415380	CID	0	7	D011803	19	44	D006463	true

Sentence: The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation.
Entity: 1255900	53	60	heparin	Chemical	D006493
Entity: 1255900	90	106	thrombophlebitis	Disease	D013924
Relation: 1255900	CID	53	60	D006493	90	106	D013924	false

Sentence: Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha-benzene hexachloride.
Entity: 85485	50	58	hepatoma	Disease	D006528
Entity: 85485	78	104	alpha-benzene hexachloride	Chemical	D001556
Relation: 85485	CID	78	104	D001556	50	58	D006528	true

Sentence: Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.
Entity: 85485	15	24	hepatomas	Disease	D006528
Entity: 85485	56	69	liver lesions	Disease	D017093
Entity: 85485	97	123	alpha-benzene hexachloride	Chemical	D001556
Relation: 85485	CID	97	123	D001556	15	24	D006528	true
Relation: 85485	CID	97	123	D001556	56	69	D017093	false

Sentence: Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.
Entity: 85485	21	30	hepatomas	Disease	D006528
Entity: 85485	56	62	tumors	Disease	D009369
Entity: 85485	119	124	tumor	Disease	D009369
Entity: 85485	150	188	ethyl-alpha-p-chlorophenoxyisobutyrate	Chemical	C012282
Relation: 85485	CID	150	188	C012282	21	30	D006528	false
Relation: 85485	CID	150	188	C012282	56	62	D009369	false
Relation: 85485	CID	150	188	C012282	119	124	D009369	false

Sentence: Quinidine hepatitis.
Entity: 48362	0	9	Quinidine	Chemical	D011802
Entity: 48362	10	19	hepatitis	Disease	D056486
Relation: 48362	CID	0	9	D011802	10	19	D056486	true

Sentence: We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver biopsy documentation.
Entity: 48362	35	44	quinidine	Chemical	D011802
Entity: 48362	45	59	hepatotoxicity	Disease	D056486
Relation: 48362	CID	35	44	D011802	45	59	D056486	true

Sentence: In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).
Entity: 9067481	64	89	cholesteryl hemisuccinate	Chemical	C013440
Entity: 9067481	91	100	tris salt	Chemical	-1
Entity: 9067481	102	104	CS	Chemical	-1
Entity: 9067481	166	177	hepatotoxic	Disease	D056486
Entity: 9067481	189	209	carbon tetrachloride	Chemical	D002251
Entity: 9067481	211	215	CCl4	Chemical	D002251
Relation: 9067481	CID	64	89	C013440	166	177	D056486	false
Relation: 9067481	CID	91	100	-1	166	177	D056486	false
Relation: 9067481	CID	102	104	-1	166	177	D056486	false
Relation: 9067481	CID	189	209	D002251	166	177	D056486	true
Relation: 9067481	CID	211	215	D002251	166	177	D056486	true

Sentence: To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine induced toxicity.
Entity: 9067481	49	51	CS	Chemical	-1
Entity: 9067481	125	127	CS	Chemical	-1
Entity: 9067481	167	169	CS	Chemical	-1
Entity: 9067481	171	203	gamma-cholesteryloxybutyric acid	Chemical	C103872
Entity: 9067481	205	214	tris salt	Chemical	-1
Entity: 9067481	216	219	CSE	Chemical	-1
Entity: 9067481	229	242	acetaminophen	Chemical	D000082
Entity: 9067481	245	255	adriamycin	Chemical	D004317
Entity: 9067481	258	278	carbon tetrachloride	Chemical	D002251
Entity: 9067481	281	291	chloroform	Chemical	D002725
Entity: 9067481	297	310	galactosamine	Chemical	D005688
Entity: 9067481	319	327	toxicity	Disease	D064420
Relation: 9067481	CID	49	51	-1	319	327	D064420	false
Relation: 9067481	CID	125	127	-1	319	327	D064420	false
Relation: 9067481	CID	167	169	-1	319	327	D064420	false
Relation: 9067481	CID	171	203	C103872	319	327	D064420	false
Relation: 9067481	CID	205	214	-1	319	327	D064420	false
Relation: 9067481	CID	216	219	-1	319	327	D064420	false
Relation: 9067481	CID	229	242	D000082	319	327	D064420	false
Relation: 9067481	CID	245	255	D004317	319	327	D064420	false
Relation: 9067481	CID	258	278	D002251	319	327	D064420	false
Relation: 9067481	CID	281	291	D002725	319	327	D064420	false
Relation: 9067481	CID	297	310	D005688	319	327	D064420	false

Sentence: A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.
Entity: 9067481	64	66	CS	Chemical	-1
Entity: 9067481	132	143	hepatotoxic	Disease	D056486
Entity: 9067481	155	159	CCl4	Chemical	D002251
Entity: 9067481	161	166	CHCl3	Chemical	D002725
Entity: 9067481	168	181	acetaminophen	Chemical	D000082
Entity: 9067481	186	199	galactosamine	Chemical	D005688
Entity: 9067481	239	250	cardiotoxic	Disease	D066126
Entity: 9067481	262	272	adriamycin	Chemical	D004317
Relation: 9067481	CID	64	66	-1	132	143	D056486	false
Relation: 9067481	CID	64	66	-1	239	250	D066126	false
Relation: 9067481	CID	155	159	D002251	132	143	D056486	true
Relation: 9067481	CID	155	159	D002251	239	250	D066126	false
Relation: 9067481	CID	161	166	D002725	132	143	D056486	true
Relation: 9067481	CID	161	166	D002725	239	250	D066126	false
Relation: 9067481	CID	168	181	D000082	132	143	D056486	true
Relation: 9067481	CID	168	181	D000082	239	250	D066126	false
Relation: 9067481	CID	186	199	D005688	132	143	D056486	true
Relation: 9067481	CID	186	199	D005688	239	250	D066126	false
Relation: 9067481	CID	262	272	D004317	132	143	D056486	false
Relation: 9067481	CID	262	272	D004317	239	250	D066126	true

Sentence: The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate (in light of the protection observed against galactosamine hepatotoxicity).
Entity: 9067481	17	19	CS	Chemical	-1
Entity: 9067481	185	198	galactosamine	Chemical	D005688
Entity: 9067481	199	213	hepatotoxicity	Disease	D056486
Relation: 9067481	CID	17	19	-1	199	213	D056486	false
Relation: 9067481	CID	185	198	D005688	199	213	D056486	true

Sentence: DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.
Entity: 19274460	47	63	cyclophosphamide	Chemical	D003520
Entity: 19274460	84	94	bortezomib	Chemical	C400082
Entity: 19274460	95	108	dexamethasone	Chemical	D003907
Entity: 19274460	166	173	myeloma	Disease	D009101
Relation: 19274460	CID	47	63	D003520	166	173	D009101	false
Relation: 19274460	CID	84	94	C400082	166	173	D009101	false
Relation: 19274460	CID	95	108	D003907	166	173	D009101	false

Sentence: A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).
Entity: 19274460	67	83	cyclophosphamide	Chemical	D003520
Entity: 19274460	104	114	bortezomib	Chemical	C400082
Entity: 19274460	119	132	dexamethasone	Chemical	D003907
Entity: 19274460	231	247	multiple myeloma	Disease	D009101
Entity: 19274460	249	251	MM	Disease	D009101
Relation: 19274460	CID	67	83	D003520	231	247	D009101	false
Relation: 19274460	CID	67	83	D003520	249	251	D009101	false
Relation: 19274460	CID	104	114	C400082	231	247	D009101	false
Relation: 19274460	CID	104	114	C400082	249	251	D009101	false
Relation: 19274460	CID	119	132	D003907	231	247	D009101	false
Relation: 19274460	CID	119	132	D003907	249	251	D009101	false

Sentence: Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.
Entity: 18201582	172	183	telmisartan	Chemical	C084178
Entity: 18201582	188	198	amlodipine	Chemical	D017311
Entity: 18201582	206	216	amlodipine	Chemical	D017311
Entity: 18201582	260	272	hypertension	Disease	D006973
Relation: 18201582	CID	172	183	C084178	260	272	D006973	false
Relation: 18201582	CID	188	198	D017311	260	272	D006973	false
Relation: 18201582	CID	206	216	D017311	260	272	D006973	false

Sentence: OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.
Entity: 18201582	120	131	telmisartan	Chemical	C084178
Entity: 18201582	140	150	amlodipine	Chemical	D017311
Entity: 18201582	176	186	amlodipine	Chemical	D017311
Entity: 18201582	247	259	hypertension	Disease	D006973
Relation: 18201582	CID	120	131	C084178	247	259	D006973	false
Relation: 18201582	CID	140	150	D017311	247	259	D006973	false
Relation: 18201582	CID	176	186	D017311	247	259	D006973	false

Sentence: Cutaneous leucocytoclastic vasculitis associated with oxacillin.
Entity: 11337188	0	37	Cutaneous leucocytoclastic vasculitis	Disease	D018366
Entity: 11337188	54	63	oxacillin	Chemical	D010068
Relation: 11337188	CID	54	63	D010068	0	37	D018366	true

Sentence: A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.
Entity: 11337188	39	48	oxacillin	Chemical	D010068
Entity: 11337188	73	87	Staphylococcus	Disease	D013203
Entity: 11337188	95	105	bacteremia	Disease	D016470
Entity: 11337188	117	130	renal failure	Disease	D051437
Entity: 11337188	164	180	purpuric lesions	Disease	D011693
Relation: 11337188	CID	39	48	D010068	73	87	D013203	false
Relation: 11337188	CID	39	48	D010068	95	105	D016470	false
Relation: 11337188	CID	39	48	D010068	117	130	D051437	true
Relation: 11337188	CID	39	48	D010068	164	180	D011693	false

Sentence: Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.
Entity: 6308526	18	28	naloxazone	Chemical	C024224
Entity: 6308526	51	59	morphine	Chemical	D009020
Entity: 6308526	60	69	analgesia	Disease	D000699
Entity: 6308526	71	80	catalepsy	Disease	D002375
Entity: 6308526	85	96	hypothermia	Disease	D007035
Relation: 6308526	CID	18	28	C024224	60	69	D000699	false
Relation: 6308526	CID	18	28	C024224	71	80	D002375	false
Relation: 6308526	CID	18	28	C024224	85	96	D007035	false
Relation: 6308526	CID	51	59	D009020	60	69	D000699	false
Relation: 6308526	CID	51	59	D009020	71	80	D002375	true
Relation: 6308526	CID	51	59	D009020	85	96	D007035	true

Sentence: Moreover, naloxazone significantly attenuated the morphine induced hypotension and respiratory depression, whereas morphine induced bradycardia was less affected.
Entity: 6308526	10	20	naloxazone	Chemical	C024224
Entity: 6308526	50	58	morphine	Chemical	D009020
Entity: 6308526	67	78	hypotension	Disease	D007022
Entity: 6308526	83	105	respiratory depression	Disease	D012131
Entity: 6308526	115	123	morphine	Chemical	D009020
Entity: 6308526	132	143	bradycardia	Disease	D001919
Relation: 6308526	CID	10	20	C024224	67	78	D007022	false
Relation: 6308526	CID	10	20	C024224	83	105	D012131	false
Relation: 6308526	CID	10	20	C024224	132	143	D001919	false
Relation: 6308526	CID	50	58	D009020	67	78	D007022	true
Relation: 6308526	CID	50	58	D009020	83	105	D012131	false
Relation: 6308526	CID	50	58	D009020	132	143	D001919	true
Relation: 6308526	CID	115	123	D009020	67	78	D007022	true
Relation: 6308526	CID	115	123	D009020	83	105	D012131	false
Relation: 6308526	CID	115	123	D009020	132	143	D001919	true

Sentence: Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
Entity: 15897593	0	11	Dexrazoxane	Chemical	D064730
Entity: 15897593	29	45	myelosuppression	Disease	D001855
Entity: 15897593	84	93	etoposide	Chemical	D005047
Entity: 15897593	98	110	daunorubicin	Chemical	D003630
Entity: 15897593	119	130	doxorubicin	Chemical	D004317
Relation: 15897593	CID	0	11	D064730	29	45	D001855	false
Relation: 15897593	CID	84	93	D005047	29	45	D001855	false
Relation: 15897593	CID	98	110	D003630	29	45	D001855	false
Relation: 15897593	CID	119	130	D004317	29	45	D001855	false

Sentence: PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.
Entity: 15897593	13	27	anthracyclines	Chemical	D018943
Entity: 15897593	28	40	daunorubicin	Chemical	D003630
Entity: 15897593	45	56	doxorubicin	Chemical	D004317
Entity: 15897593	65	83	epipodophyllotoxin	Chemical	D011034
Entity: 15897593	84	93	etoposide	Chemical	D005047
Entity: 15897593	186	202	myelosuppression	Disease	D001855
Entity: 15897593	207	223	cardiac toxicity	Disease	D066126
Relation: 15897593	CID	13	27	D018943	186	202	D001855	false
Relation: 15897593	CID	13	27	D018943	207	223	D066126	false
Relation: 15897593	CID	28	40	D003630	186	202	D001855	false
Relation: 15897593	CID	28	40	D003630	207	223	D066126	false
Relation: 15897593	CID	45	56	D004317	186	202	D001855	false
Relation: 15897593	CID	45	56	D004317	207	223	D066126	false
Relation: 15897593	CID	65	83	D011034	186	202	D001855	false
Relation: 15897593	CID	65	83	D011034	207	223	D066126	false
Relation: 15897593	CID	84	93	D005047	186	202	D001855	false
Relation: 15897593	CID	84	93	D005047	207	223	D066126	false

Sentence: Dexrazoxane (ICRF-187) is recommended for protection against anthracycline induced cardiotoxicity.
Entity: 15897593	0	11	Dexrazoxane	Chemical	D064730
Entity: 15897593	13	21	ICRF-187	Chemical	D064730
Entity: 15897593	61	74	anthracycline	Chemical	D018943
Entity: 15897593	83	97	cardiotoxicity	Disease	D066126
Relation: 15897593	CID	0	11	D064730	83	97	D066126	false
Relation: 15897593	CID	13	21	D064730	83	97	D066126	false
Relation: 15897593	CID	61	74	D018943	83	97	D066126	false

Sentence: EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.
Entity: 15897593	58	78	hematologic toxicity	Disease	D006402
Entity: 15897593	109	120	dexrazoxane	Chemical	D064730
Entity: 15897593	259	268	etoposide	Chemical	D005047
Entity: 15897593	270	282	daunorubicin	Chemical	D003630
Entity: 15897593	288	299	doxorubicin	Chemical	D004317
Entity: 15897593	304	315	dexrazoxane	Chemical	D064730
Relation: 15897593	CID	109	120	D064730	58	78	D006402	false
Relation: 15897593	CID	259	268	D005047	58	78	D006402	true
Relation: 15897593	CID	270	282	D003630	58	78	D006402	true
Relation: 15897593	CID	288	299	D004317	58	78	D006402	true
Relation: 15897593	CID	304	315	D064730	58	78	D006402	false

Sentence: RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.
Entity: 15897593	27	38	dexrazoxane	Chemical	D064730
Entity: 15897593	47	63	myelosuppression	Disease	D001855
Entity: 15897593	68	79	weight loss	Disease	D015431
Entity: 15897593	85	97	daunorubicin	Chemical	D003630
Entity: 15897593	102	111	etoposide	Chemical	D005047
Entity: 15897593	198	209	dexrazoxane	Chemical	D064730
Entity: 15897593	226	242	myelosuppression	Disease	D001855
Entity: 15897593	244	255	weight loss	Disease	D015431
Entity: 15897593	274	286	cytotoxicity	Disease	D064420
Entity: 15897593	292	303	doxorubicin	Chemical	D004317
Relation: 15897593	CID	27	38	D064730	47	63	D001855	false
Relation: 15897593	CID	27	38	D064730	68	79	D015431	false
Relation: 15897593	CID	27	38	D064730	226	242	D001855	false
Relation: 15897593	CID	27	38	D064730	244	255	D015431	false
Relation: 15897593	CID	27	38	D064730	274	286	D064420	false
Relation: 15897593	CID	85	97	D003630	47	63	D001855	false
Relation: 15897593	CID	85	97	D003630	68	79	D015431	true
Relation: 15897593	CID	85	97	D003630	226	242	D001855	false
Relation: 15897593	CID	85	97	D003630	244	255	D015431	true
Relation: 15897593	CID	85	97	D003630	274	286	D064420	false
Relation: 15897593	CID	102	111	D005047	47	63	D001855	false
Relation: 15897593	CID	102	111	D005047	68	79	D015431	true
Relation: 15897593	CID	102	111	D005047	226	242	D001855	false
Relation: 15897593	CID	102	111	D005047	244	255	D015431	true
Relation: 15897593	CID	102	111	D005047	274	286	D064420	false
Relation: 15897593	CID	198	209	D064730	47	63	D001855	false
Relation: 15897593	CID	198	209	D064730	68	79	D015431	false
Relation: 15897593	CID	198	209	D064730	226	242	D001855	false
Relation: 15897593	CID	198	209	D064730	244	255	D015431	false
Relation: 15897593	CID	198	209	D064730	274	286	D064420	false
Relation: 15897593	CID	292	303	D004317	47	63	D001855	false
Relation: 15897593	CID	292	303	D004317	68	79	D015431	true
Relation: 15897593	CID	292	303	D004317	226	242	D001855	false
Relation: 15897593	CID	292	303	D004317	244	255	D015431	true
Relation: 15897593	CID	292	303	D004317	274	286	D064420	false

Sentence: Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.
Entity: 6817363	30	40	aniracetam	Chemical	C036466
Entity: 6817363	42	52	Ro 13-5057	Chemical	C036466
Entity: 6817363	59	67	impaired	Disease	D007859
Entity: 6817363	59	67	impaired	Disease	D008569
Relation: 6817363	CID	30	40	C036466	59	67	D007859	false
Relation: 6817363	CID	30	40	C036466	59	67	D008569	false
Relation: 6817363	CID	42	52	C036466	59	67	D007859	false
Relation: 6817363	CID	42	52	C036466	59	67	D008569	false

Sentence: The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session.
Entity: 6817363	14	24	aniracetam	Chemical	C036466
Entity: 6817363	26	36	Ro 13-5057	Chemical	C036466
Entity: 6817363	38	63	1-anisoyl-2-pyrrolidinone	Chemical	C036466
Entity: 6817363	112	140	impaired cognitive functions	Disease	D003072
Entity: 6817363	324	335	hypercapnia	Disease	D006935
Relation: 6817363	CID	14	24	C036466	112	140	D003072	false
Relation: 6817363	CID	14	24	C036466	324	335	D006935	false
Relation: 6817363	CID	26	36	C036466	112	140	D003072	false
Relation: 6817363	CID	26	36	C036466	324	335	D006935	false
Relation: 6817363	CID	38	63	C036466	112	140	D003072	false
Relation: 6817363	CID	38	63	C036466	324	335	D006935	false

Sentence: (2) partial (rats) or complete (mice) prevention of the scopolamine induced short-term amnesia for a passive avoidance task.
Entity: 6817363	56	67	scopolamine	Chemical	D012601
Entity: 6817363	87	94	amnesia	Disease	D000647
Relation: 6817363	CID	56	67	D012601	87	94	D000647	true

Sentence: These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.
Entity: 6817363	40	68	impaired cognitive functions	Disease	D003072
Entity: 6817363	87	97	aniracetam	Chemical	C036466
Relation: 6817363	CID	87	97	C036466	40	68	D003072	false

Sentence: Nicotine potentiation of morphine induced catalepsy in mice.
Entity: 11900788	0	8	Nicotine	Chemical	D009538
Entity: 11900788	25	33	morphine	Chemical	D009020
Entity: 11900788	42	51	catalepsy	Disease	D002375
Relation: 11900788	CID	0	8	D009538	42	51	D002375	true
Relation: 11900788	CID	25	33	D009020	42	51	D002375	true

Sentence: In the present study, effects of nicotine on catalepsy induced by morphine in mice have been investigated.
Entity: 11900788	33	41	nicotine	Chemical	D009538
Entity: 11900788	45	54	catalepsy	Disease	D002375
Entity: 11900788	66	74	morphine	Chemical	D009020
Relation: 11900788	CID	33	41	D009538	45	54	D002375	true
Relation: 11900788	CID	66	74	D009020	45	54	D002375	true

Sentence: Morphine but not nicotine induced a dose-dependent catalepsy.
Entity: 11900788	0	8	Morphine	Chemical	D009020
Entity: 11900788	17	25	nicotine	Chemical	D009538
Entity: 11900788	51	60	catalepsy	Disease	D002375
Relation: 11900788	CID	0	8	D009020	51	60	D002375	true
Relation: 11900788	CID	17	25	D009538	51	60	D002375	true

Sentence: Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.
Entity: 11900788	34	42	atropine	Chemical	D001285
Entity: 11900788	44	52	naloxone	Chemical	D009270
Entity: 11900788	54	66	mecamylamine	Chemical	D008464
Entity: 11900788	72	85	hexamethonium	Chemical	D018738
Entity: 11900788	102	111	catalepsy	Disease	D002375
Entity: 11900788	140	148	morphine	Chemical	D009020
Entity: 11900788	154	162	nicotine	Chemical	D009538
Relation: 11900788	CID	34	42	D001285	102	111	D002375	false
Relation: 11900788	CID	44	52	D009270	102	111	D002375	false
Relation: 11900788	CID	54	66	D008464	102	111	D002375	false
Relation: 11900788	CID	72	85	D018738	102	111	D002375	false
Relation: 11900788	CID	140	148	D009020	102	111	D002375	true
Relation: 11900788	CID	154	162	D009538	102	111	D002375	true

Sentence: Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.
Entity: 11900788	37	45	atropine	Chemical	D001285
Entity: 11900788	47	60	hexamethonium	Chemical	D018738
Entity: 11900788	66	74	naloxone	Chemical	D009270
Entity: 11900788	90	99	catalepsy	Disease	D002375
Entity: 11900788	111	119	morphine	Chemical	D009020
Entity: 11900788	125	133	nicotine	Chemical	D009538
Relation: 11900788	CID	37	45	D001285	90	99	D002375	false
Relation: 11900788	CID	47	60	D018738	90	99	D002375	false
Relation: 11900788	CID	66	74	D009270	90	99	D002375	false
Relation: 11900788	CID	111	119	D009020	90	99	D002375	true
Relation: 11900788	CID	125	133	D009538	90	99	D002375	true

Sentence: Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.
Entity: 11230490	8	22	cardiotoxicity	Disease	D066126
Entity: 11230490	81	92	doxorubicin	Chemical	D004317
Entity: 11230490	97	113	cyclophosphamide	Chemical	D003520
Entity: 11230490	141	152	doxorubicin	Chemical	D004317
Entity: 11230490	157	173	cyclophosphamide	Chemical	D003520
Entity: 11230490	223	236	breast cancer	Disease	D001943
Relation: 11230490	CID	81	92	D004317	8	22	D066126	false
Relation: 11230490	CID	81	92	D004317	223	236	D001943	false
Relation: 11230490	CID	97	113	D003520	8	22	D066126	false
Relation: 11230490	CID	97	113	D003520	223	236	D001943	false
Relation: 11230490	CID	141	152	D004317	8	22	D066126	false
Relation: 11230490	CID	141	152	D004317	223	236	D001943	false
Relation: 11230490	CID	157	173	D003520	8	22	D066126	false
Relation: 11230490	CID	157	173	D003520	223	236	D001943	false

Sentence: PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).
Entity: 11230490	30	36	Myocet	Chemical	D004317
Entity: 11230490	60	71	doxorubicin	Chemical	D004317
Entity: 11230490	148	164	cyclophosphamide	Chemical	D003520
Entity: 11230490	187	198	doxorubicin	Chemical	D004317
Entity: 11230490	199	213	cardiotoxicity	Disease	D066126
Entity: 11230490	298	311	breast cancer	Disease	D001943
Entity: 11230490	313	316	MBC	Disease	D001943
Relation: 11230490	CID	30	36	D004317	199	213	D066126	false
Relation: 11230490	CID	30	36	D004317	298	311	D001943	false
Relation: 11230490	CID	30	36	D004317	313	316	D001943	false
Relation: 11230490	CID	60	71	D004317	199	213	D066126	false
Relation: 11230490	CID	60	71	D004317	298	311	D001943	false
Relation: 11230490	CID	60	71	D004317	313	316	D001943	false
Relation: 11230490	CID	148	164	D003520	199	213	D066126	false
Relation: 11230490	CID	148	164	D003520	298	311	D001943	false
Relation: 11230490	CID	148	164	D003520	313	316	D001943	false
Relation: 11230490	CID	187	198	D004317	199	213	D066126	false
Relation: 11230490	CID	187	198	D004317	298	311	D001943	false
Relation: 11230490	CID	187	198	D004317	313	316	D001943	false

Sentence: PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.
Entity: 11230490	61	64	MBC	Disease	D001943
Entity: 11230490	162	168	Myocet	Chemical	D004317
Entity: 11230490	189	200	doxorubicin	Chemical	D004317
Entity: 11230490	241	257	cyclophosphamide	Chemical	D003520
Entity: 11230490	319	327	toxicity	Disease	D064420
Relation: 11230490	CID	162	168	D004317	61	64	D001943	false
Relation: 11230490	CID	162	168	D004317	319	327	D064420	false
Relation: 11230490	CID	189	200	D004317	61	64	D001943	false
Relation: 11230490	CID	189	200	D004317	319	327	D064420	false
Relation: 11230490	CID	241	257	D003520	61	64	D001943	false
Relation: 11230490	CID	241	257	D003520	319	327	D064420	false

Sentence: Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine induced cardiovascular impairments in rats.
Entity: 2594614	71	79	BN 52021	Chemical	C045856
Entity: 2594614	84	95	bupivacaine	Chemical	D002045
Entity: 2594614	104	130	cardiovascular impairments	Disease	D002318
Relation: 2594614	CID	71	79	C045856	104	130	D002318	false
Relation: 2594614	CID	84	95	D002045	104	130	D002318	false

Sentence: Administration of the local anaesthetic bupivacaine (1.5 or 2 mg/kg, i.v.) to rats elicited a marked decrease of mean arterial blood pressure (MBP) and heart rate (HR) leading to death (in 67% or 90% of animals respectively).
Entity: 2594614	40	51	bupivacaine	Chemical	D002045
Entity: 2594614	101	109	decrease	Disease	D007022
Entity: 2594614	101	109	decrease	Disease	D001919
Relation: 2594614	CID	40	51	D002045	101	109	D007022	true
Relation: 2594614	CID	40	51	D002045	101	109	D001919	true

Sentence: Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.
Entity: 2594614	82	90	BN 52021	Chemical	C045856
Entity: 2594614	117	128	bupivacaine	Chemical	D002045
Entity: 2594614	179	187	decrease	Disease	D007022
Entity: 2594614	179	187	decrease	Disease	D001919
Relation: 2594614	CID	82	90	C045856	179	187	D007022	false
Relation: 2594614	CID	82	90	C045856	179	187	D001919	false
Relation: 2594614	CID	117	128	D002045	179	187	D007022	true
Relation: 2594614	CID	117	128	D002045	179	187	D001919	true

Sentence: When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.
Entity: 2594614	5	13	BN 52021	Chemical	C045856
Entity: 2594614	61	72	bupivacaine	Chemical	D002045
Entity: 2594614	111	119	decrease	Disease	D007022
Entity: 2594614	111	119	decrease	Disease	D001919
Relation: 2594614	CID	5	13	C045856	111	119	D007022	false
Relation: 2594614	CID	5	13	C045856	111	119	D001919	false
Relation: 2594614	CID	61	72	D002045	111	119	D007022	true
Relation: 2594614	CID	61	72	D002045	111	119	D001919	true

Sentence: Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine induced cardiovascular toxicity.
Entity: 2594614	28	36	BN 52021	Chemical	C045856
Entity: 2594614	173	181	BN 52021	Chemical	C045856
Entity: 2594614	221	232	bupivacaine	Chemical	D002045
Entity: 2594614	241	264	cardiovascular toxicity	Disease	D002318
Relation: 2594614	CID	28	36	C045856	241	264	D002318	false
Relation: 2594614	CID	173	181	C045856	241	264	D002318	false
Relation: 2594614	CID	221	232	D002045	241	264	D002318	false

Sentence: Benzylacyclouridine reverses azidothymidine induced marrow suppression without impairment of anti-human immunodeficiency virus activity.
Entity: 2257294	0	19	Benzylacyclouridine	Chemical	C034753
Entity: 2257294	29	43	azidothymidine	Chemical	D015215
Entity: 2257294	52	70	marrow suppression	Disease	D001855
Entity: 2257294	104	120	immunodeficiency	Disease	D007153
Relation: 2257294	CID	0	19	C034753	52	70	D001855	false
Relation: 2257294	CID	0	19	C034753	104	120	D007153	false
Relation: 2257294	CID	29	43	D015215	52	70	D001855	true
Relation: 2257294	CID	29	43	D015215	104	120	D007153	false

Sentence: Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT) induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.
Entity: 2257294	42	49	uridine	Chemical	D014529
Entity: 2257294	51	54	Urd	Chemical	D014529
Entity: 2257294	96	110	azidothymidine	Chemical	D015215
Entity: 2257294	112	115	AZT	Chemical	D015215
Entity: 2257294	221	237	immunodeficiency	Disease	D007153
Relation: 2257294	CID	42	49	D014529	221	237	D007153	false
Relation: 2257294	CID	51	54	D014529	221	237	D007153	false
Relation: 2257294	CID	96	110	D015215	221	237	D007153	false
Relation: 2257294	CID	112	115	D015215	221	237	D007153	false

Sentence: Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT induced anemia and leukopenia was assessed.
Entity: 2257294	24	34	toxicities	Disease	D064420
Entity: 2257294	59	62	Urd	Chemical	D014529
Entity: 2257294	94	113	benzylacyclouridine	Chemical	C034753
Entity: 2257294	115	118	BAU	Chemical	C034753
Entity: 2257294	140	143	AZT	Chemical	D015215
Entity: 2257294	152	158	anemia	Disease	D000740
Entity: 2257294	163	173	leukopenia	Disease	D007970
Relation: 2257294	CID	59	62	D014529	24	34	D064420	false
Relation: 2257294	CID	59	62	D014529	152	158	D000740	false
Relation: 2257294	CID	59	62	D014529	163	173	D007970	false
Relation: 2257294	CID	94	113	C034753	24	34	D064420	false
Relation: 2257294	CID	94	113	C034753	152	158	D000740	false
Relation: 2257294	CID	94	113	C034753	163	173	D007970	false
Relation: 2257294	CID	115	118	C034753	24	34	D064420	false
Relation: 2257294	CID	115	118	C034753	152	158	D000740	false
Relation: 2257294	CID	115	118	C034753	163	173	D007970	false
Relation: 2257294	CID	140	143	D015215	24	34	D064420	false
Relation: 2257294	CID	140	143	D015215	152	158	D000740	true
Relation: 2257294	CID	140	143	D015215	163	173	D007970	true

Sentence: This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity.
Entity: 2257294	20	23	Urd	Chemical	D014529
Entity: 2257294	87	90	Urd	Chemical	D014529
Entity: 2257294	127	130	Urd	Chemical	D014529
Entity: 2257294	139	147	toxicity	Disease	D064420
Relation: 2257294	CID	20	23	D014529	139	147	D064420	false
Relation: 2257294	CID	87	90	D014529	139	147	D064420	false
Relation: 2257294	CID	127	130	D014529	139	147	D064420	false

Sentence: In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.
Entity: 2257294	17	23	anemic	Disease	D000740
Entity: 2257294	28	38	leukopenic	Disease	D007970
Entity: 2257294	64	67	AZT	Chemical	D015215
Entity: 2257294	143	146	AZT	Chemical	D015215
Entity: 2257294	158	161	BAU	Chemical	C034753
Entity: 2257294	201	204	AZT	Chemical	D015215
Entity: 2257294	213	219	anemia	Disease	D000740
Entity: 2257294	224	234	leukopenia	Disease	D007970
Entity: 2257294	367	382	megaloblastosis	Disease	-1
Relation: 2257294	CID	64	67	D015215	17	23	D000740	true
Relation: 2257294	CID	64	67	D015215	28	38	D007970	true
Relation: 2257294	CID	64	67	D015215	213	219	D000740	true
Relation: 2257294	CID	64	67	D015215	224	234	D007970	true
Relation: 2257294	CID	64	67	D015215	367	382	-1	false
Relation: 2257294	CID	143	146	D015215	17	23	D000740	true
Relation: 2257294	CID	143	146	D015215	28	38	D007970	true
Relation: 2257294	CID	143	146	D015215	213	219	D000740	true
Relation: 2257294	CID	143	146	D015215	224	234	D007970	true
Relation: 2257294	CID	143	146	D015215	367	382	-1	false
Relation: 2257294	CID	158	161	C034753	17	23	D000740	false
Relation: 2257294	CID	158	161	C034753	28	38	D007970	false
Relation: 2257294	CID	158	161	C034753	213	219	D000740	false
Relation: 2257294	CID	158	161	C034753	224	234	D007970	false
Relation: 2257294	CID	158	161	C034753	367	382	-1	false
Relation: 2257294	CID	201	204	D015215	17	23	D000740	true
Relation: 2257294	CID	201	204	D015215	28	38	D007970	true
Relation: 2257294	CID	201	204	D015215	213	219	D000740	true
Relation: 2257294	CID	201	204	D015215	224	234	D007970	true
Relation: 2257294	CID	201	204	D015215	367	382	-1	false

Sentence: When coadministered with AZT from the onset of drug administration, BAU reduced AZT induced marrow toxicity.
Entity: 2257294	25	28	AZT	Chemical	D015215
Entity: 2257294	68	71	BAU	Chemical	C034753
Entity: 2257294	80	83	AZT	Chemical	D015215
Entity: 2257294	92	107	marrow toxicity	Disease	D001855
Relation: 2257294	CID	25	28	D015215	92	107	D001855	true
Relation: 2257294	CID	68	71	C034753	92	107	D001855	false
Relation: 2257294	CID	80	83	D015215	92	107	D001855	true

Sentence: Cyclophosphamide induced cystitis in freely-moving conscious rats: behavioral approach to a new model of visceral pain.
Entity: 10840460	0	16	Cyclophosphamide	Chemical	D003520
Entity: 10840460	25	33	cystitis	Disease	D003556
Entity: 10840460	105	118	visceral pain	Disease	D059265
Relation: 10840460	CID	0	16	D003520	25	33	D003556	true
Relation: 10840460	CID	0	16	D003520	105	118	D059265	false

Sentence: Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.
Entity: 10840460	0	16	Cyclophosphamide	Chemical	D003520
Entity: 10840460	18	20	CP	Chemical	D003520
Entity: 10840460	129	137	acrolein	Chemical	D000171
Entity: 10840460	158	166	cystitis	Disease	D003556
Relation: 10840460	CID	0	16	D003520	158	166	D003556	true
Relation: 10840460	CID	18	20	D003520	158	166	D003556	true
Relation: 10840460	CID	129	137	D000171	158	166	D003556	false

Sentence: Morphine dose-dependently reversed these behavioral disorders.
Entity: 10840460	0	8	Morphine	Chemical	D009020
Entity: 10840460	41	61	behavioral disorders	Disease	D001523
Relation: 10840460	CID	0	8	D009020	41	61	D001523	false

Sentence: At the time of administration of morphine, histological modifications of the bladder wall, such as chorionic and muscle layer edema, were observed.
Entity: 10840460	33	41	morphine	Chemical	D009020
Entity: 10840460	126	131	edema	Disease	D004487
Relation: 10840460	CID	33	41	D009020	126	131	D004487	false

Sentence: Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.
Entity: 8278214	0	12	Hyperalgesia	Disease	D006930
Entity: 8278214	17	26	myoclonus	Disease	D009207
Entity: 8278214	39	45	cancer	Disease	D009369
Entity: 8278214	91	99	morphine	Chemical	D009020
Relation: 8278214	CID	91	99	D009020	0	12	D006930	true
Relation: 8278214	CID	91	99	D009020	17	26	D009207	true
Relation: 8278214	CID	91	99	D009020	39	45	D009369	false

Sentence: Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.
Entity: 8278214	6	12	cancer	Disease	D009369
Entity: 8278214	99	107	morphine	Chemical	D009020
Entity: 8278214	118	130	hyperalgesia	Disease	D006930
Relation: 8278214	CID	99	107	D009020	6	12	D009369	false
Relation: 8278214	CID	99	107	D009020	118	130	D006930	true

Sentence: Vancomycin was curative in 95% of 43 patients with proven infection.
Entity: 3934126	0	10	Vancomycin	Chemical	D014640
Entity: 3934126	58	67	infection	Disease	D007239
Relation: 3934126	CID	0	10	D014640	58	67	D007239	false

Sentence: Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.
Entity: 3934126	0	16	Thrombophlebitis	Disease	D013924
Entity: 3934126	74	88	nephrotoxicity	Disease	D007674
Entity: 3934126	93	104	ototoxicity	Disease	D006311
Entity: 3934126	144	158	aminoglycoside	Chemical	D000617
Entity: 3934126	164	174	vancomycin	Chemical	D014640
Relation: 3934126	CID	144	158	D000617	0	16	D013924	false
Relation: 3934126	CID	144	158	D000617	74	88	D007674	false
Relation: 3934126	CID	144	158	D000617	93	104	D006311	false
Relation: 3934126	CID	164	174	D014640	0	16	D013924	true
Relation: 3934126	CID	164	174	D014640	74	88	D007674	false
Relation: 3934126	CID	164	174	D014640	93	104	D006311	true

Sentence: Blockade of both D-1 and D-2 dopamine receptors may induce catalepsy in mice. 1.
Entity: 1687392	29	37	dopamine	Chemical	D004298
Entity: 1687392	59	68	catalepsy	Disease	D002375
Relation: 1687392	CID	29	37	D004298	59	68	D002375	false

Sentence: The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined. 2.
Entity: 1687392	4	13	catalepsy	Disease	D002375
Entity: 1687392	25	33	dopamine	Chemical	D004298
Entity: 1687392	79	87	dopamine	Chemical	D004298
Entity: 1687392	109	118	catalepsy	Disease	D002375
Relation: 1687392	CID	25	33	D004298	4	13	D002375	false
Relation: 1687392	CID	25	33	D004298	109	118	D002375	false
Relation: 1687392	CID	79	87	D004298	4	13	D002375	false
Relation: 1687392	CID	79	87	D004298	109	118	D002375	false

Sentence: Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.
Entity: 1687392	0	8	Dopamine	Chemical	D004298
Entity: 1687392	20	32	fluphenazine	Chemical	D005476
Entity: 1687392	49	58	SCH 23390	Chemical	C534628
Entity: 1687392	77	86	sulpiride	Chemical	D013469
Entity: 1687392	95	104	catalepsy	Disease	D002375
Relation: 1687392	CID	0	8	D004298	95	104	D002375	false
Relation: 1687392	CID	20	32	D005476	95	104	D002375	true
Relation: 1687392	CID	49	58	C534628	95	104	D002375	true
Relation: 1687392	CID	77	86	D013469	95	104	D002375	true

Sentence: Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation. 3.
Entity: 1687392	15	24	SCH 23390	Chemical	C534628
Entity: 1687392	30	39	sulpiride	Chemical	D013469
Entity: 1687392	55	64	catalepsy	Disease	D002375
Relation: 1687392	CID	15	24	C534628	55	64	D002375	true
Relation: 1687392	CID	30	39	D013469	55	64	D002375	true

Sentence: D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride. 4.
Entity: 1687392	12	21	SKF 38393	Chemical	D015647
Entity: 1687392	37	47	quinpirole	Chemical	D019257
Entity: 1687392	62	71	catalepsy	Disease	D002375
Entity: 1687392	83	95	fluphenazine	Chemical	D005476
Entity: 1687392	97	106	SCH 23390	Chemical	C534628
Entity: 1687392	110	119	sulpiride	Chemical	D013469
Relation: 1687392	CID	12	21	D015647	62	71	D002375	false
Relation: 1687392	CID	37	47	D019257	62	71	D002375	false
Relation: 1687392	CID	83	95	D005476	62	71	D002375	true
Relation: 1687392	CID	97	106	C534628	62	71	D002375	true
Relation: 1687392	CID	110	119	D013469	62	71	D002375	true

Sentence: Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists. 5.
Entity: 1687392	15	24	SKF 38393	Chemical	D015647
Entity: 1687392	30	40	quinpirole	Chemical	D019257
Entity: 1687392	88	97	catalepsy	Disease	D002375
Entity: 1687392	109	117	dopamine	Chemical	D004298
Relation: 1687392	CID	15	24	D015647	88	97	D002375	false
Relation: 1687392	CID	30	40	D019257	88	97	D002375	false
Relation: 1687392	CID	109	117	D004298	88	97	D002375	false

Sentence: Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan induced rat paw edema model, respectively.
Entity: 19719056	71	82	acetic acid	Chemical	D019342
Entity: 19719056	91	99	writhing	Disease	D010146
Entity: 19719056	117	128	carrageenan	Chemical	D002351
Entity: 19719056	145	150	edema	Disease	D004487
Relation: 19719056	CID	71	82	D019342	91	99	D010146	false
Relation: 19719056	CID	71	82	D019342	145	150	D004487	false
Relation: 19719056	CID	117	128	D002351	91	99	D010146	true
Relation: 19719056	CID	117	128	D002351	145	150	D004487	true

Sentence: The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.
Entity: 15266362	46	73	hypertrophic cardiomyopathy	Disease	D002312
Entity: 15266362	93	114	biventricular failure	Disease	D018754
Entity: 15266362	145	155	dobutamine	Chemical	D004280
Relation: 15266362	CID	145	155	D004280	46	73	D002312	false
Relation: 15266362	CID	145	155	D004280	93	114	D018754	false

Sentence: It is likely that the hypersensitivity (eosinophilic) myocarditis was related to dobutamine infusion therapy.
Entity: 15266362	22	38	hypersensitivity	Disease	D004342
Entity: 15266362	40	52	eosinophilic	Disease	D004802
Entity: 15266362	54	65	myocarditis	Disease	D009205
Entity: 15266362	81	91	dobutamine	Chemical	D004280
Relation: 15266362	CID	81	91	D004280	22	38	D004342	true
Relation: 15266362	CID	81	91	D004280	40	52	D004802	true
Relation: 15266362	CID	81	91	D004280	54	65	D009205	true

Sentence: All- trans-retinoic acid induced erythema nodosum in patients with acute promyelocytic leukemia.
Entity: 14648024	0	24	All- trans-retinoic acid	Chemical	D014212
Entity: 14648024	33	49	erythema nodosum	Disease	D004893
Entity: 14648024	67	95	acute promyelocytic leukemia	Disease	D015473
Relation: 14648024	CID	0	24	D014212	33	49	D004893	true
Relation: 14648024	CID	0	24	D014212	67	95	D015473	false

Sentence: Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.
Entity: 14648024	0	16	Erythema nodosum	Disease	D004893
Entity: 14648024	33	57	all- trans-retinoic acid	Chemical	D014212
Entity: 14648024	59	63	ATRA	Chemical	D014212
Entity: 14648024	69	97	acute promyelocytic leukemia	Disease	D015473
Entity: 14648024	99	102	APL	Disease	D015473
Relation: 14648024	CID	33	57	D014212	0	16	D004893	true
Relation: 14648024	CID	33	57	D014212	69	97	D015473	false
Relation: 14648024	CID	33	57	D014212	99	102	D015473	false
Relation: 14648024	CID	59	63	D014212	0	16	D004893	true
Relation: 14648024	CID	59	63	D014212	69	97	D015473	false
Relation: 14648024	CID	59	63	D014212	99	102	D015473	false

Sentence: We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.
Entity: 14648024	39	42	APL	Disease	D015473
Entity: 14648024	57	73	erythema nodosum	Disease	D004893
Entity: 14648024	81	85	ATRA	Chemical	D014212
Relation: 14648024	CID	81	85	D014212	39	42	D015473	false
Relation: 14648024	CID	81	85	D014212	57	73	D004893	true

Sentence: Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.
Entity: 14648024	0	5	Fever	Disease	D005334
Entity: 14648024	30	37	painful	Disease	D010146
Entity: 14648024	38	58	erythematous nodules	Disease	D004893
Entity: 14648024	133	137	ATRA	Chemical	D014212
Relation: 14648024	CID	133	137	D014212	0	5	D005334	true
Relation: 14648024	CID	133	137	D014212	30	37	D010146	false
Relation: 14648024	CID	133	137	D014212	38	58	D004893	true

Sentence: ATRA seemed to be the most possible etiology of erythema nodosum in our patients.
Entity: 14648024	0	4	ATRA	Chemical	D014212
Entity: 14648024	48	64	erythema nodosum	Disease	D004893
Relation: 14648024	CID	0	4	D014212	48	64	D004893	true

Sentence: Delayed-onset heparin induced thrombocytopenia.
Entity: 11827497	14	21	heparin	Chemical	D006493
Entity: 11827497	30	46	thrombocytopenia	Disease	D013921
Relation: 11827497	CID	14	21	D006493	30	46	D013921	true

Sentence: BACKGROUND: Heparin induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.
Entity: 11827497	12	19	Heparin	Chemical	D006493
Entity: 11827497	28	44	thrombocytopenia	Disease	D013921
Entity: 11827497	73	80	heparin	Chemical	D006493
Entity: 11827497	107	115	arterial	Disease	D001157
Entity: 11827497	119	125	venous	Disease	D054556
Relation: 11827497	CID	12	19	D006493	28	44	D013921	true
Relation: 11827497	CID	12	19	D006493	107	115	D001157	true
Relation: 11827497	CID	12	19	D006493	119	125	D054556	true
Relation: 11827497	CID	73	80	D006493	28	44	D013921	true
Relation: 11827497	CID	73	80	D006493	107	115	D001157	true
Relation: 11827497	CID	73	80	D006493	119	125	D054556	true

Sentence: Delayed recognition and treatment of heparin induced thrombocytopenia contribute to poor patient outcomes.
Entity: 11827497	37	44	heparin	Chemical	D006493
Entity: 11827497	53	69	thrombocytopenia	Disease	D013921
Relation: 11827497	CID	37	44	D006493	53	69	D013921	true

Sentence: OBJECTIVE: To describe and increase awareness of a clinical scenario in which the onset or manifestations of heparin induced thrombocytopenia are delayed.
Entity: 11827497	109	116	heparin	Chemical	D006493
Entity: 11827497	125	141	thrombocytopenia	Disease	D013921
Relation: 11827497	CID	109	116	D006493	125	141	D013921	true

Sentence: PATIENTS: 14 patients seen over a 3-year period in whom heparin induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications.
Entity: 11827497	56	63	heparin	Chemical	D006493
Entity: 11827497	72	88	thrombocytopenia	Disease	D013921
Entity: 11827497	134	148	thromboembolic	Disease	D013923
Relation: 11827497	CID	56	63	D006493	72	88	D013921	true
Relation: 11827497	CID	56	63	D006493	134	148	D013923	false

Sentence: MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin induced platelet factor 4 antibody tests, and outcomes.
Entity: 11827497	63	78	thromboembolism	Disease	D013923
Entity: 11827497	91	98	heparin	Chemical	D006493
Relation: 11827497	CID	91	98	D006493	63	78	D013923	false

Sentence: RESULTS: Patients went home after hospitalizations that had included heparin exposure--in most cases, with no thrombocytopenia recognized--only to return to the hospital (median, day 14) with thromboembolic complications.
Entity: 11827497	69	76	heparin	Chemical	D006493
Entity: 11827497	110	126	thrombocytopenia	Disease	D013921
Entity: 11827497	192	206	thromboembolic	Disease	D013923
Relation: 11827497	CID	69	76	D006493	110	126	D013921	true
Relation: 11827497	CID	69	76	D006493	192	206	D013923	false

Sentence: CONCLUSIONS: Delayed-onset heparin induced thrombocytopenia is increasingly being recognized.
Entity: 11827497	27	34	heparin	Chemical	D006493
Entity: 11827497	43	59	thrombocytopenia	Disease	D013921
Relation: 11827497	CID	27	34	D006493	43	59	D013921	true

Sentence: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.
Entity: 8841157	0	9	Valsartan	Chemical	C081489
Entity: 8841157	17	31	angiotensin II	Chemical	D000804
Entity: 8841157	74	86	hypertension	Disease	D006973
Entity: 8841157	143	153	amlodipine	Chemical	D017311
Relation: 8841157	CID	0	9	C081489	74	86	D006973	false
Relation: 8841157	CID	17	31	D000804	74	86	D006973	false
Relation: 8841157	CID	143	153	D017311	74	86	D006973	false

Sentence: METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.
Entity: 8841157	73	85	hypertension	Disease	D006973
Entity: 8841157	168	177	valsartan	Chemical	C081489
Entity: 8841157	186	196	amlodipine	Chemical	D017311
Relation: 8841157	CID	168	177	C081489	73	85	D006973	false
Relation: 8841157	CID	186	196	D017311	73	85	D006973	false

Sentence: The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).
Entity: 8841157	40	45	edema	Disease	D004487
Entity: 8841157	73	83	amlodipine	Chemical	D017311
Entity: 8841157	147	156	valsartan	Chemical	C081489
Entity: 8841157	172	182	amlodipine	Chemical	D017311
Entity: 8841157	191	200	valsartan	Chemical	C081489
Entity: 8841157	211	221	amlodipine	Chemical	D017311
Entity: 8841157	239	249	amlodipine	Chemical	D017311
Relation: 8841157	CID	73	83	D017311	40	45	D004487	true
Relation: 8841157	CID	147	156	C081489	40	45	D004487	true
Relation: 8841157	CID	172	182	D017311	40	45	D004487	true
Relation: 8841157	CID	191	200	C081489	40	45	D004487	true
Relation: 8841157	CID	211	221	D017311	40	45	D004487	true
Relation: 8841157	CID	239	249	D017311	40	45	D004487	true

Sentence: CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension.
Entity: 8841157	32	41	valsartan	Chemical	C081489
Entity: 8841157	70	80	amlodipine	Chemical	D017311
Entity: 8841157	118	130	hypertension	Disease	D006973
Relation: 8841157	CID	32	41	C081489	118	130	D006973	false
Relation: 8841157	CID	70	80	D017311	118	130	D006973	false

Sentence: Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.
Entity: 8045270	23	30	KF17837	Chemical	C081198
Entity: 8045270	88	98	cataleptic	Disease	D002375
Entity: 8045270	165	174	adenosine	Chemical	D000241
Entity: 8045270	197	206	CGS 21680	Chemical	C061282
Relation: 8045270	CID	23	30	C081198	88	98	D002375	false
Relation: 8045270	CID	165	174	D000241	88	98	D002375	false
Relation: 8045270	CID	197	206	C061282	88	98	D002375	true

Sentence: KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).
Entity: 8045270	0	7	KF17837	Chemical	C081198
Entity: 8045270	25	34	catalepsy	Disease	D002375
Entity: 8045270	46	57	haloperidol	Chemical	D006220
Entity: 8045270	80	89	reserpine	Chemical	D012110
Relation: 8045270	CID	0	7	C081198	25	34	D002375	false
Relation: 8045270	CID	46	57	D006220	25	34	D002375	true
Relation: 8045270	CID	80	89	D012110	25	34	D002375	true

Sentence: A repeated treatment with fluvoxamine (twice daily for 14 days) potentiated in mice and in rats (weaker) the amphetamine induced hyperactivity.
Entity: 2576810	26	37	fluvoxamine	Chemical	D016666
Entity: 2576810	109	120	amphetamine	Chemical	D000661
Entity: 2576810	129	142	hyperactivity	Disease	D006948
Relation: 2576810	CID	26	37	D016666	129	142	D006948	true
Relation: 2576810	CID	109	120	D000661	129	142	D006948	true

Sentence: The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.
Entity: 2576810	4	17	hyperactivity	Disease	D006948
Entity: 2576810	29	40	nomifensine	Chemical	D009627
Entity: 2576810	72	83	fluvoxamine	Chemical	D016666
Relation: 2576810	CID	29	40	D009627	4	17	D006948	true
Relation: 2576810	CID	72	83	D016666	4	17	D006948	true

Sentence: Severe congestive heart failure patient on amiodarone presenting with myxedemic coma: a case report.
Entity: 20635749	7	31	congestive heart failure	Disease	D006333
Entity: 20635749	43	53	amiodarone	Chemical	D000638
Entity: 20635749	70	79	myxedemic	Disease	D009230
Entity: 20635749	80	84	coma	Disease	D003128
Relation: 20635749	CID	43	53	D000638	7	31	D006333	false
Relation: 20635749	CID	43	53	D000638	70	79	D009230	true
Relation: 20635749	CID	43	53	D000638	80	84	D003128	true

Sentence: This is a case report of myxedema coma secondary to amiodarone induced hypothyroidism in a patient with severe congestive heart failure (CHF).
Entity: 20635749	25	33	myxedema	Disease	D009230
Entity: 20635749	34	38	coma	Disease	D003128
Entity: 20635749	52	62	amiodarone	Chemical	D000638
Entity: 20635749	71	85	hypothyroidism	Disease	D007037
Entity: 20635749	111	135	congestive heart failure	Disease	D006333
Entity: 20635749	137	140	CHF	Disease	D006333
Relation: 20635749	CID	52	62	D000638	25	33	D009230	true
Relation: 20635749	CID	52	62	D000638	34	38	D003128	true
Relation: 20635749	CID	52	62	D000638	71	85	D007037	true
Relation: 20635749	CID	52	62	D000638	111	135	D006333	false
Relation: 20635749	CID	52	62	D000638	137	140	D006333	false

Sentence: To our knowledge and after reviewing the literature there is one case report of myxedema coma during long term amiodarone therapy.
Entity: 20635749	80	88	myxedema	Disease	D009230
Entity: 20635749	89	93	coma	Disease	D003128
Entity: 20635749	111	121	amiodarone	Chemical	D000638
Relation: 20635749	CID	111	121	D000638	80	88	D009230	true
Relation: 20635749	CID	111	121	D000638	89	93	D003128	true

Sentence: Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.
Entity: 20635749	14	17	CHF	Disease	D006333
Entity: 20635749	21	31	amiodarone	Chemical	D000638
Entity: 20635749	80	94	hypothyroidism	Disease	D007037
Relation: 20635749	CID	21	31	D000638	14	17	D006333	false
Relation: 20635749	CID	21	31	D000638	80	94	D007037	true

Sentence: This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients.
Entity: 20635749	87	97	amiodarone	Chemical	D000638
Entity: 20635749	104	107	CHF	Disease	D006333
Relation: 20635749	CID	87	97	D000638	104	107	D006333	false

Sentence: Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment.
Entity: 19203554	81	99	glomerulonephritis	Disease	D005921
Entity: 19203554	117	131	sulphasalazine	Chemical	D012460
Relation: 19203554	CID	117	131	D012460	81	99	D005921	false

Sentence: A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.
Entity: 19203554	25	43	ulcerative colitis	Disease	D003093
Entity: 19203554	54	62	red eyes	Disease	D005128
Entity: 19203554	64	80	pleural effusion	Disease	D010996
Entity: 19203554	82	94	eosinophilia	Disease	D004802
Entity: 19203554	99	120	urinary abnormalities	Disease	D001745
Entity: 19203554	141	155	sulphasalazine	Chemical	D012460
Relation: 19203554	CID	141	155	D012460	25	43	D003093	false
Relation: 19203554	CID	141	155	D012460	54	62	D005128	false
Relation: 19203554	CID	141	155	D012460	64	80	D010996	true
Relation: 19203554	CID	141	155	D012460	82	94	D004802	false
Relation: 19203554	CID	141	155	D012460	99	120	D001745	false

Sentence: Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.
Entity: 19203554	22	36	sulphasalazine	Chemical	D012460
Entity: 19203554	75	80	fever	Disease	D005334
Entity: 19203554	82	90	red eyes	Disease	D005128
Entity: 19203554	92	102	chest pain	Disease	D002637
Entity: 19203554	150	167	pleural effusions	Disease	D010996
Entity: 19203554	182	189	steroid	Chemical	D013256
Entity: 19203554	296	312	pleural effusion	Disease	D010996
Relation: 19203554	CID	22	36	D012460	75	80	D005334	true
Relation: 19203554	CID	22	36	D012460	82	90	D005128	false
Relation: 19203554	CID	22	36	D012460	92	102	D002637	false
Relation: 19203554	CID	22	36	D012460	150	167	D010996	true
Relation: 19203554	CID	22	36	D012460	296	312	D010996	true
Relation: 19203554	CID	182	189	D013256	75	80	D005334	false
Relation: 19203554	CID	182	189	D013256	82	90	D005128	false
Relation: 19203554	CID	182	189	D013256	92	102	D002637	false
Relation: 19203554	CID	182	189	D013256	150	167	D010996	false
Relation: 19203554	CID	182	189	D013256	296	312	D010996	false

Sentence: One month after steroid therapy, the pleural effusion disappeared, and PR3-ANCA titer normalized 3 months later.
Entity: 19203554	16	23	steroid	Chemical	D013256
Entity: 19203554	37	53	pleural effusion	Disease	D010996
Relation: 19203554	CID	16	23	D013256	37	53	D010996	false

Sentence: Is phenytoin administration safe in a hypothermic child.
Entity: 17049862	3	12	phenytoin	Chemical	D010672
Entity: 17049862	38	49	hypothermic	Disease	D007035
Relation: 17049862	CID	3	12	D010672	38	49	D007035	false

Sentence: Intravenous phenytoin was administered during the later part of the surgery for seizure prophylaxis.
Entity: 17049862	12	21	phenytoin	Chemical	D010672
Entity: 17049862	80	87	seizure	Disease	D012640
Relation: 17049862	CID	12	21	D010672	80	87	D012640	false

Sentence: Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline.
Entity: 17049862	10	19	phenytoin	Chemical	D010672
Entity: 17049862	71	82	bradycardia	Disease	D001919
Entity: 17049862	98	106	atropine	Chemical	D001285
Entity: 17049862	111	121	adrenaline	Chemical	D004837
Relation: 17049862	CID	10	19	D010672	71	82	D001919	true
Relation: 17049862	CID	98	106	D001285	71	82	D001919	false
Relation: 17049862	CID	111	121	D004837	71	82	D001919	false

Sentence: The cardiac depressant actions of phenytoin and hypothermia can be additive.
Entity: 17049862	34	43	phenytoin	Chemical	D010672
Entity: 17049862	48	59	hypothermia	Disease	D007035
Relation: 17049862	CID	34	43	D010672	48	59	D007035	false

Sentence: Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children.
Entity: 17049862	18	27	phenytoin	Chemical	D010672
Entity: 17049862	47	58	hypothermia	Disease	D007035
Relation: 17049862	CID	18	27	D010672	47	58	D007035	false

Sentence: Amisulpride related tic-like symptoms in an adolescent schizophrenic.
Entity: 16225977	0	11	Amisulpride	Chemical	C012052
Entity: 16225977	20	37	tic-like symptoms	Disease	D013981
Entity: 16225977	55	68	schizophrenic	Disease	D012559
Relation: 16225977	CID	0	11	C012052	20	37	D013981	true
Relation: 16225977	CID	0	11	C012052	55	68	D012559	false

Sentence: Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.
Entity: 16225977	0	13	Tic disorders	Disease	D013981
Entity: 16225977	76	87	risperidone	Chemical	D018967
Entity: 16225977	89	99	olanzapine	Chemical	C076029
Entity: 16225977	104	115	ziprasidone	Chemical	C092292
Relation: 16225977	CID	76	87	D018967	0	13	D013981	false
Relation: 16225977	CID	89	99	C076029	0	13	D013981	false
Relation: 16225977	CID	104	115	C092292	0	13	D013981	false

Sentence: However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.
Entity: 16225977	46	63	tic-like symptoms	Disease	D013981
Entity: 16225977	134	144	quetiapine	Chemical	C069541
Entity: 16225977	148	157	clozapine	Chemical	D003024
Relation: 16225977	CID	134	144	C069541	46	63	D013981	false
Relation: 16225977	CID	148	157	D003024	46	63	D013981	false

Sentence: We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).
Entity: 16225977	30	43	schizophrenic	Disease	D012559
Entity: 16225977	67	101	involuntary eye-blinking movements	Disease	D020820
Entity: 16225977	120	131	amisulpride	Chemical	C012052
Relation: 16225977	CID	120	131	C012052	30	43	D012559	false
Relation: 16225977	CID	120	131	C012052	67	101	D020820	false

Sentence: The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.
Entity: 16225977	4	21	tic-like symptoms	Disease	D013981
Entity: 16225977	71	82	amisulpride	Chemical	C012052
Relation: 16225977	CID	71	82	C012052	4	21	D013981	true

Sentence: Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11.
Entity: 12852481	0	7	Aspirin	Chemical	D001241
Entity: 12852481	9	29	acetylsalicylic acid	Chemical	D001241
Entity: 12852481	31	34	ASA	Chemical	D001241
Entity: 12852481	96	119	developmental anomalies	Disease	D000014
Relation: 12852481	CID	0	7	D001241	96	119	D000014	true
Relation: 12852481	CID	9	29	D001241	96	119	D000014	true
Relation: 12852481	CID	31	34	D001241	96	119	D000014	true

Sentence: Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.
Entity: 12852481	108	111	ASA	Chemical	D001241
Entity: 12852481	297	322	gastrointestinal toxicity	Disease	D005767
Entity: 12852481	364	377	malformations	Disease	D000014
Entity: 12852481	383	386	ASA	Chemical	D001241
Relation: 12852481	CID	108	111	D001241	297	322	D005767	false
Relation: 12852481	CID	108	111	D001241	364	377	D000014	true
Relation: 12852481	CID	383	386	D001241	297	322	D005767	false
Relation: 12852481	CID	383	386	D001241	364	377	D000014	true

Sentence: RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.
Entity: 12852481	64	90	ventricular septal defects	Disease	D006345
Entity: 12852481	92	96	VSDs	Disease	D006345
Entity: 12852481	102	117	midline defects	Disease	D009436
Entity: 12852481	119	122	MDs	Disease	D009436
Entity: 12852481	136	156	diaphragmatic hernia	Disease	D065630
Entity: 12852481	158	160	DH	Disease	D065630
Entity: 12852481	163	166	MDs	Disease	D009436
Entity: 12852481	172	176	VSDs	Disease	D006345
Entity: 12852481	254	267	malformations	Disease	D000014
Entity: 12852481	281	284	ASA	Chemical	D001241
Entity: 12852481	321	334	malformations	Disease	D000014
Relation: 12852481	CID	281	284	D001241	64	90	D006345	true
Relation: 12852481	CID	281	284	D001241	92	96	D006345	true
Relation: 12852481	CID	281	284	D001241	102	117	D009436	false
Relation: 12852481	CID	281	284	D001241	119	122	D009436	false
Relation: 12852481	CID	281	284	D001241	136	156	D065630	true
Relation: 12852481	CID	281	284	D001241	158	160	D065630	true
Relation: 12852481	CID	281	284	D001241	163	166	D009436	false
Relation: 12852481	CID	281	284	D001241	172	176	D006345	true
Relation: 12852481	CID	281	284	D001241	254	267	D000014	true
Relation: 12852481	CID	281	284	D001241	321	334	D000014	true

Sentence: Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis (GDs 6 to 17).
Entity: 12852481	15	28	malformations	Disease	D000014
Entity: 12852481	47	50	ASA	Chemical	D001241
Relation: 12852481	CID	47	50	D001241	15	28	D000014	true

Sentence: Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.
Entity: 11858397	0	18	Torsade de pointes	Disease	D016171
Entity: 11858397	30	44	metoclopramide	Chemical	D008787
Entity: 11858397	91	115	left bundle branch block	Disease	D002037
Relation: 11858397	CID	30	44	D008787	0	18	D016171	true
Relation: 11858397	CID	30	44	D008787	91	115	D002037	false

Sentence: We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.
Entity: 11858397	59	83	left bundle branch block	Disease	D002037
Entity: 11858397	98	116	torsade de pointes	Disease	D016171
Entity: 11858397	162	176	metoclopramide	Chemical	D008787
Relation: 11858397	CID	162	176	D008787	59	83	D002037	false
Relation: 11858397	CID	162	176	D008787	98	116	D016171	true

Sentence: This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.
Entity: 11858397	28	46	torsade de pointes	Disease	D016171
Entity: 11858397	52	61	cisapride	Chemical	D020117
Entity: 11858397	66	78	erythromycin	Chemical	D004917
Relation: 11858397	CID	52	61	D020117	28	46	D016171	true
Relation: 11858397	CID	66	78	D004917	28	46	D016171	true

Sentence: This is the first documentation that metoclopramide provokes torsade de pointes clinically.
Entity: 11858397	37	51	metoclopramide	Chemical	D008787
Entity: 11858397	61	79	torsade de pointes	Disease	D016171
Relation: 11858397	CID	37	51	D008787	61	79	D016171	true

Sentence: Apomorphine: an underutilized therapy for Parkinson's disease.
Entity: 11009181	0	11	Apomorphine	Chemical	D001058
Entity: 11009181	42	61	Parkinson's disease	Disease	D010300
Relation: 11009181	CID	0	11	D001058	42	61	D010300	false

Sentence: Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease.
Entity: 11009181	0	11	Apomorphine	Chemical	D001058
Entity: 11009181	75	94	Parkinson's disease	Disease	D010300
Relation: 11009181	CID	0	11	D001058	75	94	D010300	false

Sentence: While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study.
Entity: 11009181	114	133	Parkinson's disease	Disease	D010300
Entity: 11009181	168	179	apomorphine	Chemical	D001058
Relation: 11009181	CID	168	179	D001058	114	133	D010300	false

Sentence: In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa induced dyskinesias.
Entity: 11009181	97	108	apomorphine	Chemical	D001058
Entity: 11009181	171	179	levodopa	Chemical	D007980
Entity: 11009181	188	199	dyskinesias	Disease	D004409
Relation: 11009181	CID	97	108	D001058	188	199	D004409	false
Relation: 11009181	CID	171	179	D007980	188	199	D004409	true

Sentence: The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role.
Entity: 11009181	38	49	apomorphine	Chemical	D001058
Entity: 11009181	129	140	psychiatric	Disease	D001523
Relation: 11009181	CID	38	49	D001058	129	140	D001523	false

Sentence: Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity.
Entity: 8988571	14	22	delirium	Disease	D003693
Entity: 8988571	33	40	cocaine	Chemical	D003042
Entity: 8988571	108	115	cocaine	Chemical	D003042
Entity: 8988571	116	124	toxicity	Disease	D064420
Relation: 8988571	CID	33	40	D003042	14	22	D003693	true
Relation: 8988571	CID	33	40	D003042	116	124	D064420	false
Relation: 8988571	CID	108	115	D003042	14	22	D003693	true
Relation: 8988571	CID	108	115	D003042	116	124	D064420	false

Sentence: We describe an outbreak of deaths from cocaine induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.
Entity: 8988571	39	46	cocaine	Chemical	D003042
Entity: 8988571	63	71	delirium	Disease	D003693
Entity: 8988571	73	77	EDDs	Disease	D003693
Relation: 8988571	CID	39	46	D003042	63	71	D003693	true
Relation: 8988571	CID	39	46	D003042	73	77	D003693	true

Sentence: From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.
Entity: 8988571	23	30	cocaine	Chemical	D003042
Entity: 8988571	90	94	EDDs	Disease	D003693
Entity: 8988571	140	147	cocaine	Chemical	D003042
Entity: 8988571	148	156	overdose	Disease	D062787
Entity: 8988571	173	181	delirium	Disease	D003693
Relation: 8988571	CID	23	30	D003042	90	94	D003693	true
Relation: 8988571	CID	23	30	D003042	148	156	D062787	false
Relation: 8988571	CID	23	30	D003042	173	181	D003693	true
Relation: 8988571	CID	140	147	D003042	90	94	D003693	true
Relation: 8988571	CID	140	147	D003042	148	156	D062787	false
Relation: 8988571	CID	140	147	D003042	173	181	D003693	true

Sentence: EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.
Entity: 8988571	0	4	EDDs	Disease	D003693
Entity: 8988571	27	34	cocaine	Chemical	D003042
Entity: 8988571	39	54	benzoylecgonine	Chemical	C005618
Relation: 8988571	CID	27	34	D003042	0	4	D003693	true
Relation: 8988571	CID	39	54	C005618	0	4	D003693	false

Sentence: Heparin induced thrombocytopenia, thrombosis, and hemorrhage.
Entity: 6615052	0	7	Heparin	Chemical	D006493
Entity: 6615052	16	32	thrombocytopenia	Disease	D013921
Entity: 6615052	34	44	thrombosis	Disease	D013927
Entity: 6615052	50	60	hemorrhage	Disease	D006470
Relation: 6615052	CID	0	7	D006493	16	32	D013921	true
Relation: 6615052	CID	0	7	D006493	34	44	D013927	false
Relation: 6615052	CID	0	7	D006493	50	60	D006470	true

Sentence: Sixty-two patients with a heparin induced thrombocytopenia are reported.
Entity: 6615052	26	33	heparin	Chemical	D006493
Entity: 6615052	42	58	thrombocytopenia	Disease	D013921
Relation: 6615052	CID	26	33	D006493	42	58	D013921	true

Sentence: Clinical manifestations of this disorder include hemorrhage or, more frequently, thromboembolic events in patients receiving heparin.
Entity: 6615052	49	59	hemorrhage	Disease	D006470
Entity: 6615052	81	95	thromboembolic	Disease	D013923
Entity: 6615052	125	132	heparin	Chemical	D006493
Relation: 6615052	CID	125	132	D006493	49	59	D006470	true
Relation: 6615052	CID	125	132	D006493	81	95	D013923	true

Sentence: Laboratory testing has revealed a falling platelet count, increased resistance to heparin, and aggregation of platelets by the patient's plasma when heparin is added.
Entity: 6615052	32	56	a falling platelet count	Disease	D001791
Entity: 6615052	82	89	heparin	Chemical	D006493
Entity: 6615052	149	156	heparin	Chemical	D006493
Relation: 6615052	CID	82	89	D006493	32	56	D001791	false
Relation: 6615052	CID	149	156	D006493	32	56	D001791	false

Sentence: If the platelet count falls to less than 100,000/mm3, while the patient is receiving heparin, platelet aggregation testing, using the patient's plasma, is indicated.
Entity: 6615052	85	92	heparin	Chemical	D006493
Entity: 6615052	94	114	platelet aggregation	Disease	D001791
Relation: 6615052	CID	85	92	D006493	94	114	D001791	false

Sentence: Cardiac toxicity of 5-fluorouracil.
Entity: 3952818	0	16	Cardiac toxicity	Disease	D066126
Entity: 3952818	20	34	5-fluorouracil	Chemical	D005472
Relation: 3952818	CID	20	34	D005472	0	16	D066126	false

Sentence: We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.
Entity: 3952818	35	50	colon carcinoma	Disease	D003110
Entity: 3952818	61	71	metastasis	Disease	D009362
Entity: 3952818	86	96	chest pain	Disease	D002637
Entity: 3952818	103	117	5-fluorouracil	Chemical	D005472
Entity: 3952818	119	123	5-FU	Chemical	D005472
Relation: 3952818	CID	103	117	D005472	35	50	D003110	false
Relation: 3952818	CID	103	117	D005472	61	71	D009362	false
Relation: 3952818	CID	103	117	D005472	86	96	D002637	true
Relation: 3952818	CID	119	123	D005472	35	50	D003110	false
Relation: 3952818	CID	119	123	D005472	61	71	D009362	false
Relation: 3952818	CID	119	123	D005472	86	96	D002637	true

Sentence: Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.
Entity: 3952818	72	91	Prinzmetal's angina	Disease	D000788
Entity: 3952818	97	107	chest pain	Disease	D002637
Entity: 3952818	131	141	nifedipine	Chemical	D009543
Relation: 3952818	CID	131	141	D009543	72	91	D000788	false
Relation: 3952818	CID	131	141	D009543	97	107	D002637	false

Sentence: A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.
Entity: 3084782	44	53	nephritis	Disease	D009393
Entity: 3084782	58	68	dermatitis	Disease	D003872
Entity: 3084782	76	85	Tiopronin	Chemical	D008625
Entity: 3084782	89	104	D-Penicillamine	Chemical	D010396
Entity: 3084782	162	172	dermatitis	Disease	D003872
Entity: 3084782	180	184	gold	Chemical	D006046
Entity: 3084782	185	197	thiosulphate	Chemical	-1
Relation: 3084782	CID	76	85	D008625	44	53	D009393	true
Relation: 3084782	CID	76	85	D008625	58	68	D003872	true
Relation: 3084782	CID	76	85	D008625	162	172	D003872	true
Relation: 3084782	CID	89	104	D010396	44	53	D009393	false
Relation: 3084782	CID	89	104	D010396	58	68	D003872	false
Relation: 3084782	CID	89	104	D010396	162	172	D003872	false
Relation: 3084782	CID	180	184	D006046	44	53	D009393	false
Relation: 3084782	CID	180	184	D006046	58	68	D003872	true
Relation: 3084782	CID	180	184	D006046	162	172	D003872	true
Relation: 3084782	CID	185	197	-1	44	53	D009393	false
Relation: 3084782	CID	185	197	-1	58	68	D003872	false
Relation: 3084782	CID	185	197	-1	162	172	D003872	false

Sentence: Transient hemiparesis: a rare manifestation of diphenylhydantoin toxicity.
Entity: 430165	10	21	hemiparesis	Disease	D010291
Entity: 430165	47	64	diphenylhydantoin	Chemical	D010672
Entity: 430165	65	73	toxicity	Disease	D064420
Relation: 430165	CID	47	64	D010672	10	21	D010291	true
Relation: 430165	CID	47	64	D010672	65	73	D064420	false

Sentence: Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.
Entity: 430165	33	50	diphenylhydantoin	Chemical	D010672
Entity: 430165	52	55	DPH	Chemical	D010672
Entity: 430165	57	65	overdose	Disease	D062787
Entity: 430165	131	153	cerebellar dysfunction	Disease	D002526
Relation: 430165	CID	33	50	D010672	57	65	D062787	true
Relation: 430165	CID	33	50	D010672	131	153	D002526	true
Relation: 430165	CID	52	55	D010672	57	65	D062787	true
Relation: 430165	CID	52	55	D010672	131	153	D002526	true

Sentence: Two patients are presented who suffered progressive hemiparesis due to DPH overdose.
Entity: 430165	52	63	hemiparesis	Disease	D010291
Entity: 430165	71	74	DPH	Chemical	D010672
Entity: 430165	75	83	overdose	Disease	D062787
Relation: 430165	CID	71	74	D010672	52	63	D010291	true
Relation: 430165	CID	71	74	D010672	75	83	D062787	true

Sentence: Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.
Entity: 16600756	24	38	prostaglandins	Chemical	D011453
Entity: 16600756	76	94	overactive bladder	Disease	D053201
Relation: 16600756	CID	24	38	D011453	76	94	D053201	false

Sentence: We investigated changes in urinary NGF and PGs in women with OAB.
Entity: 16600756	43	46	PGs	Chemical	D011453
Entity: 16600756	61	64	OAB	Disease	D053201
Relation: 16600756	CID	43	46	D011453	61	64	D053201	false

Sentence: In addition, correlations between urinary NGF and PG, and urodynamic parameters in patients with OAB were examined.
Entity: 16600756	50	52	PG	Chemical	D011453
Entity: 16600756	97	100	OAB	Disease	D053201
Relation: 16600756	CID	50	52	D011453	97	100	D053201	false

Sentence: RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).
Entity: 16600756	22	26	PGE2	Chemical	D015232
Entity: 16600756	31	40	PGF2alpha	Chemical	D015237
Entity: 16600756	87	90	OAB	Disease	D053201
Relation: 16600756	CID	22	26	D015232	87	90	D053201	true
Relation: 16600756	CID	31	40	D015237	87	90	D053201	true

Sentence: However, urinary PGI2 was not different between controls and patients with OAB.
Entity: 16600756	17	21	PGI2	Chemical	D011464
Entity: 16600756	75	78	OAB	Disease	D053201
Relation: 16600756	CID	17	21	D011464	75	78	D053201	false

Sentence: In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).
Entity: 16600756	17	20	OAB	Disease	D053201
Entity: 16600756	29	33	PGE2	Chemical	D015232
Relation: 16600756	CID	29	33	D015232	17	20	D053201	true

Sentence: Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.
Entity: 16600756	13	22	PGF2alpha	Chemical	D015237
Entity: 16600756	27	31	PGI2	Chemical	D011464
Entity: 16600756	94	97	OAB	Disease	D053201
Relation: 16600756	CID	13	22	D015237	94	97	D053201	true
Relation: 16600756	CID	27	31	D011464	94	97	D053201	false

Sentence: CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.
Entity: 16600756	21	24	PGs	Chemical	D011453
Entity: 16600756	68	71	OAB	Disease	D053201
Relation: 16600756	CID	21	24	D011453	68	71	D053201	false

Sentence: Acute low back pain during intravenous administration of amiodarone: a report of two cases.
Entity: 15686794	6	19	low back pain	Disease	D017116
Entity: 15686794	57	67	amiodarone	Chemical	D000638
Relation: 15686794	CID	57	67	D000638	6	19	D017116	true

Sentence: Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.
Entity: 15686794	0	10	Amiodarone	Chemical	D000638
Entity: 15686794	89	108	atrial fibrillation	Disease	D001281
Entity: 15686794	110	112	AF	Disease	D001281
Relation: 15686794	CID	0	10	D000638	89	108	D001281	false
Relation: 15686794	CID	0	10	D000638	110	112	D001281	false

Sentence: Postoperative myalgia after succinylcholine: no evidence for an inflammatory origin.
Entity: 12760988	0	21	Postoperative myalgia	Disease	D010149
Entity: 12760988	28	43	succinylcholine	Chemical	D013390
Relation: 12760988	CID	28	43	D013390	0	21	D010149	true

Sentence: A common side effect associated with succinylcholine is postoperative myalgia.
Entity: 12760988	37	52	succinylcholine	Chemical	D013390
Entity: 12760988	56	77	postoperative myalgia	Disease	D010149
Relation: 12760988	CID	37	52	D013390	56	77	D010149	true

Sentence: The incidence and severity of succinylcholine-associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine (n = 32 for each).
Entity: 12760988	30	45	succinylcholine	Chemical	D013390
Entity: 12760988	57	64	myalgia	Disease	D063806
Entity: 12760988	121	134	dexamethasone	Chemical	D003907
Entity: 12760988	142	157	succinylcholine	Chemical	D013390
Relation: 12760988	CID	30	45	D013390	57	64	D063806	true
Relation: 12760988	CID	121	134	D003907	57	64	D063806	false
Relation: 12760988	CID	142	157	D013390	57	64	D063806	true

Sentence: Incidence and severity of myalgia did not differ significantly between the two groups: 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group, and severe myalgia was reported by five patients and three patients, respectively (not significant).
Entity: 12760988	26	33	myalgia	Disease	D063806
Entity: 12760988	106	119	dexamethasone	Chemical	D003907
Entity: 12760988	140	147	myalgia	Disease	D063806
Entity: 12760988	206	213	myalgia	Disease	D063806
Relation: 12760988	CID	106	119	D003907	26	33	D063806	false
Relation: 12760988	CID	106	119	D003907	140	147	D063806	false
Relation: 12760988	CID	106	119	D003907	206	213	D063806	false

Sentence: In conclusion, there is no evidence for an inflammatory origin of succinylcholine-associated myalgia.
Entity: 12760988	66	81	succinylcholine	Chemical	D013390
Entity: 12760988	93	100	myalgia	Disease	D063806
Relation: 12760988	CID	66	81	D013390	93	100	D063806	true

Sentence: IMPLICATIONS: Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine induced postoperative myalgia.
Entity: 12760988	32	45	dexamethasone	Chemical	D003907
Entity: 12760988	53	68	succinylcholine	Chemical	D013390
Entity: 12760988	134	149	succinylcholine	Chemical	D013390
Entity: 12760988	158	179	postoperative myalgia	Disease	D010149
Relation: 12760988	CID	32	45	D003907	158	179	D010149	false
Relation: 12760988	CID	53	68	D013390	158	179	D010149	true
Relation: 12760988	CID	134	149	D013390	158	179	D010149	true

Sentence: Levodopa induced oromandibular dystonia in progressive supranuclear palsy.
Entity: 12691807	0	8	Levodopa	Chemical	D007980
Entity: 12691807	31	39	dystonia	Disease	D004421
Entity: 12691807	43	73	progressive supranuclear palsy	Disease	D013494
Relation: 12691807	CID	0	8	D007980	31	39	D004421	true
Relation: 12691807	CID	0	8	D007980	43	73	D013494	false

Sentence: Levodopa induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy.
Entity: 12691807	0	8	Levodopa	Chemical	D007980
Entity: 12691807	17	28	dyskinesias	Disease	D004409
Entity: 12691807	51	70	Parkinson's disease	Disease	D010300
Entity: 12691807	75	98	multiple system atrophy	Disease	D019578
Relation: 12691807	CID	0	8	D007980	17	28	D004409	false
Relation: 12691807	CID	0	8	D007980	51	70	D010300	false
Relation: 12691807	CID	0	8	D007980	75	98	D019578	false

Sentence: Protective effect of edaravone against streptomycin induced vestibulotoxicity in the guinea pig.
Entity: 12600698	21	30	edaravone	Chemical	C005435
Entity: 12600698	39	51	streptomycin	Chemical	D013307
Entity: 12600698	60	77	vestibulotoxicity	Disease	D015837
Relation: 12600698	CID	21	30	C005435	60	77	D015837	false
Relation: 12600698	CID	39	51	D013307	60	77	D015837	true

Sentence: This study investigated alleviation of streptomycin induced vestibulotoxicity by edaravone in guinea pigs.
Entity: 12600698	39	51	streptomycin	Chemical	D013307
Entity: 12600698	60	77	vestibulotoxicity	Disease	D015837
Entity: 12600698	81	90	edaravone	Chemical	C005435
Relation: 12600698	CID	39	51	D013307	60	77	D015837	true
Relation: 12600698	CID	81	90	C005435	60	77	D015837	false

Sentence: Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat cerebral infarction.
Entity: 12600698	0	9	Edaravone	Chemical	C005435
Entity: 12600698	120	139	cerebral infarction	Disease	D002544
Relation: 12600698	CID	0	9	C005435	120	139	D002544	false

Sentence: Diazepam, unless contraindicated or risky, remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations.
Entity: 12091028	0	8	Diazepam	Chemical	D003975
Entity: 12091028	92	100	ketamine	Chemical	D007649
Entity: 12091028	215	229	hallucinations	Disease	D006212
Relation: 12091028	CID	0	8	D003975	215	229	D006212	false
Relation: 12091028	CID	92	100	D007649	215	229	D006212	true

Sentence: Steroid structure and pharmacological properties determine the anti-amnesic effects of pregnenolone sulphate in the passive avoidance task in rats.
Entity: 11860495	0	7	Steroid	Chemical	D013256
Entity: 11860495	68	75	amnesic	Disease	D000647
Entity: 11860495	87	108	pregnenolone sulphate	Chemical	C018370
Relation: 11860495	CID	0	7	D013256	68	75	D000647	false
Relation: 11860495	CID	87	108	C018370	68	75	D000647	false

Sentence: Moreover, PREGS is able to reverse the amnesic-like effects of NMDAR and GABA(A)R ligands.
Entity: 11860495	10	15	PREGS	Chemical	C018370
Entity: 11860495	39	46	amnesic	Disease	D000647
Entity: 11860495	73	77	GABA	Chemical	D005680
Relation: 11860495	CID	10	15	C018370	39	46	D000647	false
Relation: 11860495	CID	73	77	D005680	39	46	D000647	false

Sentence: The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine induced amnesia.
Entity: 11860495	32	37	PREGS	Chemical	C018370
Entity: 11860495	115	126	scopolamine	Chemical	D012601
Entity: 11860495	135	142	amnesia	Disease	D000647
Relation: 11860495	CID	32	37	C018370	135	142	D000647	false
Relation: 11860495	CID	115	126	D012601	135	142	D000647	true

Sentence: Moreover, enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine induced amnesia.
Entity: 11860495	72	77	PREGS	Chemical	C018370
Entity: 11860495	164	175	scopolamine	Chemical	D012601
Entity: 11860495	184	191	amnesia	Disease	D000647
Relation: 11860495	CID	72	77	C018370	184	191	D000647	false
Relation: 11860495	CID	164	175	D012601	184	191	D000647	true

Sentence: BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.
Entity: 11752998	47	56	adenosine	Chemical	D000241
Entity: 11752998	105	110	acute	Disease	D059787
Entity: 11752998	115	122	chronic	Disease	D059350
Entity: 11752998	220	229	adenosine	Chemical	D000241
Entity: 11752998	262	278	hypersensitivity	Disease	D004342
Relation: 11752998	CID	47	56	D000241	105	110	D059787	false
Relation: 11752998	CID	47	56	D000241	115	122	D059350	false
Relation: 11752998	CID	47	56	D000241	262	278	D004342	false
Relation: 11752998	CID	220	229	D000241	105	110	D059787	false
Relation: 11752998	CID	220	229	D000241	115	122	D059350	false
Relation: 11752998	CID	220	229	D000241	262	278	D004342	false

Sentence: The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US, using both acute noxious stimulation and capsaicin-evoked mechanical hypersensitivity.
Entity: 11752998	83	92	adenosine	Chemical	D000241
Entity: 11752998	154	163	capsaicin	Chemical	D002211
Entity: 11752998	182	198	hypersensitivity	Disease	D004342
Relation: 11752998	CID	83	92	D000241	182	198	D004342	false
Relation: 11752998	CID	154	163	D002211	182	198	D004342	false

Sentence: Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.
Entity: 11752998	67	71	pain	Disease	D010146
Entity: 11752998	127	150	mechanical hyperalgesia	Disease	D006930
Entity: 11752998	155	164	allodynia	Disease	D006930
Entity: 11752998	183	192	capsaicin	Chemical	D002211
Relation: 11752998	CID	183	192	D002211	67	71	D010146	false
Relation: 11752998	CID	183	192	D002211	127	150	D006930	true
Relation: 11752998	CID	183	192	D002211	155	164	D006930	true

Sentence: RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h.
Entity: 11752998	9	18	Adenosine	Chemical	D000241
Entity: 11752998	41	45	pain	Disease	D010146
Entity: 11752998	114	137	mechanical hyperalgesia	Disease	D006930
Entity: 11752998	142	151	allodynia	Disease	D006930
Entity: 11752998	169	178	capsaicin	Chemical	D002211
Relation: 11752998	CID	9	18	D000241	41	45	D010146	false
Relation: 11752998	CID	9	18	D000241	114	137	D006930	false
Relation: 11752998	CID	9	18	D000241	142	151	D006930	false
Relation: 11752998	CID	169	178	D002211	41	45	D010146	false
Relation: 11752998	CID	169	178	D002211	114	137	D006930	true
Relation: 11752998	CID	169	178	D002211	142	151	D006930	true

Sentence: CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of hypersensitivity, presumed to reflect central sensitization in humans after peripheral capsaicin injection.
Entity: 11752998	68	77	adenosine	Chemical	D000241
Entity: 11752998	81	97	hypersensitivity	Disease	D004342
Entity: 11752998	168	177	capsaicin	Chemical	D002211
Relation: 11752998	CID	68	77	D000241	81	97	D004342	false
Relation: 11752998	CID	168	177	D002211	81	97	D004342	false

Sentence: These were evaluated with respect to the duration of lithium therapy, age, sex, and family history (whether or not the patient had a first-degree relative with thyroid disease).
Entity: 10354657	53	60	lithium	Chemical	D008094
Entity: 10354657	160	175	thyroid disease	Disease	D013959
Relation: 10354657	CID	53	60	D008094	160	175	D013959	false

Sentence: PATIENTS: One hundred and one patients (28 men and 73 women) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration.
Entity: 10354657	66	82	bipolar disorder	Disease	D001714
Entity: 10354657	93	100	lithium	Chemical	D008094
Relation: 10354657	CID	93	100	D008094	66	82	D001714	false

Sentence: All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).
Entity: 10354657	55	70	thyroid illness	Disease	D013959
Entity: 10354657	96	110	hypothyroidism	Disease	D007037
Entity: 10354657	137	144	lithium	Chemical	D008094
Entity: 10354657	228	235	lithium	Chemical	D008094
Relation: 10354657	CID	137	144	D008094	55	70	D013959	false
Relation: 10354657	CID	137	144	D008094	96	110	D007037	true
Relation: 10354657	CID	228	235	D008094	55	70	D013959	false
Relation: 10354657	CID	228	235	D008094	96	110	D007037	true

Sentence: Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.
Entity: 10328196	9	17	toxicity	Disease	D064420
Entity: 10328196	46	55	sirolimus	Chemical	D020123
Entity: 10328196	66	75	rapamycin	Chemical	D020123
Entity: 10328196	81	90	psoriasis	Disease	D011565
Entity: 10328196	107	130	capillary leak syndrome	Disease	D019559
Relation: 10328196	CID	46	55	D020123	9	17	D064420	false
Relation: 10328196	CID	46	55	D020123	81	90	D011565	false
Relation: 10328196	CID	46	55	D020123	107	130	D019559	true
Relation: 10328196	CID	66	75	D020123	9	17	D064420	false
Relation: 10328196	CID	66	75	D020123	81	90	D011565	false
Relation: 10328196	CID	66	75	D020123	107	130	D019559	true

Sentence: After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.
Entity: 10328196	25	34	psoriasis	Disease	D011565
Entity: 10328196	47	70	capillary leak syndrome	Disease	D019559
Entity: 10328196	101	110	sirolimus	Chemical	D020123
Relation: 10328196	CID	101	110	D020123	25	34	D011565	false
Relation: 10328196	CID	101	110	D020123	47	70	D019559	true

Sentence: OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%).
Entity: 10328196	59	68	sirolimus	Chemical	D020123
Entity: 10328196	77	100	capillary leak syndrome	Disease	D019559
Entity: 10328196	195	204	sirolimus	Chemical	D020123
Entity: 10328196	226	235	psoriasis	Disease	D011565
Relation: 10328196	CID	59	68	D020123	77	100	D019559	true
Relation: 10328196	CID	59	68	D020123	226	235	D011565	false
Relation: 10328196	CID	195	204	D020123	77	100	D019559	true
Relation: 10328196	CID	195	204	D020123	226	235	D011565	false

Sentence: Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone induced apoptosis than did normal T cells, particularly in the presence of sirolimus.
Entity: 10328196	54	63	psoriasis	Disease	D011565
Entity: 10328196	105	118	dexamethasone	Chemical	D003907
Entity: 10328196	194	203	sirolimus	Chemical	D020123
Relation: 10328196	CID	105	118	D003907	54	63	D011565	false
Relation: 10328196	CID	194	203	D020123	54	63	D011565	false

Sentence: CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.
Entity: 10328196	39	48	sirolimus	Chemical	D020123
Entity: 10328196	57	62	fever	Disease	D005334
Entity: 10328196	64	70	anemia	Disease	D000740
Entity: 10328196	76	99	capillary leak syndrome	Disease	D019559
Relation: 10328196	CID	39	48	D020123	57	62	D005334	false
Relation: 10328196	CID	39	48	D020123	64	70	D000740	false
Relation: 10328196	CID	39	48	D020123	76	99	D019559	true

Sentence: Muscle rigidity was induced by haloperidol (2.5 mg/kg i.p.). 5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG). 5,7-DCKA injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone.
Entity: 9630698	0	15	Muscle rigidity	Disease	D009127
Entity: 9630698	31	42	haloperidol	Chemical	D006220
Entity: 9630698	61	87	5,7-dichlorokynurenic acid	Chemical	C066192
Entity: 9630698	89	97	5,7-DCKA	Chemical	C066192
Entity: 9630698	112	119	glycine	Chemical	D005998
Entity: 9630698	261	272	haloperidol	Chemical	D006220
Entity: 9630698	281	296	muscle rigidity	Disease	D009127
Entity: 9630698	354	362	5,7-DCKA	Chemical	C066192
Entity: 9630698	499	510	haloperidol	Chemical	D006220
Relation: 9630698	CID	31	42	D006220	0	15	D009127	true
Relation: 9630698	CID	31	42	D006220	281	296	D009127	true
Relation: 9630698	CID	61	87	C066192	0	15	D009127	false
Relation: 9630698	CID	61	87	C066192	281	296	D009127	false
Relation: 9630698	CID	89	97	C066192	0	15	D009127	false
Relation: 9630698	CID	89	97	C066192	281	296	D009127	false
Relation: 9630698	CID	112	119	D005998	0	15	D009127	false
Relation: 9630698	CID	112	119	D005998	281	296	D009127	false
Relation: 9630698	CID	261	272	D006220	0	15	D009127	true
Relation: 9630698	CID	261	272	D006220	281	296	D009127	true
Relation: 9630698	CID	354	362	C066192	0	15	D009127	false
Relation: 9630698	CID	354	362	C066192	281	296	D009127	false
Relation: 9630698	CID	499	510	D006220	0	15	D009127	true
Relation: 9630698	CID	499	510	D006220	281	296	D009127	true

Sentence: Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia.
Entity: 8480959	29	39	lovastatin	Chemical	D008148
Entity: 8480959	68	88	hypercholesterolemia	Disease	D006937
Relation: 8480959	CID	29	39	D008148	68	88	D006937	false

Sentence: OBJECTIVE: To evaluate the efficacy and safety of lovastatin in women with moderate hypercholesterolemia.
Entity: 8480959	50	60	lovastatin	Chemical	D008148
Entity: 8480959	84	104	hypercholesterolemia	Disease	D006937
Relation: 8480959	CID	50	60	D008148	84	104	D006937	false

Sentence: Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).
Entity: 8480959	0	8	Myopathy	Disease	D009135
Entity: 8480959	42	50	creatine	Chemical	D003401
Entity: 8480959	185	195	lovastatin	Chemical	D008148
Relation: 8480959	CID	42	50	D003401	0	8	D009135	false
Relation: 8480959	CID	185	195	D008148	0	8	D009135	true

Sentence: The effects of REM sleep deprivation (REMD) on apomorphine induced aggressiveness and quipazine induced head twitches in rats were determined.
Entity: 7197363	15	36	REM sleep deprivation	Disease	D012892
Entity: 7197363	38	42	REMD	Disease	D012892
Entity: 7197363	47	58	apomorphine	Chemical	D001058
Entity: 7197363	67	81	aggressiveness	Disease	D001523
Entity: 7197363	86	95	quipazine	Chemical	D011814
Entity: 7197363	104	117	head twitches	Disease	D009069
Relation: 7197363	CID	47	58	D001058	15	36	D012892	false
Relation: 7197363	CID	47	58	D001058	38	42	D012892	false
Relation: 7197363	CID	47	58	D001058	67	81	D001523	true
Relation: 7197363	CID	47	58	D001058	104	117	D009069	false
Relation: 7197363	CID	86	95	D011814	15	36	D012892	false
Relation: 7197363	CID	86	95	D011814	38	42	D012892	false
Relation: 7197363	CID	86	95	D011814	67	81	D001523	false
Relation: 7197363	CID	86	95	D011814	104	117	D009069	true

Sentence: The incidence of parkinsonism was higher at higher doses of haloperidol and in younger patients.
Entity: 7161250	17	29	parkinsonism	Disease	D010302
Entity: 7161250	60	71	haloperidol	Chemical	D006220
Relation: 7161250	CID	60	71	D006220	17	29	D010302	true

Sentence: Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.
Entity: 7161250	0	9	Akathisia	Disease	D017109
Entity: 7161250	32	46	benzodiazepine	Chemical	D001569
Entity: 7161250	47	56	lorazepam	Chemical	D008140
Relation: 7161250	CID	32	46	D001569	0	9	D017109	false
Relation: 7161250	CID	47	56	D008140	0	9	D017109	false

Sentence: Hepatic veno-occlusive disease caused by 6-thioguanine.
Entity: 7053705	0	30	Hepatic veno-occlusive disease	Disease	D006504
Entity: 7053705	41	54	6-thioguanine	Chemical	D013866
Relation: 7053705	CID	41	54	D013866	0	30	D006504	true

Sentence: Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.
Entity: 7053705	22	57	veno-occlusive disease of the liver	Disease	D006504
Entity: 7053705	94	120	acute lymphocytic leukemia	Disease	D054198
Entity: 7053705	165	178	6-thioguanine	Chemical	D013866
Relation: 7053705	CID	165	178	D013866	22	57	D006504	true
Relation: 7053705	CID	165	178	D013866	94	120	D054198	false

Sentence: Treatment of ifosfamide induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.
Entity: 6402369	13	23	ifosfamide	Chemical	D007069
Entity: 6402369	32	51	urothelial toxicity	Disease	D001745
Entity: 6402369	78	112	sodium 2-mercaptoethane sulphonate	Chemical	D015080
Entity: 6402369	114	119	MESNA	Chemical	D015080
Entity: 6402369	149	160	lung cancer	Disease	D008175
Relation: 6402369	CID	13	23	D007069	32	51	D001745	true
Relation: 6402369	CID	13	23	D007069	149	160	D008175	false
Relation: 6402369	CID	78	112	D015080	32	51	D001745	false
Relation: 6402369	CID	78	112	D015080	149	160	D008175	false
Relation: 6402369	CID	114	119	D015080	32	51	D001745	false
Relation: 6402369	CID	114	119	D015080	149	160	D008175	false

Sentence: The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.
Entity: 6402369	52	57	thiol	Chemical	D013438
Entity: 6402369	67	101	sodium 2-mercaptoethane sulphonate	Chemical	D015080
Entity: 6402369	103	108	MESNA	Chemical	D015080
Entity: 6402369	118	137	urothelial toxicity	Disease	D001745
Entity: 6402369	149	159	ifosfamide	Chemical	D007069
Entity: 6402369	161	163	IF	Chemical	D007069
Entity: 6402369	218	229	lung cancer	Disease	D008175
Entity: 6402369	251	253	IF	Chemical	D007069
Relation: 6402369	CID	52	57	D013438	118	137	D001745	false
Relation: 6402369	CID	52	57	D013438	218	229	D008175	false
Relation: 6402369	CID	67	101	D015080	118	137	D001745	false
Relation: 6402369	CID	67	101	D015080	218	229	D008175	false
Relation: 6402369	CID	103	108	D015080	118	137	D001745	false
Relation: 6402369	CID	103	108	D015080	218	229	D008175	false
Relation: 6402369	CID	149	159	D007069	118	137	D001745	true
Relation: 6402369	CID	149	159	D007069	218	229	D008175	false
Relation: 6402369	CID	161	163	D007069	118	137	D001745	true
Relation: 6402369	CID	161	163	D007069	218	229	D008175	false
Relation: 6402369	CID	251	253	D007069	118	137	D001745	true
Relation: 6402369	CID	251	253	D007069	218	229	D008175	false

Sentence: There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment.
Entity: 6402369	50	55	MESNA	Chemical	D015080
Entity: 6402369	153	161	toxicity	Disease	D064420
Relation: 6402369	CID	50	55	D015080	153	161	D064420	false

Sentence: Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone.
Entity: 3461217	28	43	prostate cancer	Disease	D011471
Entity: 3461217	85	107	N-nitroso-N-methylurea	Chemical	D008770
Entity: 3461217	112	124	testosterone	Chemical	D013739
Relation: 3461217	CID	85	107	D008770	28	43	D011471	true
Relation: 3461217	CID	112	124	D013739	28	43	D011471	false

Sentence: More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.
Entity: 3461217	75	99	prostate adenocarcinomas	Disease	D011471
Entity: 3461217	101	104	PAs	Disease	D011471
Entity: 3461217	132	154	N-nitroso-N-methylurea	Chemical	D008770
Entity: 3461217	175	198	testosterone propionate	Chemical	D043343
Entity: 3461217	201	203	TP	Chemical	D043343
Entity: 3461217	236	241	tumor	Disease	D009369
Relation: 3461217	CID	132	154	D008770	75	99	D011471	true
Relation: 3461217	CID	132	154	D008770	101	104	D011471	true
Relation: 3461217	CID	132	154	D008770	236	241	D009369	false
Relation: 3461217	CID	175	198	D043343	75	99	D011471	true
Relation: 3461217	CID	175	198	D043343	101	104	D011471	true
Relation: 3461217	CID	175	198	D043343	236	241	D009369	false
Relation: 3461217	CID	201	203	D043343	75	99	D011471	true
Relation: 3461217	CID	201	203	D043343	101	104	D011471	true
Relation: 3461217	CID	201	203	D043343	236	241	D009369	false

Sentence: Within the same timeframe, no L-W rat developed a similar palpable PA when treated only with TP.
Entity: 3461217	67	69	PA	Disease	D011471
Entity: 3461217	93	95	TP	Chemical	D043343
Relation: 3461217	CID	93	95	D043343	67	69	D011471	true

Sentence: A dystonia-like syndrome after neuropeptide (MSH/ACTH) stimulation of the rat locus ceruleus.
Entity: 2840807	2	10	dystonia	Disease	D004421
Entity: 2840807	45	48	MSH	Chemical	D009074
Entity: 2840807	49	53	ACTH	Chemical	D000324
Relation: 2840807	CID	45	48	D009074	2	10	D004421	true
Relation: 2840807	CID	49	53	D000324	2	10	D004421	true

Sentence: Dexmedetomidine, acting through central alpha-2 adrenoceptors, prevents opiate induced muscle rigidity in the rat.
Entity: 2569282	0	15	Dexmedetomidine	Chemical	D020927
Entity: 2569282	87	102	muscle rigidity	Disease	D009127
Relation: 2569282	CID	0	15	D020927	87	102	D009127	false

Sentence: The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing muscle flaccidity and anesthesia in rats and dogs.
Entity: 2569282	48	63	dexmedetomidine	Chemical	D020927
Entity: 2569282	65	70	D-MED	Chemical	D020927
Entity: 2569282	95	112	muscle flaccidity	Disease	D009123
Relation: 2569282	CID	48	63	D020927	95	112	D009123	false
Relation: 2569282	CID	65	70	D020927	95	112	D009123	false

Sentence: In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat.
Entity: 2569282	63	68	D-MED	Chemical	D020927
Entity: 2569282	82	97	muscle rigidity	Disease	D009127
Entity: 2569282	118	128	alfentanil	Chemical	D015760
Relation: 2569282	CID	63	68	D020927	82	97	D009127	false
Relation: 2569282	CID	118	128	D015760	82	97	D009127	true

Sentence: In contrast, D-MED prevented alfentanil induced muscle rigidity in a dose-dependent fashion.
Entity: 2569282	13	18	D-MED	Chemical	D020927
Entity: 2569282	29	39	alfentanil	Chemical	D015760
Entity: 2569282	48	63	muscle rigidity	Disease	D009127
Relation: 2569282	CID	13	18	D020927	48	63	D009127	false
Relation: 2569282	CID	29	39	D015760	48	63	D009127	true

Sentence: Seizure activity with imipenem therapy: incidence and risk factors.
Entity: 2343592	0	7	Seizure	Disease	D012640
Entity: 2343592	22	30	imipenem	Chemical	D015378
Relation: 2343592	CID	22	30	D015378	0	7	D012640	false

Sentence: Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.
Entity: 2343592	46	72	cerebral vascular accident	Disease	D020521
Entity: 2343592	74	77	CVA	Disease	D020521
Entity: 2343592	82	93	head trauma	Disease	D006259
Entity: 2343592	113	126	renal disease	Disease	D007674
Entity: 2343592	137	145	seizures	Disease	D012640
Entity: 2343592	179	198	imipenem/cilastatin	Chemical	C044650
Relation: 2343592	CID	179	198	C044650	46	72	D020521	false
Relation: 2343592	CID	179	198	C044650	74	77	D020521	false
Relation: 2343592	CID	179	198	C044650	82	93	D006259	false
Relation: 2343592	CID	179	198	C044650	113	126	D007674	false
Relation: 2343592	CID	179	198	C044650	137	145	D012640	true

Sentence: All seizures were controlled with therapeutic doses of phenytoin.
Entity: 2343592	4	12	seizures	Disease	D012640
Entity: 2343592	55	64	phenytoin	Chemical	D010672
Relation: 2343592	CID	55	64	D010672	4	12	D012640	false

Sentence: The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin induced diabetes mellitus. 1.
Entity: 2055425	105	119	streptozotocin	Chemical	D013311
Entity: 2055425	128	145	diabetes mellitus	Disease	D003920
Relation: 2055425	CID	105	119	D013311	128	145	D003920	true

Sentence: The effects of insulin treatment on in vivo and in vitro urinary bladder function in streptozotocin-diabetic rats were investigated. 2.
Entity: 2055425	85	99	streptozotocin	Chemical	D013311
Entity: 2055425	100	108	diabetic	Disease	D003920
Relation: 2055425	CID	85	99	D013311	100	108	D003920	true

Sentence: Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol. 4.
Entity: 2055425	100	108	diabetic	Disease	D003920
Entity: 2055425	136	139	ATP	Chemical	D000255
Entity: 2055425	145	156	bethanechol	Chemical	D018723
Relation: 2055425	CID	136	139	D000255	100	108	D003920	false
Relation: 2055425	CID	145	156	D018723	100	108	D003920	false

Sentence: Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol. 6.
Entity: 2055425	94	102	diabetic	Disease	D003920
Entity: 2055425	130	133	ATP	Chemical	D000255
Entity: 2055425	139	150	bethanechol	Chemical	D018723
Relation: 2055425	CID	130	133	D000255	94	102	D003920	false
Relation: 2055425	CID	139	150	D018723	94	102	D003920	false

Sentence: Under isoflurane anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.
Entity: 1711760	6	16	isoflurane	Chemical	D007530
Entity: 1711760	57	69	hypertensive	Disease	D006973
Relation: 1711760	CID	6	16	D007530	57	69	D006973	false

Sentence: The extent of neuronal injury was determined by 2,3,5-triphenyltetrazolium staining.
Entity: 1711760	14	29	neuronal injury	Disease	D009410
Entity: 1711760	48	74	2,3,5-triphenyltetrazolium	Chemical	C009591
Relation: 1711760	CID	48	74	C009591	14	29	D009410	false

Sentence: Amiodarone pulmonary toxicity.
Entity: 1595783	0	10	Amiodarone	Chemical	D000638
Entity: 1595783	11	29	pulmonary toxicity	Disease	D008171
Relation: 1595783	CID	0	10	D000638	11	29	D008171	false

Sentence: Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side-effects, the most problematic being pneumonitis.
Entity: 1595783	0	10	Amiodarone	Chemical	D000638
Entity: 1595783	122	133	pneumonitis	Disease	D011014
Relation: 1595783	CID	0	10	D000638	122	133	D011014	true

Sentence: The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.
Entity: 1595783	4	22	pulmonary toxicity	Disease	D008171
Entity: 1595783	26	36	amiodarone	Chemical	D000638
Entity: 1595783	155	171	hypersensitivity	Disease	D004342
Entity: 1595783	172	183	pneumonitis	Disease	D000542
Relation: 1595783	CID	26	36	D000638	4	22	D008171	false
Relation: 1595783	CID	26	36	D000638	155	171	D004342	true
Relation: 1595783	CID	26	36	D000638	172	183	D000542	false

Sentence: The clinical and radiographic features of amiodarone induced pulmonary toxicity are characteristic but nonspecific.
Entity: 1595783	42	52	amiodarone	Chemical	D000638
Entity: 1595783	61	79	pulmonary toxicity	Disease	D008171
Relation: 1595783	CID	42	52	D000638	61	79	D008171	false

Sentence: Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis.
Entity: 804391	12	23	proteinuria	Disease	D011507
Entity: 804391	58	66	rifampin	Chemical	D012293
Entity: 804391	89	101	tuberculosis	Disease	D014376
Relation: 804391	CID	58	66	D012293	12	23	D011507	true
Relation: 804391	CID	58	66	D012293	89	101	D014376	false

Sentence: Light chain proteinuria was found in 9 of 17 tuberculosis patients treated with rifampin.
Entity: 804391	12	23	proteinuria	Disease	D011507
Entity: 804391	45	57	tuberculosis	Disease	D014376
Entity: 804391	80	88	rifampin	Chemical	D012293
Relation: 804391	CID	80	88	D012293	12	23	D011507	true
Relation: 804391	CID	80	88	D012293	45	57	D014376	false

Sentence: Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.
Entity: 28952	8	17	potassium	Chemical	D011188
Entity: 28952	27	39	hypokalaemia	Disease	D007008
Entity: 28952	47	61	chlorthalidone	Chemical	D002752
Entity: 28952	104	116	hypertension	Disease	D006973
Entity: 28952	143	149	sodium	Chemical	D012964
Relation: 28952	CID	8	17	D011188	27	39	D007008	false
Relation: 28952	CID	8	17	D011188	104	116	D006973	false
Relation: 28952	CID	47	61	D002752	27	39	D007008	true
Relation: 28952	CID	47	61	D002752	104	116	D006973	false
Relation: 28952	CID	143	149	D012964	27	39	D007008	false
Relation: 28952	CID	143	149	D012964	104	116	D006973	false

Sentence: To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.
Entity: 28952	27	36	potassium	Chemical	D011188
Entity: 28952	61	73	hypokalaemia	Disease	D007008
Entity: 28952	193	205	hypertension	Disease	D006973
Entity: 28952	220	232	hypokalaemia	Disease	D007008
Relation: 28952	CID	27	36	D011188	61	73	D007008	false
Relation: 28952	CID	27	36	D011188	193	205	D006973	false
Relation: 28952	CID	27	36	D011188	220	232	D007008	false

Sentence: In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.
Entity: 19893084	40	59	acute renal failure	Disease	D058186
Entity: 19893084	71	81	gentamicin	Chemical	D005839
Relation: 19893084	CID	71	81	D005839	40	59	D058186	true

Sentence: Oxytocin is a commonly used uterotonic that can cause significant and even fatal hypotension, particularly when given as a bolus.
Entity: 18513945	0	8	Oxytocin	Chemical	D010121
Entity: 18513945	81	92	hypotension	Disease	D007022
Relation: 18513945	CID	0	8	D010121	81	92	D007022	true

Sentence: Oxytocin induced hypotension at cesarean delivery may be incorrectly attributed to blood loss.
Entity: 18513945	0	8	Oxytocin	Chemical	D010121
Entity: 18513945	17	28	hypotension	Disease	D007022
Entity: 18513945	83	93	blood loss	Disease	D006473
Relation: 18513945	CID	0	8	D010121	17	28	D007022	true
Relation: 18513945	CID	0	8	D010121	83	93	D006473	false

Sentence: Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.
Entity: 18513945	0	11	Hypotension	Disease	D007022
Entity: 18513945	27	35	oxytocin	Chemical	D010121
Entity: 18513945	130	136	stroke	Disease	D020521
Relation: 18513945	CID	27	35	D010121	0	11	D007022	true
Relation: 18513945	CID	27	35	D010121	130	136	D020521	false

Sentence: Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP) induced cystitis.
Entity: 18483878	114	130	cyclophosphamide	Chemical	D003520
Entity: 18483878	132	135	CYP	Chemical	D003520
Entity: 18483878	145	153	cystitis	Disease	D003556
Relation: 18483878	CID	114	130	D003520	145	153	D003556	true
Relation: 18483878	CID	132	135	D003520	145	153	D003556	true

Sentence: VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide (CYP) induced cystitis.
Entity: 18483878	106	122	cyclophosphamide	Chemical	D003520
Entity: 18483878	124	127	CYP	Chemical	D003520
Entity: 18483878	137	145	cystitis	Disease	D003556
Relation: 18483878	CID	106	122	D003520	137	145	D003556	true
Relation: 18483878	CID	124	127	D003520	137	145	D003556	true

Sentence: A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without CYP induced cystitis (150 mg/kg; i.p.; 48 h).
Entity: 18483878	181	184	CYP	Chemical	D003520
Entity: 18483878	193	201	cystitis	Disease	D003556
Relation: 18483878	CID	181	184	D003520	193	201	D003556	true

Sentence: The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with CYP.
Entity: 18483878	44	64	bladder inflammation	Disease	D001745
Entity: 18483878	134	137	CYP	Chemical	D003520
Relation: 18483878	CID	134	137	D003520	44	64	D001745	false

Sentence: Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.
Entity: 17923537	38	45	uveitis	Disease	D014605
Entity: 17923537	59	81	fluocinolone acetonide	Chemical	D005446
Relation: 17923537	CID	59	81	D005446	38	45	D014605	false

Sentence: OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.
Entity: 17923537	53	82	elevated intraocular pressure	Disease	D009798
Entity: 17923537	106	113	uveitis	Disease	D014605
Entity: 17923537	131	153	fluocinolone acetonide	Chemical	D005446
Entity: 17923537	155	157	FA	Chemical	D005446
Relation: 17923537	CID	131	153	D005446	53	82	D009798	true
Relation: 17923537	CID	131	153	D005446	106	113	D014605	false
Relation: 17923537	CID	155	157	D005446	53	82	D009798	true
Relation: 17923537	CID	155	157	D005446	106	113	D014605	false

Sentence: Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa induced dyskinesias.
Entity: 15096016	30	42	bradykinesia	Disease	D018476
Entity: 15096016	47	55	rigidity	Disease	D009127
Entity: 15096016	122	130	levodopa	Chemical	D007980
Entity: 15096016	139	150	dyskinesias	Disease	D004409
Relation: 15096016	CID	122	130	D007980	30	42	D018476	false
Relation: 15096016	CID	122	130	D007980	47	55	D009127	false
Relation: 15096016	CID	122	130	D007980	139	150	D004409	true

Sentence: Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.
Entity: 12734532	13	21	Dexatrim	Chemical	D010665
Entity: 12734532	23	42	Phenylpropanolamine	Chemical	D010665
Entity: 12734532	58	79	myocardial infarction	Disease	D009203
Relation: 12734532	CID	13	21	D010665	58	79	D009203	true
Relation: 12734532	CID	23	42	D010665	58	79	D009203	true

Sentence: Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.
Entity: 12734532	41	44	PPA	Chemical	D010665
Entity: 12734532	50	67	myocardial injury	Disease	D009202
Entity: 12734532	85	93	overdose	Disease	D062787
Relation: 12734532	CID	41	44	D010665	50	67	D009202	false
Relation: 12734532	CID	41	44	D010665	85	93	D062787	false

Sentence: We report here the first case of Dexatrim (PPA) induced myocardial injury in a young woman who was using it at recommended doses for weight control.
Entity: 12734532	33	41	Dexatrim	Chemical	D010665
Entity: 12734532	43	46	PPA	Chemical	D010665
Entity: 12734532	56	73	myocardial injury	Disease	D009202
Relation: 12734532	CID	33	41	D010665	56	73	D009202	false
Relation: 12734532	CID	43	46	D010665	56	73	D009202	false

Sentence: In addition, we review the 7 other cases of PPA related myocardial injury that have been reported so far.
Entity: 12734532	44	47	PPA	Chemical	D010665
Entity: 12734532	56	73	myocardial injury	Disease	D009202
Relation: 12734532	CID	44	47	D010665	56	73	D009202	false

Sentence: Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.
Entity: 12013711	0	11	Risperidone	Chemical	D018967
Entity: 12013711	41	60	visual disturbances	Disease	D010468
Entity: 12013711	64	77	schizophrenic	Disease	D012559
Entity: 12013711	110	113	LSD	Chemical	D008238
Relation: 12013711	CID	0	11	D018967	41	60	D010468	true
Relation: 12013711	CID	0	11	D018967	64	77	D012559	false
Relation: 12013711	CID	110	113	D008238	41	60	D010468	false
Relation: 12013711	CID	110	113	D008238	64	77	D012559	false

Sentence: Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.
Entity: 12013711	4	17	schizophrenic	Disease	D012559
Entity: 12013711	55	58	LSD	Chemical	D008238
Entity: 12013711	98	101	EPS	Disease	D001480
Entity: 12013711	162	173	risperidone	Chemical	D018967
Relation: 12013711	CID	55	58	D008238	4	17	D012559	false
Relation: 12013711	CID	55	58	D008238	98	101	D001480	false
Relation: 12013711	CID	162	173	D018967	4	17	D012559	false
Relation: 12013711	CID	162	173	D018967	98	101	D001480	false

Sentence: They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.
Entity: 12013711	47	66	visual disturbances	Disease	D010468
Entity: 12013711	125	136	risperidone	Chemical	D018967
Relation: 12013711	CID	125	136	D018967	47	66	D010468	true

Sentence: This imagery resembled visual disturbances previously experienced as "flashbacks" related to prior LSD consumption.
Entity: 12013711	23	42	visual disturbances	Disease	D010468
Entity: 12013711	99	102	LSD	Chemical	D008238
Relation: 12013711	CID	99	102	D008238	23	42	D010468	false

Sentence: Risperidone administration was continued and the visual disturbances gradually wore off.
Entity: 12013711	0	11	Risperidone	Chemical	D018967
Entity: 12013711	49	68	visual disturbances	Disease	D010468
Relation: 12013711	CID	0	11	D018967	49	68	D010468	true

Sentence: Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin induced heart failure.
Entity: 11861791	14	30	poly(ADP-ribose)	Chemical	D011064
Entity: 11861791	72	83	doxorubicin	Chemical	D004317
Entity: 11861791	92	105	heart failure	Disease	D006333
Relation: 11861791	CID	14	30	D011064	92	105	D006333	false
Relation: 11861791	CID	72	83	D004317	92	105	D006333	true

Sentence: Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.
Entity: 11861791	63	77	cardiotoxicity	Disease	D066126
Entity: 11861791	81	92	doxorubicin	Chemical	D004317
Entity: 11861791	94	97	DOX	Chemical	D004317
Entity: 11861791	124	137	anthracycline	Chemical	D018943
Relation: 11861791	CID	81	92	D004317	63	77	D066126	false
Relation: 11861791	CID	94	97	D004317	63	77	D066126	false
Relation: 11861791	CID	124	137	D018943	63	77	D066126	false

Sentence: Thus, we hypothesized that the activation of PARP may contribute to the DOX induced cardiotoxicity.
Entity: 11861791	72	75	DOX	Chemical	D004317
Entity: 11861791	84	98	cardiotoxicity	Disease	D066126
Relation: 11861791	CID	72	75	D004317	84	98	D066126	false

Sentence: Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.
Entity: 11861791	136	140	PJ34	Chemical	C434926
Entity: 11861791	200	219	cardiac dysfunction	Disease	D006331
Entity: 11861791	231	234	DOX	Chemical	D004317
Relation: 11861791	CID	136	140	C434926	200	219	D006331	false
Relation: 11861791	CID	231	234	D004317	200	219	D006331	false

Sentence: Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals.
Entity: 11861791	17	21	PJ34	Chemical	C434926
Entity: 11861791	45	64	cardiac dysfunction	Disease	D006331
Relation: 11861791	CID	17	21	C434926	45	64	D006331	false

Sentence: Thus, PARP activation contributes to the cardiotoxicity of DOX.
Entity: 11861791	41	55	cardiotoxicity	Disease	D066126
Entity: 11861791	59	62	DOX	Chemical	D004317
Relation: 11861791	CID	59	62	D004317	41	55	D066126	false

Sentence: Fluconazole induced torsade de pointes.
Entity: 11302406	0	11	Fluconazole	Chemical	D015725
Entity: 11302406	20	38	torsade de pointes	Disease	D016171
Relation: 11302406	CID	0	11	D015725	20	38	D016171	true

Sentence: OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.
Entity: 11302406	32	43	fluconazole	Chemical	D015725
Entity: 11302406	55	73	torsade de pointes	Disease	D016171
Entity: 11302406	75	78	TDP	Disease	D016171
Entity: 11302406	92	103	fluconazole	Chemical	D015725
Entity: 11302406	122	125	TDP	Disease	D016171
Relation: 11302406	CID	32	43	D015725	55	73	D016171	true
Relation: 11302406	CID	32	43	D015725	75	78	D016171	true
Relation: 11302406	CID	32	43	D015725	122	125	D016171	true
Relation: 11302406	CID	92	103	D015725	55	73	D016171	true
Relation: 11302406	CID	92	103	D015725	75	78	D016171	true
Relation: 11302406	CID	92	103	D015725	122	125	D016171	true

Sentence: CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.
Entity: 11302406	106	109	TDP	Disease	D016171
Entity: 11302406	143	154	fluconazole	Chemical	D015725
Entity: 11302406	197	200	TDP	Disease	D016171
Entity: 11302406	212	235	coronary artery disease	Disease	D003324
Entity: 11302406	237	251	cardiomyopathy	Disease	D009202
Entity: 11302406	253	277	congestive heart failure	Disease	D006333
Entity: 11302406	368	379	fluconazole	Chemical	D015725
Entity: 11302406	384	387	TDP	Disease	D016171
Relation: 11302406	CID	143	154	D015725	106	109	D016171	true
Relation: 11302406	CID	143	154	D015725	197	200	D016171	true
Relation: 11302406	CID	143	154	D015725	212	235	D003324	false
Relation: 11302406	CID	143	154	D015725	237	251	D009202	false
Relation: 11302406	CID	143	154	D015725	253	277	D006333	false
Relation: 11302406	CID	143	154	D015725	384	387	D016171	true
Relation: 11302406	CID	368	379	D015725	106	109	D016171	true
Relation: 11302406	CID	368	379	D015725	197	200	D016171	true
Relation: 11302406	CID	368	379	D015725	212	235	D003324	false
Relation: 11302406	CID	368	379	D015725	237	251	D009202	false
Relation: 11302406	CID	368	379	D015725	253	277	D006333	false
Relation: 11302406	CID	368	379	D015725	384	387	D016171	true

Sentence: The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.
Entity: 11302406	4	7	TDP	Disease	D016171
Entity: 11302406	22	33	fluconazole	Chemical	D015725
Entity: 11302406	91	125	premature ventricular contractions	Disease	D018879
Entity: 11302406	143	166	ventricular tachycardia	Disease	D017180
Entity: 11302406	168	172	NSVT	Disease	D017180
Entity: 11302406	312	323	fluconazole	Chemical	D015725
Entity: 11302406	347	350	TDP	Disease	D016171
Relation: 11302406	CID	22	33	D015725	4	7	D016171	true
Relation: 11302406	CID	22	33	D015725	91	125	D018879	false
Relation: 11302406	CID	22	33	D015725	143	166	D017180	false
Relation: 11302406	CID	22	33	D015725	168	172	D017180	false
Relation: 11302406	CID	22	33	D015725	347	350	D016171	true
Relation: 11302406	CID	312	323	D015725	4	7	D016171	true
Relation: 11302406	CID	312	323	D015725	91	125	D018879	false
Relation: 11302406	CID	312	323	D015725	143	166	D017180	false
Relation: 11302406	CID	312	323	D015725	168	172	D017180	false
Relation: 11302406	CID	312	323	D015725	347	350	D016171	true

Sentence: The possible mechanism is depression of rapidly activating delayed rectifier potassium currents.
Entity: 11302406	26	36	depression	Disease	D003866
Entity: 11302406	77	86	potassium	Chemical	D011188
Relation: 11302406	CID	77	86	D011188	26	36	D003866	false

Sentence: In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.
Entity: 11302406	74	89	QT prolongation	Disease	D008133
Entity: 11302406	93	96	TDP	Disease	D016171
Entity: 11302406	127	131	NSVT	Disease	D017180
Entity: 11302406	136	170	premature ventricular contractions	Disease	D018879
Entity: 11302406	257	268	fluconazole	Chemical	D015725
Relation: 11302406	CID	257	268	D015725	74	89	D008133	false
Relation: 11302406	CID	257	268	D015725	93	96	D016171	true
Relation: 11302406	CID	257	268	D015725	127	131	D017180	false
Relation: 11302406	CID	257	268	D015725	136	170	D018879	false

Sentence: CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.
Entity: 11302406	45	56	fluconazole	Chemical	D015725
Entity: 11302406	87	118	prolongation of the QT interval	Disease	D008133
Entity: 11302406	131	134	TDP	Disease	D016171
Relation: 11302406	CID	45	56	D015725	87	118	D008133	false
Relation: 11302406	CID	45	56	D015725	131	134	D016171	true

Sentence: High-dose methylprednisolone may do more harm for spinal cord injury.
Entity: 11058428	10	28	methylprednisolone	Chemical	D008775
Entity: 11058428	50	68	spinal cord injury	Disease	D013119
Relation: 11058428	CID	10	28	D008775	50	68	D013119	false

Sentence: Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.
Entity: 11058428	30	48	Spinal Cord Injury	Disease	D013119
Entity: 11058428	77	95	methylprednisolone	Chemical	D008775
Entity: 11058428	138	156	spinal cord injury	Disease	D013119
Relation: 11058428	CID	77	95	D008775	30	48	D013119	false
Relation: 11058428	CID	77	95	D008775	138	156	D013119	false

Sentence: In the NASCIS, there was no mention regarding the possibility of acute corticosteroid myopathy that high-dose methylprednisolone may cause.
Entity: 11058428	71	85	corticosteroid	Chemical	D000305
Entity: 11058428	86	94	myopathy	Disease	D009135
Entity: 11058428	110	128	methylprednisolone	Chemical	D008775
Relation: 11058428	CID	71	85	D000305	86	94	D009135	false
Relation: 11058428	CID	110	128	D008775	86	94	D009135	true

Sentence: Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.
Entity: 11058428	9	16	steroid	Chemical	D013256
Entity: 11058428	17	25	myopathy	Disease	D009135
Entity: 11058428	162	169	steroid	Chemical	D013256
Entity: 11058428	170	178	myopathy	Disease	D009135
Entity: 11058428	211	229	methylprednisolone	Chemical	D008775
Entity: 11058428	244	262	spinal cord injury	Disease	D013119
Relation: 11058428	CID	9	16	D013256	17	25	D009135	false
Relation: 11058428	CID	9	16	D013256	170	178	D009135	false
Relation: 11058428	CID	9	16	D013256	244	262	D013119	false
Relation: 11058428	CID	162	169	D013256	17	25	D009135	false
Relation: 11058428	CID	162	169	D013256	170	178	D009135	false
Relation: 11058428	CID	162	169	D013256	244	262	D013119	false
Relation: 11058428	CID	211	229	D008775	17	25	D009135	true
Relation: 11058428	CID	211	229	D008775	170	178	D009135	true
Relation: 11058428	CID	211	229	D008775	244	262	D013119	false

Sentence: OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine induced impairment in word recall.
Entity: 11022397	68	79	tropicamide	Chemical	D014331
Entity: 11022397	84	95	pilocarpine	Chemical	D010862
Entity: 11022397	97	108	scopolamine	Chemical	D012601
Entity: 11022397	117	142	impairment in word recall	Disease	D008569
Relation: 11022397	CID	68	79	D014331	117	142	D008569	false
Relation: 11022397	CID	84	95	D010862	117	142	D008569	false
Relation: 11022397	CID	97	108	D012601	117	142	D008569	true

Sentence: Compared with the young group, the elderly group had greater scopolamine induced impairment in word recall 60, 90 and 120 minutes after administration (p < 0.05).
Entity: 11022397	61	72	scopolamine	Chemical	D012601
Entity: 11022397	81	106	impairment in word recall	Disease	D008569
Relation: 11022397	CID	61	72	D012601	81	106	D008569	true

Sentence: Acetazolamide induced Gerstmann syndrome.
Entity: 10692744	0	13	Acetazolamide	Chemical	D000086
Entity: 10692744	22	40	Gerstmann syndrome	Disease	D005862
Relation: 10692744	CID	0	13	D000086	22	40	D005862	true

Sentence: Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.
Entity: 10692744	6	15	confusion	Disease	D003221
Entity: 10692744	27	40	acetazolamide	Chemical	D000086
Entity: 10692744	96	112	renal impairment	Disease	D007674
Relation: 10692744	CID	27	40	D000086	6	15	D003221	false
Relation: 10692744	CID	27	40	D000086	96	112	D007674	false

Sentence: Hypomania-like syndrome induced by olanzapine.
Entity: 10565806	0	9	Hypomania	Disease	D001714
Entity: 10565806	35	45	olanzapine	Chemical	C076029
Relation: 10565806	CID	35	45	C076029	0	9	D001714	true

Sentence: Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.
Entity: 9061311	11	21	superoxide	Chemical	D013481
Entity: 9061311	26	43	hydrogen peroxide	Chemical	D006861
Entity: 9061311	72	91	acute liver failure	Disease	D017114
Relation: 9061311	CID	11	21	D013481	72	91	D017114	false
Relation: 9061311	CID	26	43	D006861	72	91	D017114	false

Sentence: Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).
Entity: 9061311	11	21	superoxide	Chemical	D013481
Entity: 9061311	26	43	hydrogen peroxide	Chemical	D006861
Entity: 9061311	98	118	bacterial infections	Disease	D001424
Entity: 9061311	136	155	acute liver failure	Disease	D017114
Entity: 9061311	157	160	ALF	Disease	D017114
Relation: 9061311	CID	11	21	D013481	98	118	D001424	false
Relation: 9061311	CID	11	21	D013481	136	155	D017114	false
Relation: 9061311	CID	11	21	D013481	157	160	D017114	false
Relation: 9061311	CID	26	43	D006861	98	118	D001424	false
Relation: 9061311	CID	26	43	D006861	136	155	D017114	false
Relation: 9061311	CID	26	43	D006861	157	160	D017114	false

Sentence: In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.
Entity: 9061311	22	28	oxygen	Chemical	D010100
Entity: 9061311	65	68	ALF	Disease	D017114
Entity: 9061311	76	87	paracetamol	Chemical	D000082
Entity: 9061311	88	96	overdose	Disease	D062787
Relation: 9061311	CID	22	28	D010100	65	68	D017114	false
Relation: 9061311	CID	22	28	D010100	88	96	D062787	false
Relation: 9061311	CID	76	87	D000082	65	68	D017114	true
Relation: 9061311	CID	76	87	D000082	88	96	D062787	false

Sentence: Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).
Entity: 9061311	0	10	Superoxide	Chemical	D013481
Entity: 9061311	15	32	hydrogen peroxide	Chemical	D006861
Entity: 9061311	47	50	ALF	Disease	D017114
Entity: 9061311	102	105	ALF	Disease	D017114
Relation: 9061311	CID	0	10	D013481	47	50	D017114	false
Relation: 9061311	CID	0	10	D013481	102	105	D017114	false
Relation: 9061311	CID	15	32	D006861	47	50	D017114	false
Relation: 9061311	CID	15	32	D006861	102	105	D017114	false

Sentence: Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.
Entity: 9061311	0	10	Superoxide	Chemical	D013481
Entity: 9061311	15	32	hydrogen peroxide	Chemical	D006861
Entity: 9061311	75	112	formyl-methionyl-leucyl-phenylalanine	Chemical	D009240
Entity: 9061311	114	118	fMLP	Chemical	D009240
Entity: 9061311	138	141	ALF	Disease	D017114
Relation: 9061311	CID	0	10	D013481	138	141	D017114	false
Relation: 9061311	CID	15	32	D006861	138	141	D017114	false
Relation: 9061311	CID	75	112	D009240	138	141	D017114	false
Relation: 9061311	CID	114	118	D009240	138	141	D017114	false

Sentence: Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.
Entity: 8617710	21	31	sertraline	Chemical	D020280
Entity: 8617710	63	83	cognitive impairment	Disease	D003072
Entity: 8617710	89	100	haloperidol	Chemical	D006220
Relation: 8617710	CID	21	31	D020280	63	83	D003072	false
Relation: 8617710	CID	89	100	D006220	63	83	D003072	true

Sentence: RESULTS: Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing.
Entity: 8617710	9	41	Impairment of cognitive function	Disease	D003072
Entity: 8617710	92	103	haloperidol	Chemical	D006220
Relation: 8617710	CID	92	103	D006220	9	41	D003072	true

Sentence: Ciprofloxacin induced nephrotoxicity in patients with cancer.
Entity: 8494478	0	13	Ciprofloxacin	Chemical	D002939
Entity: 8494478	22	36	nephrotoxicity	Disease	D007674
Entity: 8494478	54	60	cancer	Disease	D009369
Relation: 8494478	CID	0	13	D002939	22	36	D007674	false
Relation: 8494478	CID	0	13	D002939	54	60	D009369	false

Sentence: Nephrotoxicity associated with ciprofloxacin is uncommon.
Entity: 8494478	0	14	Nephrotoxicity	Disease	D007674
Entity: 8494478	31	44	ciprofloxacin	Chemical	D002939
Relation: 8494478	CID	31	44	D002939	0	14	D007674	false

Sentence: Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.
Entity: 8494478	19	25	cancer	Disease	D009369
Entity: 8494478	40	59	acute renal failure	Disease	D058186
Entity: 8494478	89	102	ciprofloxacin	Chemical	D002939
Relation: 8494478	CID	89	102	D002939	19	25	D009369	false
Relation: 8494478	CID	89	102	D002939	40	59	D058186	true

Sentence: Case report: pentamidine and polymorphic ventricular tachycardia revisited.
Entity: 8475949	13	24	pentamidine	Chemical	D010419
Entity: 8475949	41	64	ventricular tachycardia	Disease	D017180
Relation: 8475949	CID	13	24	D010419	41	64	D017180	false

Sentence: Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.
Entity: 8475949	0	23	Pentamidine isethionate	Chemical	D010419
Entity: 8475949	49	77	ventricular tachyarrhythmias	Disease	D017180
Entity: 8475949	89	107	torsade de pointes	Disease	D016171
Relation: 8475949	CID	0	23	D010419	49	77	D017180	false
Relation: 8475949	CID	0	23	D010419	89	107	D016171	true

Sentence: Pentamidine induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.
Entity: 8475949	0	11	Pentamidine	Chemical	D010419
Entity: 8475949	20	38	torsade de pointes	Disease	D016171
Entity: 8475949	63	72	magnesium	Chemical	D008274
Entity: 8475949	84	98	hypomagnesemia	Disease	C537153
Relation: 8475949	CID	0	11	D010419	20	38	D016171	true
Relation: 8475949	CID	0	11	D010419	84	98	C537153	false
Relation: 8475949	CID	63	72	D008274	20	38	D016171	false
Relation: 8475949	CID	63	72	D008274	84	98	C537153	false

Sentence: Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.
Entity: 8475949	0	18	Torsade de pointes	Disease	D016171
Entity: 8475949	74	85	pentamidine	Chemical	D010419
Relation: 8475949	CID	74	85	D010419	0	18	D016171	true

Sentence: Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.
Entity: 8475949	0	18	Torsade de pointes	Disease	D016171
Entity: 8475949	93	104	pentamidine	Chemical	D010419
Relation: 8475949	CID	93	104	D010419	0	18	D016171	true

Sentence: Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.
Entity: 7710775	26	41	malondialdehyde	Chemical	D008315
Entity: 7710775	43	53	oxypurines	Chemical	-1
Entity: 7710775	59	70	nucleosides	Chemical	D009705
Entity: 7710775	89	106	cerebral ischemia	Disease	D002545
Relation: 7710775	CID	26	41	D008315	89	106	D002545	true
Relation: 7710775	CID	43	53	-1	89	106	D002545	false
Relation: 7710775	CID	59	70	D009705	89	106	D002545	false

Sentence: During ischemia, a time-dependent increase of plasma oxypurines and nucleosides was observed.
Entity: 7710775	7	15	ischemia	Disease	D007511
Entity: 7710775	53	63	oxypurines	Chemical	-1
Entity: 7710775	68	79	nucleosides	Chemical	D009705
Relation: 7710775	CID	53	63	-1	7	15	D007511	false
Relation: 7710775	CID	68	79	D009705	7	15	D007511	false

Sentence: Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).
Entity: 7710775	7	22	malondialdehyde	Chemical	D008315
Entity: 7710775	136	144	ischemia	Disease	D007511
Relation: 7710775	CID	7	22	D008315	136	144	D007511	false

Sentence: Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.
Entity: 7710775	17	32	malondialdehyde	Chemical	D008315
Entity: 7710775	184	200	acetylsalicylate	Chemical	D001241
Entity: 7710775	234	242	ischemia	Disease	D007511
Entity: 7710775	294	305	hypotensive	Disease	D007022
Entity: 7710775	311	324	nitroprusside	Chemical	D009599
Entity: 7710775	384	392	ischemia	Disease	D007511
Entity: 7710775	424	439	malondialdehyde	Chemical	D008315
Relation: 7710775	CID	17	32	D008315	234	242	D007511	false
Relation: 7710775	CID	17	32	D008315	294	305	D007022	false
Relation: 7710775	CID	17	32	D008315	384	392	D007511	false
Relation: 7710775	CID	184	200	D001241	234	242	D007511	false
Relation: 7710775	CID	184	200	D001241	294	305	D007022	false
Relation: 7710775	CID	184	200	D001241	384	392	D007511	false
Relation: 7710775	CID	311	324	D009599	234	242	D007511	false
Relation: 7710775	CID	311	324	D009599	294	305	D007022	false
Relation: 7710775	CID	311	324	D009599	384	392	D007511	false
Relation: 7710775	CID	424	439	D008315	234	242	D007511	false
Relation: 7710775	CID	424	439	D008315	294	305	D007022	false
Relation: 7710775	CID	424	439	D008315	384	392	D007511	false

Sentence: Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops.
Entity: 7650771	12	20	toxicity	Disease	D064420
Entity: 7650771	59	79	echothiophate iodide	Chemical	D004456
Relation: 7650771	CID	59	79	D004456	12	20	D064420	false

Sentence: Acute renal failure in high dose carboplatin chemotherapy.
Entity: 7565311	0	19	Acute renal failure	Disease	D058186
Entity: 7565311	33	44	carboplatin	Chemical	D016190
Relation: 7565311	CID	33	44	D016190	0	19	D058186	true

Sentence: Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.
Entity: 7565311	0	11	Carboplatin	Chemical	D016190
Entity: 7565311	39	58	acute renal failure	Disease	D058186
Relation: 7565311	CID	0	11	D016190	39	58	D058186	true

Sentence: We report a 4 1/2-year-old girl who was treated with high-dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma.
Entity: 7565311	63	74	carboplatin	Chemical	D016190
Entity: 7565311	104	130	embryonal rhabdomyosarcoma	Disease	D018233
Relation: 7565311	CID	63	74	D016190	104	130	D018233	false

Sentence: She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.
Entity: 7421734	8	23	ovarian failure	Disease	D010049
Entity: 7421734	73	88	Hodgkin disease	Disease	D006689
Entity: 7421734	113	122	estrogens	Chemical	D004967
Entity: 7421734	169	187	endometrial cancer	Disease	D016889
Relation: 7421734	CID	113	122	D004967	8	23	D010049	false
Relation: 7421734	CID	113	122	D004967	73	88	D006689	false
Relation: 7421734	CID	113	122	D004967	169	187	D016889	true

Sentence: Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.
Entity: 6732043	17	49	obstructive sleep apnea syndrome	Disease	D020181
Entity: 6732043	74	82	androgen	Chemical	D000728
Relation: 6732043	CID	74	82	D000728	17	49	D020181	true

Sentence: We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.
Entity: 6732043	167	202	syndrome of obstructive sleep apnea	Disease	D020181
Entity: 6732043	238	247	androgens	Chemical	D000728
Relation: 6732043	CID	238	247	D000728	167	202	D020181	true

Sentence: A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.
Entity: 6732043	19	27	androgen	Chemical	D000728
Entity: 6732043	49	72	obstructive sleep apnea	Disease	D020181
Relation: 6732043	CID	19	27	D000728	49	72	D020181	true

Sentence: Previous reports have favored a role of androgens in the pathogenesis of sleep apnea.
Entity: 6732043	40	49	androgens	Chemical	D000728
Entity: 6732043	73	84	sleep apnea	Disease	D012891
Relation: 6732043	CID	40	49	D000728	73	84	D012891	false

Sentence: Effect of captopril on pre-existing and aminonucleoside induced proteinuria in spontaneously hypertensive rats.
Entity: 6454943	10	19	captopril	Chemical	D002216
Entity: 6454943	40	55	aminonucleoside	Chemical	D011692
Entity: 6454943	64	75	proteinuria	Disease	D011507
Entity: 6454943	93	105	hypertensive	Disease	D006973
Relation: 6454943	CID	10	19	D002216	64	75	D011507	false
Relation: 6454943	CID	10	19	D002216	93	105	D006973	false
Relation: 6454943	CID	40	55	D011692	64	75	D011507	true
Relation: 6454943	CID	40	55	D011692	93	105	D006973	false

Sentence: Proteinuria is a side effect of captopril treatment in hypertensive patients.
Entity: 6454943	0	11	Proteinuria	Disease	D011507
Entity: 6454943	32	41	captopril	Chemical	D002216
Entity: 6454943	55	67	hypertensive	Disease	D006973
Relation: 6454943	CID	32	41	D002216	0	11	D011507	false
Relation: 6454943	CID	32	41	D002216	55	67	D006973	false

Sentence: The possibility of reproducing the same renal abnormality with captopril was examined in SHR.
Entity: 6454943	40	57	renal abnormality	Disease	D007674
Entity: 6454943	63	72	captopril	Chemical	D002216
Relation: 6454943	CID	63	72	D002216	40	57	D007674	false

Sentence: Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR.
Entity: 6454943	23	32	captopril	Chemical	D002216
Entity: 6454943	78	89	proteinuria	Disease	D011507
Relation: 6454943	CID	23	32	D002216	78	89	D011507	false

Sentence: Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.
Entity: 6454943	6	15	captopril	Chemical	D002216
Entity: 6454943	84	95	proteinuria	Disease	D011507
Entity: 6454943	107	132	puromycin aminonucleoside	Chemical	D011692
Relation: 6454943	CID	6	15	D002216	84	95	D011507	false
Relation: 6454943	CID	107	132	D011692	84	95	D011507	true

Sentence: In one patient, enflurane administered during a donor nephrectomy resulted in unexpected partial motor seizures.
Entity: 6153967	16	25	enflurane	Chemical	D004737
Entity: 6153967	103	111	seizures	Disease	D012640
Relation: 6153967	CID	16	25	D004737	103	111	D012640	true

Sentence: Epileptic foci delineated and activated by enflurane were surgically ablated and the patients are now seizure-free.
Entity: 6153967	0	9	Epileptic	Disease	D004827
Entity: 6153967	43	52	enflurane	Chemical	D004737
Entity: 6153967	102	109	seizure	Disease	D012640
Relation: 6153967	CID	43	52	D004737	0	9	D004827	false
Relation: 6153967	CID	43	52	D004737	102	109	D012640	true

Sentence: Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.
Entity: 3183120	11	27	cerebral lesions	Disease	D001927
Entity: 3183120	44	54	tiazofurin	Chemical	C033706
Relation: 3183120	CID	44	54	C033706	11	27	D001927	true

Sentence: Enhanced stimulus induced neurotransmitter overflow in epinephrine induced hypertensive rats is not mediated by prejunctional beta-adrenoceptor activation.
Entity: 2886572	55	66	epinephrine	Chemical	D004837
Entity: 2886572	75	87	hypertensive	Disease	D006973
Relation: 2886572	CID	55	66	D004837	75	87	D006973	true

Sentence: Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics.
Entity: 1079693	65	72	uveitis	Disease	D014605
Entity: 1079693	149	164	corticosteroids	Chemical	D000305
Relation: 1079693	CID	149	164	D000305	65	72	D014605	false

Sentence: We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.
Entity: 1079693	8	19	chloroquine	Chemical	D002738
Entity: 1079693	23	41	hydroxychloroquine	Chemical	D006886
Entity: 1079693	89	106	chorioretinopathy	Disease	D012164
Relation: 1079693	CID	8	19	D002738	89	106	D012164	false
Relation: 1079693	CID	23	41	D006886	89	106	D012164	true

Sentence: Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.
Entity: 1079693	26	41	corticosteroids	Chemical	D000305
Entity: 1079693	118	127	cataracts	Disease	D002386
Relation: 1079693	CID	26	41	D000305	118	127	D002386	false

Sentence: Water intoxication associated with oxytocin administration during saline induced abortion.
Entity: 803783	0	18	Water intoxication	Disease	D014869
Entity: 803783	35	43	oxytocin	Chemical	D010121
Entity: 803783	81	89	abortion	Disease	D000031
Relation: 803783	CID	35	43	D010121	0	18	D014869	true
Relation: 803783	CID	35	43	D010121	81	89	D000031	false

Sentence: Four cases of water intoxication in connection with oxytocin administration during saline induced abortions are described.
Entity: 803783	14	32	water intoxication	Disease	D014869
Entity: 803783	52	60	oxytocin	Chemical	D010121
Entity: 803783	98	107	abortions	Disease	D000031
Relation: 803783	CID	52	60	D010121	14	32	D014869	true
Relation: 803783	CID	52	60	D010121	98	107	D000031	false

Sentence: Oxytocin administration during midtrimester induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.
Entity: 803783	0	8	Oxytocin	Chemical	D010121
Entity: 803783	52	61	abortions	Disease	D000031
Entity: 803783	184	202	water intoxication	Disease	D014869
Entity: 803783	287	295	asthenia	Disease	D001247
Entity: 803783	306	318	irritability	Disease	D001523
Entity: 803783	323	332	headaches	Disease	D006261
Relation: 803783	CID	0	8	D010121	52	61	D000031	false
Relation: 803783	CID	0	8	D010121	184	202	D014869	true
Relation: 803783	CID	0	8	D010121	287	295	D001247	false
Relation: 803783	CID	0	8	D010121	306	318	D001523	false
Relation: 803783	CID	0	8	D010121	323	332	D006261	false

